<SEC-DOCUMENT>0001193125-12-168265.txt : 20120418
<SEC-HEADER>0001193125-12-168265.hdr.sgml : 20120418
<ACCEPTANCE-DATETIME>20120418153801
ACCESSION NUMBER:		0001193125-12-168265
CONFORMED SUBMISSION TYPE:	PRE 14A
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120615
FILED AS OF DATE:		20120418
DATE AS OF CHANGE:		20120418

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Galena Biopharma, Inc.
		CENTRAL INDEX KEY:			0001390478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PRE 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33958
		FILM NUMBER:		12765888

	BUSINESS ADDRESS:	
		STREET 1:		310 N. STATE STREET
		STREET 2:		SUITE 208
		CITY:			LAKE OSWEGO
		STATE:			OR
		ZIP:			97034
		BUSINESS PHONE:		855 855 GALE

	MAIL ADDRESS:	
		STREET 1:		310 N. STATE STREET
		STREET 2:		SUITE 208
		CITY:			LAKE OSWEGO
		STATE:			OR
		ZIP:			97034

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXi Pharmaceuticals Corp
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GALENA BIOPHARMA, INC.
		DATE OF NAME CHANGE:	20110922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXI PHARMACEUTICALS CORP
		DATE OF NAME CHANGE:	20110921
</SEC-HEADER>
<DOCUMENT>
<TYPE>PRE 14A
<SEQUENCE>1
<FILENAME>d336720dpre14a.htm
<DESCRIPTION>PRELIMINARY PROXY STATEMENT
<TEXT>
<HTML><HEAD>
<TITLE>Preliminary Proxy Statement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SCHEDULE 14A </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>INFORMATION REQUIRED IN PROXY STATEMENT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>SCHEDULE 14A INFORMATION </B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Proxy Statement Pursuant to Section 14(a) of
the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of 1934 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>(Amendment No. &nbsp;&nbsp; ) </B></FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Filed by the
Registrant&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Filed by a
Party other than the Registrant&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the
appropriate box: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preliminary Proxy Statement</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Definitive Proxy Statement</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Definitive Additional Materials</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting Material Pursuant to &#167;240.14a-12</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B><BR>&nbsp;&nbsp;&nbsp;&nbsp;Galena Biopharma, Inc.&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Name of Registrant as Specified In Its Charter)</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR>
<TD COLSPAN="5" VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</B></FONT></TD></TR>
<TR>
<TD HEIGHT="32" COLSPAN="5"></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payment of Filing Fee (Check the appropriate box):</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">No fee required.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title of each class of securities to which transaction applies:</FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aggregate number of securities to which transaction applies:</FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the
filing fee is calculated and state how it was determined):</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposed maximum aggregate value of transaction:</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total fee paid:</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fee paid previously with preliminary materials.</FONT></TD></TR>
<TR>
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify
the previous filing by registration statement number, or the Form or Schedule and the date of its filing.</FONT></TD></TR>
<TR>
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amount Previously Paid:</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form, Schedule or Registration Statement No.:</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Filing Party:</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date Filed:</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g336720g01c85.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>310 N. State Street, Suite 208 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Lake Oswego, Oregon 97034 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2">May &nbsp;&nbsp;&nbsp;&nbsp;, 2012 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dear Stockholder: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You are cordially invited to attend the 2012 Annual Meeting of Stockholders of Galena Biopharma, Inc. to be held at the offices of
TroyGould PC, 1801 Century Park East, 16th Floor, Los Angeles, California at 9:00 A.M., local time, on Friday, June&nbsp;15, 2012. For directions to go to <U>www.troygould.com.</U> Valet parking is available at your expense directly underneath the
building and paid self-parking is available in adjacent buildings. Three hours of free self-parking is available at the nearby Century City Mall (http://www.westfield.com/centurycity/directions/parking). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The notice of annual meeting and the proxy statement on the following pages cover the formal business of the Annual Meeting. At the
Annual Meeting, management also will report on our current business and operations and will be available to respond to questions from stockholders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Whether or not you plan to attend, it is important that your shares be represented and voted at the meeting. I urge you, therefore, to return a signed proxy card or vote by telephone or over the internet,
so that you can be sure your votes are properly counted, even if you plan to attend the meeting. Information about voting procedures can be found in the proxy statement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">I hope you will join us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sincerely, </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark J. Ahn </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g336720g01c85.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>310 N. State Street, Suite 208 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Lake Oswego, Oregon 97034 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>NOTICE OF ANNUAL MEETING OF STOCKHOLDERS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>To Be Held On June&nbsp;15,
2012 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notice is hereby given to the holders of common stock of Galena Biopharma, Inc., that the Annual Meeting of
Stockholders will be held on Friday, June&nbsp;15, 2012, at the offices of TroyGould PC, 1801 Century Park East, 16th Floor, Los Angeles California, at 9:00 A.M., local time, for the following purposes: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To elect two directors to serve until the 2015 annual meeting of stockholders; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To consider and vote upon a proposal to allow us, at our election, to issue shares of our common stock in satisfaction of future milestone payments to the holders of
our outstanding contingent value rights; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To consider and vote upon a proposal to approve the issuance of shares of our common stock in lieu of cash payment of milestone #1 to the holders of our outstanding
contingent value rights; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To approve an amendment to our 2007 Incentive Plan; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To ratify the selection of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2012; and
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To transact such other business as may properly come before the Annual Meeting or any postponement or adjournment thereof. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are pleased to take advantage of Securities and Exchange Commission rules that allow companies to furnish their proxy materials over
the Internet. We are mailing to many of our stockholders a Notice of Internet Availability of Proxy Materials instead of a paper copy of our proxy materials and our 2011 Annual Report on Form&nbsp;10-K. The Notice contains instructions on how to
access those documents and to cast your vote via the Internet. The Notice also contains instructions on how to request a paper copy of our proxy materials and our 2011 Annual Report on Form 10-K. All stockholders who do not receive a Notice will
receive a paper copy of the proxy materials and the Annual Report by mail. This process allows us to provide our stockholders with the information they need on a more timely basis, while reducing the environmental impact and lowering the costs of
printing and distributing our proxy materials. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Only those stockholders of record at the close of business on April&nbsp;20,
2012 are entitled to notice of and to vote at the Annual Meeting or any postponement or adjournment thereof. A complete list of stockholders entitled to vote at the Annual Meeting will be available for examination at the Annual Meeting for any
purpose germane to the Annual Meeting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All stockholders are cordially invited to attend the Annual Meeting. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By Order of the Board of Directors,</FONT></TD></TR>
<TR>
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">May &nbsp;&nbsp;&nbsp;&nbsp;, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kwang S. Lee</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Corporate Secretary</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g336720g01c85.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>310 N. State Street, Suite 208 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Lake Oswego, Oregon 97034 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Annual Meeting of Stockholders </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>To Be Held on June&nbsp;15, 2012
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROXY STATEMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This proxy statement is furnished to holders of common stock of Galena Biopharma, Inc., a Delaware corporation (&#147;<B>we</B>,&#148; &#147;<B>us</B>,&#148; &#147;<B>our</B>,&#148;
&#147;<B>Galena</B>&#148; or the &#147;<B>company</B>&#148;), in connection with the solicitation of proxies by our board of directors for use at our 2012 Annual Meeting of Stockholders to be held at the offices of TroyGould PC, 1801 Century Park
East, 16th Floor, Los Angeles, California, at 9:00 A.M., local time, on Friday, June&nbsp;15, 2012, and at any postponement or adjournment thereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Notice of Internet Availability is first being mailed to our stockholders on or about May &nbsp;&nbsp;&nbsp;&nbsp;, 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our board of directors is asking you to vote your shares by completing, signing and returning the accompanying proxy card. If you attend the Annual Meeting in person, you may vote at the Annual Meeting
even if you have previously returned a proxy card. Please note, however, that if your shares are held of record by a broker, bank or other nominee and you wish to vote at the Annual Meeting, you must obtain a proxy issued in your name from that
record holder as described in more detail below under &#147;What are the voting rights of the holders of Galena common stock?&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>IMPORTANT NOTICE REGARDING THE INTERNET AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL STOCKHOLDERS MEETING TO BE HELD ON JUNE 15, 2012: </B><B><I>This proxy statement, the accompanying proxy card or
voting instruction card and our 2011 Annual Report on Form 10-K are also available at http://www.envisionreports.com/GALE.</I></B><B> </B></FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>QUESTIONS AND ANSWERS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What is a proxy? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A proxy is the legal designation of another person to vote the stock you own. That other person is called a proxy. If you designate
someone as your proxy in a written document, that document is also called a proxy or a proxy card. By completing, signing and returning the accompanying proxy card, you are designating Mark J. Ahn, Ph.D., our President and Chief Executive Officer,
and Kwang S. Lee, our Vice President, Finance and Corporate Secretary, as your proxies for the Annual Meeting and you are authorizing Dr.&nbsp;Ahn and Mr.&nbsp;Lee to vote your shares at the Annual Meeting as you have instructed them on the proxy
card. This way, your shares will be voted whether or not you attend the Annual Meeting. Even if you plan to attend the Annual Meeting, we urge you to vote in one of the ways described below so that your vote will be counted if you later decide not
to attend the Annual Meeting or are unable to attend. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What is a proxy statement? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A proxy statement is a document that we are required by regulations of the Securities and Exchange Commission, or &#147;<B>SEC</B>,&#148;
to give you when we ask you to sign a proxy card designating Dr.&nbsp;Ahn and Mr.&nbsp;Lee as proxies to vote on your behalf. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i)
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What is in this proxy statement? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This proxy statement describes the proposals on which we would like you, as a stockholder, to vote at the Annual Meeting. It gives you
information on the proposals, as well as other information about us, so that you can make an informed decision. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At the Annual
Meeting, stockholders will act upon the following matters referred to in the attached notice of annual meeting and described in detail in this proxy statement: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">the election of two directors; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">the proposal to allow us, at our election, to issue shares of our common stock in satisfaction of future milestone payments to the holders of our outstanding contingent
value rights; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">the proposal to approve the issuance of shares of our common stock in lieu of cash payment of milestone #1 to the holders of our outstanding contingent value rights;
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">the proposal to approve an amendment to our 2007 Incentive Plan; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">the ratification of the appointment of our independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2012. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, management will report on our current business operations and respond to appropriate questions from stockholders.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Who is entitled to vote at the Annual Meeting? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Only stockholders of record at the close of business on April&nbsp;20, 2012, the record date for the Annual Meeting, will be entitled to notice of, and to vote at, the Annual Meeting or any adjournment or
postponement thereof. These shares include those (1)&nbsp;held directly in your name as the stockholder of record and (2)&nbsp;held for you as the beneficial owner through a broker, bank or other nominee. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What is the difference between holding shares as a stockholder of record and as a beneficial owner? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Most of our stockholders hold their shares through a broker, bank or other nominee rather than directly in their own name as the
stockholder of record. As summarized below, there are some important distinctions between shares held of record and those owned beneficially. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Stockholder of Record</I> &#151; If your shares are registered directly in your name with our transfer agent, Computershare Trust Company, N.A., you
are considered the <I>stockholder of record</I> with respect to these shares. As the <I>stockholder of record</I>, you have the right to these shares to grant your voting proxy directly to us or to vote in person at the Annual Meeting.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Beneficial Owner</I> &#151; If your shares are held in a stock brokerage account or by a bank or other nominee, you are considered the <I>beneficial
owner </I>of shares held in <I>street name</I> and your broker or nominee is considered the <I>stockholder of record </I>with respect to those shares. As the beneficial owner of these shares, you have the right to direct your broker or nominee on
how to vote these shares and are also invited to attend the Annual Meeting. However, since you are not the stockholder of record, you may not vote these shares in person at the Annual Meeting unless you receive a proxy from your broker or nominee.
Your broker or nominee has provided voting instructions for you to use. If you wish to attend the Annual Meeting and vote in person shares held in street name, please contact your broker or nominee so that you can receive a legal proxy to present at
the Annual Meeting. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii)
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What does it mean if I receive more than one proxy card? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">It means that you have multiple accounts at our transfer agent or with your broker, bank or other nominee. Please complete, sign and
return all proxy cards to ensure that all your shares are voted. Unless you need multiple accounts for specific purposes, it may be less confusing if you consolidate as many of your transfer agent or brokerage accounts as possible under the same
name and address. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What constitutes a quorum? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our bylaws provide that the presence, in person or by proxy, at the Annual Meeting of the holders of a majority of outstanding shares of our common stock will constitute a quorum for the transaction of
business. On the record date, there were 60,756,503 shares of our common stock issued and outstanding, exclusive of treasury shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For the purpose of determining the presence of a quorum, proxies marked &#147;withhold authority&#148; or &#147;abstain&#148; will be counted as present. Shares represented by proxies that include
so-called broker non-votes, as described in greater detail below, also will be counted as shares present for purposes of establishing a quorum. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What are the voting rights of the holders of Galena common stock? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Each share of our common stock entitles the holder to one vote on all matters to come before the Annual Meeting. The following voting rights are associated with respect to the proposals: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">As to Proposal&nbsp;1 regarding the election of directors, you may vote &#147;FOR&#148; or &#147;WITHHOLD&#148; with respect to each of the nominees.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">As to Proposal 2 regarding the issuance, at our election, of shares of our common stock in satisfaction of future milestone payments to the holders of
our outstanding contingent value rights; Proposal&nbsp;3 regarding the issuance of shares of our common stock in lieu of cash payment of milestone #1 to the holders of our outstanding contingent value rights; Proposal 4 regarding the approval of an
amendment to our 2007 Incentive Plan, and Proposal&nbsp;5 regarding the ratification of the appointment of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2012, you may vote
&#147;FOR,&#148; &#147;AGAINST&#148; or &#147;ABSTAIN.&#148; If you elect to abstain, it will have the same effect as an &#147;AGAINST&#148; vote. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>How will my shares be voted if I am a stockholder of record? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you are a
stockholder of record and do not vote via the Internet, via telephone or by returning a signed proxy card, your shares will not be voted unless you attend the Annual Meeting and vote your shares. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you vote via the Internet or telephone and do not specify contrary voting instructions, your shares will be voted in accordance with
the recommendations of our board of directors with respect to Proposals 1, 2, 4 and 5. Because our board of directors is not making a recommendation with respect to Proposal 3, if you vote via the Internet or telephone and do not specify voting
instructions with respect to Proposal 3, your shares will <I>not</I> be voted with respect to Proposal 3 and you will be deemed to have abstained from voting on Proposal 3. Similarly, if you sign and submit your proxy card or voting instruction card
with no instructions, your shares will be voted in accordance with the recommendations of our board of directors with respect to Proposals 1, 2, 4 and 5, but <I>not</I> with respect to Proposal 3. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>If I am a beneficial owner of shares, can my brokerage firm vote my shares? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you are a beneficial owner and do not vote via the Internet, telephone, or by returning a signed voting instruction card to your
broker, your shares may be voted only with respect to so-called routine matters where </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii)
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
your broker has discretionary voting authority over your shares. Brokers will have such discretionary authority to vote on Proposal 5 regarding the ratification of the selection of our
independent registered public accounting firm for 2012, but not on any of the other proposals. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We encourage you to provide
instructions to your brokerage firm by returning your voting instruction card. This ensures that your shares will be voted at the Annual Meeting with respect to all of the proposals described in this proxy statement. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What happens if a director nominee is unable to stand for election? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our board of directors may reduce the number of nominees or select a substitute nominee. In the latter case, if you have completed, signed and returned your proxy card, Dr.&nbsp;Ahn and Mr.&nbsp;Lee can
vote your shares for a substitute nominee. They cannot vote for more than two nominees. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Is my vote kept confidential? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proxies, ballots and voting tabulations identifying stockholders are kept confidential and will not be disclosed to third parties except
as may be necessary to meet legal requirements. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What is the purpose of Proposal&nbsp;2 and Proposal 3? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposal 2 and Proposal 3 are intended to satisfy applicable marketplace rules of The Nasdaq Capital Market (&#147;<B>Nasdaq</B>&#148;)
regarding the issuance of shares of our common stock to the holders of our outstanding contingent value rights granted in April 2011 in connection with our merger acquisition of Apthera, Inc., or &#147;<B>Apthera</B>.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At the closing of the Apthera merger, we issued to Apthera&#146;s shareholders shares of our common stock constituting approximately
19.9% of our issued and outstanding shares of common stock immediately prior to the merger. We also issued to the former Apthera shareholders &#147;<B>contingent value rights</B>&#148; entitling them to future payments of up to $32 million in the
aggregate, which we refer to as the &#147;<B>contingent consideration</B>,&#148; based on the achievement of specified development and commercial milestones relating to our NeuVax product candidate acquired from Apthera. The payment of the
contingent consideration is subject to the terms of a contingent value rights agreement between us and the Apthera shareholder representative. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Under the contingent value rights agreement, we are entitled to pay the contingent consideration, at our election, in either cash or in shares of our common stock, except that we may not issue any shares
in satisfaction of any contingent consideration unless we have first obtained approval of our stockholders in accordance with Rule 5635(a) of the Nasdaq marketplace rules. Proposal 2 if approved by our stockholders, will satisfy this requirement.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On February&nbsp;15, 2012, we entered into a first amendment to the contingent value rights agreement relating to the
achievement of milestone #1, the enrollment of the first patient in our NeuVax PRESENT Phase 3 clinical trial. Under the amendment, we agreed, subject to stockholder approval, to pay the $1&nbsp;million contingent consideration triggered by the
achievement of milestone #1 by issuing 1,315,789 shares of our common stock, which we refer to as the &#147;<B>initial milestone shares</B>.&#148; The number of initial milestone shares was determined based on a value of $0.76 per share, which was
the closing price of our common stock as reported on Nasdaq on January&nbsp;18, 2012, the day prior to achievement of milestone #1, and is subject to increase as described in the discussion of Proposal 3, below, in this proxy statement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv)
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What vote is required for the proposals? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following votes are required with respect to the proposals: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">As to Proposal&nbsp;1 regarding the election of directors, the two nominees receiving the greatest number of affirmative votes cast, known as a
&#147;plurality vote,&#148; will be elected. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">As to Proposal&nbsp;2 regarding the issuance, at our election, of shares of our common stock in satisfaction of future milestone payments to the
holders of our outstanding contingent value rights, the affirmative vote of a majority of the shares present, in person or by proxy, and entitled to vote at the Annual Meeting is required. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">As to Proposal 3 regarding the issuance of shares of our common stock in lieu of cash payment of milestone #1 to the holders of our outstanding
contingent value rights, the affirmative vote of a majority of the shares present, in person or by proxy, and entitled to vote at the Annual Meeting is required. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">As to Proposal 4 regarding the approval of an amendment to our 2007 Incentive Plan, the affirmative vote of a majority of the shares present, in person
or by proxy, and entitled to vote at the Annual Meeting is required. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">As to Proposal&nbsp;5 regarding the ratification of the appointment of BDO USA, LLP as our independent registered public accounting firm for the fiscal
year ending December&nbsp;31, 2012, the affirmative vote of a majority of the shares present, in person or by proxy, and entitled to vote at the Annual Meeting is required. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">An automated system administered by our transfer agent will tabulate votes cast by proxy at the Annual Meeting, and the inspector of
elections for the Annual Meeting will tabulate votes cast in person at the Annual Meeting. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What are the board&#146;s recommendations?
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The recommendations of our board of directors are set forth together with the description of each proposal in this proxy
statement. In summary, our board of directors recommends a vote: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<I>FOR</I>&#148; election of the directors named in this proxy statement as described in Proposal 1; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<I>FOR</I>&#148; approval of the issuance, at our election, of shares of our common stock in satisfaction of future milestone payments to the
holders of our outstanding contingent value rights as described in Proposal&nbsp;2; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<I>FOR</I>&#148; approval of the amendment to our 2007 Incentive Plan as described in Proposal&nbsp;4; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<I>FOR</I>&#148; ratification of the appointment of BDO USA, LLP as our independent registered public accounting firm for fiscal year ending
December&nbsp;31, 2012 as described in Proposal&nbsp;5. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For reasons described in the discussion of Proposal
3, below, in this proxy statement, our board of directors makes no recommendation as to how to vote on Proposal 3 regarding the issuance of shares of our common stock in lieu of cash payment of milestone #1 to the holders of our outstanding
contingent value rights. You should consider the factors described in that discussion in determining how to vote on Proposal 3. If you do not specify voting instructions with respect to Proposal 3, your shares will <I>not</I> be voted with respect
to Proposal 3 and you will be deemed to have abstained from voting on Proposal 3. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>How can I attend the Annual Meeting? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You may attend the Annual Meeting if you are listed as a stockholder of record as of April&nbsp;20, 2012 and bring proof of your identity.
If you hold your shares in street name through a broker or other nominee, you will </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(v)
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
need to provide proof that you are the beneficial owner of the shares by bringing either a copy of a brokerage statement showing your share ownership as of April&nbsp;20, 2012, or a legal proxy
if you wish to vote your shares in person at the Annual Meeting. In addition to the items mentioned above, you should bring proof of your identity. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>How can I vote my shares in person at the Annual Meeting? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shares held
directly in your name as the stockholder of record may be voted in person at the Annual Meeting. If you choose to do so, please bring proof of your identity to the Annual Meeting. Shares held in street name beneficially owned may be voted by you if
you receive and present at the Annual Meeting a proxy from your broker or nominee, together with proof of your identity. Even if you plan to attend the Annual Meeting, we urge you to vote in one of the ways described below so that your vote will be
counted if you later decide not to attend the Annual Meeting or are unable to attend. Attendance at the Annual Meeting will not cause your previously granted proxy to be revoked unless you change your proxy instructions as described above.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>How can I vote my shares without attending the Annual Meeting? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Whether you hold shares directly as the stockholder of record or beneficially in street name, you may direct your vote without attending
the Annual Meeting. You may vote by granting a proxy or, for shares held in street name, by submitting voting instructions to your broker or nominee. In most instances, you will be able to do this over the Internet, by telephone or by mail. Please
refer to the summary instructions below, the instructions included on the Notice of Internet Availability of the proxy materials, and if you request printed proxy materials, the instructions included on your proxy card or, for shares held in street
name, the voting instruction card provided by your broker or nominee. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>By Internet</I> &#151; If you have Internet access, you may submit your proxy from any location in the world by following the Internet voting
instructions on the proxy card or voting instruction card sent to you. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>By Telephone</I> &#151; You may submit your proxy by following the telephone voting instructions on the Notice of Internet Availability you received
or by following the telephone voting instructions on the proxy card or voting instruction card sent to you. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>By Mail</I> &#151; You may do this by marking, dating and signing your proxy card or, for shares held in street name, the voting instruction card
provided to you by your broker or nominee, and mailing it in the enclosed, self-addressed, postage prepaid envelope. No postage is required if mailed in the United&nbsp;States. <I>Please note that you will be mailed a printed proxy card or printed
voting instruction card only if you request that such printed materials be sent to you by following the instructions in the Notice of Internet Availability for requesting paper copies of the proxy materials</I>. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Can I change my vote or revoke my proxy? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">You may change your proxy instructions at any time prior to the vote at the Annual Meeting. For shares held directly as the stockholder of record, you may accomplish this by granting another proxy that is
properly signed and bears a later date, by sending a properly signed written notice to our Corporate Secretary or by attending the Annual Meeting and voting in person. To revoke a proxy previously submitted by telephone or through the Internet, you
may simply vote again at a later date, using the same procedures, in which case your later submitted vote will be recorded and your earlier vote revoked. Attendance at the Annual Meeting will not cause your previously granted proxy to be revoked
unless you change your proxy instructions as described above. For shares held beneficially by you, you may change your vote by submitting new voting instructions to your broker or nominee. All written notices should be addressed as follows: Galena
Biopharma, 310 N. State Street, Suite 208, Lake Oswego, Oregon, 97034, Attention: Corporate Secretary. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vi)
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Where can I find the voting results of the Annual Meeting? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will announce preliminary voting results at the Annual Meeting. We will publish final voting results in a Current Report on Form 8-K
filed with the SEC within four business days following the Annual Meeting. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>If I am a stockholder of record, how do I consent to receive my
Annual Meeting materials electronically? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stockholders of record that choose to vote their shares via the Internet will be
asked to choose a delivery preference prior to voting their shares. After entering the access information requested by the electronic voting site, click &#147;Login&#148; and then respond as to whether you would like to receive proxy material via
electronic delivery. If you would like to receive future proxy materials electronically, which we urge you to do, click the applicable button, enter and verify your current email address and then click &#147;Continue.&#148; Stockholders of record
with multiple Galena accounts will need to consent to electronic delivery for each account separately. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vii)
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U><A NAME="toc"></A>TABLE OF CONTENTS </U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Page</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc336720_1">PROPOSAL 1 &#151; ELECTION OF DIRECTORS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc336720_2">EXECUTIVE COMPENSATION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc336720_3">PROPOSAL 2 &#151; APPROVAL OF ISSUANCE, AT OUR ELECTION, OF SHARES OF OUR COMMON STOCK IN SATISFACTION OF FUTURE
 MILESTONE PAYMENTS TO THE HOLDERS OF OUR OUTSTANDING CONTINGENT VALUE RIGHTS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc336720_4">PROPOSAL 3 &#151; APPROVAL OF ISSUANCE OF SHARES OF OUR COMMON STOCK IN LIEU OF CASH PAYMENT OF MILESTONE #1
 TO THE HOLDERS OF OUR OUTSTANDING CONTINGENT VALUE RIGHTS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc336720_5">PROPOSAL 4 &#151; APPROVAL OF AMENDMENT TO 2007 INCENTIVE PLAN</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc336720_6">PROPOSAL 5 &#151; RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc336720_7">STOCKHOLDER PROPOSALS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc336720_8">OTHER MATTERS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">i </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc336720_1"></A>PROPOSAL 1 &#151; ELECTION OF DIRECTORS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors currently is comprised of six members divided into three classes of two directors each. Each director serves for a
term ending on the date of the third annual meeting following the annual meeting at which he or she was elected and until his or her successor is duly elected and qualified. The terms of the current directors in Class I, Richard Chin, M.D. and
Rudolph Nisi, M.D., will expire at the date of the annual meeting in 2014. The terms of the current directors in Class II, Mark J. Ahn and Stephen S. Galliker, will expire at the current Annual Meeting, and the terms of the current directors in
Class III, Sanford&nbsp;J. Hillsberg and Steven A. Kriegsman, will expire on the date of the annual meeting in 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
following is information concerning Dr.&nbsp;Ahn and Mr.&nbsp;Galliker, the nominees for election as directors at the Annual Meeting, as well as the directors whose terms of office will continue after the Annual Meeting. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD WIDTH="50%"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Class&nbsp;of&nbsp;Directors(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Age</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Position</B></FONT></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sanford J. Hillsberg</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">III</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chairman</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark J. Ahn, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer, President, Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Richard Chin, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">III</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stephen S. Galliker</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Steven A. Kriegsman</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">III</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">70</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rudolph Nisi, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">I</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Current Nominees </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We believe that Dr.&nbsp;Ahn and Mr.&nbsp;Galliker will be available and able to serve as directors. In the event that either is unable or unwilling to serve, our board of directors may reduce the number
of nominees or select a substitute nominee. In the latter case, if you have completed, signed and returned your proxy card, Dr.&nbsp;Ahn and Mr.&nbsp;Lee can vote your shares for a substitute nominee. They cannot vote for more than two nominees.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Class II &#151; Term Expiring at the Current Annual Meeting </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Mark J. Ahn, Ph.D.</I> (49)&nbsp;has served as our President and Chief Executive Officer since March&nbsp;31, 2011 and as a director
since 2007 and has served since September 2011 as the President, Chief Financial Officer and sole director of our RXi Pharmaceuticals Corporation subsidiary, which we refer to as &#147;<B>RXi</B>.&#148; Dr.&nbsp;Ahn is also an&nbsp;adjunct
Professor, Biosciences at Creighton University.&nbsp;He brings more than 20 years of experience in the biopharmaceutical industry. Prior to joining Galena, starting in&nbsp;2011, Dr.&nbsp;Ahn was Principal at Pukana Partners, Ltd., which provides
strategic consulting to life science companies and&nbsp;an Associate Professor, Global Management at Atkinson Graduate School of Management, Willamette University. He previously served as Professor and Chair, Science&nbsp;&amp; Technology
Management, Victoria University at Wellington, New Zealand. Dr.&nbsp;Ahn was also founder, President, and Chief Executive Officer of Hana Biosciences. Prior to joining Hana, he served as Vice President, Hematology and corporate officer at Genentech,
Inc., and held positions of increasing responsibility at Amgen and Bristol-Myers Squibb. Dr.&nbsp;Ahn also serves on public and venture capital-backed board of directors for RXi Pharmaceuticals, Access Pharmaceuticals, Mesynthes and ScribesSTAT.
Dr.&nbsp;Ahn is the author of over 50 peer reviewed journal articles and books. Dr.&nbsp;Ahn received a B.A. and M.B.A. from Chaminade University; and M.A. from Victoria University. He was a graduate fellow in Economics at Essex University, and
obtained a Ph.D. from the University of South Australia. Dr.&nbsp;Ahn is a Henry Crown Fellow at the Aspen Institute. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our
board of directors believes that Dr.&nbsp;Ahn is qualified to serve as a member of the board because of Dr.&nbsp;Ahn&#146;s extensive prior experience as both an executive and director of a number of pharmaceutical and biotech companies and his
scientific and academic qualifications as well as his expertise in financial and other related matters pertaining to the operation of publicly traded pharmaceutical companies. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Stephen Galliker, CPA</I> (65)&nbsp;has served as a director since 2007.
Mr.&nbsp;Galliker served as the Executive Vice President, Finance and Administration, and Chief Financial Officer of Dyax Corp., a biopharmaceutical company focused on advancing novel biotherapeutics for unmet medical needs, from 1999 until his
retirement in July 2008. From 1996 to 1999, Mr.&nbsp;Galliker was the Chief Financial Officer of Excel Switching Corporation, a developer and manufacturer of open switching platforms for telecommunications networks, and was Excel&#146;s Vice
President, Finance and Administration from 1997 to 1999. From 1992 to 1996, Mr.&nbsp;Galliker was employed by Ultracision, Inc., a developer and manufacturer of ultrasonically powered surgical instruments, where he served as Chief Financial Officer
and Vice President of Finance until 1995, when he became Ultracision&#146;s Chief Operating Officer. Mr.&nbsp;Galliker is also a director of Mitomics, Inc. Incorporated, a privately owned medical device company. Mr.&nbsp;Galliker was also a director
of Osteotech, Inc., a medical device company, until its merger into Medtronic, Inc. in November, 2010. Mr.&nbsp;Galliker is a Certified Public Accountant and received a B.S. from Georgetown University and an M.B.A. from the University of Chicago.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors believes that Mr.&nbsp;Galliker is highly qualified to serve as a member of the board because of
Mr.&nbsp;Galliker&#146;s extensive prior experience as the Chief Financial Officer of a pharmaceutical company and as a director of a medical device company as well as his expertise in auditing and financial and other related matters pertaining to
the operation of publicly traded pharmaceutical companies. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE &#147;FOR&#148; THE
NOMINEES FOR </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ELECTION AS CLASS II DIRECTORS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Continuing Directors </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following is a description of the directors in
Class III and Class I, whose terms of office will continue after the Annual Meeting. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Class III &#151; Term Expiring at the
2013 Annual Meeting </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Sanford J. Hillsberg, J.D</I>. (63)&nbsp;has served as the Chairman of our board of directors since
2007. Mr.&nbsp;Hillsberg has been an attorney with TroyGould PC since 1976 and is a member of the firm&#146;s Management Committee. Mr.&nbsp;Hillsberg was a founder and until December 2007, served as a director and Secretary of ImmunoCellular
Therapeutics, Ltd., a publicly-held biopharmaceutical company formed to develop cellular therapies, including dendritic cell-based vaccines for the treatment of brain and other cancers, and its predecessor company since February 2004.
Mr.&nbsp;Hillsberg served as a director and Secretary of Duska Therapeutics, Inc., a publicly-held biopharmaceutical company, and its predecessor company from 1999 until January 2006. He previously served as a director and Vice President of Medco
Research, Inc., a then publicly-held pharmaceutical company. Mr.&nbsp;Hillsberg is a member of the Board of Governors of Cedars-Sinai Medical Center and has also previously served as a Commissioner of the Quality and Productivity Commission of the
City of Los Angeles. Mr.&nbsp;Hillsberg holds a B.A. degree from the University of Pennsylvania and a J.D. degree from Harvard Law School. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our board of directors believes that Mr.&nbsp;Hillsberg is highly qualified to serve as a member of the board because of Mr.&nbsp;Hillsberg&#146;s extensive prior experience in founding and serving on the
boards of a number of pharmaceutical and biotech companies as well as his expertise in legal and other related matters pertaining to the operation of publicly traded pharmaceutical companies. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Steven A. Kriegsman</I> (70)&nbsp;has served as a director since 2006. Mr.&nbsp;Kriegsman has been a director and the President and
Chief Executive Officer of CytRx Corporation since July 2002. He previously served as Director and Chairman of Global Genomics from June 2000. Mr.&nbsp;Kriegsman is an inactive Chairman and Founder of Kriegsman Capital Group LLC, a financial
advisory firm specializing in the development of alternative sources of equity capital for emerging growth companies in the healthcare industry. He has advised such companies as SuperGen Inc., Closure Medical Corporation, Novoste Corporation,
Advanced Tissue Sciences, and Maxim Pharmaceuticals. Mr.&nbsp;Kriegsman has a BS degree with honors from New York University in Accounting and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
completed the Executive Program in Mergers and Acquisitions at New York University, The Management Institute. Mr.&nbsp;Kriegsman is a graduate of the Stanford Law School Directors&#146; College.
Mr.&nbsp;Kriegsman was formerly a Certified Public Accountant with KPMG in New York City. He served as a Director and is the former Chairman of the Audit Committee of Bradley Pharmaceuticals, Inc. (NYSE, the company since has been sold). In February
2006, Mr.&nbsp;Kriegsman received the Corporate Philanthropist of the Year Award from the Greater Los Angeles Chapter of the ALS Association and in October 2006, he received the Lou Gehrig Memorial Corporate Award from the Muscular Dystrophy
Association. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Kriegsman has been a guest speaker and lecturer at various universities, including California Institute
of Technology (Caltech), Brown University, and New York University. Mr.&nbsp;Kriegsman has been active in various charitable organizations including the Biotechnology Industry Organization, the ALS Association, the Los&nbsp;Angeles Venture
Association, the Southern California Biomedical Council, the California Health Initiative, and the Palisades-Malibu YMCA, the Carlthorp School, Loyola High School of Los Angeles, and the Westmark School. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors believes that Mr.&nbsp;Kriegsman is highly qualified to serve as a member of the board because of
Mr.&nbsp;Kriegsman&#146;s experience as the Chief Executive Officer of a pharmaceutical company and as a director of a number of pharmaceutical companies, his experience as an investment banker for pharmaceutical and biotechnology companies and his
expertise in financial and other related matters pertaining to the operation of publicly traded pharmaceutical companies. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Class I &#151; Term Expiring at the 2014 Annual Meeting </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Richard Chin, M.D.</I> (45)&nbsp;has served as a director since 2009. Dr.&nbsp;Chin is a physician with extensive expertise in drug development. He has overseen multiple Investigational New Drug
Applications (INDs) and New Drug Applications (NDAs)/Biologic License Applications (BLAs), and has authored a major textbook on clinical trial medicine. Dr.&nbsp;Chin is a biotech entrepreneur.&nbsp;Most recently, starting in 2008, Dr.&nbsp;Chin was
the CEO of OneWorld Health, a nonprofit pharmaceutical company largely funded by the Bill and Melinda Gates Foundation, engaged in developing drugs for neglected diseases in impoverished countries. OneWorld Health became part of PATH in December of
2012.&nbsp;From 2006 to 2008, he was the CEO and President of OXiGENE. From 2004 to 2006, Dr.&nbsp;Chin was at Elan Corporation, where he served, among other roles, as Senior Vice President of Global Development. Dr.&nbsp;Chin has also held various
clinical and scientific roles for Genentech, Inc. between 1999 and 2004, including Head of Clinical Research for the Biotherapeutics Unit, overseeing approximately half of the drugs at Genentech, and began his career at Procter and Gamble
Pharmaceuticals, where he served as Associate Medical Director. He received a B.A. in Biology, magna cum laude, from Harvard University and the equivalent of a J.D. with honors from Oxford University in England under a Rhodes Scholarship.
Dr.&nbsp;Chin holds a Medical Degree from Harvard Medical School and is licensed to practice medicine in California. He is currently on the Adjunct Faculty of UCSF Medical School, and serves on the board of directors of several biotechnology
companies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors believes that Dr.&nbsp;Chin is highly qualified to serve as a member of the board because
of Dr.&nbsp;Chin&#146;s expertise with drug development, his experience as both an executive and director of drug development companies, and his scientific and academic qualifications. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Rudolph Nisi, M.D.</I> (80)&nbsp;has served as a director since January 2009. Dr.&nbsp;Nisi has held various positions at New York
Westchester Square Medical Center (NYWSMC). In addition to having been on the Active Staff in Internal Medicine/Cardiology since 1963, Dr.&nbsp;Nisi was also Director of Medicine since 1975, Chief of Cardiology since 1975, Chairman of Medical
Critical Care Unit since 1975, President of the Medical Board from 1977 to 1978, Chairman of the Board of Trustees since 1983 and from 1976 to 1978, Chairman of the ER Committee since 1984, and Vice-President of Medical Affairs since 1993. In 2011,
Dr.&nbsp;Nisi retired as Chairman of the board of directors at NYWSMC and now currently holds the position of Vice Chairman. Dr.&nbsp;Nisi was the Chairman of the board of Medco Research Inc. Dr.&nbsp;Nisi has also served as an Attending Physician
at New York </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Hospital, a Clinical Assistant Professor of Medicine at Cornell University Medical College and an Assistant Dean at Weill Medical College of Cornell University. Dr.&nbsp;Nisi has also served as a
director of Tempra Technology, Inc., a thermal research and development company, since 1997 and on the boards of Touchtone HMO and New York Presbyterian Hospital. Dr.&nbsp;Nisi holds a B.S. degree from Fordham University and a Doctor of Medicine
degree from the University of Rome Medical School in Rome, Italy and is a fellow in the American College of Cardiology. Dr.&nbsp;Nisi is also a graduate of the Director&#146;s college at Stanford University. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors believes that Dr.&nbsp;Nisi is qualified to serve as a member of the board because of Dr.&nbsp;Nisi&#146;s prior
experience as a practicing physician and owner of a hospital, his prior experience as a director of a number of pharmaceutical and biotechnology companies and his medical and academic qualifications. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Meetings of the Board of Directors and Committees </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our board of directors has a standing Audit Committee, Compensation Committee, and Nomination and Corporate Governance Committee, as well as an ad hoc Strategy Committee. The following table provides
information concerning the current membership of our board committees: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Audit<BR>Committee</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Compensation<BR>Committee</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nomination<BR>and&nbsp;Corporate<BR>Governance<BR>Committee</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Transaction<BR>Committee</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Strategy<BR>Committee</B></FONT></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sanford J. Hillsberg(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="3" VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark J. Ahn, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="3" VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Richard Chin, M.D.(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stephen S. Galliker(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Steven A. Kriegsman(4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rudolph Nisi, M.D.(5)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="3" VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Hillsberg served as the third member of our Audit Committee until May 2011. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Chin was appointed as a member of the Audit Committee in May 2011. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Galliker is the Chairman of the Audit Committee. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Kriegsman is the Chairman of the Compensation Committee, the Transaction Committee, and the Strategy Committee. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Nisi is Chairman of the Nomination and Corporate Governance Committee. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The functions of each of the committees are described below. During fiscal year 2011, our board of directors held 33 meetings. Each director attended at least 75% of all board and applicable committee
meetings for which he or she served as a committee member. Directors are encouraged by our board of directors to attend the Annual Meeting, and all of our directors attended the last year&#146;s Annual Meeting. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Audit Committee </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our board of directors has determined that each of Dr.&nbsp;Chin and Messrs. Galliker and Kriegsman, the current members of our Audit committee, is &#147;independent&#148; under the current independence
standards of the Nasdaq marketplace rules and Rule 10A-3 under the Exchange Act. Mr.&nbsp;Hillsberg served as a member of the Audit Committee until May 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Audit Committee assists our board of directors in fulfilling its oversight responsibilities relating to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the quality and integrity of our financial statements and reports; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the independent registered public accounting firm&#146;s qualifications and independence; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the performance of our independent auditors. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Audit Committee reviews our financial structure, policies and procedures, appoints the
outside independent registered public accounting firm, reviews with the outside independent registered public accounting firm the plans and results of the audit engagement, approves permitted non-audit services provided by our independent registered
public accounting firm, reviews the independence of the auditors and reviews the adequacy of our internal accounting controls. The Audit Committee&#146;s responsibilities also include oversight activities described below under the &#147;Report of
the Audit Committee.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Audit Committee operates pursuant to a written charter, which is available on our website,
<U>www.galenabiopharma.com</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors has determined that Mr.&nbsp;Galliker, the chairman of our Audit
Committee, is an audit committee financial expert. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Audit Committee held eight meetings during 2011. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Report of the Audit Committee </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Audit Committee&#146;s primary duties and responsibilities are: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">appointing, overseeing and, if necessary, replacing the independent auditor; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">assisting our board of directors with oversight of the preparation of our financial statements, our compliance with legal and regulatory requirements,
the independent auditor&#146;s qualifications and independence and the performance of our independent auditor; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">preparing the report the SEC rules require to be included in our annual proxy statement; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">resolving disagreements between management and the auditor regarding financial reporting. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Audit Committee provides assistance to our board of directors in fulfilling its oversight responsibility to the company&#146;s
stockholders, potential stockholders, the investment community, and others relating to our financial statements and the financial reporting process, the systems of internal accounting and financial controls, the internal audit function, the annual
independent audit of our financial statements and the ethics programs when established by our management and our board of directors. The Audit Committee has the sole authority (subject, if applicable, to stockholder ratification) to appoint or
replace the outside auditors and is directly responsible for determining the compensation of the independent auditors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
Audit Committee schedules its meetings with a view to ensuring that it devotes appropriate attention to all of its tasks. In discharging its oversight role, the Audit Committee is empowered to investigate any matter brought to its attention, with
full access to all of our books, records, facilities and personnel, and to retain its own legal counsel and other advisers as it deems necessary or appropriate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As part of its oversight of our financial statements, the Audit Committee reviewed and discussed with both management and its outside auditors our interim financial statements and annual audited financial
statements that are included in our Quarterly Reports on Form 10-Q and Annual Report on Form 10-K, respectively. Our management advised the Audit Committee in each case that all such financial statements were prepared in accordance with accounting
principles generally accepted in the United States of America and reviewed significant accounting issues with the Audit Committee. These reviews included discussion with the outside auditors of matters required to be discussed pursuant to Statement
on Auditing Standards (SAS) No.&nbsp;61 (Communication with Audit Committees), as amended and as adopted by the Public Company Accounting Oversight Board in Rule 3200T. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">BDO USA, LLP (&#147;<B>BDO</B>&#148;) currently serves as our independent registered public accounting firm and audited our financial statements for the year ended December&nbsp;31, 2011. BDO does not
have and has not had any financial </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
interest, direct or indirect, in our company, and does not have and has not had any connection with our company except in its professional capacity as our independent auditors. The Audit
Committee also has selected BDO as our independent registered public accountants for 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Audit Committee discussed with
BDO, which audited our annual financial statements for 2011, matters relating to its independence, including a review of audit and non-audit fees and the letter and written disclosures made by BDO to the Audit Committee pursuant to Public Company
Accounting Oversight Board (United States) Rule 3526. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Audit and non-audit services to be provided by BDO are subject to the
prior approval of the Audit Committee. In general, the Audit Committee&#146;s policy is to grant such approval where it determines that the non-audit services are not incompatible with maintaining the independent registered public accounting
firm&#146;s independence and there are costs or other efficiencies in obtaining such services from the independent registered public accounting firm as compared to other possible providers. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, the Audit Committee reviewed initiatives aimed at strengthening the effectiveness of our internal control structure. As part
of this process, the Audit Committee continued to monitor and review staffing levels and steps taken to implement recommended improvements in internal procedures and controls. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Taking all of these reviews and discussions into account, the Audit Committee recommended to our board of directors that the board approve the inclusion of our audited financial statements in our Annual
Report on Form 10-K for the fiscal year ended December&nbsp;31, 2011, filed with the SEC. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Respectfully
submitted, </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Audit Committee: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stephen S. Galliker, Chairman </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Steven A. Kriegsman </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Richard Chin, M.D. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Compensation Committee </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee is authorized to review and make recommendations to the full board of directors relating to the annual salaries
and bonuses of our officers and to determine in its sole discretion all grants of stock options, the exercise price of each option, and the number of shares to be issuable upon the exercise of each option under our various stock option plans. The
Compensation Committee also is authorized to interpret our stock option plans, to prescribe, amend and rescind rules and regulations relating to the plans, to determine the term and provisions of the respective option agreements, and to make all
other determinations deemed necessary or advisable for the administration of the plans. Our board of directors has determined that each of the current members of the Compensation Committee, Mr.&nbsp;Kriegsman and Drs. Chin and Nisi, is
&#147;independent&#148; under the current independence standards of the Nasdaq marketplace rules. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The executive officers of
our company are responsible for maintaining the employee compensation policies for our company. Included in this role is to ensure that the policies are sufficiently attractive to retain our company&#146;s existing employees and to incentivize
prospective employees. It is also the responsibility of the executive officers to make recommendations to the Compensation Committee regarding compensation adjustments for our company&#146;s employees. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee operates pursuant to a written charter, which is available on our website, <U>www.galenabiopharma.com</U>.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee held three meetings during 2011. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Nomination and Corporate Governance Committee </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Nomination and Corporate Governance Committee assists our board of directors in discharging its duties relating to corporate governance and the compensation and evaluation of the board. Our board of
directors has determined that each of the current members of the Nomination and Corporate Governance Committee, Drs.&nbsp;Chin and Nisi and Mr.&nbsp;Galliker, are &#147;independent&#148; under the current independence standards of the Nasdaq
marketplace rules. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The principal responsibilities of the Nomination and Corporate Governance Committee include: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">identifying individuals qualified to become members of our board of directors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">selecting, or recommending that our board of directors select, the director nominees for the next annual meeting of stockholders;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">developing and recommending to our board of directors a set of applicable corporate governance principles; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">overseeing and evaluating our board of directors and its dealings with management and appropriate committees of the board of directors.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Nomination and Corporate Governance Committee also established a policy under which stockholders may
recommend a candidate for consideration for nomination as a director (which is discussed in greater detail below under &#147;Stockholder Recommendations of Director Candidates&#148;), articulating expectations to each director, reviewing practices
and policies with respect to directors, reviewing functions, duties and composition of the committees of our board of directors, reviewing policies with respect to significant issues of corporate public responsibility, recommending processes for
annual evaluations of the performance of our board of directors and Chief Executive Officer, reporting questions of possible conflicts of interest of board members and overseeing the maintenance and presentation to our board of directors of
management&#146;s plans for succession to senior management positions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Nomination and Corporate Governance Committee
operates pursuant to a written charter, which is available on our website, <U>www.galenabiopharma.com</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Nomination and
Corporate Governance Committee held no meetings in 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Nomination and Corporate Governance Committee has not
established any specific minimum qualifications for director candidates or any specific qualities or skills that a candidate must possess in order to be considered qualified to be nominated as a director. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Qualifications for consideration as a director nominee may vary according to the particular areas of expertise being sought as a
complement to the existing board composition. In making its nominations, our Nomination and Corporate Governance Committee generally will consider, among other things, an individual&#146;s business experience, industry experience, financial
background, breadth of knowledge about issues affecting our company, time available for meetings and consultation regarding company matters and other particular skills and experience possessed by the individual. The Nomination and Corporate
Governance Committee does not have a formal diversity policy. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Transaction Committee </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The <I>ad hoc </I>Transaction Committee was established by our board of directors to advise management on acquisitions, dispositions,
strategic partnerships, capital-raising transactions and similar matters and to report and make recommendations on such matters to our board of directors. The current members of the Transaction Committee are Drs. Nisi and Messrs. Hillsberg and
Kriegsman, with Mr.&nbsp;Kriegsman serving as Chairman. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Transaction Committee met two times in 2011. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Strategy Committee </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The <I>ad hoc </I>Strategy Committee was established by our board of directors to assist our board in fulfilling its responsibilities relating to the development, articulation, and execution of our
company&#146;s long term strategic plan and to report and make recommendations on such matters to our board of directors. The current members of the Strategy Committee are Dr.&nbsp;Nisi and Messrs. Hillsberg and Kriegsman, with Mr.&nbsp;Kriegsman
serving as Chairman. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Strategy Committee met five times in 2011. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;16(a) Beneficial Ownership Reporting Compliance </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our executive
officers and directors and any person who owns more than 10% of our outstanding shares of common stock are required under Section&nbsp;16(a) of the Exchange Act to file with the SEC initial reports of ownership and reports of changes in ownership of
our common stock and to furnish us with copies of those reports. Based on our review of copies of such forms we have received from our executive officers and directors and any greater than ten-percent beneficial owners, we believe that during the
fiscal year ended December&nbsp;31, 2011, all Section&nbsp;16(a) filing requirements applicable to these reporting persons were met in a timely manner, except that reports of two of Mark Schwartz&#146;s transactions were filed late due to
administrative oversight. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Code of Ethics </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have adopted a Code of Ethics applicable to all employees, including the principal executive officer, principal financial officer and principal accounting officer. A copy of our Code of Ethics is
available on our website, <U>www.galenabiopharma.com</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risk Assessment of Compensation Policies and Practices </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2012, the Compensation Committee reviewed the company&#146;s compensation policies and practices for all employees, including executive
officers, and determined that our compensation policies and practices do not create or encourage the taking of risks that are reasonably likely to have a material adverse effect on the company. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Board Leadership Structure and Role in Risk Oversight </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Currently, the positions of Chairman of the Board of Directors and Chief Executive Officer of our company are held by separate individuals, with Mr.&nbsp;Hillsberg serving as Chairman of the Board and
Dr.&nbsp;Ahn serving as President and Chief Executive Officer. Mr.&nbsp;Hillsberg, an independent director, has served as the Chairman of the Board since 2007, and since 2007, we have continuously had a separate Chief Executive Officer. The Chairman
of the Board is appointed by our board of directors on an annual basis. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board currently believes that this structure is
best for our company, as it allows Dr.&nbsp;Ahn to focus on the company&#146;s strategy, business and operations, while enabling Mr.&nbsp;Hillsberg to manage our board of directors and serve as a liaison between the board and the company&#146;s
senior management, led by Dr.&nbsp;Ahn. Additionally, our board currently believes the separation of offices is beneficial, because a separate Chairman can provide the Chief Executive Officer with guidance and feedback on his performance and the
Chairman provides a more effective channel for our board to express its views on management. This structure can also enable Mr.&nbsp;Hillsberg and Dr.&nbsp;Ahn, and the other members of our board, to be better informed and to communicate more
effectively on issues, including with respect to risk oversight matters. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board does not believe that a formal policy separating the positions of Chairman of the
Board and Chief Executive Officer is necessary or desirable. Our board continually evaluates our leadership structure and could in the future decide to combine the Chairman and Chief Executive Officer positions if it believes that doing so would
serve the best interests of our company and stockholders. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Compensation Committee Interlocks and Insider Participation in Compensation
Decisions </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are no &#147;interlocks&#148; as defined by SEC rules with respect to any member of the Compensation
Committee. Mr.&nbsp;Kriegsman (Chairman) and Drs. Chin and Nisi are the current members of the Compensation Committee. None of Mr.&nbsp;Kriegsman and Drs. Chin and Nisi have ever served as an officer of the company or acted in such capacity.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Transactions with Related Persons </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>General </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Audit Committee is responsible for reviewing and
approving, as appropriate, all transactions with related persons, in accordance with its Charter and the Nasdaq marketplace rules. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Policies and Procedures for Related Person Transactions </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Transactions between us and one or more related persons may present risks or conflicts of interest or the appearance of conflicts of
interest. Our Code of Ethics requires all employees, officers and directors to avoid activities or relationships that conflict, or may be perceived to conflict, with our interests or adversely affect our reputation. It is understood, however, that
certain relationships or transactions may arise that would be deemed acceptable and appropriate so long as there is full disclosure of the interest of the related parties in the transaction and review and approval by disinterested directors to
ensure there is a legitimate business reason for the transaction and that the transaction is fair to us and our stockholders. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As noted above, our Audit Committee is responsible for reviewing and approving, if appropriate, all transactions with related persons.
The procedures followed by the Audit Committee to evaluate transactions with related persons require: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">that all related person transactions, all material terms of the transactions, and all the material facts as to the related person&#146;s direct or
indirect interest in, or relationship to, the related person transaction must be communicated to the Audit Committee; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">that all related person transactions, and any material amendment or modification to any related person transaction, be reviewed and approved or
ratified by the Audit Committee, as required by Nasdaq marketplace rules. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Audit Committee will evaluate
related person transactions based on: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">information provided by members of our board of directors in connection with the required annual evaluation of director independence;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">pertinent responses to the Directors&#146; and Officers&#146; Questionnaires submitted periodically by our officers and directors and provided to the
Audit Committee by our management; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">background information on nominees for director provided by the Nominating and Corporate Governance Committee of our board of directors; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any other relevant information provided by any of our directors or officers. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with its review and approval or ratification, if appropriate, of any related
person transaction, our Audit Committee is to consider whether the transaction will compromise standards included in our Code of Ethics. In the case of any related person transaction involving an outside director or nominee for director, the Audit
Committee also is to consider whether the transaction will compromise the director&#146;s status as an independent director as prescribed in the Nasdaq marketplace rules. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">All of our related person transactions will be disclosed in our filings with the SEC in accordance with SEC rules. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Acquisition of Apthera, Inc. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On April&nbsp;13, 2011, we completed
our acquisition of Apthera. Immediately prior to the acquisition, Mark W.&nbsp;Schwartz,&nbsp;Ph.D. served as the President and Chief Executive Officer and a director of Apthera and Robert E.&nbsp;Kennedy, our former Executive Vice President and
Chief Financial Officer, served as the Chief Financial Officer and a director of Apthera. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At the closing of the Apthera
merger, we issued to Apthera&#146;s shareholders shares of our common stock constituting approximately 19.9% of our issued and outstanding shares of common stock immediately prior to the merger. We also issued to the former Apthera shareholders
contingent value rights entitling them to future payments of up to $32 million, in the aggregate, of contingent consideration, based on the achievement of specified development and commercial milestones relating to our NeuVax product candidate
acquired from Apthera. The payment of the contingent consideration is subject to the terms of a contingent value rights agreement between us and the Apthera shareholder representative. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Hillsberg, the Chairman of our Board of Directors, owned approximately 2.4% of the outstanding shares of Apthera at the time of
our acquisition of Apthera, for which he received the same consideration on the same terms and conditions as the other stockholders of Apthera. Our board of directors was fully informed of Mr.&nbsp;Hillsberg&#146;s ownership interest in Apthera
prior to submission of our initial letter of intent to acquire Apthera, and Mr.&nbsp;Hillsberg did not participate in any vote relating to the Apthera acquisition taken by our board of directors. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Director Independence </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rule 5605 of the Nasdaq marketplace rules requires that a majority of our board of directors be comprised of independent directors. In
addition, the Nasdaq marketplace rules require that, subject to specified exceptions, each member of our Audit, Compensation and Nominating and Corporate Governance Committees be independent and that our Audit Committee members also satisfy
independence criteria set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;). Under Rule 5605(a)(2) of the Nasdaq marketplace rules, a director will only qualify as an &#147;independent
director&#148; if, in the opinion of our board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered
independent for purposes of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, our board of directors, or any other board committee: (1)&nbsp;accept, directly
or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries; or (2)&nbsp;be an affiliated person of the listed company or any of its subsidiaries. For purposes of determining whether a lawyer
is eligible to serve on an audit committee, Rule 10A-3 under the Act generally provides that any partner in a law firm that receives payments from the issuer is ineligible to serve on that issuer&#146;s audit committee. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors has determined that all our non-employee directors, including Mr.&nbsp;Hillsberg, are &#147;independent&#148; as
that term is defined under Rule 5605(a)(2) of the Nasdaq marketplace rules. Our board of directors also determined that each of Dr.&nbsp;Chin and Messrs. Galliker and Kriegsman, the current members of our
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Audit Committee, satisfy the higher independence standards for Audit Committee members established by SEC and the Nasdaq marketplace rules. In making such determination, our board of directors
considered the relationships that each such non-employee director has with our company and other facts and circumstances our board of directors deemed relevant in determining independence. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Stockholder Recommendations of Director Candidates </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The policy of the
Nomination and Corporate Governance Committee is that a stockholder wishing to submit recommendations for director candidates for consideration by the Nomination and Corporate Governance Committee for election at an annual meeting of stockholders
must do so in writing to the Corporate Secretary. Such recommendations must be received at our principal executive offices not less than 60 days and not more than 90 days prior to the anniversary date of the immediately preceding annual meeting of
the stockholders. The written recommendation must include the following information: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a statement that the writer is a stockholder and is proposing a candidate for consideration; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the name and contact information for the candidate; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a statement of the candidate&#146;s business and educational experience; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">information regarding the candidate&#146;s qualifications to be a director; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the number of shares of our common stock, if any, owned either beneficially or of record by the candidate and the length of time such shares have been
so owned; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the written consent of the candidate to serve as a director if nominated and elected; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">information regarding any relationship or understanding between the proposing stockholder and the candidate; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a statement that the proposed candidate has agreed to furnish us all information as we deem necessary to evaluate such candidate&#146;s qualifications
to serve as a director. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As to the stockholder giving the notice, the written recommendation must state the
name and address of the stockholder and the number of shares of our common stock which are owned beneficially or of record by the stockholder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Any recommendations in proper form received from stockholders will be evaluated in the same manner that potential nominees recommended by our board members or management are evaluated. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Stockholder Nominations of Directors </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our bylaws specify the procedures by which stockholders may nominate director candidates directly, as opposed to merely recommending a director candidate to the Nomination and Corporate Governance
Committee as described above. Any stockholder nominations must comply with the requirements of our bylaws and should be addressed to: Corporate Secretary, Galena Biopharma, 310 N. State Street, Suite 208, Lake Oswego, Oregon 97034. Such nominations
must be received at our principal executive offices not less than sixty (60)&nbsp;days nor more than ninety (90)&nbsp;days prior to the anniversary date of the immediately preceding annual meeting of stockholders; <U>provided</U>, <U>however</U>,
that if the annual meeting is not held within thirty (30)&nbsp;days before or after such anniversary date, then such nomination shall have been delivered to or mailed and received by the Secretary not later than the close of business on the 10th day
following the date on which the notice of the meeting was mailed or such public disclosure was made, whichever occurs first. Assuming that next year&#146;s annual meeting is held within thirty (30)&nbsp;days before or after the anniversary of this
year&#146;s Annual Meeting, nominations must be received between March&nbsp;16, 2013 and April&nbsp;15, 2013. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Stockholder Communication with Board Members </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stockholders who wish to communicate with our board members may contact us by telephone, facsimile or regular mail at our principal
executive office. Written communications specifically marked as a communication for our board of directors, or a particular director, except those that are clearly marketing or soliciting materials, will be forwarded unopened to the Chairman of the
Board, or to the particular director to which they are addressed, or presented to the full board or the particular director at the next regularly scheduled board meeting. In addition, communications sent to us via telephone or facsimile for our
board of directors or a particular director will be forwarded to our board or the director by an appropriate officer. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Beneficial Ownership
of Galena&#146;s Common Stock </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following tables set forth information with respect to the beneficial ownership of our
common stock as of April&nbsp;20, 2012, the record date for the Annual Meeting, by: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any person known by us to be the beneficial owner of 5% or more of our common stock, including any &#147;group&#148; as that term is defined in the
Exchange Act; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">each current director and each named executive officer identified in the &#147;Summary Compensation Table&#148; under &#147;Executive
Compensation&#148; in this proxy statement who was still serving in such capacity on April&nbsp;20, 2012; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">all of our current directors and current executive officers as a group. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Beneficial ownership is determined in accordance with SEC rules, and generally includes voting or investment power with respect to
securities. Shares of common stock subject to options, warrants and convertible securities that are exercisable or convertible within 60 days are deemed to be outstanding and to be beneficially owned by the person holding the options, warrants or
convertible securities for the purpose of computing the percentage ownership of the person, but are not treated as outstanding for the purpose of computing the percentage ownership of any other person. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless otherwise noted, the information below is based on the number of shares of our common stock beneficially owned by each person or
entity at April&nbsp;20, 2012 and the number of shares subject to any options and warrants granted to these individuals that are exercisable within 60 days of April&nbsp;20, 2012, which are indicated by footnote. The percentage ownership is based on
60,756,503 shares of our common stock outstanding on April&nbsp;20, 2012. An asterisk (*)&nbsp;denotes beneficial ownership of less than 1%. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:89pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name of Beneficial Owner</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount&nbsp;and&nbsp;Nature<BR>of&nbsp;Beneficial&nbsp;Ownership</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percentage</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark J. Ahn,&nbsp;Ph.D.(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">536,249</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kwang S. Lee(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark W. Schwartz,&nbsp;Ph.D.(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">626,413</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Richard Chin,&nbsp;M.D.(4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">287,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stephen S. Galliker(5)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">422,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sanford J. Hillsberg(6)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">789,339</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Steven A. Kriegsman(7)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">817,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rudolph Nisi,&nbsp;M.D.(8)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">466,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All executive officers and directors as a group &#151; 9 persons(9)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,970,501</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes of 474,960 shares of common stock underlying stock options. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes 7,500 shares of common stock underlying stock options. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes 275,828 shares of common stock underlying stock options. Also includes 337,661 shares acquired in the acquisition of Apthera. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of shares of common stock underlying stock options. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes 412,500 shares of common stock underlying stock options. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes 687,500 shares of common stock underlying stock options. Also includes 120,839 shares acquired in the acquisition of Apthera. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes 812,500 shares of stock underlying stock options. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes 462,500 shares of common stock underlying stock options. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes 3,433,288 shares of common stock underlying stock options, including 12,500 shares of common stock underlying stock options for Rosemary Mazanet, our Chief
Medical Officer who joined the Company on a part-time basis on February&nbsp;1, 2012. </FONT></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Executive Officers of Galena Biopharma
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Set forth below is information regarding our current executive officers (other than information relating to Mark J. Ahn,
our President and Chief Executive Officer, which is set forth above under &#147;Continuing Directors&#148;). Each officer&#146;s age is indicated in parentheses after his or her name. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Mark W. Schwartz </I>(57), Executive Vice President and our Chief Operating Officer, joined Galena as part of our acquisition of
Apthera where he had been the President and Chief Executive Officer since January 2010. Prior to joining Apthera, Dr.&nbsp;Schwartz served for five years as President and Chief Executive Officer of Bayhill Therapeutics Inc., a company developing an
innovative DNA vaccine platform for the treatment of autoimmune diseases, where he completed a successful partnership with Genentech for the development of the company&#146;s type 1 diabetes vaccine. He had also served as President and Chief
Executive Officer of Calyx Therapeutics, Inc., as well as positions of increasing responsibilities at DuPont, Trega Biosciences and Incyte Genomics. Dr. Schwartz is on the advisory board of BayBio, is a past board member of the Biotechnology
Industry organization (BIO), and is on the faculty of the San State University in their Master of Biotechnology Program.</FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Kwang S. Lee (39),</I> Vice President, Finance and Corporate Secretary, joined Galena in October 2011. Prior to joining Galena, he was
the Corporate Controller and Sr. Director of Finance for Bayhill Therapeutics from July 2007 until October 2011. He has held various positions within corporate finance and accounting throughout his career focusing on corporate financial strategies,
budgeting, public reporting, and financial controls. Prior to joining Bayhill, he held managerial positions at MeeVee, Inc. and Perlegen Sciences, and was part of the finance team responsible for transitioning Genitope Corporation from a start-up
entity through its successful initial public offering. He is a Certified Public Accountant and holds a B.S. degree in Economics from the California Polytechnic State University at San Luis Obispo, and is a graduate of the Lucas School of Business at
San Jose State University. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Rosemary Mazanet, M.D., Ph.D.</I> (56). Dr. Mazanet has served as the Chief Medical Officer of
our company&nbsp;on a part-time basis&nbsp;since February 2012. She is a life sciences investment professional and executive with management and extensive drug development experience. She has been a partner at Apelles Investment Management, LLC
since&nbsp;2009,&nbsp;and the President of Rosemary Mazanet LLC, a private consulting firm in the life sciences, since&nbsp;2004. Prior to that,&nbsp;Dr. Mazanet was a General Partner, Director of Research and CSO of Oracle Partners, LP, a health
care hedge fund.&nbsp;Dr. Mazanet received her M.D. and Ph.D. from the University of Pennsylvania School of Medicine (where she is a Member of the Penn Medicine Board of Trustees and Executive Committee for the Health System), and trained in
Internal Medicine at the Brigham and Women&#146;s Hospital and Oncology at the Dana Farber Cancer Institute, both in Boston. Dr. Mazanet led Clinical Development teams in Oncology and Infectious Disease at Amgen, Inc. from 1993 to 1998, and has also
served as the CEO of several life sciences companies including Breakthrough Therapeutics, LLC, and Access Pharmaceuticals. She has served as a Director for numerous public and private companies. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc336720_2"></A>EXECUTIVE COMPENSATION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Summary Compensation Table </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table shows the compensation paid or accrued during the fiscal years ended December&nbsp;31, 2011 and 2010 to Mark&nbsp;J. Ahn, Ph.D., and Noah D. Beerman, the only individuals who served as
our principal executive officers during the year ended December&nbsp;31, 2011, and to our two other most highly compensated executive officers who were serving as such as of December&nbsp;31, 2011 and to Anastasia Khvorova, Ph.D. and Pamela Pavco,
Ph.D., who are officers of our RXi Pharmaceuticals Corporation subsidiary, or &#147;RXI.&#148; Pursuant to SEC rules, we are providing compensation information for Mr.&nbsp;Beerman, because he served as our principal executive officer during part of
2011, and for Drs. Khvorova and Pavco, for whom this disclosure would have been required but for the fact that they were no longer serving as executive officers of our company as of December&nbsp;31, 2011. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:97pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name and Principle Position</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Salary</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Bonus</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>($)(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Awards<BR>($)(2)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>All Other<BR>Compensation<BR>($)(3)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark J. Ahn, Ph.D.(4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">320,680</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">157,746</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">670,115</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">225</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,148,766</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Noah E. Beerman(5)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">246,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">411,686</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">658,186</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Former President and Chief Executive Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">376,731</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">90,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,455</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">496,486</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark W. Schwartz, Ph.D.(6)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">235,673</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">108,177</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">224,264</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">213</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">568,327</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Vice President and Chief Operating</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kwang S. Lee(7)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38,077</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36,156</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">124,278</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President of Finance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anastasia Khvorova, Ph.D.(8)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">331,667</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,326</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">389,293</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Scientific Officer, RXi Pharmaceuticals</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Corporation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">283,752</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49,941</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">198,572</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">532,565</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pamela Pavco, Ph.D.(9)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">292,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,255</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">74,190</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">374,245</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President of Pharmaceutical Development,</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">RXi Pharmaceuticals Corporation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">281,197</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38,933</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">203,006</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">523,436</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The year-end bonuses shown in 2010 were accrued at December&nbsp;31, 2010 and paid in March, 2011. Of the bonuses shown in 2011, $300,000 were accrued at
December&nbsp;31, 2011 and paid in February 2012, while $30,504 relate to off-cycle bonuses paid in 2011. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amounts shown reflect the grant date fair value computed in accordance with FASB ASC 718 for the indicated year, adjusted to disregard the effects of any estimate
of forfeitures related to service-based vesting. The assumptions we used in valuing options are described more fully in &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and in the footnotes to
our financial statements incorporated in our annual report on Form 10-K for the year ended December&nbsp;31, 2011. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amounts shown consist of life insurance premiums paid by our company, except as noted in footnote&nbsp;(5). </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Ahn became President and Chief Executive Officer effective March&nbsp;31, 2011. Of the amount shown in the Option Award column, approximately $279,175 relates
to performance-based stock options as explained in the Employment Agreement section below. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Beerman resigned effective March&nbsp;31, 2011. The amount reflected under &#147;All Other Compensation&#148; represents stock compensation paid to
Mr.&nbsp;Beerman in connection with his severance agreement. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Schwartz became our Executive Vice President and Chief Operating Officer effective April&nbsp;13, 2011. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Lee became our Vice President of Finance effective October&nbsp;17, 2011. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Khvorova resigned as our Chief Scientific Officer and became Senior Vice President and Chief Scientific Officer of RXi effective September&nbsp;24, 2011.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Pavco resigned as our Vice President of Pharmaceutical Development and became Vice President of Pharmaceutical Development of RXi effective September&nbsp;24,
2011. </FONT></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Amended and Restated 2007 Incentive Plan </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For information regarding our 2007 Incentive Plan, see the discussion of Proposal&nbsp;4, below, in this proxy statement. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Outstanding Equity Awards </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table shows vested and unvested
option award grants outstanding on December&nbsp;31, 2011 to each of the named executive officers in the summary compensation table: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option Awards</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number
of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>Exercisable</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(#)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>Unexercisable<BR>(#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Exercise<BR>Price<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Expiration<BR>Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark J. Ahn, Ph.D.(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">05/23/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">01/10/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">04/18/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">01/15/2019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.66</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">01/14/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">01/13/2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">174,970</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">225,030</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/31/2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">225,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/31/2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark W. Schwartz, Ph.D.(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,664</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33,336</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">04/13/2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Vice President and Chief Operating Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">250,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">09/07/2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kwang S. Lee(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.76</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10/17/2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President of Finance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pamela Pavco, Ph.D.(4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">145,311</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">05/23/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President of Pharmaceutical</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36,596</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,230</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">04/18/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Development, RXi Pharmaceuticals</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32,312</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,688</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">01/15/2019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Corporation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,273</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,781</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.66</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">01/14/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,625</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.41</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">04/15/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.65</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">09/26/2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Of the stock options shown, all options with an expiration date through January&nbsp;13, 2021 relate to Dr.&nbsp;Ahn&#146;s stock options granted in connection with his
membership on our board of directors prior to his position as the President and Chief Executive Officer. All such options are fully vested as of December&nbsp;31, 2011 and have an expiration date of 10 years from the date of grant. The stock option
grant with an exercise price of $1.38 totaling 400,000 options vests as follows: 100,000 fully vested on March&nbsp;31, 2011 and 300,000 vest in 12 equal quarterly installments beginning on June&nbsp;30, 2011. The stock option grant with a price of
$1.38 totaling 225,000 options is a performance based grant which vests as to, (i)&nbsp;50,000 shares upon our common stock trading at a minimum closing price of $3 for 30 consecutive trading days, (ii)&nbsp;75,000 shares upon our common stock
trading at a minimum closing price of $4 for 30 consecutive trading days and (iii)&nbsp;100,000 shares upon our common stock trading at a minimum closing price of $5 for 30 consecutive trading days, in each case so long as Dr.&nbsp;Ahn remains in
continuous employ through the vesting date. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The stock option grant with an exercise price of $1.28 vests in 12 equal quarterly installments beginning on July&nbsp;13, 2011. The stock option with an exercise price
of $1.00 vested immediately on September&nbsp;7, 2011. Each grant has an expiration date of 10 years from the date of grant and is subject to Dr.&nbsp;Schwartz remaining in our continuous employ through the vesting date. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The stock option grant with an exercise price of $0.76 vests in 16 quarterly installments beginning on January&nbsp;17, 2012 and has an expiration date of 10 years from
the date of grant. The option grant is subject to the employee remaining in our continuous employ through the vesting date. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The stock option agreement with an exercise price of $5.00 is fully vested as of December&nbsp;31, 2011. The stock option grant with an exercise price of $7.50 vests in
16 equal quarterly installments beginning on July&nbsp;18, 2008. The stock option grant with an exercise price of $4.19 vests in 16 equal quarterly installments beginning on April&nbsp;15, 2009. The stock option grant with an exercise price of $5.66
vests in 16 equal quarterly installments beginning on April&nbsp;14, 2010. The stock option grant with an exercise price of $4.41 vests in 16 equal quarterly installments beginning on July&nbsp;15, 2010. The stock option grant with an exercise price
of $0.65 vests and becomes exercisable in three equal installments on the sixth, twelfth and eighteenth month following April&nbsp;1, 2011. All stock option grants will vest and/or become exercisable provided that Dr.&nbsp;Pavco remains in the
employ of RXi Pharmaceuticals. </FONT></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Termination Agreements </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Robert E. Kennedy </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We previously entered into an employment agreement with Mr.&nbsp;Kennedy for a one-year term expiring on April&nbsp;13, 2012. Mr.&nbsp;Kennedy was entitled to receive an initial annual base salary of
$175,000, which was subject to increase to $200,000 upon our completion of a financing transaction with net proceeds of at least $5 million and to $225,000 upon our completion of a financing transaction with net proceeds of at least $7.5 million
during the term of the employment agreement. Our April 2011 underwritten public offering satisfied both of these financing criteria. Pursuant to the employment agreement, Mr.&nbsp;Kennedy was granted a 10-year stock option to purchase 30,000 shares
of our common stock at an exercise price of $1.28 per share. The option vests and becomes exercisable in 12 equal quarterly installments beginning on July&nbsp;13, 2011, provided, in each case, that Mr.&nbsp;Kennedy remains in our continuous employ
through such vesting date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The employment agreement provided that if we were to terminate Mr.&nbsp;Kennedy&#146;s employment
without &#147;cause&#148; (as defined in the employment agreement), then he was entitled to: (i)&nbsp;continue receiving his then current annualized base salary for the remainder of the term of the employment agreement, and (ii)&nbsp;continued
vesting under the option for the duration of the term of the employment agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The employment agreement further provided
that, in the event the parties have not entered into a new employment agreement by October&nbsp;1, 2011, then, upon Mr.&nbsp;Kennedy&#146;s written request, he would be terminated without cause and become entitled to the benefits set forth in the
preceding paragraph. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;23, 2011, Mr.&nbsp;Kennedy resigned as our Vice President and Chief Financial Officer.
He remained as a consultant to our company at current base salary under his former employment agreement and his option continued to vest in the usual way through April&nbsp;13, 2012. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Employment Agreements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Mark J. Ahn, Ph.D. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have entered into an employment agreement with Dr.&nbsp;Ahn under which he was engaged to serve as our President and Chief Executive
Officer. Dr.&nbsp;Ahn&#146;s employment agreement provides for a three-year term expiring on March&nbsp;30, 2014 (the &#147;<B>Term</B>&#148;) and that Dr.&nbsp;Ahn was entitled to receive an initial annual base salary of $400,000. However,
Dr.&nbsp;Ahn&#146;s base salary was subject to reduction to $350,000 if we failed to complete a financing transaction with net proceeds of at least $5 million by September&nbsp;1, 2011, and was subject to increase
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
to $425,000 upon our completion of a financing transaction with net proceeds of at least $7.5 million by September&nbsp;1, 2011. Our April 2011 underwritten public offering satisfied this
financing criterion. Dr.&nbsp;Ahn will also be eligible to receive an annual performance bonus, the amount of which shall be determined by the board of directors in its sole discretion upon the recommendation of the compensation committee thereof,
provided that the amount of such bonus shall in any event be not less than $100,000 for each year of the Term. Pursuant to the employment agreement, Dr.&nbsp;Ahn also received a signing bonus of $100,000 and was granted a 10-year stock option to
purchase 100,000 shares of our common stock at an exercise price of $1.38 per share. The option was fully vested and immediately exercisable upon the date of grant. Further, Dr.&nbsp;Ahn was granted a 10-year stock option to purchase 525,000 shares
of common stock at an exercise price of $1.38 per share. This option will vest and becomes exercisable (i)&nbsp;as to 300,000 shares in eight equal quarterly installments beginning on June&nbsp;30, 2011, (ii)&nbsp;as to 50,000 shares upon our common
stock trading at a minimum closing price of $3.00 per share for 30 consecutive trading days, (iii)&nbsp;as to 75,000 shares upon our common stock trading at a minimum closing price of $4.00 per share for 30 consecutive trading days, and (iv)&nbsp;as
to 100,000 shares upon our common stock trading at a minimum closing price of $5.00 per share for 30 consecutive trading days, provided, in each case, that Dr.&nbsp;Ahn remains in our continuous employ through such vesting date. The option will vest
in full and become exercisable as to all 525,000 shares upon the occurrence of a &#147;Covered Transaction&#148; as such term is defined in our 2007 Incentive Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The employment agreement provides that if we terminate Dr.&nbsp;Ahn&#146;s employment without &#147;cause&#148; (as defined in the employment agreement) during the Term or if he terminates his employment
for &#147;good reason&#148; (as defined in the employment agreement) then he is entitled to: (i)&nbsp;continue receiving his then current annualized base salary and medical benefits for a period of twelve months following such termination (the
&#147;<B>Severance Period</B>&#148;) and (ii)&nbsp;continued vesting for his option for the duration of the Severance Period. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Mark W. Schwartz, Ph.D. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have entered into an employment agreement with Dr.&nbsp;Schwartz for a one-year term expiring on April&nbsp;13, 2012. Dr.&nbsp;Schwartz was entitled to receive an initial annual base salary of
$225,000. Dr.&nbsp;Schwartz&#146;s base salary was subject to increase to $275,000 upon our completion of a financing transaction with net proceeds of at least $5 million and to $300,000 upon our completion of a financing transaction with net
proceeds of at least $10 million during the term of the employment agreement. Our April 2011 underwritten public offering satisfied both of these financing criteria. Pursuant to the employment agreement, Dr.&nbsp;Schwartz was granted a 10-year stock
option to purchase 40,000 shares of our common stock at an exercise price of $1.28 per share. The option vests and becomes exercisable in 12 equal quarterly installments beginning on July&nbsp;13, 2011, provided, in each case, that Dr.&nbsp;Schwartz
remains in our continuous employ through such vesting date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;23, 2011, we amended our employment agreement
with Dr.&nbsp;Schwartz to extend the term of the employment agreement to September&nbsp;23, 2013 and to increase his base annual salary from $300,000 to $350,000. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The employment agreement provides that if we terminate Dr.&nbsp;Schwartz&#146;s employment without &#147;cause&#148; (as defined in the employment agreement), then he is entitled to: (i)&nbsp;continue
receiving his then current annualized base salary for the remainder of the term of the agreement, and (ii)&nbsp;continued vesting under his option for the duration of the term of the agreement. The employment agreement further provides that if in
connection with a change of control of our company during the term of the employment agreement, Dr.&nbsp;Schwartz&#146;s compensation, benefits, title, or duties are reduced, or if Dr.&nbsp;Schwartz is required to relocate more than 50 miles from
his current residence in connection with such change of control, then Dr.&nbsp;Schwartz shall be considered terminated without cause, in which case he shall be entitled to the benefits set forth in the preceding sentence. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Director Compensation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In the discretion of our board of directors, each non-employee director may be paid such fees for his services as a director and be reimbursed for his reasonable expenses incurred in the performance of
his duties as director as our board of directors determines from time to time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth a summary of
the compensation paid to certain of our non-employee directors in 2011: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fees&nbsp;Earned<BR>or Paid in<BR>Cash&nbsp;($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Stock<BR>Awards&nbsp;($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option&nbsp;Awards&nbsp;($)(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>All Other<BR>Compensation&nbsp;($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total&nbsp;($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark. J. Ahn, Ph.D.(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">68,723</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">96,223</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Richard Chin, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">181,700</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">235,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stephen S. Galliker</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">141,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">197,373</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">338,873</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sanford J. Hillsberg</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">97,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">388,768</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">486,268</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Steven A. Kriegsman</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">81,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">486,128</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">567,878</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rudolph Nisi, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">326,078</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">390,328</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amounts included under options awards reflect the grant date fair value computed in accordance with ASC 718 for the indicated year, adjusted to disregard the effects of
any estimate of forfeitures related to service-based vesting. The assumptions we used in valuing options are described more fully under &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and in the
footnotes to our financial statements contained in our Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2011. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Ahn was appointed as our President and Chief Executive Officer effective March&nbsp;31, 2011. As Chief Executive Officer, Dr.&nbsp;Ahn receives no additional
consideration for his services on the board of directors and as such, all fees reflected above were earned prior to such appointment. </FONT></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cash Compensation </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under our director compensation plan, each
director who is not an employee received the following cash compensation for service on our board of directors and committees of our board of directors during 2011: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an annual retainer fee of $20,000 for each director, payable quarterly, </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an annual retainer fee of $10,000 for the chairperson of each committee of our board of directors other than the audit committee, payable quarterly,
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an annual retainer fee of $20,000 for the chairperson of the audit committee of our board of directors, payable quarterly,
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an annual retainer fee of $40,000 for the Chairman of our board of directors, payable quarterly, </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a fee of $1,500 per board meeting attended by the director, such fee payable for meetings attended in person or telephonically,
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a fee of $1,500 per audit committee meeting attended by the chair of the committee, such fees payable for meetings attended in person or
telephonically, </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a fee of $1,250 per audit committee meeting attended by other directors who are members of the committee, such fees payable for meetings attended in
person or telephonically, </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a fee of $1,250 per all other committee meetings attended by the chair of the committee, such fees payable for meetings attended in person or
telephonically, and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a fee of $1,000 per all other committee meeting attended by other directors who are members of the committee, such fees payable for meetings attended
in person or telephonically. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Historically, independent directors have also received an annual grant on options. On
January&nbsp;13, 2011, as part of their annual grants, Messrs. Galliker, Hillsberg and Kriegsman and Drs. Ahn, Chin and Nisi were granted an option of 50,000 shares at an exercise price of $2.31 per share. These options became fully vested at
December&nbsp;31, 2011. These options have a ten-year term and are exercisable for two years following termination of service as a member of our board of directors, unless the director is terminated for cause, in which case the options are
terminated immediately. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;25, 2011, Messrs. Galliker, Hillsberg and Kriegsman and Drs. Chin and Nisi were granted
an option of 100,000 shares at an exercise price of $1.18 per share. These options became fully vested immediately upon grant. These options have a ten-year term and are exercisable for two years following termination of service as a member of our
board of directors, unless the director is terminated for cause, in which case the options are terminated immediately. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
March&nbsp;25, 2011, for their service as a member of the Strategy Committee established by our board of directors in connection with our acquisition of Apthera, Mr.&nbsp;Hillsberg and Dr.&nbsp;Nisi were each granted an option of 100,000 shares at
an exercise of $1.18 per share, which vested immediately upon the grant date. Mr.&nbsp;Kriegsman was granted an option of 200,000 shares at an exercise of $1.18 per share, which vested immediately upon the grant date. These options have a ten-year
term and are exercisable for two years following termination of service as a member of our board of directors, unless the director is terminated for cause, in which case the options are terminated immediately. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In order to facilitate our recent equity financing completed on April&nbsp;14, 2011, we entered into written agreements with all of our
directors temporarily suspending the exercisability of the stock options held by the directors. The directors&#146; stock options again became exercisable when we effected an increase in our authorized shares of common stock following stockholder
approval of the increase at the 2010 annual meeting of stockholders in July 2011. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Reimbursements </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our directors are reimbursed for their expenses incurred in attending board of directors, committee and stockholder meetings, including
those for travel, meals and lodging. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Tax and Accounting Implications </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Deductibility of Executive Compensation </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As part of its role, the Compensation Committee reviews and considers the deductibility of executive compensation under Section&nbsp;162(m) of the Internal Revenue Code of 1986, as amended (the
&#147;Code&#148;), which provides that corporations may not deduct compensation of more than $1.0 million that is paid to certain individuals. We believe that compensation paid to our executive officers generally is fully deductible for federal
income tax purposes. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Accounting for Share-Based Compensation </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We account for share-based compensation in accordance with the requirements of FASB ASC 718. This accounting treatment has not
significantly affected our compensation decisions. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc336720_3"></A>PROPOSAL 2 &#151; APPROVAL OF ISSUANCE OF SHARES OF COMMON
STOCK, AT OUR </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ELECTION, IN SATISFACTION OF FUTURE MILESTONE PAYMENTS TO THE HOLDERS OF </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>OUR OUTSTANDING CONTINGENT VALUE RIGHTS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Background </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On April&nbsp;13, 2011, we acquired Apthera, Inc., or
&#147;<B>Apthera</B>,&#148; pursuant to a merger agreement among us, our wholly owned subsidiary formed for this purpose, Apthera, and Robert E. Kennedy, in his capacity as the representative of Apthera&#146;s shareholders. Pursuant to the merger
agreement, at the closing of the merger we issued to Apthera&#146;s shareholders shares of our common stock constituting approximately 19.9% of our issued and outstanding shares of common stock immediately prior to such issuance. We also issued to
the former Apthera shareholders &#147;<B>contingent value rights</B>&#148; entitling them to future payment of up to $32 million in the aggregate, which we refer to as the &#147;<B>contingent consideration</B>,&#148; based on the achievement of
specified development and commercial milestones relating to our NeuVax product candidate acquired from Apthera. The payment of the contingent consideration is subject to the terms of a contingent value rights agreement between us and the Apthera
shareholder representative. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the contingent value rights agreement, we may pay the contingent consideration, at our
election, in either cash or in shares of our common stock, except that we may not issue any shares in satisfaction of any contingent consideration unless we have first obtained approval of our stockholders in accordance with Rule 5635(a) of the
Nasdaq marketplace rules. Rule 5635(a) of the Nasdaq marketplace rules requires stockholder approval prior to the issuance of securities in connection with the acquisition of another company where, among other things, the number of shares of common
stock to be issued, including shares issued pursuant to an earn-out provision or similar contingency, is or will be equal to or in excess of 20% of the number of shares of common stock outstanding before the issuance of the stock or other
securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The purposes of Proposal 2 are to satisfy the Nasdaq marketplace rules in order to allow us to pay contingent
consideration in shares of common stock and to satisfy our contractual obligations under the first amendment to the contingent value rights agreement described under Proposal 3, below, in which we agreed to undertake to seek stockholder approval at
the Annual Meeting of the issuance of future milestone shares. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Future Contingent Payments </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the contingent value rights agreement, we are obligated to make contingent payments upon the achievement of specified development
and commercial milestones relating to our NeuVax product candidate<B>. </B>These milestones are as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:31pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Milestone</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Event</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Consideration</FONT></P></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Milestone #1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Enrollment of the first patient in our NeuVax PRESENT Phase 3 clinical trial</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">$1 million</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Milestone #2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certain enrollment or analysis accomplishments regarding the clinical trial of NeuVax</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">$1 million</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Milestone #3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Regulatory approval of a new drug application or biologic license application for NeuVax</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">$5 million</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Milestone #4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cumulative net sales for NeuVax exceeding $100 million</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">$10 million</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Milestone #5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cumulative net sales of NeuVax exceeding $300 million</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">$15 million</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If Proposal 2 is approved at the Annual Meeting, we may, in the discretion of our board of directors,
elect to issue shares of our common stock in satisfaction of any and all future contingent consideration that may become due to the holders of our outstanding contingent value rights. If we elect to do so, the shares would be valued for this purpose
at the closing price of our common stock as reported on Nasdaq or other trading market at the time the future contingent consideration becomes due. Except as described under Proposal 3, below, relating to the payment of milestone #1, our board of
directors has made no determination whether we would elect to issue shares in satisfaction of ongoing future, contingent consideration that may become due. Even if Proposal 2 is approved by our stockholders, our board of directors may determine to
pay any future contingent consideration in cash rather than in shares of our common stock, based on our cash on hand, our cash needs, the prevailing market price of our common stock at the time, and other relevant factors. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Hillsberg, the Chairman of our Board of Directors, and Dr.&nbsp;Schwartz, our Executive Vice President and Chief Operating
Officer, hold contingent value rights to receive approximately 2.4% and 7%, respectively, of any contingent consideration paid to the holders of our outstanding contingent value rights in the same manner as the other holders of our outstanding
contingent value rights. As such, they may have an interest in Proposal 2 that is different from our stockholders generally. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The issuance of shares of our common stock in satisfaction of future contingent consideration that may become due to the holders of our
outstanding contingent value rights may result in dilution to our current stockholders. Future sales of shares of our common stock issued in satisfaction of future contingent consideration, or perceptions that those sales could occur, also could
adversely affect the market price of our common stock and our ability to raise capital in the future. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If Proposal 3 is not
approved, we will not be able to issue shares of our common stock in satisfaction of any future, contingent consideration as long as we are subject to the Nasdaq marketplace rules or similar rules of another stock exchange. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>OUR BOARD OF DIRECTORS RECOMMENDS A VOTE &#147;FOR&#148; APPROVAL OF THE </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ISSUANCE OF SHARES OF COMMON STOCK, AT OUR ELECTION, IN SATISFACTION OF FUTURE MILESTONE PAYMENTS TO THE HOLDERS OF OUR OUTSTANDING
CONTINGENT VALUE RIGHTS </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc336720_4"></A>PROPOSAL 3 &#151; APPROVAL OF ISSUANCE OF SHARES OF OUR COMMON
STOCK IN LIEU OF </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CASH&nbsp;PAYMENT OF MILESTONE #1 TO THE HOLDERS OF OUR OUTSTANDING CONTINGENT </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>VALUE RIGHTS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Background </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
February&nbsp;15, 2012, we entered into a first amendment to the contingent value rights agreement relating to the achievement of milestone #1, the enrollment of the first patient in our NeuVax PRESENT Phase 3 clinical trial. Under the amendment, we
agreed, subject to approval of our stockholders, to pay the $1&nbsp;million due upon the accomplishment of milestone #1 by issuing 1,315,789 shares of our common stock, which we refer to as the &#147;<B>initial milestone shares</B>.&#148; The number
of initial milestone shares was determined based on a value of $0.76 per share, which was the closing price of our common stock as reported on Nasdaq on January&nbsp;18, 2012, the day prior to achievement of milestone #1. As discussed under Proposal
2, we are required under Rule 5635(a) of the Nasdaq marketplace rules to obtain stockholder approval of the issuance of the initial milestone shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The number of initial milestone shares will be subject to increase to the extent that the $0.76 price used to determine the initial milestone shares exceeds the closing price of our common stock as of the
most recent trading day prior to the receipt of stockholder approval. Therefore, if our stockholders approve Proposal 3 and the closing price of our common stock as of the most recent trading day prior to the Annual Meeting is less than $0.76, the
actual number of the initial milestone shares will equal the quotient determined by dividing the $1 million milestone #1 amount by the lesser of (1)&nbsp;$0.76 and (2)&nbsp;such closing price of our common stock. In such event, we would issue more
than 1,315,789 in initial milestone shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The number of initial milestone shares is not subject to decrease if the closing
price of our common stock at the time of the Annual Meeting is greater than $0.76. Therefore, if our stockholders approve Proposal 3 and the closing price of our common stock at the time of the Annual Meeting exceeds $0.76, the value of the shares
of common stock issued as initial milestone shares would exceed the $1 million milestone #1. Based on the $1.76 closing price of our common stock as reported on Nasdaq on April&nbsp;16, 2012, the current value of the initial milestone shares is
approximately $2,315,788.60. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The initial milestone shares are being held in the escrow established under the escrow
agreement, dated as of April&nbsp;13, 2011, among us, Computershare Trust Company, N.A., as escrow agent, and the Apthera shareholder representative, pending approval of the issuance of the initial milestone shares by our stockholders as required by
the Nasdaq marketplace rules. If our stockholders approve Proposal 3, the initial milestone shares will be released from escrow to the holders of our contingent value rights and we will prepare to file the resale registration statement described
below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The purposes of Proposal 3 are to satisfy the Nasdaq marketplace rules in order to allow us to release the initial
milestone shares from escrow and to satisfy our contractual obligations under the amendment to the contingent value rights agreement in which we agreed to undertake to seek stockholder approval at the Annual Meeting of the issuance of the initial
milestone shares and future milestone shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If our stockholders do not approve Proposal 3, the initial milestone shares
will be cancelled, and we will pay the $1 million milestone #1 amount in cash within three business days after the Annual Meeting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Whether or not Proposal 3 is approved, we will pay in cash an interest factor of 10%&nbsp;per annum on the $1&nbsp;million milestone #1 from February&nbsp;10, 2012 through the day immediately prior to
release of the milestone shares from escrow or the cash payment of milestone #1, as the case may be, less certain legal fees of the shareholder representative to be paid or reimbursed by us. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Resale Registration Filings </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In the first amendment to the contingent value rights agreement, we agreed that, if Proposal 3 is approved, we will, at our expense (excluding any underwriting commissions and discounts or other brokerage
fees incurred in connection with the resale of the holders of the milestone shares), prepare and file with the SEC within ten business days after shareholder approval a registration statement on Form S-3 or other appropriate form under the
Securities Act for the purposes of registering resale the milestone shares plus a reasonable estimate of future milestone shares associated with the achievement of milestone #2, which is triggered by certain enrollment or analysis accomplishments
regarding the clinical trial, for resale by the holders (the &#147;<B>Resale Registration Statement</B>&#148;). We have not agreed to pay milestone #2 in shares of our common stock, and our board of directors retains the discretion to pay milestone
#2 in cash or, if Proposal 2 is approved at the Annual Meeting, in shares of our common stock. Unless we have a resale registration statement in effect that covers such future milestone shares, we also agreed to prepare and file with the SEC within
ten days following the achievement of each milestone which we determine to pay in shares of our common stock a registration statement on Form S-3 or other appropriate form for the purpose of registering the future milestone shares for resale by the
recipients of such shares (collectively, the &#147;<B>Future Resale Registration Statements</B>&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have agreed to use
commercially reasonable efforts to have the Resale Registration Statement and any Future Resale Registration Statements declared effective by the SEC and to respond to any SEC comments within five business days after receipt of such comments until
the Resale Registration Statement, or any such Future Resale Registration Statements, as the case may be, is declared effective by the SEC. We will maintain the effectiveness of the Resale Registration Statement and any Future Resale Registration
Statements for a period ending on the earlier of: (i)&nbsp;the date on which the initial milestone shares or future milestone shares covered thereby may be sold without any volume restrictions under Rule 144 under the Securities Act; or
(ii)&nbsp;the date on which all initial milestone shares or future milestone shares covered by such Registration Statement have been sold. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If our stockholders do not approve Proposal 3, we will not be required to file a resale registration statement unless and until future milestones are achieved and we decide to pay such milestones in
shares of our common stock, assuming Proposal 2 is approved at the Annual Meeting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The interests of Mr.&nbsp;Hillsberg, the
Chairman of our Board of Directors, and Dr.&nbsp;Schwartz, our Executive Vice President and Chief Operating Officer, in Proposal 3 based on their respective ownership of contingent value rights are discussed above under Proposal 2. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The board of directors makes no recommendation with respect to Proposal 3, because the advisability of such proposal is dependent upon
such factors as the prevailing market price of our common stock and our cash position at the time of the Annual Meeting. Our board of directors cannot predict such factors with reasonable certainty. Therefore, our stockholders should make their own
determinations as to how to vote with respect to Proposal 3. Before deciding how to vote, stockholders should consider the prevailing market price of our common stock and consult with their own brokers and other advisors. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>OUR BOARD OF DIRECTORS MAKES NO RECOMMENDATION WITH RESPECT TO THE </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ISSUANCE OF SHARES OF OUR COMMON STOCK IN LIEU OF CASH PAYMENT OF </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MILESTONE #1 TO THE HOLDERS OF OUR OUTSTANDING CONTINGENT VALUE RIGHTS </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc336720_5"></A>PROPOSAL 4&nbsp;&#151;&nbsp;APPROVAL OF AMENDMENT TO 2007
INCENTIVE PLAN </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Amended and Restated 2007 Incentive Plan of Galena Biopharma, Inc. (formerly RXi Pharmaceuticals
Corporation) (the &#147;<B>2007 Incentive Plan</B>&#148;) was originally adopted by our board of directors on February&nbsp;23, 2007 and approved by our stockholders on June&nbsp;19, 2007. The 2007 Incentive Plan was subsequently amended by our
board of directors with the approval of our stockholders to increase the maximum number of shares of common stock available for issuance under the Plan from 2,750,000 originally to 8,750,000 at present. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On April&nbsp;13, 2012 our board of directors approved and recommended for the approval of our stockholders an amendment to the 2007
Incentive Plan to increase the number of shares of common stock under the 2007 Incentive Plan by 3,750,000 shares, to a total of 12,500,000 shares. If our stockholders approve this proposal, we may make awards of the additional shares under the 2007
Incentive Plan as described below and to register the issaunce of the additional shares under the Securities Act of 1933, as amended. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If stockholders do not approve this proposal, we will not implement the amendment, and any outstanding awards of the additional shares under the 2007 Incentive Plan will terminate and be of no further
force or effect. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of April&nbsp;10, 2012, there were 7,438,137 shares subject to outstanding options under our 2007
Incentive Plan and only 24,717 shares were available for future issuance, without giving effect to the amendment that is the subject of this Proposal 4. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On April&nbsp;13, 2012, the Compensation Committee awarded under the 2007 Incentive Plan to Dr. Mazanet, our Chief Medical Officer, options to purchase 150,000 shares of common stock. The award to
Dr.&nbsp;Mazanet was made subject to stockholder approval of the amendment to the 2007 Incentive Plan and will not be effective if such approval is not forthcoming. Subject to stockholder approval of the amendment, Dr.&nbsp;Mazanet&#146;s stock
option will vest in sixteen equal quarterly installments starting July&nbsp;13, 2012, subject in each case to Dr.&nbsp;Mazanet remaining in our service through such dates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Except for the foregoing award to Dr.&nbsp;Mazanet, no employee, director or consultant has been selected to receive an award under the amendment subject to this Proposal 4 and no term or condition of any
such award has been determined. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors believe that the grant of options and other stock awards is an
important incentive for our company&#146;s employees, officers and directors. Our board anticipates, therefore, that our foreseeable needs under the 2007 Incentive Plan will exceed the number of shares of common stock currently available. The board
of directors believe that our 2007 Incentive Plan is in the best interest of stockholders and our company, as equity awards granted under the plan help to attract, motivate, and retain talented employees and non-employee directors, align employee
and stockholder interests, link employee compensation with company performance, and maintain a culture based on employee stock ownership. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The complete text of the amendment to our 2007 Incentive Plan is attached as Annex A to this proxy statement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A summary of our 2007 Incentive Plan is set forth below. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>General </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The purpose of the 2007 Incentive Plan is to advance the interests of our company by giving stock-based incentives and other incentives to
selected employees, directors and other individuals or entities who provide services to us or our affiliates who, in the opinion of the Administrator (as defined below), are in a position to make a significant contribution to the success of our
company and our affiliates. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Administration </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The 2007 Incentive Plan is administered by the Compensation Committee of our board of directors or by such persons to whom the Compensation Committee may delegate such administration (collectively, with
the Compensation Committee, the &#147;<B>Administrator</B>&#148;). The Administrator has full authority, consistent with the 2007 Incentive Plan, to select who will receive awards, to determine the type of awards to be granted, as well as the
amounts, price, terms and conditions of any awards, to issue shares upon option exercises and interpret option agreements. The Administrator has the right to determine any questions that may arise regarding the interpretation and application of the
provisions of the 2007 Incentive Plan and to make, administer, and interpret such rules and regulations as it deems necessary or advisable. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Participation in the 2007 Incentive Plan </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Employees, directors, consultants and advisors who provide services to us and our affiliates, who, in the opinion of the Administrator, are in a position to make a significant contribution to the success
of our company or its affiliates are eligible to participate in the 2007 Incentive Plan. However, only employees are eligible to receive so-called incentive stock options, or &#147;<B>ISOs</B>.&#148; Approximately 25 employees and directors and
approximately 5 consultants and advisors who provide services to us currently are eligible to receive awards under the 2007 Incentive Plan. The maximum number of shares for which awards may be granted to any participant in any calendar year is the
total number of shares of stock authorized under the 2007 Incentive Plan. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Types of Awards </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Administrator in its discretion, may award (i)&nbsp;stock options, (ii)&nbsp;restricted and unrestricted stock, (iii)&nbsp;stock units
including restricted stock units, (iv)&nbsp;performance awards, (v)&nbsp;stock appreciation rights, (vi)&nbsp;securities convertible into stock or otherwise based on stock, and (vii)&nbsp;cash awards, on such terms and conditions as it determines.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Rules Applicable to Awards </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">No awards may be made after the tenth anniversary of the date the 2007 Incentive Plan was first adopted by the board, but previously granted awards may continue beyond that date in accordance with their
terms. Unless the Administrator expressly provides otherwise, awards may not be transferred other than by will or applicable laws of descent and distribution, and generally only the participant may exercise an award during such participant&#146;s
lifetime. The Administrator may determine the time or times at which an award will vest or become exercisable. Without limiting the foregoing, the Administrator may at any time accelerate the vesting or exercisability of an award, regardless of any
adverse or potentially adverse tax consequences resulting from such acceleration. Immediately upon termination of employment of an employee, the unvested portion of any stock option will terminate and the balance, to the extent exercisable, will
remain exercisable for the lesser of (i)&nbsp;a period of three months (90 days) or (ii)&nbsp;the period ending on the latest date on which such stock option could have been exercised without regard to this provision. The 2007 Incentive Plan
provides exceptions for the vesting of options upon an individual&#146;s death or if the Administrator determines that the termination of employment resulted for reasons that cast discredit on the individual. The Administrator will determine what
will happen with respect to an award granted to a participant that is outstanding upon the cessation of the participant&#146;s service relationship with our company, including disability, death or retirement. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Stock Options </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
Administrator will determine the exercise price, if any, of each award requiring exercise. Unless the Administrator determines otherwise, each stock option will have an exercise price not less than the fair market value of the stock subject to the
stock option, determined as of the date of grant. On April&nbsp;16, 2012, the closing price of our common stock as reported on Nasdaq was $1.76. A stock option intended to be an ISO granted to a
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
person who owns (or by application of attribution rules is deemed to own) more than 10% of the total combined voting power of all classes of stock of our company will have an exercise price equal
to 110% of such fair market value. Awards requiring exercise will have a maximum term not to exceed ten years from the date of grant and will vest, either quarterly or annually and all within four years of grant date. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Effect of Certain Transactions </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In the event of a consolidation, merger, sale or other disposition of stock in which our company is not the surviving corporation or that results in the acquisition of all our company&#146;s then
outstanding common stock, or sale of substantially all of our company&#146;s assets or a dissolution or liquidation of our company, the Administrator may provide for the assumption or substitution of some or all outstanding awards by the acquirer or
survivor. If the holders of stock will receive a payment upon consummation of the transaction, the Administrator may provide for a &#147;cash-out&#148; payment with respect to some or all awards or any portion thereof, equal to the excess, if any,
of (a)&nbsp;the fair market value of one share of stock times the number of shares of stock subject to the award or such portion, over (b)&nbsp;the aggregate exercise or purchase price, if any, under the award or such portion (in the case of a stock
appreciation right, the aggregate base value above which appreciation is measured), on such payment and other terms as the Administrator determines. In the absence of an assumption, substitution or cash-out, each award requiring exercise will become
fully exercisable, and delivery of shares of stock deliverable under each outstanding award will be accelerated and such shares will be issued prior to the transaction on a basis that gives the participant a reasonable opportunity, as determined by
the Administrator, following exercise of the award or delivery of the shares, as the case may be, to participate in the transaction as a stockholder. Any shares of stock so issued with respect to an award, in the discretion of the Administrator, may
contain such restrictions as the Administrator deems appropriate to reflect any performance or other vesting conditions to which the award was subject. All such awards will terminate upon consummation of such transaction. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Equitable Adjustment </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In
the event of a change in the outstanding common stock resulting from a stock dividend, stock split, recapitalization, or other capital change, the aggregate number of shares available under the 2007 Incentive Plan, the number of shares available for
individual awards, the terms of outstanding awards, including stock option exercise prices, will be appropriately adjusted by the Administrator. The Administrator may also make adjustments in other circumstances if it determines that the adjustments
are necessary to avoid distortion in the operation of the 2007 Incentive Plan and to preserve the value of awards; provided, however, that no such adjustment shall be made to the maximum share limits, or otherwise to an award intended to be eligible
for the performance-based exception under Section&nbsp;162(m) of the Code, except to the extent consistent with that exception. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Amendment
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to the Administrator&#146;s obligation to exercise its discretion consistent with qualifying awards for the
performance-based exception under Section&nbsp;162(m) if such awards are intended to so qualify, the Administrator may at any time or times amend the 2007 Incentive Plan or any outstanding award for any purpose which may at the time be permitted by
law, and may at any time terminate the 2007 Incentive Plan as to any future grants of awards; provided, that except as otherwise expressly provided in the 2007 Incentive Plan, the Administrator may not, without the participant&#146;s consent, alter
the terms of an award so as to materially and adversely affect the participant&#146;s rights under the award, unless the Administrator expressly reserved the right to do so at the time of such award. Any amendments to the 2007 Incentive Plan shall
be conditioned upon stockholder approval only to the extent, if any, such approval is required by law (including the Code and applicable stock exchange requirements). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Certain Federal Income Tax Consequences </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following discussion summarizes certain U.S. federal income tax consequences of the issuance and receipt of options under the 2007
Incentive Plan under the law as in effect on the date of this proxy statement. The 2007 Incentive Plan provides for the grant of ISOs and NSOs, as well as other awards. The summary does not purport to cover federal employment tax or other federal
tax consequences that may be associated with the 2007 Incentive Plan, nor does it cover state, local or non-U.S. taxes. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Incentive Stock Options </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">An optionee realizes no taxable income upon the grant or, for regular tax purposes, upon the exercise of an ISO. However, the exercise of an ISO increases the optionee&#146;s alternative minimum taxable
income by an amount equal to the excess (at the time of exercise) of the fair market value of the shares acquired upon exercise over the exercise price and this increase may give rise to an alternative minimum tax liability. With certain exceptions,
a disposition of shares purchased under an ISO within two years from the date of grant or within one year after exercise produces ordinary income to the optionee (and a deduction to our company) equal to the value of the shares at the time of
exercise less the exercise price. Any additional gain recognized in the disposition is treated as capital gain for which our company is not entitled to a deduction. If the optionee does not dispose of the shares until after the expiration of these
two and one year holding periods, any gain or loss recognized upon a subsequent sale is treated as a long-term capital gain or loss for which our company is not entitled to a deduction. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Nonqualified Stock Options </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In general, in the case of a so-called nonqualified stock option, or &#147;<B>NSO</B>,&#148; the optionee has no taxable income at the time of grant but realizes income in connection with the exercise of
the option in an amount equal to the excess (at the time of exercise) of the fair market value of the shares acquired upon exercise over the exercise price; a corresponding deduction is available to our company; and upon a subsequent sale or
exchange of the shares, any recognized gain or loss after the date of exercise is treated as capital gain or loss for which our company is not entitled to a deduction. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In general, an ISO that is exercised by the optionee more than three months after termination of employment is treated as an NSO. ISOs are also treated as NSOs to the extent they first become exercisable
by an individual in any calendar year for shares having a fair market value (determined as of the date of grant) in excess of $100,000. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Equity Compensation Plan Information as of December&nbsp;31, 2011 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:49pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Plan Category</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of&nbsp;Securities&nbsp;to<BR>be Issued Upon<BR>Exercise&nbsp;of&nbsp;Outstanding<BR>Options,
Warrants</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>and Rights</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(a)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted-Average<BR>Exercise of<BR>Outstanding&nbsp;Options,<BR>Warrants and Rights<BR>(b)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of&nbsp;Securities<BR>Remaining Available<BR>for Future
Issuance<BR>Under&nbsp;Compensation<BR>Plans (Excluding<BR>Securities Reflected<BR>in Column (a))</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equity compensation plans approved by security holders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,163,137</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.03</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,299,717</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equity compensation plans not approved by security holders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">TOTAL</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,163,137</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.03</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,299,717</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc336720_6"></A>PROPOSAL 5 &#151; RATIFICATION OF APPOINTMENT OF INDEPENDENT
REGISTERED PUBLIC </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ACCOUNTING FIRM </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Appointment of BDO USA, LLP </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">BDO currently serves as our independent
registered public accounting firm and audited our financial statements for the year ended December&nbsp;31, 2011. BDO does not have and has not had any financial interest, direct or indirect, in our company, and does not have and has not had any
connection with our company except in its professional capacity as our independent auditors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Audit Committee has
reappointed BDO to serve as our independent registered public accounting firm for the year ending December&nbsp;31, 2012. The ratification by our stockholders of the appointment of BDO is not required by law or by our Bylaws. Our board of directors,
consistent with the practice of many publicly held corporations, is nevertheless submitting this appointment for ratification by the stockholders. If this appointment is not ratified at the Annual Meeting, the Audit Committee intends to reconsider
its appointment of BDO. Even if the appointment is ratified, the Audit Committee in its sole discretion may direct the appointment of a different independent registered public accounting firm at any time during the fiscal year if the Audit Committee
determines that such a change would be in the best interests of our company and its stockholders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Audit and non-audit
services to be provided by BDO are subject to the prior approval of the Audit Committee. In general, the Audit Committee&#146;s policy is to grant such approval where it determines that the non-audit services are not incompatible with maintaining
the independent registered public accounting firm&#146;s independence and there are costs or other efficiencies in obtaining such services from the independent registered public accounting firm as compared to other possible providers. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect that representatives of BDO will be present at the Annual Meeting, will have an opportunity to make a statement if they so
desire, and will be available to respond to appropriate questions. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Audit Fees </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The fees for 2011 and 2010 billed to us by BDO for professional services rendered for the audit and quarterly reviews of our financial
statements filed by us with the SEC were $235,600 and $188,300, respectively. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Audit-Related Fees </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Audit-related fees for 2011 billed to us by BDO for professional services rendered in connection with certain registration statements and
other filings related to the acquisition of Apthera, Inc., various financings and the spinoff of RXi Pharmaceuticals Corporation were $172,400.&nbsp;Audit-related fees for 2010 billed to us by BDO for professional services rendered in connection
with certain registration statements filed by us with the SEC were $9,600. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Tax Fees </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The fees for 2011 and 2010 billed to us by BDO for tax compliance, tax advice, and tax planning were $10,500 and $7,500, respectively.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>All Other Fees </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Except as described above, no services were rendered by BDO for 2011 or 2010. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Pre-approval Policies and Procedures </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">It is the policy of our Audit Committee that all services to be provided by our independent registered public accounting firm, including
audit services and permitted audit-related and non-audit services, must be approved in advance by our Audit Committee. Our Audit Committee pre-approved all services provided to us by BDO for 2011. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>THE BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE &#147;FOR&#148; </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RATIFICATION OF THE APPOINTMENT OF BDO USA, LLP AS OUR INDEPENDENT </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>REGISTERED PUBLIC ACCOUNTING FIRM. </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc336720_7"></A>STOCKHOLDER PROPOSALS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any proposal that a stockholder intends to present in accordance with Rule 14a-8 of Exchange Act of 1934 at our next Annual Meeting of
Stockholders to be held in 2013 must be received by us on or before January &nbsp;&nbsp;&nbsp;&nbsp;, 2013. Only proper proposals under Rule 14a-8 which are timely received will be included in the proxy statement in 2012. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc336720_8"></A>OTHER MATTERS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Expenses of Solicitation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will bear the cost of soliciting proxies in
the accompanying form. In addition to the use of the mails, proxies may also be solicited by our directors, officers or other employees, personally or by telephone, facsimile or email, none of whom will be compensated separately for these
solicitation activities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have also engaged Georgeson Inc. to assist in the solicitation of proxies. We will pay Georgeson
Inc. a fee of $7,000 plus certain out-of-pocket expenses and flat fees of $6 per completed proxy solicitation call and $4 per telephone vote. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delivery of Proxy Materials to Households </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Some banks, brokers, and other nominee record holders may be participating in the practice of &#147;householding&#148; proxy statements and annual reports. This means that only one copy of this notice
and/or proxy statement may have been sent to multiple stockholders in your household. If you would prefer to receive separate copies of a proxy statement or annual report either now or in the future, please contact your bank, broker or other
nominee. Upon written request to us at Galena Biopharma, Inc., 310 N. State Street, Suite 208, Lake Oswego, Oregon 97034, Attention: Corporate Secretary, or by telephone at&nbsp;(508)&nbsp;767-3861, we will promptly deliver without charge, upon oral
or written request, a separate copy of the proxy material to any stockholder residing at an address to which only one copy was mailed. In addition, stockholders sharing an address can request delivery of a single copy of annual reports or proxy
statements if they are receiving multiple copies upon written or oral request to us at the address and telephone number stated above. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Miscellaneous </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our
management does not intend to present any other items of business and is not aware of any matters other than those set forth in this proxy statement that will be presented for action at the Annual Meeting. However, if any other matters properly come
before the Annual Meeting, the persons named in the enclosed proxy intend to vote the shares of our common stock that they represent in accordance with their best judgment. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ANNEX A </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Amendment to Galena Biopharma, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Amended and Restated 2007 Incentive
Plan </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The reference in Section&nbsp;4(a) to the 2007 Incentive Plan of Galena Biopharma, Inc. (formerly RXi
Pharmaceuticals Corporation) (the &#147;<B>Plan</B>&#148;) to the maximum number of shares of &#147;Stock&#148; (as defined) that may be delivered in satisfaction of &#147;Awards&#148; (as defined) under the Plan shall be 12,500,000 shares. All
related Plan information also shall be amended accordingly. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g336720g22s07.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">GALENA
BIOPHARMA </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 ADD 5 ADD 6 </FONT></P>
<P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">C123456789 </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext </FONT></P>
<P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">Electronic Voting Instructions You can vote by Internet or telephone! Available 24 hours a day, 7 days a week! </FONT></P>
<P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">Instead of mailing your proxy, you may choose one of the two voting methods outlined below to vote your proxy. VALIDATION
DETAILS ARE LOCATED BELOW IN THE TITLE BAR. </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">Proxies submitted by the Internet or telephone must be received by
1:00 a.m., Eastern Time, on June 15, 2012. Vote by Internet </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">Log on to the Internet and go to
www.envisionreports.com/RXII Follow the steps outlined on the secured website. </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">Vote by telephone Call toll
free 1-800-652-VOTE (8683) within the USA, US territories &amp; Canada any time on a touch tone telephone. There is NO CHARGE to you for the call. Follow the instructions provided by the recorded message. Using a black ink pen, mark your votes with
an X as shown in this example. Please do not write outside the designated areas. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS OF GALENA BIOPHARMA, INC. AND MAY BE REVOKED BY THE STOCKHOLDER PRIOR TO ITS EXERCISE. Annual Meeting Proxy
Card 1234 5678 9012 345 </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">IF YOU HAVE NOT VOTED VIA THE INTERNET OR TELEPHONE, FOLD ALONG THE PERFORATION,
DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">A Election of Directors &#151; The Board of
Directors recommends a vote FOR the listed nominee. </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">1. Nominees 01 &#150; Mark J. Ahn, Ph.D. 02 &#150; Steven
S. Galliker FOR WITHHOLD </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">B. Issues &#150; The Board of Directors recommends a vote FOR the following
proposals. </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">2. Proposal to allow us, at our election, to issue shares of our common stock in satisfaction of
future milestone payments to the holders of our outstanding contingent value rights. </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">3. Proposal to approve
the issuance of shares of our common stock in lieu of cash payment of milestone #1 to the holders of our outstanding contingent value right. 4 Proposal to approve the amendment to our 2007 Incentive Plan. 5 Proposal to ratify the appointment of BDO
USA, LLP as our independent registered public accounting firm for the year ending December 31, 2012. 6. In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting and at any and all
adjournments or postponements thereof. The Board of Directors, at present, knows of no other business to be presented at the meeting. C Non-Voting Items Change of Address &#151; Please print new address below. Meeting Attendance Mark box to the
right if you plan to attend the Annual Meeting.</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">D Authorized Signatures &#151; This section must be completed
for your vote to be counted. &#151; Date and Sign Below </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">Please sign exactly as your name(s) appear(s) hereon.
All holders must sign. When signing in a fiduciary capacity, please indicate full title as such. If a corporation or partnership, please sign in full corporate or partnership name by authorized person. </FONT></P>
<P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">Date (mm/dd/yyyy) &#151; Please print date below. Signature 1 &#151; Please keep signature within the box. Signature 2
&#151; Please keep signature withint eh box. C1234567890 JNT 3 3 C V 0 2 5 5 8 7 1 </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g336720g01c85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g336720g01c85.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0Y^4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````40```&\````&`&<`,``Q
M`&,`.``U`````0`````````````````````````!``````````````!O````
M40`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"^(````!````;P```%$`
M``%0``!J4```"\8`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!1`&\#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U5))))2DDDDE*25#J'6^F]/<VJ^T&]^C,=GOL<3]&*V^[W?REQ_UA
M_P`8EU;CA],:UEX=^EMD/#(/\U_HWV_Z3_!U_P`O_!I3O_6'ZUU=(NKI:&$A
MP-YL<0=GYS,>IFZVV[^7M^S,_P`):L'+^NV?U*P8W3V_9:['!C7<VF3M'N^C
M7_8_[<7'=5Q/M&_K.(7.8]V[,I<2YU3W'Z0<\N?9C6.^A9_@_P":M_,]2Q]7
M\EM63]J=QB5V9`_K5,=94/[5PK:DI]9Z+EC-Z<S(!W,<^UK''4EC+;*JG?\`
M;;&J\L+ZD#9]6,&EQ'JU,_2LD$M+R;FM>/S7>G8QZW4E*22224I))))3_]#U
M5))))2DDDDE/"=1^KC.C];NS*<<9.!U5CZ=A+IJOL]S6^I6YMK*\MP]!CVO_
M`,-Z:Y?(K^K!,MQLC"=_P5@N9_VWD!EG_LPO8+:J[JW5V-W,=H05YI]:^@8V
M#U2RW(R/2QLEQLIK8POL(.MC1N].ANUY_P!-O_X-)3GX3^ET/%F+U.L/`(->
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M4*<OIN;;A9;2R^EVUP[']US/WF/_`#%WGU/^KS<G/RLOJ%8MQ\6JO`JIL`<Q
MSF!EF7N8[VOV9/\`TUN?6CZI8W7;,7)$5Y6-8R7GA](<'6TO_L[G5K9PL1F'
MBLQV&=LESN[GN)?;8?\`C+'.>DI+7774P5UM#&-$-:T0`/(!22224I))))2D
MDDDE/__2[3(^NO3ZLS(P\?"S\]^(_P!*^S#QGW,;8/I5&QOY[5/#^MC<O)KQ
MF](ZI4;7!OJ78KJZV_RK+;'!K&M5#ZB_T_ZS_P#IVN_($#KW5OKIT6W&R;[L
M!^%EYU6*VFNNPV-9:YT?I'N:UVVMOTMJ2GM%B='^M_1.L]2RNFX-CG7XDDEP
MAKVM=Z3[,=T_I:V6>W<@_73JN5B=/KZ;TP_Y7ZN_[+A`<MG^DY)_=9C4^[U/
M\'^C7)]5Q>H=$IZ;E=(Z)E5#ZN.?NRG&K;?C'=]L]5E5CKOT_P#/_0_1;WI*
M?1.I9]'3<#(ZAD;C3BUNMLVB7;6C<[:-%/#RJLW#HS*9]+)K9;7NT.UX#V[O
M[+EA_67.Q^H?47J&=BN#Z,C!LLK</!S)U_E-_.6A]6__`!.]+_\`"='_`)[8
MDIT++&55NML.UC`7.<>P`EQ7-U_XP>A6L%E%6;?4[Z%M>)<YCA^\QVQ;?5O^
M2LW_`,+V_P#4.7(_5C'^M5WU6Z0>CYF+BXXQ@'-OJ=8\OW/EVYKF-:W;M24]
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MJ=5^K&;797UOIV);CMJ<6^H]EM3_`+$]OOV[O<RK^<V?S?Z1)3__T^WS_J-]
M5>HY=F9EX#7Y%QW6/:^RO<?WG-ILK9N4<3Z@_5+#R:LJCI[1=2X/K<ZRUX#A
MJU^RVQ[-S?ZJI.Z[U07VN]<!M>?]F##Z&WT_M`QOH;_MN[T_^#6_UK+NP^GN
MOH(%@LI:"1.C[:JG_P#0>DIF_I6!9U*OJEE6_-IK-55KBX[&.,O].O=Z3'O_
M`#K-GJ*TYK7-+7`%KA!!U!!5'KF7=A=*R,F@AMM;1M<X2!)#=T?R=RJXV9<W
MJN/BC/9G5756N>`*P6FLU;'33^]ZCOI)*;%'U>Z1C])LZ-3C[>G7![7X^YY$
M6:VM:XOWL:[=^8Y97_C;_4L:#I__`(-?_P"EEI]9R<VJW#IQ'/:;WO#_`$VU
MN=#6.L]OVES*_I-1>DGJ)QW_`+1!%@M<*BX,#C7IZ;K&T.?5O_JI*5T[HO3.
MF8)Z?A4BO$.Z:BYSP=_T];7/=[EC#_%Q]56B*Z;ZV=F,R;PT?U6^JC7=;ZFS
M!ZC:S&<\XUM[*\@&L,:*W.:S=6ZQMKMD>[]&MO+RJ<3&LR;S%=32YQ&IT[-'
MYSG?FI*:71OJ]TOHC;6X#'M]8@V.LL?:3M^B`ZYS]OTE9/3,$]3'537^O"G[
M,+I/\T7>MZ>R?3_G/=]!9_0^KY65=9BY['5WN:+J=U3Z@6F/6H;Z[*_5^R6.
M8QUK?ILMJ3]:S<ZC+KKQS:*A1;=:**Z['^QU3?H7N;_I/\'[TE.EFX6)GXMF
M'F5-OQ[F[;*WB00@7=%Z;=TD=&LJ)Z>VME`I#WM_1L#6LK]1CFV[=K/W_>GZ
M/D7Y/3:+\AP?98"[<W;!;)]-WZ,OKW.KV;]BR+>M]69@9&VH'(:+K:LC:?2%
M-1?._P#-^T,<ST?2_/\`4KO_`-*DIZ&JJNFIE-31756T,8QH@-:T;6M:/Y*J
MNZ1TYW5&]7]&,]E9I%[7.:36=?3L8UPKM;_QC$?*R:L3&LR;C%=32YQY.G9O
M\IRQ>G]<SWU95>52[[8VEV5BU.JLJW`#WXK&V5A]SL:W97ZM3?TGJUI*?__4
M]`;_`$__`*X?RK0R?YH_%O\`U07RTDDI^ILC^8L_JG\BH],_G7?U?XKYG224
M_4UG\Y7\3^1$7RJDDI^HC_1[OB_\JED?S0_K-_ZIJ^6TDE/U(_\`I%7P=^0*
M1_GA_4/Y6KY9224_4F+_`#1_K._ZHIC_`$9_P=_%?+B22GZER/YK^TW_`*IJ
M:S^D5?VOR+Y;224__]DX0DE-!"$``````%4````!`0````\`00!D`&\`8@!E
M`"``4`!H`&\`=`!O`',`:`!O`'`````3`$$`9`!O`&(`90`@`%``:`!O`'0`
M;P!S`&@`;P!P`"``-@`N`#`````!`#A"24T$!@``````!P`(``$``0$`_^X`
M#D%D;V)E`&1``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$!
M`0$!`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#_\``$0@`40!O`P$1``(1`0,1`?_=``0`#O_$`'\```("
M`P`"`P`````````````)"`H%!@<"!`$#"P$!`````````````````````!``
M``<!``$#`@(&!@@'`````0(#!`4&!P@`$1()$Q0A-C$BM!5U%D$CM7:V"F&!
M,G,D=!<W1U>'&"@X&1$!`````````````````````/_:``P#`0`"$0,1`#\`
MO\>`>`>`>`>`>`G_`.0;Y5:MQA<J;2V#>B.G2%C@'NH.[[8GL;)#2W`%=R5;
MR.C5Q"4N]XT.0CE"&0E'#)G2HLYRI/Y4'1A:D!36M?-GNW4UD:9ES7"GQ2K6
M^P1M9@I8K@LAK,TI,/D(V/*M,MCGBZDH^<.""*4:FLZ0,/M(^.'J(A8^XOUM
M+<>>JYI+.06EH65N^W0E5E7+@[MU*4FC;EI%#HTD[=J**J.G;^GUEBLJH8QC
M**'$PB(CZ^!*?P#P#P#P#P/_T+_'@'@'@'@1.W_MKG'FV3B:KH=^;.M)LBS5
MK5<CIK9:XZI97LB;Z44VC:5"`XE&Y99P((MG#P&K1980(57W#Z>!6^^0;_,0
MW"LR#K$N48FLP.D,+`D6\7Y5VPOS2@-XB2$'-$:G%H:HV*\R)D/IS*K,9")A
MDA.U;.WSPZBT<%<#JC)BZ,2R]Q8XO-25>L4XWE^C\[FY^1LMLQ*_VJ4%`)UA
M,3\E)6>Y8G<I=<I(N7=*KO(5ZL2*DU#*"Q>R(=>X#TQC3]'4UN343.RP7.-2
MWI$BY?J).+'DN>6.X4&.$!**8&F=$CXAF03![?>X#\!'T#P+NOPC-TX/XRN6
MZ.^=L`N%*I"R-XKJ4BR=S52F+G-2NEQ$1:6+9=9S!3KVH76-D#,W94G2:+U,
M5"%$WIX#7O`/`/`/`/`__]&_QX!X!X!X%4'HOXZXKB;M;1MIIF1M=CYJ[GHN
MDY(>N2DO>DI?%^C-(1;3$5!)7&J3\/?:[5.B)J/=52.D6,HV.Q>648]91-J9
M!%T"'+]7/C*<.OKQN&]'<V2)`]BA\QUN%W*GM3D$?Z[^2=?B:S<7($-^/TAN
M28@!?03F$?<`;[BDWS%GDPVL>2=U9PQFT6<A'2--Z`RV_P"2KV"OS3):*G:K
M.@C&ZID,]`V")=*M)!B]L)6SE!4Y#`8@^O@3&I'QW5NNX7U'UGA5#)T#CEXJ
M=+@Z?S1B]@-N+]S:X;5:AHMCS*)L>?S=R>7#)'%BHT&+YR9XG8FM2>R3)R07
MK8KAZ"JN'>YNN>&.HK)K<DXN25QO=F5EN@<XTIC)P8ZJ$E*/I>5+;HN68)/(
MFQ@^E'2["33;E<Q[A<_M`R"KANL'Z*G)G6^0]DY1$:KDLN*J*Z2"%GJD@=%.
MST>>,E[W$#8V21S_`$EB&`PH+D]S=XB'U43&*(^@2?\``/`/`/`__]*_QX!X
M!X!X&`M%7@;I`2E7L\:WEX*8;_;/V#CW@50I5"+(+(K)&3<,WK-RD19NX1.1
M=LNF15(Y%"%,`4>?E:X#S?`NH+G;M&UQ>B9%L-EE;WG51I=!L-RT.19R2J$A
M<8Q@XERTW*H=A!6:16:H@K8UY%LR4:K&CU"')[P7/7K3S+ELJK(XWAE=<RB1
M2$8:!OR\7MMY:JD`H'?1L!)PT/CD$X5.3ZJ)R5AS(L#C_52!A*4_@=VZ(W*^
M2W$E^I;Z[V5[8;=B;[IUN)IJ2^[CH.H=E<S85G;R..5U[X[]TN&%[^V*@"2:
M39TH)/U1_`.(\'6SY0-O+&0F.,MSZ$IZ#P8S[+0*B3<,@ACN#*"X92#G9X>U
MYG5DG?L/]3ZJK0#B7U$?<`"`7$.`^'-_QZ[1.LZE4>=\7F748=M8Z]A25UB9
M2P-5"&`(2VUN$LZ&'E;E<&!<IF$6X%!4H&0.F;]8`=+X!X!X!X'_T[_'@'@'
M@'@'@*9^8'EVR=2\]4^H5>A2&@O4]0KL2_1@2M#6V@Q=P(YKR.NU%)TLQ2DG
MF=V1S&N9F/7<HM9"HJ3*/JD[%D\9A^>?T%3-6Y<V:^8/L4(ZKF@YY.N868:"
M"YV,@FF;W1L]`.UT6QY2NV!@9-VP=%(4KAJJ0X``B)0"V;\0?Q[1VI[QO>S]
M'TN)NV9XKD^9<-TG.;M!QEEH%JM=,KU+N'1#N8KLXU<QD]'5?:6[@K5-9!5J
M64=.Q.`NF8&(%K*"K\#5H>.KU9A8FO0$0U391,)!QS2*B(QFB'HDTCXYBB@S
M9-D@_P!E-,A2E_H#P,OX!X!X!X!X'__4O\>`>`>`>`>`>`GWY/?B7S/Y!;%@
MVIHJQ=2V7&=(SQ9]9W;999I=L4979A+7K/)]!NFK]TLWBUGCZ$5.0P(OS';G
M$B#Q91,&7XIE4/BN95C.89<S\L.G)2$U-*HE0=6>X6>8D+3>;@_1(8Y4Y*X7
M*:?2;D`,)07=G`!]`#P.I^`>`>`>`>`>!__5LW:'\UG/]5V/8<5S/FCY!.JI
MO!+LXS/6+7R;Q[H>UY[3](CVC=W,T.2M<0HR0+98,CHA7*0)BF!A]4SJ%_6\
M#:\B^5Z,V+3*3F$9\>/RM45Y=IYG!IW/7>)+9EV9U9)P)CNIZZWVW6&/@JY`
MQC5,ZRRBAS+*>T$FZ2[A1)%0&OB/H`B/Z`_$?]7@+#X^^7GBON7H[=N7<!N5
M@F='P9&2D9%Y,P2$34M(KT%<'U"LEMR";"4=JW>J5RVM",W3X&[=$3ND#(BL
MF<3E":/2&]4?EO!-=Z-TM*<6S[$Z!9-(N25:8(2E@/7:K&K2DH6'C7+V.;OI
M$6J!OI)'71*<WH`G#]/@;'CFI5G<LBRW:J4233IVO9U2M/J9)IJFQF"5N^UN
M-M,&259(N'B+.2+&2J0+I$55*FK[B@<P!ZB&WV.PPU2KT[:[&_1BJ]68:4L,
M]*.`4%O&PT*Q7DI1^N"1%%119L6QU#>TIC>TH^@"/X>`E""_S!?"]QBF]ESW
M/^XM*I4D+D\!?:#PYT;8J99V+9RLT&5K\VA2$TW\<HLW.!3B4A@$H@8I3`(`
M$ZN/>]LI[;/>ARO.>CJ:TST((LW(;O@6A8>S?.;%^]#,&=9'0HN'7L[E!*'5
M.[^R(L1D4R/US$%=$#AA=9^2WDG"NT\GX+UZ^N*!NNY9S&Z+E2MAC#-:%;B3
M%OLM+B:8UN!5U&T?>I66J;P6C-XDV1=@5-)%=1TLDW.$H]UV&I<\XCL6_P!]
M)+*T3#\LT#8+HG`,T9&=4J6:U*6NEC+"Q[ATQ0?2QH:%6^V1.NB55;VE$Y`'
MW`'QA&QU+HG#\;Z`H"<LE1-RRO/M@I2<^S2CIU.I:74XFYUPDU'H.GR#&6+#
MS2(.$2++$26]Q0.<`]PA!GOOY=^,?C8NF*4+INT6V-L&XO%S0J=0JQ[.UIM6
M9SL%6WVA:*N5^R_EJCM)BP(H_<D*Y<+'35!%!44C``,S^]9_9_O'[IO]A]M]
MY][]9/[7[3Z7UONOK^[Z7V_T?U_?Z^WV_CZ^G@?_UGO?!B!B;W\Z`&`2F'Y>
M-^,4#^H?JF9Q9DQ_'T'VB00$/]`_AX'*^[NK?FDX3MF'ZC?](X'LF`;MW+CG
M.$9G5$RK7GVD5>G[%:YH\>5S<;':8:(E92#JD&JV6?@R2!=Z<JQ6I""*10G#
M\S_5&H9#@%-Y<Y7>*G[F[_N8\W\PL6)E/OJLC(I,U]HV]^HU-]]#5?%LS>N'
MSF7236"(?NV+E1,R)%1*%?/JG,]^X+IO$^K\7_%QU)0T/A]GKR$KO5AG\!4K
MW2'*<NA-'Z0>7NM4;3)G340U!51W:FAE8]Q^X%))\L9FB8PB@%@;Y*=NSOI/
MX+^P]\R:<;6/.==X.TN^U&5;KM5C*Q%BSIZ_2:O@:+N4FDO&**&:OFPG%1H\
M1514`%$S``2_^-L0_P#SOX._$/\`Z;<R?TA_Y+4KP.I]8B`\L=+@`@/_`,?]
MD_`!]?\`PZL?I^CP*[GQDY_\IMR^+CXYW?$O1G)N+9:SYABFDU"[5C-SU"Y3
M5S&\759_+I2D-98&,BH0D2=F@@U*DJK]5)94Z@@H1-,+$_,M>Z'JV-56'ZLT
MG/\`5]W25G5KI<LMIKN@4%\FO8)-6O-:Y5Y*1EY-DE&U@[)!RHNY4.X>D65+
M[$SD3("$NO.7<1[*^?TW//0M+97G,[S\&UD3?QRYSM)2&EVG<;%2$MM4FF_M
M?UJXUIX?[B.D6IR.&JP?@(D,<A@C9V5T/TK\9?&/9O`'>\S:-OYZV+CWJC*^
M"^_AC5Y![)3<WA.APV><N=7'8M"%B]E.D5!I#640%M9O4!4'ZI'9VP/7^-V[
MU3,_B"X+T:]SC&LTF@_'#R_=+A8Y-04HZ!J]7YGI$Y/S+]0`,8C.,BF*JZ@@
M`B!"#Z`/@5V,N8:SVB?JGY"]B^-?H;M*G?)KGEUPKGBMU.TX?6UN;>#:K)&@
M:`U%'5[]45830]BL[12Y"M$I.2-%V31^B[`[OT\"0'QR;9TKMOQ2?(%\3^Z4
M_0*K\B7'_)FPX3"46=F:NCJ5\S[5\-N#?F6RP;HEQ-".)QFQEX^"4=IRYHY!
M5*/66D"F=B8@?__7M*[U\&_Q8=,:Q<-PV+DZ!GM0T"0++W:S0&B;%G@6>:^B
MF@M.2\+G.AU2O.IQZ1(!<O1:?<NU/518ZAQ$PA@\G^!+XEL2TJD:]GO(4$TO
MV<62+N%)EK)IFV7]C`VJ#<D>P=A;UJ_:59JPXEH1^F1PS679JG:N4R*I"50A
M3`$_)KEC!K)TC2^N+#0D9WH'.,]G\NSV]2\[9Y%&C4^U/#O+.C4:@[FE:179
MZQ`H9N^F6D:E,NF`_9J.C-?ZGP.\/V#&58O(R39M9"-D6KAC(,'K=)TR?,G:
M1T'3-VU7(H@Y:N4%#$43.4Q#D,("`@/@0]I/Q]<B9SRG<^(*9D:<)RQ?HZ^P
M]CR!*Z:$ZA#0VG.WS^[PT)*/K8ZLM5AYE])N5@:Q;UFW:JKJ';D2,<PB$!T_
M\M[\,:1"))<=?323*4B::>_=.D(F0@`4A"$+M`%(0I0```/P`/`9-SKQGS5R
MCAKKFO",R:T_$7R]I7?4.0L-NN[%Z:[%.2TI/9&_3]GG';2835,11!1T9$"&
M$I2E*(AX"RVW^7(^+&+2%E7,WW6I0B:KA1A6ZKUYU%"5V'2<N%7)V</$M=8!
MNP9$56,)$R?@7U\"?'&OQ[<Q\&,+PQYVKUWC3Z*\AGEJD]`UC3-;F71:^@^0
MB&#&5TNTVAY#Q;09-RI]NT,BFJJL)U`.8">T.RK\TXFXZ59=?K4E(W1,?BKG
MG=GHO[[L95DL<>79/17--_ETLN%2.DK<DBO?O#,!D`$/I@N"7]7X&S[-B^4]
M#YA<\7VZA5O3,MT&%<0%OI=KCTI&'F(UQ[3@!DS^U9F_9.$R.&CMN=)VR=))
MKMU$UDR*%#EEOXRYQO7*$?Q!8Z"[7Y@B\TI6.M,RC;QH-?+_`-,<]CX2(J]-
M<V^OVJ,O;V(;Q->:M715I10\DV(=)X9=-98J@2$JM6K=&K%=I5.@HJL5&H04
M36*O6X-DWC(6OUV!8(1<+"Q$<T(DU81D7'-4T$$4RE(DD0I2@``'@<+?<B<\
M2'4,'V>?.T6?3$#G+W(T-1A[#;()]+9L_=KR"E0MT#"SK"IW>*;2*_W+4)E@
M^49N$D54#)G01,0/_]![LGW9U`SO5\?$U!DUAJQWTZY^8UF1:\QA4O\`IHWZ
M]C,2!D\@27)/IA],'I+TX$<LX90QY#V.`$6@**@#<NS]6N.*\_R^A4-TS8V5
MGHN!5Q%=^Q0DFQ8O0=^S#/;*F9HX`4C++5NTNTTC_I25,50OZQ0\#Q[>UFW8
M9RKLNJT-_&Q-MJ5>8KPLO,,49.-AUY.PPT&O,.F#E5)HY+$LY-1R4JP_0]Z0
M"H!B`8HA'_,]BN<=U/D>4-^M:CTY4M'S';K)8V$5!9,TDJ9)YR^R@M;DDGV8
M_162;RQ+D^04(]*=)02%%/T,0?`Z+V-HNSU2S\Z4K&9*W1S_`$^\7B*L04&L
MY/9[<XB:QFECMC=.,;;-/UJEMD"R48D9PH=V1?Z("5(IC#Z>!T?D]YT6[H%I
M_P#<JS?-K0UTVX-*.XFV.?1=JE<L2_=IJC*6^,RRQVFBL+"NJH[(HFQ=>WZ"
M:1CD*H)_4(-6_M?IB"P[L>WPN)6FR*XYIO3=6IFQ1\MBK2D5Z$S*VV"(KCF8
MJ$UH,9>)DM78QY`?>R(67>F2,*15?<7U!H6J:=4<8S:Y:I?)!1A4Z)7G]BFG
M#=NH\?KH,D1.E'Q,<@!G,M.2SD2-6+-$#+O'BR:*13**%*(00X=ZVU+5KC;L
MIZ(KEAJ&BR-;C-ASA*PXWJ6+MGU2E"QS;1\NA&>IU.J/[U(\[6Z781SZ?9IB
MWE(V=BG!B)KG<D*'W]G;7MF>ZS3*UFTCK;6GM<%U_7+PUQ',,DU*]KFHMNR^
M&9+(U_49N'</F2$?;'G_``D*1Y).7!D@*@8`$0"2G'M^O.I<V99H6BRL/.VB
MVQ$G,C.P:M76935?<V*8_DN8<?R5+SU20F9.F%CUY%".>+M&\@HNDF(%(!0!
M==L[8ZSA<$V$&-(BU]0A6F_:E0-C"J2I\F98)DUDNS205LH`0\238JW)UQK7
M$H07(!)%EF$X4JC8DHT9@VK4]+JN.9O=-3N[X[&JT2N2-CF5T43NG:R$>W,H
MFPC&2!3N)*8E7/L;,FJ)3K.W:R:*93*'*406)S[W)NLW6=^KFK9W9%=YA<5M
M/2&&9],8CM>1.+@S95P[JQ8'`Q5TH<;9]+G,9OKJ+AG<Y!LG:DTSGXY9)J#D
M54O`_]&X!'?]^O\`U`D?[1=^!+[1_P`JN?XI6O\`$\-X'N7[\DVO^[\O^P+^
M!%GFK\TS?\!#]O:>!*><_,5,_P"?E_[%=^!MO@<=4_(6A_Q:[_MSWP-DT'\M
M-O[R4S_&$'X'C-?GRA_\K;O[/B_`R+O\Z,_[I2_]KPO@8;+?RLY_O-</\2R?
K@>HI_P!MK)_"+A^U2O@9K0/RN'\=IO\`BZ"\#UK#^?<^_P!S:_V%EX'_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g336720g22s07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g336720g22s07.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X007:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C`M8S`V,"`V,2XQ,S0W-S<L(#(P,3`O,#(O,3(M
M,3<Z,S(Z,#`@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z-$$R-44Q1#,X.3,P,3%%,4(S04,Y0CA%-#4R
M,#%$0T,B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z-$$R-44Q1#(X.3,P
M,3%%,4(S04,Y0CA%-#4R,#%$0T,B('AM<#I#<F5A=&]R5&]O;#TB4%-C<FEP
M=#4N9&QL(%9E<G-I;VX@-2XR+C(B/B`\>&UP34TZ1&5R:79E9$9R;VT@<W12
M968Z:6YS=&%N8V5)1#TB=75I9#HP9#=B93DS-2UD-SDQ+30Y9&0M.&5A9"TX
M-C%C,#-F93AB860B('-T4F5F.F1O8W5M96YT240](G5U:60Z.3DU-60Y-CDM
M830T9"TT8F$T+6$T,V8M,3DY93(W,6(Y93(Q(B\^(#QD8SIC<F5A=&]R/B`\
M<F1F.E-E<3X@/')D9CIL:3Y3=&AA;F%K;W1T:3PO<F1F.FQI/B`\+W)D9CI3
M97$^(#PO9&,Z8W)E871O<CX@/&1C.G1I=&QE/B`\<F1F.D%L=#X@/')D9CIL
M:2!X;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O9G0@5V]R9"`M($Q!1$]#
M4U\R,S$V-S=?,3`\+W)D9CIL:3X@/"]R9&8Z06QT/B`\+V1C.G1I=&QE/B`\
M+W)D9CI$97-C<FEP=&EO;CX@/"]R9&8Z4D1&/B`\+W@Z>&UP;65T83X@/#]X
M<&%C:V5T(&5N9#TB<B(_/O_M`$A0:&]T;W-H;W`@,RXP`#A"24T$!```````
M#QP!6@`#&R5''`(```(``@`X0DE-!"4``````!#\X1^)R+?)>"\T8C0'6'?K
M_^X`#D%D;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!
M`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#_\``$0@#*P)L`P$1``(1`0,1`?_$`1$``0`!!`,!
M`0$````````````'!08("0,$"@(!"P$!```'`0$```````````````$"`P0%
M!@<("1````8"`0(#`P0)#0H*!0(7`@,$!08'`0@`$0D2$Q0A%1;6&)@9,2)6
M%U>7UUC802/4E;8W=SBX.5EY"E$R)%5VEK=XF;EA<4(S-+1U)C8G@9&R)2@Z
ML\5'2*&Q4G)#-46U:"E)1'1EQF>GB*@:$0`"`@$#`@,%`0<,"@H-"@<``0(#
M!!$2!2$&,1,'05$B%`@R87&!D4(C%:&Q4F*R,W.T-746-L&S)#1TM78W=SAR
M0U-CTU0E51=XT9+"TI/#1,0F5F:VUH*#9)349=48"3GP\:3D148G_]H`#`,!
M``(1`Q$`/P#W\<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<
M`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<
M`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<
M`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<
M`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<
M`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<
M`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<
M`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<
M`<`<`<`<`<`<`<`PNN#N!ZKT-+)-$+3L3X85Q-A+=G-U.9G54PJG<Y2623`H
M^Y(TQ_Q18?IS,*CVEN`J/0I,X-5^1@0/%N_;OIWW;W5&I\%BN^5UFU)2BG&/
M^ZSU:5=6O13FXJ3Z0W/4T7O'U*[,[!Q+<[NO-ABX]4'+JI2E-K\BJ$4YVV:=
M7&$9.*ZRVKJ1_J)W"H?N%-Y2TPJ%O,;AR'+F1#7F2*TH9#+#(P2RJI<Y*F)%
MZA*Q-S85,&4!0/5*3AC6]1^7T\'-G]2?27-]-,'"?)Y=61RV1!SMKJ3\NF,G
MMJBK):.R4W"W5[(Q6SIN\3G?HKZ[X7K=F<OD\'@78G;/'W5TTVW27G9-K4I7
M-U0UA5"N#I<5YEDI>;K+;]DV(\Y"=^'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`
M'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`-;.XVWMFT!>M*UI"VJ'+F&Q*]LB5OB
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M*5C\'%1L/5/N<7]=\V98Y+8Y5R-"XQ&!/QXV)CD:52%9)T=\*'`!1BR5KR\$
M%CK)!@H.09$'!A_7(O$#RZW+=K<?@TRLIE:W&4EU:]CJ7[%?LW^H;1ZX?1IZ
M6^F_;F1R_!9?-69-6?FTI778\H[,:?"Q@VH8T'N:Y&_<]='MKT2VRW1K,.[/
MLDP80Y1Q:HC/4UVS2PSU$?E(^CDX7A$:W/*#Y<Q+Z)`L3\<8$/M%A2$`LBR#
M&09NZ.S^,LUW3NZ6./C'P54I_L?'5?B-P[?^A;T@Y5VK(S>>6SEK<9;;\9?F
MX</E<A%]<1_'YU,(M^'EN2T4FI*=+V[CEYUG7PI4PQ^M5#B&GIK/_+<V:0'I
M/?,=S;7H2/+3R=(;EO,Q!4?F`\?C%XS>@P^(/@L./[9P,K(\JR5NWSHPZ->$
MO+U_)\?C?ZAS+TR^D;TT[R[K7!\IE\Q#$_3^)A:UVT1EY5_Z+WRUECR6]?.V
M[7IHM(:Q>CW?M9]QR\YBWW8J=(_6I)E<O\K:V/")FD!8%"=C>M<&Y()RP=)S
M\G&C(MQSR9DO)6,B*3YQC&`#P8R^V>/HE0H2MTMC%O5KVJY]/A_WN/ZOX'>7
MTC^FG;^5VY3A9?,2AR^+C67;[:&XRNIY^R2KTQUHD^+Q]N[=HI6ZM[HN$$3#
MNT[),$H=V5%%JA,2H)'"6@D:A@E(SQ)I'K*JN-<,P1<Q+!DXN4D8)+S@.,!1
M=09P(S]=YD*.S^+LI5DIW:N$GXQ_)O5:_)_8]?O_`'.AT[@/H5](.4X7'Y'(
MS>?5]N'EVM1OQDMU'<4>)@EKB-Z/&;E+KJ[OB34?@,B-B^XC=]36"XQ6-L%<
M*FY)<E>U^4:[L[^H5Y996[-*%Q/&8EDJ,K+@42N'DD>`8+"+&/$`6.N,XWC>
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MHE:I,%8.+GY.&(10@96XP/`<%_K7)\WM;C\?CYY4)6^9&M26KCIJZ'9^Q_9?
MJ?C,GZC_`$:^EO:7IKG=X<;E\U+E,;A\;*A&R['=;LM[=ERTE)1QHRV+)BHI
M*2:I^%MR^,M.T>ZGL3"T3JH:HQ4YQB*O[FE)6%S#)C0B<:]AL'D#(4/!,N(S
ME(H6R0\*D..@AEA!@`@9QD0KC%[2XVZ45.5VCLKCT<?"<I)_D^Z*T,YV3]$G
MI-W%D4U9V9SL8V<KQ.,]EV.OS>=EYE%S6N++XHPQX.M^"DY.2DFDI[F_<$NF
M-P*&R="PUV8X2"/VPZK2U+0_#2EJ(-.$T;:`I@%R0HP!1R`[(C\"&+(S?:'(
M,?:\QM';N#;DV4RE;MC*M+JORH;G^3[_``.8=N?2MZ=\OW1R'"Y.5RRQ<7*X
MRN#C;2I..9ARR+=S>.TVII*&B24>C4GU(XH#N8WY:2Z9)I#'*O3%Q^HRYVBR
MU,DC(&-X%J.PWODA1E3*E>!H/C!S,(\`<!'Z#`0>/S<9-S=\CVMQV)"$JY6M
MRNV/5Q\/F'5^Q\=JU^_U\.AMWJI]''I?V3C\?;Q.7S4Y97//"GYMV/)*I=T7
M\-K';C1TG\K7&>KU7GZRV[/@5CR'NJ[%M4X6QM/&*F&@33;7^.`,.89.)5E#
M:<MM1BD1@A@EX"\J4R.$I!)!>'`2S!FY&$S`@X#7K[1XV="M<[MSKNEXQ\:X
MUM?D_MGK^`V3B?HB])<[MJOF+LWG5E3XWG,AI78^W?QN+QMU"T>*WME/,M5J
MUUE%047%IN4FWAW)+VK>-$O#%'JS4*C(Q4KR(#FRR$XG"J=-E&K'@&`IY0E'
MY!!MDK\)\>+J`)9/BR/PCR.TP.V./R;7"R5NFZQ=&OR':E^3^T6OX33O3;Z0
M?3+N_F)8')Y?,PI6;RE.M=M">W"LYF%3^+&DM6N/HW]-&Y6:*.L=M6K3N+7A
M,(-9$D<X_6Y2^(V$^Q5L+1LT@*3&MS;<\_KT@Q86;)CS#%8F2+)S!"`,`<J1
M#%@.`YP`,F3VU@4W55QE;I.M2?5>/EPG^Q]\G^`L.\?I+]-NW^YN(X?"RN7E
MBY_%4Y-CG;0Y*RSB<'.DH-8\4H^=DV12:;\M16KDG)Y=:&;/6!LXQWBY3]MB
MS:?6UR'5^Q!BR%R0E*&4N#PV2!/<PN3LZB.</7R`X/C+R47Y008\'7&19P_<
M'%8W%68\<=S:MHWO<T^N^4>FB731(X-]3OHQVKZ-<EVUB=K79MU7,=O+.N^9
MG7-QN>9EX^VORZJM*]E$'I+=+<Y/=HTEGKS7CS`.`.`.`.`.`.`.`.`.`.`.
M`.`.`.`.`.`.`.`.`.`.`.`.`.`8[[!;8:]:MM#<ZWE:,;A![Z,9$6C1Z@QR
MFTR6`$$O"&'PII*72>2*1J!@*SZ5*86688#!@@>+&>;)VUVCW%W=E/$X#%G?
M*/VY](U5K]E9;-QK@M-7\4EJD]$S5N[.].VNR..?*=R9,:*.JC%*4[;)?L:J
MH*5EDGT6D8M+5:M+J>?K>/\`M"::O74-3ZUP%N<+#+>4/QJY31RPKQ!&%.J`
M8XQ9U21E8-&W6<])<9)/2$KEF8T$6?59RXX&B2>A>ROIWHY*SYKG<USP%!I.
MB.D++&M%*N5B4K*8/KYCKA&Y_O>M6ED_-O??U)\GP?'*SCN+>+G63C*%65).
M^%*>K>156W&BVU=%3YLYU1_?7"UNNKS-;),,Y#-TVR@+%L&ZJLME[-)16#9#
MZHDUAP.8J`FNJZH+76C%DA')6PG)IK4N3EIFJ1M@/5HRR30+4:3TKVA*/!3_
M`*+9./1AY]$-T84PV4WU+2/GT+VQ?160;<Z9O;)RBZYS\S>I<^/]2^$??'"9
M%N5C3?EY$+9;[L6[1M57?<:W.FQ)0M@FXJ,XV5P]#/9IL6.P/8*DV";R-FA[
M1)M8)8G85$A<TS4GEUZ;$V\U26+0AC&K,*"YR=92&O:-P"0#J(!)Q(.OF*TX
M#.`_4%+)Y^O,R<.$[Y8V73%[4Y>7C8M$O,LEIX063ER@V_;&3\(2:]#_`$I<
M/B=E=H86-FN&/;R+R+OB:CYE]]T:ZH+7363Q\.$DOV\5XRBGZV>>/SV:.`.`
M.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`:+NY
MP,(=N-5_$((?_)>\?[[.,?\`TP:-_N_\7-^[4_DC+7M\ZK]Q:?2[Z-8R?H/W
MOHF__2+AOXCS)KUVV.)Q8ZS&32\?^;FR6/:,./;A1N!UQ[<_9QX<_P#JYL?#
MI_++^!I_\V/5GH578^T:](O^0>W_`&/]CVJ7Y!SBLZLT;G!I?3+ZS=,^,/3/
M_DSJ?GV9Z],^S./_`%\HWI_I;(_V+_MF0:SW)79_TV=S+:]?EK?8_P#G;N8B
M#MWFE"M6*Y"86+&:VI_&,X&'.,YPU[>YSTSC/MZ8Y<]Q_P![6+V^9/\`7H-^
M^K"$UV1G)II_ICE?9_OG:Q!5F'D8"T=3BL?^2<8S_P`X#['SL:V#U^S]CKGI
M_P`?,EB)]?X>7\7F=,[-JMUO^&7]8\GV/_U9Y`RYVY,+^\P/'F`ZYUEM3ICQ
MA]OMV/Q[/;[?;CF&X?IFZOP^:K_\2<&]!H3_`.D1/1Z+O'C?9_,`H8XK+-M7
MT-+STF-B=>@PYZ=)5H[]GV^S^^Q_Z^1Y%/?A_P"PA^YRB/J?78N0[(UB_P"3
M\'V/_BW>!B'9AY&)_)/UXK_QQ56/^<!]G.A;@+'ZO_VOM_XN9C$3^6C_``=G
M\:1WKLZJW^BN'\,OY-Y+V/\`]=:S-?=LTH-SO>!&EXS\YZEL=,C#C/7,CCO3
M'MS]G/,'P:?R,?\`!+?W+/.7TXUV/T\QVHO3^AG+^S_>+RTZ*.*SHPT"P:7D
M/WP8UCQ8&'..OWF+WSTZ]>GV,9Y5Y!/]/R_@Y?VVHSOJ=78OJ5O3B]?T5D>Q
M_P#.W"EGZIFE?.WKD/F%^+-Y3WH'QA\6>N^[=TZ8Z]<]>N.5>4Z\+:UX>1'^
M*LS_`*WPG_T%<N]'I_1K"]G_`+$V$=;`'$^[)#CS2NOWFMHO_O@?U*PJ?K^K
M^IUQR\X]/='^&H_=V&V>E==GSF+\,OZP]N>Q_P#./)F8-KFE8IZL,Y,+QC,,
MV+Z9\8>F>ELH<9Z>W]3/,'B)_/7?[.G^ULX'V/7/^G_,K:_Y0X'V?_=DR$--
MCBLNUG=#2\__``VDB]@PY^U^K<B`NOLS]CP^W_BYD>;_`'NK_"?_`#V1TGZA
M*[%A<-K%_P!<'[/_`&_RB)IH<3BV77J:7^^OIIC_`)P/V<V/L)TQ]G[.>7="
M?RB_@<G]Q2;QVY79_06GX9?R'W9['_S?P9/6V)Q08*ESDTO&/@'7#VY&''V6
M'4OI]G/ZO7'_`*^8_B$_/?\`"7?NL@YEZ&5V/N:>D7_*G/\`L?\`NW<Y<=$F
M%XJ:\>I@/9<\LZ_;!]G7:*Y.GZOZO*.;UR:-/]Q7]IK,/ZFPF^^^VM$_ZNXO
ML_\`9SBC9+V?Q@'$]L_`,(_#L\JQGPBP+IG[TU89Z9Z9STSTSS6>\_W[#_P3
M_P`98>0/KYC*/.=B[DU_Z%Q\?YSY$W"\TL\!C@#@#@#@#@#@#@#@#@#@#@#@
M#@#@#@#@#@#@#@#@#@#@#@#@&#V\&F;!MA$86_,BIOAVQ5"3%HMC6^V#4>#C
MX=848<43RD97P118E2^O9F<V%(GM%CQ>(C(5!0?4IR!8W'L[NW([8RKJK%*W
M@\ZF5&73KTLJG%Q;C[%9!2<JY>_6+^&4C5^Z>V<7N3%J<ML.4Q+H7XUNG6NV
MN2G'KX[).*4U[5U\4M/'=O;-I+2^PTZKJY-8==IT_"<4CPV)I33K)&)^:SS$
M@J0M"'%A48HK252)R0`<,HLKA*E0E*A.,SH+(LXY[M[+XKM_G.S\/N+MO.Y#
M!W5;;%5DSG2K:O@L?D97GUPBY1WJ*C'2,DCYF]\=R=_\#ZB\GV)WIC8/-8D,
MC\S/(Q80NGCW:64?W1B?+7624)J#E*R7YQ2]NJ.[1^8PH`X,]QZG2/7BK;(:
MT\=F,?DMVX<FJ=1M4J)4H\,U#3Z(N-[K71"N"6J9'1(Y$C;W$!2@A:4(.<B9
MN3W+S6.L'B;J.9MQY[ZLB-#HECV)-;_G:YK$2T;5M;KDK(;H2KDF5J^'],^P
M<U]R\MFY7;69?5LNX_S5G1S:9-.54N-</G=)-+RK7?'R[-ED+(RBF1OW!JXI
M1UV69Z;J;:F)5]'M?(A6T5@4,N&+V5%5"]:374#`.=XMJ%1N8P]WDCT@:6Q/
ME2J*8@H2VPHD.,8*$<9JWIQR7-0XRWF>5XRW*R,^^Z=MF/.F:T\ZS\VJ+)US
M4(MS:478Y;V_;HNZ>KG$\-5@X/`<9R57'TX./5&F&1&Z+_>J_BE=5"R#L:VJ
M3EL2<=-=$V_3;VJMT[NFT98*-V9$QV%(FY(!N@FP-=3N%VBRS)$C)QA.T6,J
MA+Z\KF64ED`Z$N:Y.F`Y!QT4^6KQXU/%?5_TVX/!C/NGM/S,7&?Q7X613;CS
MJ;?6>/YT(1LKU^U7"4G7XPUKU5>U^AGK+S_)9D.Q>]U5F92;AC<CBWT9==JB
MNE66J++)TVZ?8MMC%6:;;-MNDK=X'/.AZU'`'`'`'`'`'`'`'`'`'`'`'`'`
M'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`+8>H3#)*X(7:11&,/[HUIE2-M<GI
MA:G1>W(UQJ50M2H5BY*>H2)E9Z$D9H"Q!"8,D&18SD(>E6N^^J+A5.<8-ZM)
MM)M>&J7NU9FN.[C[AX?%MP>)S\S%PKYQG973=97"R4%*,)3A"48RE&,YJ+DF
MXJ4DM%)ZTA?557NIV5+I6\#<E&5"Q7D]?$(^L.RJ<<N&7!3DU0WF#RH79=E?
MG#Z^(WU)OBSGS!]9XYF7!:0ML2T7A)KPTT]OLT6GWE[B^Q>^.],&OR<+E^4I
MJ4(1VPRKXK;7Y?EQTC8EMAY56Q>$?+AIILCIRE5C6Q"%*UDU[""FU"((T3>5
M%&$M"D&!,@1@&F2!08(($%(U)2L9"'&<%IB@_P!Z6#&'S>4Y.;LLWOQ>YZOQ
M?CK]U_C9)/O/O"S)GFV<KR4LRQ:3F\FYSDG*<VI2<]TDY662ZM_%9-^,I:]=
MHJ6JX^H+5L-:0!D5%$)DQ2EIAT=;CRTZ,+@%(06:C;B3`$I0NZO!8<9\(,*3
M>F,>8/K&>9EV+2RVR2^[)OW?=^XOQ(JY_?7>_*U.CD^8Y7)IE*4G&W+OLBY3
M\O=)J=C3<O*JW/Q?EPU^Q'3JG4Q3RGP^HJBMC_`F`C!YT&C!OA1E+R74M('Q
MM8NB8MS3%J0EX^UP>6$S&/&'&<16=FKPNM7_`,N7NT]_NZ?>Z%>OU#[_`*=?
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M&UB&(U.R"RC+%G/4"7/E8Z%_:\F6=FI:*ZU+_92]^OO]_7[_`%+NOU$[_IK5
M57.<Q&I1E%)9F0DE*SSI))6:)2N_.R7@[/C?Q=2I.=8UJ]*1+'BO8.[*QK4S
MD-4Y11A7*1N*,8#$B\1ZI`::):E,+"(LW.?&#(<9#G&<<ECEY4%MA98HZ:=)
M-='XKQ\"SP^\^\..I6/Q_*\E10JY5J->3="*KFFIPTC-+9)-J4?!IM-,^$M6
M5BA:PLB*N8(C9@&@4`:$L1CZ=L">4F5(RS@H"F\"4)I:1<<5@6`=<%G##U\(
MQ8R>7ERGYDK;'/W[GK[_`!U]Z3_`37][=YY.:^1R>7Y.SD'%Q=LLJ^5FCE&;
M6]S<M'*$)-:Z;HQ?C%:<2"I:K:UY+JV5I`&YT3JCEJ=R0PZ.I%Y"U0ZX?3U9
M*Q.W%J"U)SX'"P9@18&)5CS<Y\S[;D99F7..R5MC@UIHY/3333PU]W3[W0GR
MN^N]\W%E@YG,<I=A3@H2KGEWR@X1J\F,7"5CBXJG\THM:*OX$MO0XE=/5(O"
M,*ZK:Z6A,3+D9@5<)C2@(TCF00F<DH\'-@\"3N"9*46>#/VIH"PA%C.`XQ@L
MW,C]FVU=4_M2\5X>WV>PJ4=_]]XK3QN:Y:MJ<)K;F9$=)5N4JY+2Q?%"4I2@
M_&+E)QT;94#ZUKE4G(1JH#"E*1,6L)3)3XLQG)TY+@HPJ7E$$F(1%E%KE6,&
M'!#C&#3,>(77/MY*LK)3<E9--Z:_$_9X>WV>PM*N\>[J+97T\IR,+YN#E*.3
M<I2=<=L&VIZMPC\,&^L8]%HCK-U3U:SB/&TUK`6L2E'AN4";H?'D0E#?AF+C
MN$)V4S<5DU'B/D@0^4+J#T8<$]/+Q@/)I9F7/[=MCZZ]9-]==VOCXZ]?O]?$
MK9??/>V>HQSN8Y2Z,+/,CYF5?/;/S7?O6ZQZ3\]N[<NOFMV:[WJ=<RG:C./$
MJ.JVNC50SVY4)29"8T,\2EG.5J&E0(X39DS)[6H<#S$X^OB)&<8(&<9&+.8_
M.YB6BNMTZ_E2]OC[?;HM??HBK#U`[\KJ5%?-\M&A1LCM69D*.VU1C;'3S--M
MD80C8O":A%2U45IVU]5U@ZE8(<ZY@CB3@I&1@E?$8^K*P0W!0`;R<%J&\P&"
MD(&I+@D/3H7A,5@/3RP=)8Y>7!ZPML3Z^$FO'77V^W5_C90Q>]N\\*?F87+\
MG39NG+6&5?%[K'-S>L9IZS=MCF_&3LGKKOEK]):OK1"G5)$5>0=&E6J3%BQ,
MEB;"G3JUARY2YFJE))2`!9ZDUR6'*!#%C(LGFC,SGQ"SG)Y>5)IRLL;2T^T_
M=I[_`'+3[Q"_O3O')MA?D\MR5E]<%"$I9-TI1@H1K48MS;C%5PC6DM$H1C'[
M*2*S'XE%(D6O*BL9C\9*=5N7-T+C[,W,Q;BXY3D),KUX&Y,F"K6Y2IBR_-,\
M0_++"'KT#C&*=EUUS3NG*;2T6K;T7CHM?!&.Y7GN<YV54^;S,K,G17Y=;OML
MM==>Z4MD'9*6V&Z4I;8Z1W2;TU;+AY3,4.`.`.`.`.`.`.`.`.`.`.`.`.`.
M`.`.`.`.`.`.`.`.`.`.`.`:*N]O4<NS5\2O.CW<R&74F>4E;GND?961'*+$
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M8R,W@^T,?'GBPS;_`"[[-TTX2FVME:<5HGKME*4DTT]J\#Z3YWHMQ7?%&)G]
MVW9"G\O7OIKVQ;ELT>^<E)]>FJ2336BE[3?_`$#I1JSK"C2$4I2T-B3BD)`3
MB4FHC)!-3L8*\DP1TRD1SK),^>'.<C`%2`K.<YZ`QCV<X_W+ZC=[]W1=7/\`
M)9-V(W^\J6RGQU7YFO;6]/8W%O[ING:/I#Z:]BVQRNV.&PL?D8K19#AYN3X:
M/3(MWW)/VQC-1^X92\TDZ..`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`
M.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`
M.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`==2D2+0`*6)4
MZLLL].J++4DEG@+5)#@*4BD`#0C"$]*H*"86/'VP!AP+&<9QC/(QE*+UBVGH
MUT]SZ-?A71D&D_$T>/'9+IL?<&?=L(X)F9ZDL>)JUME4\%&+"4VT1SJ'2-Y7
ML*<LGT)$0LQI95)+VBR('EFJ%7E8R6MR`GL-?J]S#[&K[7R'.?(X]J55^O54
M^7.,8RZZ[ZI23KE[E'7K#5\XCZ:\'3W9/N3'JKA7=6_,@H^-CG%RDO9MLBFI
MK[KTZ2>F\OG'3I`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X
M`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X
M`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X!JVW0W"V>KK:C633;46KJ(F=
MK7]6=[7`XRK8RP+`@]?QF)4@MKAK4M2(%:P2=2)TD4@76(`18AE$IB"D@O%D
M>3,>`"MT?9'<G5W+'8ILFC[:L=@'C<"Y:@I*[KWEUS%J?<RI0RH8]$IW5L*9
M3#5+H)/E0-2K#DM'D8RRS!^$.0*QW%-T;`U3BE10776J&G8/<39JR,5OKE13
MQ)<Q-IDF8XTJ)M:\[EK^66<>Q0&L:\:U"MP78!D`%JI"0+(<*?%@";]*=K87
MNQK'5&R4(1+6%-/V(P,IA+Q@1<DK.R(ZN51NRZOE:4PLA0CDM>SAJ7-2L!A9
M>1C2^8$/EF`SD"-NVWMW(MY-5&+8:4PUE@;R[VCL%7YL;C[DN=FPA+3-[V+4
M+<X%K7$DA4-0]((26L.#D.`EG'B"'[7&.`4?N*[ESS3F!T(*IJGCEQ6]LWM-
M5.J%6QJ;3];6<#;9A:*&6.Z>2S>6M<0G;RBCK4W0U2$8$;6J4&''%],>'`N`
M0U2>RW<JG]KPZ)36G>VNA@ZQX(%.W:J=ZK&M"PF.*)C,"?'&-0$W66+$2!V3
M$8\)1*AQ0I\&C#DTX`<9X!4>X=W))+H?=NG<'1:^RN]X'?R?8M]MD^M3#G.U
M*R@-!Q>!2=\G\+@)9`AV6FC[9+5"YW:$I@78QM1&#0%J5`<)C0+WV%[A,6A-
M;Z(W!KVH@5[UANIN+KMKHSS=LDIXV`B"7>&6^NG<<6-1"G"]]8#8U@KW>IP3
MY:C)I*CRC2A`P!-.]6VL?TEUCL2_'9A5S:1M`&>)U-5S2,>)%<-VS]W1P^HJ
MGC9))2E6<ZSB<NZ-((9))PTB01RH0,ED#Z`1MV\-SI3MQ7=DLMTUNW4;MAK=
M:L@I/9^C&Y]%(V^#S1O`2^Q*0Q9].*3J)'75G5\ZMSVQNF"_)5%*#2@#,RG&
M+(&P7@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@
M#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@
M#@#@#@#@#@#@#@#@#@&I+=S6_;]PW.U-W9U$BE#VB_T54&Q5+2VK;RM.9TXC
M7MMW.55O#;+(_+XC5EL^H/8SJ[.)4(E"$CQA5%C`9GPCQ@#"8';LVLO3=[5#
M9RTM(.W)J6Y4GLDLV-MZ]:#M>3VA?MSBQ7$]B08&\J5VK]1J79*^R"6(UZE6
MXO9H2?=P1!*,&$`<@9K./;TFFP^UFT&QNTL\E$42ND:B6N^G2'72WY]74[J#
M7>/N;-8%C2HVQ(H"(OT9L[82TTI?OXMK-%DF,,C>V"6*"3%)>0/K1_0"P>W_
M`+/W^V4_,G2;:.;',R*Z'=GMJT)C/[MKW<;WH)IL:2HGF4HG9;,X=>,1]$XN
MRQ>\97I'UKQ@!(B5`QX`Q/TGIOO$Z(45C6^$ZQZ*VS$V"V;_`)VP3R1;E6W!
M'UY;+DO*PK>2%.L50:F2Y$U+&DF;A1B"4X*`#]/X^N,BSC`&2_<)UOW"VEU[
MTFFD/KFD5&S&L>W%#;:3JB'6W'Y#5<R-K^.3Z/2^LHW<JFLSG`*=3F<8&G<E
MT9*`<0G,P-.$0@@R!&FHE-;)5'>D5?6?LH]MC4!F>Q'1N?WG1.P$)/L:/P5:
M,EP>$S8R0W3J`N\J]X*VQ/C#<8[HDQR@)8SC`A+\6`,T=@M8;&M#?;MW[,1M
M7%R:\U89]Q4%E)'1R7)I,L/OFLX+$(3F*MQ#6J0N9:9UC:@2_*A4DR03D`B\
M&YSD(0,%=D.SW(U.S&NMQZ?6(S592;7O11^WVSNJ+^%4353Y.:T>W)6[7G0Y
M+>WN&*PMF1-CRJ3R1H3%IF&7",*6*,I7!-D]6!E5LII-8.X&Y%42^X)*"/:C
M:TUC+)'4,9K^:R)@M20[?V8A>(*.Z7)P;$"(J&_>!JQ:K+A2Q&M,<T\BD"AQ
M`).-$FR("&ZS[8LRT_WHKG:75"SK%G,)MJ*/-/[X1;9^_P"T;<F<WAK$VEN-
M!V;7TNGF9BZ'36G9(0J;<MRQ60D41][4ED#(-!G)H&Z7@#@#@#@#@#@#@#@#
M@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@%CR2S*]ASRU1V5S6,QU]?$2
MUQ9FAX>$+>XNB!N4HD:]8A2*3BSE*9&J<DY9@P8R$`S@8S[18Y7JQ<FZ#MIA
M*5<6DVDVDWJTG]_1_B-DXCL[NON#C[^6X/CLS+XS&LA7;;55.==<[(SG"$Y1
M3493C7.44WJU"37@RW7>^:58%GNY\M6!-*[U+DC]&X2AI2J/5,_O;WJG\HY4
M`?G-WN%;YP>G4OTIO7IX!=*L./SK([JZ;''IX1;\=-/QZK3[Z,O@>F'J+RF/
M\WQO!\I?C;*Y[X8ULH[;?*\N6JBUI9Y].Q_E>;#3[2.R5=M/GM*%])LR$&LK
MF,`&YT+D;6)`M&:F:%A84JG"G)1PAI'Y$9C`<YZ@5E9^P,/6#P,U3=;JLWKQ
M6UZKQ7ZZ?XF49^G'?U6=;QEG#<E'D*4W96\>Q3@E*V#<H[=5I*BZ+U]M4UXQ
M9UF&^J4E*HM%&[5@3ZL.1HG$I,U2=I6G&(7(EY4-ZL!9"H8A)UA$>7C+%CV#
M"C-SC^\%TC9Q^=4MUM-D4GIUBUU6FOZZ_&BMRGI?ZC<)2\GE^#Y3&QXV3K<K
M,>V"4ZW5&<6Y17Q0E?2I+Q3MK3^TCH*=CJ#1^5ZJXZX3^>B3N)/G2YE+\U`K
M=4[$F6`\2O'B3'O*LI*`>/M1'F!!C[;.,<F7&<C+PHM>CT^R_%+73\2U^\7-
M/I'ZHY&[R.W^7GMLE6],6YZ3C5*Z4'\/VHTQE8UXJ$7+P15'6\Z:8F_+J\VA
M!6MM"V*7K*]=)FI,EPT(Q.`%;ED\U2$OT2<;2IP,SKX0Y(,ZY^USTDA@9MDM
MD*K'+7311?CTZ??ZK\998/IIZA<GE?(\=PO)WYCNC3LACVREYL]CC7HHZ[Y*
MVO2/B]\?>CZ;;QIQX"YC:K/@SB!E/4IG<2.2M2C#:H1G,J=60MR6I%Z8U,?)
M&\`PBZ9"):3C/_.!ZI8&;#3?58MWAK%]==?#_M7^)^XAE^FOJ!@.F.;PO)U2
MR8QE5OQ[(^9&:NE%PUC\2DL>]IKQ55C_`"'I2#]D*!2J#$BFY:V(5%*$J0Q.
M;+V0!Q:I<Q"DZ-.,L2O`@G*HZ'*TL.?:)+CS,?:^WDZXSD6MRHMTTU^R_8]K
M]G[+I]_H7]7I#ZI75*^GM[F)4RA*2DL6YIQA=\O.2>WPC>U3)^RSX'UZ%:>;
MMJ".KAMC]9D(:'$MT1L@T+C)&M(J"[N)P$Z%L$2<I`9A<K/'@!9?3Q#%G&,8
MZ\DA@9ML=U=5DHZ-ZJ+\%XO[R,=Q_IQW]RV,LSC.&Y+(Q'3.Y3KQ[)1\JM.4
M[-5%K9%)N4O!+Q.-%>5-N3*3(V^T(*L8%"DE&0\)I*U'-IJI0@6NA"<M6!3D
MD9QK:W*#PAQGKDHD8OL!SGB6!FQGY4JK%8EKIM>OBE^NTOPD^3Z:^H.'R,N(
MRN%Y.OE(P<G5+'L5BC&<*W)Q<=4E99"#>G24XKQ:.NU7[23Z[$,+-:\`='I2
MM,;4[4AE+0I7G.!,@'%#4124I4(T:DN3%B09!C'BPKQDK^_]G(SX[/KAYDZ;
M%6EKJXO333=K_P!KU^\5<[TN]1^-P9<GR'!\I3QT*U9*R>-;&"@Z%DJ;DXZ*
M+QVKT]=/*>_[/4Z[CL/1#26::Z6_7;>62A<W,X:N6,Q`"V]F)2*79:,1BL.`
MIFU.O(&<//VI8309%TP+'(QXWD)](4VO5I=(OQ>NB_#H]/O%7$])_4W/DH87
M`<M;.5E=:4<:V3<[G*-4%I'[5DH34%XR<9)>#*LMNFHVY"G<E]E0I&WJR')2
ME6J9&UE)E"=G492NIQ)PU&`&%-RD.2SLXST+'CIGIGDD<',E)PC58Y+3IM?M
MZK\?L+''].N_,O)GAXO#\C9E5RKC*$:+'*,K8[JDTHZIV1^*"_*75'39[YI6
M0Y6!8K5@3N)O;</*[#=)VE7E(TYCA,OPXJ,$JA^4CS%E);AYF>@?1CP;U\&>
MO)I\=G5:>939'5Z+6+77=MT^_NZ??Z%QR'IAZB\4JWR?!\I0K;O*AYF/;'=;
MY[Q?+CK%:S^9C*C:NOFIP^TM#IF;%4,2J$A-N"N2U@%;2A&F'+68)X5K\I<4
M3(E$7E7XL'NJMG5%IP].IHTYF`]<@STF7&<@UN5-NW1O[+\%HW^+5:_?*\/2
M7U/LH63#@.7>.X6S4EBVZ;*(USNEKMTVU1MJE-^$59!O[2.^Z7M3#(5DYWM*
M"-A02FT_)BV3-*8&"7@IH.:C<B-4AQY;B2_(A$Y^P8%65G'7QAZRPX_.L>D*
MK&^OA%^S77\6CU^\RVPO3+U#Y&?EX'"<G=8Y61TACVR>M3M5JT4?&MT7*:_)
M=4]?LL^V^\:<=4JY<VV?!EZ-M5#0N"I+)6H\A$L*=%[&8E4FEJ1`)/`\-:E+
MD(LXS@\@8/[X.<<A+`S8-1E58I-:KX7UZ)_K-/[S)<KTU]0<&^O&S.%Y*K(N
M@IPC+'L4IP=4+E**<=6G5978FNFR<9>#13R=AZ)4KRFM/;U=G.)RYR;"D)<L
M9AJC'%G*;#W5$`D*O)@E+<2])!'`Z>(L*DO.>GC#UF?&\@H[W3;MT3UVOP>N
MC_#H]/O,NK/2?U-IQ99MO`<M'$C778YO%M457:[(U3;VZ;;'3:H/PDZYZ?99
MVW2^:59%F6]XM2!-B["U:W92+I.TIE'KVT+N->C\HU4$?J48(^NR8#IX@82&
M]?[P72$./SK([H4V..B?2+\'IH_PZK\:*&%Z8>HO)8_S7'\)REV-Y<+-T,>V
M4=EGE*$]5'3;-WT[7X/S8:?:6O=(N>I5+:WO">R(6<U.HB@-KB7(FP:->,],
MT+"0I%`5&2SQ&I)`A,#@.<]0*RL_8&'K*\',4G!U3WKQ6CU7C_V'^)EM9Z>=
M]TY=N!;Q'(QS:$W96Z+%."C*V+W1VZK25%T7K[:IK\EZ4Y@OZD94J*11JV(`
M^K#TI"XE,U2EH7'FHU)+VH3J0%IU0Q"(.(C3@,(L8Z""B.SCV%BZ36<=GTK=
M;39&*>G6+77I_P!\OQKWEWRGI;ZD<)3+)YC@N5QL>,Y0<K<:V"4XNF,HMRBN
MJED4)KQ3NK7Y:UK,>MRKI:]$QN,6!$']_4-A[R0S-#\W+W(YI2F)2E+D6C3G
MF'C1$&+20B,QCPAR:'KGVXY);AY=,/-MKG&O735II:^[7W]&8_ENP^]."XZ7
M+\UQ6?B\7"Z-4K;:;(5JV2DXUN<HI*;4)M1UU:B_<R1.6QJ8X`X`X`X`X`X`
MX`X`X`X`X`X`X`X`X`X`X!K\V]V_F&N\O11J,1F'.Q6:9G]M*E<J>T[6-8="
MW5G;R(V@"K?X\`(G$+D(0CRLKSR_#CHE'U]O0^SNS</N/#EE95MT'\[5CI5Q
M<M%9&3<WI"?AM\'L3_9HT7NONO+X#*CCXU=,E\G;>W.2CKY;BE!:RCXZ^*W-
M?L69&3BX5L4BU,2-*Q)5H[4L*KH8K2F+E)9;,EL+'52X)CO0EFK36O']X`PH
MC!O_`"O!]CFM8'#0R\K-QI6.*Q,:^U/1?$Z?!-:]-WMT;T]FIG\SEI8N-AY$
M8*7S5]-;6K^%6^+UTZ[?NI:_<+-O*\WZN[&KVO&9YJ&(`F,+L.9*9=<DA6L;
M'@<)>Z[94\;9RTBAO"L=W+$[&J%D2C&2R$0NA8O%D0+[@>!HY+C<GD;H9ESI
MOIK5>-!3G^=C=)SEJGI&/E*/AU<O%::.TYKFK\#D,?`IGBU*ZFVQSOFXQ_-R
MJBH1T:UD_-U\>BCX>ZC+MEWTG2L6T:.)-JJ1YJA//4\1(7N"QG5NAY)6"T:)
M>G18<US8J/,P-.(!/G'%"#@./$+&>5J^V*)=[_T5G=)8WS;J=C24E%/Q:;VJ
M271ZO1/4H2[CO_H=_2:%,7D?*JU5ZMQ;?L32U:?BNFK6A(-"6#:\]*G7WSZ^
M^#"8_(F]MB+R%M?(\":-*F/-CDXN((O)A&/S/AG>E1Z'(SA9+59)\POH'KS'
M=P<=Q''RH_1>1Y[LJ<K(ZQGY4E.44O,A\$MT4I:):QUT9D.#S^4SE?\`I+'\
MF-=B5<M)1\R+@FWLG\4=LFXZOI+35$+T]N#(K1>-?FA?3,JAY-R,\]<ULD>C
M&S$8*'#6<3DG*B*I&[+G1X+=!X\01+4:#.$^,CZ8']IG-<SV;C\53R%T,VFZ
M6%.J*A'=O?F2VOS$XJ,=O[64^O3PZF'XGNR_DK<&J>';3'+A8W.6W9^;CN^!
MJ3E+7]M&'3K]PKUP[>,]47+%JZ,8%+I%4@H[BXIL2WRA2AK?%@KQLL"$:X-,
M><HNGP0O+"ND'O5Q;/=+$H(78\X!N`\H<-V?=RW"V\DK%#*>_P"7JU@G=Y*W
M6])3C8]5\-/EPGYEJE7\+6I7Y;NNGB^6KP'6Y8RV>?8E-JGS7MJZQ@X>/Q6[
MY0\NMQGU3*CM-L+*:+4UJDC,:+?`3,Z>J7UP^%YO.%4?8X)$#Y0L7)(A7R17
M)'@1WEX+%Y6,Y+Q]@(Q""'E/M3MW$YZ.5/*M\OR%4HK?54IRML4$G9<U".GC
MU\?>D5.YN?R>$GCPQZ]ZN\UR>RRQQC5#>VJZDYRU\.GA[F<Z[8&;$:CQ[8-%
M`6%RGC_#:_?DE>E3%-B/K'R;NT>:D[.GFJ-*Y)2$9IKYC):K)1@"NN/-]@1Y
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M7^"0VRC&V6%-4DMB$(@.\QBX'-7&$L.$WC2"6HVPU,ZJ%"ETC3N0,DO`$PCK
MO)[/OQ^VX\UYD7FJ,+;*=:]T,>U[:Y[5-V:Z[933K25=U,E)ZRTML?NJJ_N!
M\3Y;6&Y2KKNTGI.^M;K(:N"KTTW1@U-MSIMBTM(ZYE<TLVX<`<`<`<`<`<`<
M`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`T8]RH.,[F:J=<8S_Y+W+]
MG&,__3(I3^[S?.V/Y%RW_OU?[BP^EGT?-KZ>N^-/_6+B?XARYKDW"++S<GM`
M#/\`YC[(_9"'/V<[;=?U/U>O-HX9OY+_`.:I_P#-SUOZ!3FO3WHW_)'`>W_)
M<DN)@!\U"BL>`/3#LQ>SPXZ?O:ZB_J=/^#'+6YO],7_>E^[R33^=E+_IR[F>
MKU\B[_&/=!&F@H`8LZ-8P`.,8I^E.F,!QCI_W.W'Q[/9_<Y6[A_>)O\`WVS]
MWCFX_5'*3[-S-6_Y?Y?^-]J$"6067_W5_6P?O+0#']X'['SL:]ST^Q_=YE,5
MO2?\//\`B\SJ':$YZYO5_P!8LWV_^S.<92[7`!]X0_[4/LU@LCI]KCV?^]=@
M\^SV>SV\PW%=<[1_\9C^M4<3]#I2_P"E*/5_USP/[7P1VM;BP8;-H>@`8ZSB
MS.O0./;UE^DOV?9_P8Y-R;^+$_@X?N<HH^K\Y/,[+ZO^3>/_`(KW>8@SLHO[
MXC[^M@_?&JK_`)`?S%5^/[G]SV<S..W\M'^"L_C:.^=LSG_1+&ZO^2.2]O\`
M[9P,V-S@`S>KMG(`YS\Z.F<^T.,^W$Q:NF?L<P?!_P!X+_!+?W+/./T]2DO3
M.G1O^I7+?Q2TMZE``QI3#\8`'&/OD1'V>''3]X2Z<?8Z?W,\J9O\NS_@I?VZ
MHROJ/*7_`.8K/>KU_1&5_COB"PM5``^=O!L^`/7[]C_[?#CK[.X&Z=/;TZ^S
MIRMRG\BV?P"_BAM7K?*7_03R2U>G]'*?_<>LCO8@LOW!)OM`?O'[-?\`)Q]Q
M=0_\'_!R[XW]\A_#T?NK#:_26<_TGA]7_63M[V__`$OE#+6Z0`S1]=8R`/3X
M)V6]GAQ^K8*OK^I^KS#8/\H6?[.C]PCA7IW*7_23RW5_REV]_$8D0Z<%EX67
M!T`#'_PSD8]@<8]GU<4-#T^Q]CI[/^+E]S?V*?\`"O\`SV1OWU!3FZ>`U;_K
MD_;_`.WN60Q)"R_OI.?ZV#]]?4;/]Z'[.+-V0Z9^Q]G'+VK^]5_`Y'[BDZ%Q
M$Y_T*JZO^0^Z/;_]W<`3WM&6#,:4=0`S_P!TM:OLAQG[$6U$Z?J?J=,<QW%?
MOO\`\N_]UDG+_1:<ES$-&_[_`.X/XSW25N@``^]7=_VH?WTGK_DX_4VIOCI^
MI^IRGR']]4?P2_M%1C?5*4OZ<=M]7_(E/_NUPICW"2R_O\QG];!^_KLGG^]#
M]G,4U?ZY^Q^KTYE,AO\`1TO\'H_=7G5NXIS_`.C#-ZO^K/;_`+?_`*3W$2MM
M067FX1YR`&<_?INO/M"'/MRV[@]?U/\`AY9\2W\E_P#,5?KXYHWHE.:[`CHW
M_5WB/;_OG:I-L)`#YMVOV/`'IATBG3'AQTQ_Y;:??8QT_P"#EA>W^D\C[TOW
M>2<X[CE+_I?[J>KU\G)_C_=1COV_P`Q:$5Z`!CI5L(Z=`XQT_P"YN[W]S'_#
MS(]Q?WK/^%E^ZQ3K7U2RD^S,[5O^6\S^-]GF9?;L`#&[<*S@`<9^;'/,=<!Q
MC/3W]6'LZXQ]CF%[E?\`R#9_A<?UK#SW]64I/Z<.13;T_IEA?VCD3T6+5J-M
M1JG!P5)D*!"F/6+5JP\M,D1I$Q8CE"I4H.$`DA.02#(AC%G`0AQG.<XQCG-(
MQE*2C%-R;T27BV?);'Q\C,R(8F)"=N5;-0A""<I3E)Z1C&*U<I2;222;;>B+
M#:;=JQ]:T#TT6)#%[4Z&.Y3>N(D;5E.L,CZ8U:^`($)4'(Q-",@1RGV?K)6/
M&/H'.,YN)X>77-PG5-36FJVOIKT7XWT7O-GSNPN]N-S;>.S^)Y&K.I53LA+'
MMW05\E"ER^'IYLVHU_LY?#'5IH_6:W:LD2A$D8K$ACLJ<F13)4"=#(VI0<JC
MZ(XXA8\$E%JLC$WI3DQ@3#>GA!DL?7./"+HGAY=:<K*II*6UZQ?B_!??(<AV
M'WMQ-5E_)\3R-%-.3''G*>/;%1OFE*%3;CIYDE*+C'Q>Z.GBM>FKNRGT(W`M
M79\$3F-+2ROSF69*&?`T#+(PHQL#HJ#A7D1*%Z+<"!)3!=`G@.`(&<X%C.9H
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M8D<`<`<`<`<`<`<`<`<`<`<`IC@R,SL,@QU:&QS&ESD28;@@2K1IQ9R$6<D"
M4E&9*SD0,9^UZ>W&/[G*M=]U*:JG**?CHVM?OZ%.RFFUIVPC)KPU2>GWM2H#
M*+-\'F%@,\L830>,`1^`P&>H#`>+&?",&?L9Q[<<IIM>!.TGXG0<F9G>0%%/
M#4VNI9(A#)+<D*5<`H8@^$0R@*BC0EB$'V9SCIG..5*KKJ6W3.4&_P!BVOUB
M2RFJY)6QC)+WI/\`7.WZ9-Z<*3TY'I0E@)"F\HOTX22\8"`H)/A\O!8`AQC`
M>G3&,<I[I;MVKW:^/M)]L=NW1;?=[#GY`B<`$J8OR<`3D`PFP+"?`"BP^1@>
M/"/!/0./*P,/LSX>G7')G*3UU;Z^/W2&V*TT2Z>!^B3)Q@4%C()$!7U]4`10
M!`4^(H!`O4!R'.#O$06$&?%UZ@#C'V,<@I2333>J\/N>WI^'J-L6FFEH_'[O
MLZ_@/L118AEF"+`(PKQ>4,0`Y&7X\>$?EBSCQ`\8?9GITZXXU:6B\&-$WJ_%
M'"6C2%)PI"DJ8M*#IX$Q9!0$X.@_-QX20AP6'H9]M[,?WWM^SR+G-RWMMR]^
MO4@H14=J24?=[#FP67@P1V"P8-$`)8C<!#Y@BP"&(!8A]/%D`!&"SC'7IC(L
M_P!W/(:O33V$=%KK[3C]*E\!9?IB/+)-\\HOR2_`4?@8C,'%A\/A`;Y@\B\6
M.F>N<YY'=+775ZM:$-D=--%HGK^$Y^2DPX`X`X`X`X`X`X`X`X`X`X`X`X`X
M`X`X`X`X`X`X`X`X`X`X`X`X!KJVST]G5^WU3%K1F1QAH9:W@,]B;L@>?>7O
M%:ME4KK]^1J$.$:0]/Z<A-$C@&>,81>,P'3&<=<XV3A^9Q^/X^_$MC)SMLC)
M-::?#&2Z]?VQZT]"_7[MGTN]+^XNQ^8Q,V_D>7Y3"R:IU>7Y<(8V-G4SC/=)
M2W2EE0<=$UI&6K3TUQ5O7MC6_:,]^*F:=0!`B^*K7?O3N/OWU/II[]^WW83_
M`(.WF%^<D^^8C\[V]/U@WPYS]KUS&!W5A8F/Y,Z['+96NFGY'E:^W]H]/OH[
M?Z:?67V#V7VO^@^0XSE;<GY'C*=U?D[=V%^A_,?Q33TE^CK=GM^.&NGQ:7:R
M=N:U6VEJYK4Z:08;M#EK:I7KB_?7H%($<2H]@,"E\2'!_B$JK%8/'B#C[0\K
M]7Q=*,^YL26=9E*%FR:>BZ:]96OW_P"^+\3,#R/U;]D9GJ+R_>%?'<DL#D*[
M(P@_)WQ<\KF+UN^/3I'D:D]'XPG[-NMI:T=L:WJ6E[3(9!.8`YID$%KZ+FE-
M7OWSAK(DPWPU+CP85-Q(,)SS[41"+ZY\60D'=<8SX/%4Y3NC#SJY0KKL6LY/
MKI^5*I^_]H_U#/>L7UE]@^HG`W\5Q7&<K3=;R>=DIV^3HH95W"V03VV-[HKC
M;5+IIK.O1OXM(UE?:2NY^]S>FL.M2?=L`C,3-\[$B^W6LMU1BRE"@OP-HO\`
M!C6AC,(!U^V]0,/7&`]<\O*>\<"O=K5;ULE+\GP=4H>_WO7[QN'!_7;Z;\7\
MQYW$\Q+SN5R,I:>1TA=Q&1Q\8O6S[2MNC-^S8GI\6B)CNCML6S9-:FPMIFT$
M1+QU!+*\PI7>^\)?>C\LL]2F6=2&\TW"(H$W3X']KD?4HSIC/VO6PPNYL/&R
M?.E"QQ\Z,^FG@E!>_P#:LY_Z=_6!V+V?WBNXL[CN3LQ5S^-G;8>3N\NF''1E
M'K-+>WAV:==/BCJUUTYJG[;EL0))<*=SFT$5BL.12UX:\H\/?1&1('S7QT2E
MKO.0`SYI)-1K@C\'BQXE!/3KCQ](YG<^'D.APKL7E1BGKIUT5R>G7_?%^)E+
MOGZO>QNZ+^`MP^.Y.M<3B8M5F_R?C=%/.5R<-)OHWRE+6NG2NS7\G6#9'VC+
MP>92XOI%B5H4F62F&/I91N)'YP4\;UR4TZK)'X6S(/./?CL*2^F>GI<>WH/[
M7E_5WE@0J5;JMU4)+V?E7>9[_=T^^=+XCZ\?3;C^$IXRWB>8=U>#ETMKR--V
M1S\>5BUK9KI&A>7+V^9X?#U,@;\[<UJVM8ZV8LLT@S>@4W%`K$`F<O?7J@M4
M4?43JM1B].@,*]<H)39"7[?!XLXZYQCF.X[N;#P\94SKL<E1.'33QDFE[?`Y
M3Z7_`%:]D=C]HU]O\CQW)6Y4.W\W`<J_)V^;DTSKA/XII[(N2<NFNG@BF5_V
MV;9B6O[%4JZ;0-0]M<K8WXYQ3>_/=IB9LK6?PLXHO!B`*CSAN$L(-#U#T\HL
M?7/BZ8S-D=SX=O(RS(UV>6X-:=->LX2]_NBR^[J^K[L7GO5/)[ZQN-Y.'&WX
M-U*KEY/F*5G(8.6F])[=%#&G%]==TH^S5JVJ8[7]P5O=T=LUUG5?K6AGL%SE
MQZ%#[^RX&HENSBR[2TY7G-Q1'J0QY1A+GJ+PX5]?;D'VW*N9W5A9/'SQ(5V*
M<J]NKTT_>?+]_OZ_>_$9GU#^M#L#N_TXR^S<'C.5KS\CBJ\6,Y^3L4X=NPX=
MR>ECEM\^+LZ+7RO9NZ%K6CVH[IG+8[(FZP*Y2C<*\MV(%B5_$/A`NL&/P=I:
MU`\E-H\^F1GQ@X1W3'B\)@/#C.>O2MB=WX./.,I5VO2RN7L\(.;?M]N[H9GL
MGZXO3KMG,HR,OBN7G&KEN+RGM\CK#!OS+;(K6Q?%-9,%#V:QEJUT)MG_`&[K
M2EE>1:((IE"$ZYBC]M-"E2I]\^E./G\G/>VPPGRT(C/+2)C<!.ZXQGQ_WO7'
M+#&[DQ*<F=\H6.,I5O3I^1'1^WV^PYSVM]6/9/!]V9O/Y/'\E/&R<OB[8QCY
M6Y+!QU38GK/36<EK#1^'CHRQJ'[8]O56?.C7F<P!?B45&77Z/#=[]ZD.@-5&
M&A\K%'J&\O\`P+XD:AJ_M>H_1BQ[/,ZAY<<AW5A9:K4*[%LNWO73P^8=OO\`
M':]/O_<-E]3OK+[![WKXR/'<9RM3PN>>=/S/)^*M]RW<ULCMF_C^7L5771>:
MGUV]2P77M.76OF*R1%6%6X$JB:T?)0$C^(?/PCK&7VO('@C/1M\'J%R6>)@)
M_;X?&49XLXQX<YN(=WX,:56Z[=5"V/L\9QK2]OLV/7\!M&#]<_ISB]OPXB?%
M<N[X\=S&/JO(V[N1Q>,HJE^^:[82PK'/VZ2AMU>NDE7%VT+<L1I-;VJ<0%$:
M-DJ5LP-=[]\&#H`S4<W.9GZRWC%Y:PVL5@B?9U\)Y7BZ9\72UPNZ,/&GNG78
MUNL?33\MVM>WV>8M?O,T_P!/_K%[#[3SHY6=QO*6063R=FD/)UTSK>8LK76:
MZP7(U*?W83TU^'6HUGVV[7A4-L...$V@BE7+YDOD:$Y)[[R0G2J[ELBQP$J<
MFH"Q^?AJF1!.?#C(?/+'[?#X<YDRNY\.^ZNR,+$H0T?A_N<(>_WQ?X"T[Q^K
MWL;N/N'B>7Q>.Y.%&!Q\,>:EY.LI1XG`P&XZ3:T\S$G/KH]DH]-=4HOC_:CN
MEHLEHF9]@5R8WM]CVQ,34Q7Q#ZH:"?,M/MK8F!XFW!7JDAU>*A'=<^'PG%>'
M.<^+I>6]WX,\5T*NW<ZJX^SQ@[&_;X?&M/O,W/E?KA].\[L_([>KXKEUE6\1
MQF(I/R-JGA7<K99)_G-=LUG5J'376$]4NFMZ7+VR+>L>="E+5.8`B1YG]@2S
M!"[W[ZCT4M2WHG0I_P!8;S"_4IQ6BCR;[?#T(-Z9S]KUH87=6%C8_E3KL<O+
MA'IIXQ\K7V_M'^-&N^GWUD]A=H]LKA,[C.4LR%Q>#C;H>3MWXLN&E.76:>V7
MZ-MV^WXZ]=/BTD*/=O6T&BJ*Q@1\QA)CG"5C*H<597OGT:H#;$Z+8#L)/$AP
M=XAJJN6##XPX^T/)Z^WQXQ;6=R8D\NW(4+-MB>GAKUE:^O7_`'Q?B9JO*_59
MV7G]\\SW15Q_(K#Y&NZ-<7Y6^+LR>9N6[2>G2/)5)Z-]86>S;K%NLO:\N&E)
M@S2*0SNOG1*VPZ/1TXEI]_><-4T,.PS4><7A4W%`\@PZW4(@]<^+PISNN,9\
M'BNN4[KPLZF5===B;FY==/:Z7[_][?XT;MZQ_6EZ?^HO`9'%<5QG*TW7<A?D
M)V^3HHVW\%:D]MC>J7%W)]--;*_VVD\ZM:(V11FPD?MR1RR'NK&TU#)*^/;F
M?WM[R,='ERB"Q.L*]6C)3^B*+CQN!]18'U&'IC[/3'\MW!C<AQLL.J$U8[U/
M5Z::)2Z='X_$<P]:_J:[0]2_2G*[#XC!Y"CDK^>Q\Z-EOE>6JZ:\J$H/;-RW
MMWQTZ::)ZOP-CUCQ0Z<064Q-,K(1*GQH4HTBE62-2A+5]`FI<.*4L90U;88H
M*"!23@0<FD"&#KCKS6<:Y8^1"YK51>OW?P?=]WW3R+VCSE?;?<V%SMT)64XU
M\9RC%J,W'PEY<FFHV*+;KDT]LU&6G0@5[IZPY7[AF3\VTT78\<<9NN:TB9A<
M5,:]-(((.*(&EV=%!`'EY3*G,A,J7B$45XDY8$X0YP4$><C7FXU.ZBMW_+24
M4WJMW2>YM+P735+QZ]?:=/X[O_M3@_FNWN,N[A?:.75APLE*ZN.1NHS5DSMJ
MKBW53*-<K*Z4I2TG*5K:<W%1JJU<L^5-\5;9'+(I&U*!JE`Y-+(X!X>GU_?I
M@%Y!*@.;<Z%MK*\MTB4.0#L&#"0<WI,GMY/5.>,6;I<MB52G*J$Y)N.V,M$D
MHZ;=&M6FM-/:F])/JC<:?6KLS@\K.S.(P<[,IMOQECXU[JIIHIQ/*>,ZYUNR
MZJRB-;CM3G"^WRLJS2VJ*+:<M.+$/3,Q":7L18F!CB)3@)K>IO%TMCOL>A:*
M$(%,C;6Q:>CC">)(2S3466O&,KL!))4!"7YG6I'F\9.3<)?%*6FJC+8G)R>U
MM:RW/37=X=6NNAE\/Z@>TZ[LBR_`R7'*R<IP\RG#R98%-^7/,G''LLA&>1+*
MFXQN61^\ZSLI;ELTO6P=5IC-F0E*ME$?='P,F9SO?*LET9AE1QGK9)"6X)N&
M;(1N(VUY4N;@8V&Y"WN):\1)^>F.O*&-R]-$]8PDJ]KZ='\3GN?CX:K:MWBM
M-4:[VKZW<!VWR4KL;"RJ.,>':O*BZ[4\BWD)9EFGF]*U95''HCD1UOHE2K*E
MJR=*%J^0U<RREND3R2[F.\I$O:`$*C5A33'6]D9HZR-19YS>V#P4G0LP1`+$
M`P9(1X`(X\0<FBL.0RZLN<)51VJ,-'[-6VY-^+]K_#[EX'-/4_O3BN]>1PLO
MB<>5$,?"V6N45!VWSNMONM:5EBUE.UIR3BIM.2KK34%.W,><R'`'`'`'`'`'
M`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'
M`'`'`'`'`'`'`'`'`'`'`'`'`'`.N<K2)S$Q*A4G(.6&")2%''%E&*C@@$:(
MI,`8@B/,"6#(LA#C.<!QG/V.12;3:3T15KHOMA.RJ$Y5UK632;45KIK)KHEJ
MTM7HM>AU\NS4$LPT3FWA*)68;C3,K4V"RG#(PEX0F#R9X0+,F#P'RLYP/KG&
M.GMY'9/731ZZ:^'L]_WBJL'.<U!4VN<J_,2V2U<--=Z6G6&B;W>&B\3],=&P
MGUOFN*`KW:$L;CYBM.#W>`T.1E#6^(S'I0F`QU#DSPXSCVXXV2>FB?7P^[]X
M0PLRSR_+IMEYS:KTC)[VNC4-%\6CZ/;KH??O!!YWI_7(_/\`2>O\GU)/G>A\
M7A];Y?C\?I/%GIYG3P=?U>-LM-='IKI^'W??)?E,K9YOEV>5OV:[7IO_`&&N
MFF[]KX_</DMT;#LHL%.*$W+D`PUNP6K3CRO+*!@PTQ%X3,^J`4#.!"R7XL!Q
MGKGAPFM=4^GCT\/OD9X697YGF56Q\EI6:QDMC;T2GT^%M]$I::L^R5Z!0G-5
MIUJ0]*0(\!RDE22:G)$FR(*D)IP!B++$G$#.!XSG&09QGKTY!QDGHT]26S%R
MJK8T6UV1ODDU%Q:DU+[.B:U>[5::>/L/@MS;3A(P%."$T;@2-0WA+5D#$N3E
MA",P]&$)F<J22P##D0@>(.,9QG.?;R+A):ZI]/'[GWR:>'EUJR4ZK(QJDHS;
MC);)/5*,^GPMM-)/1O1GR!V:C"TYI;FWC*5J1(DA@%J81:I8`1@1I$X\&9"<
MI`(H6,EAZCQD.?9[,\;)IM:/5+7P]GO)I8&=&4X2IM4ZX*<DX2UC!Z-2DM.D
M7JM)/IU77J!N[46!2:8YMX"T:D*-68-:F"!*K'D`0)5(Q&X"0I&(T.,`%T%G
M(L>SVXXV3Z='U6OA[!'`SIRA"--KG9!SBE"6LHK7645IUBM'JUJNCZ]"H<E+
M0_.N,=.N<>WV8_X<_9]G`T9^\`<`<`ZZI6E0D#4K5*=&F!D&!J%1Q:<@&3!A
M++P,TT0"PY,,'@..N?:+.,8]N>147)Z13;*M-%^38J<>$[+7KI&*<F]%J]$M
M7T2;?N2U.(QR;BAJRS5Z(LQ`0%4N`8J(`-$E&$8@J581&8$G($$L6<#'T#G`
M<^WV<BHR>C2>C\/ND\</+G&$X56.-LML&HR:G)::QCT^*2U71:OJC]"X(!FD
M$`7(Q'JDV5J8D*DD1JA&'P>)607@>1G)@^8'J8'&0X\6/;[<<;9::Z/1/3\/
MN#Q,J,)62KL5<)[)/:](SZ_#)Z:*71_"^O1].AQENS4<%&,IS;S0.(QE-XRU
MB885QA6!B,+1B"9G"H982Q9%@'BSC`<]?L9X<)K75/IX]/#[Y-/!SJY61G3;
M&5*3FG"2<$]-'/I\*>JT;TUU7O&79J"6,[+FWX)+68;C#<K4V"RW#)@2L(1C
MR9X0+,FCP'RLY\?BSC'3KGC9/731ZZ:^'L]_WB*P,YS5:IM\QU^8ELEJZ]-=
MZ6FKAHF]WAHM=3L%*TIQZA,2I3FJ4>2PJTY1Q9AZ7)P/,)PH*`+)A&32_M@^
M+&/%CVX]G(--)-IZ,HSHOKKA=9"<:;-=LFFE+1Z/:WT>CZ/371^)UO>[3DO!
MV'-NR4);[M";ZU-Y8G'QY+]!@?F^'*WS,9#Y77Q]<=.G([)ZZ:/737P]GO\`
MO%;Y#.W^7Y-N]5^9ILEKY>FN_33[&G7=X:>T_3'9J)"M&:Y-Y0&T18'$1BQ,
M`*`1N`B*"M$(S&$HC0CQD.!^'Q8SCI]GA0F]-$^OAT\?O$(8.;8ZXUTVRE<F
MZTH2>]+QV=/BTT>NW730Y!.+>`PXD2]&$Y.EPN/*$J(P80BSXNBPXO(\"+2Y
M\&?UP6,`]F?;QMEIKH]-=/P^XE6)E2A&R-5CKG/9%[7HY_L$]-'+JOA77KX'
M.0>2I)*4)CBE"<\L!I)Y!@#23BC`X$`PHTO(@&%C#GKC.,YQG'(--/1]&4K*
M[*;)571E"V+:<6FFFO%-/JFO:F<F<XQCKG.,8_NYSTQ[?9CVY_X>0)4F^B\3
M]X(#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#
M@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@&`.UD1E#_`&(P
MG,T<>GAV40ID;*G>F]N5+4D1LU-;45>79V,<"2S$\849B"3SC%A^20&H4:@G
M`\^+)8]BXBZFO&DIRBH*;=B;2W5^7)):?E?%[%KU:?W3U+Z(<[PO%]IY5?(9
MF-CX,.1NLY.F=D82RN.EQ>3554JVT\B/S4MD:H*3C=;59M6BG'%E/72@#4G&
MZU-,E,(3P',<E,<%#7I0L6[/9A\X1$3,YL"1E0O<,+5X$V'\(3$V%JU*/S\9
M+P87EGDIS:A=7Y[LW1EN72C=![=?8NFNSQT4NG7KVN[NVJ6=..#SO'P[DERG
MS&-D?-U1C#MWYK#G+$5F[;"&R#L^2;C9Y--\?+:FX3K6*\DI#RR&S*`25V4L
M,E=E>U+D&*.C@W6)'%EIL#K!@G)RDAV+$2-4:*+/P6E`J](B2GEB#CQ9`*3Y
MFIPDJ+()2BOEUN2<)>6U/_8:RZ==-6TS'ONSA[>.R:^WN5PZ*<K#JCVW7\S7
M"S`OAQM]69I)R7R$K,AR@Y6.OS;K*YQD]%)6TWU=8Y4=2-RN`33-ADJ$+LY.
M`V5S/6*M:BZE6M+A7`'L./)//.?C"TWN,)V%0EOA'@'4&18JRR\9V.4;(?+=
M4EJM//\`,34]/O==VFFAF,OO3M&?*V9='*\=_1.49U5UJZM0CW`^4A;#/=+Z
MI*A2L^<<?+5.L=WQ:%='7$G/7/V8974L:3GQ_9%VKJG$<<VLF`QI%:L[=["`
ME&<22&O4CW#EZ4>$ZG";*M(<26$.?!X`T_F:E&*OM@U&+5_Q)[Y.N"A_L]))
M]5KH]3&1[NX:K&Q5W!RV#?7C8MT.XX^?78\W(GQN%5@N23;SI4Y<+%OK\SRK
M863DUNW.]H[&7M)1%IQN-0*9L[))4%-E$Q,F+/36J<'N%ML,'L`>:@&E3C$<
M^)2#DQYHL]'M2G4!)R>+(LBH6VPER%5MMD)60=GQ;D]%)R\GK]SHTOR4UKH:
MYRW,\=?ZF\)R_,<IQV1R6';RS>2\FFR-=.79EK@TIJ4EI3*4+(17]YUSJ=BK
MBDE8JFMIP>JE`85!9*SR9_>4;CK*]F1IR1M\'JU/-K:<)4PI##$Q94`PX1-V
M*!E$IPE,4%.:`L(!9*"$JNLK'2CY]D951BU>MR;G9MK47^WTDO%:Z;9/V]=E
MH[O[;JIPGW'R>'D</BX\Z^X:5D5SGF<E+#XNO&OFE)O-V9-4GYU;LC"6/E3<
MEO;G\&UTY'B5'0^KI<S1-RBY+-4#:;%'9M#&]@"4E.`>)>4W'IP&Q4]0<RK2
MQ.YP2B336Y>+!N?/R(Z*R8+17VPE:IZV/<GNI_.:1U_*\5\*Z]8].G2>ONS$
MKC"OG^:P,CG:<UV\K8LFJSYC@W+E75BNQ2:R4E=2UBP<IQC?BIP7EI5_0*\4
M$B0*'^JY8L@C<S.S1=T>,A+RX+Y?>ZDFWRX[,`D%I3C9%Z=6\I\A=BLFD%9<
MV\63`^2'),/F4TXUW060Y)U/<DHU?F]T?VO1/X7H_AE[^LLNZZK%;7Q?-X-?
M<UN15;P]ZS*H0Q>%B^*=^+N<DJ-T:K-<66V<ECY2VOS&K,A;L=MEXNAUO9Z]
M4/+.G##DA<L4%-+A(1KIZ@-@:1NC4H]VQZ2*!HE+4>[",P8:WD'Y*-,$L`,D
MO`L=@PXNV65/)VR>][>J6D'O;E'5QZI[?8VNBV]6<I].<'T=YG)[OY#NN&/D
M7/D)/%B[84*&%-9LK,C&\R_'BIQMCC*.D;YP4H06/*-DFJ%!3[TD-T5T[V2J
MM9,PQNW9^GBN<1M"V,SG5SY"7Q+7[E-`-C4HQAS=WE,L)6X-,)$E`0A%G!63
M_$;4R%@5X-L,54NR5,-WQ:M34EO4=7X):->.NLO'3ID^YJO3/B?3OEL#L^'!
MSY/,X'!ED_W1.RVODJ<NF6=7B.RR/YNJJ54J=L9JQSR4G-5:5[+^:L>.AP!P
M#%7:QE(=V"O#'Z,.<R@39.G)7.HZV,JR1C5H5-9V"TQP]4QH"CU3@E335R;?
M!X0#P0K&0?G`<%>,&7XBQPLL5<U#(=:4)-[='O@Y=7X?"I??6J]NAV[T/Y"W
M`Y3EH<7FT\?W1=QE<<*^RZ%"C./(8-N1&-TW&,)2PZ\C75K?4K*EJY[98+IJ
MWF*<$8)D]?2U=-&%4QKMB'T3`Y.">7U*6?30PQI4O+*-)G``%LQX\-R?*@TL
MEK7@\O'F"";GWDT/>ZK(*B2:I6J6VS\Y\6GY'BOB>GVH]>G3TM=W?P%TLVSA
M>5P*^WLJ%T."I\^NN6+R;CRR^8C!M/#;=L$[YJ$7+)Q9;GL3A;@*MLLQL6HF
MJ`S5/+URDMTJ]4!I<4BMAH0MCN$EYA"=W,P67'S%9#NE3>Z##25`U#BAZ%YR
M6$157YO$4U*=D'2EI8M4T[M:])Z>WP;W=5HI=??F)=Z]G1S:\G.Y3CI\!5!U
M\C%VURC?S3NXIU9DJEJ[U%U66?-1C.N,*,GX])M3NHVO7-2[.ZB*5K)D,4?'
MID^:ZVIX>[,QM=2]#,ZX73:19"<D)%!D+D%M,6".4^G`K1-RT(<BP;D!M%9,
M5"*MM@[HQ?GO<GOBXS45^W:UTZ:Z-Q]W3!U]UX=.#CU<YS&%9SF-CW?TCLEE
M56K/Q9XF?##HZ2?SDZW9&I0KWNJZ_&D]'!2A;`*V?PB`>IK&7"AQ->)HU*FL
MV).YP'+:(->3EK+F7NC"8PY<X@E"XDK,@"6)/E8J3&^?^MX,+J_-5>RV'G>;
MNB]RZ4;X/;K[%M3^#QT36G4S4N\.+DG73S.`N?ERTLC&L654G7VY\_AV/$\W
M<E"MXT)R^1<E9Y5=T/+^-QED+1,8F<6?G@;S&9*CM$->67'+0F8&%R*1RFP)
M59+.HJ5:-U"1Z>2>[(AX_"N*R82WI<""8,O'LYC>0MHNK2A.+Q/-A*N.JUC"
M,'YBT_)UE[/:_`Y1ZF<SV]S7%X\>.S<.SLI\MQ^1QV([JW+&P<;C[8\G#R]V
M['\S*TUIEME?9I*$9OJ08IKLX;<(2&II>7`C:T<(NBC`82])U@-KQPME0(IP
M%L&F]2G<27).H39D.<83>MP(63LB%YF;]9*W?%=#YCS5)RW+3Y?<VXZ^[31[
M/'3V'2Z.[:XY:CD\[@/N>/,0R9Y#S*90?;*R[ISP_,W;95NN4+%@K6SR6EY:
M2VKO$5V]I7QD53>N)4[,#)*'HS:`GX5='4F?*EEC3AR@*]6D(3&BL1*T,2]&
M=@:4*H*5*<0`60X+\`(/)K=<E1;!62@O(^)+9I"*FOVFK37735IEK;W9QUW&
MY-/;?+X-'*9.%2NW7\S74\*,,##KS81G*2^0E;="V&ECJ=ED+9+7?NET"JSG
M9,:1M[U7LQ5V>BRQN5B/86!S.,>M?BXA6J4^"">0A].]#"I;1DB92QC49/;U
MGZUU'G)DSRL=VN4+(+%>J@M5TNW3^/3V>.N[PT:Z^Z[GWCVS9S%F7QW*\?#L
MRSSJ\"GSZTJ><>5R$HYOE?:I^&Q367)1KV7X_P`>D5LR`D`[AAFMK4&IF][A
M[4YW=*CRL$-+DF?871[M)I>YL*AL8R(U*'=G3&&>[@ED@:SS4J%5T\LL.,B+
MQU?R5_*/YUQG-8\?:M)6J,4]7NBG[>NY:M>+]O+.+CV!W#ZOWR[YMQN0S:>V
M\9/=;7*G+YBK'Q:[XV72R,:JV27GN4WD0C9=7KOG+13CUX<MG93E0V3E=:B:
M'(VVDGU(YQ>&I6IR7V&V26`+[9:5*7W0J>"H>ULN2%2$(TQ>5"M0[E9,'A*6
M63<0CQ56D\=4N]NU:2EJE!QFJWXZ;F]4^O1*#]K;VKC\3T9X3;F=M5<)/N"R
M[F*)5Y.7*RN&#9CYL.,MC+S8U/*LNWUW-62V55X$]L7?*=FV/FH'AD<`<`<`
M<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`
M<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`QANR_G6JI.A;&^,M[RQLL;
M;IQ8B]:Z*43B@B;K-6J"IL1=&0A4D.;R0M<35AH%)B<K*9((`1>88#IE<'CH
M9=3G*;C9*;A!):IR47/XGKT71+IKU?N1V?TY]+<'O?A;<S+S+<?DLC+LP\"$
M*XSA/)JP[<V7S,Y3BZZG"N-477&<O,M4FMD):P^5MM9*P@EN05O#A2QUB6;@
M9&Y3+W<IKS3P&5]>30N*\$<,.#8&!,Q27"<HH:#S%Q9F3_`49C-Z^'Q4]SMG
MY*GY;>U:^9JET6[['777QZ-:=4;]/T)[0Q[99>3R_(+@Z,[]%761Q:G9^E7=
M34O+@\A+Y'2V5CLE)7[:905>Z<&=H&W4N=U3*7&8/&%"*UWA?'Z/<721.R8M
M6XQV7HH=)#K&3IV(XUE2!4'GJTF&_P!:,TA-D`_`,8<\A^AJ8*7FV3W4Q3M2
MBO!Q<H[.O5^">NG5E"7H-P7'T9$^9Y+-AD<'CPOYBNNBJ3C7?BSR\=8$I7)7
M2VJ%5OG^2HSL4H[HQ92DN[#^K:$LK!7C07&5JY+7*4DZ2K`O@[H6PL^9)FLT
M`64;>5`\X3Y1B7^9E9@T83,)LAZAQ,^"K4W3YLO-2<_LK3RE+;KXZ[_;IX>S
M4OK_`*<^+HSY\'+ELA\S77+/DUCP\E<1#+6)*Q-W*;S?B\U4;54XJ4?.UT;J
M9NWLO9U#R"1P".E)ZL=&IBNHYJDCDH&0Y2J:R*#1917):IE3X>6\Q?'LJ5?O
M`2(PLA2`(,#&$6>2KAJ9J/E62UM3=6L5X1BI2W]>CT>BTUZHLZ_07@.0JQY<
M1RF7*WFZ;;N(5N/7%2KQL2C,R8Y[C=+RIJ%_EU>0KHRG7*4G&+1=C-LY)OO8
MS^4R2%LB>911+6SDUL+,^KU3&O07*4S9@.'%V7-*-8D5H5+QY+L$I.:`'IQC
M(R9@80XHSXJKYNNFJR3HFYIMI:IUZ[]$GHT]/AZKQZZ&"Y#T:X?^F7%<+Q'(
MY,^W\Z?(5V7W4PC="?$NWY[RZH6SC*,XU;\5RLBWYD8VJ#C)EFJMQY(Q?$"^
M30>.IX_53LFAUQ.+;(G0]07-'B12^*LA<`2GL97O1A$ZQA.-2:O$D.`0Z%^`
M`A$&XS77"56;8U62\RZ.ZM-+[*C&3W]>CTD]--5K'[J-@I^G[B.3^5Q>&Y++
MGRO-T2R^*KLHKC%XE5&+DW/.DKGY=_EY,XUQH5L'/&GNDE9#3[/VVL%G,5-<
MAKR))WZ(Q\JRI\6W2IW5MH*N6EPHY`9%3SH^G/6S'&)D,LU.J`0DP-J.R$W(
M3R>D%PV/-*==DW7.6R&L5KYBW:[NO2/P^*U?Q+IT9+5Z$]J\A&&;Q/+9\^+S
M\I\?A.S&JC8^1@\M363%7RC#$_N12C.ISMTR:TX)UV:_0=L;&7*&]A:Z]AGQ
M;.&A?8%9MSA+GDI`LK!G+F2AT52E:GC9PV^79)B1."4R8)Z7(G8G(C<83G=3
MX?%BG9*VSR:Y*$VHK56/;IM6[K'XGJWH_A?3JB$O0WM'&JMY/-Y;D?T%QM\,
M'D+(8M3G#D;7B1KCC0ED)3Q=<J>^RQPL2Q;-(-VUZ35,=HZKKQJK-QG#BH8S
M;.9DC\VH_"G/$SM)H6(M<Z/1XU"4HEM:E\D1IS3"_,,$,[Q`+$`!@@6-/$Y>
M3.V-"4E5)I_=?71+[K46_P`'CX'.^W_17O?NS.YG$[;JADU\-D2HLG\4?-M7
MG.%=45&3=ED,>VR*EMBE'24U*4%*F-FU,)DL_AD#B+)*I`9(Y9*84_/!;0>@
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M((X$UH`C51`U9$"R#%:D1*D'O(L>"<X(-P*?]!5N2KC;+S)K?'X5IY:<=7+K
MKN^+71=/A?7JB^?TX\7;?#C<;EK_`-)YM;S<-RQXJI\;">(K)WZ6N<<I0RI3
MC76I5OY><78G9!JMF;93QL<7AA>H'$1/M6*FU9=Q+1)W@Y*WQ:1/4<:X\YP$
MQ8P)AO2_*1_.6*B%N$H2PMIA0!B&<5G%-</1.,;(63V7)JK6*ZRBI-J?7HNB
M2:U^TG[&8Z/H9VQF8F/RG'<IGKC.;KLCP[MQZE*S)HIR++Z\U0ODJH;J(55S
MI\QR>1"<HQC7-.D8W'G1HBFDFO(IB1.D0*N-B`;*7?W0=38HP^RT[#@H`P96
M$6"4B9`IO3`*&@RH6`'YWEECQF?]"8Z^-V3\I3\M_"M?,W*/3K]C5ZZ^.B\-
M2_?T_=LPC+/LY;._1-&>^*N:QJO-7+?,TXJV1=^R6"YW.SS')7[*I1\O=*)*
MU6;*K+#7+GA5&6Y!73Q#)Q.X`](754K?UC-6DG20Z5IY2T*&]*E;7!0[K,&H
M@ICU`,IPYP8+`^G+3+XM8T5!2;R8SA"::Z:SCNCM>O5:>.J74T?O;T?Q^U,:
MK`HS+;>[<?D,/"SJ9U1C1"[D,:67C2QK8V2E97&J&VUV0K>]K8G$C4W;6R4Q
M0FI37,,^,2(4KNT]M(F#R:TBI1$PM[ZH\AQ%&2S\V*'WB%+A*(K#>(P`C,'^
M#.`\NEPV*_C5L_(\SRM=JU\UMKPW?8Z:ZZZ^S0W"OT*[0NFLVKE^1_0$N1CQ
M$;'BU*W]+SNG3'=7\PU\@_+=GF*3O49*'E;DV<Z?;></CDSLL;@45,<+2=G1
M'2QKM)79,C.0QB5O\5DRNQLI6)0<T'!-CXE*0#=A;@PM26`>0""//(/AZ*XR
MG;9/;3%.W2*UUE%2CLZ]?'1[M/!E.WT([;XW#R.0Y?E,Y8O"45SY=58]4IJ>
M1C49./'`W715J:O5=KO=+C*N<HJ47$ZA6YDE7,B29-U?,)D/DBEO@L2&?)UX
M'P=M+F2+O'H'Q(%BRD30HH<A.)RK)-,6=6\8O(Z'%XQ%\)5&;IE9+SHISE\*
MT\M.2U777=\*>CZ?%X]&5I_3WP^-R5G;V7RN2N?PX3S,I1QX.E<9"[(JWTR=
MVZ66U1"?E3C&K2^*\W\W-N9@;+1^,59\>6@D+8WA#.GVKU[%'%'O8MVF\>>G
M9H4)8L>Z^Y<JD2\AF.7$Y5>F&6F#G`_MP]!6/Z+LMR_E\5[H.M6)RZ:1DDTY
M::Z-:I=->ISZ?H]RG,][?T8[+G+)P+.,IY&%V1'RG5AWU56QEDQJ\[;.$KH4
MS\OS%*QIQ^%ZJWGC<ZK0IB\0U')IX\&9K]?EH9&<\(R8K8[S'6F.S(]4I\M,
M%@<!OIF$YF!"&>>@5%8#C))F0U8<'EZ_GW&N'QK5O\J"DY1^^M.ON33]IE>/
M^GKO5W-]PV8?&8"^>AYMUL6GDX%5]M^(HQUEY\%3%V1:2A"ZF;;5D4\O.88X
M*.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.
M`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`0-:=/U_8$JBCM*Y
M`M9U9A9,>4,*=U;$*.Q69N?&Z:)(JZI%Z8]8M3(G]D)6=$`TZD16#2ACR0:8
M#.0Q,W)QZ9PIBI1^UKHWL;3BY+3HM4VNNJ\'XI'3^R>_^Z>U>$SL'@\6O(H3
M=\;Y563G@6V4V8DLFN4)*$)3HNG5^>4ZU)PG&*LA"2B/.LU/D,JH!=KR=&-&
MY@A":3%2Z+EN3%%LH75AS2X%HVH23W.:AD:DKRE`#'?!XRC<'^:25D-[^E<U
MS6M,&FMVW;+1RU3\W37776*ZKX=-5IHV;VO6/OZWD82GP>'9&REYDL=XN2Z[
MLG?5=^EG!6[O-4\>N6ZMQQ=BG!U;+)IU-QUPJ$A;)G!/8;S'#HL>4[1P"211
M@A-1BYS?$,N7N+`F6MAY+?B2O3:6H."\86%&%Y,`7@)8Q8S)'D\UQA%UQDI]
M):QE^=23BD]'UVIZ+;I[->I9XGJ[W[;C86);Q./EUYL75D.5&0Y<S"NF>+"N
M^4+$Y_+TV2KB\3RI1DHRFW.*9PDZKTDF-"QD2U[):RHP!Y)B89.S^2F>B(Z9
M$"KD3Y&B$[DR0EE4C+PKP;[MP:/S/(\73I%\OGM>8X1W[]-VU]5NW>7XZ;=?
M9]K[I4L];?4>Z#Y*S`QI9LLUU/*^7MUE3*]93XF6D_*>.[HJ3JV_,;5M\S;K
MK]H=:J>5*8X>IL![D8I5DQUD9"J31XXF\%S6]NTN;GE]`A0$#7YC3V_J51.&
M?*,D`3`A-",``XPERF;%22KC'9TC\+_-)I1:6KZ;DDGNU?N)<GUA[_HIRZZ>
M*QL18.E6/*./>GP\+*:L6RJESFU#YBFBNN?S2MFW%R@XRE)NILFNE:BK^21X
MBQ))(&%TP2B?9&-^C1ZHE/!TK8AA:$YU;V@E*EQ5WN`DQ)XL8'YX3!+,G^8/
M')+.3REDQL=48V+JHZ2_*;<GHW_MFKU^YIMTT++DO5KO!=TX?+6<3AXO*4MS
MIQU1D1BY9DK)Y<U59:Y2_27GSC;ITV.$<?RML64Y'K13BM>QF*9T[R+$M1*'
M>1M*J0QP]%<[HC62-]331Y1HVXD2Q<QN<T6JRQM.4J4.1D>8`0$Y&`S2Y3-4
M9)5QCL>D7I+6I-16U-OHFHI?%J_'3Q9=Y'K%Z@48N3&GC*,1X%D:L>V-&0I\
M37.&/3+$JE.QJ$+J\2FJ2R?-L:5NV2E;8WTDNM50GHV52HM*1/JAW<C8PYOR
MV51=4IL5@3_#J4FK7$XAK+2*&MN+@;>7@MO"G<?$F/R,W(E"G(YGRF8I22IC
M%);DMLO@?Q?G%U\7O?CK'JNG1%Q?ZP=^U9&155PN)BU44K(KHAC9,8X%\OF)
M/DJU*QRC98\V^3E>YT:65*,%&JG:4ZVU&F;WHPFV)*T*&=X]Q-DB*ED5`X5N
MS+LR,A76#8L5M)I2-G<P3I>6(A=@]=GSD_A,P),FR`N4S'**=,9*4=6MLM)M
M;=+&D^K6Q=5HO'IU8I]7N_+LK&A9P>'D4Y&/YUE#QLEPY"V'R\H\C9"-J<[:
MWATR4Z=E/P6[H-77*4D3_6:O+`/KI2K$X-)U;-.8VS&H4[`XFJ(L,UB4&L9Q
MTE9'TU"(:B-I!!7(LI7$L.#``/"$XS&;7'Y3)QE:EI)6O<]=5\77K\+6OVGT
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M<U9+>&.2*T(@'%#_`.DX$7X3@EC#>861;CVORX*Q3CHXM-II-2]FCZ.*?3W=
M>FIO?I_W-R_;7+6_HK!IY2.9CNJW$MKMMA="%E>3%N-,H6ZU78]5R<9+][:G
MK7*<7#"C6>G4:QV*33I[8R(LTMSK'F$F2L`4%2.1'PPI)GS2C7-YYR9>K'!4
M!GF.@E2+(2U`0EX`I/P*^7*9KBFZXR<VU)[7K8OB^!Z/P^)_9T?A[D=#J]8O
M4#(QZ++N,QLFS-OLJOO>/?OY2N7S$7A6SA.*E"*S+H[<95W:RJ<IN5-;763Z
MJ4@-0V-1DM>G%$[Q\QW<8V9)V<0)R[EHI(A)M-9DA&!U->D)$W7"">A-(;\&
MFD#$3D2<CPQ?+9Z3FH14HRT4MK^%:Q?E^.FCVKH]7X]>K*UWK?ZD1JNS8X&/
M5D49:JKR%CVZX=3GCS?&PW3=2IG+#I3A=&=^V-L58E;;K]H]<JC6AC*U59[]
M(E4C>3#W]V/D\6&==GNQT9'Y`P2`QO:TY+F@CJ^)),E$M6$I@$Y9Y1@A%J#\
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M@$?DSPCEDEC3>VE(!+T+=-W-$%0H]8,T_P`O.<)S"@YY;7\ADVU1\V$>KUW:
M/6;BML9-ZZ-Q3T6G3WZFH\_ZG=V<MP^'^F,''4IV*YYCJNC9FWX]4L;'R)V.
M>R=F'7-PK\I1AKIYL9LCS.M-0G,Q>#+9DZDPQQ/@(Y2;+HJ8YJXB>@3Q\ZCQ
M+\-.$GN4;>@*)$2``7<1Y>3,G^9D6<W/Z4S%/]YAIIOV[9:;M=?-TU\=7KK]
MG3IIH;8O6+OVOD&X<%A0@J8YJQEBY*KCE*<KUS&SS=WG*R<I*<F\50EL56Q(
M[2S6VH41DD<D=EOL;5Q5X+<(ZY))-&"14@H='EQDK@A8_6MAR="GDCM(%)IH
M'D*P8RSP@*R$`"\8ECR>;)0@ZHR4XZ-;9?G=$HIO1]=JBOLZ>'7VE#']7^_<
MB.'AW\/C9E&=CNN^N6/DM<Q&NFO'A.[98I3ECU45QB\1U)2@Y34I2GKRG:O4
MP68X,I,U?6]K;HRB=D,2*D[(!%#W5$V,30GME$G,097D/>4442?X2J&:V^,!
MPO)_7S<9@N6S7I9Y<7-S:<MK^)-M^6^NFGQ/HOB\.O1$E?K1ZASA5R-G'8UN
M==F3JGE/'N<\JN=EULN,G)3V.G?DV_FZU'(T=:\S\W#2['/6^N)M53!"3'E:
M]I4,G/LEJG9H(K)7)PFCNH=UKG+3D[LQNT-=<O&9"LQDD3>-&`H[&"BP>67D
M-&/)Y-&7*_:HMPV.'Q12BM$H]&I+3:NNNO3J_$P6%ZO=W=N=[Y7<<,>O&NMP
MEQ]F$GDX]<,2J-4*\52JNJRZ_*\BIJ2O5KE!N<I;IJ5(SJ%6Z14M>$4BG+8^
M+VN*,"M^+>FX2HYA@J]B<X,R&)U+08T^@B[PT&J4@0IPYP<YK>N1!/P$%3],
MY+2A*-;K3D]-'XS34GXZZR3T?7PC'W&07KWW=?37@9&)QMW&U79-\:'39M5V
M9"ZO,N4HVJW?DU6QKM;F]88^/HDZVY98<PYPP<`<`<`<`<`<`<`<`<`<`<`<
M`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<
M`<`MV52V,0=D5R68O[3&6!#D@*QX>UQ#>WIQJ3BTR<!BE2,!>##U!H0`#UZB
M$+&,8Z\J4TVY%BJHBYV/P26K,MPG!<SW)R4.'X#%OS.4MUVU4PE9.2BG*348
MIO2,4VWX)+5EJ$W14BER:&=/9,*.<W^/BE;*A+D38-0Z1H"%>Z"?$(,*,^H;
M0MK4I49-#U#Y*<P?]Z`6<5G@YBC*;JLV1EM;T?26J6C^[JTOOM&<L].^^ZL.
M_D+>'Y&.%BY7RUTW18HUY#G"OR9O;\-GF65PVOKOLA'QDDZ:5L!2![8TO)5K
MP$QJ?G<]A9G`,F:LI7%Y2Y384MR4WU'A,5$96D^,/_)\X'7^^#UG?'9ZDX.F
MS?&.K6U]%[_U&7<_2SU(KS+^/LX/E%G8M$;K8?+V;JZI;MMDEMU49;)Z/V[9
M:?9>E=;K9K%V=GQB;)_$5SS&7)&SR!L3OS<8L:'5Q<<M"%O7D8/\:=6K=<>F
M+!G[82C];Q]O[.4Y8>7"$;)5S4))M/1Z-):MK\'7[W4QF7V+WE@X.-R>9Q>?
M7Q^93.VBR5-BA;7"OS9S@]NDHQJ_.2:Z*'Q_9ZE_%&E'E%GD&EG$G``:2<4,
M)A1I9@<"`868#.0#`,.<9QG&<XSCENTT]'XFL3A.J;KL3C9%M--:-->*:?5-
M>U')R!(.`.`.`8$[30:926P&@R/Q1]?53W!F*-0*1-;:<N0P&=M]N1.4N+\Z
M.9(1XB1(HXWX/]</)83@(!I\"R,8"Q[#Q.115C-63C%1L<IIO1S@ZY122_*^
M)Z:>S77[IZ?]%.Y>W^'[6OCRN=C8U&-R5V1FX]EBA/-PK.+R<:NBNMZ?-/YB
M>SR5N<'=&UQ48RG'&)+64F3-R-:X4;.5<7;JU%6SY$`0@Y2N<;S'#)TT%6.2
MU8#T<VP!KMA'\2A\PH(G`LSS<`)$87E7E5.3C'(K5SMWJ6_HJMT'LU]CZ:[/
MVNFG71]FO[RX:W+LQ\7N7C*^:MYC](4Y7SBC"OAEEX=KP';K^;L:J\W]'O;)
MJB4=CE9&,ZP76,];'F+J))6$QD"BNY0].E]/"6(*7,BW69XM5@D<5*94Q9)@
MK0]QLB8M0846$\2("$9/AP(6`"D>7CRKFJK815D$JENT\MJMQEK_`+GJ^GLU
MUU+"?>7:^;Q^;5Q'-<?B5<MA4U\+5+*C7+B[:N-OHR7=)M+CO.NE*$92<%<[
MHV:Z1<E:[?3%IIXNCCBFKYAF7IG-!-%[MED,4$+*1(J-;'EU0%R'(_)/>U#N
M<6D^'LFAR(SH9X?"7@7*LL[$=SM5L/):<4M?]M\Q-6;?=IUWZ?<]IFLOU"[)
MMYFSEZ>:P/T!.F>)"KSE&4.8?*0OARCHTUC3&I2M^>46E'6&NLM"OJ*KGKHN
ME?PW54R83;$D3$\T6K4QE0SE56SLMKSR2S,IY&()7WKS)-&G9.(M,9Y`UH3P
MD^'(B\A#367C0C#S;82546K?BU\QNN$8Z?[IMDGUZZ::F*I[V[7PL7!_2_.<
M?DPXG$NJYF,<B-KY*V[C,+'Q'4NOZ16/D534K([U2X.S5*2D[T8H5,<T?:#(
MS59.6-'(VZE4J:%&156S+'!TJQLA>+?5#;,@("<*5I&\Q&F.%U]_F)!X!DS`
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MDW71.+1UXAUH1`N!GN:ZP+8<4]QDLUB-B8)9F92V(U$F+SEZ!DP).'DH7BQA
M.9DF+RJI)PA?6KIR4JY;]-E:\O6#_8M[?L_M7[UK)9W?P^17D8>#W%QM7.9N
M75E\=E/-5<,'C*Y<4[L"R6J^6LG''E_<CVN?RDUM;MAYDXW>#9R/-VNC+6?Q
M"C3(H4F02H;*@>7[)4[0'P%.VHI1AD1KPG,P6D+J$9BXQ.VF=#1&G8-PGZX_
M`_15DLFS*VMNS6.K2^![]7'73KKM\-9>&BTU.;>F\O1KELONWD>\?E++K.1E
M/&5TZJ-<*:S963QO.G#2WS?EFHTQGD1U@H5N#MTI,!;+V=+G@+_9R.VU+-'K
M:GPHDI.;TR=L05;)84^((,*8E,I.`9><O2966[94=/3DC;?'@&1^V?(G@0P;
M*\5TJ<J8;NO5V1DG/;K[---NGB]Q?]T9GIGA>GG*<7V99P,.0R^"P?FHJ<I6
M3Y+'RZ9YGRCN>OE>3*J6,H?;DLS;N4>FRKFKGCT<`<`Q=VB95#FSUTX*(8\V
M#%8_.75=+XDPL1DH7KT#G6-A1EF4_#I0#!NI".4OJ'Q8P`>$V1X4YQC!&1AR
MW$S49VQ4XUW2K2C)O:DU.$GU]FL4_O\`A[3M/HMR-.'R'+8E7(8_%<WE<;7#
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M*4L2BHI&SS2MG*4RU\*R26.O$3SADRO`<9@GUA;48#VB/+`;0651&$(V70=E
M:?FO=KYD7&:C%?LVM=-/9N7N;6`I[OX##X_#P^3Y[CKN6XJB^7,VK+C='E,>
MW$Y"O&Q:7JUG3J\Y4.$=_E2R82Z1KG*%KEU5.BS2'0^G9N*.(:P3UF_LGP:I
M/4O-[?>YG4>#8Q#($HPQR:RGUW+*S)<`$5D2T!V3<`*&,NO\WCM;%?7YKMWI
M[O"K?![-?8]%]C[FFG7KFI][]LSA+"K[@XU<M;S,N0HN^;C&-7#?/X=_R$KM
M4J['35*7Z/U4M*95J&Z<8RG^CH1/XH[N"%[ATK33QIKJT(?-[#]PGIVZ:S*>
MV8T/%>.J![#@/Q8E8(T$?J%^,CPVEA$6/(,Y\.<;GWXUT%*N<'CRMA*,->L8
MP@U--?DZR\%^5XG+?4GN/M;G,"K)XWD,&?;%_+<=E8>#Y\968F)A<?;5G53I
M_P#)I7Y#7ET-)Y$FIQ4M-2%%59R,]"-P2T=.28DHJ9PJY/#,P,U,O+V`,@[(
MRH[-&TX#GTS4G4HSD?Q1GH5XL9'@W)8O'F^676I;7?6[E<K-V_IY.YO9K[^N
MOE_J:]#HU'>/$5Y*Q;^Y>-ESL>=AR,LOYU2@^#69=;/CE;^5;*,XV_H[[6CV
M[%*.U=U'64U:GZ+N<HJ2:/[17LF?17F0FB"EZ':ACW9$Z>XBZLZ'RACM),P-
M+RG.,&6%1A&6HP7GIDH00PEET2KG&JZ$9VP7E?%IY>D(J2;_`-KU::]FNFOM
M+;([R[=S>,S</A>=X[%S^6PZ?T-*65&E<:J>/PZ<JJV>J7&ROMJG"*DX>;*#
MFM5-2E32*ALM)%&V.N573%?.X^L9)=+Y,3'S#TTBJ(B(5H@/J]$_X%T?W<!S
M((@3"`0Q9&UF9\'0T&3)GFXKM=L;8+'DG&,=WV;-TWYC7L777?\`MON=+NWO
MWL[(YR[EL3FN/J[8RJ[L7%QW>HRHY1Y7(3CR,Z/]HJ:N4UFM))9,?BUA+9/$
MC07=&M=&T56L4EBQ;O>4L?UD?1M$@13&-4[()/,'=K2-\>CC8YR5G4B5*&\P
M:-(E$I2ICQ`$`&`F8#CZI8%G)OYN4)N./%)MIQE8HQ3;<FHOV]6]&U]XYEQ&
M5Z<<QZM7+O7)P\V5';6-1"^=M$\3(Y6C'Q:K)67WV5X]L5&-Z5MMBKLLA&2E
M)N#<=+$>T<B&:EL`BWW&&IF:E'9"2PLR=`ZJ+*C\E@3I:IBI*WD"=Q1/W*%.
M8U$YSX3%Y;QC/7`2@XN5+B:UKC>2KW*U/5ZK8XS5?CTW:Z[ON;/NFVX^1Z*\
M3&-_:LN`I[AGD<O5-W6RG5'C[\?-KXQ1E-^5\UYV^.3)=8TRP&M-9M[8.:@>
M&AP!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!
MP!P!P!P!P!P!P!P!P!P!P!P!P!P"+[;A+Q.XPB;X\O:6Y\9I3&)6UFOJ-6N9
MSU4;=T[D%&XD(%*1;Z=4`K(,B*,P,.<XS[?L<N\.^&/:Y6)NN4)1>FB>DEIJ
MM=4;IV)W'Q_;/,V9?*U7V\;D861C6*F<86J.15*O?7*<90W1;3TE'1K5&."#
M5>6I$L88C)E&!L#7&C$KL<6P.87D^1CK2V*]P8VY$["0DL(<6@)3Y9H1*/\`
M!,`\?V^1!R<N7IDYV>7+S7/IU6FF^N?7IKK^;T]W7[AUW)];>"ONS>2AQ^:N
M4OS%*I.^ORECKD.,SM+/S6]W_P#)RKW1:A^=W;?AT?R=K+8BM`J$HEL"`[2%
M&^1V2^1'7[W6FC3NBKMOPICY9CUE4&0$$U\`6<J1#3"&I%]KC`,=2Y7&4EI"
MS9%J4?B6NY.;Z]--/C]G7H35^LO:=&5!58'*/!Q+*<C'W9%/F2R*IY\]M[5.
MWR&\Z2_-I6)5KKK)Z5<S5ER?LS%ME$R+0LJ\!N(:XPE(<TRUF5AM!=:C<[.:
MYW$]-*E:W/"DLC!9:3R32`9\0<9%[)/TO"O9*F&LU]I3ZQ?YM5M)+1Z-+7QU
M3,?#ULQ.+7'Y?"\>[.0J:^;KS)*W%MB^.AQME5<*O)MC"RJ+GNE;OC-K1Z+K
MDM6\2'`:]@T&,<3'@R'1&.1<;L:4`@US&PM"1K$X&DE_:%&+,I?,$$/L#D73
M'LYB\J[YC)LR--N^<I:>[5ZZ?@./=W\['NCNODNY84K'AR&??DJI-M5JZV5F
MQ-]6H;MJ;ZM+J7IR@:Z.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.
M`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`:?M^0;*BMYBS3UM
M[$P2-?!"#"MIJ>,+WF.G.WO5U\Y:J5):7L,L+H8G\L(P96EYP6`&?*QU\0MT
M[>?%_)2^=IQK+?,>CLDE+31=/WR'3\'X3WU]+LO1]=A92[^X'M+D^8_24]MO
M)Y$*KU5Y=6D(QER^`W6I;FGY,EN<OC>FBP<$7O=X1=-D=V>OAST_[A//V>GL
M^QJSUYGM>W_^+8'_`&Z_X<]*1E],VJU[0].--?\`CM7_`,2'HCJ?WS][&OOB
M)>[NC_\`!T=]\N3^2).^+W/W4E]:K=R!MK.,ER4*/$(X.4B;(3,YQY8/[W'-
M<O9\U9Y22KWRT2\$M>B75]/=U?WSY-]\_H_^F?*_HFJBCB_TA?Y5=#W4PK\R
M6R%4E9:G7&.B@U;9K%+XY>+D'EN:J.`.`8US_:BM:VDMIQ62)I.%RJ:JVZVW
MLQ$S85I'=@<G%2T$M<=.`I")?(2W$L@L:<82@A]:0+Q^$0LARF/Q&5E54W5.
M&VZYUK5Z:-+767NCIKU^XSL':WHEWAWAP_"<WP\\)XG.\W9Q=*G;ME5?77&U
MV7IQ^"AUN<HV)R;\JQ;=4DZ+!=O*_G\T:86U,<G(4/<KD<+0KE`XT=Y3[%V0
MY^<O>C(AD2N3M+0)(F,`4N.1!2C/\`,C#YI>13Y'#9.-1*^<H-1A&37Q>$GH
MM&X[6]?%)ZZ?>9D>YO03NKM;MV_N+.R<*56-@X^7.$?F%K3DW*BOR[IT1Q[;
M5*47*F%SL4-TE%[)I2TPW!$Y#:,PJ5$6[%22&-;:Z*UBM%@AC=@K`IQN*-@<
M,G"$YKHR%Q0^\P8+#A+[Q3=<Y\W'2TLPKJL2&9+;Y4VTDGU7N;7L4M'M]^U^
MXT7D^P.<XKLOC^^\ET/B.0NLKC&,]UU6W<JYWPT_-PR/+N^7;D_,\B[1+9UB
MEAVX@3\WV,\%1V8IFBN4;RI7*S$K*H4.*QFD)T6S'RFE$]J7=HDSN\E!"WHG
M$A(-80:`T&?#D6`W=G#Y%<JH;H.=K6BZ]$UNUU:T<4O%IO1K0W?E/0CN?B\K
MB,">7Q\\_E[*8P@I71C7&ZA9/GNV=,:K<>JIMWW43M54XRA):Z;BK<*I4BA<
ME&&2&'):%SL&F`4UD"RZQ@#FJ93HRV8RN#D^=E.Z<*;W<+PY$<:$(1YZ#\)<
M+F-)_#H\CR?'PEIKN?3[&G7=[B-'H#WU?57=%X:KGW1^@Y-V->5D.N-RR+/@
MZ83JD[//6ND8MN*UCK9Q>]U6Y+PN-C,Y)93<!)3.GDQ8XTURS7Z2RLH#F`B4
M&29&`,=5>'*LU&%%ZH'E9-QD0,BK?T?R]=JE7O\`=\7AOV:Z[=K^+V:ZZ==#
M/S^F3O53^6AF<;+D8]95ZY*2K^>EQ^]7O&6/-^?'7RXVNWRWOV:*24MSS8:-
M02Q8[62AE=7.02)@020@TEUB#.A(;7)].CZ<.!R:2,JEP6^M3BSDA(4H,P#I
MGIU$'&;/'XVW(QI9:DE7&3CX2;U2U_)B]%I[7H:)VQZ4<QW-VEE]Y59-%/%8
MF5/'DG5E6S=E=*OETQ\>Z-<-DEI.V4(ZZ]=$VL@.8XY8.`.`.`.`.`.`.`.`
M.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`:D>Y5O?9FFMO:00V)`C!4'V2FE\1
MRS'Q?5$\N&91=GJ&BY-<2%R@,,@,PC#@].CDJC64)Y!P#R@$'Y/R(H)0Q\`L
MV:=R><ZN[69HG;8^JS(,T:4U3=CI,JMC4E:7J27O;NX0]7(##8NWRJ=NS0UQ
MF9&.[0,)#@JSAJ7'GFJG7*`D9P`)IB_=>UPL$U&EK*'7W92TF&LLQG"2(U:<
MI,J`J4MEZKHBUVZ)Q>6T$+-DZW722H4[B/)S`2I"@$I<"$SHWJ%`$7TSWDZ<
MLB+ZU*I/2]\12:;%:HQ+='+`QQACF\:K37N231DACO9,ZFC3)B4C7%((9(DK
MB['&IRE@&K(CBT@S@B3!`J:+O5:@.\;B3XPLEX/[K/)CK!$H?!FJOFT<U?DV
MY]82JW=8YDG;U<K2-B2'VK#X4Y9).5+"%C6K2C(<TR(019P!:T7[Q=&2>PX8
M_HI"I,HRW=/-7-A*@BXZO>T-P2>8;3;)NNNE=Q\4F5SO$%`H?YJ<WLV&4Y$D
M&W+"E3BH=1-G098$Q[D[D7=7?;SD>\6M-3.QKQ7+.UVU/*5O^MI9%[*Q2\6D
M(2KQ;01`,CC+A&[)B$&2.3PVB/.6-RS+<$(0GD*BCN`5YU[@]:Q-JB=KK9$7
M9-0[%3&+5_J&SU1%,N<VM5[)J"1W#8#^F>W:7M\56Q9NC<8<Q@./]T@1F,BH
M@1JH]2D*$!B!8_>J@SLT6\]47'G`BNZUK3MMW$U[!S6&J)A`Y/#^X';B**Q=
MM*K*/SN%6<C<!Q7(DI"@W`!MKX:<-<DPE0XPN`F%[[VFF<5<K_12]!=L61:Z
M,6TSU+W]SK4M4RR(W3FXX?1-WLL$&QR!W<7YU9[!G[,2D$<F2(EB==@["@(2
M5."0)C<=]6JP=/-VMAZ0C#^Q2O45-L]$7!AMUC:LMYMQ:S19W=I*Q*2(5-G0
MA]BH7]MPA&L1.96#P^8(@SI@(\@8T4[WE:KQ!M-F78",SA-=FR6MVB=[3!RK
M"!!.IJ"F[YS(JJ:R).='F;K9"@8RK@\QE&$05ZXE/Y:L81DY.,*`O=Z[PU(.
M@*G^\S7UB6T*R][&30MPRE-A4<-A-G"+LUQEXI*TO$M+?F1RCC14CH8%H=4K
M6Y&84(CC"BDRHDTP"XV#N]:XR$$<<$]<;'H8K+=H$NG$<GCI6+4CA;QL"?:%
MD5(LA;<\YF1@EQ;+**Q6#6K22AHTZ-4E,R9D0SBR`*M6'=GUKNMJI]UJ.'W[
M8OWWZLK>YRV^*U?[S<ZVKRX7RS8O6$CME,6_8#$&J6R6H7Q'E8$:I`U>06H<
MST*0\E0,#$RKN^#7<G;JIN*U6-=3E/6IHTBVN8ZV6PQ;,+7=7*9;00/7BL4D
M?G\<FYL(6@ESS8K0UDL2IG1N`W1?A4-:0B(-#P"<;,[W&G%4M.'B2,]WK"&Q
M)L(IGI$?@#0[JZL.U5OJ(ZXW\@GA)<O*P0KKVQYRVX'EM$Y$N3>H"I;S%81E
MA&!FI1FY-,[$VQ?]-UJI?5<PUHF:NO[6*=$;:VA994C6J$>4`FH;P;*T:9Q+
M395MJQ<VHT3RWB"J;S52?J9@#*S@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@
M#@#@#@#@#@'GU[J;]8[7L!%B(BLL1.W"K1K,-!%*Q;YDW959?'P(Q&N:K8"K
M#"E/EX#U)PWFX"'IGSA>+PAZ-VE5C3XZ;N5;EYK^U-Q?@O9Y-GZ_X#ZI_1'Q
MG:&9Z5YMO/5\3/+7,V)/*Y&>)9M\FG32N/!\DG'7727GQ;>J\M:;I:R3)A>/
MEC_]Z77_`'@O_I!LW_VN?_SS,<VGR,']C1_X5_\`V8]DPX'TUWK\SVYXK_\`
MS=O_`,)GKIH@U8?2M3G.`E8UYM>1$Q8->B`VKA*1L2(1PE;>6ZOH$2G)F<^,
MK"U7@L77'FF=/%GCG(**SKE'3;YLM-'JO%^#T6OXE]Y'P<]388]?J+SM>(JU
MBQY;*4-DW9#:KIZ;9NJESCIX2=-6Y=?+C]E2ORS-&'`'`,(+CA6KLGMT"6QY
MHXM-AK\1G)C4G=7!O;<IW%FD\1C:!Y4E-9K02A>3G<PXE,L4@`I<42480Y$4
M$(L]A7\M3A;L6">,MW71-]'&4FNNNJTT;2Z1;]YZ0]/^XO6GANPW=VCQU5_:
M=7S&EDJX3LW5VX^5D3JB[%:YU*J,)V55MUX]U\6TIMJE05FU,B2A-,(C+',A
MRKN92F0J)@!O>O6.9\Y<_A%_AI[MB+E%S!B=)`6F*);TN5)^%J,@10NI?MGR
M)\Q<O)N@G&V$5MU738MREIN^%I:]7HM&]?$O^YN1]=.=JGV_SV#3+#Y;C\:B
M.*[*=E:PZ_FJ,N-7S+>+=70[)2OL5<'3;:IKXNE8C;!J5$I"1=3!)FY),2W5
M_ESW,R5!QTKEI=K/S\R'QR2)PM@GAW0'2-LRE1M("`J4BAD3EX!C*7IFG;9S
M%U7R-D6Z=%%1_)CY:3U771/:]7+71J3?M,?R_*^NO/<3+TZY3#ML[?=%&+3B
M.*6-BOC**;ED8\G9Y54UCV*RW*<W7;7F6SW-7:EI@J[5J:OJAUD=M/$])4QY
MPFPHI+7AI$G^]]&)D!:](GY'F,M<E?XVQS)(F`>2\G*U*,24DK.0!\7CK?-\
MM17LJIC6U)0W13^W*.B:^)Q4G'71Q23U;,Y+O7UK[=XR&%Q'!8_%V0RZ\/YG
M%JMW?/9&(X4SIG\Q9CT9%V)*QPGB0JKM5ED])/3;3'VFM,(0OD2IUF"UH25N
M?')*\15O=E2AG@4=D8YL_P`<:S6%H9E2EM@:Y7('%<42/JF+-(+'D0,$AQR>
MO-YS(C&,()NW=%2:6LW':I/5OK-:13?CU?O+SC?4+ZANY,7$IPN/KR,CEXY&
M/5DSJC&W-OH6'1D6*ZVV,;,V$:**937YR49SCMD[&RY&U@U'9JFF,10S(TEG
MF;>QMC@^"2J#+'**DT:*BT<`R`,C`I"8<X-=?FGIRL(SPB]*>=D'E8STI2LY
MF>9"Z4/C@VTM?@^&6Z6OQ;>CFD^J\4O$Q&9ROKOR'?7'\]E<?&7(<?;=9"G=
M%8#>/D/)R'<UD>0E"S.C"<G;!KS:ZU+>T?:=BI)^D3;-`;/R-YED4@3(O<GA
M2LK)P<5=?NTS7&1U6[(%==F@0)BI/E0A">D)2*2S>I)XL&A#T.S/KJ>/\I&-
M,[&DM)I*:BMVC4^OPZ/1MK3JNA+;R?J/Q?$V]NR[+Q,?@\[E+H5U1AR,*XYU
M6)!7QJG'/3G)X_EW.%L[:Y1TLK6R3US&?)[#HRN`VOTB;&M>80F5!2JC_`=Z
M=:J,0I#A!P$7@`J5E#++R+IXQ`%TZ],],)7CWVQW5Q;C]S[G4\_\;VQW!S&,
M\SB\2Z_%4I1W16JW0BIR7W7&+4I:>":U\44R#6G`[):E3Y"W[#PSHRR#CG,3
M:\-:(2=2G$J(5IE#PWMY:U&:F#D>#B<F%>'V^+VXY/D8F1BS5=\=LW[-4W^H
MWH_N,O.Y>R>Y^T,Z'&]Q8KQ^0L;2K\RJR>Z,MLHRC5.;A-2Z.$]LM>FAT6ZZ
M:I=B(LI;9['%9$VC\@E<1-*7@R&0QV*A)'(G5JR+`?5)F<M0`1_A^V`#.1=.
MF,YQ-+!S(.:E7).N2C+I]ER^RG]_V%SE^G??&!9FTYG%Y==G&Y5&-E)PZT7Y
M.JHJM_8RM<6H:]&^FNK1^!NFJQMH'8N;LIJ$QS7LP#"3#SCA.;6RBDB])A(4
M0-9YB5@#ZP6?+\/IA!,QG(1ASE\CEJ6QURW:)_@;VIZ^'CT^^1?IWWM'+>#/
MC<B.2J86M-12\NR[Y>$MSDH:2O\`S2^+7S$XZ:Q:4F$FE*"BCR#2SB#BP&DG
M%#"84:48'`RS2C`9R`99@!8R'.,YQG&>N.6K33T?B:=97.J<JK4XV1;336C3
M71II]4T^C3.3D"0<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`QDO+4BH
M-A+%HBV+`+F!,_UID,KEE,2"*3:010V(R.;Q97"9,ZB1LZLAN?#7*)."A!DM
MP)5$@)/'D``CSX\`8^S[M3Z<VH8]K+'C5D3-\D%2-U-.,K>[JM0^7XCC)?)V
MSD>D"&4%2HE[;+"C5ZG?$#<_ISBG)&>66G+-"C`%/@"36_0?79MMQ)>9*.R3
M;+/J!OHV=OJNY+25%717[-E],8$MY-9TK$UVP]1T^4.9B!R>"E"U+ZXP`#,%
M!*++`H].]N352C7.NW2#PZ1'&5=JLKTIB2.6SR7S1K)UI5R=-+!5JZ-DF=G)
M$]HR7)`F*+5*P&K0(DQ:;!OD8R#($?L/:5T@C#9$6UCKJ2(!P.?4'840=B['
MG)CZQK]6($_5AKC'2'@Y\,6*813<$DZ]O9VA0(Y'T5&G*`J%)@SA`6^/LV:#
M&0ANKPRLI;F,L>NM<ZN1HH%MV<G=(I5-/6R=>=4!C+\EE)#VRS6O+5/R[MDA
M)48>2C<8+&H&1CRN`;%&2`L#/`DE;JAO,KC9,=,C#@.>/SO.'N1MBE(8B<<R
MI_DRMR=I$J=B3S/5&*C3,F^9G'L#T#@#'.1Z(ZQ2"F*.H5-7XHE7VM(F0R@B
MH._/D6?ZJ.8H,_UD0HBTD;5P'<!R^OY6Z-*X2DQ1ZY.X'#.\9^0FA`A]Z[3>
MCCNQR6*I:N>HQ$)=6>K-1OT1B%CV#'8XLA.EDN#-M:D?NY#(PA*<*V>RP^4M
M"+"I:0')2L9X!F8&!'-N]HN@W^(7<HI5PEU473;T<V@9@V:HG$VD)3*JW*L>
M)VEL<N3,"Q\&T%GV'*H<D/#XTZA(VB!@!20:,1Z%0!+NNND3]7^KMMZK7U=4
MSOBNK2'-H\E2NX(9&Y%#:IL")H([**W3S.JJ^I\E\+=7(UX<?>@65N<",O(R
M`C%D@L\0%`'VF-*C!UJ89"9H/-1UCK!3D$P*T[`R%KKK36S3+AUQCR@/O[HZ
MAKRP3/6A4*O-5..,8)7&*2<>7P"[#>V7J*IEQ=AJH3(U-C%WS46R&;"'/YB5
M-%=I45%Y9!ZQ='9^3.Y"Q_2,$*GKTTF%+\JA+D#D86J&=X",D@=H_MM:HGTZ
MS4;B*S!+"(ULLNV]BZAOLV>MLMC&P+I8;W:3G/(_,D#\GD38<MF4G<U`DI:C
MT8"G`XDLH!7@"`"E5'VO]/Z'D=+RFI(A.(.Z472V==8N%EMZT"6^34BFDCU,
M&"N+2;!2L:"TF"(2:1KE;3[\+6'HQJC08,$4,1>0++;>SYH@VQ:)0K[VDG<H
MU`]?PZQ0MM>[0L-X#&:?0W%'K\C3(TJ'"1'JD[O"+6A[,ZLCKX\N;:-I2EE'
MX*`(`P.6==H31BR(^HC<NKN5+T3G$[QB,E5)K.GS6Z3!-LM;\9OJ]WN5.38_
M)%+Q*K*MB'-KLM<19"I(RD`F2B3I,>GX!E17FJ5+UG=5@;$1YB<E5R69&&^$
M2F=2!^='UZ40MJE4CFS;$R%"]08(#$VR65+3DA(_,]"G$6D39)1)TZ<H#([@
M#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@&E#N+S*HX_=4>1SNMK
M7F#N9`6X\AR@[;:2MI)1"=W<!:4XR%5M+VO"T)H!"%@:D!WA$'J#&/#G.\]M
M4YEF#*6/;3"'F/I)UZZZ+]E.+T_`?1?Z2NW^_.5].LO([8Y?@\#`7*61=>99
MQL;7/RJFY)9G(8MFQII+2MPU3TDWJE@`.S];<`'G-$[%=/"+K_[CV#_N9_\`
MZ%\V+Y7D_P#C&-^.K_A3U-'LSU?W+_TE[2\?]VX/_P#&3TS4ZH;U=3UNJ:42
MYN;%$(C)S>@<P+BG%$C,:$@TZ9<6Y(VYP`K)*S@)F#R"3<"QGQ`#GKC'+LU2
M69:IM.:LEJUIH^OLT;7XFSXX^H%651WSR].=95;F0Y+(4YUN#KG)6R4I0=<[
M*W%OK'9.<=--LFM&21RU-0'`'`,1+,H":SF;S\U%*8HV0&UV>LVJ6D+&IR63
M!`37+NXNAF(X8%64S9&\EK`%><>$0DF<9,"$8L!QS-8O)48^/4I0F\BF4W'1
MK:]Z2^+IKT]R\3O79OJEV[VUVWQ<,G!SKNZ.#OY"S%E"VN&+-Y]5=:^83B[=
M*G!RVP:5O2#<5JR,XOK!*(]!)9#\NM4N;2M<CEY;BYNEDN)3H>5.U<O1HGE$
M;)BT,/4D@6X"!:QB2JTJHHLTOJ'&2\W-O*U67PNTN4TM-$H+3X-K:>W67WIZ
MIKI]TW#FO6?A>6[FP>?5'.4YU=*@ZZZ^/K=:>%'%G.J:QW/*BW!MTYBLJLKE
M.$]&]Q4F;5&>-"YCG)5F-#Q.8P6Q.4;$^M[JZQPL]O?[-<3&!Q7'.`G]T8B(
M]8^4"-P--&Y%F)`*C/,'G(.2SY?'G&6.ZI1QYZJ6C2EU5:U2TT3UAJTOAZZ+
M0M.0]<>V,_&R>VI\-D8_;6:[J\CR9UU9#C.CCJU=7!5^17=*_`5UM$8K'E&V
M5,=L4I%ONNDLPDK.[+GZW3CK&/CCZ@C$N-2N;Z=$5,ADREV<F+"UW</>LFAS
M@PJAMJLI68$Y2`6#<^$997@J0YVBJ:C73_<NY.4>BW:1T3T2TC)-;EIT7A[6
M97"^HW@.'Y"C&XO@8Q[2CETSR<52KI65&C'C57=LJAY6/EUW1615*J+A6TX+
M6,Y[KJ*T_?DQDR?"+/7G2>T(;:T*L,IP3X51E0V3QH$BC.&!$`LER1?`RE`A
M"GP>H."--E4$."Q*,]*+YJM[*W4O*JG7*&GVM8/66K\'OU>NB773QT,)/U]X
MNZ''\;;PM4>&X7D.,R\%PEMR(V85N_(\^;;KG\Y&=SGLA%JSR&W-5(O!\UWE
MA5IAN2(RB/8E32UP%N8F>1M:\Y@4EQN-3R+2`MV/0*,+DPW-',@'(U"<(C$Q
MB80!!&`X72C7R5/RGR5T)>4W-MQ:U^*4)+37ITVZ-/QU]FA@.-]6."GV2_3[
MGL++_0E]^;9=;CV05\7D9&%DT.J,X[)*N6(XVPFU&R-BDG&5:UB1VT37NB23
MNH+$2-E@R-T87DR3M<=PE1!+43A\F5BP\]JPK%A1"I3[Y`421D?G$*$9"P0A
M'X%G-Y#N",)0AY3>-!-;7+K]A1A+73[4=.K]J;CX&]8/U,XV%?AX,N)LN[4Q
M*+JECV7[IZQPZ<3`RE;M6W+QO*<IS2V3KMLQTE4UI.MC4L_SJ=R)<4J0H&5Z
M:JS5)W@W&%*A*XP)VFIBQE,18&6=Y#FEE99Q9H<^`(R!8%CKX>6&+G5X^/&.
MC<XN?3WJ:CH]?N;=-/NG,^TO43B^V>V<3&G"VWD<>_D(RJ7PQE7FU8BC<IZ-
M;JY8TH2BUJU--/34Y6778,1UW5TA#),X,;B[Q%LBKO+5#@^/AH,F-K<Q25S9
M4[VZ+S&DY8SDJ,(R2A@(2GC`+`,X#G&83Y+SN26??!2BIN2CHE[6XIZ):Z/3
M5^+1)R/JR^>]6(>I'<.'5DXE&?9DU8L84TIZ6678]=LJ:X*U0M</-E).=D%)
M;NJTAQ9H_G#4_P`<:+%<TS4WM\N4U"\.!'KI56\JEB=F&>L+6%>C0+F!,X-R
MH.4(22@'('(],//ASC/+V//?'&V=2<VX^8ETC.,=>FG5IZ-==>CBF=!Q_J23
MSL7E\_B:9YUMN+'E*H/9C<AC8LKDH.#WSA?*%E;\YRDX78]5T>NJ)1;]>BHF
M^O=A(DK7()4/7F.500A2)0MPW.21](Z)7%_`:K5^A3&R5OPV(1&&?KX$K<46
M(W)80AQ:2Y)W5QQFW&GYF5FOCHFTTNG7X7N?NU;>FII67ZK3YSC,;M3(G?B\
M(N[,CDW.4O,5>/?*J5=#48[Y+'G\Q<HQ^!V7SG&"G)MSQ6L85PJO(+#EZP+@
MNBT0CD>6+2_'Y2I2SM"1O/.)\SH9@@9J?.08%[<`Z=?;S'Y5L;\FRZ*TC.<F
ME]]ZG,>\.9H[C[LY/N#%K=6-FY]]\(/36,;;932>G35*773IKKH7MR@:X.`.
M`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`:I>ZCLE=^D</HS<F&R-8Y:Y5'
M=<,BVY=-(F&'+':;TU<KPAJMAF\+?WMK'(6V9U=:$J9%H6Y$O1)WEO.4E'C#
MY8,Y`MFSNXZNU+M&,:]V[$9/:DU2QO6JQKCG2%P8F=/#6W=;;\6J]4Q&NX\S
M11*&R2JYFBX8'$TP3<JRP-I:C)BUQ59(X!<FBG=,CF[]LN-3ME-/M<N#=1KW
M=ACLX31FDR029@VTV$U+6QW*=O:FX\"HV0Z^JW@A3GJ6-"XDEB``XLS'`("D
MO>O*9M4%^YC=K2-TI:0J9Y]YE<IO>!M<FL`JKH]LB]S]C?X*)H5SN)3N.*-=
MLIE+8@:Y`6DQ(252A06C:WH]"!>-?]Y!AL/:FK==FW7V1(8Y9\QU]@Z6RUMA
M,HEC4];(:23?=F$Y-@J2/J!*D;1&("L974SWJ5Y2TPD]/A24(P!8$I7+W1&6
MAKTVLI&PJ1E29;K!KV5M\6[-<D2N:FV]6FBN;0E-C6C`V0#"5X'"N[!K8N&*
MFA6J*&<\OC>8$\"<[`^`8T'=YY^<;(I&`H*$;F`YWO%]A-\F+IXMDI<=KYM[
M;A/<<0.E5KFN&MP)K*U-?/:9M4I5!",!#LWG)0^,A>E<20+QL/N26Q9W:2V_
MWAJNLI5KO*X+JRZ7YKU*)-F,SAFF+(_T&P71!)LRIG9F"A=$K.YOAT?>4:YL
MRDRZ-"OTARQ&-.K,`ZY?>'70M_;(-:6O#FE7L^S:'36=6&Q6$2[P=#><\U6A
M>RVN:9,,J`-KFH2;!J9DFB.,81$XCLJ/(3G84)U28XP";]R=B+UK#<+M/55"
MY/B'17:*X[NAMYPY.@B\@3OC=`=:YI;+(S(Y0\Q=:\,X$4QC111RUNPC-4H\
MF8R''B#@(&#$6[[\PN2F2IS5NK;9%)<^27MEXBS98%OE.S*J@W<3V#F=&MKB
M[+(W!RC6J2PI?7#D(28&%:89*U*KR8(11Z`0&0RGO)A-ADVLI@U1L5[KEFV8
MANKT)EY\P9V!OFUA/VY;]I7(F8X+LQ@''Y%%IHVH9%Z3/JTQ\:>$XC5B5>6<
MB"!1G[O1'UE?\GH>[=67:%JZV>)!$K2D$-MYILG#%,HWV^GSN%.+5$V4N#1=
M3,VLN`QA:Q>L&:VF#=<D&`(&089D@"XJJ[IMKW-=?;^@#3K*774,W+'=$L%)
MIS.S59KI4M?:X5/>45FM6X;HNF&^HWM3<9+:J,<$Z`'O&.K24WGHU*1S$!<M
MI]WJ'UG>=L4]FEI,]H*TL&[:82RGXH1M2J16]1FC2;?61-PXVH8E)C-7KK6"
MGW2D?Q*CS<O8/MD'HS`*L@?MP]R:X(9VK)-W%6G7:.Q5X?(=1\[IJN)A:Q,A
M(=H/L"?3S?$)5-W6,Q5,6Q/#,OM,["MB3Y5^9[JQX5X<*L>2!C3M9W:+@7TS
MM,LUWK&3UB[:Y;%0#7Y5?3C\,S2"_?2B>Y.LU"736+M'I/&DP2LRV,7$YGQI
M806K.4-:$3@H"U'F(23@)F;N\B*1-L7E,7U5GBVO;,W"@NG=46"_31NC$=DL
MTE>Q=TZTOJA["HC2YS8G6`RFI$SRYMR9.XXPQ21'Y:D3B0J0%@8C0[O>V+*=
MF*6EB6MEOS:[?I"A(U*Z?5R"+ADM4WY9/<YL7M\R2P(W-DD)-=;1BK=)HR2)
M.C$<TI%[03ZTL*=49Z<0$_L_?;ADB92W9AUSEJTV5%T1(:O;5DX0-1S_``.^
M]]YSV^8\YS52;%E!$!ES79L,`]J&?/O``F1?X0*_5I%)`0+YU][R27965T)7
ML!UDGXIA:]>-MDV.0VRMF>TM,PMWV<N'4XV:D+%#,S()W%8A85,KW)Y/-&RG
MIV56CR0G5+3LH0`;#]('"[7;4JA'39&P(C:=ZN%?-:RS[`@9,7(B$EE*DQ2:
ML6,!<*QB*^A(+$`C`D.,$#$5D6,8SG..`94\`<`<`<`<`<`<`<`<`<`<`<`<
M`<`<`<`<`<`T@]R&CF:R;NCKXX2"%-1R>OVYOPGD5Y%5JM&`IX>#@F@8S+OK
M?*E/G)^<84>A,\6<9#YN?#X0[YVSR$\7`E7&,Y+S&^E6]>"]OE3_`!:_@/I#
M](GJ3R/9_IQE\;B8O(WUSY6R>ZCAGR$$W54M'<N'S]LNG6OSHZ+1[%KJ]>X]
M2XQX!_\`?.K,?:B]N=MD^,8]F?LY^=ACIS8_TQ:_]KM_^K__`-N>K(^NO-[E
M_P`G\YX_^K$O_AD]/=,MI;-4E:-!1B8XIL@T80EG(W/#VD-`E9TA(3$SP%S>
M<.9`\`ZA/PK4^;C[;S1]?%GE6=/S,RV;U3=DGU6C\?=HM/O:+[Q\8_4+,ER'
M??,9\U.,[N3R9M3K\F2<K9-J57EU>6UKUAY5>U]-D=-%)?+4TX<`<`PGN2L;
MUDUU,%K0P4;]S54E8T$4C*]8Y%NLP3R4]8FM01*TI]1,#%E3'UI"<D2Y"M,$
M8AP(K)(A8'S.X67Q]6#+$OW;[FW*22TCM_>_8V^NK>C7CUU/1OI]WGZ9\-Z=
MY78_<*S/TASD[IY.1"-;JQ98ZA+C=8.F=]VV^$[)JFZJ*C<U-6).)"310ME)
MV.!*,4Z8UEP>.URQV#%L2.'*%=SN,=G\8?5KADLMZ&S#3LC:UK3BCW$\A2K&
MM$3D&`XSG-_/D<5V6+S]?,E-PEME^:3A))>&O5M)I)I::G1<_P!3^S[>2Y2I
M]P*Z?)9>?=@Y/D9<8\37?@Y%,*]72K5*ZRRF$H40G74J58I:Z$_)Z5DKKK=<
MU=JV4Z+K)Z=:3I!X,VRL]/\`"2>1D*CHO&CWYF6EIDA1SQCU:I.E/&A3Y5C3
MA$,D'7..>=5#E*,E2WQK\M3FX_:V_:EHU[NB;6KTU\3EUOJ)P^#ZO=O=V49,
M<W'XR/&UYF99C1E\U*AQ63D*FV#E)JK\U7.R"NGY4;6HV2Z9;-"<Y(TM:51C
M&%"9N1)S\8%X\8.)3%%FXP+'L%CQAS[?U>8:;3FVO!MG"<^VN_.NOJ_>IVSD
MO9T<FUT^\5'DI:#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@
M#@#@#@#@&-.W3]JQ%J(D\DW.2UBJU\:GF$`E8+ACS7*8"!Y>IM'XW!!NS(\M
M[JWJE.9R\MP48QD#\A6(LW&09!@80+\DU34A)93$9=,*_K=]F=<%HQPJ1R*/
M1]QD40*2KTB]M$RN;BF-7MA:-W2)U2;P##@E:46<7X3@`'@"($D.U+UJDHI]
M75'0.-3BRK%:JAD<DHJEVYRF2F2V5,5<H/3V(XUU'3WEGC`Y>\J'IW7NPRFU
MO/5FKE1A>31FB`B&CX+VV-LZ:C%PUI0&O,OK>]YG/;992)-1$-8W.<V,WBF5
M;V#-E4/ED70.RR9G)SGM`O6G)LJCTJU0(8Q%*AB,`C&)77VJR**JK>B&5S42
M*N7>P*5A,`L1EH)*CG45G#I)"M4*5"I9$T2*G4,/9CW4,4;%9R<C#:R*1%%C
M+;ACSD#9`\ME6GJY/.W=EASL[L,2>H7*Y%[D;'V0(X9X2I$^PES/3(USR:S*
M/"6K.:,X$`\>0#\D0A!Z@:S8ALYVJD.LEJ[(%0.#593VC-LRIPL5ML/6][JJ
M=T7=L=AS0U'JDU93&#,<Z:K!?Z\EC6B:#$2+*MQ:'%*B($(K."``9&.[CHIK
MR73^HZJLZHK>';C'VL5"JJ;*C9&NHITHC<(46592*:-;?'P01L+7Q$LTT9;N
M`HAP\&4P/,'X2L@7RNUEI@B7UZDCB]K@,.K5Y<;2>:%B;/6[7!)Q.%#S&'6%
M6U.FX^+*9B"45W(H84<RN*%Q0%Y-R("G"D)1`"0):F]<4E.7V'SJPX96TJDE
M7JGAU@4OEC-'79YKU<K;1)9`YQ)]="#ED46JF88BEAZ,T@P:00@&BR5G.,@1
MBQ:E:7`9WZ'QC737`MB.30)EDL:8*PKHMM]'6[X;,ZP:G=J;6<*<M/`I&J,=
M&$@T&`M:PX:A($HPP0\@5A%K+J:^&S1X;:)H1V,GEBM%C6`XM]>01;\66Q"'
M("QDF\H4IFHP+M/HH^)@J4[@IR-P1+P><$8#\>/@$-UVZZ#73<-\RV*02F':
MX-?K>88U;UEN];1MO>VZU)13<9S'G9)8[HSE!D[B[TK/&]J*<T2Y1GW2LRUB
M,P#!B8($UPS6;5:ORJ^;*_HJBX:54TBDKY5R*)UY!V+[W<HE;>I;9:X0@EJ:
MDPHPZOS4(:==E%@D9Z8&"S.H"PX"!BKNO>FA.I<D(L+9.EG.32NU81-6N12Z
MO]3+!V`=15RUM;#%9<&TGRLZZF?PO$W1D>4C4(Q]-3)W%$4)*')I"8P!8$R[
M0373W6W4YU+V+B,&9]5F-@A<&7U@MKE%)8FGBSB_QB&Q2,(*D0-#@%8R,3J[
M-I04:-O,+:R2PF^`HHC(P`7FYZRZ?/#S9AKQ16O3D_6$=!5EO^\:]K]6YS%5
M$CD"ZN%M@@4-8U#TJ85,?2'M!SA@PPDQO3C(%@28K(`(+O[M]ZEWJ.),@6&$
M58Z?.KK7;V6DUI&*X8W6\K0I9U5/!)-G)SV!4HF;8YK7(67HWPX<3/,$+U)1
MA@QB`G+YJ>GIKG'&?YO>O1CS!8M#FB*MGWM*_$ZQ.&066#E\!0,J/W1E8SQV
M(SS`G5I`2$M.A>>JLCP*NIG`*DIUQU44`DI*NE**/+E4H:)O*RE,$A!H'N81
M&2N$R89,[`-;1!4O<8FSJL>DBD>/-1/*Q0N+R!6>:<,"G-FN6GL2<(?)F>E-
M>(TYT..1M<&?6Z!UZT*ZC'8+CA_E;9'G!.VIS(5F8O#QA>M()$G]<K584&!&
M:9X\@6S4%WZIPYGO.EZ;0,==QK1QR(K^Q*XB->J87&J].S63+=*-EA$<:65O
M:7M"?7\J2.)8&,I0#(E&2^F#\#!@"<:3N&";"4]5U[U<XK'BMKD@$2LV!.S@
MTN;"M<XA-V-%(HZO5,SRF1.K8>K:G`HP1*@HLTO(N@L8SP"3^`.`.`.`.`.`
M.`.`.`.`.`.`.`.`.`.`.`>>SNKQ^P738.,*(JID1+>&LFHLP+1?+Y6*?*D+
MZ_9,R8PMM03TA0;X!!_PG*P`AX^UR6'P8$+HW:5E$.-DK%!R\U^-2G[%[79'
M\6GX>I]6/HAY3M3"]*LVKG(8DLI\S:UYO"T\C+;Y-.FE]G*X3BM=?S?E-+QW
MO<TM8XX=<W@'U7SCIX!=?_C`EOV.F>O_`-33S:?/Q/V-?_U>/_#'LN/<'IWN
M6E7&ZZ_^JV+_`/$)Z\J&*5D4G4Q*_)HEQ5=Q`M7D]U-?3LJ0,2()V37D]O:3
MG4S)F,]5`TJ<1N?MLE@SGPXXYR#3SKG'[/F2]FGM?LU>GWM7]\^"WJ=91;ZC
M<[9B[5C2Y;*<=M2I6UW3TTIC.U5+3P@K+%'P4Y::N6>69HHX`X!A#<UC76Q7
M8PN,.C<N75!6Z5D26/[J(;Q))"KL4]4VJ%B=`:G/?G\=>(?0KP!;^@"S#S<'
M]0!SC&>P<7!LP91OG!9MK;AKKT4.NFO@M[U77W+0](^GG:7ISR?ISE8G<&9@
M5=_<O.Z6!YLI[J(X"C9&$IJ4::%G3\ZEN_5RC"#KTDUK`S+8<\%&(2O!.+>5
M1E2PUQ]_U[<2966IB,J43^,I'A/%G,;,6ZH%:MF5.07-*WY&G2(RBC`A+%G`
MA9"S&Q_.LCY=*M4I^2EM^*.R6FY:Z/1[=K?5O5=3IO(=J=LQYGD<67&\!#F8
M96?^A*:WC..5C1P<B54LFM6NN<8VQQWCV7Z66VRG!N:6BG@^?/4=U]ETFE#O
M;:IF1V.X-]?."!`H;K*EL)4/Z0B+)G%::TC<FAI<E)YI`GDX@E6%G+`J&/S!
M9$+'K'KMY&%52I4W4G--ZPC+3XFEKHVEUVZM;M5X',JNU^.Y7U4P.&X6C@8<
MA9Q$)YU<YQLX_%S(T2EDRK@K57;;7%1FL2$YU/*E*B,=BTCDO3Y[PJK&$*9!
M(RI:\GL"0UPD)"90E)<CS,"%D99:M*B5FA3@S@KSC2235'E^:,`1#R'&+S5!
M9=BKCLAN>D?=^+5?=T3Z>!QWOZKCZ>\^2IXK$E@<?'*DJZ)2C)UQ731N,IQ6
MYZRV1G*,-VR,I**;DCEJ:@.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`
M.`.`.`.`.`.`.`.`8*[PZ?"WAA2^A[`=DZ'7V35Q:#3,VQJ6-Y4N?)U*X[F'
MP\[!<@@DQ8TL=C+(^.ZP*HG)+JD>\H%B019B+&1@8A5AVR[C-FV@5SW[<,'E
M%SZZ4([:T;;.T78'-R9=O:PB[S$Y]1RAX%*TQ:QED\,M^NF>2+U`BC,J3%;J
ME`+"=9@(`,/*G[*^TL+F)\TDEO:^&*E^SW;IV%5,4+0V>T1QN)TFN"^)Q+8]
M'4SX4^.B,RRHE:+:WIE"Q6N4D&(S@K3U@,`,,`XZM[)VST`?-`#E%QT$)ITV
MG5-S21.+*V64CED\!!=A-J+.E;`G6'@&WIVA;"-B"DC87@M+_AY+@!?E6G4I
M1HP*37O87N2#5K%8J3<U3)WZ'P_5."GY8&F4L\:LH%`]QE=O@]6%/DP6LU4*
M:B91DPUA+R%?Z,I0N5FJ_+4A1%`;,>WMHA9.E,8N[,BD\+LZUI:MDS=&[4.D
MUGX66E&4EF7)9]8.5TQEW/71N+39E67$K;G=<PIUZES*!D\Q48`*5$D`PEMK
MM(;D;-Z6;$T=<^S%/5A=5S22W)8X/FN4%<@U7;\DMR/1=F=Y+L.GNAGL6<*G
MMI1,.61F,B*F/#8HP4G;TIF2PYQ@"?\`N;=KVR=ZX#KQ"6&QJ^&=3=*;:UF_
M/MMLJI>JDTKV#U+DNNT1L%.@B[#AF1NT/EC^"2*/)3)<8,3X`C"0/(!E`0%,
MNRS=$\D=JKG?8R.I$UDPW9,E3(_=\E>9>L==A.W556C:&II%E3[N*=*.JR6U
M^?/&L.5651ZXQ(3Z-,H(,7G`<%:]F&U\$5FWWE)M?IY&V7?2O]L;(A)#;+WR
M)RNO(SV^&;2N1U:)ND[!@E\-DK\TXD"K"\L+>O)SY*@KQ"ST`S4U9T`L76P[
M>A*TS:#G0;9D+FYU)53@2_RJ,U)*7M9;[G)ROBT2.(V.&HY2\V"C7D0T+FN+
MC"K+J%I<BDZXHA*!C[JWVIKWJ'3#N#ZOS:\X4RRG="*C;(E/*C1RPANJ60/&
MGU;ZXOC@WM#M[D6A;44G@@G)&!,H+5FMYH"S5`5(<F\`QFLSLD[)V#1^Q%6M
M4UU1KY5L-8:.7JT4<CUBCC5<(4W;:QI`85!@IFQC3X<G&9HRGU6)2V#\UI6*
MB"1IEO@59`R/H[3R\*VMC;&[Z9+,8[&04/4T19(9>-:/AU13ON#5!3SU43GM
M-`51$A8)7)ZSGE2*FAC/4I5K:-R/,6'*3`K0*,%@;3+8JJP;UJJIH5+U,2CQ
MRF<4Q,]@69#[R<FAX:*_<VVPI+`X@>:#S5+7(K`CC>W'"6Y"$Z/FJPCZF#"`
M0&M3NB]K&W-Z+*73>O[-K1G:G_6-JU^&P6JUR5R(K>0,&U50;&EVK70&).N)
MS()<SUT=''8`_0&^26WG!4F`(,3#`Q1V`[2]C.%D;MW+=*AHL*K-I*AOVA(]
M6FLT)L%_M*&2B\]JJ_MR@[S&TN[CZ=5(Z5?T0GB1.`%@R42D@Y:A*3MXA($X
M&<\'[<=P,&R^FVS*VVHZ3-JCJ]!&]IG(A#E2@V2ECZP6Z]6`]#K)0P'12#2H
M-T6:-Z8I4QN;:Z(VA6YLZPEQ2'I?3`<45[=EY-/=5QOHXSZHDU9)E5_MY4$B
MZ"<H)L\QNWZBUJAC*JDZAR.<F5QE#+*Z&,-69`H+;36\](),F3*"#<'`6)(.
MS04JW9=MIXO<08U"G':U-L.&G01XM:PBC-H4(556X];N!:GS$;B@V6F$)AK^
MI&:$0&TYG593A`:N.&(#'Y7V3KQ!"CVX=MUU-)NT;6K+1>'Z72V[$#9M7KZZ
MSG:&4_>RV$:6E2K:X//HFEVK>,MK^PHW<\YP;$9QPP%!)(2`3I4/:YV*H;<F
M?[%0"WJG?:FG3JF:S*#LIKELS9FB+L>G5,:Y1"=LLI>$KC.T%TL<AI@DE8XF
MO*P#U"WE>WGF@7#RN&!N$H2'2.NZ.IZOY>B@#;*(-6,%A[^VU2@?&NL6YUC,
M9;&58@KUMDRURD2"%HCD62FPE<H.5EHPEA-&(>!9X!+/`'`'`'`'`'`'`'`'
M`'`'`'`'`'`'`'`'`-&W<HO5QK.\8XQ)*^J:5%*:];7'+A.1:RX=RAFO+R3E
M,3BY)@P2;"(.","#Y)(DGB$+PBR/QXQOW:^!'*P)6.VZ#\QK2'GZ>"_W.+CK
M^J?2GZ/_`$SQ.\?3;+Y*_E>=P9PY6RO9A_TA\II55/<_T3BWX^][M'OFK=$M
M8[=K>O`>W+WX!=*7USSGPB]F1Z%9Q]C/V<9LOIG'-D_0\/\`=\K_`/J_^\/6
M$?0;CMR_](>[O'W=Z_\`X>>HNEG0;W459/!B-"WF.D$BR\:%K]R^[4@E3,C.
MRF0?#BA6P>D)R/PE^B-,2^'&/*%D'3/.3YT5#,M@FVE9):O75Z-^.[KK]_K[
MSXL>HF%'C>_>9X^%EML:.3R8*=GG>9+;;);I_,1C?N>FLO.C&S77>E+5$F\M
M331P!P##RVMH<5O>4)K8M&C.BQJ-`*R7XYGE*S,;6S<]P::]+R^-J$<58"!O
M#;XE^7-24,:543DC&1YZ"S6'Q7S6!9E-M7:O8M8_$HZ.?1O<^CZ;5XIZG?\`
ML3T6?=_IKR7=\K+(\U&R?Z/I5N-#YB&'&%N<_)LFLF^7E6:4_+UR2LKL5C4?
M"-6W9>UCD59D*7&M%*RUXU`I"4YM[4Y>GKD<EG$8C+BDDZ4<G-`M2JD<B%AM
M-\Q*,2Q(:$81A]@;N7%X:E:TK5&F<XZ-KX]L926U[>CUC\7CT:-OR_1WLBO(
MYFRFGF(8_!YF;0ZYVU[L]8^'D9%<\>2QDX2C.A/(CML2JM@XN+^U-;-;,V>:
MOF3N!Q@`)?%+#D<!1O1`%/PO+QL;D`E-F,-RY]2Y/DCJ2;A"4C&X^1[X*,!Y
MOEAZ<Q\\.B&7"&EGDSKC/3\J.J_*:7V5XZ[==NCTU.=<AV+VYQ_>G'X$J>5?
M`YW$X^;*EN/S.*KJVY?,60IEMQZFO.E:J-_RLH2V;WJ2M3<Z/LRK8/.UA"5*
MODC"E6NB1$!06E1.X,C2NZ$D"D9IP0HG).:5G]<-#U!GPF&!Z#%:9V.L7+LQ
MXZN,9:)OVKV/\*__`)(T?U![9K[.[UY+MFB4YXN'E2A7*;BY3J>DJIMQ27QU
MRC+PB^OQ0A+6*DSEJ:<.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.
M`.`.`.`.`.`.`8RW'LU&Z0LB&1":-2DJ*R>MK`L!PF2##P\+F4Z&6+1=8M4>
M3PUACSN[/BF622^6X!1Q)@,)<)C/,`((\#`!9F=^-;S_`(?`T2-_?3WUXKMF
M5(V^)/B=?$QV6\*F1D<)LWO*9J6Q=J;UK<J"O.4EAPG$C4EXP,Y,>66!WC][
M]7T*1L<G:P%C"S.RR0(D3_((7-V-@/-CD5=9PI,3O3G'DS<M2KH@RJ7!&<G,
M.*5$@P$`O-&`L0'W%-QJ^7UV^6+.FYXK]&WW)=M1-+`H;GM]E3\?23K/<OCL
MGC:!C*?"SAPNN7-^4HPIC1)$28S`3#_"`1@'4C.X\.?DUI310SKT=0U_8\*J
M%DF3>DDLG?Y_.YZ97Q,4,BT0CD6<<N,1EJNTV5.UN!"TX9IIHA'$D$Y";D#F
MCF]NM4L01QR99@^Y22R40:',9SI7EAL9:A[LUKK]UKTM1[WBZ0Q&DF)5I,0$
M)I@<8.,6CQC'1*LRG`BR-=P^OU8,N\Q1-$9AA##&)+F5-2VP99[^9)'KW7U\
MB<XHPHZI0OB@IO33O"42=T):EQJ8C"D!'G"-1$`3_#=N*)GDJB\(CDH=5$KE
MJUV:&]D60V8-JUO?V+$_R\1V2%KV-/B+O;=]ZR0A,)<,I\8&UF`P+(QDA-`I
MBS=+75OC1DL735:D9THYT%Q]3$9<0Y-&*L<I>V6F-X9C60#NV8K44%<CWO!Q
M`!H4I91PP^!4ER<!^)-T=>G.0Q2*,LJ?I!(9L_I8W&6N/5]/WPYR<%#];T<,
M.\QKC2I.E:F]QH67"5+3AEI$R5E-4&&!(,(,-`I$AWKUPC$P>8"ZR.99EC/*
MSH,2T-]36F[#DDP1OT7C+K'88H;8>J23%R8WF<LA2X+<8H"E"[I##!8+-\6`
M*@@W;UP<W>+L2&;K5#G.%\;;H60"(R[RI4=-XNY36O3619EDPB5H['B;$YKV
M`[S`E.Q+2OPG$,:-0`L"8:MN&`W,QXDE>NBQX:,`'@Y0J9'ID-1KD[N^,+BR
M."-[0-ZUND3(\1U4G7MYY9:Q"8$.#BP>8#Q`1.9NAKP3&4DO-F:XEC4H):ZJ
M#3HE+2%K,UUVZNC-9KA(F@YE+=H^GJ]:TF8D?JR"1LX#"1J0@">3D8%02[>T
M`MAD\L!+-%2B*UG%&:;S)>3$Y><<VQE_>99'6MR3MQ3$-R=O/>H,[)\E(RCS
M@"1BR(.`"+$,"SP;ZZT8:'Y\62N4,[?%E[:WR0Q^K.QV,QD$XO\`842&K<"G
M2+I1DMS9+*FDK4J4>THIQ9CT^,B-R2$T"46;9*GWZ#NUBH)*I!$V-22UNBYP
M8']J4HI&?-W>M@P]0U.;:D="9H">,IK6-I$3A>6K,("(K&%!.1@0RP[VU.KL
M:=5W*T$H@RUA>XTS0<Y^BLT1JK#62.(4^^%1].V.44:S6"PP2*Y&YI*CAXS'
M)3U`I`'RC!8*`JZG?C51&S?$2JT$R=AP>YM9SRI9)`C:D,L9&Q*]OD!=W%8V
M$(V*>L+(K"M7M2T:=4A1@-//"640>,L"_FS:JC'4%A*"IB8D;*KARR>3M^<H
M_)$$<88XTF.A$@,.D*EI`S'NL95,RDER;BCQN"(TOH:2'Q!R("Q%6^.L;<_*
M(T\3IS8G5K6JVR48>H/-VYO@[HCQ-<C:YR\J(^%GBK@IQ7[GE.4L/+$J``@9
M7C+5)1'`7>Z;;46R0!%93U)G9HC:]SG;404Y0V8(Y!DZKT<B=;$6!BY[&"0'
M,\28HFXN*A<4G,2&H$^#TYAP#B/-`L!HW)95Y$NDBF$O@((V;!,&L\.=VP+@
M[/DLL5ZEZ2&`>CV8AE+;FVM5#@[H3TSP0X+A&)3#1#3EB`6$T"GTOO[1MM0^
MKG52J?(M.K$1UR4OK<R+S-W>HL^6/%*UD[8%2<1%DIJ^$X^^TQ$E2;"8EG-`
MO`>,PDH"C)`%RN&\FO3!));%Y?(7V$KHA/'.O5*R415\0LKH\,TCIN(.:YG>
MB$BMM4,J*1WU&B##S3"<EDJS58@X1)E"@L"1HOLI3LRF)D`CTF/6RW#5)75.
MT"8GU*:X?!1,0435I;3E3<2F6R&(%S]D]XMX!Y5IQ.90<@R()V"@+%#N]K0.
M-Q67%V%D<?F+&PR9F</AN4!""/215"&MK>78@QG`I84.)'9#&TJLK0$"0.J_
M"95@DPA3@@"/F/N'4*L0MK[(%S[&&.3QBOYG&$RB%V*Y2M'&IS7S38XW.P&9
MLA2EGAJ9CCCP6J4&EN;@G+3`,&::286,G`$NE;=4(?&;6F)4P7&QNEFM*]V`
MZ$1&8*26YF7+7UN1N36%*Q'&R0@];&5P/`W!5'`RGSD8`A&7D8%GI=\M:56'
M$O,JE*-R:UI:%3'W"L+*0R@TPN13F(.YK9&5$4`^/::,2BL9$@=#$1"@*%2S
MJ`F=/UK)@$>P[N/4C(9&Z))(CDU=PXV)Q:3PR92QAD)1,E-?4MK+5L><TJ-B
M4M\7D12*HW)0V(S5QZA[(#GTX/-#@H0%<E_<%HB..D03-SJ<]M*F;S6'VT\#
M0O[9]XT<#K>]IR^_'*(Z/GC3/Z=RH1U;A-9HTQV"_$M",2<)65`&9<4D[1-(
MTQ2V/GC5,<D:D3TT*AE#)RI;G`@"E(HP`?V2SR#,""+&<A&'.!!SD.<9R!<'
M`'`'`'`'`'`'`-,W<(@]9R2Y6!=,7J*MSF7!&].42]T=9%DJAI`.SL,!@'R(
ML3FV)R?,&+&$XC,&ASC(LXZ"QS=^W,C)JPI1IC-Q\Q^%L(>Q>R33_"?0GZ5.
MY.\N(]/<K&[?Q\VW#?)V2;IYCC^/BI.JI-.G*NKLD]$OC2<7T2>J9@<.IJ&\
M`_\`O57F/M1>WYI=Y>SV9]OLB/7FP?.9_P"PM_\`K%7_`'QZ<CWSZG[E_<7*
M^/\`ZS\-_P#:CTC5$F1(JLKI(VF$'-Z:%QLA$:E;%C*F,2E-*4!`R&AQ*(7M
MA0B\8R$@X`32L?:BQC.,\YCFN3R[7+7<YRUZI^WWKH_OH^0W?EV1D=[<M?EJ
M4<J?(Y$IJ5D+I*3MDY)VUMPL>OC.#<9>*;3)$Y;&IC@#@&-%DV_6L1M:'T[(
MHLVNJNV$IJQ_<E6&$+<C.2%'D0=-($3AGUKVJE#JS'(F_!8#?3FIL9%X0],X
MRF+A95V)/-KFU&EZ)==7K]K33HMJ:;]^IV+L_L'O#GNQ\_O_`(G-NHHX*:C1
M7'S_`#)J34LR5$X?!3'&KMA=?N<=\;&EJ]48Z-5IPT,-;&L6I,":%%T)H=(8
M)#2GB&"C]@HG66,#.2?*G-/$`D,3O&5,D2K<D'(UH0A'GR3<F!%C&3GB7^>Y
M_.62\AR4Y:2U@U%OX5NZJ6UK75?=6AUO-[)[@?<%V:N^^4OJ[=GET9N6ZLM7
MX,Z\:^UQQJY93=U61''MI4XVTMM+S(*#3)YS8M9D45+%$SK)JC[)!7)VA#Y4
M'HH\ZMY\M:3"3D,5BQ`"$;&\_$"A:F-;3?*38'ZD)AH2,A,\&/\`ELIY\%1;
M*5EB4U9K)/:_&4O%K31[O'PZ:G,%VEWC9ZF8-7;W,WY7(\G35F4\KOOJL6+:
MFIY.2VYW5>1&%D;X[K&O+<(.Q..Z<*PD#7+:VK^5LC.7'F:3PF+2)K8"L)`E
MLC>]L:%S2-`<(`A18]VD*@D_K.,%]0?:XZ=.6&57.G*LILENG"R2;Z]6FTWU
MZ]?'J<V[SXK-X'O#E>#Y+(>7R&%R.319>]VMTZ;IURM^/6?YQQ<_B>[KUZE\
M\MS6AP!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P#'
MVX*[U[E\CBCG<F8Z&1EL[K%HCA]F[A%SU32KEU?V$[MK:WII`T$N>12ZL(ZO
M-%@HTT!C80'Q8`(8!@8K3N-=NR$J(N%U1Q25OS*HBSC#X_&YR_3.1LC9,+EJ
M$X+PR(2)>I/;8HX6%8D6<W@DH84J]"L"8<0I3'&`-`^&;7;MUSYBB$4=V2*J
M!,L$=6MDK><7R_2)];ZX;R)>U"2N+&*VY*4ZQ-D890Z$-^33%:1I:5F4Z?*<
M@(22P+Y31C2X+G4>N;(F32\V?KK5OV`GL]AR2;+1.@FD22PYPNL,R;.4P\<_
M8[76I#3Q+#DSPD<EA!F1%FB",#M5`]:36C3Z1_@+A#6V!V/:%=3U5&5<Z`QN
M3;=+$HKUZKMB<68F6B%$)FSJXE&\HX\2-.5CTZ4`4P@&8"8!8->5#V\IW%JD
ML-E9F.*A<8O4DY@;/(K4E\/E+6T$F4ZBJGWM'16$2;D]`Z02%I41*C"@&7!(
MB`'QG'8\T"]':B=!F*!HW5S20(BO200.$HG0JS)*J9,`DC!%M?:]8REZ&7G@
M,]]L34UQY#]OG*CR0XZB-\8\@=2,:_43"[O=MB(G=R1ACT>6F1M]C"*P,@C3
M-+)=*Y)('1BD3N.8":CP3.?V@J<A-CLC4+1.[@5Z0\DK)"<('T^UOI]#HB\F
MWU.:MDKU\73:T)M,G-PC,$='EVL5.FIB3JW5C@JQH`>ROL75-\1=4XRCDSM@
MHH*\)RH>1Y`O>,4AIE!YPLL^-!A#-+X?.TV%CN"U'@U%#YU-W&R$[9'\LJV9
MGQV,JI$[[!R0"!F"E((-524W"=/YAI70"VV"BM6V";RV1S*=1.83.274OOR-
M^_YVG;%<&=G&20!$C115L128@HAJQ-(8S%J1!*"!T<2TY*L!HPE`X!SHJ?T,
M.9W*(MJBIQMD+98[-UK:VVP8!1`XO7+VA?X1)2#T4S`X0F+UHZ(0Y8E))B1%
M'RCCR$0DY*I26:`J@C6B&@ASJBV/@$BEJ=VM*U7]^C%DPF'M%KR.;+U48L"<
M2R"0=Y11&1)D#TTB2X,&E/"@=$.<Y,PK"<(8'!':@U+,8V]JG,SJBQIBNG4J
M<Y!+@/L/AKC-9]>C;%FR3M3HQP9U9VM<59T7E,<1*F0PL].^IE3:8H)4G'D'
M&`2=&M5=:"8O8C7&(2WJHC=3>F03<A#,):Z,\A944BE<G0M;4;F3*R&!B0/\
MU=CB$K0)&E(]8,L``EX``(%%D^BNJ\R+6%2.KQ+@N)CH8NR5.;';3%?OMXMB
M0.Q2@UKEZ(TU*X/=Y2M4:3G.2A'/!F?#^M)_)`N=FU@KHVGYS4%BH$%C-ML/
M3_*;;=!LR"$'SN72-:D6+)48E@WN0$=D*436ARE7MQB=>G4(2583_6!RHR!T
MU^G&N+JH"M=*\&Z.0%B)T"[N<RGKD]A?6UE@C`W2;WTNE"ATS+$*&LF$PEVR
M=EQ+6MA2P)V%?C/$!W"-1==T:A<J;JW1M2AQ,]6M-:'N3M>5+P8U',"V3F@0
M/:<HR8/,>4&-KD\"#ES=&TTQ(K//3&#*$!R0[4K7B`Q:P()$ZU;VN`V@Q&QJ
M:5^-YD[C`%[$KCQ,6=&YL@[J]KHI%R9`RD``Z9:D:(;J=CSUF3U'4W@%,<],
MM9WO*X3[5J!_,=RT);\:^OTL>#I.)N%+!)U,K,<7]2.4K1`G+H6<>X94G*"5
M7E&B&442`L"X5^L%(N\'AM=O<272"-0`QT,BPI+,YU)I*B"^QI\AC^G63B02
M5SFSXCD$/DBYJ7DKW!24L;E(DYH1%8`$(%1,USIDR..<2Q#0IV!VM)#=*I$B
M?Y2WF$V<VR1KES?*6M>A>T[DQG(Y`RICBTR(Y.B"$ORL$^2,98@+/C&FVM\+
MD,1E<3KPR.R&#)FMOCKHSS2P$!Q;.RPR"5^V1QW+3RH">3Q5+%:PCQ&&IT`L
M;AGLR54(D2LH)_`*K)]3=<YMB6!F%3QJ4%3>2RR7R1._Y<G9*KD4[K05/3-R
M1I%J\Y,RBDU<BRW+2T($Q)_7)X@94Y\[@%Y1ZCZJBD\>[+CT-;FR:2$]V5N3
MN2:N$#UTA01%KDCB@;#E9C2T.4F00%E+<E"0@@U?[K3B/$8('BR!:)NJ6NY@
MF/.*IC*<J/N<X=F]&B`M0MQJBR;);[BFZ=U;4BLE`^-4@M-H2/YJ):6H1@<D
MI1I90,EAQ@"TRM'M7"6TAH#5P3&]-%$D&)(43*P5>01-!$RX*A8_/52PY0)&
MCB!(&\KJ/(P)P!#@6/#C.`*'5FET+@T.MN!3*52FU(I<CBYK):RR%U?T#<M"
M[.[D\N2LU&DD1Z=`_O"IS%A>I:`M"52`HH(4A6`8QD"[CM-M<3I`V2T-?J4D
MI9I)\6MDC;)Q8;0]HWHR46C,EXBW-JEB-9EK?)#=,I-<V\0\M[J4\G)UA!Z<
M)118%+,T:U5.;E+.IJ1O6-*O)WFM:^235>W@"8T6.PDDI4BR2GD(4S8TVW(2
M4)1`2RF_#CXDP2AD)A$@=SYENM@9<GGJ:OE3=,R#S7`V2,TZL-C<W-^.36,C
M,ES\8S2Q"5(IOZ2W)*5A[7`4.H2GE0#"C`,A"$">8)`XA6,08H%`6!!%X?&4
M?N]A8&L`BT#8CR<:H$0F`,9@\!$>>,>>HLYR(6<\`NW@#@#@#@#@#@#@'GC[
MKM5LDVV%BSJXKHNG/)K%J1A+>:C8YVJ\LM]?C,""[N=O0(\DK(C<]",)#`AS
MC(O,SD60AZ3VAEV4<;.$%-KS7X6.'L7L5<_QZ_@/J]]#O>W(]N>E&;A8M>;.
MJ7,VSUIY2["CJZ:5UJKXO-3?3[;MBWT6Q::O6"9KU%?`/JZP#IX!=?\`X;8E
M]CIG_P#.6YM?Z1O]UG_AI?\``'L^'JMS6Y:4\KKJO_\`8,K_`.'SV`4(A+;*
M2J5N)&2,I#74/2%C3("FI.(!#$B+"(EL)<'4E`5D(?M20J5`2\?:X,'C'BSQ
M?D).>?=)^+ME[=?:_;HM?OZ+[Q\#?5#)GF^H_.Y=BDIV\ME2:E-V23E=-];'
M"IS?OFZX.7BX1UT4M<LS1!P!P#&2R(OKLOL1#%9\B0&V3;Y"9Q9C3/>&7X:>
MIB\/J(UF>$N,FQ<MJS@PX&"34WJS,FX_7,Y'CF5Q;>2CC.[';^5I>C\--;.C
MU7Y6OW==.G@=E[0YKU9Q>T[.;[7LMCVAP$I5VI;/)4N3?DS5M4NF2[?AB]\;
M/*BJW\"VL@!D7ZI"C):Y`*VQ&I&V`$0<"U-8&9:&-%S1JS"3*L1*R>A[(;+Q
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M69KC#*8D/0FMK(C0DD-R4U*I"%24<!,`/C\S]<$+.<BZYSG/,;E676Y-EN1+
M=?*;<GKKJV^IRKO'D^<YKNOD>7[FR%E]PY.9;9DW*2FK+IS<K)*4?A:<F]-O
MPI:)=$7OR@:V.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`
M.`.`.`8O7/J;7=YS1MF,P<Y23@J/1N+/S`UN*=.SR5HA=HQBY8?E1YR-0O9W
M)BGT43G85-YR8U2D--(.\>/(&0!CY%.VC7,6]W##;5L.JA$@AC6><N+K@@*Y
MMKP6K`8<E,(;($A)(]VI=1HV4:,O`3%(52_(\^(TC*<#KN?;`J%Q:!M8+&M-
MM/+4H'%M>&X5?ENC4[LK'9K1'G$@1\$4(E@6=5:"I;Z142H1*S4A!2DDY*)0
M0>!*55:/0JI;79[58Y]-51C2%^<O@H316[)"!S"7U[7E:S&4(&F+09B/CQ+\
MQU8S'^Z6XY*TI5X%!Q)`?4F`X!9<5[;U0PV15O*F65R[+Q7;?'XF/+LR5E(&
MV8US$%*%QB41E#,_0)R:0NT=>FA&N2R9N)028E23GRUH"Q8+`!UF;MFT:V18
MR&+9/9+TQ!C2YJ;#%KPR)WR/R=RIZ#4>JL&/OC?'TJILDJ>(5JQJT18<9;T#
M\B"XD)PGX+\L"9FW3VN([4#W3,1>YE'8ZZ6\RW2@7A<6UX=8Y*&"WH[=;8UL
MN7II7(2HFGF$<+P%`:2:$"0\XL`PB%@80+>BVBM/QRK;,J56OELA8+.JB(TB
MYNCHO;@2)JKBN&J3,]:)6MR1-:8O,L@R65'F)7Y04<Z&JB4QYQHS$Y><`6Y,
MNWS5TR.=3E4UL=&8M<HW+6Y0%='EZUCLN,UG':B(GZ18Z1U8-8J=X5%$(7%L
M58.:%B\!BP2;"@T0^`?2C2AHC5"W-3$.<4LT!<+KA,:XV24P1YTBL4<)(->`
M*&:5O!6R7R.2U:F=EJ^)N+N8L=BG%,B`8XDX!E4$#DG/;^JR<N#HXJY?8#><
MJ?(M.F41"N/KC8S:$0KJ*U6V3QN.=F!>8L$LB$*;0KFE9ZAH6+"1JQI\*#1#
MX!2"M#V.$T)M/5]<2YS>I5L74,LKP+]8Q4<`B:W9YA<NC+:M5G1*'H%&6KUL
MIR>J*].IQX2L8*+QG.<"`[3=V^ZW2/;W.,2N4M]A25]K"=.S\S)8DB1)K(JZ
MRG^T6J2-;67&2B"FYV=I&>@<6T7^!+&\`!Y++7>)8("SY%VY8.SQ1TCM5.CF
MB*E-;UO2$C02!^`SH4\$K9_CSG7=C-#E&8H8_EWA1!R)Q<X>YDGH?,<%I:=<
M=E(A:L-H&P>-QX<;+7(B798L9LFMI<>95"5I3I(FTMS"TLX65K.;V]&N7)#U
MC<:N&8N-5*<'K#`!,"0`DHL"Y>`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.
M`.`.`.`.`.`.`.`:)NYG?%[5C>D;8JSD<O:&)37;:XJ4S`T;0KT@W$QY>B#3
M3#J80*HN$_))(,9"<+"O&,8\6/!D'-_[6X_C\K`E9E1@[%8UU="Z:+_=7N_L
M'TT^CCTQ],^\_3/,Y/O'#P,CDX<M97&5]O;D)*M4TM)+EIQR=-6^L5Y6NNWX
MMQKG'M_MY@`LXG%E]<!%G'_=K?\`^STST_\`Q/S9?T-PW^YU?CQ/^R>M8^@?
MH,Y)/C.'TU_XQV1_PIZHJ3='1[I^L'A[.4*'AT@<57NAZLM[)5'+U;,C/5&*
M"I(`N0EG#.'G(@K0X58S_P`[CQ]><FSHPAFVPKZ05DDO#PU>GV>GXNGN/B3Z
MC86%QO?_`#7'\=&,,"CE,F%<8NEQ4(W345%X[=#226CI;KT^Q\.A)_+0TP<`
M<`Q8L[7N-SRP<S1SLB0Q^<J?@\=>$I'?TJ2/EUTX*7Q9Z*,>O3HI7A><\*1+
M<JBC<$E*,=/#X0YYEL3DK<?'\B%494+=OZ=7O6B^+36.FBTT\=#MG9GJMS';
M':O]'</B,3+[:A\VLYRJW3O>?"-,-^1LE/&V*JM4JN4=\H/77=)$1-M40G,>
MCST9LW`G0FD&^&QJ)20I-$RX["0LLK8WP898$B9#)7NTF-CJ-$+SEB,(`%Y\
MDK!@\YY>SS+_`#)5K%LB[W*4H_%K+6+7P_#T4=S?1/[KT-]S.^.Y/TKE\='L
MWE*;.Y+<O(RL=RRG?F.[&NI3Q=<1.%6.K[;5LJM;<EYDW&*1+XJLC)]/O(76
MQXC)$4EF1EKR.PI3'8E((&[K#G)*K\1C"O6CCI,:(;D"=&1D"SS2BR0F849-
MZCS9?-VK-CLJG&48>7&$924TM/>ENW:MM]/;IIH:"N]N9J[^QWA<1GXF3A\>
MN,Q\'&ORJ,VJ*KE'I=""O>1*R<[9ZU;92FX>4H:14Q5/#VR`US$HDS/A\E:V
MAJ"%"^GGE*`N*=8><X@.1B3F')RFK'J_"C)*&,HA($LL`LA!C/++,OGD9,[K
M([9REU7NTZ=?N^]^UZLT#OGG\SNCNW/YWD,:.'FWW_'2DX^7*"5;4]R4G9\.
MMLI)2G:YSDDY-$A\MC4QP!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!
MP!P!P!P!P!P!P#";;:T;FIB04]+8&!?((#-7624?)XFUQE,\KVJUK20(T6NM
MD*'$ML6N#=$VRRVT$=><#%Z$HJ3D+U'A(0'9$!#=C[66?7=LAA1CHWN=4J*Q
MLRH&VV#&!I(7*=RJYK,^W"S%:DI=B.$L#]#6)\2^[<-X0D2!G&FZY">27P"*
MK7W.LUHH'6J706U(\JG,KUCMZP+3.1LT1>/%8D:TVD%S1;UC;A">E83R9VVD
MJ1MQ(2?,3#"0,'@-!U`N`6TVQ:O[\5>54_1FV)D[5!0ZW7Z>.\4099V_8:QH
MO:+]9=927$761Q@G#-64,K]LEJG*#"58WIY"4B5B&(U*+($D1C9.57+/]39!
M!+(<H?7&Q.O]R6Z]0U2Q05:OA\CJT^@4IL*6NKHP*G$MP9W28R1`]!R?UPI3
M_K.2L)19&!C=6>Y^S4GIA--URQ,Y66W1/05PK^NR8RQ(S-CTFP<9JUVN67-^
M2VSSTP4DDF,D9$86@1"6+G1,:MS`H(R>#@&3NK5\WC,+"B]7W&MPZ'XJ^SK(
M8K0BD62(JXNR`8F\`9H'(O>1*%4BB%JU\4]+FB4Q\E44F4J,IW9(5Z%86G1`
M83?/EV6(J:G).S6.TS9;/J=CLRM9[+B$+18IN9';94-5,<;C75.V%1)N37!`
M+$E)!#<[)CEZ,^-9<23/3DJP<`S>/MVR!W)K;%TEU#(B=G)=B5TR*]'4LA(;
MATU\-.*%NQ*V:,$MBH!07-4F<SDHR<8*+P`/D*"3C!`1*JW7M56JLI@=%+7!
M%[E<.F4]U^=,,C:6;*=1]A=B*UI"0>\$STI?$CC*4'D/BU8O+"0%`DD;4+!8
M1D#$,#G)VON5TU5B<TA<W@$VNTBYK'*F$+6R*O:^EDMJ:&7!;,7S&H$[2)K4
MUE$;'51&)I#68Z3$)FIZ,0*$XU20Q3A<E`E.\ML9_$-:JEM"G6-TFTU>ZUB.
MQ,LCLLAF6&8JZ"A+?$9G<PE\(+=DIL,L&2QQVPS-R<0E)+8^.(?$`XM*,.0,
M5+(WENUNMF^R(1/F4NGF9AO!SJN<.T:BKO#WYP9-&Z0OZKX)#'1I2!><6>?,
M9L[2`(9%XFMYBR%<C2!-7H3<D`9&2[8RR&73F1VNW6*@!8+?)]=TJAT--K24
M$1Y#8DNIYGE"8\,;9DT<2X<&B4.1Y1"TD:Y`$X!HAY+\C/`.'8#:VQ61_P!B
MOO7R5E2M=2ZR,UGT$4D9D$J0;,WE\6V\P2VJ$RWRE!SN"-O,!CC"<V1\U.\%
MK)<$X1O7"8&`*O3^T,MD<$F=KV?,2(E/8+9%XQ25:ED((F)]:2HU/)#7].1#
MUZA.5+2Y+-R"&!U3/1B@30\CD!64I0$9R400(W;=G;Y>ZFJP,HFR.!WI%=PX
M1J/L,RQV'QPAE7+Y'-F_R)E'VR7I98O94TTJ5Y:']I*]08%&!V$4H\XP@6``
M6B\;8W6UP"['53;:!%((1LV\5)'%1Q%19R9"FS;JK:E5.1D/^'??J16VUX_+
M\&N2L1C?YJH!V08%@C@$DR39NZFND]CI*WRA"XI*QW)I2FZAN8M@CS&DM*K)
MU86N;1/C\E/2)5"UJZ$NEF2J(#D"),4U'*8_ZP)03"E`>`1A1^XMZ3JRXG%Y
MW,D<?92FR\0/YODUE'"5@JYW275'#WY.^OC2M;K`3NU183EJ3HQE*D>W,L\Q
ML+3C$`D`$BP7;JPY!2FKBI9.F-5*K/OQZA5\SU(V1X:NH:O+>+R3Q>2+6-(D
M%'HU\5RROX_#TK@YI1I`*7O)^0&&XQT`@ZS]Q]QX'%HI8K>SO<LB*^Q[YA30
M5%Z^95YEB1/6*_/C\^P`G`:5QZ`N]M(H%/,(!I@DHE4F9FTUI"'#NF)X!FO;
M=MV;%8EJRN33M1&%=UVY-T4F5JH]%0.;;!'+738^XXDQ@1OK&8B;7.(.T-CJ
M4T\TCS3Q)C"C_&)0+/`*5JE<U\VPM?J[N-4.,6/#Z*K!U=I3$8>F3UG/7"P%
M,N-CUZU,X/B%S"H02EF9@A6QU6J69C+RC4(SP*$^4BY<!!<(V<OY5C7%P/G>
M9D"UIYO-')(S9:*U8``9]?Y%:+%`U[<ZY8V\I+Z1!'6Y2KR(0\*S0B'["3,E
M!`[NE&U%OW%(HXFLVQ4"LA9!=67K*0@NM&##M(K7U1C5G31M!'"V4J7N@E$^
M=U!Y.6X\L#:25DLS`B"#N`5"Y[]O.OY%MNF:+<-REI1_U!315&LB%?F$%)+[
ML%M:9DF7C^&PK#PM[.J$2@&,W(R`=1FB.,Z&8`[4[O>Z(?(]AB,72(+94NV6
MEU.M@'**UN21\$7L\:QF6&:XJOAM.86L2M]C2`I*J$/PHT^0C'@9B7)O`)6%
ML6\/>VDA@;#9;094B"":YO3.8W.E<%)%,GG%F[&0R:-Q)CRT+)+,RGH^L69M
M)(:%0#D"E2(_`Q`'@/`(07;BVI#MO7^'2:4M:BC&/9"T*VE`3&V++E42KR+:
M-PO8=L=<H6%*CF[22VV)EU)5R5Q,5LA9!A;4:6%>I1'!`CB<[Q[,MD75113%
MWAKOZ.[,+&A36$!CT/\`C6;T'9VO=U7G2*&,H+#.>8^9,6MSBA446J`G8$[O
M<57>F*!AP2DY`VBZX6DCMBG*VD9]@U[8LR55Q73M8#U6GKD<7.E4CAS2]N*]
MJCKX9F4Q9F>5*HQ2@0.P"G%.D&`!X,&A'C`$Z\`<`<`<`<`<`<`<`TC]QV;Z
M]1N[8\BM97(R)"9`&Y0E`TR"JVM-EL$\/`"A"3S9A='41N3P#ZB`9@G..F,8
M\6!9SO?;./R5N#*6&HNOS'XJQ]=%^Q:7]D^CWTC=M^JW+^G&7D]CUXDN*7*V
M1D[:.2MEYGE5-_%AWUUZ;6NCBY^]Z-&OL=L:6>`?5RF_3PBZ])GKSUZ=,]>G
M_<[^YS8_D^<]T/\`M;O^^/5,>QOJ)W+2GC==?^*<[_\`:CTYTVI:5E35JK81
M'#9%,'C![2)0<A4'B;C6=(-'DX]L*(;CC,D"#U$0`!0L^T.,!Z8YRO-4XYEJ
MLT\Q62UTU\=>OCU_&?&CU!ISL?OKF*.345R,.2R(V[5.,?,5LE/16.5B6[71
M3;DORFV23RU-/'`'`,,[?HFT)Q;[3<$=D<<0+*T)C:*MF%>C$;[P0N"I:&U"
MG5Y$6:<P?%3&XX0X]*4;DTM&7@>0XSUQF\+D,3'PI85D9-6MN;7L:T\O1>W:
MUKU][/0G87J9V7VUV#?V#RV)EVX_,2R)\A?">GESA&'Z-=56J5_RUU?G?G)1
M496SVIM=8L:]:;'(;:W,-A$!0"JZ-U['5;"A>$8L6H=&9U%Y*X+GXSW`4VI$
M;<CCY@V["CU!XE:LS(_+#[1WD^4Q7*U*RQJV<Y)M/\WNA**2ZZZMOXM-%HEI
MJ;MF^L/:-N9R\(<EREJYK,SKX7SJG_R:LC#R<>N%*\]V2G9.^*O<-D%55!1W
MOI&0GC7R;NU/.,:\MD8W9TO,FX#X5%'<21G11\$G2O"B#-#ZN9_2$+W%(ER>
M<HRA`DPYJ#<@#@OPF<MH<CCPS5;\4H+'\O=)=7+;IN:3\$^B6NNU(U3C_57M
MO`[_`*N8W9.3@4]M/BHY>35NMG>\>54<RVF%NYPKG)0A!7.WY>$-S<M8&2U1
M1F00ZMHC&)2J;5;\SM?I5YS2E(2(,9]2H-3D%%)DZ1.8:E2&%E&G`))"H.`(
MW``8'X<8K,MKORIVU)JN3U6OC_9]O@M7HNAQ[OSF.*[@[OS^9X6%U?&9%VZ"
MMDY3^S%2DW*4I)2DI2C!RDX0<8.4MNKD?EL:B.`.`.`.`.`.`.`.`.`.`.`.
M`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`69);&KV%N+*SS&>0R)N\DR<&.M<EE
M#(Q.+]E,H0I%&&5"Z+DJETRG5N:8H?D!,\!B@H.>F3`8R!=^22<XSC)1><9%
MD><9`'.,CSG`LBSC..F19SC&>OV>N.`456\1AJ=&5A7NC"W/4E-<?AUF5K6]
M&Z/Y[6D]X._N5N.-+5NIK<@!YZGR`&9))QXQ]`XZ\`K(2208!@!10,%^+)>`
ME@#@OQYSD?@QC&/#X\Y]O3[/`*>\.3''FER?G]>U,;$R-ZUT>'EX5(VQI:&I
M$G-5.+BY.*TPA&@;TB4`S#SC1@+++P(0LXQC.>`=E-EO6DHW!'E&K3F)\*&]
M<FR0>28E6E@-P>C4E>,`DZLK(1>(`O"8'IGKG'3@'10OT=7N;S'FQY95CS&\
MMX)"QH7%"H<V#+PE$O:@O+8G.&J:\NB+&3D^#P%^>5U&#Q!]O`.\>)O1I%*E
M5E&E0$E&K%B@_)!"0H@HK(SU2DTSPD@*+(!G(QBSC&`8ZYSTQP"W&^9P)QS$
MT[5*X@O%-V53((,0WOK,JS+HZE3(%:Q[B9:94/+^RIT;NE--4H\&D`*5%"$+
M`3`9$!=6221>'Q%%9\(?"'J6#/A#TZ>$/7'L#T_4X!0VEVBDC"]%L;E'GX+2
M[JHY(BVE8VN@6U_:@DB6L3T%&8?A&[MP5!>34I_A.)P,/B#CKCJ!\JY3$D<E
M:H@ND<<23%^;7)S9(NK=VPB2O+.TC3@=W!J9#E`71Q;6PQ65A2:24,HG)H/'
MG&18Z@5WR4^,>7Y1.,"S@60>6#&!9`/`\"\/3IG(#,XSC/ZF<]?L\`!3IP@R
M4$@D)8A9$(L)0,`$(7]\+(,!\.19_5SP#\].F#@G'D$8"G'@2?'EEXP08((B
ML")QX>A0\@-$'J'IGH+./U>`?N4Z?)@SLD$Y-,`6`PW)0,F&`)$(9(!C\/B$
M`H8\Y#C.>@<YSG'V>`?62RNO7)9?7(L"]H0]<BQUSC/V.N18\6?_`%\`HC<[
MQ=Y7/[>TNC`[.<=7$LTH1-RUN7+F)S4-R)X(:G],F--4-BXYI<DZH!"@(#!)
MU!9N`^`819`^USY&D#FR1IR>&-$\R(MR^'&!<X($SF^E,J8I0[^Y&H\X"IS+
M:49X!J?(+'@@H81#\(<XSP"K93I\^7U()SY/A\GJ4#/E>#^\\O[7];\'ZG3I
MTX!^>E2^`XOTQ'EJ`Y`H!Y)?@/!D.09`<'P]#0Y`+..@NN.F>G`.;&,!Q@(<
M8"$.,8"'&,8QC&,=,8QC'LQC&.`?(P%#QCS``'C[&/&$(L?;9Q[,>+&?LYQC
M_P!/`*2WR"/.3D]L;4]LS@[Q<Y"DD;.WN2%4Y1U0Y("71M3/;>F.,5-!R]L4
M%J"`'@+$:0,)@,9!G&>`57R2>F,>47TQUQC'@#TQXL=!=/9[/%CV9_N\`^<)
MTX1X-"02$P/BP$S!0,##@77Q8P/`?%CQ=?;_`'>`4Q.]1Y:\NT=2NS,KD+,C
M:7%]8DZ]"H>6EO?!.1;$N=FPLT:Y"C>!LZP*0TX``*,I3L%Y%Y0_"!\2%ZC4
M797212MV8X['6M,-8]/LA7H&AE;D9?4)BMT<W(U.A1I@8,Z",-&$&/%[<^W@
M'P4\18Q_,C!#JP&2EM:$;\;'BES<-_0,#BI5MK>\F-(#<N*5H7*VT].2HR6$
MDTQ.8`(LB`+&`.5\=H[&6QPD$D<F6/LR!/DUU>WQ8A:FQ$E\S'4QP<EYA"5.
MG\TS'M,'@/B%_=SP#@>I%%8X:T!D3['F$Y]=$S&PA>G-M:S7EZ59_P`#9VC"
MX\@;BZ*<@_6DY/C-'T^U#GIP#Z89'%I%[US&'Y@??=#LK9GS+"Z-SG[K?4>0
MY7-+KEO//]$[)<F8\T@[PG`\6/$''7@%?X`X`X`X`X`X`X`X!I7[B=$3*S;I
MC[['T]W&HTT";VXP5<3]=%F3!Y;N[GBPH0)V]66:O\!V/$;XL9R#PXZ>SF\]
MM<A1BX,J['1N=C?QP4GX+VZKH?13Z3?4[M[LST[RN,Y67;:R)\I98OG\&&3=
MM=52^&<K(M0U3TCIT>KUZF`@]0;/R`>,(MKNN0BQC_SE=?U<9_\`X+S8?TSB
M^_#_`/!K_LGJ*/KYV6I)[^Q_'_FFK_ACTN4\V*&2J:X9U>'(*IKA,90*`O*L
M:]VP<D:$A!F'):8`L:M=XP9\TS(<9&/KGI[><NS9JS,MFM-'9)].B\?8O<?'
M?O\`S*>1[XY?/Q_)=%W)9$X^5%0JTE;)KRX)M1AU^&*;T6B)'Y;&HC@#@#@#
M@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#
M@&L[=G0%!NIL!K!(;$!'W;7RLZ[VA@-U0I0^O['*IVUWFEIS+(QLRED:QY#'
ML+JM&%YZ.38J&G/+P08+]<QP"%'#2+?8I"D7QK<1_:9>ZW)LA+']2ZV?:,JC
M3##YKL6SSW6K,6CSPD]UA3T?0I#K$ET3"F2,KXI=P&J5)X$"8W`$>SG1?N9K
MVJ0(Z[VRCL>=V6RMM)744MEUEVI,I*U5W=\`;/O0U3+5[I#UAPQTY/371H2O
M:,8U9$9,1+2P'.2<PDT#)^H]7-O8:Z7QB4[&3!]AEE:](X17C`^6R[3&?5%;
MA<=RT&R6%VN96<7:R6H.3?,"L<XDZNA3JFPXA$,M6H;BP,/)KV\>Y7/H\XP.
M7;?1:60>7ZV3.G9ZV.TOM)M9)/)9)KCNM2P'=YK_`"U2AA6)W^6W56\E>Q%K
M22,+8@H]$D+`2@*R!45O;O[A1!=6-<3V]=(Q!X3(CEA\#;+WO!F*:(8*V=3'
M8,"12)I:<NDR;@U/5-EMZ,UUR5[I/L`M&D"!*C+4$@6X;VR]_)2C@P['VF9I
M!(6"O8I''N0([4N1$O73M/VW[;U0EUBF+6Q@9%STX+=@)BUR\KU8_/4)"U)X
MAD+<Y*/`OY@T/[@S(R#8#=D4*F*LX-7V-BKQ+=-DH8>\4]`ZFJ:'W32[N+-;
M'R1D=U5@PA[?&R9I'$Y6_M\@.;'-O3@,$<4!]RSMG;*&T7VVX+75NPJO+6TG
MU&E.O3C949D<Y:#&6P)#`:`AK;9$!PWL*)1*XTPJ:D7*%#$\@0IG=.J(3J09
M+R;@($OI-8-DK;T7W=IU5<5B)IIL&7L7&-9I!<3S/XS.JHKJ>K)4[US&['7(
MGA\D1#G!Y9,'-J(=D.3%2F&H&8L8#LI_",#&Y1VX=^X=8.RTNH_8B,5S$KUM
M119ZJN&NW;7;BWA.LM_75\=6,Z1&0)]*@,S?*2KJ5QP^6MR!<O&H=4F5!*HG
MS!$`9&;;:,;+6W,ZMGM*7`UP^>5?V_MM]6V*SY3-90BLQ!<]]XUX.@UKDRF)
M0DL8_AQPI56J=7`@E"L-4KRS$Z/IYA80("<^WIW$$S@?+&':-(LEY,-=(`E6
MNMY706\*JV'W!Y3L+FOBYDOB$F4,;O(=4GYO@V95EN<'5L7L1!6`+$`_-+`O
MVTM!-ZY-%K4(A6Y%A-,RE-]M+S"G=PV-NYJ1,6N;1JL@KDN$J4<08VAG;)VZ
M;'IC9>YJVUM(+7)S\_KQ70*(('71:'[YR27Q&07'LT7/4T(VKU?N-`@2VY8K
M%%GJIJRB3:GGT)509G@+22V31JG@EZY&N]YK&V6)!D"<4C>K!Y@0)"V-U"[@
M-DV'>;W5.W9T!A\\7%FP)L23&<119&XV:LU`R@AZ,N.LR]-$%</S4-FK@O:#
M)RUY'884:H($Y9HBP*[MUI=L].)C!)AJK=YD#6UQJC8%'1X^PK3M=6[JI<]W
M3K3/$3N^/."9>I>3YE6%22:*.DG685R%K,D!3B0%8<3X0`09%.WWNG7=[O5E
M,^PZL%732S6.Q+.CS3:TF#<,P/AFL>J=4Q!^ET\(IU,AM1\:9'0$@;'!H/;V
MA)(6&6>IRJ0.!.`@`Q1@G;K[EETT]JS;DKOY[@=W0F`1N4M3=;MJ6R.VJILR
M2:QTO75HGN4N2,KTZ`.GMI1%\<WN/8-/9""U/VGJ?6*2P`9/W#H;W/INQSAL
MB&\RA@6O$BG+FT."*R[6@YRE4ZQC>5-#9*);$&4]=%43,\W?4)!T60^8S%$U
M>-46,TX\LHX#*"":T;O-L#WH;9SL>>^63=4;LEAUIF"&PY,EC%9BDD=E(JU=
M<P]-7[>KK"45H^R4EO5.C(Y.V'QO:$2[*5*M`868!BQ"M#>YS$OC(P[<U4^%
MN+K63M'D#S?-XOH@IX7ME`;<D;`<ZOL97JV))+Z)126)*CDX5'JO>I*=06-(
M46,@#ML';Z[@RQ!2R*U]LR[)20*0:"3&=M+S9]IBS()CK0^0PZ\72+2IJ8XX
MY"C]OHF54YC;']`YJ#Y"'"@2].0M.3I0+DV"[?NZC_L-MC>NKNQT:HEZO8$>
M<V!P+?YOY;SF(:O(Z99H-8461,JA@;2S;%1$/:>5H,+GME2)@@2E"&:85P#)
M6;:J;)R]!IPRL^PL^A#'4"2TUEZ")NJ=N<NG+V_0)814B1=*XU&*\Q;3/7%F
M91+%(7A*S%NC<BR6H*."H4$&@8EL6D7=#3P./-#GN1X9]\V"S8@MEHKGLAY0
MPC;]S85K%'+W9FLNKHX39M2S(Q8)<HADA+`9"UP"CFQ:N$'(<`7Y&-%=VR)B
MBF*G:M]B84[GJ:YF1[-M3^R0N3%$WW8=NVOK64OF8=6)TICTCKF\$`8(X'I\
M+&Q^B30J5!")*,Y2!"6PW;@[AEXU1?-7O6S['+VBW7S:^-'1R8VI82*`.]<V
MDVV`1K4_*6!EK(YSA[K2*"5MS.^Q@M8]LDE`T$.6#R5)(23@,H=G=-[NEVW#
M?M=`+"<(7&&2C*2KJ:(*XDDW0VP_Q.H[4N>S;4@;!'F%.VL<O^^Y$;!)86<:
MM:0I9W3Q."?!2DE.(0%.F.FNQEY=I>8:F6'9J*PMB+1JUOBRFRKB%)&],K-:
MG)A20M_G;<)-+W=DF@H)%VY7(P)"#<'2XQ>J!@&3\BP!0-T>W#<6VT])DJ2S
M4=?-:&4SYN;RUECV).3D$+L=GU+6J9O$V9W9$K16,VA$DU[=$[;'6<8F53[Y
M,=AK2%JQ:1P"A:Y=MW8[5VD]H(U`[GCKU:MJ0^D(%6[R=)9I#VM$13;G+LK+
M!E$E9V%UD#1-K":)L?AQ+0I%@<&(""\JC`&",*`I-@Z;=TF=:IT]2*?:B-Q&
MVZJ;I\F>+SB]XW6S26U'*147=T2A3C-5C)7K.Y&EUY<LGAKX22:-:!<D8SA'
MXR=@!"@#+N@89O;1D=B-?3$^LKT8%5XSMR?Y]);ALEWLB-T_8-QW=+VAJ3F2
M>!9#(%525FY0QJ0A5.8A+3"ER;&2RDZ,Y0!L3X`X`X`X`X`X!YU^[*BE:C8B
M+#9%$G*28K!I",+/(=56I+YV'Y_R+(D]VD#E0S1!SCJ(G/H^F,8!]OYG.D]H
M.E<;+S-NOFOQ5[]D?]S^'^S[_8?6?Z%\G@Z?2;-CR4<)W_IJW3S:.Y;9:>31
M^5P[6,EXZ*?YWQW?#M-70VJQ/`/_``R>"^U%]K\:=O+V^S/L_P"C8^SS:MV-
M^T_[7+/:D<[M/<O@XM=?^*=]?]\>Q&@0G@H^H@*A'C4AKB'!/$I.8CU`C<,*
M'!F3SXP$,<.-R+KXA(<829S[2OM.G.,<CI\_=IX>;+W^]_LOB_'U]Y\`/5*5
M<O4GGI4J*J?+Y>U15T8Z>=/319/]T):>"N_.K\OXM27.69H8X`X!K+UXW!B:
M*8[?QJZ[=0$N=:;!6$6Q-3X>66;':N2RE'$(V4D+(*Z9;P/IV$A?7J:(TS&,
M]>O7F"QN2KJMR89EB6RV3BGXJ"T73WI-^SJO:>QO53T"YW+X#L'EO3G@;IXO
M,=JX+NLIBW&_D98\\J]R<M/SGD1=LM/A48MZZ(MG:;;+UDQJEKH.U_M6^<WS
M7MGI&`P@8T4IA]$2B8H&1W3+$Y@@.#.Y%(UA>,`%C&?#G/4.>F:?(<AO2CAV
M.,DK-4EHVU'5/JNJ6NOXC,^C'H;+#[=YOD/4_@M7=QO"Y_'2O4M+,;*YG'Q9
MVU2@_L6P\VF75/Q2ZHE77C;&#2G4NG))([51.=C22&1R!.CFM-QAW77:=6(I
M:N95>`)RB0/ZA.D-68QX0EBQ[0^S.,<N,3DJI8%<YR;N:4&]&_CVZO5_V?`T
MSU8]#.X^&]=NX.+X;@[*>SL3D+\ZJN"_-0X=<C\K"Z&LFW1&4HU-ZN2?1^#9
MB2LV[E)O;>C4A^_,L1;$M5?U--IF^&G$DRA&PRF>%M`I`O`!$4GRD=$R)22(
M02LXS@.?9]C/,?5R5SXF,_,TS$]9)_:V;VG]SV:-^"]K.Y5>@_"0^KS/XFOM
M^N[TFNY7E,3#J46\6=V/ANU45O=)[JG.N23EKU6ON)HWIW!C8=3Y[(->[I3-
M$_)C4:F[$^QY1@MR(B"J=%Q%4_)?4D9`8@-=DYR,0L!%^N>SI]C/+CDN5A\F
MY85C\Y*,NB\8MZ:IZ:=?9]PYY]-7H%S"]<>,XGU5[>E?VS++R,2ZF^.M;RHX
M;RHTRVMO>JY0M2]Q3:&W4BU?KM@UVS-TDM#`TV2T-,&/EQI0$K>VH:NC$BD"
M1O4)$>!"3EGK\JC/-&9G&3,]!=/9RGA\M77==\U8Y5.4=G373X=6^G@GJM-?
M'V%WZI?3QSG<V/VMC>C_`&X[^0NX>R[+^4C)RLG9R6311*R,Y_:2K\M;$EHE
MJDR1J+V?9\7=M`UV-:Z8Z*GVW#&&ET3HHQZ!,W+ZA3SE6W,AH"?#Y;@A(.<,
M!$/.<@QG..GV.7>-R,8WVQR9_`[/@>G33;N]WL75MFH^I7HSR4O3SLS+[1X.
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M3V:O73P.D5^A';__`.;Q87]'ZY>B]'.XV!;7+>L:-MV&[HU2TE&QM[)6/3IT
MZO1F4%X[DUN"A[GBM=7&V`V`A]+2]Y);VH_Q29HDD7BC:Y.:LLLU*-/ZUM,=
M2#18R'..H_9C/+O+Y;'^4LJHFWF*J3Z)ZII>U^S7KIUZZ/34XUZ:?3_W8_4_
MM[G^[^W[O^B?.[CQ:966QTQK<?(R9UUQ;4E)UV*N44U[O%%DZJ;4>EF%IMM[
M6UYF9!-J"@U6-TA.`6,R53"C&:6.<;9TY*1./+@[KPJ5I@<@QCKG.?9C'3$G
M&\GN;67-[FJDD^O64-S]G37KX^XV#UN]$G=P'#9OIEP>L,3CN:S.2MHCT6+B
M\Q;BUY-TG)KRZH.NF,DWIT77Q*#MCN0QR=DH5SUJNPD19^S]8PB?FQ=8$`ES
M)(5RDH^..(5!6,^0Z80G`STZ>TH>/%C..0S>7KLKKLP;?S2M49M)]-??JO#7
MQ,KZ&_3[R?"\GW/@^L';DE;'LSD,S"CDPUV6TPBXY$-K?6O?&2?NE%]=2_I;
MN+#FC:*-OPK>;D6MK)KK9\JFCCE0$,7*E$/LE#$53FJ.\OU!I[6H&)']K@0/
M,STQ[?;RK/DZWF1NKMUPHU3W))OJGIT27BOU?8C6.#^G_N#-]%\SBWP-L_5[
M)[LXW&Q*]K^9>/EX$\J%<5]E1MCI;U:>G7P,?=O=RWI>\AD>NEQ*Q03.K.Q<
MI)7QL9.&H<_@C]`4;>Y&#6(@F&+V,+H:6$/F>#H<+J#/7&>6F9RKLL<L>R4,
M?Y=M/1K26]+P:UUZ]/'[QU/T$^GO`QN-LXOU7X"K^DT>]N!Q95Y,9>:L/,HS
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M)W%*GR4*+/M@I)I\&M99A@VX2X;J0_\`1(7@LW&/,STSCV^VQNY9?I>K2R4<
M%PZ]'HV]R\--?%+^SI[;KM[Z>\^?TS]S9.?V]N]5<+GL/RY2363CX4L-Y=DN
MEFQ53IULEOCX)-/QTXH9M$_AU<V*+=[74KKN1/\`M:[5P8,TLY^316MI2L;D
M)[65A&:2!%%0&$D!\96>@L8QT%GVYC/EE'!OB['\ZO,VK\K2'NZ>Q=?PE7GO
M1/C[/67M&>!PE=/IS;B]M59[VM4/)Y#'C9)6MRBW/)TE-Z26JZZHR7J;<ND"
MX/7\7G=NLIEJ-U,0F8SUO7&F#>23#*V03)^>'()"8).!Y;P'+#LAQC&`]<],
M?8YDJ>6Q(PC7;-^=&I2ET;TZ:O5KIK[UKK^,X]WW]/GJ3_27E.8[;X'(79-_
M<69B85E<4J7IR$\2FJ&LFTO,<*H;GU>BU;(^@NUS"X[16Z:Y6DF44BMJ_7I5
M5@1&8]S*Y)9JN1D$',^`EX4J%LC.1EA!X@YQG!?LSC'*-?)0>7*_S=<"5<=O
M1_:<FM5TZ)^'7VFT]S^B')X7HOP56/PLZ_4BKF^<AR+TTMCC\?"B4HVMO:HX
MZE)O1ZIRZK4P6J+<^Q9'J8<(Z[G-ZO"/;KBBS\<8>ER_$U0[;#.L,9&\TL:0
M@@Q@5-";T1><!R/&`=.O7'7EC7R<YXOENV2S%>M=?';*3T71-=5[%UT]QZ7[
M[^GOM+B_6Z#I[=HQO3C+].%D4I1EY+Y2K@ZLN^:T<FLB-DO.DGHM9:^#,WK-
MVSBJG8G7`^%7`C(J-"7LXEN4M,H\AC&NJ^/0]>=E],/("9UAV3E9AF`Y^T\P
M77&>GLO[>6QW?5*JS\QK-2>G36*3TZK7PU:T/-_97H9S</2KN_'[@X"<^_+'
MV]+BFX[KU'D<C*KBJ5%M?W7I7%:_:VK0OK0"X)+=<"N.6/TL73)N2['6RR0E
MU6^7X2H*@=$N8T@0Y+3)NK>E1G="O%XQX#GID6>3\/ESS(WV.3E4KGL?[5QB
MUI]SJ:[]5'8/">G7=/;_``?$856!E3[0XN[,JA_QZ=4EDRGK*7YR4XZS\%KX
M+0SRYF3S`.`.`.`.`.`.`.`.`:EM^*@NVQ-J]+Y3#(K8,IHB#5]M@FV%:H:X
MK,)GL4G34@*N(WAA0677*D^</B5@DB6./GC5E1A>HRJ,P4$S`A`12=;/=X66
MI:26/TJ4UU8S6]5I-;M\Q:JT0OLJJD-H7[&[7:&Z8L4XG2-A>"*W0P1\:71Z
M0JR'(?GDGB:3'`P+0!84?EO>EC<#GC(9&E+Y,&'7?9F:5\^2:(5%)C;$V**M
M':9'6]<O;@UV##V^#LJ"/AJEQBY@4"MM=&52ZHUQB<\`#D`&2E8O'<X9=SXE
M$;"&7.M2_1I4<GG:J!UA%E2@USHYYEZM[QF/2+XB;U3%=):&.$I2TAI0D8S#
M#?.ZX5%`8Y3K5[9B(6]W$)C5%<3M_;'&4Z&CU/0/UF/SK&7=C3NT<*VU-96E
M?9[:<WY`G,6."_*X2,:U>F*/(PI&`(1`4U-9/?/23R7GH*TC,FC^#;O%!H]*
MXY4T;C:@U/&]Z?O+I'J3,TT!(DS<>_P2C<G'9P$PP4M<\*,EE%FX;0,TXY<N
M[+KK):T=:JID:S;V+4@V6+`G^S(9!H#`I5*+%>I]\/UP:V1>SY@V8LFIV:-D
M)GH!Y[8UN:H]$K)R4F6F%I@(5@T^[M!^S-.I)?!6TK6U1,"FR=J<QRN"W9=6
M;C-=X437,I:L2R4E[C4_1U[%Z17.+:U)LHR'-_<``*R`*E.B`MNY&_N')]P+
MNV$H^IYBQQ!!`=3*-9XH^RR&2MHFK4P;@W"HOBSH)"%$S(CB5U>M;GY@<\+3
MPI'4G&"$)F#E"$Y,6!%Y=M]]-N2J'K[S,?D2PO6N++CH:>Q5,TIL7F#6[7&3
M3T+*\D3W!RA]!>RZR&EG1*3<,9IJ-&6:=E(,E8(#-ZXXIM1+XYVVG1&?.'N7
M13;"`3/9A?%BR:F3'5"&GKK;'I18L!;[">F=6W%3)[C(UK*4N>0EN1>#R"0@
M(SY($9=O^)7QKQ-)M"+=C=UV*T[+61/+,CEO3MK1-TXKY8RM`7&31&]X^AO*
MS81'D"QY69)B#C"$Z5F7ECR2K2)30)U"T#`J::T=P&5&RIWUHBVT%",4CV+N
M>8,\"NJZ&A[#"9@]$ZOL]36K&EQ-UVB[J*P.:ZXG4@?4"Y62)/()BK2IVG)/
M0XT"<YE2NS;M$K&C<RK/<>4R%^[LTJMVGYQ55TMK8^U1KRTRRN)3'I>$4EO.
M'M2JOG]ICR^,I&!8%Q"U-SNM.]SB`5A.>!O5@LF<)C%V^0NL+E5>KEI[J4=$
MIKB/8DK:%N=U[60>OQ%G^4,?DO"=$!:E\E<:+TBDKS0E'>84`"[N`.`.`.`.
M`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`:9>X2_2ULN5@3L.LMJW
M&DS!&\PR30F%65(VI(>)V=L":35L/N*`-A:PD`<&"+&C,.P$P.<FYQG`0[OV
MY"F6#)V95-$O,?PRE"+\%UTE7-_JZ?</H7]*?%\%F^GN5;RG>7!]OWKDYI8^
M9F<?CVS7E5?G5#*XK.L<&_A4E;&+<6E!--O`X4NLC(1?_`7L-G[7/L^]3>WM
M]G_!LWC/-@\K&_YPQO\`PE7_``!Z=CP':&Y?_P#3^T_'_G/AO_AX](U0FJ#J
MKKHY6RKHXJ-A4;,4,#FF6HW%E.&TI1&-:Y(Y.+LX)E:$6<EF`.5*#0B#G`C!
MYZBSS'-267:HR4EYDNJTT?7Q6B2Z_<2^\?(3OV%5?>W+5T9%>73'D<A1OKE"
M==R5LM+(2KA5"49_:C*%=<6GJH1712+RV-2'`'`,0'3136IZDEE2QS@QBM[M
ML)V)RH,=EWE.V3Y:1.!#PFP9@E.,,C2EGAR''L\&`^W'7KB[.(P[)3E)2_.)
M[NOCN>K_`.Q][H=\X[ZF?6+BN(X?@\#DU#C^":>&E5#=5IBRP]-VFZ2^7G*&
MC?MU\="I$:5Z\)7%X=B(7DMQ?IO++$=E(7%5U62N;0W,!D+B:7D62NJR+_X-
M@.`]`XQUQ[>O(?H;"]TMK<GIKT^*.U_@T]GO+&SZB/5>[#QL"SDM<3$X_&PJ
MH^7'X,;$RWG45IZ:Z1R6[-==7X/H?,/TGUT@<88H=&(/ANC\<G)%BM:(+BL'
M@N5I8H?"DR\PS(_&8$F.*!)\`SGP].F<]<\FHXG"HJC3!-UQGN6K;ZZ::_B?
MX^I/W#]1GJWW3S>3W%S7)NWELKCI8-D_+@M<:>2LR4$M-$Y9"\QR7774I8M#
M]9Q15[AF8,=B/2"#16N'%"!Y<2\"B,+>%S['6TD19P,E90.3B:/S,?;BQG&,
MYSC'$>(PXUNI*6QPV]7KHM==5^VU]I?1^ISUBCSF/W%'D8?I7%Y/*Y"$_)K?
M]U9E4*<BR2<7NWPA%;7T3U:2U/AST+UC>&!=&E\#&<UN$#15JH`%V7E'_![?
M+39PE:P*"C`&X\$E.$H\><Y%G['7IR1<+A*#AI+K6H:Z]=$]4_O_`'2;!^I_
MUEX[DJN5Q>42RZN4GR,=:JY1^;LQEARL<6G'KCI5[=-$NOB=.?=OS5JS&Y_:
M9?7XW!OD[FH>'I.!W7I_6.*N.H(JH4B-*,P=@1K(VDE9QXNGVN<_9SGD)\)@
M3<FU+=/Q>OW-OZWXO87';'U4^MG:&=A\CP7*JK+P*552W57)0KC?/)C';)./
MPW62FNGMT\"ZBM+]>27LI_+A6<.!#^U2<C.7-<(HE[98&?6K:M*+$;G)8DT/
M4#38#C.`Y\7BZ=>5I<7B.2DDUM\$GHOL[=?PKQ][ZF$L^HCU6MP)<=/D$Z)8
MEN-)^5#<Z;\V/(60;TZJ65%6=>O3;X%MH-!-7FQQK1V1U_DMQJ,M.7!5675<
M8-IPE=GEZ3YZ&&"`<(MPD"P6/%C[!V<?J8Z4OT)@:UO27YI+3J_8]>OOZ^)E
MK_JC]:<G!YCCK^5W8?/.7SD?*K7F[ZJ:9>"6U.%%*>G[!?=UJ:S1O6Y?'D$6
M50<1K(VP=SKI.C$YK/#\)O#^DDSBW"%X\Y_PAX1%F9&'PBQC'3'LZ=(V<-@6
MQ4)1>V,-JT>GMUU^_K[2PQ/J1]7<'EI\YC\GMY.?(UYSGY<-?F:J)8]=GA^3
M5)QT>J]K1U1:':R#D<UE0X$(;S839)6>4G#=W$1:]OES4ULKZ0`G)W@("K;F
M<@'VO3`?#UQ[>1EP^#.R=DHO=.+CXZ:)^.FG@_NEROJ<]98\5QO#0Y11P.)N
MQ[<9*JM.%F-;9=3)RVZR<++9OKXZZ/P*@;I'KJ>ZLSV=##3'1@L&&V@TJQ.R
M[Q(YG`H=B!1IT*!YGE8PCC&/3B+\/@,Z^+..O)OT5B_#UG\,HM=?V*VI/IU6
MGCJ6M?U'>K%6#D\95GPC@Y?%97&VP5->D\3-R_G<BM]-?BR/C4M=8Z:)Z%O1
MWM\ZK11O3-C%7F4*5)/HQ9A02G=P"/XOB!RY0Q.(QA-#D8$ASD>+)>?M1>9G
MK[.G2E5P>!3#96I+XU+77KJO^S[3,<O]5OK?SN3++Y3EE;=/BLCCGK56TL7*
M4(W5I-/1R5<$I+JMJT*BYZ':QN\;>8BX0#!\??8]+(NX-^7-:$LQFF\O*G4B
M2AR$>!8RLDQ(5&!9R+(,XZ8]G)WP^"X3AME\::;U>OQ2W/1KWO\`4Z%CB?4[
MZSX/-8_<&+RSARV-DXM\)^7!M6X>*\+'EU3^QC-UZ=$UU:U/ENT-UE:V3,=1
MP0P#5B.3J*%D#=W`8R62R%[8Y2]*4<(WS0^]%;,F%G.<Y\&"\8#TQG/6'Z&P
MG%P^/:XN/C[&T]/P:=!E?4YZQYF>^4NY./STLK"R925-:W7<?797B3:VZ/RX
MW6>SJY-OJ5&?Z1:YV:=(#Y?"C%YLI40I4^B*=%B;UZBO8LJAD5--\H6/:W1U
M8-/TQ]J/'3(L9SCD;^(Q,C=OW_$HIZ/V16B7_9+3M?ZCO5GL^K$IX+D8U1P:
M\RNC6J$G7'/R8Y>2H[D_WS(BK-?%/5+HP1I!K<G>%+Z5!`X<5JVJ7%68)Q6#
M"H6THB&WUTH'@1F1>-B2B\..F<>9TQXNOMZS2XG"E9YNUIZP:2;26Q:1T7L6
MGCIX^TGG]27K!9@0XV?*-XE=/)517EP6V'+S\S/BM%_M\NKU^S^3H6VX=O75
M9T5Q!<NK\9ZF"+E3C%C!NZX0FM6LF>9^>87D0Q",ZRGHIQ@>1=/#@/\`>]<9
MHV\%Q]TXV34MT'JM'IIJV_Q=?Q&8Q/JN];<''Y#%QN4C&CE:HUY25->EL(8G
MR*4EII_>S=?33[3?B785I7KR3E2,N&#P:L:[/95!PG-88:-LN%UP]3Y)@1@Q
M^`IX<0X,Q@/3R^G0/LY,^&PI=9;V])K[7LGXK\'@O:E[3`S^HKU6G"%4L^/D
M5W<==&/E0459Q5?DX,M$EJZJVUUUW:ZLHZG0[695(5DI,@IF'A=#LP)0>!W7
MA+%%\P\4#RVX(\S)6`_#(\I_%TR+']]C.,\?H7!UE+26LEH^K\-NW3\77[_4
MOJ?J<]8Z.+APT>3B^/AGK-4736VLE9?SOF:[=?[X^-K71^&FA54&D^NK:C:D
M*2$>6G8T]:IFD/O!5GT1-2*UBV"!+QD7A%EG/7FY\0\"R/`O;GDT>'P85*J,
M7M6WV]=(/5+7W:^/O++*^HSU:S<G)R\GDMUN9+D)7:UQTF^4A"&;KT_VV,(]
M$THM:HMN']OO5F"8?,1FOQ(!R.1M<K=S?>Z\TU4]L\Q5SU"J$,PS.?"7*%IB
MC(?;C.1>'[&,<DAPF#"4I)2W2DI/XO;%[ET\$M?=[.AE^XOJH]:^Z5C1YGE5
M9#$P[,:I*JN*C39B0PI1T2_XM"-:?BM-?%ZE23Z):T)BE*<N"B],M.MA0J39
M=%N"%!]VMZ5LL<PTL`P8&)]2)`!SU]A>>N0].O(PX7!@ML%-+63^U^R6C_$O
M#W%I;]37K#==#)ER4?F:UQBC/RH;HKAYRLX])M-KR92?^R6BEKH2_25#UEKQ
M$U4(JEA^'(TL?%\B/;\*#%(1.SF$@*Y3@9OV^,J/3ASG'V,9^QRZPL&C`J=.
M/JH-Z]7J:%ZD>IW>7JQST.Y>^,KYOF:\:NA6;5%^57KLBTO';N:3]Q,7+PY^
M.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`
M.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`
M.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`8']P?<L_
M2"G6.UBXW&G]$OEJUH?EDOD+S'8_%HPQ0&;6))).L.CT:ECVXF(6:$G%D(TR
M(9J@\T`<9Q^J!YI!?VQ774(A!Q#8</`<YQ@05%P>$73/3Q!\56!%X<_9QUQC
M/_!P`'^V*ZZB$$.8;#@8%G&,B$HN#PAZYZ>(7AJP0O#C[.>F,Y_X.`>E?MY[
MG';QT[)+7%'(PQ(6N;-K%'UT.D3S)([+8M(JJK*V(U*D*B0QF)/;<8M9K**(
M/1J483"#TP_MA8SCH!E%=UQP;7JH;(O.SE3NWUS4L.?9_/'-CCKY+')GB$80
MFNLB>BH]&D#H_.9#,TIS51X$J<XT*<D8\!S@.>`?,:NFN)6I5$M4B2A3%*8>
MA;W=?D+<Q21PG44;IK'&Z)/2L93?*%ZN-.Z52(E$8<,`%!?7'VV.`=^$6]55
ME(4#E7UCPB:('5=+&UJ51F3L[R2Z+8(_K8K,B6P2%6=[P^&I$W'(U@B?&`DX
MO(19QUQU`LRJ=FZ*NF.J9/`+'CK@WHIY.ZR7)G-:7'WI#.:WF<T@4KCRQB>\
MH'=.M2R*O7C"?Q$X"N2(AJTV34V0FY`^'K9FF(]=#'0;U+R6VPY%3L@OQL`K
M2+"(N95<8ET3@CS)CYJ:2"*),$2F=-*4M.8K"I/RN`,HL9>!B"!<J>]:55OJ
MN,I;9KE0_-\*9K(7-A$RCYJA)`)$]+HVP3-3X%XBR8T]O[8H1I%@A8(4*2!E
M@$(0<XX!5'&W*I:%*Y$[6=7K6L;#L)W)(XS2-HE+>H$8L)"0N(4N11J0X1S>
MH!@)F`BR(@S'3J`70#XD5O57$79A8)/8T*8GR3S-KKJ/,SG)6A*ZO$]>VAQ?
MV>'(&\Q7A6HD;FQ-"I80DP#SC$J<PW`<@!D6`)%X`X`X`X`X`X`X`X`X`X`X
M`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X
M`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X!H%_M'7\W\
MZ?\`[Y:W\E^^^`?R`>`.`?U[_P"S8?S>#9_VG3/\C#5?@&_=Y9FF1,[M'WYN
M1O#&^MJYF>FAQ3EJV]T:71*:B<6Y>E.",E2C7(SQE&ECQD(P"SC..F>`:LS^
MT31(*4UOHELL.W$<5UOBDKK]C=EL@1O,KDD(F,HK"2KT;J^K4'J$<H82*>8F
MEA>D^`JF5E)-2D!\)@<E@=353MU4#4EY-UP5Q<*BSG"F2+"JIQB[LTP-\30:
M7N=MW]<:0QL<6MO)<Z^L&-M.U\A8G;*?)9CTQGH<*2RQ%Y&<!8;MV>*W1N1:
MQCD3\_.;_=,=GZJ<+7YO@LNJ1J9-J[TW-5O$$Q'82\$S68O,_O!YA9HG`YL\
M,#=3TOJ!&!487@9"[8]MFNMLYTZ3223R31!.Z:LR/5`<8CK)%U3&1"Y-=-0W
M8K>B279O5?\`O=,\4TW-Y)(L91!0*%&!%",R6,L#&]9V4:@-8BV!ON:;I!(T
M59%!3JHG7[HR+2ZSV@V1V3:&B1Q<YH*;WZ"/^=G9'&7)D.\*50UI4!Q0R5:3
MS1@4^\>SKJ?-XF_U?([)-@SC>>R%XV>T.2>+UF7*G.171JC;U$E5BP&.3$8:
MZ-%<UQ('Y_8218,4)EC8(_/4@HX`@).0=LFCJ5EH]@G^X75N)K3:9VW443*;
M,T&">QH\Q"[T<R@4SGBU`0Y.-5,ZJ^I2\-!BLXL^-><``#C"21>(#;.F7HEJ
M-(XI51!Z%<0E4HU99@1)U)"T)8D9I)G7PF`4A.#X,X_OO%CI]G@';X!\C&`O
M&!&#"`.1`!@0Q8#C(S1A++!C(LXQD1A@\!#C[.19QC'MX!]<`H1TGCJ>3-T,
M/>FTF6.[&\R9KCIBLD#PX1Z.KV)K?GI&@R+"A0VL[E)VXA2<$.0$FKB`BSC)
M@.H%=X!\A&`61A",(A%BP`P(18SDL60!,P$>,9ZA%D`\"Z9]O3.,_J\`^N`.
M`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.
M`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`:6>\F
MW8MBO8+0<;:44CEZ=OLR_I@W/A"%;"6JB8!`'Z"64IGJ`]G?U[@BE*6S0M36
MB0I1+EJX8LDB#Y`\\`\:_P!5?I6,!AX2];1AQ%PRS&";&M/.3"S3<@^&4Q88
M/U-GA>?:)B#U<@`Z9R5TX!^#[6.E1`C!#*UN_6(TGE(,BL6U!EJO-++.#%$N
M/@;(5L_!@>`FL`.KD`74(BL9Z\`]DO9K;,U#"+1UVE+,AB\X`*K;^C#2PD-R
M.#.5$3^J8;6E6+J_1(FED4M[6PHZ<-;'%&N3@<$KD4(1W7!Q8L@;JN`0);FO
MC#<4]H2P7:?W!$%^OD_<;#86"N+%=89$)ZX.4;<(R8PVY'F\L::?1-.E<1'D
MH3\EA`I#U\62QFEF`8_9UOO9N;;XC\:F\!9VNVMCAWP0O`.5A=%C`G=JI5J*
MDD!25.F"A9)ZQ0%>T/;DE//-*0.HL$IC!!%D0$6T'1FPM<;/H"YDKGDUK2&Q
MYQ1L<T>[$=`LGI9'&$`L-R%I$M=S)>P0Q<06Q-:%W]$XD&%*G@?F#58$,"U7
M[0+8QZ;D&#MDU1KZVQ5<UB<,26SFQ&]60W-;BAC]]KT+4^$813N0KC6Y:\MH
M,G-9"EG($FR+)IF<`2E=FF=M6!:EP3F"6LV09HME#&4RTA&IEK9($K@STS8=
M8-<APY,JLH)3K64H?VF4Q_!.0%J5R8XI1Y!@$JPL"B[&Z(3FZ++?)FU3J.I$
MKU!Z]:1.3HHE[3+")C7U2;<5TWR`I5$U2$A($;YL*SO(3$IB<T!C&:5X<X-+
M$`"XVS4>ZU5/;>U_.K09Y=,[_K*>5G%IXO?[&7H@H)<S3U,P.$O@[DX'Q=B<
M8/F>Y:?4,1`%+VTM20:DPL0"4R8".Y#H1<;Y89$V#;3*40"V$=BX:UKS8CNE
M0$M$WKUZB1;2UN#@:Q('"OV%JD6&P)28I*-6ZA+&`)`S<X`IC#V_[K4@C#C.
M[;3+WUK;ZT"_%-%HW^:PO$BC-Z0R9V=(4*!RE80LR>YJMCJ]M6-I8!)6Y:\*
M``$H*$<>H`X6#02_B4460SFXF"PQ0)WUQ?(@Y/DKM[`0(*BGU-2:50![C8GA
M3''IK5)ZI4K65_5E*GE,N?E2<P(21*%"L"1+?T\ONT-@GJ>@M=B:ZC=WZ*FK
MH(BE%K,RY^BS`ZTF[GLSX0T.X&XE4=B"R5!_@IY:$Q#(LY]*6:)<-8!QT#J/
ML%4M@HK$LRRV*WW&*4!.JO:7Q"X2M-9#^MET=UH$0SC629?\/M[='971KL:A
M7"4!4K,2`!ZORU!:HY2!#U#ZI[6R2-0URG=@3"KU[8Y1Y:_(WB;2)Y?`21@=
M:#7GSJ--A*E2UM3JZ,=2O+`[MRA0K;'@<K<73!V0JE216!.,_P!,;=D=K7!+
MXA;R&#1BTYP?,2"V53*D$FB[^=7FMD49;"2C2*0MJ^8UVOHIW`V(S<X;%[?,
MU@%/E^4(M4!LJX`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X
M`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X
M`X`X`X`X`X!@E=FL=U2^^W6[*CMZLXDEE5$QVC)C![2I4VUV9T:8[-YS,0N"
M,PF>Q#"4MXQ.!I5R0XI02>6D)SG['3@%DBUCV\$$817!IV()L>!$3`BTL-R$
MR)EBR,N+CQFZ>@XZ`>>N$6?\&QGVX!P#\SK'MV+)V<V_IUG*B.EQ!1G.EAN<
MGQ(D&"R8L=G-T]38X46'`0HA=4P0XZ8!TX!>=,ZO7/%K_9[SMRW:TEGPK2CW
M2D6B-6TNHJEK2L;U*XW*0'.1I\_EX5B9E,CN"D*4LH@I/A2:(.?MLXR!GCP!
MP#3*BKSO(IR-G6Y;>-;.`2*XM91JA(0QZM4KNIM*&VW8:RDD=EMI<,PS_#-P
M4\]1]#)<@"`3(O9!'I,A,6'X"!T)G7O>E-II%B%W?4J.\D5H;%,ZDY9'J_4P
MUXI]=#IW+M;Y8<G50W!J*<1RPD3!$G-(4+"9<S+#W%0$*DO.<`3O8KEW%7&Q
M-<XY!8UF)5XTO"PG8VPD:BEIDJDSBMC57S5F/B<>DDIB[BDJ-N=S9E"G0[R4
M\K*5X;75&B6)@#,,`Q[ULCW>9&W50JV"F3%ZU/;U?(+C:%H*$3&N5,S75**I
M[7D$3=:\C2U,EE--[9-K@>P(\E`"\-"XX"@9Z8*418$1QJH^[8BA<7@J^%5@
MIB*"853*_A)8&G6Q'$7Z+[\QNQI0\Y"U+W1OG#5)-<5"QUR:0:QN[)(6L8""
M7!0M2F)@*ZZ(^^N8R5\:WN$3*=6]:T+YLF0_-]\;T[I8;JJ;-6A<)\3"))K5
MQL\-KXCN6TQ,^!C_`*(*TXHX2/.`)D3M7=9:YA7KL^3M6.`/MX;7+;/(+CFN
M;HHK"GXI=0UVHR5M1$*(FN>H?8FO"=8DEBP"YYEC5(%+<H*1Y\A82(#&_6J?
M=Z"WZ6H^UTCM'7%BLBN:5FY)MA1ZK8C-2YY(JXUO<+%)GL9:FEF*8:/(DQMD
M^6A2IBILG5Y1EA"$D*?`0)0>ZQ[NRL5>S,BWY<3+S&_?1*\1H:;7E97,!=5U
MEL#7I"M?87'L0I?9$?.IIO6J7@67Q6ZH757D>,%'^$C`$PR=_P"ZI)S*H0QR
MO&^K%+/1-B(IJY?%U'S^/2':MI@]6/=<.$U5+<MC^?K)*7QSEC&J41]M:I<F
M=6TE6)O+0')S,@01)6KO<KG"`@C\@*9HT2]CQ)3$@=93Y:HBZJW==4"O,M]_
MM3DS_$K?4RFTUB#W%@"7.26,*CS%N!DF`1S=VI7<FV)K_5.;R)G@C3M*Q'M;
M/;;A.G"*O]2L0&KMU7G7#J^2B&0:7,J61QR7;FW:K4#1,8CC42%*@<RTXPMQ
M).0+CA>HVT<.M/1"ZF"EK)7-4.J#6_73>>GK?O\`@4^D=EI:[C2Q?`]BR9HF
ME&(U.K+U3LE"$UP7B)0N-B-KT9T3!&UH2Q`5;MY::[94C=^K$KN2(.#7&JZU
MK[A4!L%<HL:-RDM-/KOWTC5ST:$U$WR=T5/9@J1;E@2UI99P68!ONX0RLF"+
MP!OTX`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`
MX`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`
MX`X`X`X`X!`EN;*592,]H2MI\KDR>4[)S]QK2K26*$2V4-JN4M<;7RE65)'F
M/-#BUP]N"U-P\A5N1J8@0OL"\(#1%@0Q&MQR54PMQHET82L+#6]VN%$,HVPZ
M5.TBG4S5"@N(2BCY:F(-415N<H,F!A9R$MW$<W>C\XT62!C,)`C]C[BL*?)V
MUITC2WJ*CDC^)HBE@IW!W"]/X'FG]<["@2=-$%K`D4D2"72^_BHX%`<<6:F5
MIBA&9P(TTM.!*C7OQKB[R)HB*:02(B2OSR;&FIE<(D\MJU9*$[?8QZF-D%KB
M2`F/!#W4$H8\@#G(!/[&I0`&(_R@F`6Q;.^$2J>WS:Z=8-,5$<B<E<X[9\U(
M:SUI+`613C/<J60QUK9\.:U_C[6PO``O)QV$1B'(19*`HZ8P("5Q;?4H"O[(
MM,QRDB>OJP4LY;W+UT0D#9&75`_*TS>VR*+21S1(X\_Q0*Y1D"QS*581-023
M35YB8@&3>`1WCN!440W2=T=4%E-Q$3>K`0NQ*:`N\H6)H]7(%8'>P5::&?$8
MVV!.#DWJ$:-P4^4`Q05G!@2@_;8`O:L]RZ3M:=-=91Y7*6JP7+$GR9#YE%7.
M'/[=B*)D+BX94MS^%$>M":QO#<X@$APL"6@=4!Q^2<+$^#`+8.W_`-:2#!@%
M)W\P(X8KLIL/3Q!_4IW^M2$,A<$M@,)R=&:!QB[P1#WC",T/0TX;8>'R\"R5
M@T"-B.X9%E3[E2IB;G%:_*;(\ZC=I.C>%,N48/E&V\9DK>3%XDWR1*G5)@:M
M'+FTTU;@A80N$49DD\))9X$@$=PC6P;8J=ECO-VE*S9<C)CAPK>98/KQO2-#
MR^-;Y/R432L'%F"5MS$=EK6J.B=2<,HC(@'F@+R!4HON1$S*U<["L2//<,/!
M=5^5%'X>B1+)!+7T5%O-FG.K@4SI$X#<.`J^JQS?E*4H1P2BDXRB#%)F2<'`
M?C1O;1$EC-ORN*&S21M=/5C,K=7F)(@Y("YM"H*XRUG?G"NUCWEL;Y)DMWAJ
MA.7U.(`9DY./`O*-P/`%BQ/N%5PI7V$R3^+32(R.,RR5M,+CK9&'^5N]ELT;
M"V'&E11(TMI@G:=-Z=T!EQ94F5!B<6<8),48ZY"!-\UVUI2OY,Q0^3/CH@D<
MGA+!/8\S'L+DB=7IIE<C30^,H6QG="D#PN?G65KTS<8C*3B-;5:Q,!P])ZI/
MYH%MM^[5(NB5K<$H;$`VNKVUQ("]?6<R:2FZ=NC"ADF:]D"=U:T3A&ITV-;F
MG$K;7`E,>2,P0>@LD*?(`MUF[@FNS\F"X-Y]CC:1JB`%NPJMFV41K2`$,'(9
M:7@EI-5BAL$Q8S"*0.?E>F:"W0LU0()):@PD#OP?<Z%2./6M/)`SNT9KN"W3
M5551R2G(UAID@:;CKZBY;"9V](3$Y&8O'%[M=Z5.:H.&(A&A*PK5C3X\\L@"
MUY1W":4*JA38M>?$4Z7.%8R*QHFSIXI*@I1I6F,N+HD,G"QL9797`6(,G0Y8
M7-<M38"T.@#BE(09(-R$"G'=Q*G#H<]*"Q.\7LE@@DOF#[!;`C$J85,=%!V!
MJDT@`XI$[4K?WMO3Q]^;W()K(C<QA;'-$H-`4%61@8$O5IM[6-HR5HAK*SV"
MBD[K(9_'CFQ9#'):3'!0.96I"BW29/,?]],<29YDX4T_#9E"Y226J].62+):
ME2F).`RHX`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`
MX`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X!I[[O?>:U
M[[/U<5[*;:B$RM*=V\XR%MK2L8*L8VYP=`Q5,VJ'UZD+T]*<%QV-H1O"4G*D
MM*N.&>>$`"!=!Y"!H+I;^TC=X'=O+M,=%.S459%3(UJA`EDKM*)N]H/6(Q`+
M6H13O":O(<XN"(T>`G$I0B,*SG&!XQG/`*]='?\`.^MJ;&#+5VF[*;;#:=9#
M"SY;*FE^G)Z-E;/-+`<K<I$R.$Z:XVG#YF`X4KTX4X1B#@6?;C&0-JG9Q_M"
M6NW=XE\TJ"/U7-J&O6#0X4_60:4OS)+H_(XDG=6YD<W.(2UL(9EB\]F<G=+A
M6G5-:,99:D`@"-QX_`!NNO>Y(OKQ3-GWM.$$G<H34,(D-AS%-#&(^328$5BC
M<>\2)<TL"4PI4['-;0E.4C)*SDT91(O`$0N@<@4.-;'U!)Q%FIY>SM;.XGPI
M)%)*_/+`TQV?K9]#F*=L"&!.1[OG$H6"CDG;S3`)PYSU6%8+\S`L9X!%D"<-
M)+H85[;7DEJ6;M=N6I*;+]*Q2\@UUEUM5=+LL<EG<9"6[$O_`,00V6UIX,.+
M7Y>$XVK!I)F"PX'D"&*M>NVS>S&N=(ZEJ!N,3V+.Z;5Q&5.[1#I0VSRN'!SH
MIP:4L/4OR=8VN)B'6$6&(],4`]2W1@IP1"_P;)P`)D=S-%HQ8,=B4A/H9IL>
M/5PT73'P/RF.%OS76D<LW+FQ61F0.9F1%-`;:EIJM,X'JO&L>5J@\`S31'CX
M!&R%^[?VP$RN:0/I$`%*F.Q9+1DZ=IR]EQ4J:/[#34*>'T^*B5R!&W3!A,IR
MRFHLQU0A'@QO,"68/PD!P$#C;;8[?$&DD1U^BLNKM`V[6O%GSF.JX=8!)E<R
M.9PR6U6=*XJW3)HEWNR,RAZD]UL9[;&FXU,!R&YGY3IA>:=@T#H3^F^W"7&7
MM!F5T'4RI[;[1J!JE+'9L1BYT?>+#A;9#9E&6=`KDA<:4NB)K;6]6!C4I%"5
M*X)BEN$@5.1&B`R/J^IM<6]T:RX-B(RN9TNMPVKG!-)PR>0QB9F,#O%%SU)T
M@7=P]WS]?'G)>W&+5A07(+>::C"8%,'R@@?#QIIJ^_-9;(ZTQ$5#42X.+@G1
M%EN*0E+AV)DI"]H1^B7IQHXJ>"9.N?<Q60-(#%YPPIL#'D7`.T9J'K8:6L),
MJ2-C)7J%*I44(QVR4,U6ZV:^'!`7[R\!"?#I<LI-`47@)167Q4$`0A'@.`.@
MLTNU:<5BU>NI:(JSW5@E$5>@J`N1J20QJ9,C='7]BDS>-PR@DK4H:6H@!!"\
MM06A,"(U-@DXPPP0%RI-8:&0PAMKLBN&G,29Y:]SUM0*%KVM6III)@/A,GDX
M7]8Z'R$QYDZ63N:=R/&J$-P2N2HA1DPI2<`8':;=:Z(9PRLMKJ^+HB)Q&9;#
M)4D(2G!0O,3G;ZZR671Y0@R?E$6TOCX^+%!Q)18`8&H'@.`ASTX!9:_2K5US
M;@-BZH&(XDH_"M,K]Y20IY1.&'N,2/+LW2`E[+?FUZ,>H:VG#6D*2U9GIO`(
MS(!FA&!>MDZW4?;X""K+KIDEY*)H*96HAT-<O(84Z<*D"1PC)"9<G)C$D0`5
MCPF=V\*9U38\."E`/`#P@6HJTWUE6&R4]14<?$?,%4+<9(<!8^D'.CQ7Z-L;
M8O(##2'8LPB2IFME1I%3F5DM>YI$I1"TY046`&`.PWZ?ZTM),13MM01="1!7
MIU?HL4FRZ%`;%C\QL4<?4@@A<,8<&!\9HNV$K6I5YS8KRW)1FIQF)R1@`J\.
MU=U^@-=RZI8M5<815K/B0)9E"UI*M]8I&B)BS+!TK>YHW]6Z8/;4,-CC>U)D
MW7!"9O0D$%``44`(0/EWU9UY?'-I=W&I8@8N9B[1(2B3(C6Y*I2W6[K9#:J!
MZ;VX](WR-MG$C<3G):F<"E2<3D/U80!48P9@#IN>IFNKTT%,+S5C$[LY*!Q;
M\-[HJ>G!.8%W8'6)N2]3A6Z'"5OZN)OBMJ$YFY&X^ZSQ),'X3Y\O`'R1J7KN
MC?G.4(*R:VQ_>D$M;'9T:G21-2EQ13B62&=2(E7EN>4P#\G2Z7.Z]*,6,F-I
M[LMRC$1A6HP8!D7P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P
M!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P#R
MV=_?L_[8]Q>Z*#M#7>):CV`S0"M7B`/S'LHLG;*Y1AU6RM2_DRJ.N$.Z$O+6
M>D6!+4-ZKQ`\Q+@7@'X\]`/(U8-S;`5ML57M;:K[*19HEO:)@A+&[3RI*^<#
MJ&L>XI-?#H9,TL7K./MQ<)60FOGJ?X9$S@[MXLOWN@Q0/`A*"<<`N^Q-T-KX
MAN0DV;WNV:.L!ANXS87M\6&ZME0.4*A-?QDB$XKXFXS*F/;&JN949#ULS(=E
M30>A,6'IT9A9^,F&%9P!Z,^R]V--M=.-VH?MM9$MT9=J>1U[.BV25:VQ60-T
MOM9!8L<]%&E98#61FC4?C1I"TIS'E+C.#O*+!X1^+!@`/86O0(75`M:W-&E<
M6UR2*4#@WK2"E2)<A6$C3JT:M,<$9*A*I3F"`86/&0C`+.,XSC/`-9IW:6U9
M!3FO]%-2BRVF`Z[1&9UW$2@3##@]/%>3^75U-)/%9$]N;:K6FA,<JG8$R)<E
MRE7M;:B](D.)*'G&`+8H'2K4.AME(W+H-:DJD]D11',:E2Q>5)X/+F1#(7*=
M;!;(MS6AD7WN?70FS(4Q;(3,C(&EW;7%PBZ\LMT+5A+"88!#DB[>6I*>R4E6
MLUA*GBP)#>L,=GPN6RM:S6#7926[]ANXZVME0KX9#4"<<LD-@RZ4^,US/QD4
M$&M;_4YR68!8!E-MWHIKYL6XR:[[!LF<P,$8J6+0]Q>X0X0XZ/1EMUXO^-;-
M1B3GL\@ATN;G!;#+"KT9#DW*R536X-ABA&J1C%@`RP,3%O;JTI5`M;8"K[94
M@7-H+7B"EN>FVOUU.LDGN:J==V&$Q1#"T]6#61$Z*N%:09UC!T3`B?2#7`U&
ME--(5$HR@.W4'9BH=SJZ@'^:V-8;G8C!!J9=9*_P\QC8HE))%!HCHNB:E3+&
MI'`"'9@84Z?0Z&DD%FDI',Q*I<LK,^I4@$E`Y+/[-VD"1CBL5F5GVI$DTH5Y
MIJ!9-D\2$J6$/=53ZM8E`FG+S"W4E:\L\-E#V:E7&@&YK5.<&+#U`2@%X`S4
MH6G-:M&7JTHRT6*6A<K:G,TN)R^^!\%D/$;;9Y,+:M\^.+9\U11@?7.&H94[
M39='@2ES<5:5&4N3HSQ$I#L!`R5:;YIU\<8XT-=AQQ4ZRLY8E8VWU0R%ZA:A
M6.;<>WJDBDHD]J<Q.#(M(*3*PD'GG(SRR@#$29@(%8D=M5Q$C)85(9:UMQD$
MC@)9,PYRH4_##$?@W*%4]91D*,(%#M@@?H4H^BM?X!>G+-Z9X!0XK?M/S6;%
MUQ&ITU.$Z.A2&Q$\6,)<6YW50U<6S&8>DB9T1(LJRV\,D;?7DEY$H;1.*4*L
MLG*DG`P.J5L91IS6>^8LZ+$LJ20V5%'!V5K1H6UJD-.8><VDV/"Y:40F9S8+
M\/+<.(E0BBR!)Q!R+KTQD#HN6S=%,Z8:ETL-M0X)D+-$EB50WOH'1LDTD51A
M%&6-X9\M7O9E<Y.KFC06V%*R21.(G)-A-YOG`Z@5^&7I5%ANZQAA<P2/[HW.
M2IE7D(T#P`I"](F1HDBME6+%+<0B3/*=@?D:P209@5&$Z@`_!X<]<`=T5R5:
M&0H(MF<Q_P!^N0SBT:+"S`@&FD&2LKR1K0AR@(.4&P-]"0`PT`E.65?@K`_1
MJ/+`IA-^TX>-B`78#%G$F0$NS"<(:DM*Z-2WWUEH=$JPQ,!()LD@8XX9:%&1
MX)>`HC\HA*,%#S@"KU[;]:VJVH7:OY<V2-(Y$O9Z0)&%2-<+$8D*J)28DYK<
MTZ)T2+(W)T8T#BG.)`>A5>$L\!8A@P("\7M\;8ZA"Y.QIY*,;BS-01IT*]Q,
M]<_O"%A:R\IFU*K58*.<W(D!AN0>2G`+)IH@%`&,(%F!N"MS<3KT<I2.@ZU`
MR&38EE2N3XI9`21F22%A%E*T(EJAPPZ,J\I25Z0)_B+'U^SC.,`2$K5I4"50
MN7*4Z)$C(-4JUBLXM,E2IB`",.4*%!P@%$$$EAR(0Q9P$(<9SG/3@%!B<RC$
MY;EKM$WE*^-S=))7$%RI)@W!:62P>2.D0EC.;@\HH>%C%)F54C/QTZ8.(%C&
M<XZ9R!;;W<%:QU[ED;>I8WH7Z#12.SF6M0BEQRQCB,N=GQAC3^K*3I#LY;WI
MXC+BG3B!X\C,1'XZ?K8N@%.2WS3BQCF\H*L:+EQ>MV5VDDWE"QP"WQF/1MA6
M25O>Y(KD*\*9G-CK2OAKL2H7%'&)"36Y0$1F!%#Q@"5R3BE!)2A.:6>0>6`X
MDXD83"CBC0X&6:48#.0&%F`%C(18SG&<9ZXX!R<`<`<`<`<`<`<`<`<`<`<`
M<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`
M<`<`<`<`<`<`<`<`U:][*_)]K'VI]WKIJYPRSSZ,4TK:(T]%Y,"I8EL_D+!7
M1K\WF%"`80[,B.6&JT9F,_K2HDL?MQCIP#^-/7=SV359<Q+A3N@0XGS<@:I4
M-VB<2E9[@B;'Y#)4F$ZB6L3X>TJ`O+<4:,]&).><#`BC!B*&,`@+AM?9"X[M
M:RF:QWQD=V\B<2ZQBRFJO*[AYH9=.?1?$R[*N&1./K!H5GNXKRD`C,MZ/PY]
M,03XA^(#^I!_9,K]L.].T+#&^Q'50]GT1<]D4/$')::8>N%`8TTPN81EM5'&
M=1#+CQ,[,;4N/L%HD9(/^3P#TP\`@.W-;ZYNR>T'8\T4S<B1:WS]QLFNRHM/
M93$F13(G2-KXLI+FC$PN2)MFK/AN<1Y`D<"SB@F8SCIY9AQ9H$!$:RS>(PG9
M"KXA:-?DQ*V[%M&XF%5,HFXNDCA\HNJ6'S:3QJ2";Y<S)'^*#ECJO]W*\82*
MD[:I)0B*/PEP<<!8]`Z1R>LIE7<G=+GCTX-K.8QUS<"4D==0."Q-$Z?V*J-`
MR*%RV8O1J)60BO).=@1H1X*+9_("7@)X1$`6Z9VZ93_WJ0)+C;FEA>G^T']B
M0LL1<&PR+'3NR]DY\>F3!3R;TBY%.FW8<MEF)0BRP.J*+(,E8)&(&4H$F-.G
M!X:@G-/K)U#9&N>K[U_N-6:MBAJM`UIJ>SKRKS&W%C,D*A1E5*DM(&>4I$:6
M%.6ZXSY)V",X.`@TWMS3&.LK8W,5]1Z,K@PIS:FR2',EAI71LNIPDMB*4\V:
MP-]Q,J!_;;,BD\31Z6-#F6K4+4+&DRWJ49^"34@&7N=9E_WL-;X"B?6!A,I&
MUH19[L4VH9>ZL3F&.FR-:Z1B-9ELTD$G:V\Q9(<@0FKG%P]*G)"#R_!@`"P(
M"N7MY)+NFIKL_7_-W8PBJ9Q4[BYO)$>5SM)';,;+0;Y"RNIT;0Q>+R:..""P
M$0FPEV:#5\>,8`FM:PD;JZB4`$N@Z%78TTE2RY3$,ILZQH#<5ID1)"G1/33+
MJME,]EE:FUN%V<7P$6:4:J=A"M]X)7'"[+>`SH'U!P<`=DWM[>FF%ER@^P$M
MJH[+(<02^.7HQ&RUGL[+]':)B*DFWVU@<(U')5\%MM)86Q=0D;6\]H<7<SR_
M"22(*H"3&76JQ$KVR1IQO`I+&H+33)65;2^.MJ\>RC"VH38$=*WI;/)V_P`[
MBCIFP'B&DX>%)T=.5GIB4A.%`3BSU*D"V+.[?<9LEQVD&99$C8F#9".Q<U!'
M$+2VFMU;VLW#BHYI9B`'G)@R$NROO3P?+LT'8(3&C8E@L&8&[JA!`K$FT^D,
MO?K0L-SG3&@L2V;)TYE;V!O8'(V'M$5T^M!HLUACS8A,>D[HK?)BX%NA:IS/
M.QA,4N3%X(-"@#E0!?%24*^5E==P37XTC;J1:EF2FT%K(`,L(>FEBDL,KV&(
M6,MF',CXGD93G69"L;SELPH,QDQ*4$K`C3!@8AJ>V8ZS*,5ZR2FUE\8<('K*
M_P"K![]%T&1.[_&'2.6W"GV3.)N70IOD?WPVZPVYW,*=4HW*-.K.=AH6)PO#
MJ-2!?D?[?<@B]GU_;C):Z9+(:W53-TAK![E?#8E$BY@Z2-T<JW:T2F4*#WJG
MEN7I-A,U.F5)\84H1*H^>VB6*2\@2M6FJD@@M@U2_+9BN=F:!F[-2I[)4N3P
MYIU[]LC*8](5<%9!R)U?)$9!(RM0+EF,.2L\WU`D@2?"4#R4X$7Q7MYN\)0O
MS6T7U)7EI6OE).$=:9,SGJB8JV4K=+-*6U`B7)9`2XJE3S0L*C<"7'F&=%^6
MDQT4@-,7*4V0(>9^U_((C%AID-S0R*KT%6IZMS)F"#OD<"3$6.ETM7M@EF4T
M^3A+++?&E')U!>#`$X<B,>#(<A`:$"9D^@3G][3;*OU%BL2HK9VMY'%<G'15
MV6MK)*7FUMC+$0RQW;5\K5!?_1,5TLS"(!8TAPD,53^`T!>2"$@%A.O;;F2A
M]D+VUVQ$4+=.9;*9!8\##%;!:H=8"&96GL#-E"1\.AEK1*3)G6%,-YD)V!<D
M6DFIET;2&#QDHS!:8#,2;Z]/DBM.7SQIER!$T67458T_-FMP:UJAU0-=6SFQ
M)DW/L5=$[F27AT>R+/<4:@"LH8"!$IE`!#\)I)H$'Q_0XQJ<[4:,S-K:J8N^
M4,LEM"C(VU/0JW='=*_S^6S251*,RU_E+-7KO<KZ_L89BU-Q&8\]`:%:@:/"
MQV4G``G[6:LK>I2$Q6H)M,(O8,%K6NHU#85,"FUZ:Y^Y98'J5-K<GEX5CN\-
MKI[KK5/&TABXO)*A<ZIURHP&`*2R4X&3?`'`'`'`'`'`'`'`'`'`'`'`'`'`
M'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`
M'`'`'`'`'`*))(S&YBR.$9E\?9)5&W8H!#K'Y(TH'QD<R"SBU`"7!J<TZI`M
M*`>2`>`F%BQ@8,"^SC&>`0]\U/5W\VV@_P`3U>?)W@#YJ>KOYMM!_B>KSY.\
M`E"&P*"URTF,%>PN)P1B-6GN1K+#8XSQ=I,<5)9)2EP,;F1&A1C6J"DQ81FY
M!DP82PXSG.`XZ`79P!P#!R<4/-7*][HEK?'6%XBUW0#5V,8>CU#2$R+N5%V;
M9\ID9DE:'$&%3LC7,DV1F->4F%63%:8PD\*8`2SQ`0+#-6-AX%2VY-=0AW7,
M9-CU8X$ZZ&.LM9B;CK^PW@JU'5T@QMYQ-&B<I75<<D<E;SH@\/Q'Q4VX<'!.
MM.4)R$9O`.5]JW?R42-V4XG\TAK:"=V&<0C8+(KCX=7PI)!+B<*/-9$YT#5R
MIK<"9,^PUHER=:M-)6*V0]6GP8G-//6@64=K[OVQ.[9(8M-5;F_I8LDRJ<Y#
M84=2&O<Q<J(86N2*YH%BB[>EEWNZ?MSFV,)ZXA8%F&X)5:<K"0@PH(%VJJ-W
MQ<GIZ=5=E>\26N:U@XU&S2IVACO&XW%4]S6E(WPV>-68TO6R"=PRKS8@WFN:
M98)0N4)564A^#AF*CP).H*';I-LXJ=^M1^?#8F>PRK-M0V8S*$R7X9D3@G?#
MD!L'D<`:HX*2MQ<C)3@3('EM5#*9%9!P')$I1J&Q8!%.GE';=5WL58MG7E%V
MPMMNA2]2B4JXC:*!R8(C-$XS&91&D,96-H7)XJ%6WM2-YAY@1E/R5S?'LI[`
M$HAJP$"OQ.A=@(!3\GB9,`:I5>S%;=C2)BV*13>,LLGG,,MJ^CY>\NB%T<6]
M1)6B3):G>O=CDTK,H$F!-):1M<BR@HE28"+D-8]T0B,EK':9N;O+7R)D1Z1-
MR6SX(V-K&\D1+5I$DE<;PEAR,O)Y,V9K-7K""ST)BQ$X)R\'@_P<@D"T)#27
M<K=WQ?8F42`FY04O+JL13QCMJ'MC:4*2+X=+88L98X9%@%(PQ9]9<$20K(TH
M'-6E,5IQJ4HPH#P,DME8KW`)0^Q7-%N0XNA%4B1ND[BGGT-0IBY^ZP6WDCMD
MEE=8PL`0X,$_40]84O`%:0J2$G`*"D"4H)<0+PH-AV-;+M<HU/K&F3_"XXSR
M]R?VJ3(70[W:,BY+6*U^)8;`*BK3%)T*<45*D(I@F3+52UG=X>VY/P$3D<,X
M"#!T!O"F<W@EIE[XVIETLFA"B6)K%BZN:K86Z;)7_.V=&VRE\CKI)&YG+JR:
M1E*F;1'!*;C40RB`%9+$:<!>U45YOZTS>K45G3=]=X`DD93[+7=JG->C?TR\
MF%U6O?FV7I5L&-)E%:2F8#F*)$A:@)7-ISZ,11A)`RCD`')8U6[\R65/66*S
M%L?BRJ?SDMP!%Y;'&DUVK]9)7]QJ)9"QKXXK6PUPB<"6IV:3$&8\QV>"BER<
MS(`#&,"1G!BW3,L34I84I)%&6"+03YRRI-,(P2U/3^;%):TV0B!%LL*4]::&
M2KF=Q1+$AQA9A:0XLDM!D.?7@1(=3V_1"ZP6:+6(HC[<Y6%:<@KZ3O,]324M
ML:Y-=EK20:62-SFUN3F<Q.U)2N,,\82)NN8J]L"@W)?IS"Q'@1[+JC[AMI0"
MVH!82$"R.6C3]O1N.-95K05/\*2V0U.;%T[)92<J%KD4SA,T>GPWT0&\T*AC
M6-XC1FX(4@$6!.,IJ;<HRIH8S1":N'WQX-LC<4ACCS))Z1DM34;U#[R8Z4Q8
MQS0WID\Z:(7))C%ESFSGDFFJ$K0+&/4'%%X-`L)=57<9-D9;W&K,5LK82;'5
ML-C4JF,5>T,;,<'5F33)KL\Q%&3U-A(V\@]Z6(3$QH1!0G(2`X]2FQD`&<>L
MK3;+34S2&[%$ES8+@XN[L[-<JD\0F3A&\N"K)PHZBDL*CL<:G6/-ZKS<M@S2
MSUH$`R@*#<FA$66!D!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!
MP!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!
MP!P!P!P!P!P#7%;=R;:PR^)E$H;#G-XKI]?Z<9X'*U%+S2;1.&E/$1F;C)5+
MRK@!H'I^;Y%,6$EK7K1FD)HH%0E4+,DIE(%&0,:OG*[?TO!G1`^QEZ8&N)O9
MB@,SN:KK8L%3*F"T-K'*`,JQ',6MX8VA&_01D>4I*2-+5.79U:SD*I$4-,+Q
M``J\6MWN"PZ:3:1O]9R":MTN?F-L7LJ6NI[ECCK,Q0R#HSK;KEL6RI?AB1N[
M&G7NZF#8\]:<_FFM^%@EV,A-`NYPV8W\CRY[7KZ!Q)8ZRJ7=K(;XQ4T_R^/T
M<2,\P>D5J-JG,C7^)Q4M$90*`Q`"`QQ$O><-(3A+@%!,`S$2/4YL/721@D^)
M:GM!J@RAP6+H9#;5IX;W)A1K,EC9L/9GXU--RL*<*$8%;=A2:H3K\'-ZH(#2
MSDP0,!&B6;M4WBNY9#(1;5N&.^J.M0[`K>Q4EAR0]?<9]>;1R"R#VV1OTC+1
MP"8(IK'8BD?$YI!A:C+NE(%E+G))@`+X6[&[U)T[FZI8$E<(F-!7Z)CD)6J]
M^IWQ$;93C<'H9I(*Y52$%CN:>NQQ*)MDG8T+,G7I_B,]S$)$C(#@($OWM9VS
MD!L0]SK>K'";)0U%4RQR"W,MBN:1T?CIC9(I]&(<B+>E%<IIFC:T[:H2A<PM
M65)1P4BQY)P:B,3@0WLO#]T4>W<6M2@Y+9<JI);)=<*=V&H!P>Y!'8>FK626
M,D=WC9>BW\C"0Q+953'%Y2S1G0J1(Y)#%AY1P`+D:;)P$3:E)>X@"SM*!6X9
M9F966X[W"[C)DK-<,U(I0F3%PQK3BJ2UXLP_PX>,LXHCB*8P(J&!<`NW15G.
M,@68^(-TG713>==+3]M6[N(M:+?Q16Z.N%MDHZ]79,,MAGU$24:6Q9^]DX1X
M->K(DJ8L(L_$(),4>:YYPJ"OQD#CCZ?N7O#-W#Z]87FTHO:=H+=?HGJ-9DE;
MIKFL:M+*TKAC]9$UC)D\121&V)"+C:'-O=LJ.@U,J7"P'&1>#&`(IM&V>Y7:
M%L4E=,1J#:NI*]D.O_;GE5_P!B03LIZI6PB-LK#-VV::_J580;$;ADH*_3-#
M))&Y5G*@<!<??;:2M7HR$IH$G_$^]2&DYU%)[6>V+]MI*T7<_=WBR:SELG:Z
MFK,^-IK1*TX8X2P)211651N<PE]BH(3AF$!Y22)O./<\A6X<,&`9)4,\[0Q#
M1AN<%@;O/V91-^LJVQSYM$[8L1468[N%:-UK`AT8M50LD3S)FNN\.*B2D-&#
M&HF2"5&-X!&8$5@"8V^^MI3*AO><2N'02JGZ&UW'93!<VDWN$2C"2T/B2PFV
M74X_N[Q)VQ`_L1:",Q[#9+TBE.WJS)4$P!9V$N21`6O8VQ>[#44\.<!U\4N`
M$L6;9FU1MXAKVZ.*N,2"K)Y8)WF.L;D1S:KL.O9XQ,\*71A,,2]T-<!."3J4
M82``'/<4VV:L*C:Q>XQ!I\DE+CL#>C9)H`Q,,WK=ZEU40=IV4*IE/('G#FTR
MVJT5DJXK"#37GU2/R%KJ4/\`62AY(P!?='VGMG.KH+CTZB2"+4TBAKQ)44M<
MZCFD;D,W5J$L1*:657[[E@$M=/D=?I"YIE"%4D6J7-.P^J*P22K",`&&U>W=
MW`X4%PL"2UO9EE#DT.KDN=1%UIV=M:F,2EBJ+#C8<KKI@2N0T*8EKD;4I2_#
M[<@.S)G`9?HCAJ%!(3@,SI+=>R<=:Z"2_`RY_73B!R^1369Q*BK'>6GXVC"R
M&JX_`G*O'&4,,JJ`%C0QS>U21?(UI)#>[-A*)4(LXX"50!B8SV-N3:,OA$LD
MD*NV$I$,HK%I<VQAAEHP-@=(PV;AT@[+W]XB+ID0TB]PHUS?2GHL?F`$V)59
M0\C`6+'`-RC([$/S,TOB9,Z(DSRV('5.C>VIP8GE(2X)2E929V9'=.C=6=S(
M`;@)Z5244H3FX$68`(PYQ@"I\`<`<`<`<`<`<`<`<`<`<`P;NJ[K!@]WS6#-
M\A:F",_,ZF]FP7#BR(CE+C<$?F8&1,6VKEI@</HDR)S;P&-!81#&-65G[)H,
M9`A2?]P[X-EJQF'"7P+G!)-8D.>HFKD,:;4TR,9%40;(Q*3)$?&US:4TON'H
M]8DRQKUN$HR3T;D$E:28D3@2E2N]B"Y;/A]5HZZ)97UX;)"ME(Q6/&W$<:S&
MUDY8UB]H;<(T+C+8TIE4$4-Q"D!:1?D1F#S$):8(C>`8\7=W()`NU*VUMN@F
MF,H;"UXE=1,;(K<'E#8$0D:&P9M`D!CBHPUEM:A$3EG>W!&HP((@HU*<9I9A
MX2\\`QEF7>W<JDDE^36Q:G/,KF$5]7AL+K`A_86B8+9PT3?N!1VVWB*S)Q+)
M+LV$2ECT^1ND7-3MB80VUP"M4Y3IC#!$`7S?7>'/KU3!;#:(-F/TG%=O[OUV
MN3+J;B4SI6U4]4.US@^.DCAT;;ELNHYI9YY2;#(QO"U&ZI3H`[>]`AR#!H"`
M)VVQ[DRG5^[Q0Y#!55KMCI3>NLLCK,S2>-,$76O%[W-9E;I7XJ=GM;LZ&H6T
MB&%'&A"C-3&(C`FDX\W(@"`MW2KN>XV5VCGM)21L*BZ";0FG[JU^;'QM5LB\
MBO9IJ#J[>DK@QDG(2+HQ8EF1Z57JI/6($ZE"K0,905."E!(!&!`O>+]STA_<
MHLPK*2`SO-@N#4"O35-RP9)%I$C/E$LC+Y'5,QD2.-,S7<K."#N3D3#L94+7
M%K`6:0?DP1I1`&1.J>Y4<V73+DZYB:*YE66J$R:.Q(^?,TF<Y-%9O5\)LXAU
M;RBD#&N$JCJ2:DI'4DI,>2C-\L63Q8/#@(&,L5[I[<]%-2V05$T0]ID#0S+V
M=V<;F9%*0"V40N*3>,H7S(8BF]UDK$+\I3*#BLJA$+$Y!912CU0LIP+#^M16
MR-92D_;88TP>F7^S&BNIJY/DT:GT9KS--7DUU-^94L9XZLQ5\#@#Y*&PIXDQ
MABHDD*53D],21U,"!G!=>V^:-DLZ:)%5DE=F2)4FLO=HE+`L,7-\LB,6,=F^
MS4J/P,N4S:\5V\JHP!22>H_PE#*25A6?+2*P``QGFW=1BT"+FJ=\JE4%[AGQ
M3@"#%@L:9',RHDS[<NK@^0-Q7M"44BB"K.J8BB'+!!0?%)4F#2RC"#2Q`933
M39J0UR\4TQ3"HUXUMP0V9/*(Z&R4Z8MS;-H(A9I>\UVG5IHJ@$[N#C5N']^:
ME>2TI;AF.*$80`./3B&!B=]::REO#6<X5NVLD)<(*DDY$I=[$;D#4XKY:MU1
M!"LHI$X,S?'4<;9$FSQ(9DN5'%XC:AI49S@\C`#C0,A(9N2[S5GNLENI9VQ8
MU0U,Q6B@K=+-620G6*%YC"YZ]RQ"<Q5O?*]7YP_-BAE)-(<E*C*TO!BA*E3'
M)3E`&/\`-NY*,^KU]JP"OWDA+&97;#2B:I,X`86ZP"HQJK=>SM:K5)KM#CGQ
M)#;&JV(QR1E*&X`7%$8]IT9X<^2L`("]Z2W>>7ESV':;(1Q9>AJYMO\`M6*3
M2/RUHPPN5:U58C[%SF-TR!L2DM865*E2X(>A&J2W),,:DXM,(&`&`=:INY,S
M6M8\+@J"L2$;?))R173O)$MELKQ[GDCC(MIHZSFMC,0PICWYF<#-7E*G)QAR
M`\M*^HQ8(&(!@>`615VWMKE]QF<:AVQ8L'55Q)#9]9FK$\CT83HB+?:(8QQ5
MBM[5QS=1'*6DNWM8)>]`>G-4A4#5/3([)BQ)DYS8[8`!(K#W)(6_6>NKA+",
MJ$S;;D6JY?,6:9H)(S-Q<QFLHKQC?'-M8V99)$>39G%#FQ1C",QK;UYZ<I:X
MI@G8,P!9NQ7<(D-5V>KB\?A:;R*HDD^<[`CSY($*$5G5?%M=+TM(Y_A\J*8G
MEA953;(ZJRF`D"J/<<+DXTCD0VE'%*!@7&Y]R`."GA;%J`G$O;D+J8Q(AM[P
M42X_$+G-;OJ*#1&1M.&%6IC$PF]TU*VL1",S)Q29/+F]>:?@HE8`D"\Z]WV;
M+%MJJH"U5LH212W6FN7F,S5=+B4CN!#;%9;$6I"35T"6QU&YI<*(_KFX`5@,
M5%G)CG-'@(#@^?DH"VX/OD);<:&GG"&*W=.Y77+:T5S57,8PE7,BI7<6VE?1
M)$AB33'DV'=J1#UD-+$::J(6@1N:8PW*E0`_Q@;*N`.`.`.`.`.`.`.`81;]
M[TP/M\THP73/:VMJW"9;;==4G$Z^I%C8)'8DFGUHN*EIB#4RL\CDL4;UAKBZ
M)\)P@PKP<,XTL(`"R+V`8%_7367_`$*W>9^C16/Y=.`/KIK+_H5N\S]&BL?R
MZ<`S3[??<'@_<)AMR2>)TW>M#OM"W8]T%9=:[#QF-Q*PX_8$>B\4E;HC5LL:
MELP2IR$Z&8)BL^:H+.P<`S&2\!P$0@,_N`.`.`.`.`17/[QIZJY35L(LBRH;
M")?=TI50BHHY)7U"U.]BRY"UGO2N/1-$J-+.=W-.V)\F"+*QG./$`/\`?F%A
M$!$L7VZKZ02RUXXX(SXNCJ"?/%;R1X=WV*J%*B3(!PTMG+;8FTO+A,%:68FS
M5.2U9"AR<I5$F$Y+"/)7F`6C\\RC9=./O>KV\A[ARIU5A;[$5*(N^UR]DLU5
M4G=L=?VH9;@M4N:9^1W,U)FG)2<9YKJF$$L/4:81H$OMFTNO+TK3(&FW(:XK
MU@AE)D21QR<L/4E1AXF1R$M,`K)V7$B-1UQ5&)O#Z@O#<K`(&#$QX"P+#L?=
MFBJML]%5\K?E*!>1)112:2!2@5HHU7SJIK85ILGQ`Z+2""52)YB^,&94H<JB
M$'B\2P:<`1B"!?KSLG4J6/6.^1V:Q*5GU2ZQ]EG#:CE3*V_#[A)7-&V-);JX
MNBA.WH2EYBH7IC1C\E482844,1@!!"!T&W;?6YZPMPS6]$W<YO<SVA2C:SEK
M@XY6I4S@K4^F;$:,YP7(TQ30KP8I(*,3`-2G%B,P84,(0+>CV[^JDF0DKVZY
MXL269#4$^/(=@NC*L;HPXUZBM@E6[)'5O2'-BHFM7$E\/2G8`J(;#`J#"PE9
MP+@'W.MRZ#A9CNU@G+.]R9LC]A2(#0F4&HFP:*LFC#Q*SW*9+4H(A'VU"1G)
M?KEBPI((XLT`1B$0?@L"NRG;K6B$C=2Y5=$'9C65:J;W$E4YB$<4>A235<X&
ME$D$FF+$#:FK:195*B<&)4PF%P`:8`:-0$L"Z5VP=+ML3DL[66+'2H9$)&DB
M+_)@GGG,R23+Y(FAJ)E3KB"#271<JEZLMJ+`DR?XG'.4V/UX(@8`L%OW4U3=
MDJM:VWM`%R-`QM<D7JTSH,U,A8W>/9EJ9P6GA(R4E*3Q0`W-9@S(1M[>2:I5
M8))*-&`"X'/9NGDN(^>W3B).C:[SI_@CB[&2=H9FY@<8F&PB)2)6K>#DB=4I
MC[M63LF4)"1Y4APC4'8#DE.:,(%CP[=W7N38>_?,Y9Z^,;;)L"MFLF=N:&/G
MR177:!P=G5[;25AQ9J1J7-3,O4)<+`IU!Y;>I\)>?*'T`H"S?"FF6%1&RI4!
MZB5?2F^KIH51+'XDE&@C+K22>YU+Y+9$ER9EU0Q5T+I)PR4/*?U"0"DD:PI.
M6!0,D":%6R%))J]G%IDS]I=H)7$;G4LF+\P$N#^2T,=:.LC8INHRG9T:Q6K/
M87J(N24P@DLP\9R,P(`"Z=>`1$V;G:QS1FM=//)/&XFAJF4R9GF;'9.$!(1-
M4+E#TVI9H4WJP*25C"J4Q(]>7G`1*6XM/XU9:89><!`E>8;.Z_P%Z51V86Q#
MV)Y10E%8RE"K<<B&7!W,QS*:Y)@U.4<08WNPV5;Z3(1Y&J"B4"*",)!N0`==
M9M/KJ@3+UJFXX*%`V(TKDJ<2GDE2W9:E2-_<,O*1P38.1N+(WH(JZ'+EJ<9J
M5N*;50U1A(4YN0`6-*MV]?&$MMPR3=KG*M7<45I=Q11562I&P2"0V.R5>ZNS
MNJ4Y3($\=ALF>PE.:OS<E%FD&IRQ#4@R3P#M.^YM$DKJX;8E+FZQEMC6XTTZ
M0GA:Y&Y&QI^=,O(/7RD`S2LL[<0<RF!!YWA-68S@:8!P,"%@"Y![:ZVE3E36
MQMR0HF;HI"9$UC`>X#(/2R,I>N:CVE0I-(`@)5)W9`-&;XC<!+5C)(%G!J@@
M!@'TAVSUM="'%0V7-!W$EG]7AX&@=/6>Z#4KH-E"G=@IRC!MBQQ=B\IT!)^"
MS7(WIA($[KCJ!S..U6NK1E_`[6[#FPZ+H$SH_)G!<:C6-S<H;']Z&N,1J""U
M1J5N:8HZ*%PRP#"W$MBL2KR<)CO`!>T-N2J[#D$@BL'GT7E,CBK<RO$A9F5U
M3K5S6U2%0[HV9Q4$E"SG*):OCZ]-@T/B`%4B/(%D)I1@`@27P!P!P!P!P!P!
MP!P!P!P#!K9';I@I>PF""&U9(YXZM:VII&]N"-K2+BFV,V@YVXQHU,+++-4N
M3I.FM74RPT2,9*,@20W`\*O%C(.`5"N]L:-G,V;(*F-9376P)J_):ZPFC;@T
MDOZ1+5E86NK<%Y\I;V4M=)ED:L9O6&)V["T_*,831AP%.J$0!'1UR:;--RD6
M0")S@R:2"Q&JJH_80(I8@ZSD5F'III!V!JBJY8I!6&98Y.,%=HV4L())5Y7X
M)2FFA]X(<J@*+<.TFF\X:I93LX8;85HQRXMMF#17[#9<)>2EC7(Z_"0]N4CK
M1XBTD2,ZI[L]J&,/JP'*,*#<'I\A"8'(&$L^.[>"2"2%T@]9[(R61,\/-<8Z
MUS.^]T8O#E<G:H*XSH%6+Y49;;HC8Y@G@C,]&EI,%#("!K5D@,SGPA-`S*J_
M4W1>XUTT^"8WL(L3QQS3)ETF<]A=SFJ-RX9H7)D"ZQ24N%Q%-,U2I1L*IO4&
MICSC4V",%FA`4:1DT#`2'CUN=!Q]\L?7>WX/5*B9O<3=;>5;G[HKH>VH(:@V
MZ52EF9?>4[:E3[(X81K*@<%)"'!S>!#+DY8#@JDXBCP,NHI(>WYKS-6:>$Q_
M8Z`RZ.L<YD+=BT9QM0XMZ%/&!.4-E(U\7M.R'>*G(D;,(Y46[JT@V,EI\*\"
MXLD(#0@93U3<>IT/KN6M<#:ED:J*C(V_6D\2APB<F<8"UA:7-_7S=2US]>2]
M-\@F<1>4BO#@G)6J'`D0@9)P80(L7`+6K';RFI?,5**;P8F"6#$;LDM*,GF,
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MZG.(1^.P:7('IW:'XHE`Z5T-4BA#>U*G@M`S3"0Q\M[C$,,E;0P&KVQ.>L`2
MK3^`&!>>,LD8%)!O]K3D9!)+Y(QA-A2*RV41$->32'FLG4A&.-V"Q#)3C`JB
MTF3*CLH#,>`XS")2`918B\!&!9J7>&AY%'6LM&P9BSPZIHBZG1:Q(TF2B20:
MSK_::*7NQJ*/&OQJU(_/CB9YJA(!4UISQEA=%"?J/H!V*RWKJF76%,HTW11\
M`B<)#5@:W=8A$'Z1OEB0"?P.I7Q#;CTRL3.<M8Z_:5UN-*4;@?D84:`X*E4%
M,44I].!QS'>VOHM=9U:2:`25)#8_)9W!)?/%S,2N(99>P+]3F-E=R6]O-<.M
M=/`=K4*18Z'B(4(CDOARF&G,,-*`EEKV;IE?7F9[&F:0!;7B3LM=0-`LK]VC
MJJT'V91YKE,.(KXMT0-R:5QF4LCJ4I*7IC!(BPDJ0'C*.2*2B@(3K/?C7QVK
M&M9Q((ZX0Y;)XI5"UW-:H2Y#KR,6%/V1A4GUP79ZUJ98>FD,7=9(2AR2M4H%
M!YAY1:<LP\SR<`5D.]U`QMB5.TP3.67.-XM)]=Q0JMY:[IF-#!GFZR79:(I2
MR)'HE:H:*,?QJ#PI_3&K$N"`G",5H@*`.O*M\-;X>B)>LP>=+I,>LF^&^/I*
MX2H).HF,&G4KK^;L`%#JJ;D)<B:'Z,.XU)V%64PB"1"">,Q006>!P6KO+3L7
MB$X>Z_A;G/9>V#R\(&M;"WA@89S'&V4Q*!S2?LTQ5,QC7(8K#EDO2M[@K2C5
M')U:A.285@L\L8@):LW;RDZ7G3K7T@;)F;-3BF)Q(:8I`7)Y62]Q?9755>M:
M1ER@*#EW<\R"W8TC\TSP$8]4(.#L^C5A3@6^#=W7<P3"Z^AG04$AED2B$<E!
MM4RDMF>E\N=F.*1E7'7PQJ"1(D1\FE1#5D+:)4K2J,G>:06068;@">*<LBM+
MR@K-:E<A1.49?U"\QM<Q(VX"H:EL<EB)6(_"4U4)&X)G`LX)Q!H@*TJCS"E!
M92@!I00)>X`X`X`X`X`X`X`X!HU[]/[P^C_];-V[_P#341P"S>]$?.]+SH7W
M:*+V!S!;3HYK8J<F^L=D2^2*:7W;JV22H]T3T7&8.C][C8-C#'=>I61-\9&X
M:P9P!%.`3$!8C"`+:[04]GG<DM&?]T2\[B7L\HB3Q9&N%0Z"PJ6R=I8-*HZB
M?2T4P9MD8JM21E?,]EYV-C2+EQSJW!0H$6$V49?7"<MN`E/LR_OP=Z[^N"O?
M_1'1O`-YW`'`'`'`'`+7?H1"Y2Z19\D\0B\C>H,['/T)=WY@:G=TA[ZI0*6I
M0]19P<$BA7'W8]K6')AJ4@R3A)S1EY%D`A8R!"2S5*JEK9+V\SXG+42^]6[8
M\;T2^B"]1VV&=5&536]QE4),,E`@1BB:0'H#2E"(XG)Q1Q9A9Q@1`1I]7IK:
M4F0H6]GE;0@9U38Y1Y$U2UR2$1Q[8HG4T3CK\S"Z#4$.[`"D8ZX)C#!FA]YH
MQGF!,\\X`P+J*T>UO+DL3F0X4J.ED->FB3-#^*0OA"P<G:;$G]J"D2XA&N2M
MRIV=YI:LD/7#\@(529[5HQ!](;DC@'[9.EU.6I+YK-).?.2G*?-J]ND*)HEJ
MIN:!C=:Q<J><W)$A"0;Z)S70!R]&,8!^#`B"C0@":$0Q`5%FU#JMDJV=TTF<
M)\HK^=2,U_RSN$Q6KAQ!*.4!F*>*PE8>4)2R1-N?\FF)DHQ*!DDG93X,].`@
MHH"RA:`Z^G&H1K$TQ<"F]SA[N02MDPC3"7&"2N;S.-+6YT"B+?(\N2/5B.X3
M%+6J0J5"%::B-,&C--(,`I9W;OH4^OB:V$ZVH!D)5@/]>1/U:=_,1YUW:M65
MK.8ZDH@"]U.E-L2-`H"$`3<J$P50#`'Y&,0'?,T!HXR/*HGEXM?$:'B[D#4R
MBL=W/0Q>)[!-:AOL6!1@M26>)JAQRE2)8@3XR,YN4A+"2<%.44G`!^.?;WUP
M=?6^:TRM/ZDFR&Y)E'*EA`V6/6PU74VS6*LQOE#-2QU>?L%*%A)(Q&#2*EA/
MDC`4C2%$@=J3:6Q,%?V!%*SD;Q"9!9EK4K:DHER@1+@H->*?LN#3HA:D:42=
MK9"Y([-D*+;S'4U,<M4"R0:N&MPF++X!^FZ"Z]&-SFUA;Y:0E=Y(Y2I=Y$J6
M`&<Z2:J'2EIYC/4H0,I;%@CXL*>"\ASYJU1E81E.J`2:6!69;HUKA,VB71YU
MAJU/'YY-BY[+61ID3TV-KL\`II70QJ4!"97C+2T*Z^7GA.3H1)O,<CS%^1>L
M,,.$!8`NW'0BHB8$/,@N60_?*C,LBUIG.]GNXE%F(Y1A0:G<)::@3H,Y?8@Y
M+U:QF6H/0GHU2T[(LF@$$``)+QIQ5)E?L==N#K8+N@9+'LNU/?KG+3#I.ZRV
MXFBR6"S#G9Q)1)TI[?*V:W'].-.4G)`DPMP-)Z<P@@90'/#]5X8UUS?->R5(
MPY0;$GRUOGQ->MSY"&D,0>(2CJIC:&1`OE,K5,[N@K9G1EKUR922!>]B5N(2
M$XU.2@`6.XZ`THXN2"19?[90S%ID#O*FB;-L_4HI,UR*1RYRF$H=$JDM!Z$0
MY.I?7)&M)-3F)C&YQ/)"6#/E#*`D.S]3*QM5X=9(\.<]89,O0U`E;I%$9<J9
M7>,**.?Y[(((ZQT\1"PLAR`99[XD7Y4@5$N2!>,A06,.`^$"R%NA-$N&'9.J
M4V2>T.$PL&9-L>46$^+&&)JK@CTLCMS,T40+A*L-<=MDF=O"MY2B$=GW@O&I
M2#2&ED9*`I[GV\]=70+&E&GG2)G:%3X)?'6V;.2)@E;*]7@9L03$Y6W%`\#E
M&H]:"I2J;22\D')4BP])YHDQF2\`=J-Z$TW&GRM)&1)KB=7BL28*E1*WZR7-
MT%+$=5/DH?*I2SH!J<)<@#7(YJ[)F\S&"3SDR\W"TQ69D)@0*L^Z,4/)GY\?
MWU++G$<EE#C+'QK.E2S#,X+7:PF>S7)"<B+*`(+0LDS$G\9`1A_P7`B<"P$6
M>`47&@-&J&:&L[^NGLSS!(>\0)A=IR^-$O>C8D_)5#4Z1R0KGV.+/BV-KX^:
M2@5-+J!8T+@(DJI6E/<$Y:S`$-S[MAU^L)0J*OGTWC3H4KC;>X9G<CD%D)C8
M-'&>1M2&)M:IY=,.J,E*=)E!H1+3G,@Q(<H;A$X2'APG`RUJ76N.4^I5K(_-
M[)6"=9@X3QW:5\E!F+*))(D,@,F84$;*0@1L\?E\RE*V2J&T@6$R9Z,`))@A
M*4!-@#(W@#@#@#@#@#@#@#@#@#@$036@J=L65H9S-8"R2&6-K:W-"-\6X5A6
M%-S.L>7!H3"].J()/"U+)$X&)A&!$-/E<H\O(<'&8$!2H_K/1$55L:R/UI'V
MPR-O3=)60DKUYB!OD;/%66#LL@*:SUIK:-[9(A'43<B5C*$H1I2,`)&#&1>(
M"GFZHZ[')9@A-JB,C;Y[)G29RIMSAP]VN$L>7,E]<I"G;L+L(FAV4R$GWGYR
M(M.,#J:<M#D*H\XXP"@-FE.J[.L7+VRE8DD5N(C1+#@>]19,P:^M,ER4`!CD
M,M.F+>V%">647@!1649`0!"`HL(0*.P:0:^,C[:#D=#R'MCM!,T(5,*=LB.B
MD90M\>/CKB1&F\L10TA\C(7*AKE1@S%9GK#R0FA3F")X!+<)H*GZX=US[!8.
MW1=Q<I1+9HL$TJG4A&.2SHS*B6.)37E>)K3!>EHS%)A!1($P5B@]0`L)Z@\P
MP#I&ZWT4HA+'6ZNKXHO@4;>9=(&:(N2(3DPHW>?-\U:9HLRWKS5!"K,G;+&?
M2%@#L&%G%.JD(@]#,\`LQ!IAK&V.;*^-]4-:-^CS0W,;0_D/4K+?TJ!J1N;<
MA$)\P_>]53B4VO"A,):<<8L,3#P4,T18"PA`N2+ZMZ\0IIL*/Q6H(2R1JUF,
MF,V#%$32`,1DK`7&RHB:T*HH,8XZF0N,<(`E7`3IB<.``!$I\T>,"P!P0S53
M7BO5[4ZQ"JHTT.C,K-<$CGG#@X.)[B8Z+'PMS=UKHN7*G]S0O;BJ6I%*\2D]
M$K5GG)QEF'FB&!]N.J^O3LZJGU?5,8/>UCL[OQCQ@"TAT*>I!(ULL?'1$O3K
M"E;:N>']S5'*3$XRA'!5GE#SDDXTL8%S(Z'II!%9K!4M:1`$)L1V.>YI#ALZ
M8^+/[DH0-#:<>ICZ@)K2468D84F,E$DED^,G`_#YF1"R!2%VM-"N.5OJJJB'
M@<6]Z:EI*9N]"F4(9'97WXG\D:5"8F3]7BT<Y?5`\!P8:XB$:(6<B%U`^83K
M31-;S+%@P6M(_%YA[G<6`;RT^O3F'-+I)'V6J$JA)ZT3>IRG?90XF)##"A&H
M25QZ=,(I.8,K(%N..G.L#LVH&=?2T+.;&MQ4N3:B`D4IR4&51:PLQK1X3*R<
MIXR5AP.R2T`SAJ3C'XBDX!8#G`%1)U0UV(]!@-4QL932XF.[,F4Y<E:)B<CY
MPTV2I5L*%4O.1L9JJ;L"!>=Z0!.#C$*<`\"*(*``"B1?2S5F%.D>>HG2L1CS
MM%'\,CCC@UA<TJEH7%M#<PD(49@''&01E*S,J!,2S9ZM!)+:B"!,'"-+Y0%T
MO.L5!R&4/TT>JOC3C)Y0Y$/#^ZJ"UF3'1T3JZR7@7*"`JPI/4C74Q%#C!!+#
MDXU@1C,\0B0YX!U2-5M>TM;!J!-5L=35N3)VZ9M\6($Y$I&.3,SLE>V)UC2H
MM>%QBYL>7H2?=H&XY*4W$%!(3!*(Q@O@%&:--=86!"]M3'3<5:&:2M<<8Y"Q
MMV71&P/3/%8H1!6EL<V(AQ`T+4)D.2$-BXLPD071$F(*6X4!()P`".G+0*B7
M6QG*:JD[WB-/,7=HH\58F6%((,Y-<A=Y;(),@7%MQ"-Y<F25/\Y='!R;UBI2
ME4+E0C<!!CJ#(%\O.DNJD@=WA^>*3B2YXD!C\H>5YF78![BLDZZ;.;ZY*?)<
MBP"=G%PL9[.$KZ84A,<31!,#GP>$`X:2ZINB<Q(OI&''IC)A)9W@CP.911,B
MF9Y*V6C2`)<2PH662N:8M:N:B?+:E3@6%68F$I#@W`%SR'5G7V56&?;$@JZ/
M.=B*71B>SY4:-R+<!O,94P96QNW@(7E)`N+>IK&.#"=@O!@LL:'QY%Z4GP`6
MN?I)JHI.`>;2D3P,F5O\V2A)&[IB$,CE$GCDV?5;:F3N92=M1KII$6UX]$0$
MM"4ZI`*RR0*.IF0)@@M1UU6:EV60:,)8^K?\`R^J4ZIR4GO2@+D[NXW)V-7K
M58W%Y4N+ZJ,/7'9&L4^,(331A++P`"1^`.`.`.`.`.`.`.`:7.^=6]SV#K'K
MXZT92M@[`2FG-^-1+\?:UJ]*VK)H[0:GY\?+Y4-G)=U[8W>I]$B"27DXX!>#
MC@>/.`>(6`,";)V%D-Q[<U+N1;'9*[O=BS>@X@IC](UG*TVOSE1=7RY>[*'%
MRNR+UT*U0E!NI:B,*;\/*I2I"E1I$XDQ)*DDM0$#KM-^OD6W9==]H#V1^[U6
MMT36NU=<W*P0-/0+%5E_I"QH\Q.67-!PVP>DE$_KPE.:2S/!1B5:`A2,I0-0
M6`H``,W>R;#;S;R>Y#;UXZ\6KK.HV<[BEG7]7]=7(B94$V!`995]1-K>N<"8
M^[OC5X@NK&K3BR2I,!YI`L8%G&.N0-XG`'`'`'`'`'`'`'`'`'`'`'`'`'`'
M`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'
M`'`'`'`'`'`'`'`'`'`+(L"Q8E5\?!)IFN7H6DYY8H\F]U1Z1RIT6O4E=4K*
MR-S>P1-I?']P4K7)86#H0F,P6'.3#,A+`,80,/V#N?:+2B"16SV&^$;C7DZE
M$&A4*F1<"M,J/RZ4V5-Y/6L'9HRXJ(,20^*I!/X8YLQ>4V30%N*01!H@#$#`
M@+F<>X;IRU&R$EPNA"F-BFQT=U$D)8HA80QMFRTM"@%&J;."5$C,F3%Z"ZI<
MIRB_&4/U)7ZY^N`\0$RPW8NF;"E(8=#9J2_/1RZQ&QO,2,TC`PO;A4<E(AEH
M(HW+5+.1%),I@$N/PUNP&]:I$A7A&0;@)I8PA`B5+W`=/EEB/]3EW8S$V'&I
MM8%9N<871^:-JPVR*M@J&SI]7K*H<8TE02:<QRN7(A\,:&TY6X&M0_5$E&$X
M$/`'Y7?<&TPM-L7O4.V%@AC4VT8GV<4KY*8[0),+750I5HOOWHS)XV1K#C5J
M5:A-(4O:?S6](?C!9YI8Q@"(#X6=P34)LBLUF3S<"=@9:]IMKV)E14BAMAL$
M@1T$\J#TJ&Z6^(/$212V05=@].,*A\;D2IN1]/\`"#2N`)?W!=/8'6;C<\KN
MEL:ZD:(%4%H.ME8B\[7PAM@%]JL(ZBE"Z2MD66M*5NFIX@^1XS0F$@,`,\)0
M#`"$!D>BLJ&N3[-8T@<E:QZKML8W>7)$[#(30-B22-JMX9@$+`M64+PX+&Q$
M,[*1":I5E!$7YA8,FE8&!C1#NX?IK84%B-F06[FB70:<P:36?'7^/QN<.9)U
M90^3YA<DL=R1IHP-RC\";)<$3;EX<"4K>8L+,++-'DLSP@319FQ%-T^[)V&P
M9H0S/A\+E-D&,Z-HD,C=&ZN80H:$<ML![;XPTO*M@A$>7/Z).J=5H"$)1ZHL
MO)OC%TX!8$IW<U7A4FED4D]R1UI75_+8!`+%=S4;^?"JVG5IB:@UW#+(L-(T
M'P*OY3+O?[?Z1`\.2)2+#DB\0`^L2^<!?]=;$TY;4SN2O*[F0)-,]?I,AAEQ
M,*9CDJ15!Y4Z,B:2-K$X&N3,B2K7!?'UI"TH",Q3YB8\LS&<A,!D0$2Q[?S4
M270>#6%%;E:Y'';/LF55!69#+&YNXRJQK+@JQX03:(0.!)HR.=2YRARF/+_>
MHF]N4$MQ:%08H&6628,('TY;\:F-$@:HFX6OY$I>XW:TL:XV&"V4H?E;)1SN
M0P6T:!H30XYP`O@;XK)1KT0RPK@*E!)021#-+"("R5'<_P!%T44M>=+KT);X
M=1CG/6.WI*XUU;3>S5Z_U9)(A$+'CTE7+8&02AD4(D<]9TKFW]<K$@EY8C"P
M@\0@@7W)=\=5H8V,KM+K)<(PGD=RPS7I@2OU:VNTO3U<]BL"&3P"`-D=70<B
M0+7B:L;B4<UB+2B3KLY$628,T`P!`E&)[(4+.*B>;\C%MP5QIJ-)9>KE=C&/
MZ)MC,.!7JAQ1S\B9K74:',/<(*M:%9#RE<PI5+6>F-+5%E#+$'`$3#W]U&3Q
MF9RYPM](R,\`I-)LG)BY%$9_'7TC7Q:-2`J[&J*/D402F2U>4)(/SWIL1K$"
M7ICSS"_$'J!+E7[$4O=1485U//6R?M<TK&/7)$Y!&4CLXQ>05M*U:E"P25KE
M13=\.*@N"Q&<7A(%5ZXL10_,)!X<]`(3C7<4TPETA.B;%>C&HD@%-WMZ1E61
MV<,R]\=M:E&4U^L,5)>HNWYE\DJ,>,C?6UJ]8O0DXR:,G!6,CX!2#.YAI$13
MCQL&KO!.W4FQ5Y%+:768ZP&TFF)FUI-Y`&*1B<-#DY0=*"01QRD0P),J4&%(
M"#32_.\O!A>1`3M`-EZ0M"U;4I"#3@IZM:D6B`/UL0H;#*&ET@K3:;0K?J[5
MOICTR-R$GXN9D"A2C+`<,TPH@W.0X\L?A`MJ4[E:Q0VKJJNQ[N"-#J>\);!X
M)4L^8B'F61V>2^RG#W3`F)A611K>O4+)6Z_X,C\00`-/_6_%@?LX!6+9VGHJ
MCY[5=6V7,U;)8MWE38ZI(6VPR>2Z16!BMV,J2SPN-ML-C$@4+E,4CQX%JTG&
M,&E)1>9D/A]O`.21;24-%(15-A/M@HD4>O1TC3%3:<+1(U4KLR02YJ/?F&.P
MV`I&<^=/<A/8TBA:>A*;LJT*1*H.5%DE)SA%@1VNW[U$0-5?NYERMJHFT+=D
MU`0I`T1B=/LB<;RA@7<<KI]PBC+%U\GC5EL!;"L$I9'1&C<2P)ABR5TQUX!<
M$TW0UMKRIVZ\9I8"Q@JYQ:9X_?$RN`64,32QU<B>G&QGB4L::'GR.'-<*21Y
M8)R4.R-$4D$3D(Q8&(`1`6ZP[^ZE261U%$&>UC#Y/?CI(&6FF)3`+.;7.QG"
M+5G'[E?2XRE=(6C,6D(JKE3>_8/^U3G-JH!I0QXP+H!;<>[E>DTN:J4>HE=A
M<J0;'GVVEHGX9KZU7]=:JFAS5Y-Q)X:TM$&6.KL=79C6IPY!`1U)PG,S[<`%
MG`$P3O;#7^M*WJVW)M8`&6O;KD5;Q&K7_$9F+F*82JX!I":RCB!F:(\O?D[W
M,U2\DA&E4I23A*3`D""$W/@X!:C1O5J?(V2NWN+W*QRW-LRVP8'74;B33*)1
M8,IF=2Y<<6M&459,3$OL0AXK$36=B1$J&LD3(+P86^3DTK`P+\9MH->9!3T?
MV`:+A@:JEY0\1^.,EC9?4R:-*9)*)RAK%EC)ZI7D@;=)5%CN1+":WJ0$K$KN
M+*0\LL\`P!`LRYMW=7->YFYU]<=K(X1+62HWJ_'QL61F;.1+'2D9?F^,2:TG
MIV8XTZ,S1!XR^NJ9.Y."E04G;\G!$H$6#/BX!0YCW!--*_F#G!YG?L.CKRR0
MJN+*>US@0_@AS)7%O/GPS6=@O-AELQD`:8/,Y#_@2)V4.9;>8ISY>3<"]G`)
MJM*^*FI@Z!HK%F*1E>K3D^876471(7>23&PY26T.$A4LL)AL7;WF42=6W1]J
M5."S*-(<6B0)S%*@11`!&8`A@S?[4,*2J%::Y&YXS=\VG=9U>WQN+3R4/LGL
MJKP.QECUS\.1R+.C^RSZ#885V'5E<4R1R0B1G!-)"(H>`@7-,MRM;:]KRI;4
MF=C^X(->L]B565.Z*X?/!KIC94\6JVR'0-)'$T7/DR"6R%T0')4R!8C3J1JB
MA$^#!F/#P"D(=[-2W3-.A:+JCKV9?T_E]4U,0QMTE>E,HM"OB74^>5T>E:V1
M6HC4XAA;$M]Z-3L%`N0"1GA.+`(HS`0*57?<&TZM9R86:!W<RO3K+6NW7B&-
MQT>FK(KG2.@GTV,W67`B)!&6HR<N57/I`D[VB:<+%B`>.II00YP+@'-7V_VG
M]GP%7:\2NUBS5B.JW"[S;-D[',(#7AE2M+B:TNT^13>>QR-1AQCK2XDY*5')
MU1OIA9#YF`X&'.0/UWWVU7CS6F>)!8+\PI%D/-L-*2\U+<K8ZGU\G9WV0J9X
M6QK*^)>A0M(R1I<J.=?3^A(*(SDPT.1`P(#BCO<!U%EL;@$JC5N%O#=;3K%V
M:ID22$V/B36LMFD!^^I&3*QAIT0*EU@-;G6^!/GKVE"L0D-A1J@XXLLHT0`/
MLS?[4,**KER6Y&]X#=$GLF#UHAC<6GDI?)).J<0O;E:T$^'8Y%G5_9IU7B.-
M.(G=F<$R1S0Y0GA-("(H8<`5!NWLU'?(U$)E&;QB4QBDZK@JX(](8.6]39IS
M59[[F+E6"]+(HU/!46B8Y06:V^M=,HR?>"=0GSGS4R@!0$G67L)4%12>$P><
MR["2>60GDZV!P!A8I+-I]*VN%("'.8O;+"(2S2&5+&"*HE9&7!>%)Z-(8J3E
M&&!-4$`,`ATWN":>^93Q37=+7+C=@(#,+/I<NO8Q.K)'8\&KT*7,]?(R"`1:
M2"6?!0EI1;JFSX5C></RSRBS,9#@#*R+R5DF<9CLPC*X+I&Y8Q-$EC[F`E2F
M`XLCZWIW1J7!3K24RQ.%6@5%F8`:66:#`N@@A%C.,`5W@#@#@#@#@#@#@#@#
M@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@'75B-`F/-3IL*U)))
MQJ5-DP!'GJ`%#\HG!YF!`(R<+/@\><=`X%US[.`>;N-]JG:AL[3NB>C[B.L\
M6UK;N14]ZV*[L=DR)KC2ROZ_VHE=].I<&EZ:')9&"7+HT_%(T.!HD."',.1Y
M4%E@":("EN_:>VKR7;")I,K]4BF/?,U][ED?5O\`;,G>'W[PU1E5<6]QI\>7
M6(.3B=;*_->'>D(&:I09PJ)P8O!X!]`,W=8-![2H+<R2;`PIV^\K55JEW5(]
MDM>XK:4EL6@;1MN:RUO>*^N2I:VEK*C.HJQU"3WBLFQS>H+0N*U=A,00H*P)
M9P"V*0[:KK'[BWHO:Y8C&99.+"VSN/8[3\M/9$F7L4`%:.M$`U^5/KU$S$#7
M$V*T%B"(+4PW/*5X-1M+B$"90`?GAR!K'A/81VBSKI)==["LJNW9/<?:XK[2
MIQL=SF$EDTSU3L^FY6WS=+&J1$7$(^EEFI-_RIA;G*4M*ST4@1KD@,%F')<%
MIR0-I\EU/VDGVT==;C2.!4TADM#Z1V!K-#J0S8+F\12T[)NJ20I;8#[.Y,*$
MI2$U'Q)GAA06ML&WG.KR<I-$H*;O)*P<!:6GW;;L;6NIMW-#9LSU[<G;XM5L
MDZW6]K>GX3?:#$V6S""VNV:(GS0CBQ#$EK]GE"@X4-=$KBJ7M37T3&!P$A)Y
M0&7G;AU_N_630^FZ5V!=&J=;$0V!99+-E[5+7&4I+`E#0CRP,+K\82!H:'A>
M6"'M+2V$FK4A9J=*A**R$02@YR!IOJ[LR[-1+3'4>J@.46I[<O4VF)9!*@W`
MU_O28QV00F92^Y9[/7>-V)&G"`@C5[:NOK0Y,9SI&W5#ZTQ80O3D%``KRL`!
ML>[BNAMC[8O<'FE9+1UE?=1UJ_(=?]LZQMJ35';E4VO(%Y!RUOF<;1Q^1PZU
M]9Y(-H;5,BC+B!4>HPE&G3$YRJ&H)`Q5L+M1[$O&L_<CTG9Y76\@@W<6VH=-
MBE^P<@7N#?(*Q;K>,J)=>K.[5@F8U@9'(XVOK=?\$82.A2$PEQ0E+3$($`\G
M`90:WZV;;:V;);V6`PPJKI-#-M-I*-L*+OKQ:[J%[BM1P.J:KI^>JY.Q8@8S
M'*PU[%!EZQJ3$+AI#U:M/ZI41@)O`,/]2^UMM9K*_:/W4L^]5+9WJI/NXXVS
M2IB9PZX9I55>]%R.=LL$NK:;KH>0E8[3@!V&Y$ZHG!O)1NR#"DHM>3DHC)X&
M?DLUCOF==R#3K<)PC]=QZ!4SKSM#5]B,C?-E[G(29'=\CK9TB![(F'#FU&_$
MM3776`NYYAZ3(52L(4P5!163!`8)37M?;3RKMR=W/5%.&J4MG[W[D[-WY3RY
M5.7<<48X/>]@PF5,:6>NY4+&Y-4A8VZ,G`7D(D3@0(X8,$G&!R(00)CV&THV
MJM>M-0H%$8G$4C;JKW$=:=M`GV5?LAG%@SB#5?(YS85EHW2:J8$=C,B4R&;A
M:8RC/R>6!O0X-5KBO&`@L#I#[1\YG';_`.YOK#.K69HE9W<EV%V.V66+8;[X
M=H%2\CMMYBSC"(*B4JTS$[R]C;4L`;,2=:%&W#=U*UQ$206`9?4"[["TLV:N
MF_H-LS,X]6,/>J4T1M'5R*5;'+`7NZ&R;-O)X@ID\D#[)U4,0H6JGXDSP8O#
M(D4-ZER<5:L1JE.BPF++4@3?I%V^3M'K[V<=*TF8\:GW$GB<PI77L\0LI=9[
M">Y/84ION)U[X2,I$52SJ2O[<]M;:2:6G:7`U>20G+)$`9H&LVG.TMMU"+Q;
M+6<%=4-R!AN'NT62YH%]C2*?`E,2WW6OCG5$.@$9?H."/4M.X\Z+48Y=*V@Q
M,N5H$PVW&7-&I&$H#A4]J_<P79EFW;+;&NM?O@2G7"K8(NL.:7],);%OOKPE
MVIYF4H((G.K7+M!:7(AE9*5X$OEF'9>5X0DHR"\GG"`RSK;1/9NM-GNXM:3"
MH9R81NW'M'*^C+Z]6T]SBRX)%*9B$OA=\/;X*7QYQ*='<UGF)^(PE`X'$G#!
MXCAH\8"#(&+ZCM6;BPK7E%J1`C*@DM)41W5*3W1U8$Y39="UC!K=%K817K/J
M-6Q]L@+NUQ5?'[`.>$T2*3&K$7NIR3EJ#4WI<A&!E/M5I+M'NGM1I/;%A-\9
MJ*K]>95N.VRHJKKTEK7;:*N[YH2)5=!'*/2=BB#"4ME6)HVN3@](<'ID`&0\
MI%YJ\63\#`RAW`U)GEI[,=O_`&UJY6PN<ETAL.['%RJN2N)T?9["@FPE0.-3
MRY4QOI#<[)F>PH4(21P:/4D!1K"<K$IJA-YX3@@:RY=VA=AYA.(M8CE)HVT+
M[)[M<Z[@MU,]?VG,8&ZU35;[KH_ZX1>%53.6-@1O3U<*=B6HGAV=BL,J0:\)
MY)!HRR$YR@#;INIKG+KI[?.S&J-6*&M5.;5U6M"@(0[35U.:VO#Y.:V=($VO
MLK>436[+"492MP`L7F$)#SC<`'X"Q#SC'`,'Y[H#?$RL'LOR7.&!O8]`H'9C
M'?>(U:<DB$K<W:8ZL-]%-)57OK`R(5KHE)E"'U*PQ4I:/,:<Y!X1C&(G`&#=
M0=GO;6#5EVGX++A1$X.C#]W$G*X558WO)HA*)&DVR?I<\5H36\N,@B94M$W8
M?TY4F*=`(R%*8*DC&%A9V0B`VE;ZZR;%;<ZYZMQAOCU?,-G5WM[J5LI:,;:+
M,DD>C[3':-M%KL:91*O[$114B0JY.:WM^6]I<O0M6!K<A4YRC#C&`@87:F=K
M;9_52[*&V5.>ZQL-PK)YWYBB^ED\F=P.K+2NW5O,%S5ZK+N1\BR$^W+[A,BC
MOI)?)9"A2+)0B<,B$M-.;B<KP.OGL\VW-=-K@U#M";1I.VW]86W^V\W>X>X9
M>VF%[.7]8JZ85)#JY1R>/MCHABU&86X<DLC\254ID9(%@$!&.@0@6'LIVONX
M9N0JA,PL^RJUJZV?JHYOIS;<F@EA2-TB-G7R_6Q6D_?6>8L(8,R.;[J]>;%7
MRYJE24DY"]HB'[HE+-RER8:!7+M[8NWMY27:`UMA>MU-Q[:SM9T-V^SF9KGT
MDD$2HM]A\JG:RP7Z*1])7C4KE$'B\4F^28@G\UM5*UB$@"P*`D0C@`9\V_HK
M.4>P';0V.J9^2SM9H!![@IM]@$_>SF=QLNN[EJ&,5LKF;#*<-SN@;+1C#Q!V
MU:,"LDM([MZI<0)2F-\@0@->YO9POUWL&IYL_P`P9FPB:]S#=??78=-6-K3&
M`R.J8SM-1+S0\5KZCYNSQUO>G^6Q%ERVN3RYF!8TZYP]X>4$11A0!@;'^X]J
M;;>Q\$TRCM+IXHO6:Y[X:H[12TN824^*8=X'K[)U<ADC0QJT,>?P'3&1E'8+
M1`.*(2><(0CCBPX]H&"D)[5.R$'OJBKV&[5B\+3.Z_M9W(+MBK;)WA"U0*.7
MU1CK1\2K"MEBR*%CG<C9F[#>YO;BK3L2=:X"6B*#@.2,"`L343M/[<ZV6;0E
ML2E95UKI86G[A<5?*MD]BO2YLH@>V5W3NWHG=6K;J*`HDZ";R^-25%$K":W8
M!1)J1*)0W*L^(PI0!2Z_[/FTRKM+#[:TJD$*ALLS5%;KUMK.=MR^V("JNRD;
M.K.9P"!1V"JX8Q.D<UXF;;`3,24D)H3B5BL1J5N-&8<(8&ZFUXQ?=\ZS[`5\
M_P!7P&OY[8FOMCUG%D6+*-EB;XUG\(>(ZJRIDB>$M7NZ#)7)8G$!3Z<:]466
M(9B$@18"S`-?=8]N2^*N;.RW:9:F#2*U^V?K5)=:K;J_XG7$1FP&2P:#A%2R
M.85;-E4=P%%)(S*:\1+D13FWHRG-D6JDQIR10$K(@,:E_9PV@<IE7DV;[@1U
M;*)QW"^X!O1;LRJ*<+FN7:]F;=:[22@JVC]%N+S##TD\D==%G,[N_*'!*S(W
M94%R"2'PG$]0.5L[2.QV-?M8(Q&HY4>JVVVI5,ME.4UM+J1=$]C3:2L3V-*)
M!,C+;K&3P<;+<5`6XC,;I$]1)V`J<"I*XO1!)_E+,.'`-FUM:IVFW]Q2I^X+
M6&&&P1Q_4.R]0Y_4TBD1D.4E-<ELR)V_$K&@3T-H?&K#GB2QLUK?$:K";S&T
M\@\@TTU)Z8X#6A4'9?O&"6+H.HEEB-1L6I)J[ADKOZ1U19,UKYY;K+W@MR)7
M"V1.H$*=G3+7ZJ(,XQD;6YDNJEO"^(SQF&H?"I/2E@>ED(0@"$``A```<!``
M.,!"$(<=`A"''3`0AQCIC&/L<`^N`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.
M`.`.`.`.`.`:'I?N_,"[W[MBR]KPF^K]&]O*.T:C@B>NH$Q2V1IHS9E5*)Z^
M[13-B=X=-'JSF-5*%8FQI:T1(6<A+'EA9Q"A:,XP@"]=D.XG/*!V'T6*)/"_
MZF3"50RCMMK-<Z]D;4HC]G[+09O6:V2U5(,L^897S0S3%,VD29`J<RE!!<^:
M\^5D!(A<`OK2C9F>3/9'NG0ZZ[<.6P2B-SJUH:D4#T5%68F),]C5!4SVRQ1M
M6-+&UN+X\/\`9-B&)D1C@:M5C$:0G`+H#ID#!GM_;/;8[%:26W<EJ;&VG$+#
M317=>)UI-EZ#7A5&;`DE=W3?4=ATOKJ$ML)2NB21:Z1&F&\+JG<PY0OA;L<:
MK3#`-.JX!/FGVZ6S4;GFPE';V%28[8/2"F&4B;JH=%VUOJK;UML"<N;=KSL1
M330T,:I[+E]RIF4^/.,=1FY3-DI).2%)`F#`20!DMVLMN[/VFIJVX)LAAN9M
MN-7+SL:A]@VMC8'2%HU1A;D=+*ALN*Q.2-S5)&>%V53DC9G!J-7HR#3S2U'4
M'B+'C`&@BDNZ-O$XTDYR6>;!/R9XF_;B[M%X5]('R(U`^!E]U:6WI9T=KV3P
M)'"(8G-K5'6$%BB-._%3`L;-*S3`A1IA*@*31`9JZ^;J;37PFO!FL78)ZHY+
MKMVA]-=MX-/$[%6R8ZX+0O\`I&:V=:&Q4N#)(DJ97>NJTFD0+8<,:`E&QE9$
MKPKP(9B7TX$?53N;W3-M+:IR/4U($=96A87;;[<&X;W6TN9(`BI2!RFUMC)W
M&=EGF9MTB87*W5D/G%&PD8F)D:UQKHW.JI*8$]/GSCA`6T@[A.Z1TW88\9:\
MTS'5?]I6EG;U/F8V^D\,ZG5UI228U%1GND##\5AD9/N@HX4APB"XY+",(G#(
MAX#P#:5&>X%,C^Y\#5N:IDS3K7L-4$S9]2YV".O[*I?MA]:Y$]_?_C9<K=F5
M-'Y29+X8_@<V+W8L7IBT$//-Z`-5&!R!JC[=?<DV^OUXJB)V->TD1G272G>J
MY9^\V9%ZFCZ:XI'6.Q4]K&F9+IRX1"*%$KI-3#'"SR;";'K!9!9)J-5AL.P<
M-9P#N'=PSN",$0U<H:Q[-=&&\Z;[OVN.CNVEN):W@;6AV<J/8N4"EE.NL+*.
MC*N,1@V<:]2%`YO`V5,E7-[B%+DH10%(@Y`VJE=P:8L?="B^NDR2H6S5&]ZP
ML."4%/%,8D32!9M?K@[.$EM]C73AV94$5=FF9U\YK2F@E$XJ_+501;]H`Q3G
M'`.SW/-K)9`-8M9;FU6NEJ*:K9W8TRK`-AUVM@T[C,VJ:Z;IC\&FJ1D>5C=*
MXZN1/,<<SPIW!#GSDYN,&DG!$'@&,#WL[NK0^X[16-O3B4V/J)M_MHBK76*X
M8?%X8VRG6ZT*]MQ6RS35>YE":,>BD=<W16<8<ET7D1@/?*5>4>A-/\82U)8$
MX=MV_+FV_P!4H9NC<NQKA3LQE=YVR7/*/-:JU:ZXIV)5'=,\AB_6Y];Y+'"I
M<AEJ"%0L)ST^K7,M[PXFFJ2O*;L%I,`9K;>WI+HYJW(91JX^1J4W/;L.7LVK
M3XA;7.RH>\3B30]U?XA.?0P9ME"J40IB:$@WPTU*G4I%"1.'`A>4;X^`:NI7
MNSN;M#J1I/N?H,O2'V<A@L\M+8G2Z2,3*,%Z.%,.D)A&Q&L"9W=693+:TMZ(
MRMQ>RXVN($GP<Y($Y"L@PE4#`0(5'OO<=O6)I(YU7M'9=2TGLYI1W)=F%KW/
MHI4>)!#W6C9I'55-+YPAD<#5-Z`JJV-]/0O;=XRTC@6C%ZHPP8?49`R2D.RN
M_FRO9RU<V8HQ>51>\]O5O"K-:XP1$F)SB\]E;17DOL13`1Q.=('P2"+7LAAH
M2V\)9H'!M+>$XBU6<E9&,"P=9NYM9%_;_P`0E[Q,9!!M*["[09^\T5I-YB,?
M;7]B?&R[HW7CE+Y$Z&,?QPZK'`E4[D($):T+>I2@0*"B<FF]1`251FS^XNY=
M.]QO5Y+/"]9^X3K_`#=^?Z/D":"`:T)-47`V*+2U-=W>(VW"?_>\;`26L@4G
M5FM)A@E#$J5E&>H-*,X!EQVQ=F);O?JY7VYCT<^0]BNN`LC$T54)6R+44,EM
M;KG^"V])$KLB0C7JU[[:[4[)48C%)J;+(TMZD)"=0J5E\`\]-`=T;>-ZHQWD
M]@["/A#W->V!W0=A*^?GN'U$\YEEX:?WA9<=A,P@:2#PM/FN6NMX5&$25]2R
MXL;1*#C0X1)LJ"U1@P/0'VP;.MBY->J_L6[K#GKC/K1HFC)N.%3I;4BAP+*>
MJ_0NSO>$*Q6+$U#:8-<CQ),C0H%XU86X31DHOR#O5I2@--_;O[C>WM\6-1D`
ML"[9$0"8:Y]QZQ;#=+6B]6L#3=RRE]GI_4%$JM.7:%1=*<LGU),<--#8C:[9
M)+]"-.NPWGY-RLP!-VGMO=PK;WM2XN2';(V'$=UK)U%2V%294K9]<WIAM>S8
MHFC\V4V!"(HQP<08W")4\NWP`[HG$HST)B@"L!*-1@@P\"O3SN/WE:.KNEVV
ME'O<OJZK-[=IM']5'QTDT>8%H];8C.W-Z;]AK/1@DT:&6DG#M:9.:R;ESV!:
MPIER4AR3IQB5E><!#VYF_NY%%2/N#5)5]E2B4,VK6UG:OC%2V*4T5J=.'5%N
M+(XTVWCK'(I#(XXGK][>&AG6%.+4XJ4Z5U9DLF2>M5^`I,>,"][U[C-K3'2V
M.[/47<%EP6X)3W']9=7KFUJ7-%5-\RU:6O-QQRIK;U><T$SC;@4EG*UK5FJS
M)&[*Q%+%*\ER;1H6P1!!8$U6_?6PD9V6[4E#M^SEDPMHVDE>YZ'8MK="J&=[
M(K=;"-53+_A59R21$5XXQ0F1T1(W).4H5$HB<.;<2$#AA2`8CA@0_*.XQMO+
MO[/(W;^#D2:L-F@+Z_;4T]BL78D3!.&@&YT:H(NR&6)35O?V)`PW56:G+PE*
M$6-*0)U`<C,P2%./@%E2+>_<V%:X;E[(F7,].JGMB]R-X27K0SI&:M4RN9Z,
MH$T!52:GY)9#)&DD$?[6:8C*S96Q/,?5)51)1);,[&*%@S1\`W]PR+6-8-,-
MZQRMZ;Q&0V-(T5H8>&!/"5CU"X6_2!)+&RI8\I<HJN9PMB&(X)9%+@>E6+QY
M,4J"3P&#)&2!YO(%NYNXJ[3NC6ZBO9ZP9?;NQN\M(4%-6@J,48VM#A#W+>BU
M*2DS7%BQU\V-3(Z32M&Y`VFGGG!`D5H"UI)J8T:D9@'[8O<(W<;HKL8ZMMH6
M$U/T,_M`&OVBT3A"5%18Y(@URL)IJ-5)*>0/:J..$-')GA5.5Q:9_6K#U2,P
M9&1+0%DBSP#=+:<UV09-`I@\4A:+"Z[4#6Q--&DM]2>NX^NC\YG,^A[LLUED
M\WC<:(@339Z6/RDV#L#NJ:A%EOI[<H7$GC\W)H&KN[]Y=CUVB;KLC!;/V;UZ
MMZN]X:!U`LZB+AB5"JI!5C[,]@Z=B]HQATE+3!']@ME(*NK&*^&Y2@.(+-;U
MI2@T`UX#!@`R@=[GV,,W&W0U8E.S,SJBO=2=&HKL!55DN3%52286F_6=([@<
MW>XIHX.D+S''Z!:[)8:VQ<3>E0(FY6?YZEVR><H(P2!$/;9WMVM[AEGI8S?L
MC>]3"X%V]].=D$\,A#)$6%WNV;;&()\KG%Y$K+!89>M2U%"#8B@2-K(F#A*G
M6.IGO4Y7G"4LL"*+#[D=XT%W`-C]9[FO:>J-8DL-[>->&[B,<3IXB#:ISW8^
M!6<:Z6W+T">/C]`AV#L&&-C8RN+GATAT/7.'FJP>D,(3*`(Z[@O<)W2H%_[W
MK35%NS3#/IO"NV8Z45*@H:17-].K-ACT1=H.$F126/A>9WBP@^(*;!B5U+;Q
MY%DD*;`@9P!/-W;S;6LE3]Z6\D=MJZHF?;<MYBKC7*F'..PYSC\RC,=K>KIK
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MQR:H1EY,2'J`-B_:IVRO#8^Y-U(1:<[<E$9I8G6!GA]66JTPIBV-B4BFM*I9
MI9%C.A-?H4\=>=>[;=GA(MK]TRI<%*D*1R`,:<LHI*6!K<9MN^Y\OTFW:VY:
MKK6EUC0-2=UIK,E\L9Z75O\`B[-==A9O'-45E41M@@P51;;#X%!U*.8#DP!H
M7KQ$Y(2F*!FJ\`6O:G<QW-9]-N[194;O5YK^7ZF?,*;ZBC%G16J`[&0"16N9
M5@;AGLB8FR-.E?RC76ZDT^\^OG,_WFJ/P0X9\Q-@A.G*`R?N[>G:UDJ/O1WL
MBME75,U[;MT,E::YTJY1Z'N<>F46CE>53,HO(K2;'-ES+)RHV]>IRJ;&XQ*M
M;\I2!)@,WE+BS3S@(?F_<BW%C^^,XJ(5DR&LXVI[@G;YIEA!9S#5YFO%202\
M]0Z]OV\J"MF5D1O%DI[(G\B>W5JK]6#R\G2("="-R3D8&4,#99W7;2OJ@W#3
M29U-?\U@#5>W<$TGU/ET*9V2ME+(*NK8GLM;[,6(%THA,B?"9C+&LY(F)6!4
MX"W`;RQ)B@F&'C,`Q4L/:K:5A6]YID>]E)#6RWM=ZWUG*-?7%YBU9IE%JNKE
MK]+KM-O6Z42Z&A;IVS6+-F0$0*0,@6AJ)):%Q:<LMU.$:F`F_:7</9)MI7LH
MV<W+777R;[G;B::5QL=6Y#6R*Q)8O>-*3F?V/51A<Q97IT9%C5*(^0F+5)Q)
MG5,!.87DP(ACZ`1W$[3VW^>/W1J(*W1>4S9I3K3J=9E12.X8Y42.M<3ZWJ>O
MQSG+S>1D;K9G>,UVHE<5:'4["%6D,94J$>"!")&:48!D=V^MG+RM^+;/5=L=
M&[KIW9K7V)5T38L`GZJK9G&VQ;-H?,U[';M#W76S$VL5EUO:"R,JUB0AP1A7
M,*IO,3&$A(&2#@&'W;QO7;/;CMF-%UV=N1/*&O2T-5721P^U9BS:Y/,15S1H
M4MST9L3$(*RP8644&B#TM*BT@8W`L7J0#SD!*)2<D4'`8W3?N9;8+.U7MA?K
MM;$DHG?W5FS]1]=KTH<U@@XBJ8F+G=M0US)K"2LD[@P53JR[4PF<K']I6+@#
M:D)!Y"5!D"EN6J3P,NML]HMD*$QHV%JG>R;NMM_;.W8Q>-#Q5'KQ.]BV*!LN
MI-JVVT4@R*D<?;8BZS=*_P!<(G]H-*4E+EZ5U"D"J7)SDPS0(TTAWTVKVMF?
M;%HVS[\BJ)EV(TCOS;.PKZI-JB:%;>T_@=SM$*A^M[,O>HK[CA,_J6N9`4Z6
M:B96I*NR_H3DZ;T+>6>`T"2=@=B=PJXWA?-;*JVVBSTE4=J+:?82OI1<#/5;
M'6!&QC-M!'*LI6268_QN(I@(&*%L4V*8'$1(B6Q2M1A7JT0C,'%9`QJM7N-;
M?I8KKI&&]IV6I'85/W2J5U(V2UHFBC7F22T<7L35F?6RGKVI+XS&D]<V)&K0
M<XNWN['+3<-CFA$L.2'8*3>G#D#T5T!-V%1%V"NG>ZT%H6TTQY=)9.@?'R!C
ML]`TJ9:]M7@E,=A2)A2!!#7I,=&%#@4UHR3W%I."8$"K!Q80,AN`.`.`.`.`
M.`.`.`.`.`:+5SMWX,+EN$%[]IPM#A8JPB`KUVVY-5@1X/,PF`J,)O(LDQ0$
MCPX&(`0AR+KG&,8Y-M!U/>W?K_#SVE/HY[??EUXV@>]N_7^'GM*?1SV^_+KQ
MM`][=^O\//:4^CGM]^77C:",9O5/>%LU>4ZV0_\`9(L%S):_<A3C-M.=EY2M
M+9?5B</<^%3W<2T[+3AP%ZCTV19(]1C!GA\>,"PV@^'^H^[_`"IAD46E#OV0
M9)&)>_HI9+8X_P"F6R3PPRB4MH6X#=)I$T.%OJ&][D"`#0DP0L4EFJ"L)BL!
M'CRP>%M!1<4!W7<253,\$=B?$P62)!,%<KQH]L)B2JI:U>##7*%+[BV/>A\B
M;?*#Z=<(W*DGPX\`\=,<;0=5IUQ[J#`G/2,39V'65*J;)"R*4S3HM?[<G4,T
MN4DK)6T'DH[5)+-;).L3%FN*<6,E+32PB.",0<9PV@D5YB7>KD8DHY%/^S$_
M#0>XO0B>M3-I'02+X7=BWZ,^D$MN@_*?X=?"0+4/@Z>D5@P<5X#,8%QM!P-$
M([T,?D\RFS#-NRVR3.Q0-I=@RYHU'V@;9/.RV9*-"T`F3\CN8EUDX&M$:(E-
MA::?@@H60`\(<YQQM!8C+KMW5(TVOS-'$'8@8&>4Q]PB<G:F31C8!J;9'%G9
MP4.SK&GY"AM8A,[Q]S=59JE0C4!,3'*#1F#`(8LYRV@JCI2/=O>VN-,;RJ[&
M[JRPQCS&(>SN.EFQRQJBL:$)(,4<CK<HMTQ&S,`AMZ<642<!:;(DY6?!U+!T
M;074FAO>F13A=9R.=]E])93FQI8PY6&FU*VB(G+C&D)V5"&.KI85<X7Y6Q(S
MQ9&4D,4"3ECSX@@QGV\;063B@>Z\'R_"3V)\>3/S;7*Z:/;"X\JTC@Y`=91?
M2V/M)^:#.<"><='$6,],G<;05<VH>[X>G@Z,]U['YR2L5RQTK5*;IALB8FKQ
MS<<'!<'&#$#M[)<37+\*#,''(,)S#?&+Q9SUSU;04,&O7=8+9XQ'BTG8C+8(
M29*CH8Q@T;V"`SQ$Z=)S4DW-C#8&U\(F$R9)3QE.HDH"LN)8Q!4>9C.<9;07
M._5AWBY4D86^42+LE21!%7UCE,71/VG.R[PDC<FC*!,UQN1,"9PN%02SOL>;
M$1*9"L3X+4)""0%E#``(<8;0=-54'=\6H(BUJW;L@*6ZOWU9*("@/TPV//1P
M63N)RI0ODD.2'VZ8FC3^M4K3C#5B,!1YIAHQ"%G(A=6T%`8]>N[-'ZQA=,I'
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MPV@HT4J;O`P-P)=H,\]D*&.J9QDSPF<XGIGLG'7!.[30:,R8NA"QHM]&H*<9
M88W)Q.9X18-7Y(+R>(>0!Z-H.A(J0[MDO7MKK+3^QG*'1F1O+>SN<BTGV*>W
M!I02-Q->)"A;5CE;:E0A1OSN>8J6E%""!4I&(TW`AYSGC:"0'9I[X+^8P&OU
MJ=G1[-BCLG?XL:[ZM;6N1D:?4B90B2/;`-9=APF=W2HUAI1:E/DLX!1HPX%@
M(LXRV@L-YI;NY2-V$_2)9V-W]]%%$D$$]/6E6QKH["@Z!>G=4,-$XK;</69B
MB)S2%*2F[Q^C+/*`8$O`PXSAM!<1<%[SQ4Q>+$*FG99+L"0QTB'R"=%ZB[/@
MF+[$DHL#2Q9YDX;EP].<<3#QC):$X\:8&<=<`QQM!RPF&]Z:M(J1!:XG?9?K
M^$)<KA)H;"=2=HHK%4XG0\Y4YY(CS%<Z!I)RXJ5!AA_A)QYPQB$/KG.<Y;06
M"QZ[]U6,-C\R1I#V(8\RRF/+8C)V=CT9V`:6N1Q1R7J75QC+\@06LG2N\>7N
MBPY2<B4!,3&J#1F"!D8A9RV@NJ$5AWBZR]X8K>1]DJOL.S2S,#KB$:<[+Q3#
MFQ1PM<3'F1P]Q7"@]8T,)+FI`B3&>(E*%0;@H(<&"ZMH+>2T%W7T+=%V=$5V
M*4;1"'&2O$+:DNC^PJ=MB#O-"3TTQ=8NA)M@"9@<I8F4F%N9Z0)1J\!@@GY'
M@6<9;056`T_W>ZI5%+JN=.Q]6RXACS&"%L!TPV0AZLF-97!=,QXI1'K>;S2V
M/+F`*GT@<X3^?C!G@\>.O&T%S+HIWK7.(*:^<;"[,KA`5B4:%9!UNIVTJN'J
MD)JC*LU$IC1]T&,QZ0Q7GS1%B)R#)GVV<=?;QM!:"BD^[@LBP(.L6=CA9"BY
M,3-2X@LTLV.5QD,S3FE'D2_W&HMTUMS*23R`&!<<EY68&#`O,ZXQGC:"E.VN
MW=4?ETE<WU!V('IRF<B:Y?,'!VT9V!<5TLEC&(P3+*)*K66L<>^R)G$:+*5:
MJ$:I3Y%GRQAZYXV@_%>NG=27DM*=<W=A]:0PKY*ZL1"O1?8!22RNDT+P5,7)
MI*.M88&Y?+"\>%S.)P`Q>'V'Y'CC:"^I;!N]!/H?BO)W->RU-8!@#67B#2W4
M;9^1P_!;(80<REXC+Q<JQEP!H.2E#2X\CHG$6')?AR''1M!1A5%W?AP5YJX;
MOV01UE(EBUPD%<BTQV1%!'U>Y*@+G!:\Q'-O>X'-6O6EA..-/3C&::'`Q9R+
M'7C:"0$9??2;FA/'V^X^T"A8$:`MI2,:/63;1*SI6HHC"4IL3MI%X`1D-Y:7
M&"PDA!@O!>/#C'3V<;01:71/=F)AS#71.>Q<57T6D1<OC$$+TCV(!#8Y+"5Q
MKF3*&&,!MK#*T2(IR/&H"M3D%J0GC$9@?CSG/&T'57Z]]UET*=B7-)V)'$E^
MFB>R'PI?HWL&L*>;#2`\M)/78M1:Y@'&:)2_M2W0[`UP`^S!N,<;072DK7O'
MH(@KKU!)^R<B@*]U/?%T'2:>;,)H>M>U3N&0*GA7&B;B`S*'12_@PN,4#)R<
M-9C!V19,QXN-H.BYU%W?GJ((Z^>GCLA/,";WDF1H(2[::;*.<31R).M$YD/Z
M:/+K@/:27PER&)0%6$K"C!XLF>/QYR+C:"H3.LN\G9QC<*PY1V49^:U(EK6T
MBF>H.S<F&W-SH)()R;4&7JY5@D[>XB0$9/3@Z%'9(+R,(O`'HTT!BG<^SNX:
M":IF.]]S/[/$ML&`DJFE*@FNONPDJD\)(7Y($N9PY^_4\K(V!8)&5D]&(1/F
M9*!XR\^$/2&B]X(R?=M+KE`IR.3;A?V;Z1#M!O8FFRQONJ6Q#N.Q&J+'$J(R
MV3H3A9ZC,M;XZH3%F("5_J"T8RPB*P#(<=(Z+W@IRS9RU7%))T#AM=_9K5R&
M;(HRVS-&LU%O]4DES="L%8AJ"3IS[+&2_HHEA.7AL*5X-+08`'R,%^''1HO>
M"YW7=/8I^D+9+7O=_P#L[#Q*F0MA*9I(Z:T;,+WUI*BJLQ?%RVYU56N:N2`C
M2XT9S?@`\81&C$,GP"%G.6B]X*&MVLN1SE;E/'';O^S<.$Y>7UCE+Q,UNINP
MJJ6.LGC!R=1&I&Y2(^SC'=<_1Y0D*,0K#3A*$@R@"*&#(<9PT7O!48EN)?4!
M6.3C!-S_`.SDPIP>BGLAY71+5O8Z.+'8F2K"W&1DN:IGM)&>O*?W`H)ZT)HA
M85'!P,WQ"QC/&B]X+;;MD;*9VA;'VC:3^S2M;"Y1QVASBR-VGU]HFA?$'YR2
M/+Y%5K:FLDI&JC;T\("%:M",`DJE226:8`0P!%AHO>"^V7>39F-R(N7QW>O^
MSPL$M*B#;7I4H9=;=FFN1%0%F-$H9X,6]H;8(<@0]I/'D:9LP;Z(@><Y`6'.
M>-%[P4Q+N3?Z&#2"L$6ZG]G-1UI+%+JME5=I=7MD$\%DRQ]4>K>U<@B15I@8
M'E2\*OUU48I3F"4&?;&9%GV\:+W@HK_M+;LKPI#*-M?[-G)0K(LP096%_P!2
M=@GC"J$Q1>!UB\.4X<+,48/BL;="PJ4#>/JD1J`X,)+`/&,\:+W@N%UW4V*?
M9$V2][W?_L[#O*V4#"6SR9SUHV87OS47%51BZ+@;W95:YJY(&-+31G-^`#QZ
M(T8AD^`0LYRT7O!37?;F\)!B<X?MQ_[.$]XL]R8WJR\.^JNQ3EBQ'B,')E,:
M=IUA9:!WQ:YQY2C),0GK_4&I!E`$4(&0ASAHO>"YYEO?M'8R=@1V%OK_`&>F
M>)(H^MTHBR69ZY[/R=/&I,SYSEID3`0]VVM*9GUKR+/IU:?!:@CK]H,/&B]X
M*?+MV]D9^\H)%.]Y?[.[-9`U)TB1L?)9K7LU(7=O2('+#TA2(W)VMA6L(2(G
MD(5A)01X+*5A"<'&#0X%AHO>"I3#?+::PSHRHL#??^SUSI1"G]-*X:?,===H
M),=$I2B",".2QDUZMM:-A?T@!BP4L2Y*4%XSG`1XZ\:+W@EBH+1[@=_R>R7N
MD-F?[/W:4YFC&G9+>60O6[8!UG4OC!"0Q$D;+$*#=8)1(XZ2B.&266X@/2!*
M%D&.@<YQF&B]X,@&"#]Z.)-+Q'XM.>R]&V*0B.%(&5AU*VB:FE]R>C"W'>^&
M]!=!*-SP:W%A3YP<$>/3AP7_`'F,!Q':"/6O6WNEL;?[H96CL,L[3[K3LGNQ
MKT3OU`W>Y4;ZBE"1G]$DM0I-[K2R9M3N):?P^4!>06HP'!H`CPV@[TCH#NNS
M%QF3Q+R.Q/*G>Q0Q\-A.LDT>V$?'&=AB9B<V*AF2USMA2IDX8R:D*$WX7"/]
M$(H&2?!D..C:#N(Z1[MK<K9G!O4=C1`OCLM43Z/+D>E&Q:98PSM6V(F57-F9
M23;8#VR7*F9M3I#'(D0%@TR<LK)F0`"'#:#B,HGNSFLY,=,,[&0F!/+W:P2&
M3&D^Q8&DB>OWG>_9N0@!;@4Q,O>O4&>K<@!PM4^8+S#!>+/5M!VUM,=W1S<B
M7IR7=CEP>4\.-KM.[KM+-CE;F1`#S@*3H,2O/MTQ45#C5!83!-@181"&'`LE
M9SCKQM!U7&B^[0\-S2SNYG8Q=FA@DPIJPM;II/L6X-[),1I"T`I8T(UEN'$-
MLER@*`1ZXD(%6"0!+P/P!P'#:"M1"KN\37SH4^0&0]DF#O1$=,B!+Q#].-EH
MTZ$Q,V2.LR-BY3@S7"B5EQTV7OJYU$BP/"83DM/4Y!YQQ@Q-H))][=^O\//:
M4^CGM]^77C:#/'2E7OFJ!8OSW)YJ7-A@'%_O<9U<KFWH`%N`(+]\4_&F+5G4
MTRZ"5""@]!Z'T_DX+4>;X_&7X8-:`SLY`#@#@#@#@#@#@#@&(IP1>8</PB\'
MGFA\73/A\7C%GP^+['BZ?J<J+P('%P!P!P#]R$6,!SD.<8%U\.<XST%TSTSX
M<_J],\`^_)-\60^49X@X\0@^`7BP'[/BSCIUQCI^KP#CX`X!^B"(.<A%C(18
M^S@6,XSCK[?;C/M^QP#\X!R!*-'C(@%F##CV9$$`A8Q^K[<XQG&.`<?`'`'`
M/L!8S!>$L`S!=,Y\(`Y$+IC[.>@<9STQP#XX`X!^Y"(.>@L9#G.,9QC.,XSG
M&<=<9]OZF<?8X!^<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<
M`<`<`P.W663F</NN>JD)DT@@"39N:3DNT["B;AEJE3#2-/Q-)+[$CD4="O\`
M#661V0:[MS&6XIL@4-Z-4J.*&`[!8L2R(DI&PFF-4:77$U50;01%X8W$%L=;
MU;!FE6_2!R/,(;V],7@PGU;JZN*PTO*QQ7'FG9QD:@\P><"SFXP\;YS)ACN<
M*U)]93>D8I=6V_O>SVOH;=V'VD^^>[<+M9Y^!Q=658U/+S;/*QL>J$7.RVV>
MC?PPC)QA%.5D]L(]9(Q<9K]OF?:RU5<->TC2R62RE)9<BLYUF^`HJZJ^/5Z)
M]-+1J<H,^_7-X?S&G"$DPOJG+.\1IG0&<8YL=G#\/B\Q?@95USI@ZXUJ"3LL
ME9MZK5;4HZZOVZ=$>K>3]!_0KL_UW[A]-.\^>YRS@^/LXS&XNK!HJGR7*Y'(
M^0G./F0\BJG'5SOG&7YR4-M<-9)LH+QMQ90&/6FRFVC*B;:VNU#4"<QC?EQ1
MEES&66<YC1/K'5#2B1`+4D5\V8`Y*#W`H(520T.0Y![<XJ5]O<=YN9ASNM>7
MCNWK&*\N$:UK%VM_LW\*47T:,OQGTM>ET^5[Z[&SNX.8O[X[5MYB2OQ\2M<9
MAXG%U*=%_+6SU<9<C;NQJZ\>;=5L6FI=$YQ1;$-#]NL/6&.0*+JX@P5K+GZ5
M3HUC0Y$;84?5Q<PV'LAH"<)#,,#1)2!N6<A&()ZD!>,AR`6,XV7"JKM[],VR
M:OE=&,8?M);OB?\`LG%[?N+7VG*,KZ?Z>(^EM>O/-Y<Z^Y,SG,.C$P%MT7'9
M$,I+,O36]?,78MD<;1Q3KKE-J2E%J5]E[`9*#H.U;C(B,2<UD!BI[NW-SFU(
M$[:M=3E:1L:DR\Y.E">6B,<5Y6#<EYP/P=?#[>G++B,%<GR=&!)N,;9Z-KQ2
MT;;7W=$SGGH7Z;0]8/5_M_TSNMMHQN8Y"--EE45*V%483MME7&6L7-5URV[E
MMW::]-37^NWG?VNF:\E3@3IN*:VU8TCBD9D[<]O1].Q"/PR*%R24KIVK4M1,
MD3R5*I-*1E(2PE^8-26/&18QT%M"[6Q9\A;1".;\O13&4HN$?-E*<ML5!+X=
MK6K;^XSV+B?1MV?G^I_-=OX>+Z@_T6[<X3&R\K%LP<./,YF1FY;QL6O`A&<L
M:6-.*E=.^3EM5<XM)^$DV3>>T$::*,E$4IC5AU:+G45O%VYC'(5KY(W"<RL!
MJB0_"JID2%,CM#VAH3&N8%N1^(M"#.3<9%C.,VF)Q'`W69--UN5&>/YDF]D5
M%0CTCN3^)3;^'3VR\#1^Q_0_Z;.<Y+NS@.X>;[TQ^1[8AR659>N/QJ,:O`Q&
MHX_S<+];Z<RZZ4,:5&W25[2K:B]55(%M0_RK;ASH5=7%1!C0)K:<)`RM*<TV
MX(BBK1G;'1#9\X:E*(+*G@4_,<L$MPB?US`LA^V'USCDF5P&+1P4>3C.WSO+
MKGJTO*D[&TZX/QWPTUEJ8_N_Z9NS^W_IQH]7L3/YA\Z^+XK.=]U5"X?,GR=U
MM5G%X-L?S\N0X]5N>2I_#IN^&/1F36SMD-&O](32U$$$C,B=6+#$VLC0M;&Y
M$V*7R42%KC#0-X6E(Q&I&=*N=@&J1@QX_*!G`?MLXYAN&X]<IR->%*6R$M6V
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M]R=ETG74_@DR^Q73;C!LE"Z]GE'U;&ZKM2Q9Y7-<E`$F66VL0P>.Y?06NXH$
MQ2B/_`;\(.2PE!\"M&$0,F]!9P'-M^BN,MXBS*Q;K)YM%,++/A2J3G+;Y2?V
MM\??X/V&HKT7](.7]#^4[R[1Y_E,[U![?X3`Y+DF\>$.(A9G9/D/B:[)1CD?
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MN=@8R2L2MS?6=\19")SIO8"OVU"R615,[3I\J&AS97YN+1JGF,B=,8`XLJT9
MS6[(AC)4$BP+&0Z,]->G@?.RS9YDE7KY>YZ:^.FKTU7L>GBO>7OJ/;4CO?6:
ME+<F32F8YG-(42HF32A"("%),&-S<XK*O0`'T$4WJ7]A4')P9_O"3`A_4Y.O
M`D,B>1`X`X`X`X`X`X`X!,%4_8?/^-N_^PMY+(B2_P`E`X`X`X`X`X`X`X!X
MGC.X;:OUMV=E!N^QWS`"ME$_;85&EU[.<Z;!B)Y682LV5':^3<UH79B;=(\#
M'@>2\J?AK'@\[P?K?)OU@7ZG[N&YS!$45JS%IUI<899-5]XAVKF(LD&GK+)H
M7,NV5F7+(>_3&1N%F.S;,F.QRH_A,ZMB1$UB2``$\E5XC1`+:@O//=1VXK82
MUNN<&L;B8<K[0=D#E\5B$VA</@E.]Q>>O$2M&.28<GLQ]"L<ZN0L>3FR4'*D
M",>5&#%2#`<8*Q'4$5['][RZ(56-T2BH'_7-QE-=[(=Q./0)N'`WB?LUGT%I
M877V(R\ERH^\:P@C0)^6S8)3R[I'9T=UN#DWN"/+AY,#PV#83H;=DSN._.Z8
M_ODG?5+(F)TAF4&B"B3.;U'JQ*M'0"$V8^L\(3+%`R&%N62-Z&K-RF+(]6H_
MP@S&319%R)`\J53;<;R/.N^H]`O&PE_"=*TMG6G>><W.KLJ9CD=AT'MA:&I=
M+5Y4$GF0GL+S(XTS6C:L^">W*CS$N4[41C(,X!T#*1-T2_OE[2-HMNK#'0M8
M2"%U=!MVI)#:M+-9HS8=3N^K-R-M3Q978^$UWR2Q+'B,C`O,<)::"$P\,:,`
M26F/4I#\*L1U!VB^X9NO:4BTP2.MP473C&1W1HUKK8=E-S-%$L&NZ#2#6)]N
M-J89Y%(9L]:;77![$\IU;8H9#I8H$]*E+$Y@\HL!Z!2U!&%:]TG<:-ZJ,KY4
M)=$I6NGNV3:?<#FA=RI+KNB7S-7!-U;BIM96#5,WZYB9.E1R.,1LG('9U5NI
MS4J+\LDH:<11*6&K_4!EB^=V&_1[31R!-3IJ]%84]]R+7W13.N<K;)2MVC5U
MU9E71.S9!LXT/)%A-;>=$7S,E$A9@YC(FXI,`L\2PX_(DXXZ@M'N8Q[9*Y>Y
M8V4+0K9?<\7?5G/=B1>'U+O5*=*(_7%GJ=B'V%1Z^)6O9'(M#89,?$M3HSFD
M:)::I)R'.2Q@*P'!^(.Y)]]^X1K''-Q&6=O&NEO)NVOKWH[%[4?W6(3[XQMZ
M_-EZG@Z.1V]+)BSREK9XM354S=>OD\@-+8@+W5B*,+#E",(E.&K!2KN[ONS&
MO%6;+R`E7JMM1*]3=I::I)&[TXQSACB>[#+>5*F60=#M?T+'-[44QZ\-?EIN
M'"4)B54@;5$;1GC'A"HR'JU!*KQW,-HHW9.JU`(5&NMPV%OC7&FL[U6MZLX9
M-L4U(2)/)WOY^3@I3*9VK<7!@I*N6@I[8/,5(5825Y.%P##0F$!:D"3.X-*H
M=(]\M<->MG]C)QJ_I3)-6KWMA#)(OL$\:KMML[+1"?0YF;81+;LCS[$W0.:Y
MJ9Q62)`P`<DY2]28(\TI0$@)7#_4!A'=?=VD>KE8:NM&L=]H=M(.V4Q3UC2R
M;;.54_M5W7)65G[1GT%&YC)IV[3:C6QA*/9V]>6T+V.,S5_?#VXIQ7I"6T\3
MD:UT(D]2'N/[II76Q'@,CU$KVKGCNU3'M?U=.IS7T\<&RF&^!2F5*'.^[X=Q
M6Q'8])AR%D8$\;:F,@Y@2F/RPI2<M``T*3$-6#+[LV69.[=T]E\WL:QDMKR5
M7N7NPV!FS2^O,BBCBR,VP<M1,":OU[^[OKD16J%K`6"/I1*S@)6KR2P"R'&,
MYF7@0-JW`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`,']
MSH?9B-71&RU.QETL.<:MS:52%YJ=F/3DO-I4]946#$+;C,6PKR!,HGK:VHT+
MPQIS!E@6+&WTGB#E1@6)9$2I0G?C3&PF/+FT[+T_&E8B#D[I$K-G4=JBPXLY
M9+&2J8YA7]A.,=E<;>VU1G)2E.H2AR48'..N<=,YE]I-!J-D9/P4HO\`$TS6
M1/5",[5NDM=X/M?HDZ-D?ETFD%W,<CVNAK#'["8#9:YR*/043DS*U#L='%^5
MX3'0`<$9-R4$K[8'7KO.-SG"_IG(Y7(\^,YPC&IQA&4H/:HRGHY);EI\/CXZ
MGT8[0^HKZ?:_7[NKUH[KCW#1G9G&XN/P=^-A8N1D<=D+$JQLC/\`*OR8TQR:
M_+<<5OS-FYV?#+32_;GL$VY6J%09?M1VZ8]!G%MJE6^J&2_*_3R#7Z60&2DN
MLB5TPN`YE*Y"@D[0@3)D_J#4`DG@R#IDO.<YMN/Y/@N/LLR8_-3R$[=-=-M\
M9QTBK5KI%Q;;>F[7[YJ'I?ZO?3AZ8\ARO=F)_3'-[KIOY:%$;_)EC]PXG(8S
MJQH<U6[W#'LQ;K+;;/+C>KM5+532T[D$A.M%8[30JY(QW%*J=J^:R+C?'^+R
M'92F\G`D]FR5N?SF%K1)GC&%42>#PFG.`CE'J/.2)<!ZAQGI+D=S59G"6<?=
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M56-J(I``O8&L\'*[1L`Q/AL<(^B42'.!LL=;5C@B).&82;@@S'ZW]MG`<=R/
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M"<#`A%XQG6^+R*L3D*LF]V1JA/5NMZ37W8M]-5XZ/H_#VGE#T@[HX;LKU.X7
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MC4&*%9K@]Y"F`;@K!A8>HA`S[.8B?.46\GR&?.,E'+ILA!=&TY;5'=U\-%U?
M4X;F_4/VYS7JUZG>HW(8N93B=Y]O\G@8-45"<ZIY$<>O%60]\5&"KH3ME#>X
MR>D8R\2V8':I;?N?,KWG^R7;ZD\$D*Q1$8F\'[4Q)3.:LI]/@_*9CA$<RM(C
MZ9YDBHLA0\'#/R8>9D0<&>6'`<ULGD.#EV_7QF++)ADQ2E);8[++?V4Y;MVD
M>JBDNBTZ:]3.=W>IWT[9GTP\9Z2=GY/=>!W;AUQS,NF.'B1P.5YF6W=?G9/S
M$LB5&-!SKPX1KVUQTELWR<C.&S]JZ+=:^EB"J-R=4HM9![2;\&OT@NNJ'1C0
MO91A9R<+LAQ+!"-0*PEB(-$'`AEA,R,.,Y#C'-<PI8D,J$LZ$IX>[XU%Z-K[
MC]Z\4>4NPLWLWC^\N.S/4/#R>0[(AD+YW'Q[/*OG0TXR\FSP5D-5.*;2DX[6
MTFV:U4=?4G9*.<32S]Z-:*0L%_L5RL:*P?7?96J<U[&7@RM4M>>J//>W,@)C
ME(`DJ%"LY.D*$5A:9C&1"SD7-NEW1AX<J\?#J^9Q8U*N4[U\<EYCLT^%^$>B
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MZBBE75E44C;9^7E[*:R6ALF-M3")J'B-UG7C,<$"UV='-45D)(!`(`<>(`,Z
M/9/S+)6-:.4F]/=J]3YV<GG2Y3D\GE)PC7/*R;;G"/V8NVR5CC']K'=HON(R
M>U;IM3KUKI3E*+W[,J=J[A2)HD$F\`RP/\H7*UK_`"MW3EF9R86C729X5F$!
M%]L$G(,9]N.%X%D3UR)`<`<`<`<`<`<`<`F"J?L/G_&W?_86\ED1)?Y*!P!P
M!P!P!P#%+8/>K3/4Y]8(QLYM%1=!2&5-)S]&F:V[*BT$<']F3+!MZES9TTB<
M4!C@C3KB\E&#*P+`!],"Z=<=0)EJ.X:KORO8];-)V%$;5K&6EKS8O/H(^()+
M$I"4UN:UE<#F9\:SE#>XDHW9N/3&#*,$$)Q(P]>H<\`TL+-)^[P./K8*BV'[
M5I-;G."I:G@!_;_L`R)`\U]'(RC5$8!L`".FKL/><+AG>FP(2_'J.OG?;\CJ
M"FCT6[N9B1.@,O\`[3IB!&5+2$:`SMY3L:%(18'G8GY"5(*_\ITQ,\PH,]]@
M`$(7?S!>KP=XL]6H/EVT4[N+^W/;._7[VFWQHDL>9HC)&EY[>,Z=&R11.-Y,
M%&XJ_-Z^_P!0D>(U'!&CRWH%(#$B'(LY(++SG/&X%&5]O#NFN"!H:E]M=GM<
MU1]V6OS"U+>VM)E38QOKFWDM+F]LS<?>AB-K>')J3%)5"H@!9YZ<H!8Q"``(
M<-07DR:;]Y2->\,QK9[M=1S+L0U)7;,?T*LQDR[)6%I)8&),Z9;-B$N7%.QL
M*<M"B`=XPI$182"L`*#@&([F"@EZ&]VHE*4A*O7M*%(B&Q@9"$97;JFI:0AE
MB;OF01-F)3`OP)!31%9`+*]L2A#@AO79]0G"6=]OR&H.RBT:[N[9(YA,FW8+
MM0-\PL-*%!84M0]O2>(Y//D("LD80SB0)]@"W>7(LDBR#)3B<I+$'/3.,XXW
M,%$3=O3NI(H<V5VCN#M!(Z]9'TB4LL!2=MR6)H0SRE*K$O2R=IB1-[@C[;)$
MRX63BUY*<"L!N<BP9C/MXU!5B]$N[>4B4MA5]=IDIL6QI5"UK:5V[YP6WK(8
MO<U+VNARM""_@I5,27/:PY:<V#`)":L.,/&5DT8AY:@PVD_9![ILRV?8]I9/
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M*BA9`:(8<YQR&Y@A5/VGNZ^EV.K?98G<7M_$/U+5Q.*VI&L6[2^QF*DZ;1V>
M)K#9LIKROH]>C24U36P$C04F<EIRE2#R,F!(*)R::(;5@GR<Z1=X"T6,,8L_
M8OM4V7&0KDSH".6'V_+"G#`6YHLBRC<BV:4;!NK<6XI<BSY9X2L&@QG.,"QU
MSQJ"F230;NQS)8RN$QN_M'RY?&F<Z.QM=*>W-,I$LCL>4!*"?'V!2\7TM.9F
M(T)`,91IA%)LX!C[3V8XW,'===&>[N^QN10Q\V"[4+U#9@Y+'J71!W[>L]<X
MK*WMQ5DKW!ZD\<7;`'LT@>5Z],6>>K5DG*#3RPF#'D8<9Q'<P5R/:@]YV(MW
MN:([3=L&)LWJUCA[GB^B%HQUIPO<3Q*7%=AL9MBD2'"UP4BR8>;Y?F'&9R(>
M1"]O(;F"M_-G[X?YY?;C^A9<OZ2O([F!\V?OA_GE]N/Z%ER_I*\;F!\V?OA_
MGE]N/Z%ER_I*\;F!\V?OA_GE]N/Z%ER_I*\;F!\V?OA_GE]N/Z%ER_I*\;F!
M\V?OA_GE]N/Z%ER_I*\;F!\V?OA_GE]N/Z%ER_I*\;F!\V?OA_GE]N/Z%ER_
MI*\;F!\V?OA_GE]N/Z%ER_I*\;F!\V?OA_GE]N/Z%ER_I*\;F!\V?OA_GE]N
M/Z%ER_I*\;F!\V?OA_GE]N/Z%ER_I*\;F!\V?OA_GE]N/Z%ER_I*\;F!\V?O
MA_GE]N/Z%ER_I*\;F!\V?OA_GE]N/Z%ER_I*\;F!\V?OA_GE]N/Z%ER_I*\;
MF!\V?OA_GE]N/Z%ER_I*\;F!\V?OA_GE]N/Z%ER_I*\;F!\V?OA_GE]N/Z%E
MR_I*\;F!\V?OA_GE]N/Z%ER_I*\;F!\V?OA_GE]N/Z%ER_I*\;F!\V?OA_GE
M]N/Z%ER_I*\;F!\V?OA_GE]N/Z%ER_I*\;F!\V?OA_GE]N/Z%ER_I*\;F!\V
M?OA_GE]N/Z%ER_I*\;F#Z#K5WQ0YZAW-[<H<_P!T.EUS8S[/L?8V6_4Y#5@C
M>::#=V6R%93A8EZ=I>?.!.,A*7S3MX3N4K2\9]N<`5O>P"Y0'KG[/VW&H+*^
MJ\[C_P!VO9B_V8[_`/ERXU`^J\[C_P!VO9B_V8[_`/ERXU`^J\[C_P!VO9B_
MV8[_`/ERXU`^J\[C_P!VO9B_V8[_`/ERXU`^J\[C_P!VO9B_V8[_`/ERXU`^
MJ\[C_P!VO9B_V8[_`/ERXU`^J\[C_P!VO9B_V8[_`/ERXU`^J\[C_P!VO9B_
MV8[_`/ERXU`^J\[C_P!VO9B_V8[_`/ERXU`^J\[C_P!VO9B_V8[_`/ERXU`^
MJ\[C_P!VO9B_V8[_`/ERXU`^J\[C_P!VO9B_V8[_`/ERXU`^J\[C_P!VO9B_
MV8[_`/ERXU`^J[[C_P!VO9B_V8[_`/ERXU!*T1TS[R-?MN6>!;.=KF#M`L^(
M37#M"[-C#>(7L]HT;)L2A('GKC]4.>-07-G6COB9SUSN9VX\YS]G.=+;ESG/
M_P#LKQN8/SYL_?#_`#R^W']"RY?TE>1W,#YL_?#_`#R^W']"RY?TE>-S`^;/
MWP_SR^W']"RY?TE>-S`^;/WP_P`\OMQ_0LN7])7C<P8\["/W<EU,:8X_;.]T
MCM%4$QR]Q6-$7>+:UEL:"MC^ZMZ8M8M;6I=(=HD*9:O3)#0FB*`+)F"^HNG3
M&<X;F"KT('N@[3PY=86MO<R[35Z01M?U<57S"K-6K,FL;2R1`B;W)<Q&O+%M
M`M0!=$:!V2FFD^/QE@/!D6,>+'&Y@F_YL_?#_/+[<?T++E_25XW,#YL_?#_/
M+[<?T++E_25XW,&<NF5:;Q5WBP_GEW-KC;?O;,7^][\W^E9G4'N'"+#_`/$_
MQ5F6V98?O_WEZI!Z+T^$GIO(/\>3?-!Y<&]09Q\@!P!P!P!P!P#0KW[>TY%.
M[1KW6,&89;#H->U-7!%'V'39^7(R!-M=3%[8X[=\?5Y%DP\1)D+\#ZF3>#&5
M3K'T9'B+`<,>`,Q;MH>=5YI=6^M7;R<R(2Z4^14\-@[?&YFR1M<@K*#82-3F
MG4O*H6"%!ZUK3A$L,,#DQ:H,&,748\YR!9R_5C<%NT\HRNV'9BRB]BV.=5Z*
MV;$:9:_*E;S7=BO#9"M@D@C[7G]G#5R"`5C)79\BZP#B,*26LJ%2A3%D#&@-
M`Q\(J7N>1.R4TM:5-L2AFA=M.<FM-C7[#PIV8-CH&5L:V.=7Q[7N*R5^1(*@
M)A^N`UJ&3)'XZ,E/Z_))1QCDJ!EW$!<<HI7NIY@NM!47MDQ-((IKE7"#8=M4
MREO>G>=VTDV$I*5S-G8)6=*(J@9)/BHVJ4-YDC.2.B!8088D`0'*DL[`%A1&
ME.\:<WITLZL1$B<+!V(5NTP71JYT3HEJ[639@+6^VK'(?ZR)L"H-FZ?OU>EH
M(2$D"U*8US!0!.XJLIS1X`K]:Z_=RQ3J#L17;Y9]N5[M%-;1JTZOK>?;'8)L
M1$HH3?:%UE[Y!O>-W6FRJ6ICJG"C*ML-8X6!Y(\"#T`QBR,L"V*BHWNPO<M@
M*G8F1S-N>WR?(%<KD-6[))&ZCZXIY?:5TKKK@:^"D*&^<S*7S.!/;25`'M.E
M5.$8(-:@>N9SV57A>!,B[6_N`Q_376R(5S;T_P`[*II.LBFPKS/[N<9>I!`+
MH;WR`3^Q6V5O1[N4[3&@D[JW3**(DX@$B6LQB(H./6#QD"*9)K-W'Y0UWFPE
MSZ^8^]GL-F9:ILCVI):6*QYX?L;&G?7]\I9FCCL2\4U%8/K44^-,J;G`IG)>
M'-<B\Q.ZJ4>788%N..N_<;:YA:I*Q7M1.8"9M2M>8ZBANU+9#GY]U:1KK((B
ML:ADVD.S03VJ0E)U\94+P*8[$UII2%06>O<QC'@\">K+I'N;N47UF9XW;R@]
MY==9BHOMF_,<\;HVL9;TJ"'N,TKJ05N/+8W$K%%XVH[9CDP7)R4).6)(2=@D
ML&,%A`O#4BKNX45:=W9VX?CC*/NBJX]'H6UQFZE2Z=TA*:J:&:M#UJ!7'&F/
MJ8Z][`M*Y=+U3BRO+L8@=4@<#,0G#+*R!B$XZM]WQ@J1B8*_OB8#><43K^GF
M*"96T;-)^\WT1%-F<76ZQVW'^<A31)B32R20D1J3W6O2.9:8G",U(6B,\0$J
M3&B.Y(\Z+UW7%:S>X8)L:7-K+#/Y?([89,3@J/O]#VE'8P]ML@=KRV"0+DK+
M:;TP+4*,<@\(52(*D2-*2$1?`+$D6K/=1DM>3F12.WK$*OTNL^X`RQW%7;$O
M<+J]XL-QFM?H-+I4RP+,H:V!E3.4(-E;@%&L$4%B/5)DRU1XTB(XH"SY)J_W
M:5K@WR>`VC<$88F>HU$,#!Y%>!A$[<YX^QG;E,HEY)CIL9>M=$-[=+I/7`U@
MW=P?GLMN2!4,JUN/0&-YP%8JW7;NZ)[UJ[&Q]E6'/ZKC4QD,9D\DJ*VT<5;Y
MC#F]HUIC,+LV4Q)JO"D7"+N\B:HK+G1[1)4TN(0ORY>)&U&DJDN1`2M9,4V0
MUTU&I9CG$GVNLI].VALY]O)AK&UK2G6P$XIM2?<B2JXS!;@9O>ZV$(&,GX%=
MG!-EUCY:Q&WKTV58E:D],M`A7M^.>\3KMI'%FP]UW3.(7+(#*HQ((V*";$P^
M+MS^TT50!3+(');8D*AU6(6PV:QN<8+61]IC<B,D1@5)HEC>YDDI`+R%JKW%
MH=8=4#9+$V.ED$1K=I#96%9LTZ2T:5R=MD'4W6M;(CI/L#6ZPR/M&NR)J">$
M".7%E'Y4!4LYJTXXTT#LR>N^Z5/'/7=W]P7K`L0?4H-;6$T)+TK+)4AV<:VP
MA/\`?8DQT+V0BS0Y,+VO'@TM:L;98=G!)F#F0C(@B-`ZZ/4ON]P:/Q=LB&VY
MLF5JX/53M+"Y<M>I&E8IP7=U&KYS#8Q(YC:[W,AI44`C$G<G)X=#WXAU(=U3
M*W(T*<2,LH"-99KSWICH>D5TU8D\A,HC5>N!LFC5Q[!Q>PRKBOH-%6K%K!?8
MW(VE8M'6]0V3-9,P*H4B#Z'X6D;,4Y&,S4BR>F/`SCT4B&Z%23RRR=I&RZ;!
M^^+:LL;8I*76P6.80.'0?,DMN6Q5Y)1?."EN&QJ#$D;$T#"DA464$+%2<@85
M^,&*2P,:%&KO<YC5,1,MPM.X;1L.2?.(>I`SP+8E974CKNV)%AI)UADDFE\\
ML231J9T[6Q:=W%(&&/$MC<M,<4(S(V[81&$Y`JUCU_W1I15<)K]1'+Q/G\$M
MS:AQE-H5?L?4U7MUG-T^Q>"G6V3,9Y<^*D2.LZS>WF+&K(X]-F#2$!`",-SF
M!.80("^]LJ^[ML@GS:[T._QXR%QG425T[(&YAM!H@+A8NPUKUE-PN=YQ:/.,
M?$VM(Z?M&/PP3"<X.[6H2HECX$I(I"H+$6!UKWA7<KM2>.LUK&.V_4A[O$8$
M@JUJ4;!5:RP6IRF`-BI+P:;E@$0E<F:;+FUNH#VSX2>D(W?#(H4HCAJ&,;<K
MRM`QP;*"[V##'U:"=3I]N-^C#@RLE5NT-OYMJU&\O4=@>JC>PW!>*9&[QM2N
MC;R3%Y\ADD>0C>D7Q8L4/!;$[(G!*!&!G]LEKUM](-A9?9>OEL3^)-+C%=2B
M(F@=[5D;M4K'+V#:9G5;%.:^C#)E'69V;%>M+0`*A(4<@P[&&*"4QQ*Y4:?D
M"%]-J7[CT-VJ-D^ULPL6<5SAF?TK8YM=A(#JM+7'++",+6KX"GV"(/:?7$+F
MWT*(Z'2HY$$1`,NQ/IQ"+`@:)ZB]U2$%:M/$VOZY;63K'=9(]AZ_AMK.)!L+
M="6:O4B%(HDTKV:K=UG">0+TSR<X`;7;,9:S"P>@C(PJ3?$!WJATZ[KIDNK-
MEN#9.;)(4JL*)V-8KXV6].G5$DCJ6`7<1(:]<DK1<D<L-1*E=@.D;`;E@=$4
M$&WD-ZDEE+/)=$YH%(E.KO=]FB0##%[8F]=NYCFK5VC+I[L4ZOD(LBQD+;L$
MM:9K43344LAMA4]13@K<8HA-C:50S'%&GH3#696!H7G.@%Z*Z'[M<T:]DR)-
M-9JQ1ZQ]9([$Z%0M.Q;''+:JZ_:)BL);8M-Y&XUPU1R&M:S8V5O<M=)*-J=G
M5L-+1M*=0D1%%"`("Z)+K_W+FFU),1$9K:[Q"DMGM/S;Y&=L8V8C57Q5LM"*
M+)<^[)1F0N"B47I&)E4*0:!I;3`/JY$N3K_&0A4N!3N2!(FA<*[EM3H9Y7&X
MS^_6TO?Z?K-DIZVTLLC3N6P/\9K5\?)L.UB$RA(!!8>)_-B8UEV;B%262D1D
MAU'Y0CCL8`Q)KO77NQ(G?7%1,7S8\NMHZ6Q??;A3ALS&YW9"ZP$L#H]!/9>[
M2MIV*JGWA5\NFK+)%+(UYD,ARS8&J,$R!*<"$:8"=W_7ON=05RK[[R<ZE<A9
M(?M]=5\S\FV=EGF1N-DT.R6<DC%(:Z,ATF33,1+/*Z,E#RXJD:DYD3)WYI:C
MECC@\!@!@6FY4)W9E$""T0"P)W`[13,5MI[(L"RKO8;>AMJ60X4+:#$R2ZG*
M];'R%JJ7@<@M9Q8%$?2G.1)4=.``\V/D!1'&N0$H[6UOW695.V9=KZ]EL=:,
M&H$OIAY:DMQL4;FDLO>X*LG:13=320LC:YF]^T39;#"36AQ6NK><`E2^Y(2*
MPJ2\@`@N'T)WCDME,IEF6'+)2L8[";VN+65![MCL8I\44BME46E4V3;-+J'1
M(M?TUITG$Y.-7&4K6[8;)*\*@)!HBC$S@2!W]@M:N[$Y6SL=,*TMJQ%-<6'/
M!8K*%0RX/<SI%8,S7%JH\9!A#([>A3`U)'RJ8U8"=L*C*R&/(%BP],[.!Y*U
M(H2`36?KUNU%WYEM>&2/89\41Z`:..*ZHY%LH><7+)-"[PF*G;Z+IHK+KBL*
MO$#_`#.EFR-@3FKY,L;E!XU!0'0)YZQ2,#$T_4KO2.#;)W4W8B=1]WFL'40Y
MM2L%S)W.1UP_O525::BEXRY!)C:H<VB'S[,G*.RVLJ62'/R)&8%>M8%J@DL#
M-]FH'?"=4#33;=UA2UFOF/[NR*66DX4M><F@L8?-:7"]Y0I.2MJAF=VM:LB:
MZHPMYS9'U>1N+,4=A&$6#R1C$!AO*=<N\LH^\IF2VS.9G'FMCK?%ALM23UO@
MTI3*&]'MF"3-$@6CV:J(RQGP#A*(`8L?D<C84RTM,1@+4=[O."8!,FU])]UJ
M3[:3F6ZQ3N51.IW&N&]K@V7>U&5!`6=Q%0%K,#^F71E9,Y&6FF!EN.L?6(E8
MX&ZY]8G+5B>DR4@]&H`D"N-7MM91.ZI=IW+]H:ZIYLNVVE"VNWW<)^>K(CU$
M.&OS$@AS394NKZ<N9%@OZG9E&[/#<84\/"]J87!*D.6>03E&F`AUMUK[G<2B
MU2,S1.[LD,]25S58B9N^[1I7N'5[:B.Y)L\[&++RC\D>SW2Y&*Q:4/86B))T
M*5Y2LC@F/R44RFC$Z&`1_KOK3WJ&BAMKHK>=TR%WM"1471%6:XO@KH;EY[;)
M(!+)(GF]DN;TPJF=Q8Y]/8F\DGOS@0I(/6"2$@3GEG`",($D3O5SND0]8ZQ>
M!7K:MK/:>.(LU5<9%RH(-6,)8EQ%MNEDUG8E53&22:<6--U1K^TLT,ECHHD3
MBD+3MJU8ZMYK>MRX`=5@T[[EC?`V-KE%[6^_6%#Y1L(<E?8MLG-8_$)#&G[4
M],&ARS&N1S^42=U.:-F2BQNA4A<',25Q$M$F-S&QHDI0%,<]=^[Z[F-R"+6Y
M/:\GH)FWN-E6U(K@B4ZJ:9,R78>I);5Q554WE>-5"VB`4FQ/C+8"$Q(R&2L"
ME446:\J%:=P2@7Q):3[NTJJ32\B/VAFL[HCL65NVQR\RQFN5PM/8Q5_U7/6I
MDD*;)A*ZRH`97S&^,*O*7PK!,*PXD'A5&E]`+XE&N>_4RUYTU5K;`M.-;&0J
MC+6;]A4$2V/=F-@<+8<*`FXZU+>5+4[(H]8>6G8`]F#AQ,(&$2,K(E&!)<FE
MY`BV/T+W7$6T-3R6VK+G%D4TSR)C62@%2R]'7D8-+*@.H",6'^O%&T$.<LM+
M=*(G8>%YIBJ8$N"A4H5!8<EN)1(0.S/:![J#S<VPKE75EV%#"'[9R#3*D9<_
MV.V/-.L5'QJ7P60+(BY00%X."D]CD2-E6M[RU$P)G<!M:I6$IU4'&%!,`M:$
MT[W;&FM,K)]BVI'?F(15CH2]1;:^$I*O;FAJ)H=?.:5#`WG"='*+@/E3!-.L
MQ49:TJMK<2L&/!I1F&A.!)]VUKW+[)GUFRNN2KNJ@R9$/BR&C0;!5*WQ.`TZ
MMU@<XEBFDE:DO,QB@-FP;-BQ)$$P].L;0-QA`!2!*248VA`QO3Z]]X,Y!)\.
MSW<Q+GC5><P>K<1[89$!(VVX-QV?+BTGGBIVVC-$Q3=R8Y'!AY-4([3)0*DY
M10'S'HAK>`9%6527<6==>J^8(4[WDSKD>Y$PF)\/,O9DD=[Q_5!745@-47@T
M^M)NO6F2+"=$US+D3H$DF?'*$;2<C).5.&4!I0P(L6TAWLHS*[0E40LPF8L[
M,NMJRM=(3-;38D)>72>;**6%JHBY,I_>J&20Z%:W&"DT9=<GJU*!T48:%)HQ
M(B#C0+GBM(=S6I+-FCMAWV%O&,Q>_P"KG&)#<;R@Y2>R->HHMB*&4MA268["
MI8RCETL0HE:U:C5P^.9R(1X/>RC)@`&@?=G4+W3K&G,E'"979=8)Y?;:QWFD
MAD6PR`VMUE&/E_4Y(ZU@585]6$P9)A5\RJ&D$+ZTS1<SKF)3(5!"\*1U=Q.B
M-0A`F35BD-\**V7FQ]VSR[=FJO;X_7T1K^<+YS'6F)O2;[W-*QV62IS@KCL<
M46SNC1-$<I7#(4PES=UA!?J,OJI4IP28!)?>1[=[1W.M!;CUI`2T$6;A&385
M!R)X'A.EC5UPPE6JB)BAP\E0-L:90G4JV%R4!+-$2V.R@80"&$..`3;VY-+(
M3V]M+:#U,A!:0XNKH4B(F#^F)"4*9V6]B&^V1,U&<AP</XAF+@K.(`9D0DR/
MR4^,^`D&,`9N<`<`<`<`<`<`<`<`<`_DH]U"CR-E?[1CM73DFG;U6]<2'8B(
M%V=8S8U.4E'6]=F0^N44DF`6!`/SEXFTI<`!1>.@,J#B\#R$'B%@#8;_`&4J
MF+*UM[X.WNNMK`4(K`I76F_*WE*4P]2H0">XE?5',QSDW9-&$*UH<\)L*D2@
M/VJA&<68`60#QG('J`CG=EV=>]']D=O,5[4V'&B)G9E?I8:XU]:4:CLK?8IN
M@\:Y1A?&)RNL!Q1S)M506%/"]]+1D$#9GH]$5@PXH*@O`&<B+NQZY/ZQ*UPB
M%7[8+O)9U.H'5;9$JN-/'=Z^K4MT++,5U"X.SPT,DM%!DU`R,2YN]40]A\*'
MP(A>\4?F@04M[S%<,,L$ML"%2>LJU9I]OC6J@EP8$<UE]@ONF5Q4S1&5L.<H
MQ-B&F)FRBR+0`C(;G="?E9ZM,+"Q(6G4F#`E-)WC-5UMJUK4!$:NHV26-,V&
MN3G(J'1TV-P.>/VS]J:=`B\V<`S3UA2UOOVGG=J4&MB9S2>ER0N+-,2&"-+`
MN39SNETGKY(KUK!`Q2R9V_3L*G*M,T%H4C7"WVUXSJK8&XC/49\H4N&%J!X>
MJ1KM8\#6X0F-I!&0$>H$M,`E$!%#AO%M.DCO:J1"8Z+23SN(O4P1R,Y3%)VI
MCE<(Q:P6)LG`R6UL1V<-<M6HBXFD9GDP;@>4HR:<J3!)Q@"?@$.Z[]\F&VE7
MM;V?/JHFK/BR:EU'<F^IJWBH9I+PVWM!LQ?FK3$GCTY>II%8]+Z\D%E4SY+2
M/W6VK"$1P5Z@PTA4$"4#+`/=HUV-4.S4G@&P*B3(K+S1C+&BJY;A'S+8!O7R
M)HEU"1>3?%>(`HM>#/$1<DS@W*7A*6HRDR:WG+DYA1Q@$?NO>9H2%*[US:-:
M6]`VZF+/M&!8">U1UTD3VP4)JS76V-]6`Y1Q/(B5<5:ZLK^Q4A2MO4#-=5:L
M11*4@Y2,Y,E`O-X[N^M[`HEZEY@M[-4'ANSBK4)PMMTB$0;:H4WBF/4EE,`)
M@ML`DIG9W4`$F$+L[DMK8K5NB)``_P!X'^D`!FI/=IM>*NDJN'6%;T+B,H0$
M(U*QC>7/TS@G(7IRU:(TTGRQ>$"E,:$8<]?:'/`/MHN1BNR)O2O6BR:TD[TS
MO,>0N+RYIG:4QUD2*7-&I>@K6AC=HVX+G4Z,E*_0%87)B_69*$:/RL#"(#1M
M%N]+=,1U0T/W,OBLJ\<JKVE3WY)+2BU,1V4#G]:0K7^B]D+<EKC$@3.R0,DL
M5%!I9"?C"@U*,Q$I6$EDB4%IA'`;@J,W8J+9*R+)K*I45A.)];#?FQUL)Q@+
MLGJU1*(LLC[;*HDBE?G!39E<87RE%@]L6>A5*BLFG),'IR33@`:B-.N^+)[-
M71(&R=?0F+I;$I"KII`FRNT<D89I-+>M3=B0Z9QJO:YC4^DC@BL>$G2(V.J'
M.5%N#8@C:UWPE7!$`0%`0,UD_>7U"7!@"AM17`X-UF4Y9UT1%S*@:5,D<6>H
M*QGUKSV,ARX2%$9\5,K!5[ZC'X0B:_>Z'*3UOC,`(0$;V%W@6-67KFAI:H)^
MGD5R6CHD?(VVZ8VUQ\$?ULW?OLVEJ_LTC$9L!S5)I!,0,[PL8D8RU)Q&6L07
M5(CP<3XP,@=C>YY2-"SBVJ@(9I;+[;K.*O1I36E0(VZ'N=HAUIN':V(U,IDR
MUQ+5(7V4U!23RY^LPB-;$H/(),485'ED9`@PW?#:%/4O:FDZR/T>AF_<9LAE
MC3^7F+3A9':TCD]UHLO8F'#;6]/9P5KJ]L1<*2M;D,QPRG78.-4$@2]`D8`B
M#7KOE1.R(-#K$LRK92PYD59T7E7659Q@<WD*BW+AW8NC1ML4PR=/4QBC'+*U
MD]K587AJ+&U(7%.A5!6'''EF^60!EKCNUZZB6NK&&`;!"E:&QDM'ML8Q736(
MV2;#X/`CD.O3)*2Y:97OWW(>X8.)6H%3RF3JO2GFMRA>0#!P@+&=>\G1<,4W
MJ*SJON&"MU-6=/J]((4M4=<91(T%,:<Q7=F]9>MC!,B(4Q-'5%32<.%J!6:)
MR5+<%)DI1RLTQ,G`NN2]WO6R*??'=7B#WJDKRKM@4&L4EN15$(B@J0-NN[+'
MI(RM.9>X3]+[E8GMCEK68F>GA.V,_JG%,A-5%+S@)L@2_L=W$J4U>M5VJBPX
MK;+DLBVM\MVUGTPA\78WB#UY0<">EC!,YQ*W);*VEWQB/N"8O`T*!`O<%(%)
M8DQ)_A.P2!'0^[!KHD(E2IWA%_L::L:NDMUW::[58<E'252,)5U&MUF3E'EY
MRX.5?S7%!OV&1YCQ+XWK/&AR(TH*TD7`(UFW>TU-@1).'J&7ZI=4JV?-\O8&
M>$11P=Z_4UL]:S-,E#*@YL`A"=C*;;J#KDGNH]S$J2.!P0XPI3&I\`=QW[T>
MK[*EK(]176Q*A19YTN1HVU#!X6H719P@VZD:T"D;?*^MDEHRU*;8Z8-R$K+<
M<XE*&U1ZTL8BBS?`!VFWO/ZFO,(S/&B+WZ[M390<BV*G")HJ\+NYUE!(^DV*
M.+*L++9(%;/'US\NU8E[>A4^L,9QN)*$@Q:5ES19-`@O8#OC5FPZWVM8.OM<
MS=YN^",=M/R&M;=C*!E:FUHHQTUP+L&131;')X<`B.&-FT44]!EM6K'`Q0X"
MP-)CT:L!8&PJ%;[TA/XYME(XXAGZG&F,IFL-N:-#C)`)VF?8,6\JEZ=H@F'4
M4I&0^M;-AQ93UR5"G>FI:D6I!FICO,`!9`^YIKP3J.HW7/;;(+H]DN)SI>=.
M6(^RB<ZZ=X]?BS7&6367%9DP&PJL8A/4(U3D](U:PM.Q8RX>7DDLW!8$77;W
M@];*3)ME$Y1BSWF5U3`9G*E;`F:HXD1O,LBNKTRW(05>DD`Y*H1II3)M>(4?
M(DRD18VLM.>2G,4A7C]'@">]==\*ZV*GZJIF&%V6S3R-Q%H=+#6'Q8QVKB"3
MQ96U,VFZ54[6*S*5C&"9M\2O9C5)BS?)(=2PK?1F'#0*P%`:O4/=^V$)UTO*
M^'"KZ\7J:PV>DVIS,PG02T(3#%TQD^\+OIK2]@'6NZ2V1,K_`!9C41Q6\3EM
M0(2U*$2E"E(5E&*<9X!?VP?=2NF@;LMO7UPB5;OKU3FS7;IKA[LYOAMA.[0[
MT[O@HES2Y.:2KXS*765$VU5+G7KHI*;4SBXE/K<>BR424<88`($T5_W0'Y5V
MU8-OW-*=)E'WPK5BM>P.-U=)6I(VV!%K4VC;]=J9M1)B7.V5<'035KD;4_K8
M^YGG/+&)08WJ_"H)-$6!9%1]YNNS'N^X#L'"I)$K$JS8.W*N@B:$1XEPC]I1
M=BWA<](JJ3L:Q;,5YQ%C/=@B;27DA9Z!L(,4F'ICS$I8Q%@7CNUW-G[7&':S
M67#(3Z"`7O1>W-R28-M5]-6ZR:W1T!J?)MB8Z6ZU@*0PIX"[I')@RCD#"J/2
M+A%!-)3*"%&`C$!6UG=UID<NA==Q:$3F63%?M1!=5K&)6%QV!BKIYEE36E=)
MMCN,9D\C%,!P)37U1.;FT*,I`DO:(].<A/4AR/H!!VPO?!K1@UM?+3UQKN?2
MJQE=4I[ZKIEMB`.T3@THHLB5:RM*RVL/F)"TC=X8[H=HV!,@,:#ERXEYPK3*
MTA0VY86`#.78KN+T;K'L!66N=AQVTUTNM%'5SBW2.*QIC=81'&^W]@(?K-#E
M<J<ULK:GA(`RUI\TIU`4B!:82C4Y4^$191WE@8XKN]WIZ5&&Z4,S#=TL)?U4
M/-BC3'85'<O$IB-AUYLA9T"L1L*>YLR-Z6'2J-:H33R<K5*1R3GHB`JD9`51
M(\@6^Z=Z>A%T=A-E1ACLEJKTF>VC'K&:Y;61"B;N3'`>WPN[A#>H@V&FRT[0
MS*G^GG!J<$QSGA3Y@PJ6L],B6#*/+`DJ#=XK5F?J(RU-$3OTF52*;RZ('P@R
ML`O,PCK7!`:]J);8;VT0^02<(H#'V[:*'+5JE$:L6)$"Q4><F+`WK?)`RVU0
MV[K#<>!GV54[182"&&9CZV-/LYACA%6V?1>6Q-CFD9FT!<3QJ&Z4Q9T97\HL
MPU.=D]`X$GHUA2=22,O@&4W`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`
M'`'`'`'`'`'`'`'`'`'`'`'`/(/N=_9L*?W<WPW%FN=X;AJ^7;!,]8V[9];-
M-(Q1\B0(BYNKA'X6WH9<[2%*:\>FE5-J51Q)823"3"B1&XS@1><@9]=NCL6J
M-$]TYUO#.=W+>VQM2?T0HH9[-L^#QYB7J&$#C6YS$YJY(UOSFY+U4;9*T1MB
M4LP/VJ/(0^/H26'`&6<[J'MMUH[2G6B74/&DGK*>LBZ2*U.C3RJB<^A2V?I+
M'N(<'3*G+X7=YH.>19$_OK>4(AW5&8+7"`<5@\T`$G2'7;MPLZ)Y*E4+USC:
M5MO0=VNA;N_QI@Q$]@',F4NSA+D@QOJ0,,F;Z2K?CW`M&))AQ"I=!J"S@GK<
MC`H+M3/;8-?'=U?:YUXRU/22YYDXV`Z.T#Q`U+K>\M3M-\)R7!3)O3I9#/I=
M79*E]\I,64<YM(3AF^N3B\`%UK=9.W:V/S#*W"O==V^1U2F@#^T/RURCJ5TB
M)+/9$EN*O),M7'NP#RE`[8DKO)4;DL$(U8^+E:[)IJ@TTP0$IR'6_4R[)7,I
MV_UC4]C2U[87JLYV_P#I&E[6K&UVB#G!WU@D(T1QA8'A37TG6,AQQP0N.&->
M:A\S"0X90@*M*=3=<9JSU&P2BHXH[M%"-Y[53*(\A84"M6]5#SJ^5)8D-*K(
M.:0*8*I-9S,@%XAMIQB?.<E&#"("CN&E6IKD\,+ZIU]J\#E%6^FVF,&(8PB:
MTT<:=>),OFE%-;"W-@4;:T-M1RUU4N,?3IR2RFM8H,-("`8Q9R!3Y-HQJ',?
MOG9DFOM<.>;DGL6M2R,C9\I_B*T(6J;ET:LD/HST_N:?MRYI3'Y>6_TKB><0
M`9QQ@@XSP#L2'2'4>6*)0ID>O=8O!LVEP9Y+<+8ZG,)D4L%7S=4Z]W=D_7"=
M6-_K)I3,#L4(.2'AI(`E7`4%!P'@%94ZAZS*V:41Q32T&.C\XLR37'-6(;8+
MW/+[+F9)">72N4-N#L(W];)B$Q8%Y2L!J94$L.#"Q>''0#([@'"I3E*TYZ4\
M(A$*234YP0&&%"$4<`19@0FDC+-*%D`L]!!$$0<^W&<9X!B*OT!TO=*K@5'.
M.MU6K*AJU'/&ZNJZ/8`CBD-;[0CDCB%AM[`U9.\A`AF45F#JW.!(,>6H1.2D
MD0?+.,"("4J[UNHNI)-/IC6=8QB#2:T<,^;`=HVF.;#I2H8F%MC#>XN19!X4
MV7CW"RHDQZTL`%BLM&G\\PW))60@17%NW]I5"F55'XIK14S&V*8^R14L*&,I
MP+FN-QF?&6M'62.NXQ#=XNVL5I&YDJ0IM/2A3R`(7$'A6``<$#I9[=>C?OQ+
M)`:NU"G>T,0S`4:]'%TZ(::&CK:24\='B2D@R4X&]75\O<V,_&`>(]O6#+,R
M+V9P!=3SI)J7(7.KWEZH&MW%TI9@KJ+5<M/8P>=#8]4$A22RIVAL\!@`C15G
M)T0'!@"?@WW0K$8:E\H9IN1@7--M5M<[(F3O84ZIJ!2B:O\`%E\,>I(ZL:<]
MR=(ZYQ>3P98D7&X\`5"LR$35X90K!8RM*:'58B`:%,I.*&!P2'4[7*51FG8:
M_5'%%\8U\`C!2#/Y*Q*FJW#=$E,";QPK*-8G.8SD,)6GM))A0L#+;SS2`YP6
M8,(@+?7:1:C.*YA<3]>*K*4Q6/U/$XR%OBR%I1QZ,43-U%E4S'V1M:@HVYK9
MZPL!6:\LB<@H!3>Y&"4%8"8+(N`<$KT:U$G!UHJ)3K]7+N?=,QB%BV:88SY3
MBD]BP,YI4Q*PS/1GIL-4_9U#`A,"]H?3.AIB,D1IX\E`R$#GD>D6I$N,EILE
MU]K-Y%.Y0GFDQ"MCY)A4CE!-:D4T>[NA&!!)4G/-2I@1IT!D/E.['CT2T*A/
MG)>0*VNU'UI<F6<1M=3,(41ZS;&>K;L1C$W#"TSFQ))&R8=(I-*V\L\"1^4O
M\33EMJTE2`Q,K0E@(-+&6$(<`75*-?:1FTS>K#F%70N43.25&]T)(7U_9$CL
MH?:6DKEEXD-7NY*T!R-QA3VYY\Y4@.+&0>/^_#G'LX!&#/HMJ"PJ(4J;=?*W
M`JKVLI'2\64*V;+H>FJ26>H]_5LZ&NAZP<FA2SU9WA;G3*Q*G\X?D@+\8NH%
M(=>WQI0^,[6PO6M56NK6SI92B0D.+%ZPWT\V>X/(Y;A8M//,7.9L@>JRCAZH
MQ48<89E@;PY%X$:<)8'(K[?NEJ\+*%9K=6"C$=.>U#'DQCSD;6?)+I:=CG\]
M&/U'C*.=[[8D4P/%C/B,D20I=G/GEA'@#]2=OW2Q`B*;4.M=6(F\NK9O21B%
M''PI4BZH[&>)3(9G7CLG(-+*>8J]/DY>E>4JO!Q:<]W6C(\O*H_(P*6[=N31
M=]8C8T\:NU(XL2AXE#\L;54<`80O<ILRPJ/3`3EG)WFN2.3M%;1XI>E/$8E5
M98F\9A8C$:<18$IKM4=<G2(VY!'6GH6Z1.^FDUAN-F<VX;B58C":6ZE`8I(H
M6''K%C*C`^K?2I,&!3H\JSLD`+R:/.0.Y'=8->HI4,PH)@I^"H:5L$V?GS>L
M,LB=9#949:B]S=;&$^,J[U*5PQ,W-Z5J'#!F,X4'*3!BQXA9SP"FS'4C62P9
M-(9C-J,K64226PMVKV3.3Q%V]8)\B#[#W2O'=I<TQA642H2^O7M8P&*1%Y5Y
M8U1J#!N$@Q$Y`J-;ZPT!3\O>9]6-516$S&1Q:(0R0R%B2GI7!]C\"8&V*1`A
MY'E0,#HX,<79D3:6O/"->)`C3IQG"*)*``#B9-6==8]5LUI%JIN!%5%8[W+9
M).ZY5,:=SB4KD$\=S)!,GIZ9G3UB1:YR60'#<%9P@^8:N'E1G/G9R/@%'6:=
MZR.)!!3G340=3B;6AEZ"=78E<Z2%9<5<ID".OK)=9,X+5,A>9A!432E)9UJM
M4><VDI22T^2P%`P$#GSJ%K'FM)E38*0K\BJK`L0^VI;7Z1D*1Q5TLQ3-&VQS
MIP6T)1$I6R1BL!G3/>%*0)`PNI6%6.AV<CR!8CEV]-)7@4Z&Z:SU4N.LLE^*
MG"A1'\#52`<GM5+>;XM4*_.]2G=5US(B95ZP@92LM_*"N+,`HQ@S@$@VCJ5K
M9=C+$H[;5,PBP&2"1B:PR(MLG;,N29BBMD0TZO9^PI`FF^++=,X,I-:G(`\C
MPL0G&%&^()@\"`I9>F.K`'!D>,T=`SGB-S"'3V//"MM-6N[)*Z^*F1$*<FIT
M5J#UZ`J-D6+("TJ4HP*0!;ZX!\K(5BC!@%AK.W#HJX0R.UVNU<J15!HB7*$L
M8BAT>P)D8VB9N<?>I+&6U#Y_DIH:Y.\2:5/N4./=))[4B&4G`)(GR6!*UCZI
M:Y6].X_9]FT]"IK8,4115MCDN?6S*I[9T,&L!HM>'ID2OS0"**C=EL"%]1XZ
M9\AT1DJ`]#"@"P!9"O0G3-<@.;%6MM4F-YTK^-_28C*8HI/)`QR<1!,L0X*R
M7EN2M\7LZ2($B-/Y:)&E?W$L@HL*Q1@P"F8[>.D06(,8QK-56(\!6XK@L_N#
M_`,*W>E"=;W-1@CS_#YB^@DX(<;G_EQP.$.?\'^TX!A>JE/::J5_L]Y4TZPP
MG.E]V2-3/K')J>6$-5<7@Z5/3H7%`FDC>D/<7YWL.N'6"M:=(E"L0R%5[H;`
M@/<"DR<`%V0VQNVEKS/(?&8!4A-?V_7MJSRDHO6T6JZ1CG-93RZJ95;0R:*-
MD;;0+$4:C-ET_51KZA&A%[B/"T#1I1`6%F),`;+ZGM2`7E6%>W-54C33"L[5
MAL<L&`RI&G7)$LAB$M:4KY'W@E&Z)4+FD`O;%I9GE*2"3RO%X3``'C(<`2#P
M!P!P!P!P!P!P!P!P!P!P!P!P"/[7LN,4Q6%A6]-O?`895\+DL_EQD?8G63O9
M$8B+0K?GY4V1QB2K7I\6)&I"::!*C).5'Y!X"BQCR$.0,6&7N-:I21OM5TC\
MW=7I'3#!#I=/1MD5?5>44.L#7]TV?ALP:L%),_$47D--,REQ3+4'J"3%!(T6
M,^L`,@('W'>X3K_+)G6$#CJ*W'1_N2H$E^USA/4$XP@D=-J!5@2JL(EP-:RT
MR:/,RVXX\G7F'9+$D.6CP,.`I58B`(VQW;M)!5^"T`3R6CA1FNM3;6%NH:SG
M.3!4=>%G+:?K26>[\,OO`*J03QN.2B;1%8<DA0//4$%$9P9D"4F[N#:U/<U<
MZRCS_*9%9S=<=J42373-"I`IESS8-(06,V1;!+$@&E)(<X["(C-&@Y4[@-PV
M#4NB1&2>:M4$IQ@791>[.N6RLI-B=(3<Z?+0TA5^Q*=Q;6%[2,2^J;C=YS'X
M`](W=T0H$PG-T?JT?D2EL'Y;DVJFPXI80G'X,"`IFMF^&LVV*MJ:Z;G"UR>Y
M!6A=RQQ@D<7DD/>9'50YL^5N=.V%%(VQO$ZL;=/8XJ:EOE9$>@58)PI+*`K2
M#/`S"X`X`X`X`X`X`X`X`X`X!"[A3N#;5E%O,TUD4>D\I@%9UPJ)1H8TO;$D
M?K:>S"<@$D(=V5<;ZZ3`G;BVK3#!CP6D&6-,$A07@[($T<`PYV$I"C+NDQT*
MM">'M$HE,:BPX4TLK^SQR<1)Z@CI-GMIL"!.^$IC\W/ZEO>WE"H+$(U"Z,P%
MZ0Y.>D$O+&!!&.WGKG<,<!+HY9<HDL8F+19/P?)V)TA\D:Q0"Y6C9(IQ;6EU
M4L+JCD+>A6[4R18T.!V3U1("D16332P*O6`=I9I)KV?;"*+*KA=`65D$GN5'
M70SZW"\J8TX6RZRQXD:6-&QG+D=$6B<S;"$2DL.2DXE"<HPSSC0C,`M6L^WK
MK]*X1$I36=X.E@08Q?'9%7LL3QZ@K%8W6,$PYXKV=192^N-9O2.RJVL=`].*
ML*%S,7HV9R48/:<I2RB2@@9=ZW5[5=5PZP)+6T^,DT!F4ZF$S5&E.*$4'BKJ
MSK%,>FJ*)M3:64T1=,3(8\L-=TR,)"43UZL_!!)IIN,@9"QF41V9QMBF,2>V
MN1Q23L[?(8Y(V980X,SXQ.R0I>UO#4X)QF)ES8XH3P'$'EB$6:4,(@YR'.,\
M`I#18\`D"^+MC#,XR^+9O#5EAPXIG>4#F&4P1O41Q*LF$?.1'GD.\<3J)>UA
MRL($,CJX)^@LX-!U`O/.<!QG.?9C&,YSG^YC'MSP"&HEL50\]=&9DA5OUY*G
MF0J%*9D:F"5-#HX.AR1K<GL["-(D4FGG`PTLRQ0$>`^`PI(?D.1>29X0*P_7
M34<6E?P-)K)A<>E^"HN<./O4A;6MR*+G#JY,4*$>2M4$^1\8/K.K0M6!Y#EQ
M6IC"$_F&@$#`$G<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`
M<`<`<`<`<`<`<`<`<`<`UBRSM3Z[3Y+NR&9K9$Z/.[5G1NTY1,D*>/-$TK=Y
MA+?2&8,V0-^3M!HSV.)2_7N.2)*F=BW`H3N6HR8$:=0(C`%I7-V@Z$V(F$KG
MET2R92R26=;S':=NB0811IOFJ")ZLV7J3#J\;"VKPNT)B\8@%M/;JG4MZW#Q
MF3*O696>2`M*`#8;0U7K*3IBL:?6SE^LL=90MA@R:=2INCK5)9(V1A`4T,Z]
M_1Q)J8HT%X]U)22U!B-$D(.-`(S!1?CR'`$M<`<`<`<`<`<`<`<`<`<`<`<`
M<`X%*9,M3*$:Q.0K1JR#4RI*I*+/3*4QY8BCTZ@@T(RCB#BAY",`L9"(.<XS
MCIP#515_9YU=IB+2J.UNYV*S*93J#,]+3WQQD"=]6$59)Y+-7YA<34R]!E&Z
M2NLVJ<J8_&U:H!N&N-$DMI8?3`R`0$U5YH5$*XL#6^Q&BQ)>M=-:-)GW2"+(
MG%!'AH)!"'Y74:XZ:R'"=`G4_&"=13#5X`IC"$&0G*<9(SYA>2@,*D'8DU^:
MJ>7TNUVK8;='G;3V@--GER0QRN$KL^0_7N[G&\([/'O)$7+0NUA29X<AMSNH
M.)&E4-X`8+(*-QDS(&0D"[6=6U7;RF^JWG\FBUIIKUV-NN*.*6/1+X6BJ7:2
MNJNKVT*S3PY*VH6Y=">M-1QY;LC&%>D>&_`QGFIC3TIH'WKWVOX1J?+6E^U[
MN*PX.S(J-U]U^=&!P:H?)U#["J$LVU;9&XK']P9RER>56K*KJD7Q(K)``H1"
M[`4!*$919@0+BTU[9]2:</L"EK'-IY8LKJZ@'O6>OW:7B84*>.U9*;?<+PER
M<+7'&EL2KI%*9TH195KCLBP%$SHB2"B<X4F*0-D'`'`'`'`'`'`'`'`'`'`'
M`'`,-;#U443C8EANDN7>A:$[G2$@>V,1"@3F)VH`5['11&S+0F93)F>2J;R.
MRYX&#Q@+;/`7@?K3!$`7Q1E(R:K=>JAIQ=8*]M?*XBK7'G.201&QEIGLQN(.
M(R(I+-(])_3HCO&$SPX`$X(P]/,R'KC($;7EJ8]6]:M6V8WV!F*O-8,K?&BY
M0%O"LE<GA,D<'!LO&O78"$+*THV2U8.L)\"M,$!C3(6MN<B4XLHRRL@8;1KM
MO7TRM]2PXRWH,BK>O8=74#?(O$UMKQ0B41**3VFI<\Q\29ID*<EO1*&RLW1L
M1^F&G)+1R0\`R/,"I/7@9/T%K!=U!UY>4*03JNIJ9-7B8OM3*)"VRA"&#(YE
M-IQ(S:Z?5#<I$<[PV/)9,$UN6%@"Z^L5*\*AJ@!('P"78W2$\BFMK#KDT2YG
M*0Q*"5;3C'-TQ"U#(5=;QF&0J(3AY5)ADN*!KGCLE;WG+7Y6#T201R,PWS,@
M-"(##Y!V\+!CN*[8XO8\6;(C1$LL8VB2DJ>1L+S$JWG.R&NE[(($K#%QL[(%
M!%H]5TEB",A*G+0`8'A`G\CRT9P5`$]:F:^W;K6(B&O<KCMAP-^8HPLD[VND
M4Y5R=HG4-IBF:X4N#.GDZE\PN163+HB_OSEXU!0R3EI0LY-.$<,T#&%7VNW/
M%75TUM$TCS;=48C%AL3_`&H%=8'JC%"B*W,UTD*)&$OA+A&F>I)5<2UZ(0)Q
M$IQK35!F`Y-.\S`$X7II_:FP*S8%LDTNKN-Q78ZE*NH>5J&=ND+Q((K%*[M&
M\Y4K?HH0Y92-PYD\PZUTJ=`K.&`MD?$8EP2U9>"D_`-@4=^(_=)'Q7AEP^84
M.&%&(\)>-J])AQ5X:?)$YA"MRIRT>1ZGQ8\/J?,\'VGAX!6^`.`.`.`.`.`.
M`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`>7V_M%=8-
M_>_I=]<;80!WLZ%5_P!LS7Z:1%@2V5:-?I&B3N5^VLR+G;`JUF</4+3U#7GR
M<A4#-+QCVX#@7MX!C=WJNR9VU=1>V#M;L9KS0DAKNY:PCL!=8+,T]_['/QS$
MO=+?KV-KU`&B4VT]L"W)[*\J2,A4I3@XP;XL8P/`18`]?[)G.65HSG.<YRUH
M,YSG/7.<^D*]N<Y]N<\`JG`'`'`'`'`'`'`'`'`'`'`'`'`'`'`,0.X2>>FT
M%WA4ICC4ZE/J!LL>G4$&#)/(/*IB:F%'$G%B"84:48'`@B#G`@YQUQGKP#17
MVZNPCVJKTT"TGNJT];GZ4V9;6JE!6/8,F,V(V:;#)#-)I5T8D4F>AMK)<3:S
MMXG-Y<#CO(2)R$Y7C\)9808QC`$A]NC4RAM(^]9O%0FL\1=*^J4K1'5N<E1!
M;/+!GB<J522T+22/;N2XV+*98\E&+TS,F"(L*C!0?+^T"'Q"Z@>E#@#@#@#@
M#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@
M#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@&@W9&@NYG6/=)G
M^[VEM)ZSW7"+*TXJC7)V:KMO"2U6ZLKW!;/GT\<'!`D8(-*O6)CB9"E*"(8P
MX%GQ].GA]H&->_M7]^7?S4.YM0I5I[H974?NAKC30YS5AVWGSV[L),>G$8FH
M%"%J7U"D1K##SXT$G.!F!P$)N1>W.,8R!Z>6Q.8D;6]*;X?-3(DB<WPY\0?,
M)(++'X1=,=0^(.>F>G`.[P!P!P!P!P!P!P!P!P!P!P!P!P!P!P#'S;:M)+=&
MJ>S5.PS#?F86QKY<]:1/#LK$WM69+.ZXDD68L.:\!"H:)O\`>CJ5YQV"C,EE
M]18"+ITR!I)U;#W\]7]:=?M;6;2;0&4M-`TO65--DG<=P+$;G"1H:TAK-#DK
MZO;T]0*DZ%:[DL^%!I)9@RRS#,A!GPXQP"=M#->NX$9W#-F=W=VZIH"G@6MK
M-2U$Q2*4?;K]:A(U=7S>:R50ZNBE^B$64(O6I)9X.@<"!C).,8QUSG/`-X?`
M'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`
M'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`--VTO=*N
M:G-S7K2G77M\6WN58,6H6$;!2MUK^X*CK9`PQ*<R^5PMN)/3V:M:0JCR7:+"
MP+)!Y@A8/Q^MXP'(L@8S7YWKMT=7*CF-]7_V4-DJWI^O4[6MFTV7;.:QO*5@
M0O#ZUQM`I.;(Y('=Z5X/>7E,3@)"<S.,FXR+P@P(6`/1"B4X6(TBP(,EA5)B
M%.`"SC.08/*`;@&<X]F<AP+IP#L\`<`<`<`<`<`<`<`<`<`<`<`<`<`<`B>^
MK614/1ET7BY,ZN0MU,U/8MK.#`@4D(U[XBKN'O$O5,Z)8I"-,E5N9#.(DLPS
M&0`&/`A8SC&>`:4JM[OF_5TUI7UPUCV-]EI56]J0N,6)`).GVDU9;T\CADR9
MD4AC+XG0O$E;G5(0[,S@2>`M202>`)F,#`$77&`,HM(.Y596T6R]SZHWAI+9
MNFUMTW4L!N1:RV%9]:V1E^B5B2-^C;$>B4ULI<6Q+D:N.J19\:D8^A><"`#V
M9$!MCX`X`X`X`X`X`X`X`X`X`X`X`X`X!KHV$K:_'O8!-,(^EEK_`%BB9JN5
M!;8G($K6H!%8JV[%BOZ!)$!TDCHS)3;Q$JAJ%N,R:26<I2D'#4I<-?G``E76
MB)SJ!4+'F*)PY^B:H4NG[SB#7G(#!N,(9)+,'^1((A'ED9?++%\)Q7#F!O9B
MCEW4+8G+S@I,'RTI0$3[(UML4[WM4MBU.)S=1HHY$8C.X4[FI/O8IDRR7.CF
MYV76,P`\M;_7]M5>+_#E93LU.\>G;)E*S*$@3RP*$P$60.0]R@4*+.6L$@#,
M*X@-$NB>'S5AIPI!>AQ;94*VU6E?:#9,U:J*66XJ2IRV*2,LI#6F4`;%A"K!
M0L^L`JT]>^XV<_SIDB/OYL3QV3*XXQO#=7M+KF.5Q,FJ["?(G8\8D+],U2T;
MN_S]*R-<@9W!A2%MBH><I1Y1BR<,"\[0A&QS[<6L=N1YI>'-:WQFIV:[*ID'
MI"JR"E<YHB?9Y+J_D[',4$@K:XJJ`0H5G@4E/,?G#-@EB-+\[RE:<"Y+\9+D
MEMC5M.4M?R66TVHURN%$;5!QR(MUB>QLF'7SG63Y8T;;)@TDOR%%&T3ZR>>@
M<5.&)Q5#,`,):KUR4#'`MOWIFDG@<0L*LI0W0>#2O79_,,:'"&$-:!WBZK*:
MT2&:0HK`<)5*H2='GC`0`=SG!:J,3&9&/S?$7D"QJG@6\%<S77%Y%4TF.8XA
M"HS7]HKD\AA690&/O%!:'1MY>SB7*3.S38,IC]KUW*4BY0L#A:",H'(QN.,6
MC;0K@,M->';>"4V-7SA=PI!#8..&V"]6'%5$#J1L2M]E-XJRCC-7R*1Q^:SU
MY?H'ER52IX97I/AN6.",A*6LP#`,86`;%.`.`.`.`.`.`.`.`.`.`.`.`.`.
M`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`:(X4]LK'_`&B;9T]Z>&IG
M).[5&N)1)KHX)&\LXW&R%K#R64-6<2$P>`XZYP'KG&.`?/\`:+IE$'/LO;RH
M&V5QIP7*(=604Z-$^M:I4>(-\568()*<A48::()8,YS@.,YZ8SG@&\IC_P#P
M*S_]EM__`%0G@%4X`X`X`X`X`X`X`X`X`X`X`X`X`X`X!AWW$/YO_>;_`%.]
MFO\`0K-N`0=VF)Q"D7:X[<Z19,(JE5)M(-7"5"8^1-!1Z<XNE88$PD\H:S`R
MCBA8R$8!8P((L9QG&,XSC@&,=".K6\?V@/>5:T.3>ZH\]NC4$OU38M3+T_F`
MMFY/&5DY*::7@P'7&<ASGQ8QG&>G3..`;T>`.`.`.`.`.`.`.`.`.`.`.`><
M*V?[5-VE:6M2RZ<G$PO)/-:FL"95G,"&ZE'MP;R91!)&Y1:0%(%X'$`%J,MV
M:CL%'8QC!@,8%C&.O`)3UJ_M%>B^Y,@D<4U3K;<B_P"20]F3R&5,M;:X/#PM
M8&-6M`VI7-S">_(RR$JA>9@H&?%D0A_8QTQG.`,Q/K(BOS$.Y-]%-;\K^`/K
M(BOS$.Y-]%-;\K^`/K(BOS$.Y-]%-;\K^`/K(BOS$.Y-]%-;\K^`/K(BOS$.
MY-]%-;\K^`/K(BOS$.Y-]%-;\K^`/K(BOS$.Y-]%-;\K^`/K(BOS$.Y-]%-;
M\K^`/K(BOS$.Y-]%-;\K^`/K(BOS$.Y-]%-;\K^`/K(BOS$.Y-]%-;\K^`/K
M(BOS$.Y-]%-;\K^`/K(BOS$.Y-]%-;\K^`/K(BOS$.Y-]%-;\K^`/K(BOS$.
MY-]%-;\K^`/K(BOS$.Y-]%-;\K^`/K(BOS$.Y-]%-;\K^`/K(BOS$.Y-]%-;
M\K^`/K(BOS$.Y-]%-;\K^`/K(BOS$.Y-]%-;\K^`/K(BOS$.Y-]%-;\K^`/K
M(BOS$.Y-]%-;\K^`/K(BOS$.Y-]%-;\K^`/K(BOS$.Y-]%-;\K^`/K(BOS$.
MY-]%-;\K^`/K(BOS$.Y-]%-;\K^`/K(BOS$.Y-]%-;\K^`/K(BOS$.Y-]%-;
M\K^`/K(BOS$.Y-]%-;\K^`/K(BOS$.Y-]%-;\K^`/K(BOS$.Y-]%-;\K^`/K
M(BOS$.Y-]%-;\K^`/K(BOS$.Y-]%-;\K^`/K(BOS$.Y-]%-;\K^`/K(BOS$.
MY-]%-;\K^`/K(BOS$.Y-]%-;\K^`/K(BOS$.Y-]%-;\K^`/K(BOS$.Y-]%-;
M\K^`/K(BOS$.Y-]%-;\K^`/K(BOS$.Y-]%-;\K^`/K(BOS$.Y-]%-;\K^`/K
M(BOS$.Y-]%-;\K^`/K(BOS$.Y-]%-;\K^`:\MI(%VZ=UK)36_M-V:-Y;FLI'
M%VN%II=)]7IP0Y%1=E6NKBULP0LEI-23*9$M>U1@<Y+R/J<+J+..F,`8YEZ%
M=EHH8#`=A#</`RQA&'.=8[.'C`@YP(.<A'<8@BQUQ]C.,XSP#<J3W'4I!11!
M.AO<E+))+`44`.J:[H`LL.``!CK,,YZ!#C&.`<GUD17YB'<F^BFM^5_`'UD1
M7YB'<F^BFM^5_`'UD17YB'<F^BFM^5_`'UD17YB'<F^BFM^5_`'UD17YB'<F
M^BFM^5_`'UD17YB'<F^BFM^5_`'UD17YB'<F^BFM^5_`'UD17YB'<F^BFM^5
M_`'UD17YB'<F^BFM^5_`'UD17YB'<F^BFM^5_`'UD17YB'<F^BFM^5_`'UD1
M7YB'<F^BFM^5_`'UD17YB'<F^BFM^5_`'UD17YB'<F^BFM^5_`'UD17YB'<F
M^BFM^5_`+7F^]T1LB%R^NYSV]NXW)(5/8N_PN81U?JHY>A?HM*6E6QR!E6^1
M-"3_`$CHTKCB#/`,`_`9GIG&?;P#47\P?LL?T"&XGT9;0_+)P#+?4M-HCHH_
M2^3ZD=H'>^CW^?-#<PS!SBFKDQ4*'UG:5IKBW(%?OVS'<L)*5:>,P/EA`+(L
M^W.<8QC@&<OUD17YB'<F^BFM^5_`'UD17YB'<F^BFM^5_`'UD17YB'<F^BFM
M^5_`'UD17YB'<F^BFM^5_`'UD17YB'<F^BFM^5_`'UD17YB'<F^BFM^5_`'U
MD17YB'<F^BFM^5_`,@-:-LX;LZ=9C8Q5[=55RFHWY@C\WA%ZUTJK>7H#Y3&T
MDKCZ],U*%[D!:TNC,L",L\!N<>,(@YQC(<\`RFX`X`X`X!_(Q@5-U3<?<J[Y
M`+9@*"=):U9=\+4K[U$8<IFYQ^TX[MS&&J-.T:AS=*H;B;2`3-('0DAD/7`(
M<0C'UQXBPF%@>C;^STU#45"][;O"U/2J**1.FHA5,9*A#;![+5V.PQ>,NLHB
MS\6WE3MRSZ\MX8_>AA3DB4&J3F!S*/;C%*D2/*@T#8EIQW6]K&74K6,<^KE=
ML99]DZHVC<2FR93*8S$W"4W7&+,N9M;:?G*9$FCS)2_O.(0ML''W9[1M\<?E
M(U#>)Q;UQ17K0)OQWLK'*LR+0XG59WD39)ZXB%EL[2DS-8S:LC:Y+HIL3M@-
MI:(`^154-(_%6-0Y<%`28I/*&O>`>`PP\HLE2!/VL_<[LR\+8U8A+[2L/2U_
MLO$YG(V:V*PL%/:+*C/:F.92R*-LE9F/J\UD-]CT24E9/="U2`MZ;G!K4J4+
MB!(E6`;+(_9<IF<@>X:II6ZJU2@1/9".R)*&HAQH9R4>4:14T`C]GR^0"4K?
M,]2CPJ:`%Y`#]?P7G[3('GAN"^]KX%7/=\?(1M!="J1Z>[-:T5'K\-[/A;ZF
M%"K$B.I!DM4OZ8NOC,R%0=-);)<FKP%"$ERH5I@AP!.642!F=K1W6K0ORY:&
MIM;043B[E8*"T7.9/JZQ#V9I>6FL]D-CM=)"ZT>"1L[<ML!?$U5)L<B=V8!8
MUY3'-DA_B+)2^H5@8CVGNYME7/<HM>%Q::V?/ZDA>^E6UDDIZ$,L>L.1/=3R
M;MN*KGD\"8:Z#$T#J3#5-_)0*'&P/B#)T-68`VC2JDZH1!(%WN??9G[!`8+*
MGK6^.$NDEG52-1K>&82XA-(8O8,1TKF4X#!E"F$^E6/=%CVU6L,I-4J`B2OD
M2&$*+):E=AD`[VQO=3VA;Z#OI[9*N@=:HG2W^X5JK4%Q,TKEKPX0R;Z@UYM>
M^1NQY(V.<')CZ5XN9SIF/)H2U!4+R%;FZ&A,$K!Z5,J`R4MWN-VSK=0.D4B%
M3CY>4HNC6)IMF:O0AJFARE4PCZ/71G651$$#(QGI3KLM=9="]U9D0RB4_D1M
M>'!`@X$),!B+;&S^W3+VNN[MM,DOB8)[UK#8_:VLZ%%%VJ.X8*YCU`[#/U>5
MD7`8HOBBX;@LDT5R0%8-:-U+>$Y290$(3C#S3@/N5]P;9JF+VM-FPID]OZYP
MK:6QF'7>Q79T;&%/9#)#^UM:VS=BUQ()$T0)<"WJWKO86*EQQ"\H1(5H7AP3
MI1N2\UK-1J0)O3]VG8IG+K0F4:H11]DDZTK2[S)X1`;*><R"8P"00>RI0EJV
MGL2Z'L:RRKLKATA+0EE#.WH5!H4TL2*B0EEIQ84@6>]=VO8=JE<-D;5`J-LV
MHY7IRYW_`!U54CS/)`BE+O)=M:CHB/OZR7N[$V9CC33%=S\<FGK&!"I6LZ=&
MXX,59P24,H"\F'NM[-3UUD3?`M7ZV+^!]3Y9LH\@L*U7Z!#G"F-[#[$ZY1V/
M5RZ.L.^%2&>UW*H6.4L3H]N+>C*C\D*]2;@&2EHP,@YOW`[=%0&@UDU13T;7
M6!O!<K13(8K;ZB<UH@JUQ?*MN*<%O\L0H8Y*I$20Q/\`5Y+:L3%@-(4"<`B2
M+CBQ)SCP,=".\!;;JI&WE4+64#R^;-3S5]CD=KVNZ1^,UG9=>9V%))BFQY++
M%'V35,;;ZJF&+$.=5*'"-R#.DN2R5&$1>70#IR+O$7.CD$ECK;J\W-2A-?%8
M5`@6S.0REN;H21/]ZK0TP_\`-0]!%U1C7*%,:KTBSVU*F!Y*B)N.`F#`6`IP
M4@0G!>^K?4WJN.RS&L=;,LNE4BU/;4:!=.Y\9'6-KV4U;O.\W0][/^`T[L-U
MKV7TGEF/(`464=AX)+&:0>5U.`OJL^]M<,_BD%4&ZPPMIF%C7)6E>1L3E:2^
M.5HF+LK1ZI-Q8[#Y-8,MC#&ECUB21UL)Q@[4(TD216]LA_EE&*>C>(#LQSO4
MVL\3RPH._P"O,19&=LM>*5NQSU/,)9EBAL;>^X?;FC+Y95O"51MN"P1]L9*\
M0RTL2-7DHL#TE)-4ED&A6A`D#M.]P2^[Q9-5:9OJ-NTID<^T\2W.]7\K)3'+
M918S;)A()E#IFQ1MM:":N?F5J>6I0A*=&U$E?T2@1R%2,].K2$@3[I?W&)WN
M?)-RX1"ZT@+?(Z`C\1=ZD=@S&3*879#E.'*\(PV,[XY.,09'UL1,<IIH)3DN
M+;BS@`<_#A%CTY9JL"`C>[Q=J6I]7[-7Z?R%O7WU"G64O4`<AREMEC-,X';^
MM>O=CT'&DJE@\3Y:9ED7%*76/&&`*2NT3A`UP2O*6C.0@<>M/=,V!L*V*?H^
M?5372N7V?<6V;4Y/N)`MK)H;:_HK<Z=ZWE0^&HY5Z]3+[AA%?L;;-')H#G*U
MT8'!.<22268:J)`IKG<^Z<G[@O<TKRIWJ9SR'ZU0?7JP:4@Q,TC\=8&^>.FN
M,_GXZS'&CH4>NL2)W3:<?;FA[-&\E*H\`_&$N2!GX,)`P_GFZ>Y<?UAK*:UK
M=MC3B:SCLQ[@;,;=OCK'6$ERUMW`KNJX')Z4<6F.YB*=/6,S=+Z>Y+#BJ]4)
MQE.")H&#*`P]M4*#`,Y=`]L=E9@U]PP5H/SHXS"E8E54UHNB;,;TKW,2&)SU
MF:YB*U$M@PAI:VZS::V#L0!ZIC3MQRYRCQJ5<W*C$JG):!*!A=KIW<MM4EUP
M-RLR+H[QB-^ZNZ330ZMH&D6L;A!+;G6BFW^S\_(J5M`P.1SD?,YC1[1&'-L=
M'$T3>\.20";!8QY(4`9BW5W`-A+&[14YV^JH,$J2Q9#+*28X!(HC)$=G(`06
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M(TS?Y(%R,:O*I&!&<3[[=TO<$D\DD.O%.1!8D<*=`RN+[<:]ACJ%':QVZ;2C
M;GOXR8XFI=Y..2ZF-J7TK<=D*%)-B%RG/I6TXQ4!F)NGW-;CU,KO5Z0D4[5T
MLFUVZR[$WQ*XK]\EP5MJ>7:\TM#+>/J.KI!$6B2H9^\66O?U$>8EI`ADG+<I
ME!(%99GDB`L^5=T[89B^_E(@Z]5XBKFLMS)3ITU2!XF,WP[M#E&J5!>N+1M)
MN3PT#+&H6Y)0XA1`$KDJ,,F2Y(`(\E"R4("&W3OA70W.%CGI=,'!^S"(@[O9
M]/,\DD)U]1IS*[==4;X(#;!CH8D:A8HVTOEB&0!U.``:D#KA.>24,TS*#@$C
M.'>-L6-KG@<IU\8TL)CL=W"']]A))9(NKZ6R#5]PN,$>D!0&"-2B<0>GKCC]
M5"7L<H,97MI5*0.#:!3ZM.@]Z`8O*N\1L<XS^(W-&JY->8PWZ\[HMLIUQ;'Y
MB3M,JFFO6_U/T4SVG%7%_`VKG2=+J/6OS\T1,I])P^A.$D2*5AH4IY@'HMHN
M\H'?<--D\'?D;R>PN"2+SE"F0OC8?$I[B,1R4/$1<VZ1MC.\H71I02A&(TE0
MG+.)\[`#`@-",`0)FX`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X
M`X`X`X`X`X`X`X`X`X!@3KE_'4[B_P#E1J]_)\9N`9[<`<`<`<`\5==?V6C2
M+>X%F[<V==>S,8GUW;+;9RJ2L<'>ZT1Q9M<$&T5P1TDIE(>JX>G4I/Z1F+'^
MO*CA^8(6<9QC.,8`CWLV=LE+JO=5`.NL&UM[4R_;C4CO\*V7=%%*!G!N&[3;
M;:M*HK=ICR2RJEF#:U)7UJEAZUX'D@U0<M)+\@PDC(RL@>I$6I.U8\YR+N@;
M,BSD(@9R*C-$LYR`?A\8,]=5_:`?@QXL?8STQU^QP#Z^:9M=_2A[.?B/T4_4
M]N,=?FL_8Q^I_<X!^9U*VMR+`_K0MFO'C`@X']X[1/Q!"/(1#"$7S6.H0C$#
M&<XQ[,YQCK]C@'[\TS:_^E$V=_$AHK^BSP!C4O:['V.Z'LYC_BH_13V^W.?;
M_P#"Q[?;G.?^//`'S3-K_P"E#V<_$?HI_P#6_P#A8]GV.`?GS2]K<>W'="V;
MQGV^W%'Z*8S[<^+/MQJQU]HO;G^[G@`.I>UH,9P#NA;-!QD0A9P&CM$PX\0Q
M9&,73&K&,>(8Q9SG/ZN<]<^W@'[G4O:[.,8SW0MF\XQD.<8S1VBF<8R'.!!S
MTSJQG'B"+&,XS]G&<<`_,ZE;6YSC.>Z%LWG(<]0YS1^BF<A%TR'Q!SG5C/A%
MX19QUQ[>F<\`_<:F;78Z=.Z'LYCI]C_R/T4Z?8Z?8^:S_<X!^8U+VMQC&,=T
M+9O&,=,8Q]X[13H'&.G3`<?-8Z8QCI[.G`/WYIFU_P#2B;.=?[OWC]%.O_%C
M/S6>N,9X`SJ7M=GKU[H>S>>O7KC-':*9QG&?LXZ?-8Z>'/ZN/L9X!^?-*VM\
M/A^M"V;\/3IX?O':*>'ITZ>'P_-8Z>'I[.GV.G`/W&I>UP<8QCNA[.8QC'3&
M,4?HIC&,?J8#C&K'0.,=/U.`?GS2]K?;_P#I0MF_;G&<_P#D?HI[18Z=!9_^
M%CVBQTQTS]G'3']S@#&I6UF/%T[H.S6,F9\1F<4=HGU&+PA!XAY^:Q]N+P`P
M'KGKGIC&/L8X!]?--VO_`*439S\1^BGZO_\`BQP#\SJ7M=G'3/=#V;SCKUZ?
M>.T4Z=>OBZ]/FL?WV!>WK]GKP#\SJ7M=G&<9[H6S><"QG`L9H[1/.!8SCPYP
M+&=6.@L9Q[/;P#5E)YOONQ[1/%()^XU<AD=;^X!2&I1;L=06F&7TR!V9H4OV
MM=GTU07KN4CS*D4Z(]`F,P1A(6U9R$2<P_/GX`VGYU-VOS_^M$V<_P#11^BN
M/[G]S5G_`(.`?.=2MK19#D7="V;%D&?$#.:.T4SD`LA$#(@9SJQGPBR`6<=<
M>WIG./U>`:C:WM+N`33:N)40X=Q6WDT:D&[.Z6M*IU1T%IH%])A^ME!QJU(>
M])CSM>CT(),\/;T:G<C<IQ)C4@0A*))'C(\@;<_FE[7?TH>SGLZ^W[Q^BG7[
M;/7/M^:SU]N?L\`^<:D[5AR+(>Z!LR'(QX,,SBC=$L9,,"$``F&9QJQU,,"`
ML.,9SUSC`<8_4QP#Z^:9M=_2A[.>S['_`)'Z*>S'L]F/_A9]F/9]C@#YIFUV
M?_UH>SGZO_TC]%/U<]<]/_A8]GMQP"-[CU_V^KBH;5L-H[G6R"MU@=;SJ9MB
M-PHS1H;>J<8Q&'5\1D+BTVKZ4\:0]4B"$W`#"QB!G/00<YZX`P@T0>M[MIY5
M-6*:=QVZ6%-']6M"KU(-BU":6)U"F4;5U5-IM.&Q6)TUR=0',C$X15.2U!P$
M*@I.,83S3\^$00-DV=2]K<BP+/="V;\6,"#@7WCM%/%@(LAR(.!?-8ZX"+(,
M9SC[&<XQ_<X!^_-,VOS]GNA[.9^S[,T?HIG'M^S[,ZL=.`15;?;<M6]V5GCU
MO]PK8.>LT>?RY2R-[U1^C^4[;(2FIU8@.I):76),`U1AF?5B;H;@PORU`L^'
MQ8"((%M)^U7+T+_04E;-]+^9G75J-R.':]X9*7TM9FJJXK+8VTQ"0,$>C[;K
M8F83FU=&6%$CP!8F4^04F!DG)8L9%D"*=I8]NU1UE:PPF.]RF^79MN^1WPSR
M50^T-I*H6-B:J=9;8NUC-9<H];$"<M0LDD!2)E/GEGA&B--P#RS?`:$"(:8U
M[V/B>B<V[AL2W^O*.7GLGJ9#-T;D(1TYJ(MBDOMUOU7C+FU8,;'C7]Q5-C"V
M,T=;F8LA&H3F";4)(1F".#YV0+VUE3;OW3<@JY?NY%>+4TI]&--]G"5;)06D
MZ=P+F&QCW?#;+X^`Q7K@N3!BC014S<)N)P5A0`9Y_G''8P7X`,]Q:E[6BQD(
MNZ%LT(.<=,A%1VB8@YQ_<SC.K&<9Q[.`?OS3-K_Z439W\2&BOZ+/`'S3-K_Z
M439W\2&BOZ+/`'S3-K_Z439W\2&BOZ+/`'S3-K_Z439W\2&BOZ+/`'S3-K_Z
M439W\2&BOZ+/`'S3-K_Z439W\2&BOZ+/`'S3-K_Z439W\2&BOZ+/`'S3-K_Z
M439W\2&BOZ+/`'S3-K_Z439W\2&BOZ+/`'S3-K_Z439W\2&BOZ+/`'S3-K_Z
M439W\2&BOZ+/`'S3-K_Z439W\2&BOZ+/`'S3-K_Z439W\2&BOZ+/`'S3-K_Z
M439W\2&BOZ+/`'S3-K_Z439W\2&BOZ+/`'S3-K_Z439W\2&BOZ+/`'S3-K_Z
M439W\2&BOZ+/`-4MV6!OY6G=FTVT$9^XU<:VKMC*8M&R)=+'*A=,S)ZSO$'C
MEJ/+8CCJQ-KPE8"&U4H@B8)X5#>I,R`TWPC#G(<@`VM?-,VO_I1-G?Q(:*_H
ML\`?-,VO_I1-G?Q(:*_HL\`U>ZV3'?.Y[IJ2M9!W'KI;FBP$'<W5NBQGH+3`
MAQ2&:3;K0'6JM@H#5FO:],`$GADK4+GOS"C,F.99>4WIR/$5D#:%\TS:_P#I
M1-G?Q(:*_HL\`?-,VO\`Z439W\2&BOZ+/`'S3-K_`.E$V=_$AHK^BSP!\TS:
M_P#I1-G?Q(:*_HL\`Q3WA@^ZFK^J5T7W#NY;L`^R:M8VB>FAHDU%Z2GL*Y0I
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M8SR=S2Z7:).TWD4[61DU2<9!XJDAL=2-C?$(I#V-M1I&5('`\`2Y,--SD8QY
MSTQ@">>`.`.`.`8)]MS^*@S?PX;@_P`L*^.`:F.V_P#OP=M#^`CO;?[PNC.`
M>E/@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@'G4L3I]81*_$+RP_
M72:F=3.N`^7C'9F>,Y,P(74(<EX]O7/LQT]O`*=K'M#W!9E0^A=HW)*YDS0_
M8;8MYKG9"R5<5KXE17=:1F(WX\Q&6IV!LJN,&4N"T;7CT<A3D>\ENJ5"F`G4
MIE"52[!.+`QZFO<)[F4?%#5>#I>VLH:YG<F<9J91;2YL;=6,=[F[;1E?;56E
M7Z2%&SQVC,IU!4!>7R/Q;*9P$B6>_P!"D1)BAFI0)6H(8#>XO6!I8PF%&]V'
MNL&E&`S@0#"C=,H`868`6.N!`,`+&<9Q[,XSP">=D>X9N=!Y7NM':7IP^<)7
M+5B0VMV]W1)"5#Z"3SFB)HLK;91M>T3.Y+%LS>TI,A:YA%&886]2^MK>K2)R
MCC`&"X!+UE;9V]FMMJ8)IQ)[)N[8R'-=?1.CGBVJ^K\NK)58[Q2KE=SF_P`+
MEK`*$()Q'E42*))?"E&"2XY(#2T8"\!%E,`"#G3<;:+:.<RXG6NW'K7.,VKH
M!HI=5$+;`J".R1OJW8Z\=H;(@%CQ>P&Z41<AS?5#1&6!I:)$Q#5`4-:<1RY)
MA.<>2HR!\I]T-_CDU%S&6U-(X@I?;%EM9[*ZYLBN+&7?54K!=D+J-KM.ASY#
M`%L(V4U\:E[8]*LM`%S3*#X@])7TE2H,*"62!+U>3&^II"N[LRVS;D^FL4H.
M273254M$KB%=Q]&\P(>H=*3XB8C<HK7L17OSLEL*22E)ZPD\3>,!QB017F(2
MQ%@07VMYRTUHLV`GSX6I/;(GVTNSR\J$B(`3%S@-+KC;PDK6WEBR$!C@ZJ\E
MIDX19"$1QH<9SC'MX!8\[W^WL)J.O8I(4Y]7[.5UNYL30&PJ5NC<;8(A)ZS3
MZI[%["ZZ3IE?'Z&6\RQ>+/!26`IC7(@I>$R0)%C0<+)JD1/`)HU>VDW8MN>5
M?$+C53=GAUOT5!9\3:%?P6*5A-Z7G4>U\JB:6K5NS>NEKPR5O=3N$HG"IX<(
M_*6EY?FG('D#$H))6)2#0`63%]W]V85VNM9=F<%RZ^MDY-6M<;4;&01ZKF(,
MCZU496SI#A[1Q6%Q./,T$.9I;(6!0J*8$1J-R<B'4XTLHLP)9990%XS#8S>J
MT+7W`9M5K89O6UOLKK.Y:K0^Q(!&T-;W753QHVV[$V#2#K+G&,M\B:VJVIP6
MN:P2HI28YQ1T-)*R+!:<Y&,#L6K8\JN!J[3]I3>/3J'RN?.>YDI>H99K4WLM
M@0E4[Z)[1*@PF7MK4WM;>G?H>0,#:HR40$)@TN1]19%D8@)]K7^8B@/]4E%?
MY'*#@%HZ`_QIE']4-VM?W5[C\`W-\`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`
M<`<`\R>^3@L:?[0KVZW5N5&(G%LTEVK<4"THLDTU(N157LRI2*2BE!*@@TPA
M04$00C+&`6<=,ASCV9`DS6797?245QVPY=L/+)C!Z\VFK>02G9VU5#/6OJ(5
M,XUK+&YM`F@!K?549;*/27)9+Y(#EK8\HEQS:OAZ9G3JPY<A%J`,>X5W"^Y3
M\3Z\'VRS2^#MTCKCMX2"YW3-2,OP/6:*W-L=E*[M2P;0A@8BJLQN(NBCX!"B
MSF]K6$!K:0RI$XN.$#3E7G`&0NC"A.@VKUS5JC`I4:-B_M`ZE0<<,/EITR?N
MN4Z8:::;C[3P$E`SD0L>SICKP"JSGN$[G!.V/@[=73E&E0KHTPM.D[+;J_P^
M&Q?MN[&V5#:NMVV<,A&9.TR.RJ&#'9(].Q2X(AMK>_-RY4VB1)#0#`E&^=]+
M?AE!7;-M58_;5X3"B[]EKK(F&R:\BB1QD^NFL:VJW79-)3KC'E3.GL9FFC"[
MK&^'2$)*QQ5NSH:640HRW]0@1]+=EMXK?M_;QBU0MUG;LPNY=0W_`%)8+-K=
MB15G:\&E>F[CL%85,R.2.4602I`R6]+6HQG.D!2D3O$5ZDL(,@\@Q(8!6H1M
MKN3.K)UJ*71FRHQ5FQ43C3+*XPE;X.V[1:B6C+9'=2Y0KMZN)?6BB(VI5)#`
MW-#0<^Q]:0LB#@P>J7(5B1>:(T"(+-GMXVKVD>X3.+OL>8S%U:KEV7J*,L\I
MBT)C1#97U.;E2N#U8^MX8M"8@L7J)+5K>S&*%BC*E.Y8*+6D8+]09DP#+C7N
M?/U=Q3N?NL+)+5V,]]QJTH95J$U&4XD*[*F%.:[,,,RL0'+FLE8UMSPL`L7%
MB4I_$A3'=#`YZ9X!KMNGN5;X+:4ULF<!1RJ!7('4O;(K9"LFRL624JD^Y.L5
MZZNU*J01:)KX=('&=8E@I'-ED5B+6ZM.)JU+$PDCHG$F"M)`R`L_;#>=%5_<
M34%.\J9931-`;*;#ZQVY3\<A$LKZ>XC*RQDE34Y8U53^L%MBU3>D$<T[6VND
M;,&\HYJ4VC<&Q>$)B@LP#(:W=OK\U\3Z</"#,CN.L,S.GEN\$M=8C'E,LAE;
M[2D.\`K!R:B(:W1W*=)6]LNZ!U>,HV-2I+BS>,2D8<Y,/&!B\KVE[C)T0LBU
MZOD#K:[G0&V_<A12W6HZOH2SRR_M2*4NI@K>OFNGI"*+-ZU%;E>0&1!DL05X
MPI23E0A$B6^I"K*.)`V,0->XNV\='.KPJ7+G9S[<CZX.BUS2$M[BL<5MOTVI
M7*5Z!.F1D(EIZDT0C20$E`*'G(<`#C'3`&QS@#@#@#@#@'G5TIUO/LM1[C?)
MWN=$(Q.9YN]8*"3U%O/<<0AT?<8IN9/(Z9'5U+QLYE8:Z:)2.1'FLAJ)<M]X
M&-#D(Y.E$#`C`-5='5'%ZO=.W'*%%K[<JRK!:.Y-!E(&K<NY:\#%SGGN2Z^T
M^U.C*]L0']P8&509*`N<D2(4N,OZQ.4J.P-007D0&W^#-VK3]"4LCL#93NJT
MW)V^*H9)8$!GFTNWI#M7IP*X9+;EC6Z.B=;EH<S(%6\C0/CP)*8,UO:UJ<Q2
M40:;@C`%?+:=&S#Y&F^?5W(25,83R%S6)U>UNXJ(]SC4.76$W3291<I8J('+
M8;#EE3R,#DY-N%29+EJ'C(LY.2X/`N8FM=0G##/[EW>[ASN&1V"LJF/."7='
M:8V/N%A)GAHC1$</D*5Y5MK:J6R=_1(2\'B"9D9_F^7E.`9H0*3'*RH)9%->
M'V8[(]R^(.NQ%%1V[8^V)=W=CY,SM7Q$Y4U&D,#'(DDD0C=):Z3:]&)I:R2T
M98G`XW(O"3CH'(%\'T=JN3&JMEP-U^XD='KED"&)P-V!N5M6)"JD[C,&:NTC
M"^'`=QBB[M\?R!(SFI5X2%)*T9F!EX`F5#(`@"JD>ODQ8%#_`&-L?W#JJ*)@
ME66)Y(>X#LK-O312>U76ED2>1O(VQ2W&,<3K)9:+:VN;J>7A&'!Y*DP1`3<E
ME@9#UG0FKUOR)5$H!NAW&'B2MZ%"Y.;(?N1M0T.32A7K9HTEJ'5(\/:$YO"G
M?J\>&Q3@W`1)7)$)*=@!PRP#`MR-UCIY+GJ%1R/[R=Q%<^6$ICJ:(-INY.U+
M:I>12AB^)6D:4+J](0F^)EP-0<6'.3DY1)QA@`EISQE@5F^J+UIUN2^HL[;G
MN6I3SXW*I*UH&7<':)[4/9<1BLFF2]F:5262>Z3I$L8X>X#3(QJ2QF"(Q@60
M8,+R(#DG-%:OUH4V#G>YG<;CAB^-166+$ZG<S:!8?'&F=*G1KA(I5ALD2XM@
M4R^0LBQJ;"SQ!$M=$XDI7B-Z!R!P0VDM6;!GR"LX;N1W*WV5KFQT>A%)=L=O
M0,[6SM#.P/JES?9*H7DQYB1G-\J;?3B5JBO4'+BBB\"-%D&`(P,C.K9DNC;4
MV;:]Q=PA3]&)X[YG9F[>U3<!0^1EQH-+$8_#V1<J*S8*>S$5_MQS:X-:HU.$
MU.).+`C<G83`7`?7^K:A+#5<7VI[H\N33Z3M\,C;FV;2[?)6$,D7QR0290VO
MSNY."3#(MCB*.'EO*$11CNUGYP4:B\S!@``4IKC>G2EBAKBOW9[B(W>:-42-
M9F>);B[BS`I\DDI,K!$*)1!204W.LC=FAWN6-)U))B!$L3A=R1J4Z;(%0$P$
MOO&M=`-E1U_=Z':WN6R:O[/=:::X:NCFY>RBIQ<,7O+8E#("XJ&A;+6]P;6\
MUTFB(:W*@!1J,C(\C+\8/!D"S%-0:T+8!.)Y#MR]_7U+!&^NGUR+>=Y-LH^A
M416UU2,-?S)&J0_$;JX1"8MZ@T]L<D3>K2*<IS`B&5@L\9(%*7PW2MM(6*E.
M]G<-RF0)[07*C4VYVT:X06VF!%%6:X%)43^H6JB8<I."2O+*+&H2G9\!Q8!>
MS@%]1JA-7)?/TM8QO=+N-.TS4/DVC)[8DW#VN,)9Y!7[O,F.0M<C<0N^6Z-F
M97UZ]81&KC4Z=P"@SE,8;YR;!P$-%L.KZFS(G#V_:ON0.D(ES7(24EG->ZVU
MKFW()VQVG"*C(A3LRMJA6<U!=9=.TB`"Y4H(P2Z]$!I(#Q9\(%=11O2UQ4F(
MD6ZW<Q4K$Y"H:TDO:3<?(&U:1)3H:C8W5=E5AM:Y&^2DG"!O;SSBU:M48`L`
M,BSTP!,M3:PZZ7@=)2*TW)[BK\.(AC69$6HW1V@8E;0=+&(B2LJ%S;)!(&MW
M:G0YD5DJ!I%:<A246<#(@8P+&<@:B9OII%DF\LAC&+ZW).(([N&LD$P[*-K[
M@.D(TC[VG7*;F2(U]-?QN1DV0+"_=R9WR9E<G8\^[RS`IOM.`7M/]O=#H-;E
MRTP@LKOW6G**%LI^J.R7:DY=NS:T-:)Y&PIC'5C+E41D:]M-4DIUI)P0BR`P
M1!Q9F`^`8<Y`[%:[::(V/<M-T:ILSOTU9+[ZGR*LZU<KOF6Z]30]ZF;@B6N2
M9GS*)?(T#>!1E`W'G""')@PE%"'D/A"+.`(+I?3Z,.6^=?Q8=Z;?I2%?<U[E
ML-$[H-IK;120E-#M3H4^)WU*_IWXMS3RU\-4Y3NCF$S"MQ1!"G/&,L.,8`]"
M/U<4(_.H[AWTZ]A?E?P#7IO`Z:AZ"2:DH3<.PG>"FLTV##8IE80ZA=A]K[GE
M+R55:*-.4T-,8(C+#W,DMK;Y4F/SD)0^I(31YZ!*%G`&'#CO+HXT-Z]V=E7]
MI`:VIK1*G)S<W%KW\1-[<W(2#%2U>O6*7<M.D1(TQ0C#33!!`66'(A9QC&<\
M`VVZ[ZLT3M!1=3[$U5M?W(U5;71!([8T(4OF[&Q3*\'QJ4-Y+FU&N32=,S#6
M]8-*>'(RA"%D&?9USP#\V.[>L+9=>;Y>"]GM_P!<8U4Q:+B!$Z[O7ZY-BP:*
M#OJD*5Q;U<L-2+D)^2O`:2:`19I><A%C.,YQP#6#VJM*HK.IY8Z57?\`N?'@
MHM$>U!)0G0S;2Y(FH//G%%6BYJFE2>R2)(:HC<>&CP4S-X\B3-*<PPM.$`#!
M8X!ND^KBA'YU'<.^G7L+\K^`:;+9VHT6J:\;CU]^^?WX[2G5#2Q)"++649.-
MU+>B3%)EK"V25,V#DT.DB]!Z@UG=R#@A'Y8Q!%UQC(?;D"BPW<;0R5VC3=2N
MUC=_2K7Z^+7AE*5T]W-*=W*MA3E8L^</=T:85,LEDB0-:8]68$PT6,"&,*<@
MTWPY`6/.`-UOU<4(_.H[AWTZ]A?E?P#6OO1HO$8M=FC;:1L7O([`DDSVL*/5
M2'<:[GQQ:@L.D-_R,HV.+G*2*5#"J<#FP*56:FR`2EO./3&>(HX8<@8XT;0<
M:E?;AD<->+IW$8'V!=I.F[Q:&EHWOO57%I`PV'K5+,DMBJI50(\P1R+MCE"Q
MD!;6TY\9@MZLE*8<0<$:0($01F"1^A[YA21)-]\+!6SKM>:7RUL9H#NU>D6G
M+D^LD3W5LO[WL6)8BGMPDQ+X3`\-<5C_`(TJ!O=G$W(!%`6'C`!M61PS3L\E
M<<NW-[F;![G?CXT_@D6U.W[1AA=TT]/J48'!0I<`HS&XVWD:B)D+DYAZ%5($
MQJ4DXP18A8`Z,<8]'Y0E"J;MZ>X^FP6IB9+HE>]K]PX\YQY'80H>"N'V1M#V
MK0.K)&[&.L)C+8UYY(4KD8YE@*'D0#\$@4&?L^JL:K1;/(=MMW%)XXK*IG%M
M5^P9WBVBCK58C+!&.121U1LTT,<'1D+4F,<47J<9#@_RRR,>8$(S"P#`E*=T
MQK+6DZF5?S7;3N9L[S"8U$Y2N/!N!L\Z('=OE;':TJ\F,Y9Y.X+WY='(C2T@
M=70HE/GTJ)'XL9&8+!?`/RRZEU$J,#&HG.\'<30-\EA*FPH\[MFXFV$C:7V+
MIHU)9EZME<(ZZNA#NJ.BD.<W`"=-DT_TR3Q""')Z;!P$8KQ:(M.'(3QO%W-V
M?#$D?C9+ESV1W>28BKK&@6H-UB<ER,KHS30'WD97@EI.Z+5(F8P))8\FIL'@
M7Q][S3TM8S(%^ZW<F95+Z\IHZA`_;9;=LF"W[,WB%9O+2Y"<G%,%F60VQ+!8
MF1^PK\D+*XNZ4I7DK)G7`%34T_JX6QVP^H=N^YH]$TO6L@M.;)6K;;:P9Y4?
MBJ1T4R%J;%*U^1-#A,6<YH.3*F;"D+@F4^$!I0,"\7`(MC#1K$M.L9#.MGNY
MC7KQ!I-*&MH956Y.V;ZY3QAC0D(C7:*$MYY6'F1DDN`!.#"WY7KVX6<8%DS`
ML"R!*4QI/7&`RYJCLKW%W_:D$BAU?2B-K#=Y=KP/CPJLN2OL<BS4!E4"3M*;
MWH>Q#"0$;K[R,5BPF$A`8--E0!TD%;Z<N9A):'>/N**L*78QE2&I=Q-KEI*I
MP)LZ(4V>G*,0NZD(5"6S)XTM!Y`_`H3*E70XL&"CLE@6T2R:/&*24Q^]/<@;
M@^>M3.S@Z;8;@M[-%342MY0##,7Q2L`SQ41JYB.)+"M/)%DX90,XP(P..`2?
M']?M;)+-H_7*#;GN:D3:1C7%I8\Z[6;?-*UNRD225Q2FR+*]>01&T#^VP]S4
M-2Q<,A$YEI.B8XP9J<)H$72&O:#4.L*B=2;.]Q&T9M8$WC\.CK<;O9M)%XSE
M%*HS<LCCT]72D)[^8.O'HZAI(W)W5`B<"1+D(^N,%!R9P"YMD:7HS75ID)"S
M:#N'RFQ6>O'&T&^N4^^>R;:N?(DS.R=J=G!,Z$N[P`($AQH@?K9!^<*,D$F8
M*$J3Y,`HCE%M,6<A*:Y;I=S=,<N;W96C:\[.[G&OJM<P3YNJ]_CB5A(.->54
MI8I\ZD-BM`60,\A2+(18^T'D(%P,U8:AO\G88<V[L=QX4BE$F0Q&.H%NWNV3
M26]OZT#KYS<U+W9V1-KDO9E#`X$N24@XQ6W&(3\J"BRR\CX!1+8KG6NM02-L
M;-K>X_.9JQ/K9&4\49-VMG`EN[V=9U65/)4J%]`^*V]7BO)1<T>^(`)?4JD)
M2X.`DF&A&6$#5_L#IVVMW?J[9=9/5T;:D+9IJW=+[(7T6W]S2^=1-X10:]%:
MMC@EMNJQHF"".96-F23/(*0!7IS#/,3E^<87P"_W/=S04B863#HU/O[0'9IM
M4V=/:?ELDJ9]W@L>%%SNM9$MBTN:6Z5Q:0KVE>)N=4(L?:CP/RQ`%D(?%C@$
M@47LOHU>VP]/ZQ(+8[ZE66A>ZN9(:P!?EA;GTW&I*K@$+=Y]*4Z20S.2(4AQ
MC9'&8PP>"\&9",PH`O#DT'4".-+]-8I)=EM?&0V_-T6LMU:>]^,Q<Q[;W"T.
MB+[W?<UJ6)(0MCBWOB98W%RI(L$OD@2AAP_O192]7XU!01<`WD_5Q0C\ZCN'
M?3KV%^5_`-9.XUB:::2W7#M>K'O7O/V+;,XK!3<+-%->[OVZNYP*K]'*%4-5
MOKFEADJ5K&],ED";!!HAE>67D\GQ"QDT&,@8HRC?[06#QUZE\U?_`.T71")1
MMN4N\BE,H)WRC\=8&E&#)JQT>GMV?$C:UMR0K&1&GGF@+`''40L8X!N\A&B-
M7V#"XA/8[M7W%S(_-XNP2]B,6;Q;$(U8V:2M*1Y:QJDADPR8E4B1+09&6+V@
M%U#G['`,,NZ!H?$(+H1LK+$NQV\\A4,L+;5!3-,]R;QED87B,E\;3^4\1UZD
MZMK=$V,'>+RSBQ!\0<9]F<8S@#[T?T/B$JD^^))^Q^\[1B*[YV;%$YD;W)O!
M@.>2$-1T6O"\R8ULDR84ADJ@;H(HUP5>8J,3DDE"'D!(,8`SR^KBA'YU'<.^
MG7L+\K^`:-![SZ!*WN9L\2G7]H*LI+!9Y,ZV>I35SOO)8$+-ED`D"Z,2A`UR
MF-2!>TN'NYX;C2Q>`SQ8Z8\00YSTX!*^O>P^C^Q>Q=7ZMLUN=\RK+6N5%/5]
M<IM@+*W,I=ADI%:1-9-)C[O>YI)4)"H;0QH_$9@H)GA-/)`+PY-!U`VZ?5Q0
MC\ZCN'?3KV%^5_`,3&359'7'<\K^#,.PNW+FVR?0R\)4YN$ZV)FUDOA2V+["
M:[-+4C:':P#)*K9&H1$J5C4)T@BBU1OE#,P+)(.@&;>K\AFR;8'<^GY!/Y;/
M8E4LKI#X#-FZMN=7YF3SRFV:3R-`)[1M;8J7H3WO(CR@*/-$0(P80"P#.`X`
MSFX`X`X`X!JR[<U$5RLH\=G')YCB8R.Z]HR'941:5I)&4TJ-;GV\X,P$D023
M,B'M>$Q["0$?I4!.5!!BDD[S"5BPL\#5CIJPUH_SKMBGVT<T)(I%*W[PE@IW
M!\D)L5:FF6P;N6:_R6&O)[H2Y-!6!M$C0$*2B3C<IS#2@X&6,./#P#=BM9-0
M+;L:XVMQBR.0JX9),2RWK#4R(Y/"FN9RVD*]A*N..COB7)SB0377Y^8TBU"6
MD#'W9J+\!PCE*<P(`+-C&O>C\2APASN<5A-#29#9,RQ/I)8C2RFM[!;#[94_
M=(HW+$4J3HV>N38M?CFD&UD#+:W%I=,&J"C?."/@%\N^N&C)TOC<\=T4(3S!
M]]W6#&7_`.^W(6E;)T,9.C$X89`D$CG"(F4Q^*D5PV+&X0PJD3<WM00I\%I0
M##P#\DT9T',9:JC<FF-.-S95E>(8U4J97=9+(IC<`;GF'/3(<R*@S=$X+"6&
M24HS+FUS-&>I;W&/`4)SRCR!CX!W7N`Z,3=XKZ"K7ZJE<BIUY="H1$6&XC&1
M^CT@12U!9CV6M9(U-FUR>'E+-*=`]J\.1:H\"YB4*#.@RE0N`4AEI'0$3C$X
MXQ_>C5N[RS)8I$F)/:@W%TE$688JDKL<-1-@YDI62N*_#-8DH'!J$!2B698`
MB5E&G(_&6!(C0GT^JBVC7!E55##;CG"BR4"PY&[M*24O)ZUP76_:!3H`"S)A
M6/>;8I>W`2C``E&EFCSD.<CQD#'Z;UGV_:DKYQDX4+4K9',^.RUM9H;9LGE+
MN[*8G)PMT3?X3&QSTX!X*MD)@CVP3<``(]E$9Z3!'D9!@"0+5I?3Z2):I<;<
M2$SMJ1Q!VK)IL.3V^Y`:@Q2#0>:*GMPGKT?83$GEIY3*%Y)6.)A+FN+.7*1G
MY*)&H.`!(3G7&I4T;X?.'<=>2IE,8&>JXW)ET\R]L<N9X@^K#8]%7)S.D:IL
ML1;%)6G5'HO>(W!8WNOJ3BA%J1GC$!&-?(M'*%DR5543A$UT\?(][F3(F2VU
M,V?W6)*YE4E>.ZHQ3-[!7-JI*S/*V,%*!&J,K\E`++3!.,,P2:!'TJ@O;WC)
ME=TZ:V)'E*-GF2V(X8[AE!B6I(4W6'32U_?6:8+K2;%E;1V&6,T0O#0G8592
MMA-(38:4R9.`_H!?[Q7NA,/?`JUCQ"T<DGMAP.<MC4DN:2C5OEGJ(DL;XA*(
M^QDSST3;(IW$T9V%Z].4F#*"<".<S5G7)G`.*-57H0RQ^*2`#?6D#(;&>I;%
M:6Q_L](WK(2-(53YD`?3!DSQ>UMKLL45_"R%*],J.*?5#:@P>>MP,`C0)(8Z
M=U?B]:L%>$2!"=54]DE5RBK6!TMQ]6,0%U?%UR=5">GG51*Q.*1J0.,)8UZ)
M,TJ\D*G`S)V0F"6&8-`QW0S;19IH-0<RU^K'35L2IJJF%(DJTM,3;9=<())+
M8^P5\ZN<Z0B9X)`TL0>0H&Y6M9$C8%`>G)3%EFE`/`D%_J;M]S*5/$!DY]:2
M:73(;A-7V/.UG.CJY/KI)F-OI\,H<!&2P[)\L.C<B31YM69,]YE)%1:=(,(<
MAX!<E:PW1VMIJJF];S2O&N9!3(T3\O2WVZ/(WHVSY-(YU'W&;-;G8+DVRJ0R
MF1V(Z+&1R=R%3CG#R>!`<$I0(`@+U5:6ZSKW)[>5]9$+GF3*4*N2.ZN3S0]T
MD"IK?8+)&Q2]KQR/*IU4H'>LH^,LT\1AN"VE.5D62@Y`("BM>AVJK(R/D?:J
MT7(D$B31I.XJ"K(M43X6;#I*TS&*.C1)C)P.21Z0QV5,:5P1N;>K3.)"HKS`
M'8$(?B`G&(T[74&E+]-HW'LI9=)F5BC3U(ESL]O;LKCL9/=%C"P^M?')Q/(:
M&M<^+5!1!>0EA/6'&=/$8+.0-$5A?SA<H_KJ-1_]S4[<`E[LRY']]SO68SD7
M@QWAK\R'&>O@\>:CHGQY#C['BSC`>OZO3I_P<`YN[WD7SD>R/C&1>#/=*B.1
M8]OA\6*'NKP9SC['BQC(NG_IX!BY0W\XW6G];+W7/Y&D!X!Z:>`:-MX/Y[;L
M8?Y*=T#K]'BN_L_^G@&T/;KK\U#9[P]?%\WFZ?#TZ]>OWMI+TZ=/;UZ\`Q%[
M*/\`-']N7_5!I']Q39P#,C:;^+%L;_`/;W^CZ0\`U'=G+]\:U/ZN[LU?R=[<
MX!OIX!H^[5V1?/;[Y6/;X?G[P/.,>WP^+.L54>+I^IUSC&.O_HX!Q=[/(_>_
M9YQC(_+SWM=),CQCKX/'AGN#R\BQ_>^+&,BZ=?;]G_AX!O&X!JD[B'[_`+V^
M?\M]R?\`=_[(\`B*K*A@B3LE0J:%H'DR4JNU7#'HQZ5S&9KE8!(]13G%,R)L
MK9`H+20LIP>U)^(^4$#'YQF!^D\0"\@`LW4%GJO.XE>3FQUK$U/4`[57;*.K
M1W?I...DH)/,5>Z<.<B6].8ZMS>]N+PP.9R,)!Y:G.`G=2PA'G`N`;!WZJ-)
MEWHVTM^JIJDDG6R5IC"DVQT:Y:\R:TK-=[8`F`SN4K,3S=4==1:J1-#:I+5E
M)'HDT:`LD6#,<`HT0UUTMJUCC,>D+W`G68U-$:[@LLF4IL(""7NWPVAAY$,/
ML7Q2@LU08G<J@;7!D3N'F$M2MFP8W8)$0,7`+=5Z_=M15)),D6+ZB'*E1,Y;
M)HV??[=4[FL4.+%::.R5,J94]CD>HD*IA>I;EY7*R,K\E`6F*#?\$R(D"4)1
M']'[@D#]93Y+ZDE;\T,D=2225-5PIR_<S&S??0A#,8YG1^9)D+.4I36'+F$Y
M2,)1B]*XKFX\9I6!$@`LJZ]:=0-HBIE&$4KA[?9;)6)$'P[P&Q!&N]7P]$PS
MF*-2X<`9):EC:`#/';/?4:52M08\HER$'`^@"L``M(5)Z)/UA7:ODMAUY*F>
M15U7S?-8*XV&%.P1PA_<MCTPY^[OQ$I)/<)G9JJQIB0<Z*E`G$D*<_RC2^HA
M9`ON?1W1QOFCG7DRCT)?'*\7.>,,\0GO)3Q'&-<XQY/9\V53=(HD.45<YGF*
M82KE:LLA()X>&4DX\0U1?F\`O)\8=3J]D%],DT,C,$;+D8D;M;8IO:1;'7LM
MQ9C3,V1[):HN^3X#9$GR2,4"7*7I2W-;3[X"5ZHP]8H(4C3@1),:>TJ9[':J
ME=JXDPYKA)!ITT2-NL6<LCBV&619R5G;9$R6.HL]BDB24"EE;IS5PV]7EV4(
M<"*+PI*5*4Y@$W2R"ZAW,Y*\R-SKF9+WV,ME/N;>ELKS$\@BJ9\D@4->NS&T
M2@IO?$2E^$Z%"1*"#1J%!)H!8$-/C!8$*W!4V@L*$]2N<,#&]2Y--X4V/+4T
MV1(%$[DL^L&:UDR5RR2I+\>M@GA8ZS*NXP2V9D!V$*,;04/!A)91P^`5!)K7
MV_84V&-,BC4'B0UC#&)#(8?:5K/9[JC:4.4&&HJ7L\QL%U`8E2*W,E.J`?DY
M*H./P6;DWS<>,#L-B;2'7*T*E2M#PGCTN>F-34;!)UERRY_92V^)H'B1QJ-6
MDZRNQG%'('E,0^N":*GOP'%P384'HV\TDL0B\@7V36VE-:3=F9L+:MAD^A#K
M]\]AC2NS`,T@BX&Y%9)I3D@C2N5$*FZ$-"2X)2<0W^GPQH_?JLPL@&1X$$"I
M6M'-.[P1D26U9+6,R9HOY#<0X.%J$IX]'EC\P&J$AQ(FV5HFEG?7F)S,60*0
M>4L5-;D#'C&G&5P"*DM"]NV1+U-D-[C6;N8;+T:M3(VJ_'Y2R_'$RDJ*QFX0
M\-]CY82I#*9&L2.1`/!@Y;G*;P!&6$@.`+DC,+T5?9&S0Z(R.!2QSF5DR:XH
M]"&2WGR91]7842?(O;,E?&&()YD\19D^')1)VJ2B0)$R5&E<',"\!`3%@S#0
M*3:;/I4S/)JYPCC+.9O:UN$,)$5KR4^LD;S;[>3';D<D[<W))DR-48DJLC7M
MJ>W4`#D!KP;'4P3PJE`RRC@-7NV7_P`I1[6G^JKL)^X;8O@$\=AGK]X;=WKU
MZ?6R=Q+P]>O3I]^]7]C_`(/%U_\`3P#J=Q7K];MV!_L]/OH]P?\`XNOS/E/3
M_P!/3KP"-="OXV&M'_8W?_\`]Z]37`/0WP#1C*,CQ_:2*C\.1=,]F.W<&>'K
MTR#YYE;YQ@?3V9#X\!^S[.O3@&0_>WR+':+[C'A\6,_-(N3&?#UZ^',46X']
MC_DY!UZ_\'`,R]4_XKNMO\`=/?Z/([P#%ON[_P`V]M;_`)!M7[MXKP#[[>__
M`(L[C7]8[;?^A77C@&QW@&CSL`Y%\S&Y>O7ICN#[^8#UZ],!^<K-\_:]?U/%
MG/V/U>O`/G>3(_KK^Q5C.1^7B/\`=#R'&>O@\>=;Z_\`'D./[WQY#@/7]7IT
M_P"#@&\7@&N61?SN%/?U<NR7\IG5/@%R:Y?QU.XO_E1J]_)\9N`9[<`<`<`<
M`P3[;G\5!F_APW!_EA7QP#2+IQ5#;;5E]J9&L>7J/.4#@W>8LN+/3)E":8AD
MC%OU5+"$#FV.R)Q:'MD<6&5."-0E4DB#GU`32Q%GE%&!`W0*]<=>:+K*15&O
ML^10.+RB0T%.(LM='-K+50QWUY*ULJ.ILM3LJ9!H7-)B2UM#"E*-U]7[T6KC
MBLA].?DHH"UGOMB4NJ,7G%S^Q&-A5JU4E=F(C$!-9#I8OR>9(Y.8-WABU8C3
MNI8@]6\L\ML2!+S@@DL`LAP!-MQZ;0JZ97+)*ZSJ?QQMGE:12O)/%(R9#\,:
MD^NGF7/U93=D5O42>9!%I1#ED^=@"PVK4[>[I5`$SBF5)R\E&`1/(.VA3<C-
MFBI7+9TG66$.8KY8H2@B(O5O]@QC;&-S![0%K8PL"UC<L[D2M84G+ZIDRDA!
MX09`4H"J`^)+VRZ6F!<B3R&76$H2RM;*%;Z!O/BS0K4!F$RV$F[T2D=$$9*<
MD'C<]E'XLHPLW!I9"='CQ"&6<,\"\F[0:M45D$VPHF$S7393-H+8LE<!)XBD
M2R68060NS^F<ST*.-$DLY3T)TP0M3H/3$F`("8#`#QG&F@4F?]NVJ[$D\WDS
ME.+)81SY[F+V^,T0<(^R1_"R:Q:41EV<T+.9'UZ!MDRCW^E4JW-,60H=C&5'
M[Q]7D2P:L"A/';:J.3I;@1'V/90H[L`U/*6Y8ZB4PL;+*9DXS^<S-VG#.J.B
M2J0P!_-5V*_-B@AB<$"0Q&H!@TH2DD1YH$EV!IE#K=I>O*?EUFV'(6.`,D_C
M[/+3SX>ME3RP6!4=ATB,A]<QQ@QM=E3+`;&4ED+/3!4*E:4A0L&I'D_S@*0J
MUGIF>-3A3399KY\05U=D@V.<E487L""?P:4W3-I]/R#V9Y;FHI9%6]P<7EY1
MI<E>+"UI"H0KL+"#%`#`(;:^WW1\'E3#&':^;'5S>P#%#ZW-CT96B9UF8JZ>
M]69<X.*-"W0)`$9C*X:X1HY:,G`<>%T5XZ!"--A.!<CAI#3<050Z&`NV=PMW
MF0YK&:_CR55#"T2H;C+JKO67QF"QMWC#F@9&(";7P!XV=O"0WHD2UU$C)2X&
MG](!UZ/T2J!@A\>05I?%DRN&U]9L>>8EA5]ZYW*BT]IIN4TW9#(4Z)Z[2.AZ
M"2+XTJ3O#4H/,3-;J4<)O`C\("RP*Q&>V;2L6*@!*.6V*M+K%]KF40W#JMCB
MS+<_0,[7<Y<>;_W<*"J;9D/6&,B6(LXPG2F"6B183>:GPD`[Z[4W7@L_7VBW
M.PI.<^5-4"*MV6+F.;7EQF=9,DPK>P6[,G(1,A:5F=PRNB&U2D<$/NQ4:2B<
M"R/%@(AI@)0,TZA"FIZGI]=+9DLCE3RB5R9$N$*/$.\BS,8A:4(>&Q\.3,12
M,I%[DMMR\H2(E*>`\E./QYP`P)H$.1_MNPB.B+7I+DMD^0@4P-S]^J457^++
MW6,OI"90=T"V)Z]3M8/=*^BT!1A/E>4J(7*?,QD>$XR`/B)=M>GX.D@#2T3Z
M:G&PR1LCT`,A9ZFDN)A&H_3].TLKB$E97ZNE[(L;E3'2D=<,.*5(E>&UX*&<
MC5IRCQ$9`V.EG$G9-P4:6;DDS))V"QA'DH[`0CR4;@.<^69@`PYR'/3/3.,_
MJ\`MJ63>)05*UKIA(&R.I'I];HRT'N:C!`'*0N^30M3*CZXR)0Y.(R!!)*#C
M(S!8Z!QG/3'`*PT.S>_-+6^-*D*UJ>6Y$[-BP`#"P*V]Q3%+$2D)9P"S@!/3
M'!%C`PA%C&?;C&?9P#SS6%_.%RC^NHU'_P!S4[<`G:==BC7>67!=MSQ;:ON-
MT6^[!6C(+DLF+Z\[AR^GZ_<K`DX$A#L^$1.+,Q"7"DU(WITX3#AGGX3IRB\F
M9`6#&`.Q7/8PUY@MU4E><CVH[BMZR77VPT-IUI'-BMOY;<<":IJW-[@U)G@R
M+2EF.3X4X;G100(P@P@[)1H@>/P"$'(&(5#?SC=:?ULO=<_D:0'@'IIX!KHW
MH[9=)[]2VB;`L:SME*@L#7,%EE5A/-9;E<J4F343;3?&6J;$'R5E;%KN(ES;
M(JG3Y"2:1U(,.+'XP&Y#P##ET[!5,/C8XLCWW!.\"\,SP@5M;NT.O<-L]P;'
M5L<$YB1>VN*!6V&I5R!<E.&4<2:`19I8LA%C.,YQP#;EK?0<$U8H.H=<*O$^
M"KNDH!&ZVA8I*XEN[_F.15N):VO+PYDI$!2YP]*0'S#0D%!$+VX#C['`.EM-
M_%BV-_@'M[_1](>`:CNSE^^-:G]7=V:OY.]N<`WT\`TO6MV.]?+,O>[-A&3:
M/N&T3,=@IBDGEFL6N&W4LIB"O,H0QYIBZ9SS&(JSE%&*"F9E(*P8H-4&A"'P
MX%@/0.`*)$^P_KLQ6I2=L2_;'N1WBY4!;\(O2NXE?^Y4QMRO$=D5ZX"<(R^K
M8C*690B./2Y..($84(@_*92<5@P(31XR!N\X!JD[B/[_`)V^?\M]R?\`=_[(
M\`IM:_S$4!_JDHK_`".4'`,3=>M;8;L)M"U@EKG(FXAI[,&@4!<2&50APCD$
M"N5RVM9K`C3HF<4#@40H<2(N@-0N*;R'%M/39$0;@)AH!@9ZPO4[7JE+X@DB
M67#)U$S9960GKZ$2T,++;?/F#;LLZQ6)M:A-#6]U=UB9KF\N4$&Y7'.(RVDL
M9YF<`,\\"[93H%7$C-E!C_9MD&,C].[=E;6RJS8)A#%V_8IGL1AN.!HG(<-+
M>WZ+RY=;KXM;RGA6XGL2Y66!O,)3@$F-`MYQ[9E-+DKJ@*F$^0(W0$G3^61B
M'G'I$4ID.SLB6)2UJV*JEBG"<[:Z0DEF*!FFC)2(/-$8,M0-2!4!=OZIHN_)
M+')L2;,+O%'UUF;:ZC!"BVEL<G-W"YNICFVFQ?#<\M*AN-5(!)5@32@IU8C`
M]%)1!Y0')0NI6N%42U?'JLL%4YNJ&H)0S%PA<X0Z2&M-:W".O(TW/JY"I8CE
MSLV"-UW)2-QSAZA(J$2N`:$_'0)0%':>VQ4B1.GRV679YB`MG3L:!`)TCCPP
MH63##L'"EC`U)'=A=32HK\![*2!G0-AB@Y(T$)V_*0)?I<A,`MQOT(HIS6M%
M8Q&_+21NFNUB%W96S(R/<#/E5(K9]]\TR-)!OQL)/D4RB&96_2A8@1RI2^$F
M!\]";YJ0!I(P)9V!U<IFXK6:SI_8[TQ3JQX$?#F",(1Q0LQ_9X#76Q4&>G-G
M1NT?<E1RUKCVW+VH4BP9DHH\MO%@&`%G`4`?MO:L4E,977+5/K#D;2[2:-5O
M5,4CA3FQMJB;%T6YR6W2TS:;[G$YA?%342X'.!B,XD9:!.(Q/Y!@,F\`L*K=
M'*>4GUE-HI=$QEXZJDC<RO;PVLU.-!%@2JA+.D04">=DP^L8^B!)XC)BG-H>
M5*`I`M<32<Y5&".)`+`$FK-%JW52P<O#+9P2X)K,.LQA!D]A4885+ML3#=I9
M9&BE![(-6YQN26]"$BC`%@SU+:WF')$)R<L>,A`L^V=7JIG]D6;"5]]3Z,/=
M_.#)8;E6C237#F%O<6N'Q^`R5S97%^KU\E#,QV)!:O1)E+6H<_0'*&=0L1DA
M/+4""!;ZCMAU&K;'!J.L&RP)7.+/,66)TAD02-APGZNW*LW67>X`184?13US
MCKECUKFB2I,N1R1,:K+/.+,-.`N>R='07!>%HV9+ILJCK2^(Z?<:S40DEGQ,
M(Q/*YA]MPM?*'55(8NYHC4A[#:ZQ(2@"-0G/*,&,S!1F`]0+9@O;UAL90S*#
MN<B7)XRMC%2PF&KVMX0G2>21NI)VDM1+))['3HBU0LJ8))(I#'0J4"1089%4
M*,LY1YN0%I@*@R]N&I&F11R1L\_F0U46=&LM<V+6>JI)'WYD0+I*[N45D4>D
M5?O+3C+FXR4E4%P(*3/+<<WIQHU1&!J<*`*A`]2Z/U0EE86,9:TG9S8^A:JF
M8$LG-B!37+,K*K@57M;"I+1Q9(M.?W%NJ%K7`&D,)/.7$G!QU).R1@"OU+I5
M4\1<*BL2&36:NI<",ACM!UCB8S'X<X'%H-?43KV*/9AC"F7NB)DCVS$A&%P.
MR!Y5#"B]2H,PG$$T#59ME_\`*4>UI_JJ["?N&V+X!-JSL$ZY$3"SY;!-ONYK
M3!%M6K85S2J%TCNM-*NKTN>6?)5TKESFTQ"+LJ1M0^N=%XNF<X,.R4``1F#R
M'&>`2#1W9,U\I38^EMI%^RN_=]V3K\LF[A5B/9O:Z4W=$(TML2$/%?2M2C8)
M2T"RD.<XX\C`,28\C(S"21#\>"@AX!CIH5_&PUH_[&[_`/\`[UZFN`>AO@&K
MS<KM.T7NI>T,V1E-S[<T;;T&JE72S5+-6+_>:+<EM>+I8HFRUB>7".M2AV<$
MJN0G`/-*RI"09E,1D1>1$@%@#%"8?V>S7RPXL_0:?[U]VN=0F5-:MDE$.F._
MEAR:+21E7E9)7,[_`!]Z9UK2\-:TD60&IU!1A1@<]!!SC@&\B"PYHKR$0ZOX
M_E7E@@T5CT.9,KS\*EV6B,M"-E;<K56"RL*5?HD0/,,P$/C'USTQUZ<`P)[N
M_P#-O;6_Y!M7[MXKP#[[>_\`XL[C7]8[;?\`H5UXX!L=X!HD*_L_^N+,\S9R
MK[<7N?T\U3RP9Q9KM!Z;W=FU:U^BEEB21PE<I6,T1C+*C:V\+@\N9I@LX"(T
M7L\8QBZBR!+.OG9<H#7_`&4J;:LW8[?&_+1I!#8;?6A>T&TTFO&+Q@FTHBKA
M,T$V,TI:,FMYKNR*0>9E,H(P8:F(&9@?D@Q@#<%P#7+(OYW"GOZN79+^4SJG
MP"Y-<OXZG<7_`,J-7OY/C-P#/;@#@#@#@&"?;<_BH,W\.&X/\L*^.`:$M>*6
M=+YD/:TA+:^IV$M#">\C*WK*I2_)2'Q@9]_*K1N,9.''5[<M&2["=R\C`88)
M.(!.?&`6?#C@&W-H[?=O((XCC"R[4#BV$)T0U"9<?.W5,J=PR+2"6N;T:0]/
M[D`YQ7R?6.5N.#3?,&6LG1P\9]BOU8%!DO;MN67UZY0I\O)D%(Y!'KDBTTD*
ME58TH8;(;9Y6Q59MLLD==3.3OS?&)PZ$H$#FXJHPM9243B6IP`*\E>I+$!=4
MHT"M>9'8&^70CPB&_2Q8ZL;<IG;<RRN/R9=,7J,L<A2H)`C#XJ4+E08W&QD8
M"6ICB8/JBPGA*`4!WQ:H[`0JA=O6YQGZBWK6L77N60&L)"RRFQ&&7O+ZH@LA
MS&6]\(?IV"#L;O&)L^&(VA];BT#@8U9(RL4!,(X!%<ST(N5N"N=VJ:R!V@)B
M*PU)=05C*I.VV(Q??/9[<;_@NNYA/["88JF88)-)\Q2IM-7'MY:=<RJ,93G!
MPVE)0)!M70"T;06GOJJY6XN3KZP:(P[NY2B?LQ!MB&5+LW'9E,T3+'I4D;&E
M&]VY=T<E!",@.,I?@U$3@>1E)#4P%.E/;\NR7&298[WDB/D*N0VJYL\L`^7"
MF7.14F8)L74CU(XZ1.\1)NEU./\`,4X"%#2D3`<$C"A-'Y9A:<E&!,FO>H<X
MIF>QN1FV''E$'966WF%QB32D7J&>1H;`MN<V/&7)(@=<#%#9.SE3'T[FK0+C
M$;T``2ST61IT:H@"BZS:4651SM3PGRVF]RC]21Z-L:-IBR:1M1#@R,5*GU`M
MKL]N6NRAK,@+])4Z2PA^8`:U-+/.+#D9&0F\`@EE[9]NQ-`6=!;IB,#ES1'"
MHBPRF.-$V3^?&VE@V32HVF0-B>3H0*V^526WV%>\%%G`-*]QF92'`/$F.)`G
M2S=()=/(#0,?:)@P1&0TO'+$](K*>;.D!+)-IHNB[NRND2DC_*5LT,;84N9C
MRD85ZHS/IA$@+*(*+"0`"PY+H%>KNW$GMNR(6Z8MI3SA#)U+?)%X7*2?>SOV
MOTMHN2#WZ0:TSVP4MNM:658;5!!(T$>!E&86>,H:8"TP]N6ZE#5*6)3;4-:V
M*0BGC]'V6*.%Q1A#5[[/[\GUIRB+1@B/S9G;I)!93%IT!$L$Z),JT[FUE*4X
M0A,)"A`R::]3[&CL1O2)QBTRFQIGMCP.:5VRN6'9^+C4<ADZ;Y._5D_R<0VN
M3.5?63&FH,?4(C!K53(W+59296H1^C0HP*!!M*YW#&;8=(WW":URNY=?HU3T
M5LI`G=ULTKUUCKY?;TR.(%S@XA4O+)!D=PM[2R`RH)7`;H\5DP\)IN!$@1!.
M-`]@GXN3IXM?S;%FN:IGE2>P!7V2-NK18I3WD2UQNM#VV1M1X(B4HNGU8\J`
ME'DG-))9``DY(`C`R`L'4&6R+%+L\'M);7L0K>(M,?7,K4JD)ZIKD#79%:V`
M9.H@YJ',U4K>G9JAKK&UA+J(\LYHD!WB%D&%"5:!C,R]NN]`>C7RNZX^^OZ.
MLEM5HGYL5SIMD;(VY@>I44(D[`_OZJ8I2WMY>]9E3L[(ES:X-+B*2J$ZPA:7
ME2)6!TWKMT;#&-JAHCEY5ZQ97RVQ9HZR1B8;#B+RZOEDQIF8WTXY`RS)0WHT
M1PQK_`00,!I19"3&5!H<B+)`N,?;VN8M]C18+@B+K`X]8K-8##&9"GL!P65V
MM8I.KDRPVOW(R2F^6NG^7U6G=QJ@Y]-Z)&:ESU$>7D"P)AI!LU6\832*&SM;
M:,Q/!%(]*6]O?91XI`TMB?59&6X/K=+YXW-KXPM1U'RI0>@`8(\X4X/&`!A@
M%&5(&'L9CKM$-K(O$WY&I0/47[M>C\=<T:V3+)HN)5LG946MIF5\O<2RW"2N
M!V$V#%"T_&33SQC$(0LY\0@/3MP!P#S+4-_.-UI_6R]US^1I`>`>FG@#@#@#
M@$#[3?Q8MC?X![>_T?2'@&H[LY?OC6I_5W=FK^3O;G`-]/`'`'`'`-4G<1_?
M\[?/^6^Y/^[_`-D>`4VM?YB*`_U245_D<H.`8%5]K1*=D-EH@CC,Y+A(XCV>
M^WMD1HETM0F*'J4/FT!46>R115X9Q"40]R8!JBLG"&(!IH1$Y`+`A9`V#N6@
M=R+$)#8TWX1%RV=80="G)$3+WI7`/=JW=T$=6QM*[2'!)3A'([M!&FXD0#"!
MF)H8`O)@0C2^D`Z;GH+:3X7$!FV'"F[++][N02J`GN-DS^O7&60S8F-WYX8M
M]\%Z>IM!&U2M95B,(DKD)O.2+2TPVH($"0TL#J./;RNAS(9#UNPYZUZ8XVG;
M?7#6SY$E=K`8"(VF:KX5H$<EP6ELJ7FL!:Q])#DU"%:G)&GSG(CA#`G&)Z?3
M;-*6=5UC60E?9)8$_8I`OGK<9*WD<C:XB\,1[2_/L7L1[F$9CLQE#''R"'M.
MRIDS48JP-0``AF9\($L5-KDHJNRDTF2OZ)TBC=K14M!H6XYO`F?#%E:RBPGU
M3(%IB`E&RX2/*:;`+P22G+$68G$+.<X'C`0(`UDTGLBCG>HS'>W&USCE4-C2
MV-[7%4TB:BE[&U5,]56LKQ2WK'=2U&P:02(Y%/S_`#`#5IY:48`&3",@-"!!
M[?VT[9C"4Q9"+LB==R=I95T:CTOC;3,DQH(V4FV\5)D;^W%29`2L3/LAV!CZ
MUU*`>7D&8V8),<6<-*<F`FVR](I;/*[H6/-LPC<1D=0,EFGI52=ZL]^1LTYG
MRIF=V1RATCD$I630;7"71"=A$6M5"P%-@DHDI.24`@L"QY-H'>STWE'MVR7N
MV8MP7W*&4GM\D7^\)(.LMC:^0VHXM_OU.-JL&<);J:4LG]VGIR1M\;+]&86<
M82)*!:6.W-=I[-,F$ZW8:SL\H26<[1MHB:^XHPAJB3V7==E6._L46)C\V9D$
MFA,@CEB%I5F71+ZM.Y,Y*I*$'C(P@`R8;=2[%CT3OZ)Q*UL,318DR@LFK9I6
M^]I`&(LT-F1<A>J_>)*::V2=?7UC1M"2PJ6\PY8I9$"E:!&L,2"1($(%&@VE
MLZAK;L84W6Z)FE%U4,TU+$K#;$SLNF%8N35*=A9(PJ$:]R<`*7B/5VANAM9V
M$`CR%H&^-DY&<`9H?)`B27Z$[`/!K_B,7VV1AIF);DK51L"ZR!M=;J1E7,6W
M1JLSF^1-AP(F)3<(U1OJ0%'$'-I19`,$Y(`D`G&=Z>2]^::0C4)M5=7\9K2$
MIHTZM[4KD1RI%*")_5T\%9<1<U+H<N4R4Q/!W=B,)=1J"3VN2J,#'X,'IE@&
M-C5VZKU\2)PE%UQYZ?D%;+:N0/K:KG;=(6-L^!=58JFE#"^2!5,48'UY>M;#
MW5W0KVUP:'',B4IEA*PO*@2H#JO7;IV&,;CF>-WC7K#A9+;,F;K(V)BL2)/3
MN]V='DK.]G'H669'H$2,9JY;D!!!@32@)$>!*#0YR60!<1W;VN<+]'2R[AB+
MI`X_82"?1Z-2!-8"];7"YJD#X_J3*_<AR8SRUD]^*E!+N-5C.4WNY&8ES]N<
M7@"Q9=I'LS6T6!(H9.EEI3)47$X_)6]O?)/D;^UM9^K@"W!^;IA/&YL?&%I^
M\K*33V\!F3S_`(V4""`T85'J0,(+$CCQ#^_AV9(E($2EN>HMHU;L=<DBV4+9
MLO+5,E7;`M@QN,N<2RE\C<E'IL&*5AV,F'GC$(0AYSX\@>H_@#@'GDT*_C8:
MT?\`8W?_`/\`>O4UP#T-\`<`<`<`UO\`=W_FWMK?\@VK]V\5X!]]O?\`\6=Q
MK^L=MO\`T*Z\<`V.\`<`<`<`URR+^=PI[^KEV2_E,ZI\`N37+^.IW%_\J-7O
MY/C-P#/;@#@#@#@&"?;<_BH,W\.&X/\`+"OC@&AK6\=T%R+M="H]K<WI[%`>
M\JGFK;&GF%Q^>&UJNW]JAN?EU<N]CXS`D\P87U6U.6"W7("%3<C6$`%YYA01
M`;<YC$^Y>ZC7E,LR/9BA.%D)'`R/+J<"<KPE17L933W#%<ACZ@#>S*F]1!$T
MG3K49"H;X0<:D+`B]68>!1&JK-]OB9O=%BR1MR]RF<R3RN;A?J/>Y*TUW,-B
MZ3EAC'`71];WIT88VVTJEDR(EKP#RB'!$1D!8S0I%`@(TBEK]P>0/DAKXTV=
M.ED0B(UJT3EA:(_3#2C<URR.4`.TG2*2"0N;*W-LTCZ\,W/CZU0)-%I,:Y!*
M]0F"A29R!+Y-?]Q(<UBAL@F\YD,,;[9B#M(`))%2,55.$%BUDUJ`O(4D6;&,
M?DR*$.$G6/[<(X92H*0DA.$)F""3@)LN)@W41N]Y9K1\4R.+.ZZMG6F"F=WK
MQDE,?^)QLD=M.,N)<M94;8KCU<AAQDA0FFKRG)T#+E:(I06)N2]0,:89`.XO
M"S7)TCT?0-3[:LTBTUGX37^J#X^VS;*?3!MG$G?DF%JE7\/O,;BEE(<I&+)I
M^1^2864288D48`R!C<=W4?::J9-(Y)/8?9#S>\9<[BP)701S_#JE$PJRILQ1
M=S:D$HB3O%_C`@*AK.R$^1B;%(`F!3C!E,2!@FM:MMYZF^:<_(9*@71Z#U7A
MSBD/CE.QF%IGI`OJV;+5X78C+<G;&^)',SHN0NS,E,:5SNL*9Q@")&(`P,EX
M9#^XHPR3+H\.TDD6#9S4AJU#(I=6!L;?*YC:V6QR8M^#V12D/@DO61\+<_*E
M2%E<$3TM%A(,A.(X:AN`VGLBY<YLS2XN;,LCCDO;4*U?'W%2V+%[&M5)BCE3
M0N5LJUS9U2MM/&(DPQ(I/3#&#.2S!@S@60*IP!P!P!P!P!P!P!P!P!P!P#SJ
MV%_.%RC^NHU'_P!S4[<`]%7`'`/,M0W\XW6G];+W7/Y&D!X!Z:>`.`.`.`0/
MM-_%BV-_@'M[_1](>`:CNSE^^-:G]7=V:OY.]N<`WT\`<`<`<`U2=Q']_P`[
M?/\`EON3_N_]D>`4VM?YB*`_U245_D<H.`8>4!B_Q[BU4FIU$O4Q);VH.VND
MLU='GF"L\DC:[$JVB7UY)%H)^E6-[Y61)K>\H9,A;"S'\93@D-0EF")'X`,R
M4<:[G"A5$G!SE!Z-.G:HFZ21A;%U->$ZP4;]KH78[<<M6M2DY95+XB2V$HCQ
M*<Q*Z$)3P%JA$F90$D`6`VU/W'V"+)PQMRD+;-053&T+]*W"04$]2Z;67"*L
MV"*;2Y3+7=H=')\BKI;RV&&EX4""82U*E1>/2ARJ+P!VH5:.[EMRB7H8<Z66
M0P(+C<(O(#TT4I5A<H9$4$IMP+!,8P3.W$G(A!)^%$DAC;T7[P"TH1KV\I:>
ML4)L@2U3<)WV3W#4;U<DEESQ`&QS=W"<(BI75*1M+6/\%L1K&G7L\20LQ[_$
M6)W;(Z-&1X5"PAQ<#%`<F%8/RG`[=FL?<.9([*45?NQDS?D=U2G%>O3<]50V
M^MIT9#Q/X>NGK1*F=@3#7(722%P8Y.@5`/,31U*ZG!486J@8`B1F@/<5J:/F
M1"H(LC+CZ1WL"7,K4XRBJ!,J5.^O>V\A5Q$Y2M5G/Y;_`"1X?J\5-QH<F-J$
MX0L*#RB"UQ&0)OM2O=Q)95%;QF-2:8GKCZ<V+!9:*7)]=Q/$FG3K%2OO$PFR
MV\31*((Y->5ZH]M=L,9AB!1@&1*U1Q0\G#`Q*<R=L]@YH\0QK76$A74E;(W6
M.B;6FI(>S0U9#FFXXTWR%J6O85CBD=QXD[&T(T"Q`<VO+6D5/*?Q`4="P-C&
MIR+8F/MDP:-A&J4.$@?IM*9FEEKE+(4_1UN;7)!"QML-CS>QNPWAG;$JQ:XE
MIDV4?IDWN\_]=R`U*(\#,#@#@#@#@#@#@#@#@#@'G!VR_P#E*/:T_P!5783]
MPVQ?`/1]P!P#SR:%?QL-:/\`L;O_`/\`O7J:X!Z&^`.`.`.`:W^[O_-O;6_Y
M!M7[MXKP#[[>_P#XL[C7]8[;?^A77C@&QW@#@#@#@&N61?SN%/?U<NR7\IG5
M/@%R:Y?QU.XO_E1J]_)\9N`9[<`<`<`<`P3[;G\5!F_APW!_EA7QP#4QVW_W
MX.VA_`1WM?\`>%4;P#TI\`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`
M<`\ZMA?SA<H_KJ-1_P#<U.W`/15P!P#S+4-_.-UI_6R]US^1I`>`>FG@#@#@
M#@$#[3?Q8MC?X![>_P!'TAX!J.[.7[XUJ?U=W9J_D[VYP#?3P!P!P!P#5)W$
M?W_.WS_EON3_`+O_`&1X!3:U_F(H#_5)17^1R@X!:.@/\:91_5#=K7]U>X_`
M-S?`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`/.#ME_\I1[6G^JKL)^X;8O
M@'H^X`X!YY-"OXV&M'_8W?\`_P#>O4UP#T-\`<`<`<`UO]W?^;>VM_R#:OW;
MQ7@'WV]__%G<:_K';;_T*Z\<`V.\`<`<`<`URR+^=PI[^KEV2_E,ZI\`N37+
M^.IW%_\`*C5[^3XS<`SVX`X`X`X!H<TLL[>)%7V*RJ"-Z*O#<HM3<J9PEELN
M^KJC-MN,!;-S+>8W64R&&Q>A)<U-J1+)W<"3S$S@I3B$87C`_'D0``:J-0+8
MW`J^;]O.2*8[I<S)C:T[L48@"R:7#>C:@=ULNWZI%KD[2^&,E$OZI%(#[".1
M((PF2$K<.J0\T2@:55@A.8!Z$(M97<WG,;8YC#('VVY5$Y,UHWN.R2/;-[#.
M[&^-#@2!2A<VIS0ZQ'HUR%60/`RS"QB"(.?9G@%?^(.Z[^"/MZ?2*V1_1=X!
MPJ)1W5TJ<]4HJ?MYE)TQ)IYYHMB=DLA+))`(PT>>FKF<]``#G/LQUX!;\6M+
MN9S:/165Q.!=N%]CTXC;=,(BZ(-DMCC$\AB[NA;W-N?6O`M70&J6Y4@=DQN#
M,!Z8"H+Z],BQU`N;X@[KOX(^WI](K9']%W@#X@[KOX(^WI](K9']%W@#X@[K
MOX(^WI](K9']%W@#X@[KOX(^WI](K9']%W@%I,MN=RN1R*2Q)B@W;@=I'#TK
M`MDS2AV2V//5,R24`<S(^H5^#5S)>"G4+,K\K(1"QG*<>,],ASC@%V_$'==_
M!'V]/I%;(_HN\`?$'==_!'V]/I%;(_HN\`^12+NN`"(0JC[>OA"'(L]-B=DL
MYZ8QUSTQC5S.<YZ8_4]O`+>B%G=SB?16-SB&UYVYY%$I>QM<EC+^V[';(FM[
MTPO2,EP:G1";G5L.3$BY$H`86+.,=0BQ[.`7'\0=UW\$?;T^D5LC^B[P#I$S
M/NEJ,(<D5GVYCL.:<2MMR3LIL29AQ2@+*-&I0Y!K`+U:<)1X!9&7X@X",.>O
M3..`=WX@[KOX(^WI](K9']%W@#X@[KOX(^WI](K9']%W@$'*=M]XD;[.HPJ(
M[8J>1UH<QD39C-V:V1`Z,@Y(>X)&40D6=6<*'`E<M:%B?!B4)Y9:A$I*&()B
M<X(`.*3[>[N0UND#M(P]L)`W1;W5[\5@V<V07EI,/8R"FX9.&W5E8-P+,,5%
MX,$FP<$C(\>;D'7@$NQRPNZ#+H\PRR,UOVZ7N-R=F:Y#'WIOV.V0/0.[&](2
M')I=$1V-7,8.2+T"DLTL6/[X`\9X!6?B#NN_@C[>GTBMD?T7>`:(YP\;]YWG
MD1BRN].02_/=PUC./2$7)=QD>Q9`>TZYDQ]M+<AT62XBA)]=^)2I792!7%/G
M1,!(:E_PK`&\8Z?=T!.:80?7O;>(.*%D!I)VS>PI1I8\?9`86/6,(P"Q_<SC
M&>`?I,^[H*DTLA/7G;?//-%X"B2=FMA333!9]N`EE@UC$,8L]/L8QUX!H!I=
MWWO#OI7QC37^H9LRQW-NY::B1K[?NE/&QSTW4Z%`G:!2YIZ15.1420QW!1C4
ML"C&L5K<B+/3)BL8-$!Z$_B#NN_@C[>GTBMD?T7>`=)9,NZ8W^7Z^LNW.A\W
MQ8*]9LIL4F\WP>'Q^7YVL`/'X/%CKTZ].N.`=+[XG<[^X+MM?2>V"_1DX!5B
M9-W5U!19Y%4=O`\DT&!E'$[&['&%&`%CJ$99@-7A`&`6/L9QG.,\`AW8Y^[H
MX]>;Y`_53H&G8Q4Q:(7D]KV!V)6.9+5F#ON'`UN2*M9T"92N+2>/)19AY(!F
M8Q@0PXSD6`-8':I>>X,3/+(S7-<Z9.*S.B/:?+7@F5T7BR)P1$FBK1#7:Q,:
MRT-(3#9&XM`E`GE,(!:5$>$H"8]4$0QA`W2_$'==_!'V]/I%;(_HN\`I1\][
MH28T9"FO.V^G/*SX3"3]FMA2C2Q=,9\(RS-8@C!GIG&>F<?8X!^%3_N@'FED
MD5[VWCCC1A+***V;V$,-,,%GH$!98-8\C&,6?L8QC.<\`JWQ!W7?P1]O3Z16
MR/Z+O`-:V]+WW'S+LT;%,:RT>1NI<SVLS$R8]>5^.3>L4#T@V`+D8)$I<->V
MA2VI4\4$L-2"3%*C#G`!!0\%$C,/+`CNI[<WI?>TDCKJ-1/1=TC4&[7L$S(R
MLW=L`&Q&6OGW4U,>Q+'9F*UU,B9,V6Q4K"@;<4\&$%*LX!E1@K(31`6%K??^
MW],;!-[C)F_0.&KWWM>=OA*V*+$ON^8Y'U5?195M]*6MW$\)=?G4"62-S"A>
M5\C).++;FIM0E*"UAP/5B(`W3$R;NKJ"2E">J.W@>0>6`X@\G8W8XTDXDT.!
MEFE&`U>$`PLP`L9"+&<XSC/7'`.3X@[KOX(^WI](K9']%W@%LS.TNYK7D3D4
MZFU?=N:-1")-"U^DD@<]C=DBFYF9FT@2E>XK30ZM#R6E2)P9&,73/A#C.>`7
M`&4]U42@U(&JNW<)6220I.2AV.V-RH*3J1J"DQYI.-7O,+)4&)#0@%G&`C$4
M/&,YR'/0#F^(.Z[^"/MZ?2*V1_1=X!9$@NCN214:D$AA';C:0(FEY>EJE5L9
MLKA`B0,"IA0NGK7$&K`T"1<4KDZ`LM(88%6H$I#Y)9G07A`K+18W=!?(X@EJ
M"LNWE\/.362])G%=L'LTTA"V'$84A4K$[MJLB5MW@)SU,`H+*,*Z9P,(<XSC
M`'%%K/[G$V;%#S$Z\[=#ZUI'Z4Q=2M0[&;)C)(D,)DKM#I8T&9'JT`05K#*&
M)8A4!Z?:*$XP_J<`N/X@[KOX(^WI](K9']%W@#X@[KOX(^WI](K9']%W@%&2
M6!W1USV\1U-5G;X,=V%*TK'5,*_MG2BTZ=\PORV#`L.U5+0J\J,-AWB"288(
MKP8\S`?$'Q`5,B4]U54`1J6JNW<I*"<H3B,(V.V-.`%0C4&I%9`AEZO"#@Y*
MJ(&48'^^`8`018QG&<<`YOB#NN_@C[>GTBMD?T7>`<)$I[JJH`C$U5=NY06`
MY0G$81L=L:<`*A(H-2*R!"+U>$'!R542,HP/]\`P`@YQC.,XX!$LBV>WZB:B
M4II$P]MEK'"5<9;I2:?L5LZ)&SNLQ>FN.1IF4+R=4C4)CXZOKXA2@0EF#5@.
M7)@C+#Z@GQ@6VJW0W+1`2'+%O:U2I5;0^/\`ZY1M-L22VH&:+R[,`E+D^.9F
MKH4$=2Q6<!RT.@EYB;W:XARG4^4;C(<`7\CO[N'N$O%`D4;[:2F78<W)C"S%
M;,[&"./D#,U@?'F-I%'S7?1+),SL8_6JVTHT:Y,CP(\PH)01#P!(WQ!W7?P1
M]O3Z16R/Z+O`-!^S3OOP/^T!=M]2_P!>Z?)[G*UKO4,'96BXKJ65FN8A0V^<
M.Q\KE"RC$,H:78E*)8),2C9UI)I@"0F&`",8BP-[)E@]SXH8RC:_[;I9A8Q%
MF%F;.;"`&6,&<A&`8!:QX$$818Z9QGVXSP#D33ONAK#@)TM==N%2>9U\!*;9
MG88\X?A#D8O`47K$(8O"`.<YZ8^QC@&D?2YYW\!LOKX.)USIBJ?PM/?`PRD/
MES7JWM9Y:CN:U,=:N7-8BHMU5)1L\Y"G31S!1!V'%F&:H6^B5!`F$!O+^(.Z
M[^"/MZ?2*V1_1=X!T%<V[I+>,):^M>W*B,&'Q@+5[+;$)AC!UR'QA"=K"`0@
M^+'3KCV=>`=3[XO<[^X+MM?2>V"_1DX!6`R/NMC"$8*E[>0P##@01!V+V0$$
M018ZA$$6-7<X$$6,]<9Q]G@&!G=`>^Y.=H1LJ58U8Z--L*'"VW$@6PV];]>Y
M.G2?%\;R6-G:WK7:/-:Q3ZG!>/"<L(!X,YSXLYQC&0/K1]\[DY<GWRS#:QT:
M6GF;Z6:9,PR.];];"44TS4=%!<4<:&VZ[O!CI&@-@48RE2K"-2-0,X&4X```
M,P#//X@[KOX(^WI](K9']%W@%''87<]+&(L=?]MP`P"$`8![.[!A&`8<Y"((
M@YUCQD(@BQTSC/MQG@'*FG?=$6'!3I*Y[<*I0/`L@(3;,;#'G#P`.1#R$HK6
M(0Q8"''7/3'LQP"I_$'==_!'V]/I%;(_HN\`P-?GSN5Y[GM4G'5AHP&P0Z%[
M`%M[>5>U_CB)L.%L)K0)X6+GD>NH'<B1$/0$($J8M`8F-3&*!F'EC+*+,`RX
MT3570LV<[A9]_,E7QZR<S?7`*]LIZ42R8P@MJ#03'[H.3/LUA\%?CG(XG(O4
MEB;BRB\X#@`Q]<YP!M%X`X`X`X!IO[:.MRY$>U[0!M68+TBQZWNK956+H@B2
MA@1"D.\$M=V]6QO26-HI2D:&8N`&Y"A4K58<JG`PT`RPY,+,`U@ZV5,JN>4=
MJB)II&EBX&9O[I%E+7`\YT2J%;?5?=5ULGRQB:E[*Y-+DU.[^4Q>E(6%'X$D
M$9DW`1Y!@&0-OCUVUD;>?,T-23)KJB(OSDK9HW&F!#),$0VNCM<8I3,92LYP
M9(`::9U78D?53I@7$^4#+NZ*LGA]69[P"!%D)[==OO3-)'Q[M!WK9ZE\CN]G
MDT./<G61)I0PR*>;-D5K;[\N:I0-,DN&'Q>W6-S8SD(RR4.&),D-P4,M*)K`
MDD_16YQ35J>6+8AG5,L;NE!9QK=(&J1O4O1*TLWJ^9N[.;-6Z3-+BN0SEABS
M@D5(70E:<W$/7ITRPQI`!LP!>4@TEDY,2U91-EG1!G>]=-=6>B7=]<XPN]+.
M$S',=:9DI0"R!_3J&J%V$EU]5,#^@&8H-,99&HP68(97A.`^Y_IS9CS7M"P2
M(72CR?1\C529\6OJ23.DB7EYMB#6BPQ&..".8MQK5'VN+1E;$2"U_J#S&1:3
MXC\%%JDRX#$NJNW+;Z;.O::5KU\6P.G&E]LM2AE[RX%T[>$4(TU+3.,.\J9*
MS'RRYR?3DF-=G8`3VC(UBC(A'^K.]X@3Y&NVFXI(]'(1(;B<\1%/6K'%I1\)
MF2AFD2R2`IJSZJGBQE>E4E7*TK!9$CGZ&;+"U`SU9$H8$YWFG9\@Q&!/-7ZK
MV)#;LB=HS:UF^R4K+636V.1JEMF<9?/OLJVUS06=)F-H99[BO2H+:+F[9>#F
MAQ:7$YI<4Q>$JC(/)$E`Q09^V%8D7;4V83=D4@LK9(VGB$>E49ADG0&_#;/&
MMA&U"S/B!'-T`EK3*)#;;.X/B<E01DSW(/"8THX:90E`R$GFGMDO\'UIB<,G
M\/@_WEGMMDLC(*36>^)5KBBM"M[),:(>\/MC.,E11I0AB3K'QE.*E8=EK=\`
M+&0E*.0*@("C_;.M&%,Z'$-O=F;9(WQ5B9EJI6T6`I9YP:S0?6!C>62:IR+"
M2NAT2L63T`ZKGH*544N\,M4C+.$H+,,5`7$/MT6.ROY,E@MR,;$8E=VI2HC+
MJBL>3QR5PYF2:G)T=2R]5)+$>9&ZP;&-?G_&##U:E9@4L&89D[(5P'`"UH5V
MN9E$6Z#E`N5EP\0AIK=J;GII99DUC2`KADTS:6DQH1"FJM,W!2GZQORE*7G!
MH"#)LIZX'D*G*T"[6KMT6#@^%.LBN%D<9-%'%$K=9&C36D(V9.;3;>N,JQ8#
MFU2*T9&V,DZF5:T8X,CX6VA3M9JF3K#@$Y+,5EK`+O<=#)F*L-3H;'K$A4:D
MNL]'.U+&/S?"W4"&1MQZREE^!-Z0N1%+65HF*>EPM$B29/.$I:)`O"2:`P)>
M1`7I+],IK(*TKRO&NZG9I2Q?%ZIW#`P/1Y3*"XWMS?X4^0%66]D.C7)=8SE1
M"&#FJC3BBFTC)1H2QB`,H"QJ[T*GL?M^`SJ>6RT3F'5S,1/[-%C&Z9IUKBG9
MU^P#E#7%X/4S-8S'R1I66\T&#SA'Z0.8R1Y9>,>1Z8"2K#U>M.S;1766_2NJ
M4+C$Y6UO%.JVR'2LQW01QOC5DP[X3GQBR7#;75"-NM5U<QC;R$9A[SZ89@LD
M)"2L`6%5_;Q%4,44PF'VLO*9VBI+3IJ#.ZQJ/-DS=';VFL&F=GO+\O*=22W"
M2HCX7@A@.(PG"A`?U-P;D&,9`V2M[>B:4"%K;4I*%N;4:9O0(DP,%)T:)&2!
M.E2D%AZ!+)3D%A``./9@.,8X!W.`>=6POYPN4?UU&H_^YJ=N`8JZ1=JOM_;[
M;-=XFSMN];HW=<\A_=3O&OXW(W^4V*T*FJ&(Z]J60I&!.EBDQ8&[*1.]2%:H
M"(9(CO$H%C(\AP`(0.WM[VLM`]"-Q^S?8FHFN,<I.:3;N.Q2#RA^8)18CNH>
M(F*GK6?ALBE-+)A($`4PW=H2GY$`D)OB)QCQ>'(@Y`F"AOYQNM/ZV7NN?R-(
M#P#TT\`\X?=SUJH_;_NI=E?7S8^`HK1IN9L/<><91!'1UD+0V/*V)4I5\DCB
MA4JC+NR.N!-3XWDJ"\`4!#D8.@L9#G.,@5S9'^SV]FZ$Z[7W,XMHW`VB31&E
MK2D\<=B)W<QA[6^L$&?75H<20*+*-(&:B<$A9H<#`(&<A]N,X]G`,XNRH,9G
M:1[<YA@QF&#U"I(0QC%D8Q"S"FS.1"$+.1"SG/\`=X!F-M-_%BV-_@'M[_1]
M(>`:CNSE^^-:G]7=V:OY.]N<`WT\`\HFMO:\T+WY[@W><FNWNNL=NV4P'=2%
MQ*(.[_)[!9S6..+-=:P>5#2E3Q*71]$,@QS4&'>(PL9GB'G'B\.,8P!0=^^T
M]V]-#[@[2-N:DZT1JEK'D/>!TXKUYE3!*[)=5:^%/`+$>G6/'I)3-'YKRC7.
ML=0G#%@C!N!)@X"/`<CP(#UL\`U2=Q']_P`[?/\`EON3_N_]D>`8S:XT=B&=
MHN1W%D;`SJK2[2<&1KV&%)79I:))AEU&PH:9]/6U8YK&ISM<3:OPVJW5&G3&
M*T*8D!XS@%IBTH$:TCKDP[%;?4\AF2QL/@$*[56@"N=PI<>](SK'C-B0/?ZI
M7&)E+F-W:#TS::EF9AJ\LS)Y*Q*`289?A-$,(&;QV@[TV&.1\0MI.W>\)%8<
M\$Q1+#@@=DIBO8P^Y81F"J%4DRD:%7WMRBZM=,'8PW&QH!8"`IR"S$1P%D4Q
MVY[:9H+6RE\N!U@+LLA]4N<UKIM<Y$ZHZWLV)M>ORR42>`25)+!J2Y;/G"HG
M5OE*D"@2=Q(DRPTDS(_5#<P.)[[=-QO#,:Q#V1B0HQBMK3K!-EQCKZK>2&VR
MX7<\3`QR9\;Y2R-L\)C*ZQ6AQ*6*F](X."AGR8O]2N&!P"!D=>VG<AM>Z);8
MD>L:,1LJ9P*N8I*(HH9G0Q<_I81'=DXKGWPZM+\VK1M;4HV#0R)HR`L!J201
M9&/(^A@#4P'0N71^7V0X8>$%HH'!^14735,M<BG[=)WIYP?!IM)7FQYHJPRR
MEF:<R2RXW("R##\I3?*6(2Q&A.*R$!0$.(>VI/P0-YA3M:\(>,/[?+\OJI1#
MY*8ED\GF$JU*F9\ME+>LEJT#V]-;MKN[DD*#A#4B)D.!Y,",M1A2!,*;4]VE
MNJVR]5218O@@;I,M!)"66SS(_+_O.P9XD#_*(]%'M7%)0Y,S]&&V9O[LZH_*
M<O4(6-Q2-PS`B;P!`!%COVZY\%UE+XW6Y$&MDF\ODTILN$";[*8X?-V^6VSL
MI/'#+NX0VRXE)6EZAD=OI`4R.*)8084NB:4PW]:,+PD`K6XFHEZVA.5=HUW*
MV%_:@(*UCQ%9!%(V!SDK,5/((NEY<CE.9RB9E3$@0QX;D$L!!9AR<:E.`HQ2
M8`TX",XKVZ[32S>?A03U?`&^(N\+4U7-@/#^^@F<1S$4@I/0SHP"F1YZ/7I,
MZ8):#$*K!;J:E:$AA1G4'F"`O&6]N6<2@IZ:4]\EX2C8WX#*UKL3);B"/3U$
MMFFJ(99`IIBC,*9*S>+Q93&`)@0J"TD(08\>#L%&I0*.\=KZ2.^9"4*S(BD2
M+UUEF,I2".RYO`B2V'(=T)*I/6I&^8I49SL8Y[2,IJPTL!>%1D)2BSTR,CT8
M%4D_;BM"9()(5);R;':0+EUAFMDX/*M7XA<4TIJ^X8W`%$M;#+1/B9D@IB<V
MR4L9U[6A;SU*"/H,'""I*(-2@3&ITUDYE-(J9:K+C38-KN^_K6=T3:RNC>TR
MV)W^XWFI0MTJ0M[\2[$2"#/-L`>6UQ(."4<]1A*8$LD7ZXG`_#-(9$51US5,
MEL!H6/5I;!UE=HYHY-#NG<UX:]D%(/BX,N4,SPWKW"82X=0FB5.B0Y+Y2ETR
M:`K/D^$P"*T?;QG<=9['94ES0\AAM.LMK:R?#Y##G>0J8<U;9W2;:4A-9U;U
M+!J9NLC`'%802JD:E4K=7%9E0J'Z<`$/`)2K+09-6J&F*]1SQ0X5'0.R4XV;
M@(5I"X^RW&23)HL](7$)?*C%V4SJS,[Q;SLI&X8*PM<$925$:`(0'G*`-B_`
M/.#ME_\`*4>UI_JJ["?N&V+X!BCVPNT'VX-W(WO#=VT^KL6N"U!]T+?>(CF#
MY+;,:UV8Y';M=,,K5A)&9LQM8"&_"TW`,A(P//B^VSG@%[6=VV-(>W[WA>R0
MY:=T&PT<MM:P-YVJPCH_)9X\XE#=%-2GI?'DJXF72N1$%@:UCPI,+R2$L61&
MY\6<],=`,F]"OXV&M'_8W?\`_P#>O4UP#T-\`\RN[FF^M&]'?YH^E]L*J:[E
MJ]H[3-DV(V1![>I6RMZ.:LNV<686R0@.B3]'EYBM(S25>GP$9PB<@4BSD&1!
M`(($9]U;L2]IC7_MN[M793^F<*A%I5=KC9LT@,O;IM;JI=&Y0R1Y4K:7A(F=
M+#7MIYZ%4`(P@/(-*%G'0018ZXX!Z.]5,Y%J]K<(6<B$*A*>R(0LYR(6<UY'
M<YSG.>N<YSG]7@&+7=W_`)M[:W_(-J_=O%>`??;W_P#%G<:_K';;_P!"NO'`
M-CO`/(9VHNSMVUMTZ-OB]MH-5XK;EM.^^&[\?<IH]R^SVU>K:(UL--&UB0C2
M1N<,K464W(`!*!D"<(LAQU%D6>N>`2D^=N;2KM^=['LWAT[H=BH[%LQON,EV
M-B/R2=O0)67"]<XZ;%2UY4OE4B)*PRFR1<(K)`2LBRI%X\BZ`\('JAX!KED7
M\[A3W]7+LE_*9U3X!<FN7\=3N+_Y4:O?R?&;@&>W`'`'`'`,$^VY_%09OX<-
MP?Y85\<`T%4#7DFLV1]IEBB;*D?7!C<>X[8KBE6KF]`61%JQ[ONJD]EZX@UR
M$$D]:GC3`JP0G#]NH-$$OK@(A"P!MU@,$[D[&IB37,)2YR=F<D4<42![%/JT
M32")69B#UX<MD"_!4*]#):1(ET<D")T8$A`74\+Z2H19QY?C2`4A/5_<E?6R
M/K'&>S2.N:Z/M14HCZFPZG$V,\L=Y*-BL;+0ZQ6'IWA7#RHJ<K=8T8-3[T1&
M'IL#P2>G`E3@2#4E.[JL)T05K967&$BR3QAKLAI?7V)OSHY0X>J5&,SI.54B
M8F%4ZRRS8QL)5;FV%#7K3/71R2*C1'Y"D;B2`.=?3.T=GZKMD1MTA2\W&MV,
MULL&0-LB?:RD+#&V.L;FIB866I@ZAK8VIJ<(.X)H.^.K&V/`3W0PMR"B4X3%
M9`D2@1"FU5VFUR?UD9U<`^N$"!(:#3)98^6-"A29_A]:ML";96EF3>_-"?"[
MWG'@R-L0@2B3IF_&4A9*+*<*8UM`S!U%9-JH8W+HYL>J=IH<Z-<(>")FYRB$
MNQS'(D=/5.WV&P^FCC:Q'&M;Y;N),K;O+3#*3)BO:(LLX@H`&;'`'`'`'`'`
M'`'`'`'`'`'`'`'`'`'`/.K87\X7*/ZZC4?_`'-3MP"DUQK?WI=0+[WS>]6:
MR[>ED5#MAN98^T<>=;PN6\XW/FI--([#8NE8W%GA=;+6-)A,@AA1V0A/4#P<
M>9CS1!P#H!VIEKCWG=L]EM")EM;6G;YK>H=2MJV/8I]<*+N2\)-/7<EL@\SA
MAS.@9YM6Z!D5!,(EHCL8$H3BR,H/ZY@/BP("S*&_G&ZT_K9>ZY_(T@/`/33P
M#2WW+-6MZ+$VV[?.WVC3+K?*YCJ`@VN:Y'$MD9Q/(3&GE/L+!(-!4!S<I@,1
MD[FJ.:TC,N.'@0DP0F8)Q^N!$+`0(ALY1_:)+0K6PZT<]>NT^W-MB0:6P5P<
M$6P.S8UB!%+6!P8%2U(`ZJQ$C4I2'`1A>!XR'(@XQGV<`V9=NC7^<:IZ(:D:
MV68ICZRP:.H2MZSF2J)KUCI&E$BB<<1M3F:QN+@VLZU:V#4IQ9)--2IQC!TS
MD`<^S@$L;3?Q8MC?X![>_P!'TAX!J.[.7[XUJ?U=W9J_D[VYP#?3P#SJM6N7
M>2U<V[W\M'4BMM`+(J+;Z_V"Z&95?5PW;%IVRA9JKAM?>[%;/!ZX<F9.`9L;
M,-QC"E0+[?KX^F<!"!0K=UR[V.Y-M:,AV<J_MV5O3^L&]-";;2AZI:Y[WD5@
M.*"I#I&B<&%H:)C6J-B5C7M,K4&`"8<0(2@@H/F@!D>>`>D?@&J3N(_O^=OG
M_+?<G_=_[(\`IM:_S$4!_JDHK_(Y0<`P\UWKN3R7>C6BR8RQIY,&D>VQVZY+
M(F("MK0/BMAFM?\`<*K@"J/*7M0@:3%;6_R-"<H(/5)O,28,&6(9I0"C`,T(
M_K+?]36Y&K5J]@:'$22`#99W`)4Y0YV@CC(6*F9"SP*74T]C"TSFJ)RCFKN3
M'I`WBRHB<@COJ7/RDKOX!J`)KU?@MXZX.THIB5LSW:592.X'^80*WB9"C-41
MIJL.&+;+L<F9,,BD;O*$R$%]@>2V_!*E8$!,E2$$%$HT6?`!$JRAKJ^\H]U4
MGIUN.4';S+]D0K!2Z#EMZ^$@[@[3L,@(1)A*\B'(%=2Y/&84JPE`2L("CP88
M$S!@`+\QJ](K4W#4[%6.R/=>L<3CU!N]?HH]*(P:\/4YJYVVM9G1NF;DS$*G
M@F,JHA<S8H4-Z16%(XG9PG4&G$H\@/`LY3'.X:HM^7N2!4)#6V+9B#O&&)WF
M$'<&9W@[;9-M(Y:B4.[.6SRZ*-SK53C$ES<`M`OR2YMIB!:A6><I=C0+NLF,
M[XBM>1R.#2%$?7S38T:=FR*M[M$D)4TI](_Z].:N'-`']&(Z-V,6F9+$3+EJ
MPXI$N1.Z0`%`3/(RV`6S`JIW8<M>-F&ZX92N?[GF%.)X94L==GVLG^OB)..@
MXPUN+DH1`AI33E0YW9[X,6C=2E:-0W&EXPFP5^M8`AZW*;[BLKBUOP\IS63.
M"VNS6Y%GB)KI]7;.\M[%*WG;)CKM)"70IB0HF)K:(I**O-?B5)IIRM&UKBRQ
MG*<&E+@*3+HOW!FPV$0(N9V1#WZ6S*<P:.G5XZ5<YUNW,L5I*[I-4LTPK<(0
MXOD/CK=(2H>VRA(\J/\`WFY-0BT!"H"PT:X"_EU>]RYS"I7GSMZ;)"WOT_,5
MHF&65.DKR1+F->U'5<^PYO5Q-9+6B"2QJ#X'9E>%GJDRD@XOVEF95*P+<B5-
M[^H+;?9V[I5S`99+W5$?MJ3PBQ*R/>5AM;+;%&CG$);I5'W%J04V<0XIR54?
M5I\R#T3MCRRS%"0S)@$LZ\U?O`Q6W4T@O282J40YHBKZ1,4YMB18Y"7,I/3]
M/$.2YQCL<:V-'(F!KLZ(R,+67Y9I[>)XP<5T(-,P4!%4D9.X56D!<Y,_3>RG
ME0RU5.9>:MCSC6<T4$6B-XL]G*A4@B+=`1/+M#%\7<8:X,2AC!E0TK6QR,7J
M"B1#`L`K$+8-VI<G;K"B2Y_)]\I:MP>.?E5RQ.L@;V"V=E'R5PUXD<>,(F:>
M"-=?SF*)V![`8Z*3U+=ZE0T'^K="U`'1BM2=Q5.P1*$O,WL9G31]AIMI5RUD
MM*K'I?(&O-D0E%?>9*XS*,2*4'V(*,-#Z\1MS3#+29;'<E&IR!8G\C`%#M&E
M.X/8\!D4$E>%TS:9')WMJ>6H=B5BT-GKH=-H(]559L64IXTA>2ZNDD087(M^
MCSB=EY)D*A,80GPF*./.`W3<`<`\X.V7_P`I1[6G^JKL)^X;8O@%!UQUV[Y>
MDBG92!4!5/;;L2J;7W&V9V3B<@M>[K]9)R!IO&R'&6-K6]M<5J\UE1JV]K&0
M$P!)AV`&Y&'S!XQ@>0+]9=9^[SL9W!.WSLGN7`-$:VJC2R2;%2-25KS;5RRZ
M:2,Z[J->*P(3>Z9[7;2UF%-KKE&;G(59`L%"-%U%D(0"`Y-"OXV&M'_8W?\`
M_P#>O4UP#T-\`T7;JZO=QM)W+*OWUT3BNID\)CVD\IU3E$7V9L6S(.$A5*+M
M;K5/?F0JNX5(S5>4Z>/(TX!'*``_7SL9*ZA+'P#'O;JL_P"T(;>ZPWOJ]+*,
M[5L6C5\UC*ZP>Y)'[^V3/?&-NE;8<V*7-I)<:J,0&KT99WC*"<$161XQXL9Q
MUQD#T"TA#7:NJ6J&OGXQ$:^06KX!#7DUN.-4-YCM&(HTLCB8@/.(3''HAK$(
M\E#&66(0,XSD(<YZ8`PO[N_\V]M;_D&U?NWBO`/OM[_^+.XU_6.VW_H5UXX!
ML=X!YF]6=>>^QHY%K5I^CJD[:=@UC)=E-B+LBTDLZ\=@6B;&MMTVI(I\D1/;
M;&:N&RI%3>E=BRA`)&9@.0YQXQ]/%D"5X)K7W:KY[C>B>UFZL!T9K>L-.6;:
ME'A-KE:]QS&8255L/4J*"IPJ&JP*_9FS*=G=F%&/J6J(%@D\X6?,R$`.`>@W
M@&N61?SN%/?U<NR7\IG5/@%R:Y?QU.XO_E1J]_)\9N`9[<`<`<`<`P3[;G\5
M!F_APW!_EA7QP#4QVW_WX.VA_`1WM?\`>%4;P#TI\`<`<`<`<`<`<`<`<`<`
M<`<`<`<`<`<`<`<`<`<`<`\ZMA?SA<H_KJ-1_P#<U.W`/15P!P#S+4-_.-UI
M_6R]US^1I`>`>FG@#@#@#@$#[3?Q8MC?X![>_P!'TAX!J.[.7[XUJ?U=W9J_
MD[VYP#?3P!P!P!P#5)W$?W_.WS_EON3_`+O_`&1X!3:U_F(H#_5)17^1R@X!
MKZ@%W7'5&W=21BDV^)O$MLSM`Z,G(6*31"52PZ3O58IMKY='(6U#B\B8/A;X
MV7*3&Q0]+0JD;4%0!286+!62S0,S)I?6_,JDT4=HG54CB3U6ILXRI9%=66R"
MN[%E^8IL6U-D!D^`R)H1/,??'R`P\+;)"%)K6T*Y&%9XU!0R0<`N-@M_;6NY
M"Z(U-;6HZ,[_`#&?,F9_(H)=%O!@3>\[,;M*(`<.OV1];LR^*IH\RUXV!6-!
M"1<AC4A2+52D38F3"1@3/L?L[LG55L(XY7%#S&QX$1%&=SE3LPU#/Y&I9\.1
M#TO>'V./4>7JV29N47;F$X68T5A,YK%.2$A`CSUR;.`*2'9/:D3PXM`ZO>,(
MVF25Q'U\EQKQ;*-"?7DY8H*X&;"L:5;(QB5%LL@=WII=X`(1LG8_0EKEF2DQ
M)N%(%CM6TV^3NNBD7=M=BH+)G=UB2*7N!E26E,XE"6R3N&H9*MX32)MD32PR
M/W$W6O8YYY92T/I_@P(5."A%*<'@64Q;"[[.B1JESY34A3S`Y:4)'&#ZCN-M
MBT,;I546IKLL1+F5GE36BFQ#=.)9.BRS74:E<VJ&@U.$TC)!X30)EHO;F[IK
M>\4IJRF*(110F0NZ2<%#K^SVAR<7A*U218P`:5BHYRC\*D4@2M"9]]SNJE0'
MX=6DF$*C3SBPX`BR%S/<]@L%4<C8)BZ.EDV2]1MWF=A5_>#]"H=!B]LK]C$?
M=&RM$]A,,#8`M=(H(VN*<49+<<N;%"0]<<H+\H80)DUJOK<Z;V'`FF[:H;XY
M#Y3&S%TA4(*@LB$GQ%\54[54^)1+'V32Z0MWE-,[?I%&QE&IRC%!Z$/VY9Q!
MA9P$#-US[V5U&;$=V&I9A9DX6'6;+D@)S#+1-12A(BL?:5H86^,QE+("FJ"_
M`$.@E?')VM(2E/F:"3%Y3>-5G"D`$W;&2#;P#O1<5B+R]^DD;!6[W-997=.S
M0MH1SMJVPU<+>S7H+=*71WC42)I-]EQSBP.#D$#HUI%H1J.I0L%`7-KA?VT-
MGKW9-<E>-=(`8:A;GET'**OL]J;QS!RA\%>DTV12QY7HH03%D4B<)(WNL5.<
MAR-ORTD#,-*('E2H`L%+M3MNMC-1O0:>;O.F$!F,N?5\3KN>VW&'E_K8HMCD
M,1A[Q74@<6AN(L94@62B".;RYH4+\QJ$B+!N5_F8$!>6NM\[>6:ZV2JGE4IH
MTQP.OWIPB+&ZU38M>O5MS,=CW.R1@EME4Z?4;/'TAL#A477JTN6U28$Z2^/)
MQ)180<`B`C:W?(UN994ST"7+6U;'&B2`A`J.NBOI:N<Y`IL-N55TZN\]=6DB
M(2&"NK"VEK%Y[8>VK"5`%!0\)5)2D(%IU_;.YI$G<71HBUDOB6?6?(RFN3VA
M3=]H&:$067V9KFU%G)JJ=)>PIVINBT0D,F<$@%WA5)LLJO`#RTAB@G($^:H;
M>VW==K@@-E1N+04]MK=M<91&2H99#<]H[).@5,2=UCC?(GKQ1DE3%'Z6REO?
MFE2++BW&MS>`H1^1+AE@;*>`><';+_Y2CVM/]5783]PVQ?`/1]P!P#SR:%?Q
ML-:/^QN__P#[UZFN`>AO@#@#@#@&M_N[_P`V]M;_`)!M7[MXKP#[[>__`(L[
MC7]8[;?^A77C@&QW@#@#@#@&N61?SN%/?U<NR7\IG5/@%R:Y?QU.XO\`Y4:O
M?R?&;@&>W`'`'`'`,$^VY_%09OX<-P?Y85\<`U,=M_\`?@[:'\!'>U_WA5&\
M`]*?`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`/.K87\X7*/ZZC4?
M_<U.W`/15P!P#S+4-_.-UI_6R]US^1I`>`>FG@#@#@#@$#[3?Q8MC?X![>_T
M?2'@&H[LY?OC6I_5W=FK^3O;G`-]/`'`'`'`-4G<1_?\[?/^6^Y/^[_V1X!3
M:U_F(H#_`%245_D<H.`8'4_/72&;UZO-#;+(7`RK![8>B,==YI+(]''A7'&M
MAK#N!STM6PN,@4HL,@#7B*I0..2S0A5(<B*'D`O+-+`S7J?NJDO%=Q=VM2NF
M>,RDE#"&BP'=3.H_`XTSR2R)/!X_5\]41"7KU=CQ:@K59YPF>4,H4)5R-K`$
MQ`I&8H`$9H%]R3N:-[4DDA[%3Q,B/BKZKACPDQ=%<)%+;.&.O;#L>1,CJVHA
MO,@;6@UB@/J&%X&ARVR1`X$+$IF"<X\0%B9[F$G26&O>UE5*U]41^'EE32'Q
MA^99%8[&]XL<V/D3&'I4J0D^R$1T<?V8]T:$_HS69.%8IP:J`2'SP,HZ&W(4
MWW.E$59J^C[/&TE7(;74V(BN2`SZ/FQF3S"PHK!7%C!"#7)(]H7PFO%"U6(:
MY$8V8."0<#S<"Z`1[6NQ]KJI%5T<DLG8GM`^[G6Q1[C)5,8C3<1-JN:=8[(O
M>#R.)O,0G$DBBT&5C,V^)>E%D6$P#D"U*G<4ZH>`);V%NEUCPJ(>*FNNH41L
M]F$84,L)D2F,."6]8*O>(_B5YA\I.E;:H2C0PUS-.9E+22ORL?E;8G$$TI1Y
M!P&(=-;/6#-932TQ?8=6S5)[(MFCJ\E4[!"$B5[6L-J:>RN_935"!]&I(=D[
ME4]B-J9$+)IB@S"+PIU).%>#3N`9E:O6\Y3LVR6^1WE3UR)"K*>T-42"OE49
M;7=XA[1&8@JDJ5WCC!*9,3D47FKLO3)%`1EGGLN4*@\`O.`K5`9>\`<`<`ZZ
MQ&D<$BI`O2IUR%<G/1K42P@I2D6)%)0B5*54F.",E0G4$C$`8!AR$8<YQG&<
M9X!\H$"%K0HVQL1I&YM;DB=`WMZ!.2D0H$*0D"=(C1I$X"R$J1*06$!98`A`
M``<8QC&,8QP#M<`<`<`MY!$8HUOKO*&R,1YNDT@`G*?I$@96U(^O9:0`"TI;
MN[ITQ;@Y`3%EA"7@XP>`8#C&.G3'`+AX!YP=LO\`Y2CVM/\`55V$_<-L7P#T
M?<`<`\\FA7\;#6C_`+&[_P#_`+UZFN`>AO@#@#@#@&M_N[_S;VUO^0;5^[>*
M\`^^WO\`^+.XU_6.VW_H5UXX!L=X`X`X`X!KED7\[A3W]7+LE_*9U3X!<FN7
M\=3N+_Y4:O?R?&;@&>W`'`'`'`/._H2V2VV4DZJVNNXOL-6+[&+GVO>72K89
M$M+%\8A9JC:6T'4^*Q<-EZ_3&TI0:U,\G:W)V4&*7%.UY?$9)RD!B@M.6!@C
MHA0=TK[(T!$U[Q;%QDYRH[O#.;2HC\#U25+HLEB&\M.-DA:6`$GH-U;E95DN
M:@MT<Q.@5AB9<E*+;S4*01I`@-H6O$\3;*Q&B9'"^\9LY&I'L;7K#:%75#8,
M+[=,<N9VA\F;Y4[L3@=7Z?65T<0Y<FF#/*DK!(CPC):EF<"SE*HP6!1%]OQU
MNNR-4.H[RVTI<KDLWMJK</BJM-!6J%,ML4TZTRQ2FK7J0/>J;9Y<X7O=[L*-
MK2IB5):Y8(].$P)Q7EC`O]W=0LK^%F5]Z>[LMR-HLAYE<PP3VR$L5K\BK#X$
M1*"IJ>XZZH7AM$7FQVP6#B42E&F`9@2LY-@Y+Z@#J7$^K*5JZ(VZ_=X':641
M2P7>#M<`*@,`[>\E>IP1.[-@=3HW^)-H-6TN7^-L4JLAI]Z+$PS`)"%`<_;F
MF$E&@56+J%DDBCE+E'>8OZ+(&1.\KGY+(6KMJFJF)K:9RYUZ2Z.RJ-ZW2%D2
MIGR1MGE(2_5Y4F"/+)&46J\:<`':&J9`*GI"+OM6'ZN.`9#)`0$?;<&-D*DC
M<C>F`YV\&KXL-Y+NQ.!#@G&;D(3&XT*K&?3Y\W@%HQR9HY6^/#8R]YG8XUH8
M$\TP[S);$NW4T1Y(]P"WU-%2:,!1/&L2&8+75-9B(YM)4IVHYI4GE9**6#.$
M64,"7(I"WV=SU=5D)[U5T2^R6QE#)'""1EH[=KY*T<?$VQ-Y`]*&)MU74N)3
M8-FGK&LP?DOR\I'E"=C/EJR!&`0)=UK,VOD_!6ME]X[:QJDR">5U`)R+[UVA
M*9FJE;:M=VG:,)?[+?'?5%J;(]%G.)5`['&*BS%(TV1ILFE@+/"9@#(4%>2H
MT^=IB^\_>)A]71K$RL<L#%V\1Y@T1RW&N^9/*LAU5SACCX&LD:@:Q1DM.`D/
MB$+&/;P"Q@K&,14;/^O9L4)4P6/R"*C,SVWROB%7%3F4B3$L^#-7@97YCXI*
MVB6Y+P(*8IQ2F&9"6H)$,#D<RSD#:>M2]ZJ[WQ?B$3.PVV-M+5VX<2)_BU?F
M*DLO<F=$Z:QMA`DD><DF4:Y2H-3HVY2((59Q&,^+@'(R)E;T0T!SWI[O:GQV
M;X:NS$G!L[;Q\G;SIXQ"D<<;%B)FUE=DRA>K:"C3\91GJDXB2##@&C(#YO`+
MCET0>8`\R6.SGO77-#GV&1E=-)>U29I[=C&NBT2:RV(YTDDB(<M6$PV9F:T\
MI;#E*A1Y9:<AQ2FF9"6H*$,#[AT,?+"4JD4%[U5T2Y6ABN9PM2QYG[=SJ>DA
MH/39.E"DI'JN:,AB2A7IA'*A8P40!6G$8((5!.1@4)&C(<`,0T7?(M)2&3N)
M[1'/*3]N00GUU32V)0(YN:0?-;\;@M!-9^PM7EE8$+*]\;R<8R-:FP:!"E<7
M5$;6LYOJV']Z'9LUQD%:(;4A<G>:[T`CL.L".GR^\(:Z(H4Y/FJJ!Q>7V+J]
M>9,M<D_I"PD-28"P`S"!"$6!?\XDC3`HKF4NG>\N%9A7&)K*8PP)">VB@D$X
M1U^D$IDZ2)DR76U@;%:IM-R40H-4JDJ)$:I)RK/3EF8,X!<@"@!RK)7][RW6
M9R:_A(+XRNR3MP)G:/J)T%]%$TKRF!K"<!(-\Q%G7*4S`Q$*"VM8848,I,:,
M(%DMLN-<G_9YK#W?-LD[!J#7,3M6Z['%5V@R^NVB&2I/::@Q>U/[+JFZ'NI\
M5#3CX%W)PF`-*82`(/-R/.`@2Y$H/*9R!5\*]Y78-W4MT.1V`ZMA$.T""\LT
M/7,K-(@/KTSFZF`<FE(F99&W*5/GE%B2%.";)V`>H)\8&-!FDM+R:=Q>Y`]W
MZ[7:76C<=>;.0J2H7#1(YOFUG1^@V"D:\G483(]:A,[PRJJ4G;0WIB$P!M;@
M8\(3_`:L5)QF`3O4*%5?*&"+JF[TU_S'-FPL-C0)L0PG0E-(9/!!G&DE2IMC
M+CJ.CD`F<[R1#`:-,'J5CQ]/#[>`4A4[1I$S8D*KOP6`4Q"/2IL.XC.V[EOR
M>LC3[-$I6%0=7Q$Y&=#HLZ.V,=?_`,&-BM5_S"8\8`,>%>F&ME/S];=+OWCK
M;A4SKR\K1MESDD@D&AZ-$P73L!!5D`L%6N0NFN.&C*J41*"*T1#:(L2=(H;%
M7IBBU))_A`S%E$`D\*2(7"7=Z&\8VW.4*=+)0N+RP]O)O;U-=LC8)Z=IZ!<H
MU5`DQ#&]I`)2:Z9'A$$D.1^9TQG/`(LLZ1)JLKV7V*Z=Z/8"2HHC$KAEN(U"
MHYVYW^92H%#L<L?K-CD-8\:PI</DNCI$'=2#4&#2S`*T!Y1F09)-R`"]8HQO
M,RJ%HO9F[SE_BJMX4$MI4M41;M[`:T4A,6X:CXBXJRM53DJ67-[UXD*EN\8E
M)2P`BLA\6.`01([PAT8M"*56O[T>S)B^43^4U:HF!5?=OQ/7$2GL7K:`6P&.
MRN9NFK#<VICY-#K.93&DY'ZU,K/5X)R8`>,XX!)]BQ"-N+-*JXL7O?6FE;Y,
MZ/5)22/N'U=K.XK9(^M;FV.\!)\O5],Y%2DYO*6@],GSA86)*HR'&!)S?+`Q
MKI>BJ4USN[8ZJXKW6]I*0L.D:[UWJFS5-H-&B+2R.U5TM239)ZI5Q1=+=<5A
M+@QUU7%H8*>7'):53Z@P8UF30E@/X!DW*CUT:CKE(4/>6OZ:>ZST)"EGB#9V
MT3G/`E=FCIX[)BA^UQ86%#ELL-(L;#P*EI!N5S<K2E!-5DY3Y`[R(QI<4L@7
M(.^I9"Q%%)*AATF5IL=M\U.P2IQ.?TZ1@>#@:O9+;W4PZ)NP<DFY",OW2N\>
M`X1J?*`O*.5_*Y@]M,;B?>:OF2O[\-Y"R-#%&.WTZN#L&/8SEY/;DR+5$XQ8
MD0=,^,XO`B<YQG&!9Z9X!34\8<UCVJC2/O87,MD2*5)80J8D3/V[U;N1+EHW
MDI-'AMR;58U7AS,/CCD7Y?@ZA-;58!=!ICPE@0=?%%5,YVM!X]?7>KM9DMVF
M'1_612*R-P[?<0DT8<[?KT^JW/+E&\:SMJA09)H';&$Z4"PD>``<RE1.`BP6
M:$#N-FME;,].D:A-W>8N(FLV"#&:JDUSZG0$Y[31J/5=)F8^N?>9FLPY0HD+
M=6,`>QF&><-RP4QN!XA^8B5"*`XFW2^LZ1MQG0&=VBY(Q<+O1%.5,Q1J8M.@
M:^1JZ1JL=L.U1)FR,2G5M4:%.2-;+1$NA9&%3KE*I`8<=Z/PE`7FA;81-&TZ
M1H.]U*I8SNT4?%:F0E,W;,?6MT@\=;'R3/@E;Q\U14D7Q1N9F9U<1@,-&D],
MA7*`XR!,I&6!W4\9C3BG1OB?O43=81*5#^2E=0QKMIG9?E-?M1YS^`2L6IXC
M%YL48CAB'XQ"RF1'?:]"C<>(",X1-H-.+9=:RB/>/NQ4[,<:@<FC<]103MJ"
M@$W,M4VYDR.-UA-&_5P\,FF*1#KS(E+L@2A":!O0`.QDXH(\E`3J_5.MK!>S
MQZ1]X:UJ\<7B)+Y.R,SG"NW#$U"V$-J-YD*]V0H3M3$`A1PA"V.:[(@APG$6
MD6'8ZX)4"`!'TB'7T!(96^4=\F5PL@<=5RN/-SJV]M*.X2QM,&:)USVTH#]5
M48FQ"FS`Y$0<:4`KP&,SB4+H-(I"6!SR>L$M7U]:+RV]TZ])&AU)JIZLN2P2
MOJI[;\CF4!@\/BZ^4EACL>#J@4:S*%34P#P@#@U(6:>6`.30Y^VP!26]\C+C
M6;#:I7>?NHF//+!)ITTM9L$[=@Y8%5&(V9,9FA)BR34]2Z8G;$U*QC7(R0#7
M>:=X?M\FAR,"@T^\QN:50PV\G[MEZTA'WB',MEX9K+@?:_KZ3QZ$3TR(%166
MR9"SZTN+?'$DY;)A&%96%"H"KTKZT!6%D&JDY/`)@2-2AQC<VES5WL[K>H[6
M]>YM>=N3#'>WR^@BU;X8SI+\:.R=HU06JT[`)B3B4X/\O(1%XQTZYSC&0(@J
M^U&*V939T18>\SLVR.E6,D0ESF*:0#M\Q4J20*:U74]O-5@P].Y:M`='2')(
MW=+`E6J3DR8Q&ZJ_2F%X%DO)@$QRQG,@;#`I3-N]_;,3C5IIL+:U?Y$B[<[.
MS3U%DQG+$MB3DNU:(1OZ,H<@0^8:F&867A65D><8&'.0.!.@+5H69R2]\2UE
M""1Q`^?L"LE'VYS"7F%IE*Y&?)6P8-6LX6M0%C6K)\POQ8R:D/!CJ(@W``(T
M.L-A^*E$4;N]9?SR-G5HRIC(D<=[<B"'P9L<:-DVQ;?(WR22'61E;W=A45-%
MS749C&)W.2)#RU*DLA&!2I3@2$T`1/Y\+2L7?*M-Y4V,]*HY`T[4D[="\^7/
MZ*1+8BH9F`I+JR:-R<P2EM4MV"2\",&L3FDAQD98\!`[TI:A0A9+&Z8][^VH
MNO@BAD1S)&_(>W0UJ8PLDCR5'&!$]DK-62C&]<\2)04WIR3,8--7'%)PAR<:
M6`0%G!=G-?=%(T3%>[UM3/YC?L6F$SA+A`*_[>DKBR..Q&$1*Q@.,E>&S5XP
M343+(7-FYQ91`*/`O2*`'8R`DT@9H%=-R`$HAT*2][&]WF53VSLTU%V..0_0
M:2+E]EAB$EGN8H>6Q:DN`6Q=\)0]S68&JR22(",P.!Y,QX,@5"3MX86?+4TN
M[X=KQI1`E[*U30E[1=NAM-B[K(WA?'6%K>P*M62A-[D\2)J4MR8@SH:<X$#3
M!#D\.2^`0LG[?=8;![2U?MBR=V/8"RME*)B+C"J]EL.-T;=0QB*V+`C9<<C7
M1*.ZT&1EQQ)*WM@MV2*%R0TPQK=TJL@62AD&<`E0]:PI4[*L4]]NPR$DCDQL
M,CZDX7;>+3O<J)(B2PQA:3A:OX+<'+""?,2K!9619RC>4*C'4E408,#JP\R0
MSFU[PJ6/]W+:T]PUWKZ%V79\T-KWM[`K5FCLRD-OQ80/C`.KIB0IPB#S1[^4
M^@4@3EMGD!\9@L^9@H#!E!7E!T+?M-LM>=RO>*33=U%-6FNIY7\)T9G<"1*M
M_MX6R*6^UN+DIU[$GRY+-J8HG.>"#$AQ\<(3C(2A``)Z8(&QQZAS]'GR41=Y
M[TUW-\HA9369*8RI8^W@0_L@GMV9&!G3.#2;JL!8F6NC[)VM$02(&#1JW1$5
M@/C5I\&`073]EXN*`QJSDG=TVOKV&2NI:=N-J<;3AO;6B2P$:N]-8;A#F]R8
MPZ[.+ZTO!+36#LM5"4IBVX2-.:<E5J0)%^4@$L.Z=)'\2<3[WS;,9PPE1E),
M<N8.W`AQ%E6)FFKG*>094ZO%X:#OO@+2&3PG^#/O8\M)_P`^8`&0*,E>8RM3
M298D[\-@J$T,3Q]5+CBA]MX88R1+']MBL9$^]-7NK6)]D[TA;DH3L`$<N7)B
M`XR:H)","R9_4=7;1T\^P*7=[.T+$J&S'F/5J[%L:_M[ID#]('Y%&)O&XJCD
M$;UG2K2'AX:WEI7IBDZ@!QZ5:0(/4!P?$!:M?1FC*N52%TK;O?6Q@.Q5^RE[
MDSNPEZ$S)F>KL.IPF>RE2Y.Q&KCPSPQ,GIRK@N9@334+80C19,QT&9GQ@93N
ME;S)DC\5E;WWE+^9HW.%@F^(/;M%>WXVMLC6EX/$>G:%*W4\@M88D"E,$?X<
MYP0$L63/#@.<\`[5>U5/+:62YOJ[O'W_`&(M@+T?&YPEA46[?,E/B$B2KG-K
M5L$D+:-458F9Z1N;*L3G)5'EGDGI32QA",L6,`29\T+9G^E"VZ_%;HE^B+P!
M\T+9G^E"VZ_%;HE^B+P#`M^U=V#!W0*IC@NXMM":^J="=@'HB<CKC3,,@0-2
M+8;6A$JBB9"7K`"*&,[NK<"59YIS<8X`.0E!)4EDC/*-`RTT6@\NKO9[N&1>
M;W!.+UD">;ZWJSK#L-FKAADZQ,LH!C&E:CVZJ817D-`C:@`R$D9366H'@>?-
M,,STSP#:%P!P!P!P#45VZM8*Q4U`BN!$%_8YRJV0W(E9;@SN1!)*"2N^U\UC
MLP>F].K0+?3*Y[#ZO:&9W#XLDG("S<D@(4J#E`P,&>W:G"MM;MN)1&#3@5T!
MWO2!&I_+P80$_N#4>7DPGSRSB<#*P/J'QA&'KC'7&<>S@&R&H^TWJY2DIUSE
MT/=[:-<]68=4$)K(E\FC4X(LQ^D(OLM#X(&3E`BZ4YY4E,FUDM`J.P82)28)
M(//02;&1@=.4=KG4NUIK(Y<=++*6NR2\;'M5Z:X]8#`<W1ZRK-GVL=SS1F5)
M<1Q>M0)5$JUFB*\MO5'".3)E*H`<X(5EA+`H1_9IU$45[BK\K[8+B":$[`5H
MV)4TFBR=Q;*^V,D->2.6Q,;X3!P/$A21@=9-:./JWD]R=&]M`-,8J4%^7@L#
M)79C1:F-JI1!YC8+G/F1^@;'\*)E,%D#<RE/D6Q<5(WV7'I`E<6)[(-1%6?K
MW&'`)B0*-7Y:8Y/D[*=2:6(#&\79OU)+,0N+<ZW$Q2UE6M[K&YVP35F:):RO
M#%LBFVNBSJI4(XD6TS4V&7&6>J9B)*C>D;:A<EZ,DD*=<I`8!(<O[=&KTJ>5
M;:\2"5IYC(-F2=VB2</\(/=#Y]'J-C6K4E\F(O40<XZ\54[5&).QNS6K:U:(
MHQTR84-,H&F&4!"EH]O[0BGUK99-GVG-($HBLC?Y%"E[U8C&3F#OET[C8N@+
MK'VPV+JE*M*;L-<@6=&8X%."5.E?2D1N1"R0:`"]HWVD=?ZP?"I?1$^NZEIF
MUQE!#8F^Q6:-ZW$1C::%ZE5JJ;FI.]1]<I5%N-?Z8Q%M/]8H4><6:XY,\?K1
MX"!?VP7;'URV3F5DS>P'6TD3I:JN$N,L21>7-S6V"<H)2MX:_,RYM(61UT4H
M#5%;W^^)U(,'")-5%)%`0`,)'DT"&H?J3JDBBG<3UYUNM,TVR;1KB60:VDTG
M$AF#134SLRE4L.-4"?&Z+M+^`+VF1M\@>H[E\5%)%9N3TR5NPMZ&`8X4[2':
M\7-RAAD]YKIY8LHA$STSNI4L42B*,<NGFX57:@4M*X/E$MAC(.*2Z2Q"LJW1
M1U$0H2.")`O(/-P<8N&I&!FF^]JW6=R]SN:I_M]&\L#CL>_N,C:Y8SD/<G.V
ML@JROKV3R4)$0-3.+/,8P2UX"W)TY"-(LCC6K3$EJTPCC@,7M<](>UW>D9D$
M8H2VGJT&`Y\H?9).B0R>/9ED24E1M/&:QMBOIBI@31:\78+&<:O4+R7)K=0(
M#GM"Y@;1I2S7)&:!E9?O:TUTV5M2V+:LN47(I?K>J.:4?(69HF;*BC+)`;!B
MM>1:5M\5;SXDM6LZES2UHVJ\F#4GX"M&>:$.`G9!@"]83KYK-']FMMP0N</B
M2];VA$4G]SPE,Y,0W.&-$_B22EVFRH4K4144FB@)\WT$G3FIRW10RFN<:PI"
MA*4X-,-`PT3]LSM]5!8FO=/K[;MTFV?CN3W/6<:<ITU.DLG#@RV3JY=$I=Y*
MG:X!DG$4)LC4^&K#U1H6\!JLU4CPH%ZX)`0(VA&GW:3MU#&`Q:\YA93'#H<V
MPALBB>=J50W:O%UK[<T<D3C:&^%()<^Q9NL[;V=Q18\)!9`@6E)2EBPL]"(T
M0&;R;M5:OIDUC%Y56<H76U1NQU`3UY42QL$Z/<1VD1U8UV<\`$7&BD37+0,=
M+QU"V*4A!"=&F0YR).:::::,"VBNUQJJ">MCBLG]F/-CM%O(MEO!(I;7DA>W
M%8EJQ9KD6V2"//,`6I7VHP4T<&(HVQ8D-1-"1.$QL&B<1'JS0+ZK?MBZWU97
M6Q%51YRM%3!-E:*0ZUR]F>IBB69C%/-1=T)&&*P-Q)8$;FUFL:.^GU.G6K3G
M%<,OTOG&FC(P(0$C4OHC1M%VRLNB(BF3C.%C'-F<2B2/Z9P;R3[/14@DL]]*
M;T34V%9>9\;KM%5"WQ^)*G/1&>B)2EJ3BQ@1%'NV1I>8RU(BA:!\Q$J.7/3%
M%VQAGISFR#;6/:2([.D5Z\*1^\%!;#6]^54T^@0)#T9K4B:<,XA>B`)-@"[]
M9>W#0&I\Y:)]6#C8*UU9Z7K*CB4DT=HQ)D9D<I]G=HK`G\M8;#TLA:)<V0=V
MRQJCVY<B1NC>F3B7)E*HD*G@&(KYV3J8;38"P5;8,^CM?XGDB<+>:Y*]H7^1
M/-;O&JNT&L*6"5R[@CJ=/%5"6/[-KS#%RXAQ4F)TH<>/"D6%(0)+DO:$T<.,
M:H\<HG42]Z/KJ.`L+=8R-"<VA4O=S6?)XK#2'AK<'!T;W&1W#(GQ6`\2]:3@
MLKRSB4B;RN`7-9^B^DMWOM>:R3&12)5/:"T_>*MCL99I2F8;$;];;C@DQUN=
M'1[D+8Q)7EY9)B@:UA!J4U2-F/>V9(L,094(DXP@<3-VCM9F!+8:1NEUW%!N
M&J=@:9M41TTC9^9_$-BY?/+`E`W(@Z$"2-$@B,KLV0JH\O9RFU0A+=E"8[*I
M)X"``2@V]N+7MHJ+%.I5MB>Y$>PKIM$RR,^3MYLLCENNRI<I6/#6L$P89AMF
M"756G"C5H51(2%(\?WX2QE@0))^SAI0GA*E@4.MJ0NO(]EWD!3>CL5N2,T60
M"H6D*">#0.C]'G->4TDUKKM'QF"6*CL$JRU*CQ!"?D`0+QU<TSTS=RZFV)U_
METMFD3BM\7OL94KQE8TB8<2*\D-NQF<-"=<J@[/+996Z-3<<G5QX+FM7F(LN
M6!(U@T`4Y00+PNSM?:Q;`S&Z)K8^+#7.5Y)WL<G1-TM(;VMCD#[KZBUB52^(
MD@9C%37(2*@2"0E8/.5H,'*#5`DHC18R$#'&>]MSMZP(Z-,-AV7,V&53&2E5
MHR.2R?1QKFTF?=@-HI%M6Q0]\/8H@C52!MEM\,;JJCZ1X*4-R`1"PML"F.&I
M,&!(S7V<M2F>3M<Q0N5LYD;-8K/93>K<9/%GM&!S0.FSB]V8EK`^0=RCCO%9
M>DVYF:%R2K4:@>4JA*)*8E4HRE&`*M46BFD-3;.1PF`O+RDV`IS,PV-;86G?
MT32>P,6QX9'74N>RV2/Q]C2H:SLJ20]<K6Q]$(B.K)6VY=S4.70/JA`41U[5
M6H<+DEB7W-))<;TYFV3%=DY%(7V4-[FZ1J5TO,;8M.,O4/<H["4TY8`Q\NU7
MQK$4U*@K'".F8:CQ*$XSBSP+EN[M7ZK[0V)-;NFKO;&'NVBVMU>@1Z6H&9F,
M(!7$0KI()`VKHJK6MX5$3B"/S`&&9'@\9H_M<C\(0+?SVH*4;K!>9>W/$EEF
M++V#JK8&V'*RY&N=9>@E=%SJT+3K7[T[Q$T\2#&@G/MIN4>>B7'#B2XPA6:V
MYQCQ#&:!>%JZ+PG8C<R27A.I^F=(?'JGUWA'WKXJO)1R5CM6DK!O:TX7+9>Y
M8`N-*;@)+W)6-[;@*00U"$HY1E2E.\C@$%S[MJ:>6/'I5K/6$U<D-UT1IQ3M
M),[.]OYSJ5%HZPT?M306IMEV:R(&UJ52`Y@9[@GN2Q(5"(EV/`9E46,Q*G\L
M"_8+V@]<V%>@G<A>9VZ6R_51*ZTMR3H':/#9;$#.:^KZ!N#B6QO<1="(HKA2
M:N6\R+K67W6YH<!,"J4+`*%(#0+GE':^I=<KKA&R96GQN.,6F,"D14H=W,Q]
M0P?0MXG4RH1=73I&?AX4>GRN4S94ADBX_)Z5XCK@M19(+"9C&0)?O/0.B=AI
M]8=@3Q7/"U-LTA'*"LB.L$D1HHK*XG`Y9+YI7#RH0*V9R7-$UKJ2SQY-;G!M
M5(O.+<#4Z\M8GP`H`&,M@=G_`$LG#V)MDDGM)!)I@Q3P2M"AL9B;WB6#DKUM
M@^6/,`-BB,J##'!;(=\YHI6&(RBD*(UQ;@%DD%IB"Q`2)&],M.J<<[JUM*ET
MC1/6_,&MT2Z!/;XRFR5?&"H1%('>3G64C)BB>4MR507)6UT<$BIR6H$+NY94
MH4J4!YI>0**D[5FG\0L%OG@7R<MM@32)6%5#PX/$MB*M;:J290:,,A)2AN?(
MDJ3)YE7,0JM(>PKHV2TN2-.A4C4C5$&JPF`18Z=MGMU#E$:H)9/)7F=26**F
MV*PTFQVY7)%!E)1G1QDL20EEEL"DG$H,AFM=2D/Q"O'DA1G9.3)$XG(XT0&9
M+!H-0T;/V[]WAE@FS=,V=*+79U#DS#`S'VA%4T5L;-?OY<>*FD?12X"0#@<A
M4.BYO2.F1J$1"7)IH1@8V2OLQZDS03^HD3_=ZQQD$+;8<<ZE3UF1+F\QDK;6
M6L8]*VO*.'D)4\J8FW4>%KTXQE&(AN:52,Y*:0J-3\`D+:[2C4RQH)5*&\Y;
M*XNQ4-`+';HJ").<<C#D[QQ>1!Y+/U_P?%X682\K$A%;HU0D[$U)RDP!G8+3
M!`8```(Y/[+^GJN/3"/>\+=`W3NN8_`WA1\61P]V3KX=<4_O*O[*C[PNA*ET
MC%BPF:V8Z`3G(#4[6XMHBDCJ@<"R@<`O*>=IC6"Q<R_#^[6HF3SG*E1(6^.O
M\2C308Z..H$XT@=W=L9F6"HVIA4.M'3]<`Q.A)3MY+L`E6G3$^`18P(X;^TZ
MR0#8.H+=IZTO<47KN<O5C2&*V#`(#93I+I-+;3>K'E1IDB=(RC=VL"8F1+TL
M8-0J4)T65KE"TG*D1@B<@2;-.U%KC/[DL6\Y/++L73:S)57\L>`?&K%AG:CZ
MOMZ!7?"F:/)!PXQ4@C[1.Z[1&!3&GGY$F.4$Y'T,#D`%5H#M;:V:UV#4]AUH
M[6N4LIMA+9HG'WV8-KM&CUN=>:EU?6R=[39C2=T72!TJ2CHRE/\`+6$HO5M^
M5):8LT]1DT#KU5VLM>JAM%%<D?E]V.\^17BV[`>]Y1-6-UPLF[;6UW5&%(X$
MDP]#A9'5,`OUZ0F$#SY^,$(AEG@,($(T"ERKM-:VS2U;.N*1RV[W"7VM-X!.
MW[S)LPY;6U?5]MJ+H@[/'DXH:)2ACK%,59@2TQIR@64(_(R/.,!%@"4M6-&H
M'J_*9._1@*<G`:1H#6*%+&Y:]A>55+ZX0Y5&Z^=+&PK6#8GVW_`\J$2U]1(T
M?JVAM:R!%X]-TX!C*V]D?45OC@(X?+;_`'DO,G?IBK=WBP(ZI?'212>$:_0!
M\<G-:1!4I:HY>QZT1D8\Y+QG*G"LS_\`:<A"!D)6G;>HJI&R_&B#2BWFE%L#
M42ZCW</QBV&J*_KY1.;]L5O05DMS&0K&9QC\IV4DQR)8X&.B@`!I0&B-"F!U
M`BR#=GS56OW6"/+*^W,>LKR9LD[8O>,T8323GUBVD7[@I<N126&HPJ49]R.9
MYAQ8?+R-M'Z7`@XQ@>`+KG/:QUZL*_)?LI()?=>;2E$@ADH;G!-,V+#9!7FO
M;&I2U(<="VM7#E9:=&R3"B6HX"1P$XHS"EK@684,*@/D@03%>S)3:9S?F.8R
MV1.=71ND:4UXHIL8EZA!8,2KRKZLVNJ&3JYO,'`"]KE,BL*!;B2EG4#(;$A2
M1*4F4I_+6XP<6!+";M#:FH99,)4W*+50XF,I@LL/CI4R;3XXRK:\V(KC:)A0
MLB9=&E;B!K,MFKFT]26J5*S#4(CDN!@*&#!8%1>>TYJ^^3VR[&5.EM%2&U9R
MFL*2!2S%J+;T\@2;)5+M41AG2F1<T:)`"TZ58_UH8S<Y;`')LBSYOC"!;5:=
MG+4FIWFK9!$U]KB=JBE$5D49/D$FB\F2+D,6I6(T-B(R%F?(.M8W:-/<*@+,
M>J%Z8MS(=VXI:B6(SO%D0'/`NSUJA6[:R-D;=+:&2P/36\H_?TGBTE(5!;-<
MK0U8-97IH?8.OC[_`!]YJ6W7<A>D6HSRU*O)1N>@<&%F`2/)NV%JS*Z9IZAW
M5NG>8!1\5LJOH4G*F[@8YXK6WDF6VP:W<'%>4M,S#W=G+3H$Q*7"50T($:=.
MW')"BL!X!E)0M#0;7.#.5?5Z)Y,8G6R;>M568_K4S@XBE-W6G,+AFV<*TJ!O
M#EN^,)PNRC*$`0DZ7)9/C%@&,Y`FG@#@&N61?SN%/?U<NR7\IG5/@%R:Y?QU
M.XO_`)4:O?R?&;@&>W`'`'`'`,$^VY_%09OX<-P?Y85\<`\WL;I>Q+Y([1D(
MK-E:)`\-,X[@ECR5KD#@G0,*BLZV[O&LLLLX#R2H7MOOUJ.A:!64H:0&^8ZD
MF"38"+!F<<`VCI.RO*$D'!"3]U+@=L)ZW;H8FE!WOMLE^')O@FL\/9!#=TDR
M4$J(57+UKCB1QM@6IUZ`#G)7`ER"XI#%):T"RYKV@K1';D5:XM9*$<!G4UVX
MMBSKE9HXVPB7US.+>4::.L&<8]%&F7)BWN<MSQ1,B,97E,6!-'PKBPY39#D7
MF@5^S.R/*;%C"N.G[BS$!GGRD]`XO43=7LP;T[5I=4%:K,>"T]ALPU]NA>;>
M2O+F[@,*+7*8JU8*)2C)"<6!7;B[,,AM^%V3%73:9W+=YQ>FP-LIYZX16:O$
ME]R7%6VRL0@<9D*$ZY$\75O-"R#9`2MB=VI"SFJ4,49DZ@K!J5.I2@<I_9IE
M1S;.6(>U3N8P2RG]NJVBS0*,3A&AIN0;)S_8:7QV;UFC8[D9D01PQBV(5L3F
MW.A3@C>4K"U'D8;5"4D1('5SV4S0MKNC(V(4H5B^OM@:\8WUBASM'9-7[=<6
MUT$VHBBJ!R`B>+CFTJMGJ(FMF6U82N97M(HR6M1"2&JD:@"=MH.UP7LK+([+
M7>V69*X-^LU5ZYR`UUJIO<S'XBL=GJ8V//D*<MODS(D9T,U%5RMF7-198DY!
M+H$TH>0D"(.`@$KLN3$5>RVO'/;F0/:5\UIKN@XH^KXU/$SK6*N#S-:\.[G#
MDC5=+>R&Q"<1DU(0J:%Z94K0.S>6N1.!.!Y3A`D>3]HHU=);@<8E?*Z+1>96
M-'Y=6\-`Q2XQE@D"05$"LCZ%?F1'9Z"%RRJHI(DY4OB@2&9K<V5\!@`E2A/@
M03`,I].M,YEJ([V,E;KA:I_"K5L9^M*<!D5>GD67(9>;3^O-1QIX<Y\FF@D"
MQQ"53;L[/IYS0::\N$C#D`DF$8LK`(+L?M<"L>.[/QIUMMJ,;=D=^ZCW?4HU
M]=F.*%@3U9&J-C(JJ6)1S$D#^FD2>CTYACIU2^3EQ,!Z0P)(,C`O72SMZRC4
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M:JU8]8RZ:G3%V#))_#$NSN&="<4E;RBT\70F`P7@>220+MU<[<JK7?89KV"<
M;93S9Q15+<]7%1?X,&UM\>0VU9=26"G00ES4R5W7,$-C!E5C\#4,*C"AQ?5R
MO!Q.!8(R!C!"NRJLC+=31R[956HE5!&OB.N7=@KQ1&D66&?]Q&O]_;22RA.1
M/%;H\JY2;6S="D>`+"$;>V#5K3"%AJKTY(%79NS*>PM=<M;/LU*V0YBK_96,
M3N01UJF$=DKQ8MV2KXBK[8.%N;/::,3!;--,Z9/'$_OC$A:'&/@PE$D(++++
MP!54_:(<RW2*2P%PPAFE;53E%5S+TT1J9Y9(A8#U3%_6->KTJ>FM?9[Z[D0*
MXG2RE'OZ/`7"3%KT"-009Y!>4F0"3LY@1L#X$W9.;.]H*YMK3((]>SLV."NQ
MV5@U_P!=ZHI%VC;V0OE;G$9XTVM(:P%)7YO=6XUK6*'8\(R,KB4CJ2!->S&D
MNQNV=9T0QSC8V(5W856V,^3>52B`5I*24DK2MUCM,IK5&RH2K9;#(BN01J,(
M4CT,9SKZE4<H$E&G*^T-`BBS>W;849U;H?6^IQ0^?HXMW#5>Q$V4NC2FA<?,
MJ*P[WMVVY<BEL<!)0?&@8PTV26U*4:=26-Z3I`^`@O&<EA`LW'9?5)8:Y-(=
MF9!)YLJDVJ8U$[FL>E:QPF-7:_:^U=1,_J"PCX]:D>D2Z,W:NKKXM5'M3FTJ
MT$D$C4B$L,0X-.`O9G[3<C9;6C$Y!L]+WJ!,5S61:QE/2@F=.["G/GH:\=T2
MQ@F:2TFBQL2*'S>MRE[5[_=)&W(V]\=VD*;+8J`E+`B^F.SE9&N#=6$HK79&
M*2RV:).FTEJUSL:GG-XBY<\E.CE::H#?W1M':@W,DUSG56IYFYB(6`&K,=5B
M86<FX"L&!E7>^@-E7%M3#]J6789)`7)KHV(4G-ZN#6Q4J@D];6E3>2M[=5RM
M9*&M];'-"NNGUL:4I1E'LJ]I`8=E:4I,(+`QDI_LOR.J&"`QTC;F8+$$,D\/
M>L$MT5<FE,1\/(-&,OLBCJ95/WD+384R<]-7(I:YFB4EB;;,?B1D&F",,6@7
M4T]F2/Q*O;Z@41V6N).EN&/PYABYK@Y+<F4\97=R3>=U^^0=8E=@JS7.)UBY
M16$Y3K_5-3TV0\D3NC7@7K",@3CL!VZ7^]IE")0LV$D#.EC=.0:JWIE+BY.6
MQV.A+;;B-W=&MI0OK>RL;1<GWU2TLR;<)SBG%H8$",H96`8,+`CNW>U4XV55
M.B-:-%\YAAFDE.1FKVYZ;8,N\N8N\5=M:7%LFR1L;YVT`BJ],GU\4)R2?-7B
M3ER(_(#OUG.%`%TPWMI2>*TULG5!VTEC.*F^&FO6=%*LIE1*YG'7\PEDN7RF
M2%"D)IDFF%ODR@+/-%1!K>%V:$)!)82,AZA`QQE?9(!+BYA[VO\`1NITY<Z(
M>W<Z0U=[Z.;1TI96U]@-\-8E(IPC4$UXF2;+I&=G0G",,:6^)(@^8?@80D`7
M0S]G5W,;E;)8NRKK:3>NL'3V5N"Z4Q^=#>'B#ZY,U*MUA4J^)\7"=%'.OK57
M4X:I1FF-?O1G+E#HE4*').:8$\"?MA>VBSWGL;&KQ;K-.K=MCM54Q52!BBT7
M\J3,;+3,KO"3$HHS+RW]*!OCU@([F]SOK<-"86H:&W).!YRI\1`&(C)V4+!;
MJTS"56YTHQ(,QFSXKF6-<0D`$"AGLO3^J]6%B!TA[[9T@;EBAO=ZH131([I#
MVU_0/)R@I,M+3JE85`%4>.S!.%4EM:7M.V[@W.=G.K$[N[2;!92./21,P7!0
M]G%0BP"VVWFEXD$%=6:HG1B4$(U;8L+(E"D\@\L0#2E0$SQOM6/43M:.6&P;
M,3QL9XKL'"+Q8X>;\02M"WI8TE):I9`S%]@S"8.\DB-EL*<L!R5\4NI\9>0>
M]H^J;AF')#0.*Z>U(XVC9NP-AQS85VK3-]6TXV@J)B\1,2.T;7/>M%1Z[X=B
M7A'*4/O:>5R=5(Y%#G8PHL+.O?G``TYV1A.X!6-KNUJMV9OFR[O:-BI32;W8
M%8P>!-TAKJ-Y2V3!U,"JO;>M4AS'-0R5'A1&I(HVK][.K8-*7@Y1%$)83<".
M\]*!8>R?;GM&P:,TRURA;I&AM$%GE]CNR=HARA''8LUW+JML[78YU%8/,K1?
MY8Y#8;CMMJ=V=D+?3R6E4F(-3>G3HB"R0.PH[0HLR`F5AV`>'5]<-KGJ]9XJ
MD+/,P'636+I5N:\9JIE+Q#[4A\F+?*^DBA1,F)Z0KDB1/)5!QHVT6#S19`M'
M'9OF`<JT)FV\N=HNHJ[9.OV*-R1IF;F.M'N[F]4GB\ZA$D:+4C3](7:"C=W!
M"H#+S)*>[1\U&WG*<&-B=:,"@#[*$D0Q4EJC.TPX_)&B)[%1:*28JLEYYL:0
M7C;NK5RD,R,&;)+<@Q(EVUR7L[\WDK$_OUDF;F6`Q&:(9AX&1]"=LIPI+:>%
M;#8N4B1,,$9[.;(_!E\7E3H^,[=:-/:R58?!FFQ9A9LM?@UK!56M@75C0K`+
M5A9DC6EG*3!@]0<!']!]I^7U1=5=73.-B6BT7*OMDW?8%`P*JM=FUF2_$&LL
MZUR=X_',/=H3%7'5AH9$VOH%^##QB6-P@'`.$86>2!:MF=F/$ZMAYM)FO9LB
M:]5L_<.S+08CJP8GUL>[>F^GTW5-PWY!/6HTU?'Q:MJVPAP`66,Y!)S/$6$2
M<6%0$S,7;*?D&H-YZPO-_N<ADERVDUSA?=+BSS-9)')FC]L,$_:$\S8G.TG%
MI7S%7%F(N/NCDR"8$;D6`"LU#YOF`,`Q]KOLKR*OOAI$7M,XN\2:[8KB?R6O
MA1*<1Z)31EAT'NR`KVIQ,BET,DD;)(C06FTKH^Z(UY(6E;$$`34ZHC(0)P.N
M[=E!^>8`DCKEL\:ZV$BA&Z5?9N5\@DL>YPZ)]JX;#X9'++7C<[?5)F:WJV;8
M,@PL7L/N9!(#/,4"2I%0Q'"`LB\>S_=R<-URJI;9:[$D=\V@?)'^&20Z5UU&
M6AF>;MOZVU:YU<D$X>@2T^,QNY\1=J3'H,E)L(4SB466<G(+(`W7:SPJR*\I
MR'0ZS3X>4YQ]BCC0Q1J%%ORMM@$7:8G'VIO@*N821W<7:S'.,K4*DH<F-3-`
MW@K)9HF],/QX$!/G`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`-<LB_G<
M*>_JY=DOY3.J?`+DUR_CJ=Q?_*C5[^3XS<`SVX`X`X`X!I@T=WWT9J:@3:[M
M/<O5:MK`BU];>H9-!Y[L%4\0E\=7&[<7BM+1OD;D$L;WEI5&(U19H2SR2QY+
M,"+&/"+&<@:K>W[NUIG%K6[>:Z2[::U,".'TKWA6V6JGF\:T;$T8<+$WMIB4
M0!#(3UDE)*95<XC+<H<6@M3DH;DA3F'I\&%`$+`'H3^LR[<GY_&F?TFZ7^6G
M`'UF7;D_/XTS^DW2_P`M.`/K,NW)^?QIG])NE_EIP!]9EVY/S^-,_I-TO\M.
M`/K,NW)^?QIG])NE_EIP!]9EVY/S^-,_I-TO\M.`/K,NW)^?QIG])NE_EIP!
M]9EVY/S^-,_I-TO\M.`/K,NW)^?QIG])NE_EIP!]9EVY/S^-,_I-TO\`+3@#
MZS+MR?G\:9_2;I?Y:<`?69=N3\_C3/Z3=+_+3@#ZS+MR?G\:9_2;I?Y:<`?6
M9=N3\_C3/Z3=+_+3@#ZS+MR?G\:9_2;I?Y:<`?69=N3\_C3/Z3=+_+3@#ZS+
MMR?G\:9_2;I?Y:<`?69=N3\_C3/Z3=+_`"TX`^LR[<GY_&F?TFZ7^6G`'UF7
M;D_/XTS^DW2_RTX`^LR[<GY_&F?TFZ7^6G`'UF7;D_/XTS^DW2_RTX`^LR[<
MGY_&F?TFZ7^6G`'UF7;D_/XTS^DW2_RTX`^LR[<GY_&F?TFZ7^6G`'UF7;D_
M/XTS^DW2_P`M.`/K,NW)^?QIG])NE_EIP!]9EVY/S^-,_I-TO\M.`/K,NW)^
M?QIG])NE_EIP!]9EVY/S^-,_I-TO\M.`/K,NW)^?QIG])NE_EIP!]9EVY/S^
M-,_I-TO\M.`/K,NW)^?QIG])NE_EIP!]9EVY/S^-,_I-TO\`+3@#ZS+MR?G\
M:9_2;I?Y:<`?69=N3\_C3/\`].S=+X__`)TX!^?6:=N+IXOG]:8^'IU\7SG:
M6\'AZ=?%XOC3P^'I[>O7ITX`QW,^W'G&,XWYTRSC..N,XV<I?.,XS]C.,XFG
M3.,\`_?K,NW)^?QIG])NE_EIP!]9EVY/S^-,_I-TO\M.`/K,NW)^?QIG])NE
M_EIP!]9EVY/S^-,_I-TO\M.`/K,NW)^?QIG])NE_EIP!]9EVY/S^-,_I-TO\
MM.`/K,NW)^?QIG])NE_EIP!]9EVY/S^-,_I-TO\`+3@#ZS+MR?G\:9_2;I?Y
M:<`?69=N3\_C3/Z3=+_+3@#ZS+MR?G\:9_2;I?Y:<`?69=N3\_C3/Z3=+_+3
M@#ZS+MR?G\:9_2;I?Y:<`?69=N3\_C3/Z3=+_+3@#ZS+MR?G\:9_2;I?Y:<`
M?69=N3\_C3/Z3=+_`"TX`^LR[<GY_&F?TFZ7^6G`'UF7;D_/XTS^DW2_RTX`
M^LR[<GY_&F?TFZ7^6G`'UF7;D_/XTS^DW2_RTX`^LR[<GY_&F?TFZ7^6G`'U
MF7;D_/XTS^DW2_RTX`^LR[<GY_&F?TFZ7^6G`'UF7;D_/XTS^DW2_P`M.`/K
M,NW)^?SIEG_BV<I?/_H]DT]F>`/K,NW)^?QIG])NE_EIP!]9EVY/S^-,_I-T
MO\M.`/K,NW)^?QIG])NE_EIP!]9EVY/S^-,_I-TO\M.`/K,NW)^?QIG])NE_
MEIP!]9EVY/S^-,_I-TO\M.`/K,NW)^?QIG])NE_EIP#`5^[@VAAO='JB<E;J
MZHF0I!H+L%$UTN+V#J@<812AVV'UF>&J.*G\,KRU)WYS:658J3HQG84')TAQ
M@`9`4,00,H-(K;JN[MI>X=8-,V5`K:@:V;:W-B.:5K+F"<114Y-5`L9+HWII
M#&E[FTGK6XX80GE!-R,H6<8%C&<\`V<<`<`<`<`_C[3S7&KK9V:[^=WS-K/L
MJ>ZHVC=5@U10*-U=VL4_<ISNH?6<NL60!C*I#+7B"T1%9$<]N:%M4)##3S4A
MBE06A*5A,`VS_P!D02QAS[BNV.2:P^]6F3:")U*J+N:A<^A;GTNP:3RY2YI%
M8"5S6H44C5"&ZHR%GK"DI"H)>##R0X$,#TH5-OM?U#CE$(W/KQNM.65W5$#M
M6M;0K2NX%#:>VVJG9Z]Z"J&FK$<71+''7-63.AI1::UIL)N0F"0)FL@E[)(4
MD*"`Y`DF/=YJK7^XZ0K`.HX4S5;;Q54;<I(*51TUY8GZT[BW!I!M^%82&"86
MV,PXE>GSBM0K4ZM$-U9WU"<01Y_B3"`ERY=@;;8-D=:U,)ALN:M=-UZNN"@*
M[BTRUP00N>T;NQ$3%DQK:=3IOFD))F**OYW6$?DYXTSJG&@3BC12G&!%+<!R
M!!>PW=P:*@;KYA,&UQ8Y#/J4D$B@+7,[04-#$QO[I5NRVI^LMBS2Q&.+PXD4
M%:7]TVD2OL6R2(:9^;VE4;T1%Y)+$!;"KO#QBJ)P_067T*VV9UVDV+K-SD)\
MRK.-8@D5JK=[6;3PI%%FMDJ])\:MR%UV>;'-NPXF)'12@:U(%BK)XBS,@;#M
M7MJ%6TV;Z";JX.DHM5S&ZEM$_?5L<?3'"8(;`N>!.D2-0BAA,9(E$0;JL0R%
M?E(X/;2!#*6TH*@\>%'A`U+ZN]X.7MU$:\S'8FN:HL+,OT%U5V0G$]1`C<$>
M72V=K-Q'#59I3+&9JB14+A52UNO2E+7URQYIR-(;XQ@&8'!9@$M75WOHY2KY
M/6!\T68P.M;P,Z42=I=+RK-,Z(I`W:(RW?![BF#(U!9G'%Q+?#H$Z,)3DA<E
MB98YY2'%!],><)*!LZUCVQKC9*[;VI8FD28$Y4XS5W+6=S?4C6Y)[+@ED(%Q
MS-.(JL:6$V*J&0AY:%[2J))=U3FW.C>H3KTB,82O.`SK^#HC]RT<_:1L_8O`
M'P=$?N6CG[2-G[%X`^#HC]RT<_:1L_8O`'P=$?N6CG[2-G[%X`^#HC]RT<_:
M1L_8O`'P=$?N6CG[2-G[%X`^#HC]RT<_:1L_8O`'P=$?N6CG[2-G[%X`^#HC
M]RT<_:1L_8O`'P=$?N6CG[2-G[%X`^#HC]RT<_:1L_8O`'P=$?N6CG[2-G[%
MX`^#HC]RT<_:1L_8O`'P=$?N6CG[2-G[%X`^#HC]RT<_:1L_8O`'P=$?N6CG
M[2-G[%X`^#HC]RT<_:1L_8O`'P=$?N6CG[2-G[%X`^#HC]RT<_:1L_8O`'P=
M$?N6CG[2-G[%X`^#HC]RT<_:1L_8O`'P=$?N6CG[2-G[%X`^#HC]RT<_:1L_
M8O`'P=$?N6CG[2-G[%X`^#HC]RT<_:1L_8O`'P=$?N6CG[2-G[%X!'EO1")@
MJ>SQAB\<P(-=S40<^XVSV9#&G/.,_P#1?U,XX!K;K:+1C/8I@*K,<8,J<]I>
M+*,J,L[=D[)^=/$)F3LF939'DS)GVWBZ]>OMX!G!J)$8H9J?K"89&(Z,9FO%
M*C&,3(VY$(8JVC0A"%G*;KD0LYZYX!D/\'1'[EHY^TC9^Q>`/@Z(_<M'/VD;
M/V+P!\'1'[EHY^TC9^Q>`/@Z(_<M'/VD;/V+P!\'1'[EHY^TC9^Q>`/@Z(_<
MM'/VD;/V+P!\'1'[EHY^TC9^Q>`/@Z(_<M'/VD;/V+P!\'1'[EHY^TC9^Q>`
M/@Z(_<M'/VD;/V+P!\'1'[EHY^TC9^Q>`/@Z(_<M'/VD;/V+P!\'1'[EHY^T
MC9^Q>`/@Z(_<M'/VD;/V+P!\'1'[EHY^TC9^Q>`/@Z(_<M'/VD;/V+P!\'1'
M[EHY^TC9^Q>`/@Z(_<M'/VD;/V+P!\'1'[EHY^TC9^Q>`/@Z(_<M'/VD;/V+
MP!\'1'[EHY^TC9^Q>`/@Z(_<M'/VD;/V+P!\'1'[EHY^TC9^Q>`/@Z(_<M'/
MVD;/V+P#75VW8K%SX=MIDZ-L!N2NXKO,07DQF;AY`25>\C"44'(DV<X++#[`
MX^QC'LQ[.`;%?@Z(_<M'/VD;/V+P!\'1'[EHY^TC9^Q>`/@Z(_<M'/VD;/V+
MP!\'1'[EHY^TC9^Q>`/@Z(_<M'/VD;/V+P!\'1'[EHY^TC9^Q>`/@Z(_<M'/
MVD;/V+P#]^$(GT\/PO'?#G.,Y#[D;>G7&,XQGIZ;IUQC/`,(=9D*)NW,[BJ5
MO1I$"4$JUA&%,B3$I2`C'KZS"&/!)`"R_&//V<].N>`;`.`.`.`.`>!!C[.F
MO-VVW:]XNS)1*:X;'V+V1F3B[K-Z]FZEL!L1S;:VXZZA[C+XG66MLUCM6XG*
M]K-;6HH3T(IX$69A.,T>32P`;1.VAVI9KIK(G?;/1ZK-,)<;L+5&8PHGTNWG
MVEMV*SFN).]L$PPX-X7#5A.F6C=5\>2&86"&:(1/C!]@P7`-OPDG<]&TA8!T
M1VTAL0&E0P@9171L&)I`QJP$E*F8+;G6'*,+2I+3EA,3X!Y(PEAQD.<!QT`I
M?PQW(_5M:_YN':^]<QDM*=E6_?8OGU;0G8,&88B&M1\USSF\EEP</T@2L@"F
M\6?+P'KG@%"=+X[AB"U(W2SI'>V2"W7M@5SB.0$W8G8X^4CCB7#LWFR8I`#6
M8TYO;SO=[@02H-R4%3E,J+*R/))V`@4E7,=Z'IBM68JJN[3[\P,HGYAN=^^_
MK=[VD3&UJ08.0L-@J2M8U>3E,*(3BP>C7>,Q%@/3(`_8X!:K5.MN92]5HV-%
M4]HE\?;IA#W<=5$);FNM8LL2"-Y\(>9!8$4,QJT++TTIE,RCZM4L*$+H->C-
M'GJ,L7`+3H72O:[6.53^;4=J+VSH/*;31*FVQ'A+L!LRI53%$LD+Q*E)<G$?
MK5UDRLU]?UAPESGE:Y#">(L:@1?VG`)_%#.XN-"-K'K+VM!-AC`X10QN%:-Z
M"0CBSLK`X.L:&DSJSE.)@<UY83U"/(?3G'!P,8,BQC/`/A;#>XHJR:H7ZR=K
M16+*8H@TQ19UZJC1I$C3ED(3Y\>K!AAA)#'_`(&67[<!2_K(<>#[7@$45?LM
MMW*71I0U&Q]J!:]6$<E]W(XC?6PB-TDPRH<HF;4I/3H]74RM0F4P=(<O;U!^
M,%*4))@DXQA+'T`R5]_=V/\`!5V[_P`?^R?Z-/`'O[NQ_@J[=_X_]D_T:>`4
M9ZGO=.CX&T;M67;T3A=WEMCZ#)5Y;1+O-=7<[TZ`@S"#6!3E*4<=[!'F^`@K
M[(QAQ[>`5(4H[K05):(59]N@*PX@]42D%L+L?A2:F3&)RE*@LC.M?FC(3FJR
M@C'C&0@$:#&<XR+'4#G]_=V/\%7;O_'_`+)_HT\`>_N['^"KMW_C_P!D_P!&
MG@%KR6T^YS#CHNGD\&[<+*=-)0BA45+6[!;+`R]RIQ0.;HA8T7AUF'@2Y4@9
ME1H,"\.,A)%[>O3&0/R*VGW.9N2^'Q.#=N%])C4I?X4_#0[!;+#PURN++1-T
M@8U7CUF!D"YJ6@R6;C'7'7[&<X]O`+I]_=V/\%7;O_'_`+)_HT\`MF/6AW.Y
M8LEC?'()VXG=;!9,.&R],DV!V6$:P2@MB8I,)E<`CUF!Y:W#!)V]7TQUQDE6
M7G&?;P#YC=I]SF8*96CC,&[<3RJ@\H40J6D(]@=EA&,,J2-+.^J&->$>LP/+
M6E,\@1*,XQUQDI2#.,^W@%T>_N['^"KMW_C_`-D_T:>`/?W=C_!5V[_Q_P"R
M?Z-/`'O[NQ_@J[=_X_\`9/\`1IX`]_=V/\%7;O\`Q_[)_HT\`>_N['^"KMW_
M`(_]D_T:>`/?W=C_``5=N_\`'_LG^C3P![^[L?X*NW?^/_9/]&G@#W]W8_P5
M=N_\?^R?Z-/`'O[NQ_@J[=_X_P#9/]&G@#W]W8_P5=N_\?\`LG^C3P![^[L?
MX*NW?^/_`&3_`$:>`/?W=C_!5V[_`,?^R?Z-/`'O[NQ_@J[=_P"/_9/]&G@#
MW]W8_P`%7;O_`!_[)_HT\`>_N['^"KMW_C_V3_1IX!8MH/O=6S6EB8<JM[>Q
M;=F"RW#@8EOO9$Y2!%E@<,*AIR1ZWD`-/"1XL@#D8,"%TQD6/L\`U_U\\=R/
M'9DA"=%7.CQE5_5BQHE(YJ[HOLJ?#K_YJJ(!"]2PDT(;'RY>*.=#!I`.0D>%
MO4O"G)?Z[P"<]:-C=X6S5>EG)L<.U@3#(?`*7K)<\23;6X&I3'Y>O@D,3QR"
M37!=$JVZ-V0Y$/+>'+*8HRKR>L*`6$SS"\C`S']_=V/\%7;O_'_LG^C3P"B(
MK#[H#D]/,:;H5VU%\BCJ5H6R!@1;*;"JGIB12#"_+"K>6HC7$Q<V)7O#4J](
M8>6`"GTQOEY%Y8^@%;]_=V/\%7;O_'_LG^C3P#H(YGW3W$L\YOKSMP+B4J]4
MU*34>Q>Q:HM.Z(58D"UM/,(UM&$E>C7`R2:2+.#"S<9`+&!8Z<`[H9!W81X\
M0*L[=H@]<XZAV`V2%CJ'.0BQUQK5G'4(L9QG^YG'`*(ZV-W/F)QCC.]PSMI,
MSM,')2RQ)K==E=A&]QE#PC:7!^5M,=1*]<25+VYI6)I5+3"$P330)$IIV0X+
M+&((%=]_=V/\%7;O_'_LG^C3P![^[L?X*NW?^/\`V3_1IX`]_=V/\%7;O_'_
M`+)_HT\`>_N['^"KMW_C_P!D_P!&G@#W]W8_P5=N_P#'_LG^C3P![^[L?X*N
MW?\`C_V3_1IX`]_=V/\`!5V[_P`?^R?Z-/`'O[NQ_@J[=_X_]D_T:>`/?W=C
M_!5V[_Q_[)_HT\`>_N['^"KMW_C_`-D_T:>`/?W=C_!5V[_Q_P"R?Z-/`'O[
MNQ_@J[=_X_\`9/\`1IX`]_=V/\%7;O\`Q_[)_HT\`>_N['^"KMW_`(_]D_T:
M>`/?W=C_``5=N_\`'_LG^C3P![^[L?X*NW?^/_9/]&G@#W]W8_P5=N_\?^R?
MZ-/`'O[NQ_@J[=_X_P#9/]&G@&!^@CSW+BXILWB#UOHJM3#WPW(,D8I1=FP+
M6H3S8RZ)`*6(V@#70#N4LC*5V\8&]2:(A2H38",X@DS(@8`SP]_=V/\`!5V[
M_P`?^R?Z-/`'O[NQ_@J[=_X_]D_T:>`?F7_NQ8QG.:K[=V,8QG.<YV`V3QC&
M,>W.<YSK3TQC&.`4'[Y/<[^X_MH?27V"_1RX!W$4Y[I3D:(AN@/;<7G!!DT1
M*+8[8E4:$O`@AR8(LC6\P>`8$/&,YZ=.N<?W>`5/W]W8_P`%7;O_`!_[)_HT
M\`>_N['^"KMW_C_V3_1IX`]_=V/\%7;O_'_LG^C3P"R=$5-TJ]FNX4=L`S5:
MP67F;ZXA<&VG)-+9=!BVH-!LN&<U*]S:)0E_-<CD_7*DL3>`DL7AP`8_;G@&
MT;@#@#@#@'E?[>-XZR:AR_:R3..RK"WJ=C=G;@E%RUQ,Z4NN7/M?SNLKJM*M
M#$\)F42CRF.O,5E<(8&HTM`=D9;&YX5'E&J@*<I20,8('6^NU8T["Z?@W<_3
M,#3%K#IFPC%C=K;MHWC+<:FK*EH8O#'D;>[)FQD'8$EJ8]U<QB(4&!][C+)&
M6(!YBP"V[;:Z=8H78C?66Z>+C/MNT<R*2Q%X;-NJ5:FF/N!>]!KVO#(4L$LT
M:F0FL^SL986A04TYRP*(<V.Q`0#1)<(0,[*_MW55GH[<&NI!O_*FF=;0N$F5
M1^Q6"OMK7615?&Y#)Y7-(_`%N75H^&7XJM2YNJAZ=Z8FZ,K7F(MR`"@)9B=,
M%,!=>M%XZ9Z[W-9MX_/0:IK+)U0AM3,:5YUXV$PEABTG9'9+8*,LR)PS%SG)
M=5D";KX01-H:\Y)4D,T83YP>#S0D)@,:7-#J,W);NCT$[BBA)7MY6K`M@IC7
MLNUSOQT9I!=PZ4GE)7T]28Z,12(EN\6ML,@CTO"@],$U-,HB0N4G*Q+U&2@(
MW/KK5@;$ZL17<K*PK#K+-M?(C-`ZU;.(II$29S6&D$`Q[D=&W"0QEB,'<M/E
M3DRH$0R%!8I>I"-1@Y.-0L`FR<G:8/$GN=9`NX/)Z\CDMF%7R6CD[35NV)RN
MB&"#Q."LZ^KCXJXH7*I+5K`4I@/OE,W/<=$=D,B>4GJ"3%!:X`&7.OVTFFM/
MU[:$"=>X+:BPN=WI)K@CKY':LMSXJ@S/)D+9ZVN"99.*<F;M*8L4_D*UB,;M
MA6Z($2@AN]:H)1%&C`GZ$]P/1R&/H'U3O;>4^+)1K$X8Y/*ZFJN.'FJ2\`*5
M*28[KA'7/)Z06.I>0J<!QG.?$$7V.`8'))YHG&ZCJ"-0#<-KB%PP"&'1^86[
M]X79IW53QQ8ZHD59U^G-2*FDIX98.Q)Y`H+-9DCB066WKUY2,Q,H4B5<`I3K
M:&J[@YF&M^[<>BC#FMC86@88I3&WV!LKBJ/IU_1*P.<W2ST,J9H3,*S7&-K<
M_)G-M5,[V:W'I"R_.,4`7;)MH=9V/77;>)I=JTELVO<;,H;H=)$E5;2PAX>T
MI,B?Y)'$4N3NN'B'L:Z,#EJAJ3JF`AFR8R(4A9PC!$D`3@4M!86B[.X2-V9=
MR"D"IR?X$YQ1/FFMGSDM=Q=CM2U[+EE8Q;.(^3A/!G--/VUE1$A+*P2@8B,&
M%C+P0G3@7]K9?>C5`V>PS]1M>P2I&T5C*JZ]VF4#L84XD?$T1UI;E[BUO#C%
MW8Q*4^S>DGI]<R1`'ZA5)AC\?G`/.4@1I6UB:909?7*!VW3;)C7;"9!1SB`.
M-,[@M:)]>HI6-(1-QLE@<H\H:%R&PGZ4TXI5*<..7)L6(),M(5D'BP8)6!.=
M'[,:54I'+59\;W22?KIO7"&'Q%?,:'O@PF#OZ"'EUP*3>4W1A(Y.I3W!81""
MG).6L1FJG9A7N05!2AX/\D#%(^8:].+6@:5/<8:&T*)W?Y'&75MUHV65/%,R
M!SS>0REU.'K$!9+.6O\`OX>4O`8`O`B8RVA(\KKG!`%P(9[J&C#.I$1M_6K3
M-)&KR],+6PZY;8M5=,RAYNA[L^PH:I:&XM`\CA=D1E^.CS@:E5)7`!!91V!F
M%@RE&!):*\M/6>7-CW'MXUK.RLL_JJ9,S*KI_9.8`;2Z\*/;7I":IG4/DKW)
M6.8QD9:,+:].#D<PN)675I<41QAB80'1MJW]+IE:5MV[!]T$,0DL_F!,GP@4
MT7L[ECFT<41V@(Z[U)<!,<9X\O?H'DBD5)R(YO/1+DBF0&C#GP$GDN('.FM[
M2=-)QJB=W5J.'*IFPR$<<0TQLT)P94D:*UF)1K6*1O#(]/JJ4.[)0*^..2MS
M4KC%D?DII9IA@RE6'$"5M>-J],M='5Z<&O=]TL9,YD0!G;FN?43?AQ$98XNH
M30Y]4M"I%$\K#9$^T7"X:RY./$(HU^CZEY/`:8[JB``9U?6RZ`?AX/\`Q27C
M^33@#ZV70#\/!_XI+Q_)IP!];+H!^'@_\4EX_DTX`^MET`_#P?\`BDO'\FG`
M'ULN@'X>#_Q27C^33@#ZV70#\/!_XI+Q_)IP!];+H!^'@_\`%)>/Y-.`/K9=
M`/P\'_BDO'\FG`'ULN@'X>#_`,4EX_DTX`^MET`_#P?^*2\?R:<`?6RZ`?AX
M/_%)>/Y-.`/K9=`/P\'_`(I+Q_)IP!];+H!^'@_\4EX_DTX`^MET`_#P?^*2
M\?R:<`L6T.ZOH0YUG8C:DO8T:M?!)<B3`%4UWEA$H51]P()"(P=:X``.3!XZ
MYSG&,8]N>`8`5]W(]+4?9FA-5*KD-*G:3MBQNOU++][.WC`%2PC51%'3FSWJ
M7`1LPPENX,E>H"HRFSC'CP9X/MN`:[&Z+Z?SVL8_-&3;&)0]\M!I[?EGSZIW
M:I]@%L$5W!JK?,0L?[\RM^:*:4K?OD/FM+;FOQDIR#$0CR4RL:DX"8K.`,H8
MG>Z-'.J]>YQW.I)*(TV7G=4LM%L:A[;1H4WA#_+VV1T7*HZW)=>3TL+D,$C3
M6*,R"#`4*8V^-RY2>0Z(S/+*"!C649EDHZ,U/!.YTF@2V-TO3E?E.<7.WQ9B
MSYO6>K.U=3/,S&X-M5)7P2.57I;<)FYJ,9HR\F140#<&&`3Y&!F;J-W$H7"-
MB=M95:EW66\M<A;IJAHY]L9[V%D]4+E"2T9F_1D2^O0:_-2F(GO#9(T21$N9
MO>):.'LB)&H+"X`&)2!$,7D-!0Z5N+4DWI8)%3*[?*A=\QLCI7NU4=EYD[+B
M4A9-M(VH4Q:I$K:?';'G)K=-&-,(64_Q"8X^I+3A4$&D`6#74G1P.I6^J4O<
MT4-Z.-:[:\UA"5T34[M1E+'YS`)\TN=\.[BB34F8\2)+=,?:QN:1YRZ)'=D=
M5JANR4J0"`H`!]*9H!4MIIZ?NXO$;#D5(MKTXU^]3-JW?`X0V5*->-VJ.1$,
MSDBI]2[KANB_8B'NRR4'*"I&G!&STQ63?+2&Y`N>,6R_(GVBWA\[JRPDRLI/
M)E\A$V(MTW%$[,+_`+536U420V++:B;8Q-#8[0DI)AJ1,]D#3A`C`4$1:8)8
M@`35KCLM$Z\LW6B6V]W"'"71.N:CRSW)%&-RW2>$<OO](>XHWJX6])-Z.7XD
M\-N9I<\*7.&+U#<BB#LD(/:E2S'FX&!M[^MET`_#P?\`BDO'\FG`'ULN@'X>
M#_Q27C^33@#ZV70#\/!_XI+Q_)IP!];+H!^'@_\`%)>/Y-.`/K9=`/P\'_BD
MO'\FG`'ULN@'X>#_`,4EX_DTX`^MET`_#P?^*2\?R:<`?6RZ`?AX/_%)>/Y-
M.`/K9=`/P\'_`(I+Q_)IP!];+H!^'@_\4EX_DTX`^MET`_#P?^*2\?R:<`?6
MRZ`?AX/_`!27C^33@#ZV70#\/!_XI+Q_)IP!];+H!^'@_P#%)>/Y-.`/K9=`
M/P\'_BDO'\FG`'ULN@'X>#_Q27C^33@%I=I^;1BR::V/L&%.>7J(33?_`':D
M<:=LH7)LRXLSG>4B/1*\MSPC;W5%DTO/M*4$%&AS[!!QP#:)P!P"S;%_>^G?
M^1LG^Q[/_P`2+N`>4+LP]C[M4;+=KO36];STX@EAVU9-6G/TXFKM*+/2N,A=
MPRV2M^%RM.TSIN;2C?1HB@="2"P=`8]G`)SUETAU6T-_M"<<K'4:GF.DX',^
MT/8T[D\;CSM*71"[R[&W=?1\+XH%*7Y^4EJPL[:01C!9@`>`O'VO7.<Y`]/G
M`'`'`,"=<OXZG<7_`,J-7OY/C-P#/;@#@#@#@&"?;=SG.J#-USU_\[]P,>W^
MYC<&]\8Q_P`6,8Z<`SLX`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X
M`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X!'=O"$"I[0$$60B#7<U$$0<YP((L1I
MSS@0<XZ9QG&<>S/`-;%:9S]1)`!>+.!?5)Q7/BZYZXS\SI!GQ=<>WKC/`/O5
M??2KFC4JBT;A%Y\7+XA*=7]1'*&B0L?OI1,K#8:WCT3L-(>)^P@,J-S:Y*6[
M>^##2S`IDRE/Z?*\D23(&3=@;[:T0B/^]FZPF6<.YK@B0HHC&%Z84@6$FO<'
M:W1T\IS&@2(FAD;[#:G(U2I-)).0+4YA`C/4I_-`N^SMMZ>J-TI\$T>LM42N
M,<O*9K!5X"BBK&.)HV]8(V0FK/(7H&YT"O\`UM;DG*(@LH1R@THGH9D"XSMH
M]>B'0EE.MV&`=E+N8Q(4&7/JI<W8+5(7LA&TEX+SEW$YMD1=S$(DWF@<,M2T
M"81HTB@)8'))MF:.ADEG$2ET_;(T\URWQASEX7I(Z-Z%L12UFE4D:CBW10@`
MW.)9$:A+HY+A)33@-K>B.4*LDE%C$$"Q+BW/I*DY0U166O*T:HY5!3I*X(FY
M8:S0Z)V*P7`^Q:;.;KE/A$Z,:S[R3R0,MN&L6$B"`P9(2,B,"!(N=DJ$]/8B
MP-N00Q'4T4(G=CJR']$>EB,+4!>\ERIU4DC,)`P8%&G$`U0!#)+-0GEC$$PH
M8<`6BS;=48ZEN!QT^BS>5B7I(A'<'OR,:N0K'%#6(FL9S<'`5\8.<GZW6%J*
M3N9:4X2YU0@Z=5Z3!H%,HG<ZB]@2*T20N1'AF-DP%5/B8.I;UYSQ%TS3&ZPD
M\A9I4O0I5#"V.[*VW"P"Z959)7%K@&HQJ"?US@%*CVYU<O[JY)@I<I8_#:M4
MW+:<ZP^LBZ%UY7^7NTX\VOBA^0J#D<D+,=*?=RUQ;<(XYLSY7G`SC"C*<"5W
M_9"B8MX<R*TX@SEB2G+?4+G,)*0"0IK<GDM0<LR#*4@IP;F5:-%D8P^O$C4%
MIO-,(-``#KR/9J@XE$%D]?[3BJ&(H):;`U+T%6<M)#-"6TQY'%RB&\A4L5/F
M6HH2@"<HL9@R>@@XSC.,Y`CYCW9U]7CEHWV=,4/;8Y+W:--+Z^/+4:Q35J:J
MVA]J8FL9=VI6X(#8LXQ29$F)#3S"3%(B3,%@%T#X@+U^=+0@XS$YDDL5J<HQ
M-;*!43"\M:5U<$@K`$6ZGFL;KE,@,''PI4C*I4'*E^$R0I,`)HC<%F%B&!5Q
M;%4@&$O5C9LJ-?!<<=2F-]?,*3A%M3NH;6Y[2MZU&$C+B2I6L#ND<2`Y)_7V
MQ42L+\28T!H@(_;=V-9'5R>6U+9R,O+`AFCDXN*UDDS>QX0P&6LT%D)Z%^7,
MQ#0[X^*7Y,E1A2''B<,C\:;!I?060.SC<W6=<UREQC5O0V7G15C]^GMT:=`N
MBMV(-Q@*)-'O3%F%2!4M4&DEX`B$HR7Z@H1F``,`(0%ER#>VFHQ#:?E3L5)"
M5MP0:F+-01@II/4N4=@-SSRNZY;9$\N"8)S"?F/2.RT(%:)&J4.!P`&93$'?
M:8&!.\(OVEK)?448@5FP^6O[C"T%BM[2QO"9<L6PAR*8STLD2EE"SY[;Y,G;
M!FB#G(B`N*7)N`84$^,"*VO=G7=6SV2_O<S%"6FKK==*6?5,R0'M0G25H(J1
M.$2Z+)2,KE<AC$FB)HW%I7D%Y*<$J<X96,X+%T`NE#MKK6YO"Y@;[H@JUV;E
MJ9N4I$SL$WQ+UARI.0D1GA+RF<3A*$8B\X3C-\`QE!%TR>3@P"B..X%)^^8&
MPQ"3H;#<9U-J]B!9417H%6&9#9K3*'2*S):-6H2`71=6***$^3D65(P*<X+R
M'`@CP$#*/@#@#@&N7MLYZP[;?K[?_P!(UO1C_P!5[R/&/_5C'`-C7`'`+?EK
M6I?(K)F5&(H*MXC[RUI1'B$`@*EP;E*0@1PP`,&`K!IV/%G`19QC[&,_8X!Y
MJ=(:,_M!VC>J5)ZF0>HNU1,XG1\3'$6.42J\MF2)"](QO#H\>K=26FJTS:6J
MR<Z"#T)+"#PAQ[.`9):G:N=S63]T$C?7>Z-:<P5CCFCTMU0C,:UAL2UYDL7N
M#[=\/MA(]O:6R(.P!3DEDMBX@8R5>>F<%8\K/B$((&^3@#@#@&!.N7\=3N+_
M`.5&KW\GQFX!GMP!P!P!P#!/MN?Q4&;^'#<'^6%?'`,[.`.`.`.`.`.`.`.`
M.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`1U<'
M[TMH_P`'4V_<TY\`UL5I_,1P#['\TG%?L^S'\3I!]G/L]G`(NUOC&A<AU<H2
MU9#-%Y<K;1:J:VR25IW27M\N3WM';8K^X:^ILUD2M12DQR(N^3H3DAI:`0C6
M1:'&%@F@>1Y`R>QVZ]2&6+SYME+S,'^+3>+.T7L',_LSWHW/,>;P5*IE()"I
M<"B2%0S6Z@&0#RH4B&:H(3K!JQ"&I4F#`E)-K]05B0VOX4I?IS)XY4R*45Q&
MU\DE3ZH/F4+L.#MZ-^BA\E?2,&6=#7R"O25$%R3'*C1@(R6%=E24ISP#H@T,
MUR51SX<;D\I3MC<?$2XPI9YFL(<X'BJ9I+IQ4Z&&O*;&7!DQ3DRFSTH8,Y-,
M/197FD&C.("646!>5EZ<TW:\V>;`E9<LS(GYM9VEQ&V2=6@0C1-D*LZMUY93
M>$LQ,5F3U_;KRTN73'0T@9!I6"5:8E0`#\G>G%,S^2(9*YE2MI-;H;$H*D:(
MW)E;.Q$L,%8;?B\5"!N++-\"MI8+TD:4!@1X\8%1>1X$(@D0`.C&-+*?B-6V
MU2[2OL(5:W#'W^,O48739P6)HTT2YM7(Y@1!E!I?K(X*4N#LL<E6<&&^!>J,
M&GP07X2@@1[96D/Q7=$?MJ'V0X0\>)D[SV8)U+87(71QE;BV4LS$.C*>Z'GQ
M]&C1M=#L>"T"AL4%$+RL+R3"U`,>("2:GTRIRE9C%YQ!#9LD>HG#@0%`!PEJ
MQS;U<4)KVH*S3M3JC4E"`M"GCM%1H83,Y";ZQ$,[(LB/.P,"HPS5^*U$V38^
MH5IR*526M05ZVFV.-RGT,3E-DOM>PH^>_19.Z1I<](2)C<CT8M))<41ZQ$>%
M-@\L)10@`60CT$UZ#%(M#W1C=G!D8*Q@]6.C.2_OB1AE+'6[A+'V!*75O4.3
MBN+70F23QZ7-)I2P)Z8;@(!AAX"B<%@=5?I,Q-L+@,)K^Q)Q'RHSL/'+]D4H
M?G0<HF3^X-$841=Q;D#L>%(C95#H@"GQ@S"4U.1@LSPD>(S`@`4!^[:FM+XG
M);2@6/'X\E.&<CBT=G[J@CB$6(9$*]290-IQ:O"(UOA<*2MY1Q0@'C3F'8-&
M9D0<@`E5=IM2SG"U4!<4\J6QY=:H;@7E'RA=E4MDQD>*B+HWJ50`@&9&7V*8
M.;EB+I@(TZHWP"`9D)@`.@MTHII=5+[4(E4^3L,J?(D^RI[23)<GEDH-A,,C
M%;L#?(W<).27MH)KZ'-S0<G4D&!4$)@G&>)9G*K(%BB[=%"@;D2!"]V\TG,X
ME*F/.S;8[B2[1QU/F,`L$E[:%1B4XL+BBF=>D+B\'EGIS/>*\@XHU*I\@`%7
M?=`*(?70F0976:TR1!(Y!+F21,U@.B-WC\BE3RRNTC<FH\PI03@;P0S90'EJ
M"SR1MRQ43D'Z[X@@7@MTVIY9]YS`39LC!1T*KV`0XM'+EP0+([5DYKBQH*7)
ML'EJ,OJQDEE6M:CSC,A&>')Y9WF`-SC`'U2^GM6Z_HI,U5>\V0QL\GBK-&3&
M@^<.#B@953/$&*$"E\=+6E&FM4Q=F*+-GJU6!B),5(\*0$@/.5&'@6^MT.U]
M4O13XA:I#'3L1VNX\L11=\]P-3M]ZYALJ,1-_=F]O1E$KI44P6P\)%3@+_"%
MA`DP#LB"D38+`H1?;SH%.B:TB%79;<<Q&^H8W-%/%Y;FT*126+2@]0B/&G-*
M":I51%.0/(RQX]*8<`.`B'@80/N#=O>A*_E<9F#*OL]6Y0\^OS(Z0^V"YO2)
MO35B2X%0YK\*TD:M4TM7OA9D!!QQ@`!5"++\!("2RP,Y>`.`.`:Y>VQ_X-VW
M_K&MZ?\`3Q(^`;&N`.`.`.`.`.`.`.`8$ZY?QU.XO_E1J]_)\9N`9[<`<`<`
M<`P3[;O\5!F_APW`_EA7QP#.S@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@
M#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@$=6_^]+:/\'4V_<TY\`UKUK_
M`#$<`_JDHK]C_4Z0?\?`+6UU[?S)+Z)U_L4-F/3*\2BO=0[.>69O84_PH?,*
MJF,2MMEFA;4)V"X$6.K@*<$"->0K/!AA+*,PE\XHO`0+Q0]K9M]UM3-(;58Y
M,@S#9;#YCE?4HLK)6XK8NUQ"#V\`Q18ZU$UWNQL;04E?GT:=8W2-+^M@:VWP
M%#+`JRKMJ)QO*"7&V0QN4E85T1?V0DJLTK`@2/T17:8.&<M"DB4NJZ+IWX&G
M9:,PU/DT]*FE:[PY-R2$)X$H:'4%<%$0I6UV,7!V4YU,0'R!N96E4KDLB>F&
M"UW7<<>'24@G,@:<HV&*P$",O)20I0[8-PL5EIEF%&58&?\`P!P!P!P!P!P!
MP!P!P!P!P!P!P!P!P!P!P!P!P!P!P#7+VV<?]S=M_P#A[C6].?\`^_$DX!L:
MX`X`X`X`X`X`X`X!@3KE_'4[B_\`E1J]_)\9N`9[<`<`<`<`QG:-0J+CJ=8B
MC+38$5;%S[)I,<RQ.\[UB[`4^3.2.LOE"Y"P,%DMS*V">I,^+%IQ:8@HK)Z@
M8L!QUX!X5NZW8^]CA_:`(KVWM4.X!M+JU7-MM='QZ+%-%X71)8O%)-,Z^"\K
MWA4TK+$+=E1#FZDY$?X5GB!DS(@ASC'AR!K,KO8[NIL=\]J]UFG<YW&M76/N
M"71"XVU*46P=RPB4&-L7V9;*%O:M96TIYJM6QJ1,SB$>"%K:XJTZEO<4JI.H
M"=DPD@#W(,[=H4H7[@)I;M%W`*U;M)9W#X=<K]/-_-UVAK*:I['8ZZ1"Q6,1
M=RJE+C7<@?W5>QI'/!>"CG)B7X#^M%8,$!".QEN]O.BX/8<FC.P_<4NN05_2
MMUWHIBT$WWWA2)%L4UYNUDU]MAK-F3W:R6-,\GCMGN2IMPC4FA$-2V*`"R7X
MD^3@,F(_$^W'*#($0Q[X;@+5-F/KS&(>C%W$MX$BY9(F"U!T8Y,KHA76PF5Q
M=R^_.7F*)RG4"(:R0YP@3X-5"P7D"*H\^=O"?3*L&*KMPMTK#C%BH[.4_&31
MW%]Z4P4QM9MD:<'))%F!78@7*R#BC9(`ARPS"/$QF%"PL"`6!!`!=S>I[6KG
M'667)>XIM-B,R.N'2VV1\6=R/=9M;G&NVALECXIDA"AQMQ*'!*J/P5Y<D2<7
MA5N38VJ%B0HY,6(W@$2E2+50&JVRNV;G,>YJV0+678VQ=>IDFSOYN^O7>&M[
M;9:I?[8<D+;9RN31VM6/#UE^>C#VHQS9F-"K.-1C,(\H0%<BKQHR[/4522/:
MK:UDCTXK&/63!Y3&>['M99Z>P4LXNV24K6Q%;-,&MUR=YXWV*X1_"QL4("QJ
M@B.$B5)$RQ,I++`O2/N?:RD[\QQIE[AVVJAWDD&1V6RE*>XAO0V(UL#<JF?K
MW:Y/AV=;21-"=L=::BSG)DHC3P"5,S<J4E8&60;D`%(=Y)VQF=PC:8S=G>]<
MUO\`%]E9FME39O/ORMBT*C>HB6.K-@'&P74%GXS#?@`F6-XE!2PLLX12HLT(
M<DC`8("[3DO;,)<HVS_/XW&/=Y?/9G5\9:D7<$WO<'%YGU=G0DJ=QE&A0V<H
M4C71$NQV10X9R'!25$O`J&/"8!AH`*]"(?VY+*D\;A=?[Y;=S*6R]S<&J-QV
M.]QG=IU=W4QL;(*]J'$A$DMPPX$<-8[.CJY,[&8`UK$3XA4$*#"5)0Q`94#[
M>E(E#$69L)O668`60C`/N+[C`&`6/9D(@BNW`@BQG]3/`,;]M=:JRU@U]L_8
M9ME_<!M:-4[7MEVK/FUH[G6V4:5H(/5M<2RPGU2V*76XU9+L^..8T6VH40`@
MP-6N`,XTD@LTP(&)T9F.K"6W=?ZFO"?=P.BS=F*,CEVU7+WCN<[>RJ*N8)Y8
ME,5C74$<U3+:A*ACE4TEEUH$*<2PLA"!>F&GR<+)Z,:@#(K76O\`2_8M0AC4
M9VFW.^^4L^.UYU?1_N7[ES1<V1N'6G9U6)'YX=V>V"FQG]_.M4.V0)%>2%)"
MI(I29",Y*;G@'<41/MP)&Y*\*M]MMTS0NG[S6"%V/[CFZY36MFD;?"(S)6Y&
MXCMT*-4WQF1JBD#FY%C$V-ZPXLE0H+,&`.0+(D2CMR,TFB,*:-Q-])I*IS/I
M36D>01#>S?9\;LR>(U/.[F=%+D_(+.4-22)9A==N1I3R4-0WG#)%Y1A@25(B
M0.G$7'MP.]9,5ARW>3:Z&&***9;^EK65W.-RI8UQ&'KJMBUR/727,-LC8Y$;
M&JYF+>^*`(\Y5^X51+F).!$<`W@$JD5UV^E%'O\`LB7NYN?BD8I-CZWD\_-[
MA&\Z=NCL\36`BJL^)O:`^U2WMK>P6"Y)FOR#DH!94*"LXZ@,`/(%CQ0WM@S=
MO<G.+[_;B.B)G=:N9',S'<#WR1FHG>Z+.D5*UDWG)5]F)56%4HM^).<8`'`,
M^F?4)R%3Y*@&2^`6W,)3VO8C4TFN@K>7>.:0N*5M%+9<15YOCOC,G8<)GDB(
MB4&<2FQIM,PP@Z82-2!*@)5"3C-^V-%@)!9AH`*Q<3#IW0FR56T!:U[=P2&M
M%K4G([C:;<>>X=NJEAK&-FMVG*;:HC+$V;9$XQA5)Y/=C4%.XK_3-R<P(B%)
MI)HR0F`3!'*8T*EK1;T@CV\.V[DQ4(G5KKA>2^Y5N,2V0)K1"D(#GQZ7*KH(
M39CHSXB[%$N)(C4*@]K5E%&C,3'!`!:+3$NW,]N<>9&_>G<D3U*/>9;2S*NX
M1O0W.^%K4\65'CV9V:W*TTBZ.R-6_4W*T2)L<2TK@XJHZX%)"3AI3<!`CR)R
MOM13HS!<4[B>W3P(<6D$U*R5W!=]$X%$6B]0M]^O#TE-664F+5)04LYE2=/@
MO(AKF<)JA,$X!!^2P++>)YV\B)]24>C&U6\,OK^UQ7:&4V\F[D6Y+!%:;!2]
M!QC9,Q;/6^36\U/);3-:JF#:Z-*HDO)2I$O2J2LFIU!9G`+^1.';4<)H]0M%
MNIO<H.CU9QZTGB0E[V[Y9BR-IE=S2?7V/Q?+MFU,".LMQN&&.K`&-%E">@.:
M`Y,-.$\&2^`4M";H[+=D=<==ZDV1WJN0>P[;9:]-8L`[DNX;G"X29`*:@5\-
MJ%Z<OOQ>@=5LRKFR&A>F(0*3E21.O3&J2BRE)0Q`6Q$Y1I"[6M?T%F]_;WU%
M#J,N:1:_!L2Q.Y5N&TYF]FP&.0"46:8U1`-N&.S/6\&;[09,*92M-+:0&+2\
M*!I@G)1*`)^:H%V^'QMOMY9]UMW7)HU>(F9]_NJ/?;?<YNJ_-=/$H89XDD2T
M%EY3>\X<YPMS`Y)$XCU2,M-YII82C"AC`[9M<=OA.M@2!1O%N,G4V?EB'`O/
M[B6[I)$E12APK9FC3PB6&VT!&7'9#(;BBS4A<SC"V]6\/R-O*.$M."1P".@N
M7:T,C2V7E]PG;LV.-RNN$"QR)[A.]QP"E]ORVP(%6*'"<JSAJS5DWG%62%G;
MR@%B,/<VHY-C'G>$`@)D447I(CE4'@RO;G>M+,K)J])<\%C"G?/?,A\DM9K)
M+$(>"4-S:;9X%62DTEGS,D5)AA`M1FN1'GDEA'XN`0VK/[;`7.L6ECW8WCF2
MJV[8:J<B9D-W[WF?D09*]U[-K5:GQY<$UMA1M->N=?UV\.B21F#]S+DB$XU,
MH-**.&6!W)U&^W(T:TV)LLHV\WGL.BX:^1ZO9FOA&^&\LU4CD5B+84R1>*&Q
ME#;(W,XZ8%V>PG),F%`2JFQY2K`F91GEG"`O6M],.WA8S=*M7*IV+VHDC76T
M%<*\>J/:>X!N0DCK17T:4.51.\,31\^VBFQ7$8J[,:J*NA","A.T+DIC:JP4
MH+$1@#%762==L"Q-6JZN!5M3N?KG'@5[`G-744S[B6Y;4]U;&7Z)3&01%$)N
M;K:"D7Q)+!JM?EI;JV`/9D[;'G$T9X"V]7DD#-&PZ*T8J:4QV%V/NIN'$)%*
M60R3-"1W[D&YI27$;`TRM]*D+N[EW*:S1QC<&J"O1R-6XJ$J==AI5A3C-$G-
M"$"(G,?:_9&=M?GGN"[<M+8ZI9.L2FN7</WG1*"D\,<*O;90)Q;U-I%N+.8S
M'79$3#2U91!F4DC;U00B3*2S1`6E84Q[7=<MUR*7'>/>E_=Z%7C:;*A\0WKW
MWD,P:7DFZ&?7A:THF5-:`!O"UINB0(6!?Z49I;>L5DY4B*+-+&("Z;%1]N^!
M,EGG)MU-R91-*R+>$"FMVCN.;LCES]+VMNL]6"'L;<5:ZM8XN`E],2I$K/3$
MJ4[4JCCH!8(D;<L"4!/NOVH]%[`:^TAL&UV_W!8LQ7?3]9W`V,3YW%MP#7*/
MMEF0UDF3>S.JM%=QC><X-B=[`G.&2,1(S09R#.0YQP"50]O:CQ""$.PV](A"
MS@(0A[C.XN1"$+/0(0XQ=O7.<YS[,<`U:[!SG6/6FXMBJ_L5^[DXX#JRPZD2
M^X+48>Y3MFX!9(9N!84GJR&RM%"S[E1NKHUP:81D0I$62H$K3M9V%20E6(!A
M`0)RE1O;:BZ[+0#=3>J6/I=U4_0*I@@N^.^$N=T5BWG.9?7=?$*4S1:AX<Q]
MPD]=21.8Z%B,0@.CS@G"8-61Z<0$IQFI=`9G";*L>+[S;;O4%I\P@%E2A%W)
M]R1-,4*6MJ9X:EZY0.Y@>>T/S6M*4-BU/@Y&Z%&8$D,.QP".4V.V&K?JPC"?
MN`;?F/URJD2&MVSZPG>P!\A7.%O.=`)D(\F6@$ID7??O:%$3,)<!)#29`$*$
MP(5!A8!@46G6;4>^+:V/K>J;?[BT_9-?*;J:Z")_#.X5N8^M%KLMK+[L:431
M6S>*XT"M^<$+K1S@00H(&<W.F5:?*10/&1^$""ZGN'1*T:RK&Y\[*;916K;!
MF3A$7F6OW=OVE0!K)=&*&L>][(CMC,CM;+/(H?9]3M%=G)9#&'1(@6$%&&."
M4Q6A3C.$!.[@^=K-G&TE/7<!W,8S7N2OL/0E/N^G<!9#0R.+2*N(G)VQP*=;
M#2#9Q1R16_&$J\Q9@@E&8^)/.&`)F,\`AW>67:WZ,VHCK.7/?<=G@U=!.-_)
M%,8[G&U#>_R1`T7C5-&**W@,3?+I2GS&U79[MUO5M#6!4G+<2$ZDO!Y1H2PF
M`25<JK1BK93"X0Q;*[RV9+WK92GM<)W'(UW+-NT3E5:^W9=+($5-I)[UN@E$
MX1N%S.%.+8]>C.-&A<$:A*:("D@9/`*RZOO:K9(\FECMW$MM$,=5L\JD*9U/
M[A^]6$YK%"ZYBUPR%XP$-H".PV$5+-6J4)C\AP6X1Y<4XI,GH\Y.P!F;%=#J
M!F[,5(8ML/OH\,IZMR1)W$GN#[KDIU)[2X*6I?Z82JXR!*""EZ,P`3@8$4;X
M?$`0@YP+(%Q_5PU%^'3?C_:&[F_EIX`^KAJ+\.F_'^T-W-_+3P!]7#47X=-^
M/]H;N;^6G@#ZN&HOPZ;\?[0W<W\M/`'U<-1?ATWX_P!H;N;^6G@#ZN&HOPZ;
M\?[0W<W\M/`'U<-1?ATWX_VANYOY:>`6S%^U9KE""'E+#++W9BB:1R>03:0$
M1[?C<)J)>YC+7`QVE,I="T=RE!6O\B=3AJ5JH?4U0>/(QYR+.<\`N;ZN&HOP
MZ;\?[0W<W\M/`'U<-1?ATWX_VANYOY:>`/JX:B_#IOQ_M#=S?RT\`?5PU%^'
M3?C_`&ANYOY:>`/JX:B_#IOQ_M#=S?RT\`?5PU%^'3?C_:&[F_EIX`^KAJ+\
M.F_'^T-W-_+3P"#XKK+&(%O*TU,1;>VDLK]^U/F-B+(Y86Y6T4W2D3%CM^`Q
MMN>VT]]M=2O;E`&5\5$#`4=@HT)F,B!D0<9X!L7K*C:QI]QFKS`V)P0OEC.#
M,ZSA_?);,IM(),MCK*1'6(QS?IO()&[F%M#(E`F3E8."446'[4.,YSG($M\`
M<`<`<`<`\0W=D[1/=PM'O/D]R30J"T\Y$0./5`HK&26+8,*2!33&%00N/N"Q
M;"Y"K)$H`VKS#/)PH`(DS(0CZ"Q[.`:R89V!^_)F]=++`LVL:K.JW2ZP((^5
MG6567G4D2)A$09;D!<TW35Z2O,5-Q<YF,L6+W,YW>!+U"IT/+$J-,()**+`]
M-<\TYEM@G6">Y=KG8-ES;.L;'JM:!41W2U.C*:P(9%9C\?Q*<2M(VO1:9VMR
M+RTU0J1/HP>,`5JD@90TR@TD0%L/6B,JD$5DL1<NVMM08@F5<;'57+%I>].J
M)3H_1+:;8QOVIM(I6I"Z^4F<17(A$M;E*8L@Q&F4&IOUPKRPE@7*R::REDDT
M=EP.UML(XO3'93I:B\YSW9U7-*E\D5;6G[ML::5DII"D"K9(5LNJ-D32G3>D
MR7DT2-0-0ASE-P"DOFDT]>J;IJC@=N7;-CB-%5CLI4,&<H[OAJJURWX)VQP6
M3<R1VD('<Q0J<'AN"-(D5E!(/0IS1X+%XQ>/`'V]:1260HK-9W;M=["&QVWZ
M"BNNDZC"3<C3QH854*KEOD+%4SO'4;,L;QP25U/%)&-G9#V$;:CRVI$A:U*L
M&F+,P!D55L/V=IZNYU7D+[?>T"7[X]_R79B6S13NSJ:9-'.U)G,&Z<2U2)6F
M>4C#B+R5Z;\@6LN6[+6>A4GI!$93FY+X!@]=.@E^OS.F5:\]NFU*2G8#F=*H
M=RMG-)ED=):`[-2G;25N,8B"]LE$*A\VD-OR]8H*6(F4"%`A,RD2I4Y.`^$"
MZ(CH[?@%$8G-C:$;$++K:HE'8ZY3.G=MM/Z0B:-=%M8+.U!C[M7D#A;HA:*Y
M,8*5MIU3(BVD*)*F<L$K4Z=/DDD@L"JL.@\B8(RXQ(OMH[3N#0]QK<>'R`+C
MO3JEY[[&M[877<+V$:EQJ!V08)+>BZN:'%N-2A3J&UR*,&49Y)HR,@2+4.K%
METS/(38[!VTME'^30:6;#35$;+]VM3W5$\/VT,+KB!VT:_(4;RUDJDKDR58U
M91D$^G*0G8.R5C`#<@P!U:UU)G=7M>M3*S]L'8)X;]194GE5!CD.XVGRE[A`
MVM$C9(XR$R]L7M,S6L+!$D(&(19SB,]Y9,81O)SF2`O``,KGY/8<J>G222?L
M:P>1R)\7*'-Z?WZR-&'AZ>')69DU6X.CHX.RA<X+E)HLB,--,&8,6>N<YSP#
MJV#B^I]KO;&K9':4EU<T]<\`GE;3-@J?9/3V`9^&[+CZZ,3(3,%FD(6]J=W5
MF<CB\K`)\G@$+`PYP,(18`QGL+5NS[-=Z,?)/VUMEA.&O=7T_44#,0;LZF)"
ME$3HV[:@V#@8I&1[V-)=G<BR:,CIZI1C!/J4R8PC(<`/-\0%6HK6^R]?++@=
MMPCM?7TMG%:);L00YYD6Y&I2I:WM>P=C2NU[.8ESFU/3,]2"+N<[F2QP2L[B
MJ5M+<KP6H3)BU)>#N`6FBT]F;5:+1=#+VO+^9++;KEE]VN,A:]P].TZ.52&Q
M8HP0ZQF>51(2TR$N;/8+5$FDYY5@;27]<YMB9P&Y>N!E0("IQC5RV8?&J?A[
M#VZ=JD\9U\L^W;*HUG4[T:IN*:KDMVU]:-93:M(X)P>5*A5688M<#T4W(W$:
MY>W9$G"2L"2F)*"!$17;B*)K]561?:NV1Q$U5.NE-^FSO-JYE6G1ONMT(U$?
M9XG6YD/GXL=XUVKQKC9RX61I<%%&*BTH%QQJD8&0GWA+A%KU:>M!G;4V--KV
MX=@5&S$R7"W5U1#+#+04W)%[X.4M;R6^EDMS(*Q8@D/]&%/D&$WF$8S@L73`
M$/LFBTNC[9*&YN[;&U`!2E34[B:XG;S:FGN#.[TIM[8.\%?.S*,QSRF)6-=]
M6@\J30GE*$ZAL4!1&%Y**+R$"CC[>:HVO&VMS^UQLB:U,=`YUJ87W&[NIZ:9
MM=6@G\5M!"U'2M$[I7:2B9I[#DCF@*>AN:!"K,5&D)BQK%8C@,F=A:EN7:"=
MQ>P+=[8%ZO#I':V/J%>UH-S-6&V/S2MUULU-=KK%IBVE2<8EJ1XL&DHZI4FI
M#$2D:=*:F"8%.I4%F`6]$M?;)B.NE]ZH$]K*\'FB=A2+*:I3#GG<K5;U$9B]
MHNLI?GN(0>3L\E:)4VL3*^31Q4LPUJUP7M0CPE$*0D$$%%`4AWULMV53B&V9
M/>W#L[8=AQ-GJ]O<9C,-W=35CS/WBCTURIZ;FD]]WN[8A=9;6P[[DIR`Y*2B
M2J#U90UJ=7E,1Y8&-2KMRV5%("ZM-0=N38YLF[33TFK2LET\WBU=>XBS+UND
M*C0R+.$H;FYT+<71M9Z8`D+4!*SYIRQ/ZO&,G"SX@.2.=N6>O=3PZ(WGVS+Z
MGDZ#6ZZ'VG)&+=[69F:IJ\R'4*K],GE:W%I7MF7-;1&ZMJAK^&@E`2JF]:5E
M8H$H5&&C&!-,ZU!L^QSQNTJ[=&TBF6F5Y2$$-FJ#=+31G?#'/76]'[8NH[,]
MWM0DD1+L2.6=*G-0>:!L"TNB5><G7-ZDO(<!`O&!:Y6I6VQ#!LO%.V9L0AFT
M;F,WL5NCF-TM32Z]Q8-F4C7FOMA3`<62/:7PN,MKRJV,)Z8H\MM3KD>5"5,G
M&<=@P"RIYI?);+>++>YEVMMAW59;MF7-8\^Q\]W5M,2])MA(_2\8N.N<!3R,
ML:&N)NU:^1,)R4@1:].-K\:=83D]1YH&24$/W)H6J;TA5#]L*7+7VX[,O2\3
MT]U;8:U2:#J+2OJ2.LSEZ9_21^5HG4->K)([G?X`F"880C,R47D0<!#P#&Q@
MTQD;-#-<89CM.W*G:];J^A=9QYO;MU=;A-DGA<#O.M=F(S$I=[UFJ]Q=HXP7
MG4[,](P%G)5(2TXT9AIB(\].8!18-HM*Z\6%JXYVT]I2P)K/U[M9N1KMZ-4E
MR1K?=7[UM[8JH&I%@YW]3F.LMCW>_#4D&F&G+T9A))YP_)P+(&;]EK]A;<M6
M@KIG':AL5RL36A]G3]5#V3MOK*BPU'63"ED%F#:Z)4\\`0^L3JV'IU.42G`R
M`N;:A5X#YR0D00,*8GHPY0HF$$,7:IV!*!7DB@#C%O4;NZOJLHX76%)6_KK"
M:?/";)\@65BSU#>\I:O),P)V.]YY4&.`U)91H`)20T'<R/33YC)O;<V/7TX2
M&O2VQW5;GZB$V.TDU)(X3):O+(E;:YMY+D="E-<LI!*EQ2+5:Y*A"%P-6#&:
M,8%Z4I6MQ4%<4XO*ONU?<A,YFZ*R6S(G;<;5YQ:(JUW'<\@V&M=NB3;\7D81
M)I[<\F5/RWU(U@RS\ED)A$)"BTX0,7H[V_G:)-58I8]VP]F$+_3)E4HZQG)V
M[NI3O*XK#J=C5OP^*UP'+XYN<=?8*LC=^S%,Y)G1N7*5^7TPT:CSTZ(Q*!DW
M;-97=<UGO]HR[MC7XG53S6Q_U'MJ',.ZVL;5`;CH5Z'*CT4-L-@Q+CSU)L46
M3M[-:G!M4MK@GR[*2S#CB#/*P!BW,^WJ[3MD3-3]VS-ILKS%D[6R24H=Z]5$
M4EF^;";->&5Y(E*@IX]VF)T;/JI!$R/")*A$24R=!"'E6LRH`JT@T1E,F>;>
M?W/MJ;3Y=+H5V$Y290FWIU23X:GBR=IX5N0^N\8*`[^4VJTEYU^VK48#0J4Y
M*$L:,11A!@@\`N-ST[G[@G?$Z?MK;-,N5]^V3L='%;-NQJ(F<J\GUSM%LLUP
MH(6YGKU3AB&V.FO26#6-;J8Z$(C7HT3;E#Y:?!(&1M,QS8BF:G'19?;,O&U:
M>)B]50ECKB\=P=3K1A\5B5.UW#*XB,>C;"_2++:A;1HH,D=%H!EFY5/IIZ[.
M<&F]`@7,WM$U:5Z)U:^Q17C:YMBQ,X-KBWS_`$21KV]>B.`I1KD2Q.YEJ$BQ
M(H+"84:6((RQAP(.<9QC/`((M37NS[LMRUK;L[M>7S*C+P2:Z-UKUZKW,U2(
MK6;M.JLQ>K#I=E>V-%(4SLI8V*<OQ[DM1>\,)7@S`"5Q:A*'T^0(T9M+K%9Y
MS*+*,[=NW+[.99<5&7HXR22;YZK/+F7/M=;AMNZ*Q4%*%+OXU;:V/EV/K8<G
M6958.8AITOB")*2:$"4J[HR\:HU<GNH=>]NG9^*U/-T+FQ(5C-N_JDW3^`1!
M8M.5MD+A$Y0O:=Z#'XPG4F(F\3L)V7A;A^E/4GD!``($&Q[0.0QE962MM[:.
MTO2IGIJ?(FC.WEU,$@P>R;CK]ZVU(Y)"G(DM8VI[\<1GX)QY>,M&`H,Y\K&<
MY`FK7#7^X=5R[#3U-VVMF422P:7A.O?IG;>35Y;F%5'6;K:SK7$5@2Y-)4#J
MR"@PKE>B4"XY0J<,$B(\T\T9`1\`BF[=.+DM9KG+^B[:]RH[NE)SG)2[0D&U
M&F+D"06$1K7;>L$,?[5CR8P+#8B&/0&Z7S"KUJ$U>['*O&M4*<DI\%`1)%NW
M_LS)J]9HALKHQ>=D.D3'8#1$7FO]G='JM4E0NR)MKI:TF;YRHA#7#FVPIDNM
M36]H<1R`YK1KQMX@H#LGX`,\T#+?:>A;@W#F3S,;C[:6QA@I/KQ+-5Y9'HKN
MMJG'(_)Z0GM@PBRYM$W(*=^/>TA\FD->-0#W!`M1N!*0D92<XG!IF1`6$;IS
M+C4[ZS9[76P88:][-,NUY<$QNAJ6..,UE-[T]29\:&E2:\&2G->S>4R)<Y.K
M*K<E2?"I4;Z/*,LP98@.BSZ-A005GKUZ[0EOSAC8YI!YJB.FNYVL3PXC-K/5
MX_3:OXVK/(EZ!.LB<7U[.]R`1F%"RM&#"M:8J5Y&<(#/ZH;.VQHVJ:VIBO.U
MM93;`ZG@D4KF'(5FVNL3FN31J&,:&/,I;@YJYT8L='#T#>7E0I.$(Y0=D1@\
MY&+.<@2)\Z'>+^C$L+Z5&K7RXX`^=#O%_1B6%]*C5KY<<`?.AWB_HQ+"^E1J
MU\N.`/G0[Q?T8EA?2HU:^7'`'SH=XOZ,2POI4:M?+C@#YT.\7]&)87TJ-6OE
MQP!\Z'>+^C$L+Z5&K7RXX`^=#O%_1B6%]*C5KY<<`?.AWB_HQ+"^E1JU\N.`
M/G0[Q?T8EA?2HU:^7'`'SH=XOZ,2POI4:M?+C@#YT.\7]&)87TJ-6OEQP!\Z
M'>+^C$L+Z5&K7RXX`^=#O%_1B6%]*C5KY<<`?.AWB_HQ+"^E1JU\N.`=&DR-
ME[-W$^_E<&L+IKI#HSK3(ZG;??UO5793C)Y-)+1ADO!Z-%6SR\":T3<UQH[S
M350@8,,-`$&/8+/`-CW`'`'`'`'`'`,2M[K3GE)ZB7O:57J_06##X9E=$U>&
MQG>3B'A4[-C8G$D:Y":GCZYPSA=G"8"\P"+)^0>>()7BS@#6_.-W]O=3'U(1
M><-<)NQ2Y-+2ZL8)[FHX?8V$KC/]5:^C$PO644POE=31)CCLKL66$DX9Q&96
MH3FHI4$E<8(>`.HO[U!I#TPM2*A8TI4/U/269":%%\1YO7,5@QV@S[^Q&7J3
MKHNGK;,,=V`HLA*^I'I47DM6G4'%$"&-*6!(U*]VHZX[LINH6ZCDY9$]PS,T
MPDZ>QB4&6:4O+C;#4I,@L;G,6A+]847B3A4BHAW4IBBSBSSSL)@*2T`S5('Q
M;'=.=(%<EOU6;58SAU#/4B)D202;-TTF5HQMC0J#962H94T(=X]$UJAP4HDQ
M+48[$R((SPYR065GS1`4=M[L4Z7+Y(A0TS24S15LYNZBQY?5^S"V<PA9$68[
M3T"I76#\GIE"5+92#&VI99J!;AJ2IU4;4$C5]51>20)JO/N0+JCVED.N"*I&
M-0@C,,3OCG8]@6TP5DR%.+Q5UA6<TO843LU."U75S(37QB!]>485:E`::I.+
M1G`;3P&@8Y_75HA!H5W#0*M.BN-<SX>:W635P(OVO$4PLF>U?$6225^."`CY
M%FEOE>JQNT:R]^N0FCPEQD8@8.-`^%O<MOJ:2RFFVOT^JQ+?8#?!5REM@EW+
M;><%K[+=CM+(BA@XWP5>Q5L9G<FN-BEJ1](`G5*6P9A3H5D10"2#0,GV#N.)
M9/J38^UJ:M2(NQQ:PXQ4479IQ)7UL`_6,I>(#6UALKLK:8&\N3."MKZDCY#3
M1%H505R^,'F^-,2>$90$=:J=U/YR=M4;7*RJ(]!VVZ:X=7]`[E6AB8/!<[8#
M+,&\QQ%'F&'&91Q\*"K%ZE(XOJACPO(,#E*$\PLPG@'2F_=2>XR^V!$2:8AC
M`]558\HJ*P)/;=SJ*SJU@LF(1FV;7-B)DU45L\B-<)I1,*C,D8,A2^!2"<HR
MS/!Z-1DP#N![JP9+F&QJOJF8%=K3>4/47!6TWM,$7?X`:/8C6.B84XVJTM,-
ME,CB">2(MCP/@BLH#3/*9QD)?584!4%`2QL+OO(=?[A?(8[59%W&M(-':K<9
M]8"FR'=K?&]VMN-;!OC.6RPY)6[X2XQV.GT,(+FL,<257IW;!B9&>8E$0>!B
MG#>\!84\95A\7UO@KF\Q.5R1BG`#[V=VQCR@;97J'%F17$%WWFW%S<%KBHV[
M0C4DN*-L]*%@5XZC&H)++`Y7;O$2QGE,KA*W6E+[[KZ(VQ\9J45KMIR91/*O
M9+X<%*VNVA\CT6D5A58:Y40J2G.!*=,Z$B6&]46!-JD(P+_E_<3L"'2?82EU
M;5!U$\USUS.O)#/T\B+>2;H<*K@]2679[&.#Q^/JFJM&^8-T].:T!3B]IWE+
MXDZQ.E5D*B3"P+WV\[G"'5J^XA3!-<M$X"]19J>W\8INY1R7LJZ51BWY!%""
M6!3!UK"L;3SJC-(4&`=QJPX6"'A,'";&%0$%-O>+=EF8PG,J>EE:E?'WV:N*
MZ-[-X?X_-65J:M6W\FO]?'4%3(\W'>PD.SA*$V.X+:R0.S(,@*L05Q(B0+4?
MN]VL:*YL.<BU[9&E7'W3)D+8Y5<:="N?69(QW7('>.RIOC\)D[O`K/:$%)J/
M4M[FG3MQ0G'PA7&GH#R#@)T*[C]D21L<I\S5;$(_`X[#=HK/9VMRLQM(?+*9
M=<(;7`!1)_DDDCK#"ZF4RB97$A4@795NI*=L8E(S3"PG9P`"7-==UI'?:Z".
MQ3<Q-;-9%";!2X]C:1N[L*OK)UEN.-5?*2!.[Y'(@X/;/,@6(D,+"8B"0F4L
MQQ:=0K+-R?D#"9I[P5OP.IZA#:6OD8E5KR2LZRL1^=HY;;=&8&^QV3T%"K@5
M8*>Y;#HPU1ZUY$>_JR$<>_7&L`$AR@#D8009@($Q/7=>F3#.*ZC"W6<H]NL>
MPK':&90FMIK0O!\%@>RH]7@FMR231F.LKW:ZJ5(U#TIC:)P4%)6TQ$F`M.5K
M@>6!01=VV>.+&2KA]#59+GA=7JJZ`D-.P[@J8HI`$E/7!<2ZO+&>$%.."N*[
M*Q]OIXYO=XGZ,Y,VG/",\;@(K!@<@9S;0[-K(+J^?8-184/%J68KBM84VQ,C
M*1/GY+:UCG)V],(4.0K2025=5;2:ODCNTY4$9-;V!66(POVBP!AM0.^5R6WL
M'KE6KMZ>.IWMCC4-OB%/402,\K8KFC,.WY3VB@4$^K5JXR6XRS7...B%)YAO
ME-1X/",8%>1Y`^&_N1W##ESC$;"@%1'+I9;MYQ>I;-DUM+:[KMLB<`VUN.CT
M2N^EXJU<DU:$M[+#&Q(V'MXW\3ZZ*B$YV4:A5C.`(-=.[;;#VSN1D8C$&A2N
M9V)1+G#3++E2-D=&2O;&0Z4MCW7M:LP8NL3WS887R^'IU"(1S+X6%4W'`^V4
MD@*`F"L^[=.+5/0IH]K0R-ACL]N"]&.5WHP,@&F!L]87A:#PBF)*:,.Z^'6L
MVH:1.0GM3D2D:R%3J`0W'`42O&`)NK3N&RBT]6&*[8Q5$-/LI\V)K[6\=?&V
M<]@AC'*[&F$)C[>Z.MC$5HKRX-S,RSQ(XJ!LS:[(E6`Y*2+#O'Y@`(52]WQ3
M'X7F86[34)KLERHI9>\;\-X87LZQ`KI*P;5A\`7/KY7,3*!8$F=ZM=V\*5*2
MJ#E-DE01E28$].4!6(QW-YW9&Q<1I%B@M604DG:AFJF6J)%9;A*'%[JMVANR
M@$[LR+H_#BX6SSMQG=*HRTS2:[J'`LU8-M5I4JD&3N`<EJ]TES@UQW+51M7&
M&&4_/&9&QIX'-6^;32T8XUJ4">7IS&)-"7:/15P4K7E&E3M)KL3(LFG`_62B
MQX/X!;[5W8YXZ'2Q.V4O24T35B:^/-B2BL=F5\XA:R&L#3IP\+LUL^I:71@E
M$U++VY+3&-ZT#6C(61L\L:S'JB\D@9>;S[+RW72LZ_NNO7)ID$.,GSG7$J;D
MC>DD1+W(K!ADVA%()$#FE/$-`I5;/#B;"?@L6<#"ZFEF8P(&.@&N!#W#-S(F
MY%9=DM9V8;KX@MVG=CV!<7FKFZP[FU8IZQK>NV>PV0((Q-G"/)9=%386J8FD
M*/*`LQV,":H`4`><`3BQ=V"<3RPI#7D`UL;,N*JV4530!1.[B;HP:6X_?>-J
M%P=[3CK/%)7,(2C6'$C>VD*9N<BW!N!Y0CB#C"1&`2Q8O<J%`Z=TMN,^K61.
MR;2)6%VF*=ZLH*=15K2N*AP7CW,V,\1>I?9AR!9+<A+.;V@HD($P!+/1@4A&
M4!C6'O!RB/L;8(VH8A*7`QGF*1,Q22[V^)V^_2.)TH*ZBI4*`M53GM9-+OV%
M9,=(DR8X7ENR=3U1#\L(1@2.I[DUS@G3O`&RD(2OLAK7RZ$NT:<KC7MM7MS_
M`%8;NT[2J2LTS24HX3ET321BU6(*2D*6LG!9[J6')9.$QYZH"9-9NXF/8R_&
M"IB*^B$79IA6UI6&RDYM8+S<D73U6XT<UF_?/J8N&(4\38K#%=`5T9<2GE8!
MQ:4(%/EAPK`$H"W=5.X%/KLE501M^JMI10RQ5Y$`33\ZQ0KYV?8A&J5>[5K5
MCK!&RM([%DD4''IF<TX4IG3"D3@E`9A$`@W/E`<E+=R-7?-D[;U9#H'$4SG0
M]82^PJ]E0)N^.[%+11R=6A6939,FM9!8T^1D[$EKD*A1E&6XE!3+!%%&'"("
M<H`PLB/<ZV+::JK.'RI57+G=#S)-9\3.PYE+&",I9*DN&4ZG()%%Z$@#15S$
MFL.0MB"^%8E;>I&A5LZ(20[*I68I)\L#)(ONXL3\.%(HE%Z:2*7^N:OL"5R&
MR=B4$)KF`.LLKZ=6#+ZEDDS00&4^[[;9$L-PD;VA0D(/69$K/4`2!0#*/`B=
M][SQL!7-[*?5*"?#-C5ZN:L9UC!C\O2R:N81LA:\895[815R*,!CK[%Z+(0X
M6HU*I6F$\%''IQ#3C"J`S]JK<*92V\K1UVFU0$,UAT17ZJQ;;5P>3O$QC13'
M)T44<:/,@:MVA,07RH5MECER8L!I"(U`OA*TD8#,'E""!@W*.\X5$8-6DO60
M&CI*Y3XV/2E?#:]V,<IE((E7,D-J8L#;)#BZ<;&-DN"/#M<HMR8EBQ.6`Q&#
M))YH%F,I@*;).]2ICT'F4D%455K'AN5.AT4:VJ^W5]0B2QYXV!:WF(V*YM%/
M'E5];64FOBMQ)9C_`#4N$#EXQK<&(3"E(%PR_NL3&1P-UDM91"KH^\K3@)X!
M"WNX"':W`N22+MCP-QMRIDM;K%$;JU_5R)(:VN+:ZG+7)M$E/+RG]X%8*`RG
MU7WL<KMGB6GYE$8PR2^*5'7%DV3.8_,#5]=*R+M8JY<=?ED!7.+"TXD"2[%C
MU+$Z,G!N#4*R'*4^/4Y4$CP!">U7<@G%96#?U-02-URB?:T=FB$L;]]\4B36
MF0_O%"1[8,JPWJAS(DG+1TNC;7`Z.'O1CV,6'TY*$)&0FBP`"''KO9K&VO+'
MFN=?F-F5QY\*)A+/+;B3H5;ZV%M%WOCI'I<W1Z%2=Z@-F-#?1JH2AO<DQ#<7
MEP\`5QAR`\DX"NO_`'G36Q?*FQ'1#2>L/#4F:T*,MA,I+5I+)20LYSD-HN[5
M$5T6K5FC"N<(T?IE3B)Y4N!R4CT8"UA:D`&1<_WZE[1"-0K`BU5!,>=FX(G>
M4-</UB1U+'FF12RS];*R8R'RP8U$YUEQ9657>(UQ;@T`R6K2)<YRG,$<5@@#
M$FW>[-::0$;;F"&5M7+JP/=A,UGM"FTDKW/Y,Y0.G=LY*[*J7BT@K5.5(:J3
M3#7\DKXK6`3GDJ\G)3VK.$R@(P)+L/N[&P2"3.6X@U,'NR"82R+PJN'.^W8J
MV0$U\OMY!)3;CA#-3SH75+N]$4^I6LY)RQ0C4)EN<&*2S$@@*`+`8.\/8*=]
M;43U2,2E22?V,%RB*5AL]JB[A%Z>=(3JT],,8>%$N0(6B1W@I5;$X7!0$J4J
M-4A3%X)-_P`)),P!/]Z[WSS6[;&X6NRU,#*UTC-7PA/"TRV4H(BJ1V`OIG9Z
M\G5XEKV]0\W`UDK%0Y4;:D:9W\DL*C"C"8]0,18`+/K#>;8&;1'>Z8$`AZE=
M2FO<PMRGXR[M)B1M;)`BE>R9+$SRIU9R!.KVW)6JN&=(H$`D!IPB#3`A`,[.
M`@04_=TV_8U(R'16UUW(8!'T1,F?66"N.)=85B&1UUL4$W8*H3XCK(UN<'7M
M\90`;7#(CG)(8K)$I&;A2#`0,QHCW(ESWJ#8>RDAK2(19\AEI12IVECQ:I,I
M@<K>)VIK0B-N:&:PJ+25V0)P#LPE.>E5-!)^5B$S&1%)3RE>`+6U-[J&-FK;
MI*NE=41^"MESU0?,&IU*L_$Q>@3=J0R]T?8RGC[##A`0,*9NA"XY*X/BEC$X
M$8"-*4>+Q%!`M8/>#CC-)K88)]7\*AI%<3JT8V2Z*+D1JVM0Q0:`;'2J,.CS
M)"H>&#(7J?OFNZAM3M25W6N*$]Q$2J(+5(A$J0.%7W'[JLIWJYFIJ(4&S22:
MWNT0!)7$PNY<?9H6%M2RYMEIUO0MNJIS=*DC+VY(4CI''9)EX4N;7E-G*<CU
MV/)`RILG;1X=]`1[4U?[LB\Q=ZOJ2?%1]<H;IB*#.-D%P%[.C;V``$9"U:A8
M9@'P#,)39.*,*48+"$8<<`QX>-\K=H/4)=?5P(Z[GEBS#:+9.NH3%`25TB$0
M;8E64\NY(P1IM?FJK%C@H6-<+I@[Q'.J?`E)YIB@Y<''@2X`V>TK926YZ;J6
MX4#6H8T-KUG`[*1LBI42M5,Z6=19JE"=K4K$X"R%:AO)=,$C-`$(#!`R+&,8
MSC'`),X`X`X`X`X`X`X`X`X!%MTV=$J=K216%-F]V>6)H,8F\+`PM)3Z_29_
ME,C:(E$(JPM*@Y*D6ODHESZA;T83SB$V%*D&3CBBL#,"!A98O<3H.(HI8"V:
M<NYC:HBRNK-9F916L6=4,0F!D`E5II*4D)"*8/.7B83*#PKW@@RUEN<:5A7M
M@1N8#%J8(@*4J[@^O;5)7EBE&OUT125E/R.E6A(]UG79RR>6SEKKLUOU[BCB
MR3UY1+I=[LNAO`5ZP]'&0A&O!ARQZ19@L#K&]QC6AA1O[TDIJS$1E*MC)%Y"
M(R)U'$AUO*I-/YK61]+EO,JLR-,2&4ML@JUY]<6@6F,.4K>6,I>=E2A`I`CE
MG[DM!6FN>@FTA,5$,MP$8B]?JD\=9!3W9`$_J?5:60-`P@*?F7$3="TVVR5M
M-+D+@W`;R"A*\+""@J<$`7;JUL;IS%Y%'Z"I*E[>B:*=3?+)()+,V50_M[/=
M;Q$)N].%=61+YI8,KL%?/&QIUZ<FU0,('-H1&,:1,%:$D;?DP"1IOOM0+/+5
M;:ZU#:TI?399(J@K%X15_#5I=SR-BO"%Z\67$ZP='N8-QQ2"&V[-&YO=S'_W
M`WJ"P'*TIBQ(F-/`!=5J;AT-4]SKX#-*SG0GF*M$+=9#:2&!QE?"XBZ6PEG#
MK!(RODIC^3(<2.9N%1J4P?1H5*,A?A!A:H3A4)S,@8J._=/UV4UH\RNG-<+.
MLR31$=DKE<+8&NH&+$251B04PAECNNG[?8;A#B,ORN]HZJ3J(^O=U2PTTSS`
MEFI5&2`*DU]PG2RC:U-J<JH;<B\.:'MUB$%@DICD8=#KB5*;&NJ/SAY87F9V
M8XIW\8)M3TJ<'EQESFW+W0?A6A$L&N)&<!?X.Y?JRB61>4-]86L2QR*=Q6EH
MU:9];Q2(QS+I-X=#[54M9SU+I7&7J/MS0VSQL,6H%J=(O7.AII#<C<%*18$@
M"":Z[@6ND(K)\D4SH2;P)9+Y9,;ZM...S(MM%99PA1?8>0(K&K5U<Y(\N,A,
M4J=3%3:TI'<#.:WI&]"D0HB$66T7`-F-56[6]IQ:?64D@CW"WV#2>112T(Y-
MXU'D%A1N55^D;G(UN?C6%TD+,ZG!83&YP;U"-T6IC$:A,(!H18R`L#`]W[M5
M#(C(5)GZL;"B44E$`3SU:18D=C['9*Q%,/O-EZ[GQAC(?W:.+&^V5%S*$Q)C
MH\M1K&I;E0'$M'@)H@@7`B[H.G+2HK>/MD"L-("PX1*9)&VICK6+JG-&I@\:
MM28.L%^`F&2*ITX/V4=".X$*AI:'&/+E1"(*9R,PJ2B&!W(SW,=,[&F%/11'
M%9"YR>YT1#(D!B*5]*A0QKLBS955C.W35;%)A)P&M$_G$0<`'X8Q/:9*G+]8
M[Y1)\Y-P!QVCM%I_7,MF.K[_`%ZK:!TX1KNSR-7+8Z6&,N,!^^-2[;%T[4IQ
M(S+*G$6AGWP&\SU1S<HC@E")8E,4*#$JU-@"@S'N-:MS=AE:.<ZZ;`.0#:WE
M"^9MKK64,`_H*"/JV*VO)9ZH<TUBA4)X&;74Z1K1IT2P3[A5@Q*%!AQ(RGP!
M>]TW?K1K%<4.CJVB7^92RM*C1)ZI:*JA[8ZOL;BLX;;EM2;C2AE,JBD.1I0,
M6GAJX:H1WO42Q*`D`QF+0@-`K5C[7P>+7MKC`4-.M[]4.Q$0:[B=;6RP,Q@B
MY7-K/I6G:<+*CBA0B=LOCE*;B;E+FZJTXS&Y``&"\&&9,].!:]4[<5QL=LM&
M:Z;*D:"HC%$-IS6"3UU4&M4D;5<;@U6,<D`JC*5'A$0D?4]Q.J!228K/(.3(
M2#AEB&,."`.5MW>UQC2-MMYJUWO1H(DE/KI9'GM'6T73EK-1*V3-TU=;M8$)
M4\PA:Z?8\66A4J&TDM/,%)[DE`)C.,`4`L#[6=Q[60]8A)=J@MGX*1NCF[&V
M0XUQ"5%?1F+U]=96O2.VW`_$R4/S=#T]H"&E;#2VT3N%"G.<`HBV\H2G`%13
M]Q37I[<82D4TU<A;^ZM)UM0U`]5W"$[@CJ=T@,IL=)L$E5*YOZ%DA<BC<<=@
MAQE03)L+23$JEL)/,"`8$--_=PU>P<M=T=0S1NKOTEA*9=+,(ZH&<7<R:Q:#
MK-OKT!+#.'6*R-YL<.P+0KR_%/8V@E+GP+51>0*O2@93.6]%'-E0U%<#!`;1
MER.W$<]F$3@\4@#8&PFMMK5F>G"V)0\L[Z]L#2B)A21$>G5')EZDYT.4DE->
M''U9'F@=ENW4IESJ&P-C([6UFO<&BEJ-%7,#TRPJ-FO]PR]\L=HI9K75BVCD
MR=V<6E5.),6W!6/&&?.2A&F8QDC&1Y`A"8]T#41C<6F&SR"SQ(IDL?M0U^8'
MB&P!S61R052ENJ1V+6TLBJ:;.+^KD:%QU_D98E+>A<HVH<2DWA<Q95D&"`ZN
M>Y'6F'Z:);*U0O2+&5_)GMU2*%T5JJ4.C7"(?3VM]@3>VY*2T6$N*BI$59MD
M&-(8C2*7)X4)`X].2:;@U&0!78-W,M5I?,7&)U97MH2V2N-N_![4*&5U&<E3
MN0+DMH@?9^U.HI0@2X;FQHIQZ.79=3$$@.1`3#(0*"U:;S`+*B'='HIV/K8$
M%I6?`IMZ9[#=I.N;X[!TCW3KO#;'UXC2=XFL#:Y8<7'V(Y5L*0L<""S#)6VJ
MTII9S/@XI5@@"6ZBW>I"YI5!ZX75C*?5R-YC,70SM57S.74)=F.-5/UTQ>"M
M[BYO)TG*D8*R;%ZTHW+5Z!*8`2<:LL]0G*/`H\B[A.MD5666J>*AL9`?&)6^
M^F=W*(U;'T5L/]77<NUVDDAALADUALC8,<(L9G"G`LD2AC.-2&$FH/4!ST"!
M8*SN;:GS%A<I"W4A>4SA4_KLJ5OTZ9*QB:5`\11OH&O;_D13JM7SMDE@UU=T
ME;R)P5?X/D0!X4HFTQ4N`!.8!R:Q;+:6M,*V;A^I\#D62Z4CEE6F[+ID*0/S
M1::N&"<86[NA%D221SZ7*RBW2L43:$A\$C<0-B=$<E1F(0DCP!>L![E=%R"-
MPAKFM9VA6T[E::!C259((8PB<%DUGAU&N</CL:]WR-<TNSS)#+X:'9N*\TM6
M!$A<CU9:0]L5E%`7=>W<(UHU]M]VIJQV&59DB:)R>9*7)E88:]-JX336,BLQ
MY9\-@)87-\NB^OXBK&%8>T%,R@PH*/*[U`@D\`B>S^X?'(1>KM7%=ZP36QUR
M>>5W");,F4B#-;B_S%3;+E3HXZPH75[;%;N\QHM+A:W+G-2A;,(LFX&I2A*Z
MC`K2[N<:JJX.W6`.N+9>JX9D#<[QB5`K!@5-`;6(J!NO))3T=;U<D+>D%QMM
M9O65@!91IV4)Q2A&4ZB5E#(X!$[CL;J%";>!L%8^O=IHI^$C95*]S="05)8K
M3T.UH:7IAN&0S6N@6TZM49512+1E*SN<D8(\M0K5;JB;DS@>:Y`)-`O!U[IE
M+/$62/=3TO9,PF(IG!6"9,SM%XLUHJR:)[;]?501,9W*6N2OC2O97H=IG'-Y
ML;.D(C3$ZTM8%)A.N$0!R3[8?1K3_8F\+&E%8VC%)9&&S##95Z^B?9'5[8\2
M^L_OX$5O$6]QGCAB//\`.8I6Y"@\MBCR-M4N*)&0N4A4'),&@5Y#W2]:QQ=U
MES+4]X*6V&1I3,)EEKKZ$X!`DX9V@J)M]\.^)Z3&SBGIR5$B`ZMBY>Q(F0!J
MMP7HTB14,@"HJ^Y5JW%F!WL)'7-FCAK@A)/6SR+0&'NC-)+0?J>:+[-ILA8R
M2X]>_6HKJY<2X&&X*,CZ@TD:0#L8L+\C@&8E+6!7E^0\N;M$"<(TJBT[G4+<
MHS/(Y'$DMA$\KJ1.$!E"`_W*XR1C"K3*F')9*MM<%:90C\H19P@9QC`$K9A\
M2$6:3F+1S)1SL6_'%99&S)9KZ2L,<27HT&4OA,=BG`X9X5.<9."<+(\"\6<Y
MX!RF1:,'+!.!T<835XD@F\2XQH;QK!(!'JE0D0E(D^3LI!*EIQF2_%X,F'#%
MTZC%G(%`C-8P>(2VP)XP,F4LPM):PKIR_J7-X=5[SF+M&&2.-Y0W=P7%LS"Q
MH!&Y2MJ`*5O)4*E2@).%"M2::!6/@R'XR4+X4C7B(<G%Y)S[B:^I+P\`,+=G
M8K/I>I;DZ%FC"I/QT-/P+.!B%C.>`6M"Z7JBO(DA@L.@$99XFW.8GI*RX;2E
MY`7G*TQQP\''.?K5:MU*6&Y&6I.,&<7T#@(L!"'&`+T)C<=3JCUR=A92%JHI
MM(4K"6M"4J4$,X#2V@D]0`@)IQ346>,*8(LYP1@8L`\.,YX!'K)0]11UXEK^
MUP9I+=IP^P61R)4L,7NH3G&L"$!%<E-B9U6+4D=9X,-N`>U-K<6D;D*T9RHH
M@*E0H--`KS15M>,4HG,V:X@R)Y992Y`XSE_&EPJ<I"I;(W&8BA`K4*Q'Y)1D
M1^'-A&$Q/EIQ92!,$#)N1C$!6S(=$3@JPFQ:.&A7O),B7!,8VP85L@3>5Z=]
M5X$ESA2\D>2#P*A^(\/@#T%CIC@'X=#8@H`[E*(K&SRW]&B;GXLYC;#0/;>V
M$Y3MJ!W`-*(+DC;R!9`04=XP%`ST#C&/9P"KC;&XW"4)C>B,PB"`"+`TA`\)
M`%F)S2PI<"+SA.$!J0H6,`Z8P(H&?LAQT`Z!L8C1ZHI:?'F,Y80F6(R59K2@
M,5$I'`X:A>E*/&GR:6F7'F"&<#&<!-&+.18SG/7@'$IB,36&+CE<8CRHYS<&
MYV<C5+*VGF.#HSA*`TN2X9J80E;@U@)!A.<9D1A&`!P#(>F.`?HHG%AG)U`X
MU'QJ$C@C=DIXF9N$<F=6]`%J0.:<W*;(R7!"U@PF).#G!A2?&"PYP#'3@':<
M6!B>`C`[,K0Z`,.1*1@<6U&M"-0VFB.;CQA4DFX$<@.'D9`L_;%"SG(<XSG@
M'8):VU/YWIVY"1ZDORE'DI$Y7GE9$:/RCO`6'S2_&>//A%UQU&+/ZN>`=!-%
MHRB$W#1QQB2#9R3$[2-,T-Y`FM.=E/DXAN$4G!E$2;E(5X@E>$(O*!UQ]KCH
M!\`B<6+8C(L7&H^7&3@G@-CH&9N`Q&@4J!K%(3&@*;#>,*A68(T>,EYP,P61
M9ZBSG/`.PGCL?2.!;LD8F=*ZDH#6HES3MB(EP*:SEF7`YM+6ED!4@0&K\Y/$
M3@6"Q'9\><>+V\`ZAL/B1X5X3XM'#@NKHG?',)K(V&!<7I)@K"5X7X&ESA8Z
M)L$`\M09XC0>`/06.F.`=LF/,"9:I<D[&SIW%:)O$L7DMB(I:K$TIS4C4)2J
M`0$\\38E/&4GR,6?)+&((.F,YQP#G+:&DI.<D*:VXM(IR3E0E+1)@)S\IR$Z
M9/DXD)6"S<D)DA18/%C/A`4`..F`XQ@#C6L+&Y)`-[BS-2]`4M*<BT2UN1JD
MA;B0K]>2O`F/),)`M)79\X)N`^,)OV^,^+V\`J)))*<HI.G*+(((+`2222`)
M11)18<`+**+!@("RRP8Q@(<8QC&,=,<`Y.`.`.`.`.`.`.`.`.`6C/8%#;1A
MTAK^P8ZVRR&RIO,:W^/NQ.3D3@D&,!H.N0"+/3*DJDH!R=02,M0F4%@-*&`T
M`!X`QN+T%T[+.)/%0L-4FE1A\B1XEXWMRP[-TD;Y6TOCC(P.#LI!*)@XM4[>
MTPY`XX5/V$[LK+"LP!0;@0'03Z!ZP'3.[Y_*:_(G4IOR1N,AF#E*UJQ4)KRX
ML]=LXD<-)1'("(FH38JUD4%.B()+V!0@3B];G"9-@D"Y3=(]5#(R1$0TO&$S
M*F71-U)R@4/K:\@>82=+E$??OB=O=DTF%("S9^^Y5K\K,K'+#TNPL-485GX,
M`IQ&A>H"5L-9D=#PU`V"CD=BB5(WY>4!;*SQ%HKUBB_PQE&ZD&1-VC[34L7)
M2.+9E(XD8C[>(!^!)"1``D"'ZNZ^P#,<%#:GB4>'$G6./L>-;D1I9K<^1.)R
M:#L+T$X9XS5#NCBTS=DHE)N3#U'O%08<(PXT1F0*81J+K8FG;]9A5013$XD<
MF:9DY/AA2XX14J9Y>QV`2_,S><M,:HVY.,[C+<\N9C<0ER\.B$A4N]2<6`>`
M+0F>C6N%EW1-[RL^")+'E,Y@49KA<T2\8G*((8U&FFQV(($L9#Y+8M7N+1:C
MP0-2N`K/2EJC,(Q)O-/\T#O-&CFJ#''Y=&6^EXYAKGK))(_-!K5TB=7B3-LP
M*@Y4ER\R1U>ELC6N3MBM&`1BX:K*W!C0E&$T(R@BX!4WO37620M:9I<JC8<$
MH2@E-K@VKI`R2-HSB62J<#4LDL9'AOE#(X*)3.7I4<J2+"5)_O5668,1*@TL
M0'R_Z8ZNR=E01QYIB)*&!NDF944S)@N38VJ74R.1V(+"79&UN",A\872,1%K
M0KFE:%0U+T[>0%0G-\H/0"UK5T,UAMFNG^N'2M6=A0/5?N5:)7J.IR4[Y'HJ
MZ-EGLZA$QG+RW!$1X6ZZ)44'S2#0^%\58SC/CQX0)+A.M53UHUN+)7;.Y0]G
M<XQ(HRK;&]_>5J-2*5/"U^?90XA>UKH:^39Q<UXQ&NZ\:I<,O`2A&9+#@/`(
M;K?MTZ@UG5\<JIKJ)G>&B.Q5OBH7^0*W1=,%Q3>TP%J)=124"TAS:'9)]Z]A
M/;QMHT0&50V$";`(_*!C`%P&:"Z>GNK:]*J)B:YS:FDIG3J7%3(''"@!4;E<
M.][.Y"YY4)GZ6'Q.=/#:<]K@*'D]"Y'DF*AEF9#P"LQC2?5R&.\0D$9J)G:G
MV$.:E[:7DIWE)SJYO2F0*I8%XG"]4^GJK+=6^4+CG%"ID8G4YO7&"/3")-SX
MN`523ZA:X3&P7:UI'5,==K$>#&I4?)U_KEQJ1T9%\.<VY]:FE<K4QUID&%M>
ML65"U.C+4KRVA(2K&>22`O`$$:^=M#6VA8W/6$]J76HILA(_,4F>;`2QXL\R
M&2*OHI5CI"D+7$&6,,3='W&"PEN2*2B4P,#\KH5Y*<)"<D#*N5T'3<XE@)U+
M:\CC_+P,8(T"0."8PQP"PE1^QXJ6U8-"<`/I`QVWI,DP'I_S+RIQUZBQG`%$
MF6L-"6`QL\<EU9,#JTQV&-E>QTK`W)N5QZ(,DDADQ9&E@=&M>A=643+*Z[8W
M%&I2G%*TJQK3FE&@&7C/`.*L]6=>J:<65WJZIHE"7..L:V-,BUE1G$J&YB<D
M<:0+VP@9J@W/IU:.'MA9GBZB%A$7USUQG.0(USV^M,\I!(<T!#/2"?3'WR/-
M??`$!R42$^)E_P#OCJ56!Z(>21Q`.<1496?`)OR'V<`_730W6=ZMF%VVZ0!(
MK75ZP/#/$8B(TPN#MCA(+8-NQXDI\?(R44\NZRR#`NGEKQ*D)2T@E24G`H)*
M-`!6F+1O4F-M;VR-%$08IJD39*V%W0JDRYT(4QF:Q,V"2"(%X=5RW*.%&PQ0
M:UI64C);4W(33"DB<@`QX$!3$V@VH:-"8@3TJQ@P>:_JE#B)[F!LA5.DF4UL
MO=Y`KE!TB,DBN4B=*>BZU.[&*QN2)>Q)%28\I05@W@%ZR[4G7.>5S#:FE]5,
M+Y`*_&<.(,:I2\@-:/6MKBSO!>'M.YDOZXB3M+PL2O):E4<6]IU9Y:\*@!QF
M!`<-E:H4O9=+2"@%L9+C58RF=L=A/[#$1!9`+WUJMUDNIRP$TD`C&\F3S!EZ
MK1)<D'@*4F^F,3FX+,+`LDWM]::'K&Y>?0$,.4MC)EA(R::^F$JDXV*91A0Z
M/"4;P)*_RQ=';#?4*E\7`4O2I*[JRSE0P'F8R!(;CJGKP[OLXDCI54;7O-D1
MMPB,W5JLN)H'^.N\:@L.=VU0C$ORA3@=HO6,=0JC""RCE*=E1A,&+R"^@'!'
M-2=<8E)%<MC]3QQ"^JY4KF@5`S'5:C;)$X-\\;'%5'FAP<53/&$3BEM"194(
MFY.E0GG/2LXPD1QPS,@4**Z1ZIPIO<VR.4G$TB=[0KFMX.5"=WAR=6MP55^K
M,:W%X>G-P=UC8D%5,;*1IS#Q$H$K(D3I@E)R0EX`IE9Z-ZXU/<,BO")P8DF<
M.YK#[@$I4J#6:`(V"O&ZLTJ6%L81EM;>H-CJ96$2\XI0Z``[+B"U($BD:?@%
MT2W3_6F<DH2I-4<;6F-3O(G]H7I37=G>&9[EU@KK4E#LS/C*Y-SPT+Y!/G14
MX*S4QY0SQ*SRAYR0<84(#B9M-M78]%2H0QTE!VN)$,3_`!@A@1H#B6XB/2BL
M8U2[^SDDA4_K2!RJJ'-;",`<XP%O0E%A\/AZ\`N"*:QT-"%-D*8M6K&T??:2
M.S=/$91SH>TNK8_K7IT?VE`R+'!0SQEH?G>1KUJY(U$(DZM<L.4G`&>8(S($
M2-6@FML8>**40J%)(=&*!L]UNJ*0IK3(E[8YVJ;5KA2\3ECV^2-*]S'(:ZK=
MZ6-K*A2.*5$E(RE+\O)*!&44!>TXTQU=LJ=2"R9[3$3E4RE2)Q0R)S>,.:E,
M[A=ZY<Z@=5RQC]XA8#'MRJQW/CQ[CA+A>:S^6E$=DDDD)8'6BFD^K,(<HL\Q
MBG(\VN\-=%SXPNHETA7N('URE*:<+'YU6N3RL4R-^-EZ7#CA:XB5J@*S#C`F
M8$>?Y@'3)T5U%(6X7DT-!BS`Q-)"0)0IW#W26Q(F=MC:<13'Z_W*4_8B[.D:
M1NX4^'8UI3EH1J1)`8)P!R.NCNJ;W/'BS'.FV%1,9&AD#5*%X'23IFZ6L\K?
MI-*),R2^-I'TB,RQC?I#,G18K1.*-2E//6F"&7GKCH!TC-#=2%!$-)74PRNH
MH$_!DL;7/;W+WQW"\DR",2I$I?'MWD2UXEQ+5)(2S+D*=W/7)T"EJ2&)RRA)
MB<@`^7;1G6Z57':MX3V!(K#F-MMC6R/J:9Y][QEN96VNC:N,0-,:%@IF\YPB
M:]>G,6J25#@44Z+"2#RDZDPD0%Q)=-];$<9=8F16*3+:^-2)G=UY\BF*N6."
M5MF9EB-:A3.U4A.FXWAJFYGO)*X>\/7IE("Q%'`P67@(%!1Z%Z>-YZ<Y#K_`
MDH$D22PI.@(2+BV<ME1M21@+4^X@K\,PI2;'T)3<>^Y(R]J6X/I358R,Y+R!
M/T3K*"P5P?'2(QU*P*Y*Y/;T^^@/6@2N3S)9([2Y_=SV\:H:#WH\2-]5*E"@
M)03C!F^'(O`$`0@7WP!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P
M!P!P!P!P!P!P!P!P!P!P!P#';9ZR)-5E<L4CBKDT,[@YW'0T%<'5\;,NS>V1
M>Q[EA$#F+L-+A>W`*-98K(5BTM08;Z=*-/@TX(B0&!R!A"Q=QB:-KB1!Y947
MON2XGKFSH)HV&/L4C4PK`C8%AJV.VFV1E<S2)W;TLP@CV8\MH,*U*)>I;5'E
MGE(C2%'`)94[SKEM45[;3153NF99JX6ZM`@->&MW7&QVI::G%MA;/.:\C)89
MM*E4/RRF-J\L*EI6E+2S2QF)P>8!:RKN(O*+"]*HU]<Q.Z%W<D8DB:PD9Z`]
MK97^XXZYN9#F*(DY$H$KII2:D39)QA00Z(!B-*\X6``4Z>;\R9I88,_LU?N*
M`4[>XBB1-!S<O?#LCAEN5A%KUBT85I$*;$UF[I&[),#&D(2V[)Q3$Y+Q"\*4
M:?`%4J[=N<S../\`9@X+\40%LLMKC9Z&'%."AW9(W:"2`)ZL59/.:PG25>QR
M-Y6(Y*4F2E";<*@G"%DM"?YP$VI-HY>8]MK`NHB3-RU1;,AHYT/$\JE+<SV&
M@;EDJBZL:HB*9&MK:85^4G=2Y$47Z=$>L+0'E85!,"`#Z@6S<EF4KJYO6U7)
M8TCL.*76<Z1Y>4(^3Q&842XP=BEC>H&(MO2+&HZ92%U8TRG`<$+S&Y(M3&Y3
M+P^$">VFQ53JY(VX=;V4TA5G8*$XNS*SIVU)C.,Y\Y8<1(51Q9..G3.0ECSU
MS]C@&LN/[K[%1A`U65:<6BZ^GW&77"Q-XX^R*FR6.)-;3&W8HM<W/_WX^-\7
M@3&WQR,N9[TK"6>(@]X.,2`2ITAAH$CB[DK<E=W)E745.3W!C#$,OB*+O+;,
MG-,=)$$H-7MS2V,*$]9+'1G=HX6E![I"M1J"'1$N&I(1&&'E`7L\;SGH(/2L
MS;*@.D([F'.%S2R,]CQE:L.CL+?V%O"NB:E"B6I9F_R%A?@N21I!E&H!Y!R=
M0(DTL?0"P6O?Z4^K:%+C2KP:5,66M94B8RI4WBQ%(Y/RJQ(;LA<T\8RID+T:
M;:"8]8D$23A'Z)4`!QN"PY$!S6-OL\1B):U/1,/2,[M:L(@=O3@A28\NK$EB
M+FESB;0J%N@8^E5/DLBS@<5[Q&:G2&-:,92@P@WS/*"!VZQ[AIUBS",17[S+
M@TCFTW:XK'3%$Q1)L`0@`S$RAT6+'EG9VI<XIE*QP5,[8B//5/C4Q.!Y/@/3
M"3<`XTN\\YCD[=:SF-/N#PXN=T3V`0>;,KVU,48&U-5ISJ.LS'+/B(I&FCEB
MA@4=(=VEK$I/S+4.!*4HR!&EI\@=*$;^S5Q@T74J-?YU.I43"H2?,%$93J&?
MS)@_1RI?`H)BRAK<G!GC$UF-OMY3`HR<J`<W(GA6>(@MH/\`,`SLJ*U6NVHB
MSR=(WK8ZN=F)EDYL1?"U".5,+)*"E*R,F25G6)$2UD<75N39.RE-+P,G.!`%
MG(@YX!*?`'`'`'`'`'`'`-349WOL&-#D)URQY/G,2E$L*<G"#)&Y15SY$Q-J
MIVATAC,[&X.+V8A):`@&\-"YL0RMA<2#DBA"L`>VGK`*RX]S5`S,;I('2E73
MW>E9S5[6)FGS-(\/;BV1*L)>_,*98RLJIH`O(2V>4B0BPI,+6NC8L3#RG&6'
M(P*FB[BJPPMI:#Z7.43=]?"&=L9$4U-3-.0.ED/E=-:YP>76')#VY"C<6?/O
M(X2484IGB"#!OASP"2RMMY),J!L"W8E!/@]RAMDQ.#)FN5JTTE/48.G$*C,U
M3/;&QK6QWBLB8C7EQ0&H5V"STBE*!2(!R<8`C`RND$\4L+F:VEP"P'\!19)F
M'*/M+4K;#?-+P/)91RM]0G",)SGPCQDO&,"Q[,Y^SP#$&_[UV%8K/KJ(TK&X
M^%,^T].[2ES;8[.(DUD;8/9=0Q]\/6N3;(RSDBXF`S1[6-J%*G<#5[PB2%F>
M4CRK-`!&+#W(@)&&)_%-5O"ET4.=70R0N1+RV,9YLLEB)F%*'$N'JBEKI'F5
MM3/:5\097G%$.<=4Y5)SQ93GE@`OJ(;S+K20V(T1:KGN%R>'TG.+&/62QQ;C
MRFM[9DZXF.DH6`06U?/8LL<T"D@U[9QJ&CUJ$U.6H,`:G4F@66U]R=O#$8F[
M+ZFDZUP55C'YQ-!JG!!#S(@K>):MK]25(6.1$$N38AB$J;NLP4$>L3Q!(M2J
M#S%*0X*G($EPO=YUE;'<;VHHUY;L5-'G-T&B16#$'D;C(6&2.$8>(0].0,(6
M"*R(U0E+5-OB5JT[DWF9/`8#`0A,`C!9W(&^.)'$Q97SR^.*HF<2EG9W1Y:X
M*X"CT:AHI2F9F=$_-:-U=G0Q8`AN`0K2HW,Y6X$A*3'9*5!3`=Y=W&5`96V0
M9NIA49)<R'##(O4RY4)H93FZX6"J'K!"]'"SCW$IQR_EKV-1@DLEQ*",)OIA
MEY#D#@#W*DZYN='MCH]Z<F%L104`W=5.F=C18D%D%+2XJTK5KLS)VIH;!/3<
M-I7.BI24C1.JA(0+(L*/&6!/]A;026&6>358:4G2H;W'T+LQSY"$Q;$D8WB+
MR5^1%R!>F9UC:R*4BB"/R<\!J@82AHT>1YP%S3<`Q$*[@EG8RH6JX$7B.EUL
M[>;Z(W!LV;92;$F"3PN9+&E8S)&<P4C"^X+.90&93I@AP>6K4`SY.0,@&G==
MW>(1;,E2U0:E4U>HA)B7WS*A%-\ECLBNZ=4P\R1:I;(PM-CGN$-<KWPP@)2P
MOW8H2#&<7@P8BP+0HC>R3S5\JRK9K5JL5A3$\@IPE#<\-S)#U[/F+123G/S&
MG>RTIRN1)$LL+,6QI.:H6I4:50H+.4`)&$('3C^^$Y9'%TB4\I*0OSPDFUAM
MS1*HH>)+'WQ@C=Y22N4<:$D4MAQK3<J")I$KZ&.&&B]ZQ\LUS)5@P+"8(&7%
M`W^U7BP*59[-F$2]N<GQN>*_<G4#D_M88^L2-JEU-&6A0D*6%Y/5%K&A:1@P
MAR9EB)8$0,J<D$@9!<`<`<`<`<`P"V@V1M"E;9C+"S,Z)WKE[K:2N"D^+MZ:
M16`Q3Y*SSUW93Y-&G-R:3"JW>4D3P2F>VD#K[G=2!EO*,M`M(6I@+$4]QUN3
M.+@SMM6+I*=&W$YLD1I<V84+XG+8VB:/,E<!15,W.*P)P&V'%G(@`'E&K->4
M2;*HE3A62E`I";N9H3UTF69J-87#XVE6EB>,R=7E:Z.12?"U"<WIA1`M+EE5
M8<6M":,PT"HAW<RTV2!9P`1P$RU+NBLM*R(A7XJ==HR"9BGC@U/CC,6<0!Q:
M#2*<PU8]IFQ4WM:IY7ERF$!`N;D(E*EL;WMJ6G9R4J'@D"_*2NMZE\6L&1*I
M%&[N;6>UW>+Q9TIB/^@5E1\ED95IB&3LSI+W9.G=&.0GKTP#@+`B5-F$*@9!
M9AX^H'7V&OB90/7NX[(A<)DS!+8'$\/<?!-XVC5M[HX"<$B4"(AN;9)@UP.,
M";D/@R>GQ@0PY\?3KP#'!#NC<57RZ0P:]Z\:WB1E.18VD$*/(86=NC")K/DB
MD2YZ=%[NWR*Q54!5)'DV/M9J@8QHG<IO-6`1E9.`$=S-J5-:%8FH^6&*7;"E
M"TC'*65-&SI"GFDFAA+:\3!4A(9(<VO:U@3>ZESV)N"ZG/;>6G+&`P\Y.!==
M@;RJZDM'8"%RJ%+WE%`C:P60(?AQ$FUQ13MAKI"N2+IDYEK8X)+%IA+<G/[B
M<8E+8D+BWY&4>6::<0!U6WN$+'B8,T5;Z#D@#7.8/,34(W*=1=),DBF)3NNH
M%-49,(2IW%Q52>/G6*G>"V\9Q!;A'"<N*=2,HP`>`52PMZD<#L&6L;M"G]L8
MJX=)*S/2XU0WJ620%)UD*;FR2B?DJ-:!J;V\]_4C4(D@ESN46E-P<B":)*6>
M!8JSN:-S4T+'MUI9V+1`1IU#3EHGC+),/*I+&XA)I,U)ES(SJV3W@V)I@!,B
M\M6<0Y+4*LG!A&2R\F@5-O[B+B>9&XZ;2IBF?R=_:6%"QHIL<E92C)!8*&O6
MU<N>W2&IE*)M0/"LXMP.$DSZ<U`H``)F09P$"3FO<Q]D%)+;IC=`S1^)(L4J
MOB(2V/S6OF(E2]L3H&L3HT-R)<MCCT1:#@EB[NV+B23V0X9RY2/T1`C1`0S/
M=Y+((4E%02"80@E[?7;[$A3\M<S'-:26`@[TT,:QI"P87EODMC3\M,6D+S$R
MA@RF,'@I5Y!I6`+H@F^ZZ2S".L9]42+T,RD\,;U!RAX;T_P&GE2+7>/X1I2R
M6;)TO+23.ZAFFGFB0#"C;EP\!_P<!0@+9?.X'+8-8]E$2^JQ.%?0U<_1/*:)
M."YPE#(]167[.IRY,[DK&!%A4QRF#TNVN2LLOPA84Z\I0$U>4I#D`%Y6/N?8
M==K:UF0Z:>);`I=1+I9$C@T&<6V6V$B>4DGC3>6*OES)A6PVDG1L[X):J3(S
MDPPLY1CB6,S!7IC`+]KS=)MEL_10N40)1`FIR02I0U6"ODQ+I"9`LBDS7Q#+
M?''4ED1^\!RE/[O>6(9V$N'5E6&GEXP-(<3D#-[@#@#@#@#@#@#@#@#@#@&*
MNS8%[D^:OQ(F1S".LTXV+S'I7\$S&3P5U>6%)05]2LEG42"'NK*_$MV9%&4"
MH992DO!HTH,#\0>H<@7;\V^"?=7?OTH-CORI\`Z:S5^M7#";"]^O-9Z-60X(
M\JMF-BC\I%Z7.<IUJ41EH"$G5D^+.`F`Z#Q@6<=>F<XR!W/FWP3[J[]^E!L=
M^5/@#YM\$^ZN_?I0;'?E3X!07S4:GY,<P'R);=#X=%7Y/*8T8Z;)[$+1,4D1
MHU[<D?6SSK0%A*ZI4+HI*+.#]N6$X7ASC.>O`(_AVG&J#TTQN1P%1-7AC:AS
MX$3?XILS>CHUHS9N\*0V8)D=6RU5"7"B3/J4X+L,HS)AR@!@#,]<"#P"^H[I
M[2\10,[7%CKACS='F)%%V%$S[';"(2&>-MV`X0L3:`FS@Y2-2;RPYP2#.`9R
M$.<XSG&,X`N3YM\$^ZN_?I0;'?E3X`^;?!/NKOWZ4&QWY4^`/FWP3[J[]^E!
ML=^5/@%DRC6R@6MVBDQF<NM-L>FQRQ$H5(Y%M5?S>L2O%A+&MC!&H^N7VR1X
MG.9N!"-(6D*R(Y:<$HL`1#\..`7M\V^"?=7?OTH-CORI\`?-O@GW5W[]*#8[
M\J?`'S;X)]U=^_2@V._*GP!\V^"?=7?OTH-CORI\`?-O@GW5W[]*#8[\J?`'
MS;X)]U=^_2@V._*GP!\V^"?=7?OTH-CORI\`?-O@GW5W[]*#8[\J?`'S;X)]
MU=^_2@V._*GP!\V^"?=7?OTH-CORI\`I.H+N]/FN59N,@>WF1NV4+ZB4/<B=
M%KV^+RFJ6/S6B,='AR.4.+HL`A1%`&>H,,/-R'Q#$(6<BR!DGP"E/IYJ9D>5
M)`Q%'IVIP/)-#T\19I20XPL8>N,X\0!AQG'7@&"]1:TUU=>LE/*;6?;MG(K!
MIVK)),27O9'8,21\?'.*QV1JG(]$DLQ*D2J</O163E.`G"8\`!DX+R`'A`FY
MHU7J^/MB)E8WJ\6EI;B0IT+<@V9V,3I$I(<YSX"B@6EC&/$(61"%GJ(8LY$+
M.19SG(%2^;?!/NKOWZ4&QWY4^`/FWP3[J[]^E!L=^5/@#YM\$^ZN_?I0;'?E
M3X`^;?!/NKOWZ4&QWY4^`/FWP3[J[]^E!L=^5/@#YM\$^ZN_?I0;'?E3X`^;
M?!/NKOWZ4&QWY4^`4-AU)J*+E.1$<<;K8R7A\>),ZE-FR^Q:4#C(I`M,<7Q[
M5A!:70YR=UYPCE!N?MC#!9%GVYX!2G'2RB7>6M<\=`6^OFC(B"VM,G5;([%&
MO")O+4'K"49:K-I=3"$BQ4:<1@S`_3FFF#*\`ACR("\?FWP3[J[]^E!L=^5/
M@#YM\$^ZN_?I0;'?E3X`^;?!/NKOWZ4&QWY4^`/FWP3[J[]^E!L=^5/@#YM\
M$^ZN_?I0;'?E3X`^;?!/NKOWZ4&QWY4^`/FWP3[J[]^E!L=^5/@#YM\$^ZN_
M?I0;'?E3X`^;?!/NKOWZ4&QWY4^`/FWP3[J[]^E!L=^5/@'7@402P"W)#'F:
M0V$Z,SA7,>>C4$XLVPK(+3.9<FD2'*ML,G\EDI[0,])X0'!2C)`=@`,CP+(`
MYP!D+P!P#"?,%(M?9B]VN536X$3-"H;1X(TQP>[+9K1C;AR%-82Q[5Y9Z\F4
M8;UK@YGHB?-4*"S3L@)`#`L!#C'`*S'-&J%A[E('B*J+QCSI*W%4[R1>U;2;
M+I5+PZ+E1Z]<M5C#;.<8.7+U)J@_P8`$Y2:,X>!&C$/(%X?-<K_[M=C_`*66
MS?Y6>`/FN5_]VNQ_TLMF_P`K/`'S7*_^[78_Z66S?Y6>`/FN5_\`=KL?]++9
MO\K/`'S7*_\`NUV/^EELW^5G@#YKE?\`W:['_2RV;_*SP!\URO\`[M=C_I9;
M-_E9X!15.G-0+'YIE*M]O]3)6%N>F=D?3MJ]FAN;4U2,YG4O[<A4YMGQ$)'E
M1'D`U(,>PT2,G.?^;#T`X)5I=2\Y8EL8F+O?DECSB)(8M9W;:O9M2B/-;UJ=
MR;S\@^^T$92IO<D9*@@T`@FD'E`,`((PAS@"I->H]6,C<B:&>3;"-;6W)RTB
M!O0[6;,)DB1,2'`2R2"2[8P$``XQ_P`><^W/7.<YX!W_`)KE?_=KL?\`2RV;
M_*SP!\URO_NUV/\`I9;-_E9X`^:Y7_W:['_2RV;_`"L\`?-<K_[M=C_I9;-_
ME9X`^:Y7_P!VNQ_TLMF_RL\`?-<K_P"[78_Z66S?Y6>`/FN5_P#=KL?]++9O
M\K/`'S7*_P#NUV/^EELW^5G@#YKE?_=KL?\`2RV;_*SP"W911$7@S>@E;!-K
M\][,TJ@YZ4#SLML#)F@_!TS8$BA*Z1Z262ZL+RWJTJ@91R96F.(-+'D(@YQG
M@&6/`'`'`'`'`'`'`,7-B/WP=-/]:-5_)AV6X!E'P!P!P!P#%W<ZU9)3NM5F
MRB!XP;:;V@::QIA)^MB$MNRX9`TU94).2C/^>2EV%+VXY5C&,^!&4://0(,Y
MP!*5)51'*(IVKJ6B&!YC550&*0!F..``"I:BBK(B9@.:_)?L-<W023*E49G.
M1&J#1C%G(A9SD"4.`.`.`.`8&7`#%Q;M:W4Y@O"N+:\QB2[@6,28F\Y)\8.A
M3Y26M[0K,SGP?X8N=YS("`YQU*71)*;C[8(<X`SSX`X`X`X`X`X`X`X`X`X!
MBYI=_%GK/_[B7?N\E'`,H^`462?^'7__`+%=/^HG\`AS5+^*YK9_`%3O^CN.
M\`GW@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@$2D?O[.?\$K'^[&0\
M`EK@#@&+];?QI=H/\D==O_R99G`,H.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.
M`.`.`.`.`1Q:_P#X+/\`\HX)^[N-<`D?@#@#@#@#@#@#@&+FQ'[X.FG^M&J_
MDP[+<`RCX`X`X`X!A9=,4DUL;7:LPTZ./`ZFI@J?;-S22*6=7\+.=F,[3]ZF
MCX.!Y$#"!6[)3;#D<I&EP+)B11'&\\6,>85G(&:?`'`'`'`'`,*]1HG)UTEV
M;V$GL==XS*;VO)\;(PSR%O<6E[9J-HD`Z>J)(>VNA9*M$@EPX^\S9,6(`?M9
M@(73'BZ<`S4X`X`X`X`X`X`X`X`X`X!BYI=_%GK/_P"XEW[O)1P#*/@%%DG_
M`(=?_P#L5T_ZB?P"'-4OXKFMG\`5._Z.X[P"?>`.`.`.`.`.`.`.`.`.`.`.
M`.`.`.`.`.`.`.`.`1*1^_LY_P`$K'^[&0\`EK@#@&+];?QI=H/\D==O_P`F
M69P#*#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@$<6O_X+/_RC@G[N
MXUP"1^`.`.`.`.`.`.`0[;5:.T_<:B?&)];65UJ6T<V2D*=VE4[-SWDVM;(K
M@YH4A1.K2J0^%/8@U@#PC,_7$@2\EY"9D00*WZ>W?\;UQ_F[)OE1P!Z>W?\`
M&]<?YNR;Y4<`>GMW_&]<?YNR;Y4<`>GMW_&]<?YNR;Y4<`>GMW_&]<?YNR;Y
M4<`>GMW_`!O7'^;LF^5'`'I[=_QO7'^;LF^5'`'I[=_QO7'^;LF^5'`'I[=_
MQO7'^;LF^5'`'I[=_P`;UQ_F[)OE1P!Z>W?\;UQ_F[)OE1P!Z>W?\;UQ_F[)
MOE1P!Z>W?\;UQ_F[)OE1P!Z>W?\`&]<?YNR;Y4<`>GMW_&]<?YNR;Y4<`>GM
MW_&]<?YNR;Y4<`>GMW_&]<?YNR;Y4<`>GMW_`!O7'^;LF^5'`'I[=_QO7'^;
MLF^5'`'I[=_QO7'^;LF^5'`'I[=_QO7'^;LF^5'`(UJ"K[3J.NH[7B.65^]I
MH]AUP6YJ8E(T1RKWH]N3T/QI2Y@I`5Y(W+)>.A@O%@'7V=>F`)*]/;O^-ZX_
MS=DWRHX!U'!LMM>@6H1O-<EA6I%*00\1N3BR`*DD9.1X#\5`\7AP/KTZXZ_W
M>`6C6$`M6LJUKRMTLGKYW2U]!HE"$SJHBLC2'N9$38&]A)<3TA<M/+2G+2T&
M#1%A&/`,B\.!9QCKD"^?3V[_`(WKC_-V3?*C@#T]N_XWKC_-V3?*C@#T]N_X
MWKC_`#=DWRHX`]/;O^-ZX_S=DWRHX`]/;O\`C>N/\W9-\J.`/3V[_C>N/\W9
M-\J.`/3V[_C>N/\`-V3?*C@#T]N_XWKC_-V3?*C@#T]N_P"-ZX_S=DWRHX`]
M/;O^-ZX_S=DWRHX`]/;O^-ZX_P`W9-\J.`/3V[_C>N/\W9-\J.`/3V[_`(WK
MC_-V3?*C@#T]N_XWKC_-V3?*C@#T]N_XWKC_`#=DWRHX`]/;O^-ZX_S=DWRH
MX`]/;O\`C>N/\W9-\J.`/3V[_C>N/\W9-\J.`/3V[_C>N/\`-V3?*C@#T]N_
MXWKC_-V3?*C@%K@B%K@FBF9_$-=Y4*(NBC&47PQ)O+`2B=G!UPJP?\6]<C,&
MOR#(/![,!Z^+V],`71Z>W?\`&]<?YNR;Y4<`>GMW_&]<?YNR;Y4<`@D53;',
M]I3^RX;95(H/OB,<#:75EDU23R090G0,J2$)5:!R:[GC&,EN!,BSYA1B<62Q
M$XS@><"Z!`N;W)N+^$[6C\1=I?I$\`>Y-Q?PG:T?B+M+](G@#W)N+^$[6C\1
M=I?I$\`>Y-Q?PG:T?B+M+](G@#W)N+^$[6C\1=I?I$\`>Y-Q?PG:T?B+M+](
MG@#W)N+^$[6C\1=I?I$\`>Y-Q?PG:T?B+M+](G@#W)N+^$[6C\1=I?I$\`>Y
M-Q?PG:T?B+M+](G@#W)N+^$[6C\1=I?I$\`>Y-Q?PG:T?B+M+](G@#W)N+^$
M[6C\1=I?I$\`>Y-Q?PG:T?B+M+](G@#W)N+^$[6C\1=I?I$\`>Y-Q?PG:T?B
M+M+](G@#W)N+^$[6C\1=I?I$\`>Y-Q?PG:T?B+M+](G@#W)N+^$[6C\1=I?I
M$\`>Y-Q?PG:T?B+M+](G@'7/A.T,@,;6V86509\8P_1UR?$\;IFPVI^5-[(_
M-ST>D:7-SO9[;V]:KPW^6`XY&J+*R+Q9*'T\.0,G^`.`.`.`.`.`.`.`.`.`
M.`:]VON8ZW.]_7)K:D)L7[XM&1VQ)1-QFQ1*"/B;*Q;RW*2X97/#V(]P4B3&
M8],$1!6#A>SJ'V9SL+[9Y*.#3R+\OY>^4(QZO76>FW7X=/;UZO0]69GT<^KV
M#Z6]O^KU\N)_HEW+EX&-AI9,G?YG(S=>/YU?DJ,([E^<:G)P7L9?[WO12,?U
MVJ79Y>5-<UI=#Y!(_#@)X\G-D@5]B+S6Z/Y=VG+J`E"GPH*SYX@GF^6'IG&!
M=>G+>O@LZSD+>,CL^9IC)RZO32.FNCTU]ON7W35>.^FGU'Y3U8YWT9Q9<=_3
M#MW&S;\MRODL?9@05E_E6^4W.6UK8G".Y^+CH6-:?<JUQI^.7Q*):38@FS76
MU8U3MA8:HJE6J!R^5-PW1K$P%&/:8+DTX3`SYIXQ$"`+IC`,]<9Y<8O;/)9E
ME%5/E[LFJ5D-6_LQ>CU^%]>OLU-F[)^CWU<[^Y;MCAN"EQ*S.[>#R.5P?-R9
M0BL7&L5=GGM4R==NY_#!*::_*6C1'[]W=-3XZ/7,MP(M3(MHF)ID-9>GA:(W
M`&]YFBV!H\2/.9$#W4H]^(#,C"7ZCPD=!]<]?#RXK[0Y:UY"CY7]S2:G\3\5
M%3>GP^YKQTZFT\9]!WKERT>[9XDN$T[+R;:.1W9<UK.G$AFS^7_,/S(^3..C
MEY>L]8Z+34RIB&V-5S8O94UE+E.`ZIR221:TO6,I1`AND58#9(Z9C&`KS<O*
M;+<3GRAC]/D9G3'3&,]>8J[B,NAXRGMURXQE#K[)-):].G5^S4XESWH9WOVY
M/L^'(O"U[XP\?)XW9<Y:5Y-ZQZ_F=8+RI>8UN2WI1ZZMK0BZ.=P[7^4"K<+8
M5/L9M/7F8[-1?U,83E=*V@WK/?8'+PO!GI)'GT(_)2!\P!GLZFAZXY<S[=Y"
MOS'+R_S>1&E]7]N6FGL\.JUUT?CTZ&Y\O]*'JGPJY=YDN+_Y$[KQ>WLG;D2?
M_*&9L\EUZU+=C_''?:]KCU^!Z,Q_;.]%IR[4?+=@DB>WO@&%V)%*Q>0FP5`!
M\S)9DR/S^SB2-^),(@YMP@CJCSC<G@R69X`X#GQ=<7\NS.8CG1X]^5\Q*N4U
MUEII%Q3_`"==?B7L]_N.J9G_`.GA]0.#ZDX/I7?/@?Z4<AQ.3R-6F9-T_+XE
MU%%NZ?RZDK-^17MBH-2CN>Y;3*:M-XZ3M><4G7T6*F@7^_:45WY!,ND>)1(`
MP1$O-;C@OJD+H>-M?/4%9Z)@@.#X>F<F8ZXQS&97!9V'1?D7;/+Q[_*GHV_B
MZ/ITZKKX]/O'$^\?IL]1NQ^V^X^ZN;EQSXOM;N.'"9OEWN<WFS@K%Y,?+BK*
M=K6MC<7KK\/0MA][A^OT=-L8EP*GV1U=L7#]7I/Z>,)S0BLR;FY)91MN<O`/
M5QO`\?KRL7EC!CIT*%UQUJ0[>Y":K:V:6X[NCU?V%IKKT\>OWON]#,\9])_J
MGRT.(LQ9<7MYKM+*[BQ]V1)?\GX:UN5GYI[<C3[-2W)^V:T9;1?<ZUJ-O&[]
M?`DV/\?:_P`2L>:3T68FD]QC9JM;"W:3X8G'#YD]R6"2FX]*`1!.#A^S(@^S
M.:O]&.3^2HS_`,WY&1.$8=7KK-Z1U^'1>/7J]#,R^C/UAAZ;=M^JKEQ']%^Z
M<_`Q,+^ZI><K>2L=6/YT/)VUQW)^8U.;@NNC*%7G=;U:LVJV>X8T1:&(B^7U
M#]<D07&&I4SK]\.<(?>#*,Y$4_*"P1["?_GU>#1"+%[/+%RK?VERN/E/#L\K
MSECRN^T]-D'H_&*>NO@M/PF2[K^A[UK[-[WR.P.8EPOZ>QNV,KGI^7ERE5\C
MASV7)3=$6[]WV*MJ4EUWHR9L?:NKJMMA+3,G!)Q3!93,\O4H38S%+&CX'KK(
M\2$`EPEY!F'O/EY].GP5D)OLZF!ZXYBL;BLK*Q?FZMOE>=&OJ^NZ6FGL\.J]
MOX#CG:/HAWKWKV-/U"X9X2X"ON'"X9^9:X6_.9^GD/9LDO)Z_'9NUC[(RT,8
MY7W7]6(:9K46\$6?D6UD=CTGJWTD.1'X`VR:1E1=MQ)LBD!7NE3AS-QY@"_4
MX"5]MC.?9C.3I[4Y2_YC9Y?]RMJ?5^,4F]/A]S]NAV7@_H<];.X(]X2P)<+I
MV/EWX_);LJ:ULQ\=Y-GR_P"8?FQ\M?"Y>7K+IHO$KK-W/M:'RX[VHU"39/QM
MKM$K'FE@B.B*4#*-FJWR/B?#`O"^#-<E@O4!]*6,DGS_`&^T/)9=K<G##HSG
MY?D9$X1C\3UUL^SKTTT]^C>AC>0^C'UBXST_[9]2LF7#_P!'.[,_`Q,'3*D[
M5;R6OR_GP\E*N'POS)*4]GN9+3QNM33'2]"WPM+F.8-L;):OBE>!(82#'L#I
M;@P`B>9`W^\PE-:4.3,>J&$X[)/_`"<#Y90X7,GF7X,=GG8\9RGU>FD/M:=-
M7^)?=T-$P/IU]0N1]1.Z/3''?'_TE[1P^1R<[6Z2I=?%IO)\B?EZV2Z?FTXP
MW>UQ(FLKN>:TU5$KNFDI)LC+-0%V(:"GF&R))%:L4[<$:U:G$QDF/J<#BQ^2
M@'XE(QDBQGP_K>>N,\O,;MCD\JVBFKR]^13YL=6_LZI=?A?7JNBU^_T-Z[/^
MC+UA[WYWMSMWA9<0N0[I[<GS>%YF5*,?DH3A"2N:IDZ[M9QTK2FM-?BZ,MUT
M[LFJS/)=;HHK(M'WIM0RP=^J_)4-1B2@0V!*!1%@Q)3A2``FD_#L#/GA+"H\
MHK[;&1=>G*L>T>6E7DVKRMN+*:G\3\81W2T^'W/IKH9;!^ACUNY#A^[^<HEP
MOR79.3F4<CKESW.>#C+*O^72H?FQ\I_`Y.O=+X>GB9*1C;BIY;'=D).U%RO#
M;JQ+9G"[/PJ9"B5(WF",1$A?,QDD+@9AX1B;U`?(,$(C)IGL\(<>WF.MX;,I
MMQ:I[-^7",H=?9)Z+=TZ=?'Q./\`,^@_?/!<MVAPN<\'YSO;`Q,OCMMS<55F
MW.BGYA[%Y4]\7OBE/;'KJ_`CQI[@U!/68IA&5/.LRU7>=PF?S8P0'&*C8@'F
M+BU8@NP\$RW(4XO+0X\8!^S]>QUY<3[=Y""FWY?P9:QWU?[X_#V?9^[^H;9G
M_2IZH\<LYY$N+TX_O>KM6W3(E_*ESBH..M2UQ?B6ZYZ-?[F8ZI.]+INLH]XV
M!)3V_P#`3)9+35:T(X(@P^?%#U'U\E1B);\2;)`VSW:W&>,[)^,A-Z!\.>O7
ME^^R^969'!?E>?*IV+XGIM4E']CKKJUTT\.IUB__`/3N^H'']2<?TKLGP']*
M,GA[>2AIFS\GY:F^&//6?R^Y6>99'2&QIQU>[H99UCNO3-M3VIJYBA4R#(;G
MH0C8Z'9=8^4A;PUXH<BFHL#PJ"Y'B02'U1N.J3`#`X#[?,_4YB\O@L[#Q[LF
M[9Y=&1Y,M'J]^FO3IU7W?U#AG>?TZ>H78G:_.]W<X^/?$]O=T2X#+\J]SL^?
MC6[&ZH^7'?1M3TM;B]>FPF*I[FA]REV$;#PO`0UG9\KJ.2>^$`4&12N&X;\O
M`FW`5"CU;5G#F7Y)^?!DSV_:8Z>VRS,&[!=:NV_G:HV1T>OPRUTU^[T\#G_?
M/I[W!Z>SXJ'/O';YGA<;E,?RI[_[FR]_E>9\,=EOYN6^'7;T^)ZDL<LS1C%>
M9[@59"WZ6M1[19$B9*Z<"&JSK`A\#=I'7];N(R4RM6CE4@1?;>>RH5A1[B%"
M0MRW$F8$I\KIG&,M1PN7?7":E5&RU:UPE-*<U[XK[K6D=6MS\-3MO;WH'WMW
M%QF!FU9'$8G)<M4[>.P<K-JQ\[/K3E&,L:B?Y-TX2ACNZ=*OG%JG?TUR07R%
MA:F)3*'-Y:VZ-HFP;RL?EZY,D:$K26G]6-R4N*@PM*0A`F_7,FB%@&`>WKTY
MC(UV3L54(MVMZ))==?=I[SD6+Q7)YO)PX7"Q[KN7LN54*(0E*V5KEM5<:XIR
M<W+X5%)O7IH0$CVPJ%XJB/7%&E4FE<5F4P<('!T4<BSJODTUE#<^O;`-OCS`
M(HA6<!0HCJP\LX_TY/HR<GC$`'MYD9<1F0S)85JC"V$%.;<DHQBTGJW_`/*2
MT6KU>AU'(]#>_<#OC*[`YB&'@\WQ_'UYN9._)KACXF-933>IWWZN*<8WU0E"
M&^?FS5<8RET.FIVXJ\$4C\F;FJQY`MD+[,(T7"&"`OCA/&AZKS)H9^BD4>\L
MKW*.'B*Z*Q'&X",0R\)\G9,+P*9<-E^=*J3JC&,8RWN:4&I_8:E[=WL_5TT9
M<5>A'>DN<RN'R[^(Q<?$QL7(>9?FTPPK:<[3Y&=%^K\Y96OYI0BVDI.U5J$V
MKEE^S5-0BIXE=3U*L"@,\50Q##7!`@6JUTB63Y:B11Q,WM."0+\G&B78-48,
M`#TA!1IAW@"4/.*5/%9U^9/!A#^Z*U)R3:T2@FWJ_#V=/>]$O$PW`>C?J#W)
MWSG>G7'8.G='&0RYY<)SA&%$,*$YY$IVZN&BV.,-KEYLY0A7N<XI_4IV%BL:
MLP%4)HG9\RDY+?''-]40.!.\HC\222Q<YHF,<L?$71&R#5X9U!_A,SD04P/-
MSCPYQQ3QMUN+\XYU0JUDEOFHN6U)O:GU>FJ7W^A#A/2GF^8[.??%V=PO'\-*
MW(KICFYM6-?E3QH5SN6-3/X[E'S80UCT=DMGB<1.R5>JK)'6B)%-5ZDF5'P%
M3,D,->5E=)+`3-`WQ3"%4O()&A3OZ=N!G)GB#A*4?^L#."H_6N'QF2L7YJ3K
M2V;]KDE-PUTW;?'37\.G733J3V>D'==':"[PR+..JIE@K.CB3RZH9\L&5JIC
MF1Q9-3E1*Q_#H_,E#\[&MU?&6HR[>5ZY6`16SS#+C@C\?&);-,*Y_63Y&6(J
M*0DLLR0/ZEV4Y,)3-A&3BP%FCP$)QI@0`ZBSTY6GPV3'&^:KG197OC'2$U)[
MI^"T]_ZQG.0]!>Z\3M67=_'\AV_R?%PS<7$VX/(TY%SR<QM441JCHY62VR<H
MK5PC%REHNI\,6YM*/$;ELJ6J)A%&N)0IDLG)<NAKTRN,FKR4*C6^*S*&MHB#
MUDC9Y*YEX2I,$@]2)2866,H`C`8RLX3.A;"F*A.<YN'PR349QZRC)^$7%=7K
MTTU>O0FY+Z>O47`YC`X3'C@9V;G\C=Q^N+ETW5X^=C14\G$R[-8PHMQZWYEK
MD_+5<93C9)1DU5@[75>"*O\`(7)%.6-ZC4ECD,<JU>8>Y([/'+)D40HAK`WQ
M'&33W);*T:@)Z(1!HR!DA,$,P&"3O+D_1&7YT:XNN4)1E)34DZ]L?M-R]BB^
MCUZZZ=.JUL9>AW>DN;Q>*Q+.-R>.S,._+KY"K*KGQRQ<1N.7?/*Z*N&-.+A<
MIQ4U-PC&$G97NE:L[,C%KQH4FB^7(@I([N\<>V=];CV>0QJ3,"P:!\CDA:5/
MZZWN[4K!X3`=1`SC(1@$,`@BS:96+;AV^5;IJXJ2:>JE%K523]J9H_>/9W,]
MC\PN'YKR93LQZLBFVFR-M&1CWQ4Z<BBV/2=5D7K%Z)IIQE&,DTI!Y;&JC@#@
M#@#@%A1FR8Q+7NQ(^SG+!N-72!+&I8$]&,@HET61QIE)($1HLYPM)RTO1`LC
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M]XQOIEZ0\UZJW3P^`Y+@\7DH>8U1FYD<:ZR%-$\BVRN#A+=7757.4I:K39+I
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MK&$4M&I=VIG<)['JX2&N*)*/!TBDY*%2U]%#6X.:#"$*=>$2DS)V!(\@&`\!
M9@!`Q6GQ67"UTI)S5;F]'^3'77Q2>O3ITZ^S5&P9_HQWK@\S9P488]^?5Q=^
M?)5SDM*,9SC9\-D*Y[]T&JX[-+4XRJE.$E(J+QL37D??W"./67IM7(9>R0DL
M:I$E`4XN[ZE7K"#D)6%XE_NM,F;#AF*#R20#`#Q$^:'.!<EAQF396K:]KBX.
M7CX):+KTTUZKHF_NZ%IQ_I-W7RO%U<MQWR]V-9@79C49R;KJIE"+4WLV>9*5
MD%&$)S:;VV;)="-$^[])+G=G9F[,K<%#O'V>2>8G:$`2F]"\A:,%)UA2IX3K
ME#D@5/9)"Q.C)5&)#`F9-\)98S,73X'/C"4Y;$HR<?%]6M?N::/1M-Z:]-.K
M-PN^F[U'QL#(Y#+^1JJQ\JW'TE;-NR=3MUE!QJE"-<XTRG5.V=2MBX*&LYQB
MY@27=$%<@LJ/Y3/*456+&YMD+HK*:BFU6ZNK<QN2%L9@A=S'12J/+D:0H.3D
MR<D9YG@",6<<LI8%RKJLUB_-3:2UU23:;?33\E^U]#0;_3?GJ.*X?E5/'G'F
MZ[+**XNUV1JJLNKG9;^:5<8Q>/;)[+)R4([G%:EJE;-P(I:J:G]IF$2>2%9B
M9.S/[8UY<',LD;^4<N;@,CV\D&I"3HTK`+QF%FX$`/VG06,\K/BLAI2K<)P:
M\4WHO#QU2_9(S<_1KNB>-#.XN_C\_CY04I6T66;*VU0U"QW4U-3:R*FM(RCH
MW\6J:*B1L=7`HVR2A<-Z9D,@G>*[;DKJWDE.69"(!YV`JD:98JRB383IQ&#\
MT0#B@XZ&%A']KR1\9E>;*J.V4HU[WH^FW\*6OZWN9:6^D?=RY?)X7&6-D9.+
MQGS]DJ[&Z_(U2^&<H1WRW245M3A)]8SE'J6I&=NJPE1!2Q`@E29NS'724*W1
MQ)C2=O;VIL:BG?Q*3P2@_)RE84H`2`M/@\1*H7E*/(&$6`UK>&RZ7MDX.6Y1
MT6[5MO3]C^'KIJNJU,YS/H-WGPELL?*MPIY?S=>-&NMY$IV6V6NKX4\9:1@X
MRDY6."E6M]7F1<=;L<MBZ^;ED$1X+D"[[X+=&'9F5H6Y,-O2-\M4+DK4<[+5
M#@F3I#/5-XRQD@R:=D?3!8!YZ]*,>,R9*Q_"O*<D]7UUCXZ+3[OCX&#Q/27N
MK+Q^3R&\6K]%79%5L9V24Y68L82M54(PE*2VS4E)J,--7*4>FO07[*PM%,E,
M#+C\U72)/(E<;`E(;V)(!8J0@+$I6I<O,B:S!-F!'`"48,`!*O%XB`FEXR/$
MT>+OE0LC=6JG%2\7TU]G2+Z^_P!WMT9<XOH]W#D=O0[GGE\=5Q,L2.0Y2G=-
MQC-O;"7E46+S-$W**;5>FEKA+2+N=ONF/*6AN=G)CE<<RYIW]6G;'I`V>\@I
M8X_M$;7'G!:'AV1%@-<WLG!6//R(1>!"S@/3&,TI8-BFX1E"6FG5-Z?$G)>*
M7L3]AALKT[Y6G/MP<3)P<M4SHC*RF=GEN611;D0BG;55-M5TSW?!HI:)-Z]+
M6:-E8B_Q!AFS+%ITYLKZ]KV3JD0QLTUJ,;XT?+CEZ\W$I]WJ6T3$E,,P-">M
M'@T`B!`">$1>*L^+NKNE1.=:LC%/JY==9;=%\.NNOO2Z=?#J9O/]'N>XOG\K
MMSD<WC*>0Q<:%WQSR$K%9D1Q5""^6\R-GG2C%JZ%2<6K(R=;4W63M@Z^;FIJ
M=)$-WBF7.7J82-ND21*B<6UZ2,PW\[*\!*]4ERBPTY*-P:G./ZY4%@QCQY$$
M,BXW)E-PKTGI#=JGJFM=.G3QU]^G@S'5^E7=67FWX7$JC.5.!',5E$I3KLIG
M:J([&X1EO\W=';.,--DY-[4F^,%^1\2;U8X?81*<ML3.ZPT;$W#`WHW8!XXN
M)6,A[.#@4N\CPH?+R9@`Q8"JRF%XL!B^.LUTWUZZZ+J^K7VM.GY/M_4U)Y>E
MW*J[R(Y_%2N=TJHI76)SG4TLE14J5_>NNMV[:VDY4*Y:-V"OW/IMI6OK2[!F
M#:_QB1L,5D,=/COG/+4[R%N7.*,!R9$M5EJ$I06XXHPX@9I?G!Z%Y'@019N(
M\'G3C&<-CKE%R4M>C2:7N^ZNC_";1B_3SZ@YV-C9^`^/NXO-Q+LFB^-^E5M5
M%D*YM2G"+C)^9&48349;7K)1::5SF[-0?(<F-[!.GD@R0.,/;E+:RM_IW>8M
MQ[J#X7;S5[TAQES6H650L(&=Y*024(<B.",8"\TEQ61X2E7%[5)ZM](O3XGH
MGT3:3TU>OL,-7Z-]R:[,K*XS'M6+7E61LNGNJQ+(U/YFQ0IG^;A.Z%4XPWVJ
MQM*MQC*2ZBS:FO2@B]V-$QDAR8QD*=TK$@8C%3":^,TA>2BW<IQD3=DHQ`7%
M5Y"H)631$J4^0=,^(.<S1XC)?VW"*>NC;?71Q731/QW)KPU3*^/Z(]UV-?.9
M''XE<U<ZI73N4;E3;14W4ZZ+-5-Y-$ZW+:IUS4M5HTI?KB>M=G0UEF[*@=6U
MJ?DV%B!,]!;0.&4IG01)QP&ES=T8,'EYP+`<'Y'C&>@L!%UQBRRL>>)?*BQI
MSB]'IKI^JD_U#0N[^U\WLSN')[;Y&VB[.Q9[)RI\QPW+Q2=M=4WH^C>Q)^QM
M=2^.6YK0X`X`X`X`X`X`X`X`X`X`X`X`X`X`X!X\X)_.\]R;^!C<7]R*'G9+
MOZH<;_A&/^NC[]=S?ZA?I!_E%VI_&IF7EH?S-?;U_A1U-_=<JYA\7^N7(_P5
MWZR."]F__N#>J_\`,O<W\5B8J[[?O+]V3_7\I+]Q9G,SV]_?W$?S=;^Z.W_2
M_P#YP_0O_1=S'\;1B';/_2>RY_!77O\`*6DG,OA^/-_PEG]I@=Z[%_>?J(_G
MO._]W\<WYZY_]%[V_P##9='^B!9SGW)?:X+^`J_MB/EWZM_O_P!.'^3G$_XU
M@8)TM_SFD_\`4Z;(_P#T?YGLOPS?YYI_[D],>HGV?4;_`*P/`?\`B#4!!/YJ
M_8;_`%R*`_T86IS<+_ZVT?X';^ZJ/?7<O^NWVI_H^YO_`!CQIOMTB_C3=L#^
MK"D?[K57-"Y[^2N5_G5?N4?+[ZC_`/,GZT?Z9L?^*Q(,M;_I^Z/]<YK?_P!?
M#R[Q_L87\S6?V#I78_\`>WIW_P!7KG_W!""+^=3[I'^KQN=^X9NYD7_57B?\
M)QOW2.E9'^I%Z*_Y5]I?QRPBW3;^('6W];)KG^YH7+SF?ZPV_P`T7?NC=/J$
M_P!:/F/]!?/?Q@W@[G_S@K!_5J;9?_.'<T'A/Y!?\Y4_KQ/FW]//^JME?Z8>
MV?UD:,-@?^E]D'^!VG/],S?S?.-\.;_A+?[6CZ6^EG[S]2/\_P#+?XIL)9K3
M^<D[L'^K[N9_[#9RWR/ZL\3_`(3C&B]Y?ZH/H;_E5VG^O8;"+&_FR>TO_#;H
MA_UE'S6<?^LW+_P&2>5.T_\`7)]=?\G.]/W,C7SN[_%W[H_]9_%/W-R'FR\'
M_*/$_P`V/]U$]5?3A_G8]%?]#&3_`!B@AB?_`+]W9._@SU;_`-.AG,AC_P!Y
M<Y_"9']J1T/M7_-Q]1O\\]Q_XF1N[HS]YWO4?ZPVRO\`HI:N:-G_`-_<%_@U
M/]L9\W_4K_.!].W^2?;_`/C.TPXKO_ZG[^H1L?\`ZHZ<S&5_Y3_E##^P>@^[
M?#NK_K08'[JLTRQ_^:OL?_75KW_1'*N;I;_6JK_`)?VV)]">5_UW.(_T=9W^
M-,8]"VCG\;/M]_U2[7^[5!SGG/?R/R7\\/\`<L^4OU*?YB_53_3K;_%)FQWM
M_?\`0MO_`/7HO[_V(AS6>X_M87^`4_\`='D;ZI_[X[!_T:<)^OE&P+FN'E<U
MUQE-?FO2"Y:PA=$N%K+IO:EE6'5D]#((LWU\<7:[R?(LI;;/<G9+)VC,->'(
M\A9Z5`M$M;B"L)O$8+P!V6V7'\E*C*OR%3&NF$+(:2<_S:TUKT3B]R2:U:TD
MWJ>L^9N]+O5;)[>[S[B[GJX/&XWA./P.2PO(R;,Y/C*HT;N+5=4L>WYNJN$Z
MO,NI5.1.;NTBMTL^R&W*UA2M<E1L[@8<V)4KTC)1X-8E*C"<L*TI,A78.ZMH
ME`1>46;XLX+Z8%USS77+;8YU.26O1Z]?N=5[3RY;F?+\I/-X>S(JC&Z4J9N>
MET8[GL<IPT_.;=-THZ)RU:Z&!(D&P],:UC8ZSJPV3V@[W;:!B0"8R,N`X%#Y
MI9\[D!%B)&MY>&9J?5S?&EY/HV[*M/@:A46$X6"@&ASL*EQN=RGF95VS$C17
M^R6^4:X+9JDVDY)ZRT?1/3KH>H%E>D_J'ZP+DN\>;CA=EX_;?'*3DLB"S<K$
MX["H>!*RJJVRF$\B$_-O\J>VNN3K3G*#7$GC+_'J!9H"AU\O)YBDU5SXBVL!
ML2/1G8<Z4/BX+P9/3W6+3%$V*R;`?!*,KQ(GA.)(2:67Z?*;`RP1=M=O(RR)
M9-$;JU#R_@E*G:EILTE'7X%IIK%ZM-ZZ]2>WF>+Y;U2R.Z,GNKMK'YSCH83X
MS^X+\C@EC4P\I82JR<2=D7@TJ'D*[%FK9QG+S?.VSE`\XU`VJ?*'@21/*Z[.
ME,)J.'P!AK)SAOO;X15)YXU.CNY-$F:95'(\9(LP]J;F]:K"W]#"D"@!`\!5
MCSG(4<UQ$.0L;A9Y-ETIN:EIN^!I)Q<9/;N;:6OM6O@=/[;]?/1#C?4[E+[<
M'EH\+R//9>==R->7Y7S4985M=5=N/;C7WJCYJR^^FIW_``ROJE;'6B*4E7S1
M\YD=DR9UB-,OQ5T24^F54,V;BE@J6B*L2J(X;DTK722+*I0G51E,UH"EY`&]
M.C=0/214`LP61Y'X+7C\_'KQ8PNOC\C'S=U$H:R>[7:HRV_%J]'JW':T:=Z8
M^I/;7$=H86#SW<.++T[PX\M'+[>R<&-N3='*\R6-#'R8XTHY$K)NF;OG;C/$
MMKE*$=NW=3HEK]9T.OY6N9H;.TCTX;53BW'"Y"K"%][=50\Z4.<A=J\-B69%
MXS7)0XN&$>6[+1C`%Y87'"G(0XY/=R.+?QRC996X+$C6JMGQ^;#1*>[3PT6N
M[=X?#H7?.^JG9G<'I;7C<AR'&6<?5V1A\7#B7@_W?'FL.-=%6>LKR-%7&NMV
MJ]96KHD\1TIMF0C75]H.:S<*?GM[8UV=8N'6N::42,:-V:$-=Q"'"007SDN`
MK4Z5G?IN].CFL(&`63<J`^<6+``AQC9Y>)".%CIMXM6D[=NJ;G*6L_=U45&*
M?LTZ'*LWO3LO#Q^P.UJK;K^S.)\O/Y:-"G5;//RLO?FZ2^"4K:,.G&QZIIK;
ML?ER6Z3>'5?ZOS5-$;,:$%-6@T1]?KO"(0[1F?6FQK)K(;;@<G2/K`HJ27'.
M4N3PZ*Q0)2A0B3XPA8U"\2;!:(D`31AS61RM#NJG*^J5BR924H5M15<XZ/S(
MZ1W2ET3?626NLGT._P#=/K1VY=SW#9^5W#PM_*U=V9F95D87&W0PZ.+S<>5-
M\>4Q57BRR\G)UKKMG^>S(4JYSR;).$7<+/0MZ9<W^^G-EL&7/B:^J#L5)$)\
MM@;?:$JB%20J90J0&E-$74)H#'W(T4]/4-J#U8,J"V[`S3`'*`AQ2GR&!LCQ
M\)5PK>/=!R@INN,K)1DNLOCDO@2D].F[HM$8K/\`5#TT6'B^F&'D<5@<;/M?
MF\"65A0S;..QLKE,O$S*$[<F,LV^M?)0AD7^4U7*]QKA*NILS:U@ALLC+%:<
MDF+&HBSC;5WSRU4,57J$2EVCK"_D,;2R-[V-L4K6TIZ.01\*I240><`DQ1D'
MC$((L\P?*WTVV4U424XTT0K<EKI)K5MK71Z:O1:I:Z'G'UG[AX+F.3X3B.W\
MF.=B<%VWA<;/)A&<:K[J'=;=.E61A8Z5.]UURG"#G&M2VI-&3/,4<<'`'`'`
M+*L9TF;)!I2[UW'$4OFS8T*EL;BSBY!:$C^Y)PX-+:AN8_UI$8M`$0"S!YP7
M@S(?%G`>N<5\:%%F1"&3)PH<M)22UT7OT]NAL7:6%V]R/<N%@=V9=F!VY=D1
MAD9-=?FRHKET=JK76:@]'**UDXI[4WHC'S7".SH:[8>PYA!W>O,W!91$CC$1
MDBQE4R=$S-%=1*'!4/@&!R=VE$>X.C$H,**`J-%A/D`A^'(O#C)<G;C[<;&I
MLC;Y-6V4HI[6W.4NFJ3>B:U>GB=5]7>7[9CC=I]I\!R6/RRX#AWCY&5CPNCC
MSMMS\K+VTN^NJV<:Z[H1E)UQ3GN4=4M7@,S::7K"*WU8.@\>0)7!7**/2[1U
MV<Z(4Y2<58SO$H9+;93RS!(%DK9FU-EJ<P`'XW!O.3Y^V&D#UV&SF^/R,K+5
M\FXJ%OD3T?Y<-KK?M46_BC[GK[SU'R'U">F?<G=W>U?<F7;/%KPN8EVYGJN<
MG+](X7RUW%W)K?#&NLDLG';6E%\+?"-[-D.V<$E-DT>]Q*&MOO:0*YC43HG0
M^H(2^-#&;>@LF>CO.4C+)#Z-E9U!W3.>HO+\(>HLXQS6.'R*L7/C=>]M:A8M
M?NRKG%?C;2/(?H7W-PG:'J1C\[W#=Y'%PX_E*Y3VREI/(XO-QZ5I%-_'=;"&
MNFBW:OHF9(<QAR$<`A6WBZGP=%5=HL8'("-0\.+"YJ4ZD:%F6,K8-Y/,/6%*
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MR.:M5(5)B4U(:[J$L.4^\HNH--/(`FR!6H"+(_,4BR*K'&Y=5*,&E7%;EX+5
M=/N?$M)+H]>B^X9/$[4];J^)HQ\*^NGBL:KYBK;Y5?G5QC1%24E5&67'R\FN
M,83=FM4&E'92M*%`I9J6`AM,A]<F('*51>6QQG2-20#@:ZH4SRSHG*-,CXVO
MJYH-=']V=2O3F)E>!&F$GX$<`1!N`SY%/,-OSK=80G&3UZ:/1Z2::3T2775>
MU=.J,GW1P7KK*VZ'/\NK</!S<6^V5LG!53E3;.O(NILIA:JZ*JI;XV5Z1C.K
M2N2M@WVS9Q4<4>I%#E5:6LS+9D[Q!O>%$HDQ:Q&MD;BP%/#*Y8!*[!<$OQ"U
MM\.*\1P2_4G&(BP8\WKC&8+'S+JXWQMIE&$9-;8Z:13T:^&"Z-R\/#J_`H5]
MM]^<YQV)W!3S'!Y&-Q]&595'&QW"<,>N]U75ZXV#7+R+)Y<M(.7EPC;.3V:/
M2H-EW:Z3/R3S(DZGIY"8\^M<CP(E+4:?'&UPD:DL3BWR`]N=%Y:24+!GI48C
MU*,TP\M245DH6`2SP.3HUTFM8Z:+KK\34?!K5+6*T;T3Z:-ZEIF^G'JUV[NK
MCG41MQ%3LKBYQL2OLKQXM5SHC97!RQZE"RU0KMC&N=,YJ:<NC-+)U>KLB11=
MWB;JM*1R=R;W<2\XX2$+J]1Z'O`7G,IE4C3)4)*IC>$A+8JRJ*&2%(<0ER7@
MO(11HQ>5R7&Z$TFX)K3QT3DM-L8]>J;DM.NJ;U+GM[M#UH[LLQ.:P,ZBNRS"
MKG5L24_*IORJO*^6QJ)2FXW56RR*U7)3=M=MV]S35S#4:W-9JW"2'2$![+3[
M#92N+-R65%I7:$'(TR!N:G*)%N9;4^O:),V)LJ4*Y.8:3D8#3?:8(>:6G*3T
MW3CI*]P4GMZ3UU;4M-4NKT:>GBD8>-7J]FPK=_(8CJR>?NX^.39+&<JLQ3E.
MRVO*=;MIIG*RSR[J;(QGI*N'2*BK>66#JHX*8ZD61EP":B;XPY-Z9N`N&UI6
MQ:.66$V)50V!\,971E:7EG5&G$9$H1$+#$V/#X1$Y#5CC<M%2E&:ZN2>NFK:
MVP>FJU3::T?1M:_=,MC]J^M^)5EWX^94X66Y-<Y6;%9*R"QL&R45?2KJ[;:K
M:XQFE"V=2N>NJLUI$?MC666R^13!NC$W1S-D;)3-5KH4[/")22@CJ!N>WYN&
M)JF`D;'E>-668H9E.$Q9YV/./)\.<&9GLP^5IIC3*=;HDXQ2T3ZMM)]8]=/9
M):Z+HG["^Y7L;UDX'@,3@,O,XVSM[)NQL2%;JJG%SOG9338E9B[[MBC*,,NO
MS)0B_+KLU3@I"DUG4.;&:T7RV/OB=*](I',XHT-9BAS-`!I=4AKBC7FQ!\5-
M[M[T7+`*2&\9RHA68FSD)>34^,!MJL3D%;;&F4=8N,9-]/%/33<M5HEHWHFM
M?'1FJ<-V;ZG0YGF<7@LO&G=CV48F3;8HUINVJ2KG!95,;*O+A!USO4*YU1L2
M<E"UN7.WWE1Z^+O126*NX8#6+0\*6I<0T)!1UQ2L\12Y>D<9`C<AF+#28G,R
M^F#2RP'EJA9`(0@YSB$L#/C;%N<?F+9+5:O5-RZ.6J_91_!H4\KTU]2,;FL>
M=^=0^Z.9OJC;"5LO/KE;E2\F>0YUI03R<276,FX2K2DDFD[1BMA:LS63XIYM
MC/OW!*R5B`N?3BGHM2N;3DBE_>`JG1_<)4N*)'&RB\NN2QEI\)2R,G%AR`&:
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MA^27-KS/Q`P@;3QFNRF/N<=CDB`!R*=/\,7N)TE+$DPK,"8:46I,!X<X%XIH
MX_,715F_X'L\7X:J4ETTZ);>NGW"MC=L^N?-X=7(/D-V%<L'7?9%*J-]=^10
M_+=?PPK6/)6^5%QC*5,9:IK;DW3RJ-&PA"BBS3)8^W,AYS(9'I<N<W%]85*$
MLGJUJ53JZO9YA!*4TH2?P*C2<IQ@R7G`<],8K-5JO<KI1E*776*23U]O1+\/
M374XWW_3S$.Y+<GF[\/*R\F*N5^+"NNFZ,V_SD8UU4I2<E)3UKC/>I;EKU)1
MY:&E#@#@#@#@#@#@#@#@#@#@#@%I36?P2M6,<GL6:Q*`1HM2G1&2&:R-GBK&
M6L5Y$%(D&[/JQ`@"I5"!G!9>3/&/.,],9X!#OSQM1/SJ-</QX5E\I^`2=`+:
MJJUTSDLJVS*^LI(SGD)7=5`)G')DF:E*HL9J5.Y'QUR<2D)ZDHH0BP&Y"(80
MYSC&<8SP"0>`>/."?SO/<F_@8W%_<BAYV2[^J'&_X1C_`*Z/OUW-_J%^D'^4
M7:G\:F9>6A_,U]O7^%'4W]URKF'Q?ZY<C_!7?K(X+V;_`/N#>J_\R]S?Q6)B
MKOM^\OW9/]?RDOW%F<S/;W]_<1_-UO[H[?\`2_\`YP_0O_1=S'\;1B';/_2>
MRY_!77O\I:2<R^'X\W_"6?VF!WKL7]Y^HC^>\[_W?QS?GKG_`-%[V_\`#9='
M^B!9SGW)?:X+^`J_MB/EWZM_O_TX?Y.<3_C6!@G2W_.:3_U.FR/_`-'^9[+\
M,W^>:?\`N3TQZB?9]1O^L#P'_B#4!!/YJ_8;_7(H#_1A:G-PO_K;1_@=O[JH
M]]=R_P"NWVI_H^YO_&/&F^W2+^--VP/ZL*1_NM5<T+GOY*Y7^=5^Y1\OOJ/_
M`,R?K1_IFQ_XK$@RUO\`I^Z/]<YK?_U\/+O'^QA?S-9_8.E=C_WMZ=_]7KG_
M`-P0@B_G4^Z1_J\;G?N&;N9%_P!5>)_PG&_=(Z5D?ZD7HK_E7VE_'+"+=-OX
M@=;?ULFN?[FA<O.9_K#;_-%W[HW3ZA/]:/F/]!?/?Q@W@[G_`,X*P?U:FV7_
M`,X=S0>$_D%_SE3^O$^;?T\_ZJV5_IA[9_61HPV!_P"E]D'^!VG/],S?S?.-
M\.;_`(2W^UH^EOI9^\_4C_/_`"W^*;"6:T_G).[!_J^[F?\`L-G+?(_JSQ/^
M$XQHO>7^J#Z&_P"57:?Z]AL(L;^;)[2_\-NB'_64?-9Q_P"LW+_P&2>5.T_]
M<GUU_P`G.]/W,C7SN[_%W[H_]9_%/W-R'FR\'_*/$_S8_P!U$]5?3A_G8]%?
M]#&3_&*"&)_^_=V3OX,]6_\`3H9S(8_]Y<Y_"9']J1T/M7_-Q]1O\\]Q_P")
MD;NZ,_>=[U'^L-LK_HI:N:-G_P!_<%_@U/\`;&?-_P!2O\X'T[?Y)]O_`.,[
M3#BN_P#ZG[^H1L?_`*HZ<S&5_P"4_P"4,/[!Z#[M\.ZO^M!@?NJS3+'_`.:O
ML?\`UU:]_P!$<JYNEO\`6JK_``"7]MB?0GE?]=SB/]'6=_C3&/0MHY_&S[??
M]4NU_NU0<YYSW\C\E_/#_<L^4OU*?YB_53_3K;_%)FQWM_?]"V__`->B_O\`
MV(AS6>X_M87^`4_]T>1OJG_OCL'_`$:<)^OE&P+FN'E<<`<`<`<`<`<`<`<`
M<`<`<`<`<`<`<`<`<`<`<`<`<`@2[+"JZ(C8&2RH^9)</B1Z7,;2-F3/:)S4
M(C6=B6M8D:XP*!2N5I93D99!P1!,()/%C[8O&,Y'`QLN[=9BRV[6DWKHUKJT
M]5UT3CXKVM>\Z?Z<]J=Z\['*Y'L_*6&\:=,+K5=*F=<9JVZ%FZ"WQA&6-I*<
M&G&<ZT^DWI!L1E^KKQ7R0UKA)\=B4HLZ)P8A(2,*$M)*#F]&4PJFY8TOH@M3
M:@3O`$ZGT1I>4QJLXLXO&3#NM_=3RT,EJ=BE="J4_?K'5ZZIKJWIJM?%)-/P
M.E\]P'K3Q_=4X9O(QR^=PN%R<QR:WN>,K)NZ-D+:=;;)RJ<Z_-BU9&JN5<](
MUZ?C_.M6D#F_(I)7PTRN-O+Y4XL+D"7)AY*;"Z5JS$"7+SE42VK7AC`!.J&6
M6>(Y4G\.<%'YSQ7C\M*$956:J459T;^Y'KT\='U7AT?M0XOMKUKRL/%R.(Y5
M3HS,>GD_@G+2+ELQHJ<O*VNR%5S=E:E*"A7;N3G6D6T_6QJMAS=C5M6R!6)W
MPR.;D[I6H)*DE6"-)G-K,1D`?T[RV#0I9*86I-2%%`3K<#$<+`\!,S5KP^7V
M)1MBMNJ2U_;:/7IH]=O1/Q7@9GC.QO6[Y.B&/S>+!4>=775*W6+B\B5=BG)T
M2JL4Y8\95QME)SIVJM.+<2^'61:\ID5D*W.$O2%MHAX9"'5T1+E&'%6Y,X7"
M-(<MP6^0X>%XDZ5>>6/"K`<J2CA"S@S/+>%7).52A9%RR(O1-=-'I)ZZK1>"
M\/`UK"XGU7NR.(HP^2Q[,SN?'NE57.$?+C7;LR)^8[*/*ANE"$EY>OERBDMJ
M+77S36-^DJ)D:X#)%[D8D?DK@L8L80I&"/QQL#'U$D7HU4@2I5S6)B3$F(CR
MDZHY0F-"<4$0Q"SRM&CE:ZG.5D5'5:)]6W)Z[5HGH]?%:K1]&9K&[=]9>,X>
MSDLWE,.K$5E$JX7?'.Z_(L\^./"<:)2A9YTI1NA*RN,+(NN;44D=R>W/JY$9
M:^G/<+,7RIL>E261&^F0$@2GP=P8(8B<7$;H](V\*(1<IP!$,>.AI)!V,XQD
M`<"EQL'EKJ8JN>E+C\/C^4G)I:)O7X>OW6BW[7]//6KGN"QH<=R*JX2[&C*A
M;IMR69"_+G76JJ93WZXS=J3UC.=>FJDVI#>'R@6Q-,T!L1/-61.L6N1NJ!.4
M-/(SXF\L;8S!9RC#'1.[ISVME1-@#P'C)`FP<2,(_'@P0;>%?(S<)*:VSM<4
M_9N3;U\-.K<M-/'JO<:I@<;ZI9EW'9,,^,<?.YFRBJ<FI41RJ;K+?-:5<JI*
MRZ>0X."F[-ED7';L3B8V9Z<,N&E@,@Z<(UPS1E@)`4XJA+7^$KI^L)=%R9^4
MJU!ZU+!,)1Y.&,L:[``!SD!HAYNU1S<]UBL\/P=%)06G33QGK][7W&\P[>^H
M'D7?RD.2DXU))MZUQ4*,R&#!UPE3&,8PEF^8MD5)4[I-*5:BNXGL?6F=L.0G
MUS)4K=!8A,9FV)P9RW%C8%J1*ED2?"IFDH23%3J7X`&HUAF!%X+`,808R`68
M/&Y3'LU5L'*R<8OV]4_A\8^SV-%"WM+UA[9Y/6OE\.>7R>?B8EDG^<:OA*4J
M);;<?51K>KC;5%J6LHQ<GN2NAVFNN,58J^72*(+C!*XRU2>,IU0LRN1-C?'I
M8`YC(*'AZ<7-6IPY/JQ84!.(\)Q"0\(LBR665FE"CD[;+%5-=)N,OR4W*/7V
M)>"2>NFC:][9A<#MSU<YOD^5Q>)SZXQAF6XV1*/]S463OQ6KI->377&/ETU5
M2<U!PG;7))*4YJWV64ZQ19CM:2L]7NS=#FEC>3GEP2%%*XY*F]N1QA3(4\8:
MRY(H*).P@<VS)@O3I`J20@"$8P@\.*EE/*VV4U3MB[Y26B_*BVY;=SV^]2]K
MT9E>1X7UFYKDN#X?D.:HNY^_)J54)-QOQIV2R(T2R+'CQ;6^O(VKS+77-R;C
M%RU.*N;!U,?K#?:DAL%*;%C*X2-,K="R4B%J/4,,?6EOIZ$XE[$[&M9K(K/+
M-/`3@@W(_P!<ZYR$7(Y./S%>-',OLUC)1>GB^KZ:]--==-%KK[B?NWM7UTXO
MM3&[[[AY.5V/D58\HUN4IVJ-]\'2IIT^4K%=&$HP<M\=/@Z)HN)6_:QN#'7"
MQ3!RR(K*!RU_;22LI6Z/M!C&`)S_`)?FQ$]D-BLX)S<$T:4`%0@&8R:(&!9'
MG-)5\K&RV*L_/0VI^UO7PT;6J\?'I[C$4<7ZRXG)<OCT\DY<WA+%HL;W67VJ
MYM4>39.F5D5I8XJQNM.+4%)I12BL^UM+&AXS(D%7D#EYT@@ZTI,W-K0E5A<Y
M&B;Y(RK<#]_D,J%I:7Q%A&J%D8$9#JG-!TSUR(=VL3G)P\J5OYG;)=6_!-Q:
M\-6VGJO:XM&[U=C_`%$Y_'_HG+YJ2X&.+F0<K++91\NB<\>Z&GD2NG;;3/S:
MUH[9XTX2Z:*,9:3RBB'25UE*44.E8))9\TDN6)0)T7-&&Y]9#&AM?E:YM,DI
M"$"=88%-XB4Y1H56"L&9!GV9S9NKD(56TRG#RZJXZ]$]4]6M'MUZ=>KTT-&M
MX;U-PN#YGA<GD,%\1PO'8_G1\N%OF4W*VRB,+%CRFY07F:2LE%U[G%275*TI
M+,M/27=\:7.OTBMT)221M."W-A'@=QUY)HJD.+*5H74LD#XJ='M.H2FJ!$K%
M1*4W(A=`8"*M51S3A&<;&H-Q?5^&^,O>O#1-/35+5&<X?M_U^LP,;.P^5LAA
MRLQ[%YEDM:EGX^3)-QG6VZ8UTSA9&M3JKE9!*/Q-K*ZFC(IF%$I(C&G2((FU
MR<$+A'GPS"AY0/.!@4K?>:[#D\X<5"H"DL[!_JC_`#"S`_;8Z>$.'S5=Y^MT
ME.32:DO!KV:+1:>[31'#O4&'.?TBE?SV93GY%U,)UWTK;5.K1QAY</+J\N,=
MLH;/+AME%]'XN5>6AI!\&FED%&''&`*))+&::::(("RBRPY&888,6<!```<9
MSG.<],8QP"T8+8<!L]@!*JVFT2L",&JU:`J10J1-,H8S%S>;Y"Y&!U9%:U"-
M4B.^T-+P9XBQ>P6,9X!>/`'`'`'`'`'`'`'`'`/+O_:^L8SV<I-G.,9R'8JC
M,ASG'7IGU\@#UQ_<STSG'_%G@'\H_@']%?\`L/F,?>(W]%TQXLVW2.,BZ8ZY
MP&'3K(<9S]G.,9%GI_Q\`]T/`/'G!/YWGN3?P,;B_N10\[)=_5#C?\(Q_P!=
M'WZ[F_U"_2#_`"B[4_C4S+RT/YFOMZ_PHZF_NN5<P^+_`%RY'^"N_61P7LW_
M`/<&]5_YE[F_BL3%7?;]Y?NR?Z_E)?N+,YF>WO[^XC^;K?W1V_Z7_P#.'Z%_
MZ+N8_C:,0[9_Z3V7/X*Z]_E+23F7P_'F_P"$L_M,#O78O[S]1'\]YW_N_CF_
M/7/_`*+WM_X;+H_T0+.<^Y+[7!?P%7]L1\N_5O\`?_IP_P`G.)_QK`P3I;_G
M-)_ZG39'_P"C_,]E^&;_`#S3_P!R>F/43[/J-_U@>`_\0:@()_-7[#?ZY%`?
MZ,+4YN%_];:/\#M_=5'OKN7_`%V^U/\`1]S?^,>--]ND7\:;M@?U84C_`'6J
MN:%SW\E<K_.J_<H^7WU'_P"9/UH_TS8_\5B09:W_`$_='^N<UO\`^OAY=X_V
M,+^9K/[!TKL?^]O3O_J]<_\`N"$$7\ZGW2/]7C<[]PS=S(O^JO$_X3C?ND=*
MR/\`4B]%?\J^TOXY81;IM_$#K;^MDUS_`'-"Y><S_6&W^:+OW1NGU"?ZT?,?
MZ"^>_C!O!W/_`)P5@_JU-LO_`)P[F@\)_(+_`)RI_7B?-OZ>?]5;*_TP]L_K
M(T8;`_\`2^R#_`[3G^F9OYOG&^'-_P`);_:T?2WTL_>?J1_G_EO\4V$LUI_.
M2=V#_5]W,_\`8;.6^1_5GB?\)QC1>\O]4'T-_P`JNT_U[#818W\V3VE_X;=$
M/^LH^:SC_P!9N7_@,D\J=I_ZY/KK_DYWI^YD:^=W?XN_='_K/XI^YN0\V7@_
MY1XG^;'^ZB>JOIP_SL>BO^AC)_C%!#$__?N[)W\&>K?^G0SF0Q_[RYS^$R/[
M4CH?:O\`FX^HW^>>X_\`$R-W=&?O.]ZC_6&V5_T4M7-&S_[^X+_!J?[8SYO^
MI7^<#Z=O\D^W_P#&=IAQ7?\`]3]_4(V/_P!4=.9C*_\`*?\`*&']@]!]V^'=
M7_6@P/W59IEC_P#-7V/_`*ZM>_Z(Y5S=+?ZU5?X!+^VQ/H3RO^NYQ'^CK._Q
MIC'H6T<_C9]OO^J7:_W:H.<\Y[^1^2_GA_N6?*7ZE/\`,7ZJ?Z=;?XI,V.]O
M[_H6W_\`KT7]_P"Q$.:SW']K"_P"G_NCR-]4_P#?'8/^C3A/U\HV!<UP\KFG
MF=V)L;1>^.NR&6W-9$IJ+8NV+&AT@PYP2"M.K$+CZZ'RH='T["G9J2+K.!L0
MOD\8)-/<%Z\;2Y`RM+$!/D24@($J]RDS9"-55(;3HJRKL:3*RKF9/K-4VN,'
MKB26+/[4$26*#O4T<+)3.R(=+14*8\;VU-Z9.X+\&XR6I\1821@?>P^W<WA/
M;@CFS=6/T%D5A6%#M>FV,SPIN6+ZU;9/?$LKVOS;&RSJ342U5%(NOFQKH6C4
M#*$,"<!)V0]1]`)&IVE[EHNXX\EDF[$RO.#SF"2$M]K>_45;CGZRPX^J9594
MWIQR@,8@)C3%2&Y>J*>V4](Z)T^#41A!I&0F>:!#5V;72W478G90=J25=**H
MDNIQFQ6O$86(FY,4TSNE%)4&M2IF!:@;TKF\N$\=)G$W)(0>:J/`:L59+$`D
M/A`!FOK&RVPP:_5(WWM*UDUN4<*:72S']<B:6\P4R?2Q/CXSITC&C0-I;;&%
MKB)L1Y`5@8TB,L1F1FY&,0$[<`<`UU;`6);!LVV+.A5DN5?-^K=%1JV&=C;V
MZ/JVFP9,[IYO)%J*=C>6EQ7J8W[H@V&\I.A.0F!-6&'9-R((,8V7CL;#\C&5
M]2LEEY$JVVWK"*VQ3AHTM=9ZZM/P2T\3UIZ5]I]C0[<[2K[CX>GE<KO7N;(X
MRVZ=E\;<''JEAX\)X2JMKA'(\W,=\K+H71<:H5J"C*3>?;(Z&/D=:'HHC*0U
MX94#H6F5!%C*8QP0E*P$*`!S@>,DB.\(\8SU]F>:]9!5VR@^JC)K\3/+G)84
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M,7B,RVJ.9',GCW9GEJO%KG#!TR9I66>;LKE#>JG%R6NCJ.KDU%,ZS4`7NUB.
M<IATQE4&G*>U`Q,4U8YA'UP<.C&XJX*A01)S2)"51(T:M"`1*A&:4/Q9%D6,
M2\M1Y&4MJJ54X1G'R]VUQ:Z-*3<E[=4_!ZEIZU=NKM[O*$L6CB:>%Y#C\;,P
MY<;\U\G=BWP_-W5QS)SRJY2<9QMJN:G7;&<=$DM<9K^L"Z85=DBF,C/NZ(ZS
M0(FIT0Y+6A]/BCARJ0.2G$K?)8SRQ"[6`^M:)>YMR)4%I`2)(D":<'`L_;<R
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M496:F1IE;?@"9TR)S3#5)\YQT&9S9>=PL*G'\W#C5\&1*&M;DTHI)Q5FYO\`
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M`$;6-1Z0@P!(!&DD!,'CQB%RUS[<:[,LLPX*O%<OACU>B\%XMO5^+Z^+-/\`
M4?E^U.=[XY+E.QN.AQ7:%F3+Y3&C*R?ETQ2A!N5L[+-]BCYLXN<E&4W&+VI$
M)3687*S;AT=$A2.-HJ6FL3M808LVMIYTF>9!%H^P.&':3/*X.2$B%N4.`@(D
MJ$(<CZB,/,%]J6&_HHPI\+?=MD\ZN=?Q-_"E)M:12\6].K?WDO:=&[<X#T]Y
M#T![EYU8F99ZB<=G<8OF;+(K'JHR;[X>5CU0^*4[(UIW6W-Z:*%4%\4Y9@\P
MIP(<`QNOF7U%&W&')[-B1\G<5`7-UAH2FXM:(+LUN,>1C1(C#528LAW48>@G
MD!%G&!E)3LXSU#C`LIQU.;;&;Q)[(=%+KIT:;U?W.FC^^CKWICP/?G,8G(6]
MFYT<+$@ZZ\MNQP_-65WS4YI1DW5'R7";7A*RM-:2;4<L5KZ\O,:9Y`KA@&ML
M?[`8*N1EK@MRI(%XD<>8FIN6$G)W0]OR4E9Q($2PT@0E*(T/@,P$18\XN;,/
MDH6RKC/6<:W8]-?"+;:\->KU:3Z/V>)MO)]C^JW'\QD<51R+OS,7BK^1FX>9
M&7E47W660:E7&S65OG6U1FE7=%[H-QE%.@2:?:P,<DFYLPK@:9]<Y9(H$YGO
M)"50X/N`%+W]P6-B!<]"7ML<>'I@`$DPDE.2H4JB3@=0G#,Q4JQN5LJK\FW6
MM04UIX+P2U:6CDD^O5M)->PRG#]K^L_(\1QL.`Y=3XVG!HS:XU2E&%.KA1"%
MDX5;+,BJF^3G&4IRKKKLK?Q5QBZ<MNC7%`@E#`353T./2-I]++<(TK>D7KTD
MA:FV1*4YC6%^)DIA))KSY2]22`($"HK(31@_6\YFCA<G*4+'='S(R^'771:-
MKQTV^SHGXKP1>8_IYZN9.5A<I9SF.N5Q+]V+OE.4(2HMLHC)6>2\=-JK=37)
MMWURUA&7QI7Z9,*7A+5;S^YPE^2Q:L)"WC>U3D^JY(F>I`V.QZ+"YGCSG(U_
ME+B'$P1HS!E$F*Q"\P7F#QRW5.=D3IKC9%VVQ>FB4=$UKHVHKII]_3PZ&KPX
M#U#[CS>`XO#Y'%GS7,XDU3&NF./*FBRI3V6WUT0UA*M**BI2C4EM6V)8!4TU
M<<9E%$;!4BIT>(RC="\.;>2C;`1N'PXQ9X7-P*&_I#9'&5"57A2A(\M9A6F/
M",)><!Z!N71RT*9RLN2A-KH]7NE+3HNGPR]C?31KQ-IGV[ZTXG;^=D<IST*<
M#,LK?EV.=CR,K*4/S<&J)+'R(RCY=T]U7E60E%S6O7O3>YM9(G.),>OKPAPG
M*-QDZ"5+C4K,A.`2U2.,-*U:Z+W9T3$#;'=>]`.3>+K@["0[[4(L8"*7'PN5
MNQXJ-K6.U%Q75^,9-))+Q277[Z+;MOT]]9.=[;PZ\;EI5=MV4XT\:"E;--V8
M^3;"%<*JY25E4*7&S31Q\VOJXZN,CNDHHE(9/&@J&J5DACM;M,M>FE$0<5,E
MS`_(6E,6V8&2X8DB9>VI$+5YF3!%^G$,H10\C`9D-K&GD)*N;FE7*UQ3?V4T
MWU\-NCUE]_KK[#4<+A?4V^/&9\^0A7Q67S%N+5;-IXD+Z9VR=FCA\O*%DIY.
MW:I>8E.,X[914H>6V)IH@/CT=4UVQ&J4!H,H4R%(R.IK<Y.\+>I^(+BL;WA2
M:H5G!B0T8#SQFX$M&6$`_`9D?+V.-S<E*U6RT?CJVM4I*'35?MM=%[-?<;_C
M=I_4'E5Y?+4\MDQIMB]\IRNJ5E=673A:UPLJBHP3RHVN$%'2E3<H[H*)<*&R
MZ#F["F+%63\0W0B!2J3QQ(@<2$A`(T8!`0\-0U4;DP"$;JM-P3YJ!</!R;(2
MC3`E^(H6:<L7D:+&_-BY661C+5:_%UT>DH]4O>NCZKWF*R>SO5'MOE)RCS.+
M++Y+E,;'R)3K<F\A.<JK5'(QVYU06_;?2MEFLZXN6DTKBEE@T#$T<('-X2J/
M>G..M,M:&]4>7,Y<B31>4IO<2<*PYY7O;LH(7NJM:2$HP\LT*4\(LY'X"QTJ
M<;D;I6>18O+4G%O[,?BCUZ:)+HDO9XHQ/!=J^J7.Y')1[;Y&$>.IR[<6V<8O
M$Q9RR<:7G2V*J%-47"JJF;E&$HNRIQ2CNE&UF^7ZU,D7MB2(*D4IX*BCKF)T
M7HP(%S),6=@2Q9>\M\>:"G\\M`0!,[MIF<>2D*6A"'.,C\K'2M*CE++::I7)
MWN2T3U3BWN2<GIU\)>UM?A,UE\!ZP<CS7!\1E<]"?<UF77Y<)[X78EM\LF%,
M[[70G.3E5D1^W;*EMZJ._K]UM9FKLAL*4UI#:^2M>4#G(DCL^`*;D;4O41V'
MB;794E)3.HW,QE'$PY2B4X*`F,!X0"ZY$#.65B\M5C0RK[&]4FEU;6Z6J]FF
MN[KIXDO=_9OK1Q7:F%WAW!RL[E;31*JENR=D(WY2LJC)RK5:N63I8J]SLB]9
M+1)HKYTRUO>(_7LE'!4^8A(ARR1$JR1H44>83V4_!SO[]1H7@IE<%^7%NP:%
M'C"DP!X!'`+\S`\\I*CDX665>8_.CM7M;>OAHVM4M'X].G3P,57V_P"KN!RG
M*\/'DY_I[$6-0X-3G?=&Z.E7DSG4[JX>78XNW\W%P:KE+8XHBG-UZ<IW;#VT
MU<VJ9>X/\(7DA3IXRWC$Y2@E'(VMV4.RA^(8VUF9I,GRC6'C-`C3NB<S'MQG
MQBO/D>;</+G:U2HR7Y3Z1U36FFK;CU2\7%HWE>G7U`6X/Z-SN:NAP-6+F0>Z
M618O+QG.BRJ-4:9766VX\O-J@HNVS&G'P:VQFA!)*E>)574G:H#+@R6Q95*\
MI58I$Z,86E>Q*FIOD:Y:W_$Q#<H0KU0TXLITY)I2W!>#A`%[!9L959E=-E4[
M(>57"/31/5/5Q2>W75=>K\/`YWE</WWQ_!\OPV;RF`^'XG!QMT/(KN=L+HV3
MHA"SY>5D9PBII3G.,JM76I+JBPY%9FHV79]:%U?-SHXHT\D8CA-S6W&DKSJZ
MDT5180Y7HW$!*)\5N3X2I1#5"(6'E)3<Y'U"$(KBO%YG9&<;&HMQ?5OIOC)Z
MZ-=5HM'IJEJC9^)[.]>%@8V?C<K;1B62Q[EYEEB<%GX^3/?LG6W.F-=,Z[E6
MIU0E;!;>K:RPITZ,YAH$47BRR%IVET<6YSC;B<4M<&]Z"8!4ORN="7!U+>%"
MO"L!V57J3\G8,QD0O%UQC#YJM\_=;-3;2:DNB:]FBT6GNTT1PWU`KYA=PO(Y
MK-KY&V^FNRO(K3A7.EIQALK<*G5&.UP\ORX*+B](Z:-RGRT-)//[W`.^Y5VG
MEQV]J[(=+=[[9>HM%T9*FQ:=I9%**O<\S"$I7XC+5)E,D0"4EM1#N`E8/R/"
M2>68'V^#/`/.KV$>^;5NB?;WCNO\CTPWGN1T;[<MN4BFM$4PAF=?G$2J0EN"
M5K3/1DC:QB=6LK&"E1/E?K1F.F,YQTX!_00C+X5)XW'Y*0C7MQ,A8VE\);W0
MCTKFA*=D"=>6C<4WB'Z=>E`HP`X'7/@,#G'7/3@%<X`X`X`X`X`X`X`X!I7[
M^>@%Z]RWM]O.L6NRR`H;'<+:K.;$J+)D#G&8SAFB*IU/=0C<VF/R57A<(*P'
ME%^F\(_;U$'I[0/#?_\`\;/=N^ZC3W\<DZ_([P#UL?V;+M(;4=IRL=IH?M$Y
M5,XNER3NMY)$1U3+GN6)2F^*1^3-;J%Y->HE%!HE`E#L3DD)83L##XLYR'IC
M&0/3!P#S_P`9[9>QS1OMN#LJJ75GFO+TKS8*+0E.5)W<<D*<K.84[;&Q/C:*
M,`2($H%!.?5"+4GY*#[0A,^QSH,^Z..EP.'QB5OGT6TRD]%II!K=IU^YT_L'
MU-YCZR/2//\`I?[`]'Z:^9_I9VSRW!Y.9)XU2QW7QUTK,CR;/F'*<G%_FU*N
M"D_%Q)[FNBMV/_;VU0U?0*X-BR:6FU%R"8*%#\XEQ@U!7#\>Y/\`AF=`L)BQ
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MW:8WN51A#JS"(I'K+]3,'PO*E>RW&\3M8*,>"(&>]$^6-<7@`CO2Y$HZ@SC`
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MSGWM[E4-?CCA7JHR#UA?GJA^4<7[>A`NGMR=_<>!:LA15GYWD*[UT7V(;==>
MOCT>B_5.R=V_5AZ7<VN[EAU\LOTYZJ<7W%C[L>M:8&'Y7G1LTR'MR'LELK6Z
M,NFMD=>F`L9[+.X31I';&O2ITIC,\FNPE66>SGE39_''P1J&PN<,#N6L<!0H
M"DES$OD*?))04XP#+\><C#D.,"S]G>_$3YVODE&[R(8\X-;5KK)UM?E>'PO]
M0]1\Q_\`J)>@.?\`4?P?JO13W#_1CCNU.2XZU/#H5[R,O+P[ZG"'S;BZ]E%F
M^3FFI;4HM-M;0];=&[JJB[=+;"E*J#F,-`Z7.U!3H#2_.*QP.G2Y]/<BCF!.
M>PHRG!@PG,QU4&F)S<"ZX\K]7FL<ISV%F86=CTJS?D9OG1U22VZ)=>KT?W.O
MWSQ;ZO?4IZ==\>G'J)VIPD.27)]T^H=7-X3MIKA!84*56U?)73==^Y/2$8SC
MI^61I..W=?TB5;$G-ZRO,`M+N'5#M'&?42-U+R76D&5><\IW3`8X9Z64#!C'
MD)0>:2//V3P\K5=Q8$(XR:L_-<?.A]%]N6FC77[/1]?U#<.VOJQ]+>)I[2KR
MJ^6W<)Z4<IVYD;<>MZ\AF1TJE7KD+=C)_;L>V:]E;(V3]L+9(K=[=C882^L?
M@/8*I]B(5`R,2EX^("7BT8TE:8R.0-_POZ5O1`5$9RJ&4H4")![0A,S[.7C[
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M2TVPVZ^WQZ/0\?\`I/ZW]E]E>B%WIYS,<Y\]9Z@<-S*==4)5?)X&GGIS=L9>
M<]'Y<-FV7MG$UGVIVG-HYF?VVS&AQJ@`=3Z_KZ,6AZR6O1.5+E&+#2RAR%%<
M%Q([WJE$V$9P4,[TN1&_:Y"''VW-GP^[>,H7([U;_=<YN&D5TW045KU]Y[%[
M(^N;T5[>K]7X9]7.-]\\KG9'';,6E[:\G!EC5_,ZY2\J7F/XE#S$H]4V^A?4
M.[7^RC#M_O->:U?6`H5L75.P\+@!)$I>!OA#Q:&$>(P*1(118"=N1`\@7JQE
M'J!$^SPA,Y2M[JXR?#X.`E;YV-=3*7PK32O[6G7Q]WO^X:SW!]9_H_RGH%Z:
M>FF-5S2[B[2YS@LO.;QJE2ZN.W_,>1/YERLF]R\I2A6I_E.!E=+M)[C?---$
MZ%1*H5B<:XV1K'*[!./?'`MA/:Z@.(,E88XO"R&*7)6;@K/I`&ITP3O^4(OF
M&IYO#AS&?GR4_)R:[HPZ+76SPUZ]/N^)P[@OJ,]/^.^H3U-]3\B'(_T;[NXC
MN+&P5&FMW*SE$UC?,0=RC7%:_G7&=CC[%(Q3V0[8&R=KU-NM"8POK$MXV!W2
M8[^@HW64O"1$3!6YH=T)Y+^<3%U1C>_Y.6E^%.4!05D/7/FXZ8QG,<;W5QN)
MEX-]BMV8V$ZI:)?:UB^G7PZ/K^H=P](?K/\`2#L;OKTZ[CYJKF7Q_:OIW=PF
M:J\:J4WFV7533H3R8J=&D):V2<):Z?!UZ1W*>TOM,\V1VY)6E<:G"UZJ0VDV
M&S@FRY["J4+J^LT<N?\`,6*#$1`=4XVG.,)Q'#2Y,.^U%@&/MN7=7>'%0QN2
MJ<;MV7.YP^%=%."C'=\73KX^)MO"?73Z)\=VCZN<'?5SKS>^.1Y>_CM,6EQC
M#.XY8M'S+^:UJDK?WQ05BC'JG)]#9%6>HUK1*ONXO&'51$1.6T]L7'-:Q$D>
M%QR4AFG<&0QUC#*C1LY(VE:%P3"R>`D"L)9?3(1#S[.:UE<SAW9/&6P4]F)3
M7&?1>,).3V]>JT\-=#R%WCZ\=C\[W5Z2<S@PSUA]D\%Q6'R.ZJ"E*W"S)WW?
M+)6M6P<)+9*;J<I=&HKJ8^1/M\7TR9JOUBRO18AG:ZE^GCODF1.@\CMI\(6E
M(5*/`HZ#SH?@2@/F+1>`\/MZ)\\R%W<?'V>;HK-9\K')71?O:TU7C]K[GA]T
MZMSOU5^E_)+F_EZ^5UY#UJQ>ZJM<>M?\ETN#G&?]T/3*^%[:5K!]-;4:\VKL
MK;AHM))?KT<Z4OF=OFQD4M1$>";2`3!B,,L">XVL+/<,PD*DMURY.!>0$X3B
M`(KJ+)F,X\.=AGWQP\N:KY%1N\F.*ZVMJUW.<9?LO#1?C/5N=_\`J*>@&1]1
M^!ZKUT]Q?T8QNT<GC9Q>'1Y_S-V;3D0:A\YM=7EPEK+>FI:+:UU6UW6G2FY*
MEO;52QI4IA)D>IG1)%KC,`-#ZXK'(RPT\C3.IAS*F/8D9*Z-^E)ST4F&D'>/
MV>3T]O-4Y3G<',X_,Q:59YE_(.Z.J6FS;IUZ])?<ZK[IX=]8OJ+]/N^O3+OC
MM'A(<DN6[A]39\_BNVFN%:P942K2NE&Z;AD;FM:XQG'3KYGL,O-5J9F%-)[^
M*EYC*8*R]F;3MN.>YERA;@$4F06##06YY4(D7I7</NTSSB0>:6#[7H8+K[,-
MR^=3G2QW3N_-8M=<M5I\4===.KZ=>C."^MWJ%P'J%;VM/@%D*/#=F\;Q>1YT
M(PUR<3S_`#77MG/=5^<CLF]LGUU@M.N57,0<0,*&C0+7YFN9/<Y&+'6'MMCO
M=S1ZKG6S9<YT=%+DDB18D?+4C-4K'`V,M,T7Y<UA^#P@R0F6+5"E.44H.&9D
M"ZMA-.:IV0?&24RQ[M6%2MGBL@K\^3T_:,MJY\D=;RQ2B6R6NY2LC"Y+[[B3
MLM;B3\E&!P>G.!YB<TD8A9R!)CMK_3#Y1YNMCI74;548;!4M:_>URC\N.%0E
M`WD-C>R)B"A@.2@;TJ4K*<XL85!)I8#0#P:'`\`0G16BM-4//R[40R"Y+6L9
MKAQE=PZ8W[;LRN)[KFOU*I,M<8A7RB7KE8(TVO2E`F$X'EA$X..$A`5*@T)0
M`X`D._=5:3V9<*:=+@BYTB6T-:C/<-=F)W5Q:@I):RI%B,E,\E-YY)<ABZX"
ML(UC4LP:A5G)DXS"Q"(+R$#(K@#@#@&/MHZS5?;LC+DTK*DR=8I9DD8E**.2
MEWCK/8,40.8GA#%K`:VT\I-*&)*O--$`H[&!8+4'%>+RC1@%D<3E,O#J\JG8
MXJ6Z+E%-PDUHY0;^R]/=[D_%'5.RO6/O3L+B7PW!O#GCPR)9&-/(QJK[<')G
M6JIY.#99%RQKI044Y0Z;H5SV[X1DIY/2EGI#D6!&IRCDQB7`TA@DQQ!9A62L
M"3&E]!$&E!SU`(/3(<XQG'V.8]-J6[Q>OM.8U72KOCD-1G.,U+22W)M/7XD^
MDD_:GXKQ,<:1U7@FOYQ`8'+[?/9DR=S)(BDKM"2RF*`/=U>5R]S$R.J@U.<\
M'JQC,RK,R,_(QBSD6<YSS)Y_+9'(K^Z(4[VU\4:XQETZ):KV:>SP.N>H_K;W
M-ZIUR?<^!P$>0G*MO)QN.Q\;):JCLA7YU45)51@E%51T@DDDEH2;:54Q>W&)
MO9)*?(&TUD?FZ41R0Q*0.47E$;D35@X"1V9'MJ.)4IC_`$RHX@TL7F$'ISAE
MFEC`+..6N)F6X=CLJVM2BXR4DI1E%^QI_@?O36J--[*[XYKL/D[>2X>.+=#)
MQ;,:^C*HKR<;(HLT<JKJ;4XR6Z,)QDMLX3A&<)1DDSL5C6$3J.+XBD03K\)#
MG5VD#NYO+FL?)#(Y(_K#'!\DDD?'$TY>\/;LL,R,X\T6<],!`'`0``$,,O+N
MS;?.O:W:))))*,4M%&*71)+V%+O+O/G>^^:_3G/2J\^-%5%5=-<*:,?'H@JZ
M<?'IK2A535!:1A%>.LFW*4I..)QJ]5MA319-)%B6BR]GQ97,(DWS!\;X%/E<
M).*/BBJ;1`A3AK?C&4:8G`,""$!P""@G!-"6'&+FCE<O&H5%6SX5)1DXIS@I
M?:VR\5KU^]J]-#;NVO6CO7M3MVOM[B?D$L:.3'%RIXM,\W"CF)K)CAY4H^92
MKE*>K3;BYS=;@Y-N=GIF:I&SNT??4"9T9'UM7,[PV+"\&I'%K<TIJ)P0JBL^
MPQ.K2'C+&']4(LXY80G.J:LK;5D6FG[FNJ?X#F7'<AF\3R%'*\;;.CD<:Z%M
M5D'I*NRN2G"<7[)1DE)/V-$*53K=7E0O0Y$PJYK('HF-)82Q.$\F;Y,SXC!T
M:D"M/#HF)Z4G^YF+"@DH1@0^(X[R"L&F#P4#`;[,Y3)S:_*L5<:]VYJ$5'=)
M]-TM/%_J+5Z+J=%[W]7N[._>.7$\G7QV+QTLR69=#"Q*<2.5F3BXRRLKR8KS
M;MKDHMZ0AOL<(1<Y:R-/:[BUE-[&URU&>O01^7Q><MZ8I6>E+S((<ZD/;":K
M"0,.%B1,Y)BS!$&>(HS(,>+&>G+;'R;<64ITM*4H2B^GLDM'I[GI[34^V.[.
M:[/RLG-X*R-63EX&3ASDXQD_(RZG3<HZKX)2KE**G'24=7HR^.6YK19#U7L8
MD$VA%@N:50;)Z]32E)&%1:Q02G2D3)&A0/H5",L>$ZS*A,W%8!DS&<E9QG(>
MF<YY7ADVUT68T'^:L<7+IX[6VNOL\39..[KYGB^W.2[5PYPCPW+3QI9$7"+E
M)XDYSIVS:W0VRLDWM:W:Z/P+WY0-;'`+5D<'B$O-;#Y1'&E^-9E&5;48YI"U
M0F]5G(,^H2Y,QGR3NH,9\6/;CIRM5D74IJJ3BI>.GM,WQ'<G/<!"ZOA<N_%K
MR(;;57)QWQZ_#+3Q75]'T*<*L:]$#RQP]A,+\O!>"C$!1A0`A:4;$$190\"+
M*-"T-Y"?`PXP/!90<=?9R;YK)\=\M?O_`'6_UVV7:[S[K4MT>0RE/7753:;_
M`#L[NK75KS;)ST>JW2;T*0=252J7)^>%<`C:USDX5@'Q:N0A6J%I;@I3K%Q6
M!JA'>E)5+$I9HP$^6$1@?%G'BSG.9UGYBC&"LDHPTT2>FFG1??T^Z7]?J/WU
M3B8N!1RF97AX;@Z80GLC!PC*$'I'3<XQE**<]S47MUTT1WOO2UK[HD+"&%L)
M;1*T2UND:$I'@DIX1N)IARTA8(H0#3`J#3A"%G`L"\6>N,^S')?G,K?&SS);
MX-.+U\&O#0MOZ=]X?/XG*/D<IY^#9"S'FYZNJ=:2A*&NJ6U))=--/8<#53U:
M,N5>6^)-X0KUC<XJR51RYQ3'N#2,PU`N$E<5:M-A82::(>3,`P,P>?$/(A>W
MD9YN59INF^B:]BZ/Q73V%7.[_P"\>15?S>?:W5797%Q4*Y*%J2G#=7&,MC22
MVMZ12TBDNA3S*'ITU?'G3-=1D#A%2$:5A5D(,)CD"-ORH$C0^).,KU2`C*LS
MH0=YA.<#SC(<XY,N0S5&4/-GMFVVM?%OQ?W^GBBZAZG>H$,7*PERV8\3-E.5
MT93W*<Y[=\_B3VSEMCK.&V73HRMFU56QSTLD9T(C1KZXY/RO=C&I*-<M]4:4
M>H"J/$#(SP''$`$((NH<BQUZ<IK+RE!5*R7EKP6O1&-AWQW?7QU?$5\EF1XR
MG;LJ5DE"&U.,=L==$TFTFNNCT!E5UV:G6IA1!FP%Q0&-:X\"?)2]2@,2-Z$2
M8QS*&!QR`*5J3!#GS?$#R`9#G`@XSR*R\E-/?+H]5[M>K\/#VO\`&(=[]V0M
MKNCGY&M-JLA%RUA&:G.>Y5M.O7=;8W\.CWR333:*)BA:7PE;$>*QAOIV<1XV
MX.61&(9!BD9!AYPCL@R<>>88F!G(S!#'U#[,_9Y/^D<[5R\V>LO'JS)/U0]0
MW==D?IGD/-R$E8_.GI)1326FND4E)K;%)=?`J#M3M9/B%A;'.'-)Z",(W)O8
M4A6%",EL0O!11+FC("B4)^J9:62#Q@%X@Y$`(NGBQC.)89N57*4XSENFTW[=
M6O#Q]Q:8/J!WEQN3E9F'R%\<K-LKG=)[9NR=3;KG+?&7Q0;>C6CT;7@VCG#4
MM;8);23(:RJ_<XF838H<4XG-<CS'W`YU9<%.+@-2O\+>XJ3#B\9,SCQCSG/7
MKR'SF5JVIR6NNNG1=5H^BZ=5T*<N^N[W9=9#D,FOYCS?,C7+RX3\^"KNUKK4
M8?G*XQC+2/@D4UNHVHFD+^6VU]&T:>4(BVY]1DH<80."`K)&0I!M^1Y1$)Q>
MD*\82BP8,P4#`NN`!Z32S\R>URLDW!ZIZ]4_O^/M+S+]2N_<YXL\OE<RRW"L
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MV&^IJVAZ9X,<T[R)Q3LB(E5[S2K4[DF5A,++#X!D."4L\.,=`X-#X^GBSG.8
MO/S7#RW;-PTTTU?AII^MT*UGJ3W]=@KC;N8Y">`J95>7*Z;CY<H2KE'1MZIU
MRE!M]7%[==-$=@VG:U-DN)@*+)<23#J:^8=2ECH0:%T/`0!2J"42N+38RJPE
M+R<#`/+-$#`AA$+'7D%FY2J\G>_*TTTZ>'XBG#U`[PAP_P"@%FS?#^0J?*<*
MVO+3DXQU<'+X=TMKUW13:BTGH<:VDZC<,J,K*YB)V52%(W*19948!'I$"LI<
MC"8(LL`A')UA`#`G9_7O$''VWLY&.?F1^S;/H]?%^WI__"\";']1N_,3:L?E
M\^*A;*R/YZ3TE.+A+35O12A)Q<?LZ-]"\(O%8]"V5+'HLU)F9F1Y-$0B2^9D
M.##S1''G&FG#-4*5!QH\B&88,8Q9^SG/*%MUE\W9:W*;]I@.:YOE>XN1GRW-
M7SR.0LTW3EIX16B222C&*2T48I)>Q%P<IF**/(6L3VP/C*`["8;NSN;6!1D.
M1X($O1'I`G9!C.,CP5DWQ=.N.O3@&I'L::%7)VW-$&S6"]'6$/DW9KBN"8$N
MM?NSD\1];&YE)\N<?4>>ZLS&K3.)J+'B4)\DC"0//AP8/[/`-PW`'`'`'`'`
M'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`
M'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`
M'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`
M'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`
M'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`
M'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`
M'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`
H'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`/_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
